PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Murakami, S; Iwaki, D; Mitsuzawa, H; Sano, H; Takahashi, H; Voelker, DR; Akino, T; Kuroki, Y				Murakami, S; Iwaki, D; Mitsuzawa, H; Sano, H; Takahashi, H; Voelker, DR; Akino, T; Kuroki, Y			Surfactant protein a inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; CUTTING EDGE; RECOGNITION; BINDING; RAT; ACTIVATION; LUNG; PHAGOCYTOSIS; CYTOKINE; PHOSPHOLIPIDS	Pulmonary surfactant protein A (SP-A) plays an important role in modulation of the innate immune system of the lung. Peptidoglycan (PGN), a cell wall component of Gram-positive bacteria, is known to elicit excessive proinflammatory cytokine production from immune cells. In this study we investigated whether SP-A interacts with PGN and alters PGN-elicited cellular responses. Binding studies demonstrate that PGN is not a ligand for SP-A. However, SP-A significantly reduced PGN-elicited tumor necrosis factor alpha (TNF-alpha) secretion by U937 cells and rat alveolar macrophages. The inhibitory effect on TNF-alpha secretion was dependent upon SP-A concentrations in physiological range. Coincubation of SP-A and PGN with human embryonic kidney 293 cells that had been transiently transfected with the cDNA of Toll-like receptor 2 (TLR2), a cell signaling receptor for PGN, significantly attenuated PGN-induced nuclear factor-kappaB activity. SP-A directly bound to a soluble form of the recombinant extracellular TLR2 domain (sTLR2). Coincubation of sTLR2 with SP-A significantly reduced the binding of sTLR2 to PGN. These results indicate that the direct interaction of SP-A with TLR2 alters PGN-induced cell signaling. We propose that SP-A modulates inflammatory responses against the bacterial components by interactions with pattern-recognition receptors.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 3, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Sapporo Medical University; Sapporo Medical University; National Jewish Health	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp						Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; BASTACKY J, 1995, J APPL PHYSIOL, V79, P1615, DOI 10.1152/jappl.1995.79.5.1615; BAUGHMAN RP, 1993, AM REV RESPIR DIS, V147, P653, DOI 10.1164/ajrccm/147.3.653; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chiba H, 1999, BIOCHEMISTRY-US, V38, P7321, DOI 10.1021/bi990353e; Chiba H, 2001, INFECT IMMUN, V69, P1587, DOI 10.1128/IAI.69.3.1587-1592.2001; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; GUPTA D, 1995, J IMMUNOL, V155, P2620; Hattori A, 1996, BIOCHEM J, V317, P939, DOI 10.1042/bj3170939; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Iwami K, 2000, J IMMUNOL, V165, P6682, DOI 10.4049/jimmunol.165.12.6682; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; KUROKI Y, 1993, AM REV RESPIR DIS, V147, P723, DOI 10.1164/ajrccm/147.3.723; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; PHELPS DS, 1991, AM REV RESPIR DIS, V143, P1072, DOI 10.1164/ajrccm/143.5_Pt_1.1072; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Rosseau S, 1999, J IMMUNOL, V163, P4495; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SOELL M, 1995, J IMMUNOL, V154, P851; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; VANDEGRAAF EA, 1992, J LAB CLIN MED, V120, P252; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Yoshimura A, 1999, J IMMUNOL, V163, P1; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	58	133	143	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6830	6837		10.1074/jbc.M106671200	http://dx.doi.org/10.1074/jbc.M106671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724772	hybrid			2022-12-25	WOS:000174104300012
J	Golldack, D; Popova, OV; Dietz, KJ				Golldack, D; Popova, OV; Dietz, KJ			Mutation of the matrix metalloproteinase At2-MMP inhibits growth and causes late flowering and early senescence in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN LEAF METALLOPROTEINASE; PROGRAMMED CELL-DEATH; FUNCTIONAL DOMAINS; TOMATO PLANTS; EXPRESSION; SIMILARITY; GENES; EXTRACTION; ENZYME; RNA	This study characterizes the expression and functional significance of the member of the matrix metalloproteinase (MMP) family At2-MMP from Arabidopsis. By transcript analysis, expression of At2-MMP was found in leaves and roots of juvenile Arabidopsis and leaves, roots, and inflorescences of mature flowering plants showing strong increase of transcript abundance with aging. Cell specificity of expression of At2-MMP was studied by in situ hybridizations in leaves and flowers of Arabidopsis. In leaves, the gene was expressed in the phloem, in developing xylem elements, epidermal cells, and neighboring mesophyll cell layers. In flowers, Signals were localized in pistils, ovules, and receptacles. In an Arabidopsis mutant (at2-mmp-1) carrying a tDNA insertion in At2-MMP, neither germination nor development of plants was modified in comparison to the wild type in the juvenile rosette stage. Starting with the on-set of shoots, growth of roots, leaves, and shoots was inhibited compared with the wild type, and the plants were characterized by late flowering. Besides the flowering, at2-mmp-1 plants showed fast degradation of chlorophyll in leaves and early senescence. These results demonstrate the involvement of At2-MMP in plant growth, morphogenesis, and development with particular relevance for flowering and senescence.	Univ Bielefeld, Fac Biol, Dept Physiol & Biochem Plants, D-33615 Bielefeld, Germany	University of Bielefeld	Dietz, KJ (corresponding author), Univ Bielefeld, Fac Biol, Dept Physiol & Biochem Plants, D-33615 Bielefeld, Germany.		Dietz, Karl-Josef/B-6029-2009	Dietz, Karl-Josef/0000-0003-0311-2182				Beers EP, 2000, PLANT MOL BIOL, V44, P399, DOI 10.1023/A:1026556928624; Borkakoti N, 2000, J MOL MED-JMM, V78, P261, DOI 10.1007/s001090000113; Brault M, 1999, PLANT PHYSIOL BIOCH, V37, P403, DOI 10.1016/S0981-9428(99)80046-1; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Delorme VGR, 2000, PLANT PHYSIOL, V123, P917, DOI 10.1104/pp.123.3.917; DIETZ KJ, 2000, PROG BOT, V62, P215; Golldack D, 2001, PLANT PHYSIOL, V125, P1643, DOI 10.1104/pp.125.4.1643; GRAHAM JS, 1991, PLANT PHYSIOL, V97, P786, DOI 10.1104/pp.97.2.786; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; Jorda L, 1999, J BIOL CHEM, V274, P2360, DOI 10.1074/jbc.274.4.2360; KINOSHITA T, 1992, P NATL ACAD SCI USA, V89, P4693, DOI 10.1073/pnas.89.10.4693; KONONOWICZ H, 1992, PLANT CELL, V4, P17, DOI 10.1105/tpc.4.1.17; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; Maidment JM, 1999, J BIOL CHEM, V274, P34706, DOI 10.1074/jbc.274.49.34706; MCGEEHAN G, 1992, PLANT PHYSIOL, V99, P1179, DOI 10.1104/pp.99.3.1179; McKhann Heather I., 1993, P179; Messdaghi D, 2000, BBA-PROTEIN STRUCT M, V1480, P107, DOI 10.1016/S0167-4838(00)00092-3; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OSTREM JA, 1987, PLANT PHYSIOL, V84, P1270, DOI 10.1104/pp.84.4.1270; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; Sandalio LM, 2001, J EXP BOT, V52, P2115, DOI 10.1093/jexbot/52.364.2115; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; TEERI TH, 1989, EMBO J, V8, P343, DOI 10.1002/j.1460-2075.1989.tb03383.x; Tornero P, 1996, P NATL ACAD SCI USA, V93, P6332, DOI 10.1073/pnas.93.13.6332; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043	34	72	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5541	5547		10.1074/jbc.M106197200	http://dx.doi.org/10.1074/jbc.M106197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11726650	hybrid			2022-12-25	WOS:000173962900127
J	Haemmerle, G; Zimmermann, R; Hayn, M; Theussl, C; Waeg, G; Wagner, E; Sattler, W; Magin, TM; Wagner, EF; Zechner, R				Haemmerle, G; Zimmermann, R; Hayn, M; Theussl, C; Waeg, G; Wagner, E; Sattler, W; Magin, TM; Wagner, EF; Zechner, R			Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; SITE-SPECIFIC RECOMBINATION; FATTY-ACIDS; GENE-EXPRESSION; HOMOLOGOUS RECOMBINATION; TARGETED DISRUPTION; LIPID-METABOLISM; SKELETAL-MUSCLE; LIPOLYSIS; STIMULATION	Hormone-sensitive lipase (HSL) is expressed predominantly in white and brown adipose tissue where it is believed to play a crucial role in the lipolysis of stored triglycerides (TG), thereby providing the body with energy substrate in the form of free fatty acids (FFA). From in vitro assays, HSL is known to hydrolyze TG, diglycerides (DG), cholesteryl esters, and retinyl esters. In the current study we have generated HSL knock-out mice and demonstrate three lines of evidence that HSL is instrumental in the catabolism of DG in vivo. First, HSL deficiency in mice causes the accumulation of DG in white adipose tissue, brown adipose tissue, skeletal muscle, cardiac muscle, and testis. Second, when tissue extracts were used in an in vitro lipase assay, a reduced FFA release and the accumulation of DG was observed in HSL knock-out mice which did not occur when tissue extracts from control mice were used. Third, in vitro lipolysis experiments with HSL-deficient fat pads demonstrated that the isoproterenol-stimulated release of FFA was decreased and DG accumulated intracellularly resulting in the essential absence of the isoproterenol-stimulated glycerol formation typically observed in control fat pads. Additionally, the absence of HSL in white adipose tissue caused a shift of the fatty acid composition of the TG moiety toward increased long chain fatty acids implying a substrate specificity of the enzyme in vivo. From these in vivo results we conclude that HSL is the rate-limiting enzyme for the cellular catabolism of DG in adipose tissue and muscle.	Graz Univ, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Bonn, Bonner Forum Biomed, D-53117 Bonn, Germany; Graz Univ, Inst Med Biochem & Med Mol Biol, A-8010 Graz, Austria	University of Graz; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Bonn; University of Bonn; University of Graz	Zechner, R (corresponding author), Graz Univ, Inst Mol Biol Biochem & Microbiol, Heinrichstr 31A, A-8010 Graz, Austria.			Zimmermann, Robert/0000-0002-7354-870X; Zechner, Rudolf/0000-0001-5483-1182; Haemmerle, Guenter/0000-0001-9900-5896; Wagner, Erwin F/0000-0001-7872-0196				BELFRAGE P, 1977, FEBS LETT, V75, P259, DOI 10.1016/0014-5793(77)80099-9; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; COPPACK SW, 1992, METABOLISM, V41, P264, DOI 10.1016/0026-0495(92)90269-G; COPPACK SW, 1994, J LIPID RES, V35, P177; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DEGROOT MJM, 1989, BIOCHIM BIOPHYS ACTA, V1006, P111, DOI 10.1016/0005-2760(89)90330-5; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Dolinsky VW, 2001, BBA-MOL CELL BIOL L, V1532, P162, DOI 10.1016/S1388-1981(01)00133-0; DOOLITTLE MH, 1998, METHOD MOL BIOL, V109, P112; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; FREDRIKSON G, 1983, J BIOL CHEM, V258, P4253; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; Jepson CA, 1996, BIOCHEM J, V318, P173, DOI 10.1042/bj3180173; KHOO JC, 1993, J LIPID RES, V34, P1969; LAFONTAN M, 1995, P NUTR SOC, V54, P49, DOI 10.1079/PNS19950037; Langfort J, 1999, BIOCHEM J, V340, P459, DOI 10.1042/0264-6021:3400459; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; MAURIEGE P, 1991, J LIPID RES, V32, P1625; MCGARR JA, 1976, AM J PHYSIOL, V230, P385, DOI 10.1152/ajplegacy.1976.230.2.385; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Quest AFG, 1997, ADV EXP MED BIOL, V400, P297; Raclot T, 1997, BIOCHEM J, V322, P483, DOI 10.1042/bj3220483; Raclot T, 1997, BIOCHEM J, V324, P911, DOI 10.1042/bj3240911; Raclot T, 2000, BIOCHEM J, V348, P129, DOI 10.1042/0264-6021:3480129; Raclot T, 1999, P NUTR SOC, V58, P633, DOI 10.1017/S002966519900083X; RACLOT T, 2000, BIOCHIM BIOPHYS ACTA, V1532, P88; REYNISDOTTIR S, 1994, J CLIN INVEST, V93, P2590, DOI 10.1172/JCI117271; Sambrook J., 2002, MOL CLONING LAB MANU; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SMALL CA, 1989, BIOCHEM J, V258, P67, DOI 10.1042/bj2580067; SOMA MR, 1992, J BIOL CHEM, V267, P11168; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STERNBERG N, 1981, J MOL BIOL, V150, P487, DOI 10.1016/0022-2836(81)90376-4; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; SZTALRYD C, 1994, AM J PHYSIOL, V266, P179; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wallace TJ, 2001, J BIOL CHEM, V276, P33165, DOI 10.1074/jbc.M105644200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N	59	471	504	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4806	4815		10.1074/jbc.M110355200	http://dx.doi.org/10.1074/jbc.M110355200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11717312	hybrid			2022-12-25	WOS:000173962900035
J	Kim, HJ; Yoon, MJ; Lee, J; Penninger, JM; Kong, YY				Kim, HJ; Yoon, MJ; Lee, J; Penninger, JM; Kong, YY			Osteoprotegerin ligand induces beta-casein gene expression through the transcription factor CCAAT/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST DIFFERENTIATION FACTOR; C/EBP-BETA; MAMMARY; CYTOKINE; FAMILY; CELLS; PROLIFERATION; ISOFORMS; RECEPTOR; GROWTH	Osteoprotegerin ligand (OPGL, also known as RANKL), a member of the tumor necrosis factor superfamily, is essential for mammary gland development during pregnancy in addition to key roles in the immune system and bone development. Here we show that OPGL induces beta-casein transcription through the CCAAT/enhancer-binding protein beta (C/EBPbeta). In both HC11 cell lines and primary mammary epithelial cells, OPGL stimulation triggers rapid nuclear translocation of C/EBPbeta, which is critical for the expression of the beta-casein gene. Mutation of C/EBPbeta binding sites in the beta-casein gene promoter completely abrogated OPGL-induced beta-casein promoter activity. By contrast, OPGL stimulation did not result in STAT5 phosphorylation. In vivo immunohistochemistry studies further demonstrated defective nuclear translocation of C/EBPbeta, but normal STAT5 activation, in OPGL-deficient mice. These data show that OPGL is a critical activator of beta-casein gene expression via the transcription factor C/EBPbeta. Our data provide new insights into the understanding of the molecular events involved in milk protein gene expression.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Ontario Canc Inst, Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	Pohang University of Science & Technology (POSTECH); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Kong, YY (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	ykong@postech.ac.kr	Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BIKENMEIER EH, 1989, GENE DEV, V3, P1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	26	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5339	5344		10.1074/jbc.M108342200	http://dx.doi.org/10.1074/jbc.M108342200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11726661	hybrid			2022-12-25	WOS:000173962900101
J	Freywald, A; Sharfe, N; Roifman, CM				Freywald, A; Sharfe, N; Roifman, CM			The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; GANGLION-CELL AXONS; MEDIATED NEGATIVE REGULATION; SYK TYROSINE KINASE; C-CBL; SIGNALING PROTEINS; IN-VITRO; T-CELLS; PROTOONCOGENE PRODUCT	Uniquely for the Eph family of receptor tyrosine kinases, the EphB6 receptor is catalytically inactive due to the alteration of several critical residues in its kinase domain. This has cast doubt upon its ability to participate in cytoplasmic signaling events. We show here that despite its lack of kinase activity, EphB6 undergoes inducible tyrosine phosphorylation upon stimulation with the Eph-B receptor subfamily ligand ephrin-B1. We also demonstrate, for the first time, evidence of cross-talk between Eph receptors. Overexpression of a catalytically active member of the Eph-B subfamily, EphB1, resulted in increased EphB6 phosphorylation. EphB1-induced EphB6 phosphorylation was ligand-dependent and required the functional catalytic activity of EphB1. EphB1 not only transphosphorylated EphB6, but together they also formed a stable hetero-complex. In addition, we identify the proto-oncogene c-Cbl its an EphB6-binding protein. Although EphB6-Cb1 association appeared to be constitutive, Cbl required a functional phosphotyrosine binding domain in order to bind the receptor, whereas its RING finger motif ubiquitin-transfer domain was not necessary. Our findings demonstrate that EphB6 is an actively signaling receptor that undergoes transphosphorylation upon ligand binding and that can initiate specific cytoplasmic signaling events.	Hosp Sick Children, Res Inst, Injury & Repair Program, Dept Paediat Infect Immun Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roifman, CM (corresponding author), Hosp Sick Children, Res Inst, Injury & Repair Program, Dept Paediat Infect Immun Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	croifman@sickkids.on.ca						Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Ciossek T, 1998, EUR J NEUROSCI, V10, P1574, DOI 10.1046/j.1460-9568.1998.00180.x; Ciossek T, 1997, ONCOGENE, V14, P35, DOI 10.1038/sj.onc.1200800; Daniel TO, 1996, KIDNEY INT, V50, pS73; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073; Gurniak CB, 1996, ONCOGENE, V13, P777; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Hsueh YP, 1998, NEURON, V21, P1227, DOI 10.1016/S0896-6273(00)80641-8; JONGEWARD GD, 1995, GENETICS, V139, P1553; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Sakano S, 1996, ONCOGENE, V13, P813; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1999, J IMMUNOL, V162, P7133; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yue Y, 1999, J NEUROSCI, V19, P2090; Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163-7258(97)00112-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	64	86	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3823	3828		10.1074/jbc.M108011200	http://dx.doi.org/10.1074/jbc.M108011200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11713248	hybrid			2022-12-25	WOS:000173813900005
J	Singh, SP; Janecki, AJ; Srivastava, SK; Awasthi, S; Awasthi, YC; Xia, SJJ; Zimniak, P				Singh, SP; Janecki, AJ; Srivastava, SK; Awasthi, S; Awasthi, YC; Xia, SJJ; Zimniak, P			Membrane association of glutathione S-transferase mGSTA4-4, an enzyme that metabolizes lipid peroxidation products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; ALPHA-CLASS; IMMUNOHISTOCHEMICAL LOCALIZATION; IMMUNOCHEMICAL DETECTION; CRYSTAL-STRUCTURE; MOUSE LUNG; EXPRESSION; PI; RESISTANCE; PROTEIN	Lipid peroxidation products have signaling functions and at higher concentrations are toxic and may trigger cell death. The compounds are metabolized predominantly by glutathione S-transferases exemplified by mGSTA4-4, an enzyme highly efficient in glutathione conjugation of 4-hydroxyalkenals, and possessing glutathione peroxidase activity toward phospholipid hydroperoxides. mGSTA4-4 belongs to the predominant group of "canonical" glutathione S-transferases that are soluble and generally localized in the cytoplasm. The intracellular localization of mGSTA4-4 was examined in hepatocytes of normal mouse liver and in transfected HepG2 cells by fluorescence microscopy and digital deconvolution. mGSTA4-4 was found to be predominantly localized at or near the plasma membrane in transfected HepG2 cells, as well as in hepatocytes endogenously expressing the protein. In vitro, mGSTA4-4 associated with liposomes, and this interaction was potentiated when the liposomes contained negatively charged phospholipids. Mutating lysine 115 to glutamic acid resulted in a loss of the plasma membrane targeting of mGSTA4-4 as well as in a significant reduction of its binding to liposomes in vitro. These data suggest preferential targeting of mGSTA4-4 to the plasma membrane that may contain the major substrate(s) for this enzyme. Lysine 115 is critically important for the membrane association of mGSTA4-4, most likely by entering into an electrostatic interaction with negatively charged phospholipid headgroups.	Cent Arkansas Vet Healthcare Syst Med Res 151 LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Arlington	Zimniak, P (corresponding author), Cent Arkansas Vet Healthcare Syst Med Res 151 LR, 4300 W 7th St, Little Rock, AR 72205 USA.		Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NCI NIH HHS [CA77495, CA27967] Funding Source: Medline; NEI NIH HHS [EY04396] Funding Source: Medline; NIDDK NIH HHS [K08-DK02557] Funding Source: Medline; NIEHS NIH HHS [ES07804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077495, R01CA027967] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004396, R55EY004396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD H, 1988, ARCH BIOCHEM BIOPHYS, V266, P416, DOI 10.1016/0003-9861(88)90273-1; AISO S, 1989, J HISTOCHEM CYTOCHEM, V37, P1247, DOI 10.1177/37.8.2754254; Ali-Osman F, 1997, CLIN CANCER RES, V3, P2253; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Armstrong RN, 1998, CURR OPIN CHEM BIOL, V2, P618, DOI 10.1016/S1367-5931(98)80093-8; AWASTHI YC, 1996, GLUTATHIONE S TRANSF, P111; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Cohn JA, 1996, ARCH BIOCHEM BIOPHYS, V328, P158, DOI 10.1006/abbi.1996.0156; Dianzani MU, 1998, FREE RADICAL RES, V28, P553, DOI 10.3109/10715769809065811; Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184; ECKL PM, 1993, MUTAT RES, V290, P183, DOI 10.1016/0027-5107(93)90158-C; ENGELMAN DM, 1969, NATURE, V223, P1279, DOI 10.1038/2231279a0; ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Forkert PG, 1999, AM J RESP CELL MOL, V20, P143, DOI 10.1165/ajrcmb.20.1.3320; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; He NG, 1996, ARCH BIOCHEM BIOPHYS, V333, P214, DOI 10.1006/abbi.1996.0383; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; JENSSON H, 1986, FEBS LETT, V203, P207, DOI 10.1016/0014-5793(86)80743-8; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Krengel U, 1998, FEBS LETT, V422, P285, DOI 10.1016/S0014-5793(98)00026-X; MAIORINO M, 1986, ARCH BIOCHEM BIOPHYS, V251, P600, DOI 10.1016/0003-9861(86)90369-3; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matsuzaki K, 2000, BBA-BIOMEMBRANES, V1467, P219, DOI 10.1016/S0005-2736(00)00223-6; MEDH RD, 1991, BIOCHEM J, V278, P793, DOI 10.1042/bj2780793; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; POLSON A, 1990, IMMUNOL INVEST, V19, P253; Salinas AE, 1999, CURR MED CHEM, V6, P279; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; SUNDBERG AGM, 1993, PHARMACOL TOXICOL, V72, P321, DOI 10.1111/j.1600-0773.1993.tb01658.x; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; van Lieshout EMM, 1999, JPN J CANCER RES, V90, P530, DOI 10.1111/j.1349-7006.1999.tb00780.x; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; Xia H, 1998, ARCH BIOCHEM BIOPHYS, V353, P337, DOI 10.1006/abbi.1998.0668; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yeagle P., 1992, STRUCTURE BIOL MEMBR; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277; Zimniak L, 1997, TOXICOL APPL PHARM, V143, P221, DOI 10.1006/taap.1996.8070; ZIMNIAK P, 1992, FEBS LETT, V313, P173, DOI 10.1016/0014-5793(92)81438-R; ZIMNIAK P, 1994, J BIOL CHEM, V269, P992	56	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4232	4239		10.1074/jbc.M109678200	http://dx.doi.org/10.1074/jbc.M109678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11714719	hybrid			2022-12-25	WOS:000173813900060
J	Valjakka, J; Takkinenz, K; Teerinen, T; Soderlund, H; Rouvinen, J				Valjakka, J; Takkinenz, K; Teerinen, T; Soderlund, H; Rouvinen, J			Structural insights into steroid hormone binding - The crystal structure of a recombinant anti-testosterone Fab fragment in free and testosterone-bound forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; ELECTRON-DENSITY; SPECIFICITY; ANTIBODIES; COMPLEX; COMPLEMENTARITY; CLASSIFICATION; IMMUNOGLOBULINS	The monoclonal anti-testosterone antibody (3-C4F5) has a relatively high affinity (3 X 10(8) M-1) with an overall good specificity profile. However, the earlier characterized binding properties have shown that both the affinity and specificity of this antibody must be improved if it is intended for use in clinical immunoassays. In this paper, the crystal structures of the recombinant anti-testosterone (3-C4F5) Fab fragment have been determined in the testosterone-bound and free form at resolutions of 2.60 and 2.72 Angstrom, respectively. The high affinity binding of the (3-C4F5 Fab is mainly determined by shape complementarity between the protein and testosterone. Only one direct hydrogen bond is formed between the hydroxyl group of the testosterone D-ring and the main-chain oxygen of Gly100(J)H. The testosterone is deeply bound in a hydrophobic pocket, and the close shape complementarity is mainly formed by the third complementarity-determining regions (CDR) of the heavy and light chain. Comparison of the bound structure with the free structure indicates conformational changes in the protein upon testosterone binding. The conformational changes of the side chains, of two residues Glu95H and Tyr99H in the CDR-H3 are particularly essential for the binding. Interesting similarities in the binding of different steroids were also observed upon comparison of the available structures of anti-steroid antibodies.	Univ Joensuu, Dept Chem, FIN-80101 Joensuu, Finland; VTT Biotechnol, Espoo 02044, Finland	University of Eastern Finland; VTT Technical Research Center Finland	Valjakka, J (corresponding author), Univ Joensuu, Dept Chem, POB 111, FIN-80101 Joensuu, Finland.			Teerinen, Tuija/0000-0002-5315-8579				AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GANI M, 1994, J STEROID BIOCHEM, V48, P277, DOI 10.1016/0960-0760(94)90156-2; Hemminki A, 1998, IMMUNOTECHNOLOGY, V4, P59, DOI 10.1016/S1380-2933(98)00002-5; Hemminki A, 1998, PROTEIN ENG, V11, P311, DOI 10.1093/protein/11.4.311; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; ISMAIL AAA, 1986, ANN CLIN BIOCHEM, V23, P113, DOI 10.1177/000456328602300201; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; JEFFREY PD, 1995, J MOL BIOL; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABAT EA, 1991, SEQUENCES PROTEIN IM; Kim ST, 1999, PROTEINS, V37, P683, DOI 10.1002/(SICI)1097-0134(19991201)37:4<683::AID-PROT17>3.0.CO;2-D; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martin ACR, 1996, J MOL BIOL, V263, P800, DOI 10.1006/jmbi.1996.0617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oliva B, 1998, J MOL BIOL, V279, P1193, DOI 10.1006/jmbi.1998.1847; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACK P, 1993, BIO-TECHNOL, V11, P1271; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Stanfield RL., 1993, IMMUNOMETHODS, V3, P211, DOI 10.1006/immu.1993.1055; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; Valjakka J, 2000, ACTA CRYSTALLOGR D, V56, P218, DOI 10.1107/S0907444999016224; Wallimann P, 1997, CHEM REV, V97, P1567, DOI 10.1021/cr960373b; Wang C, 1997, ANN MED, V29, P365, DOI 10.3109/07853899708999363; WHEELER MJ, 1994, IMMUNOASSAY HDB, P365; WILKE TJ, 1987, CLIN CHEM, V33, P1372; Yang C, 1999, ACTA CRYSTALLOGR D, V55, P1681, DOI 10.1107/S090744499900997X	42	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4183	4190		10.1074/jbc.M105579200	http://dx.doi.org/10.1074/jbc.M105579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11707437	hybrid			2022-12-25	WOS:000173813900054
J	Zhan, Y; Virbasius, JV; Song, X; Pomerleau, DP; Zhou, GW				Zhan, Y; Virbasius, JV; Song, X; Pomerleau, DP; Zhou, GW			The p40(phox) and p47(phox) PX domains of NADPH oxidase target cell membranes via direct and indirect recruitment by phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SIGNALING PATHWAYS; ACTIVATION; INSULIN; BINDING; 3-KINASE; P67(PHOX); SURVIVAL; KINASE	The Phox homology (PX) domain has recently been reported to bind to phosphoinositides, and some PX domains can localize to endosomes in vivo. Here we show data to support the conclusion that the p40(phox) PX domain binds to phosphatidylinositol 3-phosphate specifically in vitro and localizes to endosomes in intact cells. In addition, its Y59A/L65Q mutant, which has decreased affinity for phosphatidylinositol 3-phosphate in vitro, fails to target EGFP-p40-PX to endosomes. However, unlike published results, we find that the p47(phox) PX domain weakly binds to many phosphoinositides in vitro showing slightly higher affinity for phosphatidylinositol 3,4,5-trisphosphate. Moreover, we show for the first time that upon insulin-like growth factor-1 stimulation of COS cells, the p47(phox) PX domain is localized to the plasma membrane, and this subcellular localization is dependent on PI 3-kinase activity. Unexpectedly, its R42Q mutant that loses in vitro phosphoinositide-binding ability can still target EGFP-p47-PX to the plasma membrane. Our data suggest that the translocation of p47(phox) PX domain to the plasma membrane does involve 3'-phosphoinositide(s) in the process, but the phosphoinositide-binding of p47(phox) PX domain is not sufficient to recruit it to the plasma membrane. Therefore, the p40(phox) and p47(phox) PX domains can target subcellular membranes via direct or indirect recruitment by phosphoinositides, while both are under the control of phosphatidylinositol 3-kinase activity.	Univ Massachusetts, Sch Med, Program Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Zhou, GW (corresponding author), Univ Massachusetts, Sch Med, Program Mol Biol, 373 Plantat St, Worcester, MA 01605 USA.	wayne.zhou@umassmed.edu		Virbasius, Joseph/0000-0003-1784-6793				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebisu K, 2001, J BIOL CHEM, V276, P24498, DOI 10.1074/jbc.M101122200; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Sorisky A, 1996, OBES RES, V4, P9, DOI 10.1002/j.1550-8528.1996.tb00507.x; Tsunawaki S, 2000, J BIOCHEM-TOKYO, V128, P777, DOI 10.1093/oxfordjournals.jbchem.a022815; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yamamori T, 2000, FEBS LETT, V467, P253, DOI 10.1016/S0014-5793(00)01167-4; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200	40	149	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4512	4518		10.1074/jbc.M109520200	http://dx.doi.org/10.1074/jbc.M109520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729195	hybrid			2022-12-25	WOS:000173813900094
J	Choi, IR; White, KA				Choi, IR; White, KA			An RNA activator of subgenomic mRNA1 transcription in tomato bushy stunt virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOCK HOUSE VIRUS; COAT PROTEIN; GENE-EXPRESSION; SEQUENCE; ELEMENT; GENOME; ORGANIZATION; PROMOTER; REGION; DISTAL	Many (+)-strand RNA viruses transcribe small subgenomic (sg) mRNAs that allow for regulated expression of a subset of their genes. Tomato bushy stunt virus (TBSV) transcribes two such messages and here we report the identification of a long-distance RNA-RNA interaction that is essential for the efficient accumulation of capsid protein-encoding sg mRNA1 The relevant base pairing interaction occurs within the TBSV RNA genome between a 7-nucleotide (nt) long sequence, separated by just 3 nt from the downstream sg mRNA1 initiation site, and a complementary sequence positioned some similar to1000 nt further upstream. Analyses of this interaction indicate that it (i) functions in the (+)-strand, (ii) modulates both (+)- and (-)-strand sg mRNA1 accumulation, (iii) specifically regulates the accumulation of sg mRNA1 (-)-strands, (iv) controls sg mRNA1 expression from an ectopic transcriptional initiation site, (v) may occur in cis and, and (vi) could nucleate the formation of a more complex RNA structure. These data are most consistent with a role for this interaction in regulating sg mRNA1 accumulation at the level of transcription.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada	York University - Canada	White, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	kawhite@yorku.ca						Batey RT, 1999, ANGEW CHEM INT EDIT, V38, P2327; Choi IR, 2001, J BIOL CHEM, V276, P41761, DOI 10.1074/jbc.M106727200; HEARNE PQ, 1990, VIROLOGY, V177, P141, DOI 10.1016/0042-6822(90)90468-7; HILLMAN BI, 1989, VIROLOGY, V169, P42, DOI 10.1016/0042-6822(89)90039-1; JOHNSTON JC, 1995, VIROLOGY, V214, P100, DOI 10.1006/viro.1995.9950; Kim KH, 1997, VIROLOGY, V232, P187, DOI 10.1006/viro.1997.8565; Kim KH, 1999, RNA, V5, P636, DOI 10.1017/S1355838299982006; Maia IG, 1996, PLANT MOL BIOL, V32, P367, DOI 10.1007/BF00039391; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miller WA, 2000, VIROLOGY, V273, P1, DOI 10.1006/viro.2000.0421; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; Oster SK, 1998, J VIROL, V72, P5845, DOI 10.1128/JVI.72.7.5845-5851.1998; Pasternak AO, 2000, J VIROL, V74, P11642, DOI 10.1128/JVI.74.24.11642-11653.2000; Price BD, 2000, J VIROL, V74, P11724, DOI 10.1128/JVI.74.24.11724-11733.2000; Ray D, 1999, VIROLOGY, V256, P162, DOI 10.1006/viro.1999.9630; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; TAVAZZA M, 1994, J GEN VIROL, V75, P1515, DOI 10.1099/0022-1317-75-7-1515; van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; WHITE KA, 1994, J VIROL, V68, P14, DOI 10.1128/JVI.68.1.14-24.1994; Wu BD, 2001, J MOL BIOL, V305, P741, DOI 10.1006/jmbi.2000.4298; Wu BD, 1999, J VIROL, V73, P8982, DOI 10.1128/JVI.73.11.8982-8988.1999; Zhang GC, 1999, RNA, V5, P550, DOI 10.1017/S1355838299982080; ZHONG WD, 1993, J VIROL, V67, P2716, DOI 10.1128/JVI.67.5.2716-2722.1993; Zuker M., 1999, V70, P11	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3760	3766		10.1074/jbc.M109067200	http://dx.doi.org/10.1074/jbc.M109067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714712	hybrid			2022-12-25	WOS:000173688000091
J	Richter, CD; Allen, JWA; Higham, CW; Koppenhofer, A; Zajicek, RS; Watmough, NJ; Ferguson, SJ				Richter, CD; Allen, JWA; Higham, CW; Koppenhofer, A; Zajicek, RS; Watmough, NJ; Ferguson, SJ			Cytochrome cd(1), reductive activation and kinetic analysis of a multifunctional respiratory enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; NITRITE REDUCTASE; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-AERUGINOSA; OXIDASE REACTION; C-DOMAIN; HEME; PSEUDOAZURIN; PURIFICATION	Paracoccus pantotrophus cytochrome cd(1) is an enzyme of bacterial respiration, capable of using nitrite in vivo and also hydroxylamine and oxygen in vitro as electron acceptors. We present a comprehensive analysis of the steady state kinetic properties of the enzyme with each electron acceptor and three electron donors, pseudoazurin and cytochrome c(550), both physiological, and the non-physiological horse heart cytochrome c. At pH 5.8, optimal for nitrite reduction, the enzyme has a turnover number up to 121 s(-1) per d(1) heme, significantly higher than previously observed for any cytochrome cd(1). Pre-activation of the enzyme via reduction is necessary to establish full catalytic competence with any of the electron donor proteins. There is no significant kinetic distinction between the alternative physiological electron donors in any respect, providing support for the concept of pseudospecificity, in which proteins with substantially different tertiary structures can transfer electrons to the same acceptor. A low level hydroxylamine disproportionase activity that may be an intrinsic property of cytochromes c is also reported. Important implications for the enzymology of P. pantotrophus cytochrome cd(1) are discussed and proposals are made about the mechanism of reduction of nitrite, based on new observations placed in the context of recent rapid reaction studies.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oxford; University of East Anglia	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ferguson@bioch.ox.ac.uk	Watmough, Nicholas J/A-6643-2010	Watmough, Nicholas J/0000-0001-5901-6750				Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; ALLEN JWA, 2001, HDB METALLOPROTEINS, P424; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; Diederix REM, 2001, EUR J BIOCHEM, V268, P4207, DOI 10.1046/j.1432-1327.2001.02335.x; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Gordon EHJ, 2001, BIOCHEM BIOPH RES CO, V281, P788, DOI 10.1006/bbrc.2001.4425; HILL KE, 1978, J BIOL CHEM, V253, P489; HORIO T, 1960, BIOCHEM J, V77, P194, DOI 10.1042/bj0770194; HULSE CL, 1988, ANAL BIOCHEM, V172, P420, DOI 10.1016/0003-2697(88)90464-2; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; KAYE GWC, 1966, TABLES PHYSICAL CHEM, P153; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Kobayashi K, 2001, BIOCHEMISTRY-US, V40, P8542, DOI 10.1021/bi002534i; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOPPENHOFER A, 1998, THESIS U OXFORD OXFO; Koutny M, 1999, FEBS LETT, V448, P157, DOI 10.1016/S0014-5793(99)00345-2; Leung YC, 1997, BIOCHEM J, V321, P699, DOI 10.1042/bj3210699; Lopes H, 2001, J BIOL INORG CHEM, V6, P55, DOI 10.1007/s007750000159; MARTINKUS K, 1980, ARCH BIOCHEM BIOPHYS, V199, P465, DOI 10.1016/0003-9861(80)90303-3; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PEARSON IV, 2000, THESIS U OXFORD OXFO; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; ROBINSON MK, 1979, BIOCHEMISTRY-US, V18, P3921, DOI 10.1021/bi00585a012; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMYN B, 1994, EUR J BIOCHEM, V219, P585, DOI 10.1111/j.1432-1033.1994.tb19974.x; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1974, BIOCHIM BIOPHYS ACTA, V333, P28, DOI 10.1016/0005-2728(74)90159-5; Sjogren T, 2001, J BIOL CHEM, V276, P13072, DOI 10.1074/jbc.M011312200; Sjogren T, 2001, J BIOL CHEM, V276, P29450, DOI 10.1074/jbc.M103657200; Steensma E, 2001, J BIOL CHEM, V276, P5846, DOI 10.1074/jbc.M007345200; TIMKOVICH R, 1982, ARCH BIOCHEM BIOPHYS, V215, P47, DOI 10.1016/0003-9861(82)90277-6; TORDI MG, 1985, BIOCHEM J, V230, P797, DOI 10.1042/bj2300797; WEEGAERSSENS E, 1991, J BIOL CHEM, V266, P7496; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; YAMANAKA T, 1961, BIOCHIM BIOPHYS ACTA, V53, P294, DOI 10.1016/0006-3002(61)90442-5	48	50	54	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3093	3100		10.1074/jbc.M108944200	http://dx.doi.org/10.1074/jbc.M108944200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11709555	hybrid			2022-12-25	WOS:000173688000007
J	Kawamura, H; Tomozoe, Y; Akagi, T; Kamei, D; Ochiai, M; Yamada, M				Kawamura, H; Tomozoe, Y; Akagi, T; Kamei, D; Ochiai, M; Yamada, M			Identification of the nucleocytoplasmic shuttling sequence of heterogeneous nuclear ribonucleoprotein D-like protein JKTBP and its interaction with mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA BINDING-PROTEINS; MESSENGER-RNA; HNRNP A1; MOLECULAR CHARACTERIZATION; TRANSPORT SIGNAL; EXPORT PATHWAY; IMPORT PATHWAY; EXPRESSION; CYTOPLASM; CLONING	JKTBP proteins are related to a family of heterogeneous nuclear ribonucleoproteins (hnRNPs) that function in mRNA biogenesis and mRNA metabolism. JKTBP proteins constituted of isoforms 1, 2, and 1Delta6 are localized in the nucleus. We show that the dominant form JKTBP1 shuttles between the nucleus and the cytoplasm and interacts with mRNA. Immunofluoreseence microscopy and immunoblotting of the subcellular fractions and overexpression of JKTBP tagged with green fluorescent protein indicated that JKTBP1 and JKTBPIDelta6, but not JKTBP2, accumulate in the cytoplasm upon polymerase II transcription inhibition. After release from inhibition, the return of accumulated cytoplasmic JKTBP to the nucleus was temperature-dependent. In heterokaryons, green fluorescent protein-tagged JKTBP1 and JKTBP1Delta6 migrated from the HeLa nucleus to the mouse nucleus, but JKTBP2 did not. Using various JKTBP deletion mutants, the 25-residue C-terminal tail was identified as a shuttling sequence like M9. It is conserved in the C-terminal tails of hnRNP D/AUF1 and type A/B hnRNP/ABBP-1. Analysis of its sequence-specific interacting protein indicated that JKTBP nuclear import is mediated by the receptor transportin 1/karyopherin beta2. UV cross-linking revealed the increased occurrence of JKTBP1 directly interacting with poly(A)(+) RNA in the cytoplasm following actinomycin D treatment. We discuss a role of JKTBP in mRNA nuclear export.	Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan	Yokohama City University	Yamada, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan.	myamada@yokohama-cu.ac.jp	Akagi, Tadayuki/E-1078-2011	Akagi, Tadayuki/0000-0002-1733-9452				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Akagi T, 2000, GENE, V245, P267, DOI 10.1016/S0378-1119(00)00032-9; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Doi A, 1998, BBA-GENE STRUCT EXPR, V1396, P51, DOI 10.1016/S0167-4781(97)00223-6; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Kamei D, 1999, GENE, V228, P13, DOI 10.1016/S0378-1119(99)00020-7; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakashima K, 1999, J BIOL CHEM, V274, P27786, DOI 10.1074/jbc.274.39.27786; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Sambrook J., 1989, MOL CLONING, pA1; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1998, MOL CELL BIOL, V18, P4141, DOI 10.1128/MCB.18.7.4141; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; Vautier D, 2001, J CELL SCI, V114, P1521; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	44	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2732	2739		10.1074/jbc.M108477200	http://dx.doi.org/10.1074/jbc.M108477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705999	hybrid			2022-12-25	WOS:000173421500048
J	Kvaratskhelia, M; Wardleworth, BN; Bond, CS; Fogg, JM; Lilley, DMJ; White, MF				Kvaratskhelia, M; Wardleworth, BN; Bond, CS; Fogg, JM; Lilley, DMJ; White, MF			Holliday junction resolution is modulated by archaeal chromatin components in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-VII CLEAVES; RESOLVING ENZYMES; PYROCOCCUS-FURIOSUS; DNA JUNCTIONS; SEQUENCE; BINDING; SPECIFICITY; RESOLVASES; RUVC; HJC	The Holliday junction-resolving enzyme Me is conserved in the archaea and probably plays a role analogous to that of Escherichia coli RuvC in the pathway of homologous recombination. Me specifically recognizes four-way DNA junctions, cleaving them without sequence preference to generate recombinant DNA duplex products. Hjc imposes an X-shaped global conformation on the bound DNA junction and distorts base stacking around the point of cleavage, three nucleotides 3' of the junction center. We show that Me is autoinhibitory under single turnover assay conditions and that this can be relieved by the addition of either competitor duplex DNA or the architectural double-stranded DNA-binding protein Sso7d (i.e. by approximating in vivo conditions more closely). Using a combination of isothermal titration calorimetry and fluorescent resonance energy transfer, we demonstrate that multiple Hjc dimers can bind to each synthetic four-way junction and provide evidence for significant distortion of the junction structure at high protein:DNA ratios. Analysis of crystal packing interactions in the crystal structure of Hjc suggests a molecular basis for this autoinhibition. The wider implications of these findings for the quantitative study of DNA-protein interactions is discussed.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of St Andrews; University of Dundee	White, MF (corresponding author), Univ St Andrews, Ctr Biomol Sci, N Haugh, St Andrews KY16 9ST, Fife, Scotland.	mfw2@st-and.ac.uk	White, Malcolm F/A-6055-2010; Bond, Charles S/B-4094-2011; Bond, Charles/AAF-9608-2020	White, Malcolm F/0000-0003-1543-9342; Bond, Charles S/0000-0002-9584-6783; Bond, Charles/0000-0002-9584-6783	Cancer Research UK [11722] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Agback P, 1998, NAT STRUCT BIOL, V5, P579, DOI 10.1038/836; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Birkenbihl RP, 2001, J MOL BIOL, V309, P1067, DOI 10.1006/jmbi.2001.4761; BOND CS, 2001, P NATL ACAD SCI USA, V1, P1; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Eggleston AK, 2000, J BIOL CHEM, V275, P26467, DOI 10.1074/jbc.M001496200; Fogg JM, 1999, BIOCHEMISTRY-US, V38, P11349, DOI 10.1021/bi990926n; Fogg JM, 2001, J MOL BIOL, V313, P751, DOI 10.1006/jmbi.2001.5081; Garcia AD, 2000, P NATL ACAD SCI USA, V97, P8926, DOI 10.1073/pnas.150238697; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, J BIOL CHEM, V275, P40385, DOI 10.1074/jbc.M006294200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; Kvaratskhelia M, 2001, FEBS LETT, V491, P243, DOI 10.1016/S0014-5793(01)02200-1; Kvaratskhelia M, 1999, BIOCHEMISTRY-US, V38, P16613, DOI 10.1021/bi9921788; Lilley DMJ, 2000, P NATL ACAD SCI USA, V97, P9351, DOI 10.1073/pnas.97.17.9351; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MUELLER JE, 1988, P NATL ACAD SCI USA, V85, P9441, DOI 10.1073/pnas.85.24.9441; Nishino T, 2001, STRUCTURE, V9, P197, DOI 10.1016/S0969-2126(01)00576-7; Sandman K, 2000, ARCH MICROBIOL, V173, P165, DOI 10.1007/s002039900122; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166	27	16	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2992	2996		10.1074/jbc.M109496200	http://dx.doi.org/10.1074/jbc.M109496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11709558	hybrid			2022-12-25	WOS:000173421500081
J	Vaillancourt, FH; Labbe, G; Drouin, NM; Fortin, PD; Eltis, LD				Vaillancourt, FH; Labbe, G; Drouin, NM; Fortin, PD; Eltis, LD			The mechanism-based inactivation of 2,3-dihydroxybiphenyl 1,2-dioxygenase by catecholic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE(II) ACTIVE-SITE; PSEUDOMONAS-PUTIDA; POLYCHLORINATED-BIPHENYLS; EXTRADIOL DIOXYGENASES; MICROBIAL-DEGRADATION; PROTOCATECHUATE 4,5-DIOXYGENASE; EVOLUTIONARY RELATIONSHIPS; SUICIDE INACTIVATION; CRYSTAL-STRUCTURE; SERINE HYDROLASE	2,3-Dihydroxybiphenyl 1,2-dioxygenase (EC 1.13.11.39), the extradiol dioxygenase of the biphenyl biodegradation pathway, is subject to inactivation during the steady-state cleavage of catechols. Detailed analysis revealed that this inactivation was similar to the O-2-dependent inactivation of the enzyme in the absence of catecholic substrate, resulting in oxidation of the active site Fe(II) to Fe(III). Interestingly, the catecholic substrate not only increased the reactivity of the enzyme with O-2 to promote ring cleavage but also increased the rate of O-2-dependent inactivation. Thus, in air-saturated buffer, the apparent rate constant of inactivation of the free enzyme was (0.7 +/- 0.1) x 10(-3) s(-1) versus (3.7 +/- 0.4) x 10(-3) s(-1) for 2,3-dihydroxybiphenyl, the preferred catecholic substrate of the enzyme, and (501 +/- 19) x 10(-3) s(-1) for 3-chlorocatechol, a potent inactivator of 2,3-dihydroxybiphenyl 1,2-dioxygenase (partition coefficient = 8 +/- 2, K-m(app) = 4.8 +/- 0.7 muM). The 2,3-dihydroxybiphenyl 1,2-dioxygenase-catalyzed cleavage of 3-chlorocatechol yielded predominantly 2-pyrone-6-carboxylic acid and 2-hydroxymuconic acid, consistent with the transient formation of an acyl chloride. However, the enzyme was not covalently modified by this acyl chloride in vitro or in vivo. The study suggests a general mechanism for the inactivation of extradiol dioxygenases during catalytic turnover involving the dissociation of superoxide from the enzyme-catecholic-dioxygen ternary complex and is consistent with the catalytic mechanism.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ Laval, Dept Biochem, St Foy, PQ G1K 7P4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Laval University	Eltis, LD (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Labbé, Geneviève/N-4531-2017; Eltis, Lindsay D/J-8272-2015	Labbé, Geneviève/0000-0001-9720-7574; Eltis, Lindsay D/0000-0002-6774-8158; Fortin, Pascal/0000-0001-9796-791X				ADAMS RH, 1992, APPL ENVIRON MICROB, V58, P647, DOI 10.1128/AEM.58.2.647-654.1992; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; ARCIERO DM, 1986, J BIOL CHEM, V261, P2170; ARENSDORF JJ, 1994, APPL ENVIRON MICROB, V60, P2884, DOI 10.1128/AEM.60.8.2884-2889.1994; ASTURIAS JA, 1993, J BACTERIOL, V175, P4631, DOI 10.1128/JB.175.15.4631-4640.1993; AUSUBEL FM, 2000, CURRENT PROTOCOLS MO, pCH1; AVDEEF A, 1978, J AM CHEM SOC, V100, P5362, DOI 10.1021/ja00485a018; BARTELS I, 1984, APPL ENVIRON MICROB, V47, P500, DOI 10.1128/AEM.47.3.500-505.1984; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER G, 1993, FREE RADICAL RES COM, V19, P79; Bugg TDH, 2001, CHEM COMMUN, P941, DOI 10.1039/b100484k; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CERDAN P, 1993, EMBO J, V12, P3339; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DUGGLEBY RG, 1986, J THEOR BIOL, V123, P67, DOI 10.1016/S0022-5193(86)80236-3; Eltis LD, 1996, J BACTERIOL, V178, P5930, DOI 10.1128/jb.178.20.5930-5937.1996; ESCRIBANO J, 1989, BIOCHEM J, V262, P597, DOI 10.1042/bj2620597; Fornstedt-Wallin B, 1999, EUR J PHARMACOL, V386, P15, DOI 10.1016/S0014-2999(99)00683-4; FURUKAWA K, 1979, APPL ENVIRON MICROB, V38, P301, DOI 10.1128/AEM.38.2.301-310.1979; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HORI K, 1973, J BIOCHEM, V74, P375; Hugo N, 2000, J BACTERIOL, V182, P5580, DOI 10.1128/JB.182.19.5580-5585.2000; Kaschabek SR, 1998, J BACTERIOL, V180, P296, DOI 10.1128/JB.180.2.296-302.1998; KLECKA GM, 1981, APPL ENVIRON MICROB, V41, P1159, DOI 10.1128/AEM.41.5.1159-1165.1981; KOONTZ WA, 1976, J BIOL CHEM, V251, P368; LADU BN, 1958, J BIOL CHEM, V230, P251; Lin G, 2001, J AM CHEM SOC, V123, P5030, DOI 10.1021/ja004280u; Liu A, 2001, J AM CHEM SOC, V123, P5126, DOI 10.1021/ja005879x; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753; MITCHELL RA, 1963, J BIOL CHEM, V238, P1151; Nerdinger S, 1999, CHEM COMMUN, P2259, DOI 10.1039/a907279i; NOZAKI M, 1968, J BIOL CHEM, V243, P2682; NOZAKI M, 1963, BIOCHEM Z, V338, P582; PARLI CJ, 1980, ARCH BIOCHEM BIOPHYS, V203, P161, DOI 10.1016/0003-9861(80)90164-2; POLISSI A, 1995, EUR J BIOCHEM, V229, P113; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; RAFF R, 1992, ENCY CHEM TECHNOLOGY, V11, P462; Riegert U, 1998, J BACTERIOL, V180, P2849, DOI 10.1128/JB.180.11.2849-2853.1998; Riegert U, 2001, J BACTERIOL, V183, P2322, DOI 10.1128/JB.183.7.2322-2330.2001; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; SANVOISIN J, 1995, J AM CHEM SOC, V117, P7836, DOI 10.1021/ja00134a041; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; Seah SYK, 1998, J BIOL CHEM, V273, P22943, DOI 10.1074/jbc.273.36.22943; Seah SYK, 2000, J BIOL CHEM, V275, P15701, DOI 10.1074/jbc.275.21.15701; SEEGER M, 1995, APPL ENVIRON MICROB, V61, P2654, DOI 10.1128/AEM.61.7.2654-2658.1995; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SONDOSSI M, 1992, APPL ENVIRON MICROB, V58, P485, DOI 10.1128/AEM.58.2.485-495.1992; Spence EL, 1996, J AM CHEM SOC, V118, P8336, DOI 10.1021/ja9607704; Sugimoto K, 1999, STRUCTURE, V7, P953, DOI 10.1016/S0969-2126(99)80122-1; Sutherland MW, 1997, FREE RADICAL RES, V27, P283, DOI 10.3109/10715769709065766; TUDELA J, 1987, BIOCHIM BIOPHYS ACTA, V912, P408, DOI 10.1016/0167-4838(87)90046-X; Uragami Y, 2001, J INORG BIOCHEM, V83, P269, DOI 10.1016/S0162-0134(00)00172-0; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887; WALSH JL, 1994, BRAIN RES BULL, V33, P513, DOI 10.1016/0361-9230(94)90076-0; WASSERFALLEN A, 1991, BIO-TECHNOL, V9, P296, DOI 10.1038/nbt0391-296; WASSERFALLEN A, 1989, THESIS U GENEVA; Winfield CJ, 2000, J CHEM SOC PERK T 1, P3277, DOI 10.1039/b004265j; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Zhao ZS, 1998, BIOCHEM PHARMACOL, V56, P825, DOI 10.1016/S0006-2952(98)00222-6	68	93	95	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2019	2027		10.1074/jbc.M106890200	http://dx.doi.org/10.1074/jbc.M106890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707443	hybrid			2022-12-25	WOS:000173421300056
J	Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B				Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B			Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP	ONCOGENE			English	Article						oncogene; transcription; hematopoiesis; differentiaion; leukemia	AVIAN MYELOMONOCYTIC CELLS; V-MYB; PROMONOCYTIC LEUKEMIAS; RAPID INDUCTION; LEUCINE-ZIPPER; MYELOID GENES; MIM-1 GENE; ACTIVATION; BETA; MUTATIONS	Oncogenic activation of c-myb by retroviral insertion has been implicated fit tumor formation in chicken and mice. These genetic alterations result in deregulated expression of the: c-myb gene and frequently in, N-terminal truncation of the c-Myb: protein. We demonstrate that truncation of the c-Myb N-terminus affects DNA binding and reporter activation. However, all three mutants, Myb Delta N20, Myb Delta N47 and Myb Delta N71 cooperated with C/EBP beta in reporter assays. In contrast to Myb Delta N20 and Myb Delta N47, however, the Myb Delta N71 mutant failed to activate the chromatin, embedded endogenous mim-1 gene together with C/EBP beta. This suggests that an N-terminal region (amino acids 47-71) within repeat 1 (R1), of the murine c-Myb DNA binding domain affects activation of chromosomal target genes in collaboration with C/EBP beta.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Abt Biochem & Mol Biol, Pauwels Str 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	Leutz, Achim/K-9643-2013; Luscher, Bernhard/A-7330-2011	Leutz, Achim/0000-0001-8259-927X; Luscher, Bernhard/0000-0002-9622-8709				Brendeford EM, 1997, J BIOL CHEM, V272, P4436, DOI 10.1074/jbc.272.7.4436; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEG J, 1995, ONCOGENE, V10, P2221; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKANO T, 1992, ONCOGENE, V7, P527; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	35	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7420	7424		10.1038/sj.onc.1204922	http://dx.doi.org/10.1038/sj.onc.1204922			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704872				2022-12-25	WOS:000171894200015
J	Polontchouk, L; Ebelt, B; Jackels, M; Dhein, S				Polontchouk, L; Ebelt, B; Jackels, M; Dhein, S			Chronic effects of endothelin-1 and angiotensin-II on gap junctions and intercellular communication in cardiac cells	FASEB JOURNAL			English	Article						connexin; endothelin; angiotensin; MAPKs	CONDUCTANCE; SYSTEM; EXPRESSION; CONNEXIN43; RECEPTOR; PROTEIN	Endothelin-1 (ET-1) and angiotensin-II (AT-II) participate in the pathophysiology of cardiovascular diseases. Regulation of gap junctional intercellular communication may influence heart function and its response to cardiac injury. In this study, we examined the effects of ET-1 and AT-II on connexin43 (Cx43) and connexin40 (Cx40) in cultured neonatal rat ventricular cardiomyocytes (NRCs) and the role of mitogen-activated protein kinase signaling in the ET-1-and AT-II-induced responses. NRCs were incubated for 24 h with either ET-1 or AT-II (each at concentrations ranging from 10 to 1000 nM), and Cx43 expression and phosphorylation increased with increasing concentrations of both. ET-1 effects were significantly blocked by ETA (BQ123), but not by ETB (BQ788), receptor antagonists. AT-II-induced Cx43 induction could be completely inhibited by the AT(1) receptor antagonist losartan. In contrast to Cx43, Cx40 expression did not change in either ET-1- or in AT-II-treated NRCs. Thus, these two connexins were differentially regulated. ET-1 and AT-II increased the gap junctional conductance between the cardiomyocytes in culture as measured using a dual-cell voltage clamp. Mitogen-activated protein kinase inhibition revealed that ERK1/2 was critical for up-regulation of Cx43 in response to ET-1, whereas both ERK and p38 signal pathways were involved in the regulation of Cx43 by AT-II. Thus, stimulation of the ERK and p38 signal pathways via ETA and AT1 receptors may partcipate in the regulation of cardiac gap junctions under (patho) physiological conditions.	Univ Halle Wittenberg, Inst Pharmacol, D-06097 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Dhein, S (corresponding author), Univ Leipzig, Herzzentrum, Clin Cardiac Surg, Russenstr 19, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de						ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; DEGASPARO M, 1994, EUR HEART J, V15, P98, DOI 10.1093/eurheartj/15.suppl_D.98; Dietz R., 1999, Thrombosis and Haemostasis, V82, P73; Dodge SM, 1998, J AM COLL CARDIOL, V32, P800, DOI 10.1016/S0735-1097(98)00317-9; FIREK L, 1995, J MOL CELL CARDIOL, V27, P1633, DOI 10.1016/S0022-2828(95)90623-1; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Haefliger JA, 2001, KIDNEY INT, V60, P190, DOI 10.1046/j.1523-1755.2001.00786.x; Hollenberg NK, 2000, HYPERTENSION, V35, P150, DOI 10.1161/01.HYP.35.1.150; Kobayashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1197, DOI 10.1152/ajpheart.1999.276.4.H1197; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maki S, 1998, J CARDIOVASC PHARM, V31, pS412, DOI 10.1097/00005344-199800001-00118; McEwan PE, 2000, J CARDIOVASC PHARM, V36, pS144, DOI 10.1097/00005344-200036051-00045; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Muller A, 1999, AM J PHYSIOL-CELL PH, V276, pC980, DOI 10.1152/ajpcell.1999.276.4.C980; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Poenicke Klaus, 1997, British Journal of Pharmacology, V121, P118; Rossi GP, 1999, CARDIOVASC RES, V43, P300, DOI 10.1016/S0008-6363(99)00110-8; Shyu KG, 2001, J MOL CELL CARDIOL, V33, P691, DOI 10.1006/jmcc.2000.1333; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Yamazaki T, 1999, ANN NY ACAD SCI, V874, P38, DOI 10.1111/j.1749-6632.1999.tb09223.x	21	103	106	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					87	+		10.1096/fj.01-0381fje	http://dx.doi.org/10.1096/fj.01-0381fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709493				2022-12-25	WOS:000172420500033
J	Yoon, SO; Kim, MM; Park, SJ; Kim, D; Chung, J; Chung, AS				Yoon, SO; Kim, MM; Park, SJ; Kim, D; Chung, J; Chung, AS			Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways	FASEB JOURNAL			English	Article						survival signal; mitochondria membrane potential; cell proliferation	SIGNAL-REGULATING KINASE; CYTOCHROME-C; DEATH; AKT; MITOCHONDRIA; THIOREDOXIN; MECHANISMS; CASPASE-3; RELEASE	The relationship between selenium and signal molecules has not been well elucidated. It was found that physiological concentration of selenite, <3 <mu>M, reduced ASK1 activity and induced PI3-kinase (PI3-K)/Akt pathways in HT1080 cells. Duration of these signal molecules by selenite was much longer than that by growth factors and other stresses. The longer duration time of these signal molecules may be important to maintain normal functions against stresses. Selenite increased cell proliferation through up-regulation of Bcl-2 expression, mitochondrial membrane potential, adenosine triphosphate (ATP) generation, and glucose uptake mediated by PI3-K pathway. High concentration of H2O2 increased an apoptotic signal molecule, ASK1, which resulted in Bcl-2 down-regulation, membrane potential disruption, decreased ATP and glucose uptake, and activation of caspases. However, an antiapoptotic signal molecule, Akt, was activated also by H2O2, but duration of its activation was much shorter. Selenite blocked apoptosis induced by H2O2, which was related to blocking ASK1 and further stimulating PI3-kinase/Akt activities. Selenite blocked mitochondrial membrane potential disruption by 400 muM H2O2. Selenite also blocked caspase-9 and -3 activities and apoptosis induced by 500 muM H2O2, even after mitochondrial membrane potential disruption. These observations demonstrate that selenite increases cell proliferation and maintains cell survival by activating the antiapoptotic signal and blocking the apoptotic signal.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, AS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	aschung@mail.kaist.ac.kr						Baum MK, 1997, J ACQ IMMUN DEF SYND, V15, P370, DOI 10.1097/00042560-199708150-00007; Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Ghosh R, 1994, Diabetes Res, V25, P165; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; HASUNUMA R, 1982, ANAL BIOCHEM, V126, P242, DOI 10.1016/0003-2697(82)90510-3; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jo DG, 2001, FASEB J, V15, P589; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Mackerness SAH, 2001, FEBS LETT, V489, P237, DOI 10.1016/S0014-5793(01)02103-2; Mandlekar S, 2000, CANCER RES, V60, P5995; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; RODEN M, 1995, HEPATOLOGY, V22, P169, DOI 10.1016/0270-9139(95)90370-4; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	44	110	117	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					111	+		10.1096/fj.01-0398fje	http://dx.doi.org/10.1096/fj.01-0398fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709494				2022-12-25	WOS:000172420500039
J	Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH				Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH			Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis	ONCOGENE			English	Article						thymosin beta-10; ovarian cancer; cDNA array	MESSENGER-RNA; BREAST-CANCER; EXPRESSION; PROSTATE; PROTEINS; P53; CARCINOMA; TUMORS; RAS	To understand the molecular changes during ovarian cancer development, we profiled differentially expressed genes in five paired normal and cancerous ovarian tissues. Among the genes that showed differential expression, thymosin beta -10 expression was decreased in four of five cancer tissues. The decreased level of expression was confirmed by Northern. To investigate the gene's functional role in ovarian cancers, we constructed an adenovirus vector expressing thymosin beta -10 and used it to infect ovarian cancer cell lines PA-I and SKOV3. The infected cells showed disrupted F-actin stress fibers, markedly decreased cell growth, and a high rate of apoptosis. Thus, because loss of thymosin beta -10 expression may contribute to the development of a subset of ovarian cancers, restoration of thymosin beta -10 expression may be a new strategy for ovarian cancer treatment.	Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Sungkyunkwan Univ, Coll Med, Dept Obstet & Gynecol, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Univ Texas, MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, 50 Ilwon Dong, Seoul 135701, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; DeRisi J, 1996, NAT GENET, V14, P457; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Fuller GN, 1999, CANCER RES, V59, P4228; Gold JS, 1997, MODERN PATHOL, V10, P1106; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HALL AK, 1991, MOL CELL ENDOCRINOL, V79, P37, DOI 10.1016/0303-7207(91)90093-8; HALL AK, 1994, RENAL FAILURE, V16, P243, DOI 10.3109/08860229409044864; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; HALL AK, 1990, MOL BRAIN RES, V8, P129, DOI 10.1016/0169-328X(90)90057-K; HENRIKSEN R, 1994, GYNECOL ONCOL, V53, P301, DOI 10.1006/gyno.1994.1138; Hough CD, 2000, CANCER RES, V60, P6281; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Iguchi K, 1998, EUR J BIOCHEM, V253, P766, DOI 10.1046/j.1432-1327.1998.2530766.x; MARIAN AJW, 1993, INT J CANCER, V53, P278; Marx D, 1997, ANTICANCER RES, V17, P2233; Meden H, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P167; Morita K, 2000, PATHOL INT, V50, P219, DOI 10.1046/j.1440-1827.2000.01028.x; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; *NIH, 1994, NIH CONSENSUS STATE, V12, P1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; VELCLESCU VE, 1995, SCIENCE, V170, P484; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	44	57	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6700	6706		10.1038/sj.onc.1204683	http://dx.doi.org/10.1038/sj.onc.1204683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709704				2022-12-25	WOS:000171551600006
J	Carmen, AA; Milne, L; Grunstein, M				Carmen, AA; Milne, L; Grunstein, M			Acetylation of the yeast histone H4N terminus regulates its binding to heterochromatin protein SIR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; N-TERMINUS; REPRESSION; H3; INTERACTS; DOMAIN; RPD3; HML	Heterochromatin at yeast telomeres and silent mating (HM) loci represses adjacent genes and is formed by the binding and spreading of silencing information regulators (SIR proteins) along histones. This involves the interaction between the C terminus of SIR3 and the N terminus of histone H4. Since H4 is hypoacetylated in heterochromatin we wished to determine whether acetylation is involved in regulating the contacts between SIR3 and H4. Binding of H4 peptide (residues 1-34) acetylated at lysines Lys-5, Lys-8, Lys-12, and Lys-16 to an immobilized SIR3 protein fragment (residues 510-970) was investigated using surface plasmon resonance. We find that acetylation of H4 lysines reduces binding (K-a) of 114 to SIRS in a cumulative manner so that the fully acetylated peptide binding is decreased similar to50-fold relative to unacetylated peptide. Thus, by affecting SIR3-H4 binding, acetylation may regulate the formation of heterochromatin. These data help explain the hypoacetylated state of histone H4 in heterochromatin of eukaryotes.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Boyer Hall,611 Young Dr E, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042421] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42421] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; DeRubertis F, 1996, NATURE, V384, P589; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; Guarente L, 2000, GENE DEV, V14, P1021; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Liu C, 1996, GENETICS, V143, P81; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200	30	169	173	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4778	4781		10.1074/jbc.M110532200	http://dx.doi.org/10.1074/jbc.M110532200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714726	hybrid			2022-12-25	WOS:000173962900031
J	Prado, F; Koop, R; Beato, M				Prado, F; Koop, R; Beato, M			Accurate chromatin organization of the mouse mammary tumor virus promoter determines the nature of the synergism between transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; MMTV PROMOTER; PROGESTERONE-RECEPTOR; REGULATORY ELEMENT; BINDING; ACTIVATION; DNA; NUCLEOSOME; YEAST; PROTEINS	The mechanism underlying the synergism between transcription factors in eukaryotic gene expression is not fully understood. In minichromosomes assembled in vitro the synergism between steroid hormone receptors (SHRs) and nuclear factor 1 (NF1) on the mouse mammary tumor virus (MMTV) promoter does not require the proline-rich transactivation domain (PRD) of NF1. Here we show that similar results are obtained in yeast. In contrast, replacing the native hormone-responsive elements (HREs) by a single HRE results in a more accessible chromatin and makes the synergism with SHR dependent on the PRD of NF1. Following hormone induction, in addition to glucocorticoid receptor, the DNA binding domain of NF1 is needed and sufficient for establishing an open chromatin conformation on the wild type MMTV promoter. Thus, NF1 acts as a classical transcription factor in a relaxed chromatin context, whereas in the context of the wild type chromatin DNA binding of NF1 is sufficient to cooperate with SHRs by stabilizing an open chromatin conformation.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	beato@imt.uni-marburg.de	Prado, Felix/G-7700-2015; Beato, Miguel/B-5564-2015	Prado, Felix/0000-0001-9805-782X; Beato, Miguel/0000-0002-2878-2222				ADAMS R, 1997, METHODS YEAST GENETI; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Eisfeld K, 1997, NUCLEIC ACIDS RES, V25, P3733, DOI 10.1093/nar/25.18.3733; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KIM TK, 1993, J BIOL CHEM, V268, P20866; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KO MSH, 1990, EMBO J, V9, P2835, DOI 10.1002/j.1460-2075.1990.tb07472.x; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SIKORSKI RS, 1989, GENETICS, V122, P19; Spangenberg C, 1998, J MOL BIOL, V278, P725, DOI 10.1006/jmbi.1998.1718; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	41	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4911	4917		10.1074/jbc.M110094200	http://dx.doi.org/10.1074/jbc.M110094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11733499	hybrid			2022-12-25	WOS:000173962900049
J	Vossmeyer, D; Hofmann, W; Loster, K; Reutter, W; Danker, K				Vossmeyer, D; Hofmann, W; Loster, K; Reutter, W; Danker, K			Phospholipase C gamma binds alpha(1)beta(1) integrin and modulates alpha(1)beta(1) integrin-specific adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; BETA-1-INTEGRIN SUBUNIT; KINASE; ALPHA; ACTIVATION; C-GAMMA-1; PROTEINS; CELLS	Integrin adhesion receptors have been implicated in bidirectional signal transduction. The dynamic regulation of integrin affinity and avidity as well as post-ligand effects involved in outside-in signaling depends on the interaction of integrins with cytoskeletal and signaling proteins. In this study, we attempted to identify cytoplasmic binding partners of alp, integrin. We were able to show that cell adhesion to alpha(1)beta(1)-specific substrates results in the association of phospholipase Cgamma (PLCgamma) with the alpha(1)beta(1) integrin independent of PLCgamma tyrosine phosphorylation. Using peptide-binding assays, the membrane proximal sequences within the alpha(1)beta(1) integrin subunits were identified as binding sites for PLCgamma. In particular, the conserved sequence of beta(1) subunit binds the enzyme very efficiently. Because purified PLCgamma also binds the integrin peptides, binding seems to be direct. Inhibition of PLC by U73122 leads to reduced cell adhesion on alpha(1)beta(1)-specific substrates. Cells lacking the conserved domain of the alpha(1) subunit fail to respond to the PLC inhibition, indicating that this domain is necessary for PLC-dependent adhesion modulation of alpha(1)beta(1) integrin.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Free University of Berlin	Danker, K (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.	kdanker@komma.zedat.fu-berlin.de		Danker, Kerstin/0000-0002-7214-4682				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; Danker K, 1998, EXP CELL RES, V239, P326, DOI 10.1006/excr.1997.3916; Driessens MHE, 1997, EXP CELL RES, V231, P242, DOI 10.1006/excr.1996.3463; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; Langholz O, 1997, EXP CELL RES, V235, P22, DOI 10.1006/excr.1997.3640; Liu SC, 2000, J CELL SCI, V113, P3563; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; LOSTER K, 1994, EXP CELL RES, V212, P155, DOI 10.1006/excr.1994.1130; Loster K, 2001, BIOCHEM J, V356, P233, DOI 10.1042/0264-6021:3560233; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Pei ZD, 1998, FEBS LETT, V423, P53, DOI 10.1016/S0014-5793(98)00063-5; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vossmeyer D, 2000, EXP CELL RES, V256, P321, DOI 10.1006/excr.2000.4831; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Wrenn RW, 1996, BIOCHEM BIOPH RES CO, V226, P876, DOI 10.1006/bbrc.1996.1443; YLANNE J, 1995, J BIOL CHEM, V270, P9550; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4636	4643		10.1074/jbc.M105415200	http://dx.doi.org/10.1074/jbc.M105415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724770	hybrid			2022-12-25	WOS:000173962900013
J	Chen, ML; Pothoulakis, C; LaMont, JT				Chen, ML; Pothoulakis, C; LaMont, JT			Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION PERMEABILITY; MOLECULAR PHYSIOLOGY; EPITHELIAL-CELLS; PHOSPHOLIPASE-C; RHO-PROTEINS; BINDING; ALPHA; INVOLVEMENT; ENTERITIS; ISOZYMES	Clostridium difficile toxin A increases paracellular permeability in colonic epithelial T84 cells by mechanisms involving RhoA glucosylation and actin depolymerization. However, we previously observed that toxin A-mediated decline in transepithelial electrical resistance preceded changes in cell morphology and tight junction ultrastructure (Hecht, G., Pothoulakis, C., LaMont, J. T., and Madara, J. L. (1988) J. Clin. Invest. 82, 1516-1524). Recent studies also showed that C. difficile toxins induce early cellular responses, including activation of mitogen-activated protein kinases, generation of reactive oxygen metabolites, and calcium influx The aim of this study was to investigate whether toxin A-induced early cellular responses contribute to the permeability changes. We found that toxin A stimulated the activities of membrane and cytosolic protein kinase Calpha (PKCalpha) and cytosolic PKCbeta. A specific PKCalpha/beta antagonist (myristoylated PKCalpha/beta peptide) blocked toxin A-mediated RhoA glucosylation. Furthermore, decreased transepithelial electrical resistance and increased translocation of ZO-1 from tight junction occurred within 2-3 h of toxin A exposure and were also inhibited by PKCalpha/beta antagonist. During this time period, toxin exposure did not induce translocation of ZO-24 dephosphorylation or translocation of occludin, or cell rounding. Our data indicate that PKC signaling regulates toxin A-mediated paracellular permeability changes and ZO-1 translocation.	Harvard Univ, DANA 501, Div Gastroenterol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	LaMont, JT (corresponding author), Harvard Univ, DANA 501, Div Gastroenterol, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	jlamont@caregroup.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047343, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43351, DK 47343] Funding Source: Medline; PHS HHS [K 34583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Clarke H, 2000, J CELL SCI, V113, P3187; D HE, 2000, GASTROENTEROLOGY, V119, P139, DOI 10.1053/gast.2000.8526; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DeVinney R, 2001, MOL MICROBIOL, V41, P1445, DOI 10.1046/j.1365-2958.2001.02617.x; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Ferro T, 2000, AM J PHYSIOL-LUNG C, V278, pL1107, DOI 10.1152/ajplung.2000.278.6.L1107; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; GILBERT RJ, 1995, AM J PHYSIOL-GASTR L, V268, pG487, DOI 10.1152/ajpgi.1995.268.3.G487; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Karczewski J, 2000, AM J PHYSIOL-GASTR L, V279, pG660, DOI 10.1152/ajpgi.2000.279.4.G660; Lee CA, 2000, P NATL ACAD SCI USA, V97, P12283, DOI 10.1073/pnas.97.22.12283; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Marano CW, 2001, DIGEST DIS SCI, V46, P1490, DOI 10.1023/A:1010696005958; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Philpott DJ, 1998, INFECT IMMUN, V66, P1680, DOI 10.1128/IAI.66.4.1680-1687.1998; Pothoulakis C, 2001, AM J PHYSIOL-GASTR L, V280, pG178, DOI 10.1152/ajpgi.2001.280.2.G178; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SULLIVAN NM, 1982, INFECT IMMUN, V35, P1032, DOI 10.1128/IAI.35.3.1032-1040.1982; Terres AM, 1998, INFECT IMMUN, V66, P2943; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	43	128	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4247	4254		10.1074/jbc.M109254200	http://dx.doi.org/10.1074/jbc.M109254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729192	hybrid			2022-12-25	WOS:000173813900062
J	Tabernero, A; Velasco, A; Granda, B; Lavado, EM; Medina, JM				Tabernero, A; Velasco, A; Granda, B; Lavado, EM; Medina, JM			Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; BLOOD-BRAIN-BARRIER; MEDIATED ENDOCYTOSIS; SYNTHASE PROMOTER; PLASMA-PROTEINS; FATTY-ACIDS; BREFELDIN-A; CELLS; TRANSCRIPTION; BIOSYNTHESIS	We have recently reported that albumin, a serum protein present in the developing brain, stimulates the synthesis of oleic acid by astrocytes, which promotes neuronal differentiation. In this work, we gain insight into the mechanism by which albumin induces the synthesis of this neurotrophic factor. Our results show that astrocytes internalize albumin in vesicle-like structures by receptor-mediated endocytosis. Albumin uptake was followed by transcytosis, including passage through the endoplasmic reticulum, which was required to induce the synthesis of oleic acid. Oleic acid synthesis is feedback-regulated by the sterol regulatory element-binding protein-1, which induces the transcription of stearoyl-CoA 9-desaturase, the key rate-limiting enzyme for oleic acid synthesis. In our research, the presence of albumin activated the sterol regulatory element-binding protein-1 and increased stearoyl-CoA 9-desaturase mRNA. Moreover, when the activity of sterol regulatory element-binding protein-1 was inhibited by overexpression of a truncated form of this protein, albumin did not affect stearoyl-CoA 9-desaturase mRNA, indicating that the effect of albumin is mediated by this transcription factor. The effect of albumin was abolished when traffic to the endoplasmic reticulum. was prevented or when albumin was accompanied with oleic acid. In conclusion, our results suggest that the transcytosis of albumin includes passage through the endoplasmic reticulum, where oleic acid is sequestrated, initiating the signal cascade leading to an increase in its own synthesis.	Univ Salamanca, Dept Bioquim & Biol Mol, Edificio Dept, Salamanca 37007, Spain; Hosp Univ Salamanca, Unidad Invest, Salamanca 37007, Spain	University of Salamanca; University of Salamanca	Medina, JM (corresponding author), Univ Salamanca, Dept Bioquim & Biol Mol, Edificio Dept, Pza Doctores Reina S-N, Salamanca 37007, Spain.		Velasco, Ana/L-6065-2014; Tabernero, Arantxa/K-5950-2014	Velasco, Ana/0000-0002-4091-8081; Tabernero, Arantxa/0000-0001-6302-6134				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Deffebach ME, 1996, AM J PHYSIOL-LUNG C, V271, pL744, DOI 10.1152/ajplung.1996.271.5.L744; DZIEGIELEWSKA KM, 1984, INT J DEV NEUROSCI, V2, P215, DOI 10.1016/0736-5748(84)90015-7; Elliot KAC, 1969, HANDBOOK NEUROCHEMIS, V2, P103; ELLIOTT JM, 1989, J DAIRY SCI, V72, P2478, DOI 10.3168/jds.S0022-0302(89)79388-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; HABGOOD MD, 1992, J PHYSIOL-LONDON, V456, P181, DOI 10.1113/jphysiol.1992.sp019332; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; HERTEL C, 1985, J BIOL CHEM, V260, P2547; JUURLINK BHJ, 1990, BRAIN RES, V533, P73, DOI 10.1016/0006-8993(90)91797-K; Kim YC, 2000, J LIPID RES, V41, P1310; KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214; Laming PR, 2000, NEUROSCI BIOBEHAV R, V24, P295, DOI 10.1016/S0149-7634(99)00080-9; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; MORGAN L, 1994, DEVELOPMENT, V120, P1399; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; OHSUGI M, 1992, BIOL NEONATE, V62, P47, DOI 10.1159/000243852; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; PETERS A, 1991, FINE STRUCTURE NERVO, P273; SATO R, 1994, J BIOL CHEM, V269, P17267; SAUNDERS NR, 1981, TRENDS NEUROSCI, V4, P56, DOI 10.1016/0166-2236(81)90020-5; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SPECTOR A A, 1978, P229; Tabernero A, 2001, J NEUROCHEM, V78, P890, DOI 10.1046/j.1471-4159.2001.00476.x; Tabernero A, 2001, J NEUROCHEM, V79, P606, DOI 10.1046/j.1471-4159.2001.00598.x; Tabernero A, 1999, GLIA, V25, P1; TABERNERO A, 1993, BIOCHEM J, V294, P635, DOI 10.1042/bj2940635; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Thewke D, 2000, BIOCHEM BIOPH RES CO, V273, P1, DOI 10.1006/bbrc.2000.2826; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TROJAN J, 1979, CR ACAD SCI D NAT, V289, P1157; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537	38	66	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4240	4246		10.1074/jbc.M108760200	http://dx.doi.org/10.1074/jbc.M108760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724788	hybrid			2022-12-25	WOS:000173813900061
J	Simeonova, PP; Wang, SY; Hulderman, T; Luster, MI				Simeonova, PP; Wang, SY; Hulderman, T; Luster, MI			c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic - Role in carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRINKING-WATER; TYROSINE KINASE; AP-1 ACTIVITY; BLADDER; EXPRESSION; PHOSPHORYLATION; REQUIREMENT; EXPOSURE; SKIN; JNK	Environmental or occupational exposure to arsenic is associated with a greatly increased risk of skin, urinary bladder, and respiratory tract cancers in arseniasis-endemic areas throughout the world. Arsenic shares many properties of tumor promoters by affecting specific cell signal transduction pathways responsible for cell proliferation. The activation of the epidermal growth factor receptor (EGFR)-extracellular signal-regulated protein kinase (ERK) pathway is important in mediating gene expression related to regulation of cellular growth. In the current studies, we demonstrate that arsenic activates EGFR and ERK in a human uroepithelial cell line. The EGFR phosphorylation by arsenic is ligand-independent and does not involve the major autophosphorylation site Tyr(1173). c-Src activity is also induced by arsenic and is a prerequisite for the EGFR and ERK activation. Consistent with these in vitro observations, exposure of mice to arsenic in drinking water, which has been found previously to be associated with AP-1 activation and epithelial proliferation, induces EGFR and ERK activation in the urinary bladder. This response is also accompanied with an increase in c-Src levels interacting with EGFR. These findings represent a potential pathway for mediating arsenic-induced phenotypic changes in the uroepithelium.	NIOSH, Ctr Dis Control, HELD, TMBB, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Simeonova, PP (corresponding author), NIOSH, Ctr Dis Control, HELD, TMBB, Morgantown, WV 26505 USA.	PSimeonova@cdc.gov						Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Burleson FG, 1996, RES COMMUN MOL PATH, V93, P131; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; FEDER D, 1990, J BIOL CHEM, V265, P8205; Germolec DR, 1998, AM J PATHOL, V153, P1775, DOI 10.1016/S0002-9440(10)65692-1; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karagas MR, 1998, ENVIRON HEALTH PERSP, V106, P1047, DOI 10.1289/ehp.98106s41047; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Negri E, 2001, EUR J CANCER PREV, V10, P7, DOI 10.1097/00008469-200102000-00002; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2001, TOXICOL SCI, V60, P279, DOI 10.1093/toxsci/60.2.279; Simeonova PP, 2000, CANCER RES, V60, P3445; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; Steinmaus C, 2000, CANCER INVEST, V18, P174, DOI 10.3109/07357900009038249; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Thogersen VB, 1999, SCAND J CLIN LAB INV, V59, P267; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Vacaresse N, 1999, CIRC RES, V85, P892; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783	33	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2945	2950		10.1074/jbc.M109136200	http://dx.doi.org/10.1074/jbc.M109136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11723127	hybrid			2022-12-25	WOS:000173421500075
J	Sue, SC; Chien, KY; Huang, WN; Abraham, JK; Chen, KM; Wu, WG				Sue, SC; Chien, KY; Huang, WN; Abraham, JK; Chen, KM; Wu, WG			Heparin binding stabilizes the membrane-bound form of cobra cardiotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2); CRYSTAL-STRUCTURE; SPECTROSCOPY; REVEALS	It has been shown previously that the long chain fragments of heparin bind to the beta-strand cationic belt of the three-finger cobra cardiotoxin (or cytotoxin, CTX) and hence enhance its penetration into phospholipid monolayer under physiological ionic conditions. By taking lysophosphatidyleholine (LPC) micelles as a membrane model, we have shown by H-1 NAIR study that the binding of heparin-derived hexasaccharide (Hep-6) to CTX at the beta-strand region can induce conformational changes of CTX near its membrane binding loops and promote the binding activity of CTX toward LPC. The Fourier-transform infrared spectra and NAIR nuclear Overhauser effect of Hep-6(.)CTX and (CTXLPC)-L-. complex in aqueous buffer also supplemented the aforementioned observation. Thus, the detected conformational change may presumably be the result of structural coupling between the connecting loops and its P-strands. This is the first documentation of results showing how the association of hydrophilic carbohydrate molecules with amphiphilic proteins can promote hydrophobic protein-lipid interaction via the stabilization of its membrane-bound form. A similar mechanism involving tripartite interactions of heparin, protein, and lipid molecules may be operative near the extracellular matrix of cell membranes.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan	National Tsing Hua University	Wu, WG (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan.			Chen, Kuan-Ming/0000-0003-1715-5319				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Chehin R, 1999, BIOCHEMISTRY-US, V38, P1525, DOI 10.1021/bi981567j; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; DAUPLAIS M, 1995, EUR J BIOCHEM, V230, P213, DOI 10.1111/j.1432-1033.1995.0213i.x; Dementieva DV, 1999, EUR J BIOCHEM, V263, P152, DOI 10.1046/j.1432-1327.1999.00478.x; Dubovskii PV, 2001, J MOL BIOL, V305, P137, DOI 10.1006/jmbi.2000.4283; Dufton M.J., 1991, P259; FLETCHER JE, 1993, TOXICON, V31, P669, DOI 10.1016/0041-0101(93)90375-S; Lin YH, 2000, INT J BIOL MACROMOL, V27, P171, DOI 10.1016/S0141-8130(00)00117-3; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SUDHALTER J, 1989, J BIOL CHEM, V264, P23906; Sue SC, 1997, BIOCHEMISTRY-US, V36, P9826, DOI 10.1021/bi970413l; Sue SC, 2001, BIOCHEMISTRY-US, V40, P10436, DOI 10.1021/bi010847n; Sue SC, 2001, BIOCHEMISTRY-US, V40, P12782, DOI 10.1021/bi010848f; SUREWICZ WK, 1988, J BIOL CHEM, V263, P786; Vyas AA, 1997, J BIOL CHEM, V272, P9661, DOI 10.1074/jbc.272.15.9661; Vyas KA, 1998, BIOCHEMISTRY-US, V37, P4527, DOI 10.1021/bi972637+; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; Wu WG, 1997, J TOXICOL-TOXIN REV, V16, P115, DOI 10.3109/15569549709016451; Wu WG, 1998, TRENDS CARDIOVAS MED, V8, P270, DOI 10.1016/S1050-1738(98)00019-X; YAMADA S, 1995, J BIOL CHEM, V270, P8696	23	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2666	2673		10.1074/jbc.M104887200	http://dx.doi.org/10.1074/jbc.M104887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714697	hybrid			2022-12-25	WOS:000173421500039
J	Chipuk, JE; Cornelius, SC; Pultz, NJ; Jorgensen, JS; Bonham, MJ; Kim, SJ; Danielpour, D				Chipuk, JE; Cornelius, SC; Pultz, NJ; Jorgensen, JS; Bonham, MJ; Kim, SJ; Danielpour, D			The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; STEROID BINDING CHARACTERISTICS; BASAL EPITHELIAL-CELLS; GROWTH-FACTOR-BETA-1 GENE; AP-1 COMPLEX; CANCER; EXPRESSION; PROTEIN; COACTIVATOR; DOMAIN	In the prostate, androgens negatively regulate the expression of transforming growth factor-beta (TGF-beta) ligands and receptors and Smad activation through unknown mechanisms. We show that androgens (dihydrotestosterone and R1881) down-regulate TGF-beta1-induced expression of TGF-beta1, c-Fos, and Egr-1 in the human prostate adenocarcinoma cell line, LNCaP. Moreover, 5alpha-dihydrotestosterone (DHT) inhibits TGF-beta1 activation of three TGF-beta1-responsive promoter constructs, 3TP-luciferase, AP-1-luciferase, and SBE4(BV)-luciferase, in LNCaP cells either with or without enforced expression of TGF-beta receptors (TbetaRI and TbetaRII). Similarly, DHT inhibits the activation of Smad-binding element (SBE)4(BV)-luciferase by either constitutively activated TbetaRI (T204D) or constitutively activated Smad3 (S3*). Activation of SBE4(BV)-luciferase by S3* in the NRP-154 prostatic cell line, which is androgen receptor (AR)-negative but highly responsive to TGF-beta1, is blocked by co-transfection with either full-length AR or AR missing the DNA binding domain. Immunoprecipitation and GST pull-down assays show that AR directly associates with Smad3 but not Smad2 or Smad4. Electrophoretic mobility shift assays indicate that the AR ligand binding domain directly inhibits the association of Smad3 to the Smad-binding element. In conclusion, our data demonstrate for the first time that ligand-bound AR inhibits TGF-beta transcriptional responses through selectively repressing the binding of Smad3 to SBE.	Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Pharmacol, Cleveland, OH 44106 USA; NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA	Danielpour, D (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Res Labs, Samuel Gerber Bldg,Ste 200,Lab 3,11001 Cedar Rd, Cleveland, OH 44106 USA.			Chipuk, Jerry Edward/0000-0002-1337-842X	NCI NIH HHS [1R01-CA3069-01, P30CA43703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonham MJ, 1996, BIOTECHNIQUES, V21, P57; Brodin G, 1999, CANCER RES, V59, P2731; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Cher ML, 1996, CANCER RES, V56, P3091; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; DANIELPOUR D, 1994, CANCER RES, V54, P3413; DANIELPOUR D, 1995, J IMMUNOL METHODS, V180, P265, DOI 10.1016/0022-1759(94)00322-N; Danielpour D, 1999, J CELL SCI, V112, P169; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; ENGLISH HF, 1985, PROSTATE, V7, P41, DOI 10.1002/pros.2990070106; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Guo YP, 1999, CANCER RES, V59, P1366; Hayes SA, 2001, CANCER RES, V61, P2112; Hayward SW, 1996, ACTA ANAT, V155, P94; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hayward SW, 1996, DIFFERENTIATION, V60, P219, DOI 10.1046/j.1432-0436.1996.6040219.x; Hayward SW, 2000, RADIOL CLIN N AM, V38, P1, DOI 10.1016/S0033-8389(05)70146-9; Hobisch A, 1996, PROSTATE, V28, P129; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsing AY, 1996, CANCER RES, V56, P5146; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kim IY, 1998, EXP CELL RES, V241, P151, DOI 10.1006/excr.1998.4034; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KUIPER GGJM, 1995, BIOCHEMISTRY-US, V34, P1851, DOI 10.1021/bi00006a005; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1986, BRIT J UROL, V58, P41, DOI 10.1111/j.1464-410X.1986.tb05425.x; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; LIBOI E, 1988, BIOCHEM BIOPH RES CO, V151, P298, DOI 10.1016/0006-291X(88)90593-1; Linja MJ, 2001, CANCER RES, V61, P3550; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Marcelli M, 2000, CANCER RES, V60, P944; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 2000, GENE DEV, V14, P627; Miller EA, 2001, PROSTATE, V48, P200, DOI 10.1002/pros.1098; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Novelli G, 2001, PHARMACOGENOMICS, V2, P65, DOI 10.1517/14622416.2.1.65; Poukka H, 2000, J CELL SCI, V113, P2991; ROULEAU M, 1990, MOL ENDOCRINOL, V4, P2003, DOI 10.1210/mend-4-12-2003; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; TAN JA, 1992, J BIOL CHEM, V267, P7958; Tang BW, 1999, CANCER RES, V59, P4834; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wikstrom P, 1999, PROSTATE, V38, P268; Wikstrom P, 2001, MICROSC RES TECHNIQ, V52, P411, DOI 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zatelli MC, 2000, J CLIN ENDOCR METAB, V85, P847, DOI 10.1210/jc.85.2.847; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	81	153	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1240	1248		10.1074/jbc.M108855200	http://dx.doi.org/10.1074/jbc.M108855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11707452	hybrid			2022-12-25	WOS:000173166800049
J	Goto, S; Ihara, Y; Urata, Y; Izumi, S; Abe, K; Koji, T; Kondo, T				Goto, S; Ihara, Y; Urata, Y; Izumi, S; Abe, K; Koji, T; Kondo, T			Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi	FASEB JOURNAL			English	Article						Glutathione S-transferase pi; doxorubicin; cisplatin; nuclear transfer; DNA damage	BREAST-CANCER-CELLS; RESISTANCE-ASSOCIATED PROTEIN; WHEAT-GERM AGGLUTININ; ATP-DEPENDENT EFFLUX; DRUG-RESISTANCE; PEROXIDASE-ACTIVITY; CONFERS RESISTANCE; ANTITUMOR DRUGS; LEUKOTRIENE C-4; EXPRESSION	Glutathione S-transferase (GST) functions in xenobiotic biotransformation and drug metabolism. Increased expression of GST pi, an isozyme of GST, has been found in cancer cells resistant to doxorubicin hydrochloride (DOX) or cis-diamminedichloroplatinum (II) (CDDP), and this increase was believed to be correlated with drug resistance of cancer cells. GST is mainly expressed in the cytoplasm; GST pi in the nucleus has been reported in cancer cells, but the meaning of this result is not known. Here, we studied changes in the amount of nuclear GST pi after exposure of cancer cells to anticancer drugs, and role of the nuclear GST pi in drug resistance. We found nuclear GST pi in cancer cells resistant to DOX, and the amount of nuclear GST pi was enhanced by treatment of the cancer cells with DOX or CDDP. We also found that a mushroom lectin, an inhibitor of nuclear transport, inhibited the nuclear transfer of GST pi, suggesting the existence of a specific transport system for the nuclear transfer of GST pi. Nuclear GST pi protected DNA against damage by anticancer drugs. These results suggest a possible role of GST pi in the acquisition of resistance to anticancer drugs by cancer cells.	Nagasaki Univ, Sch Med, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Histol & Cell Biol, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University	Kondo, T (corresponding author), Nagasaki Univ, Sch Med, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Nagasaki 8528523, Japan.	kondo@net.nagasaki-u.ac.jp						Ali-Osman F, 1997, CLIN CANCER RES, V3, P2253; Awasthi S, 1996, INT J CANCER, V68, P333; Bai F, 1996, CANCER, V78, P416; BATIST G, 1986, J BIOL CHEM, V261, P5544; Beutler E, 1984, RED CELL METABOLISM, P77; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; Chen ZS, 1999, MOL PHARMACOL, V55, P921; CHU G, 1994, J BIOL CHEM, V269, P787; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOTO S, 1995, CANCER RES, V55, P4297; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; HIRATA S, 1992, CANCER, V70, P2381, DOI 10.1002/1097-0142(19921115)70:10<2381::AID-CNCR2820701002>3.0.CO;2-9; HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451; ISHIHARA T, 1994, J LUMIN, V60-1, P269, DOI 10.1016/0022-2313(94)90145-7; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; KANO T, 1987, CANCER RES, V47, P5626; Karni O, 1998, FEBS LETT, V429, P421, DOI 10.1016/S0014-5793(98)00645-0; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MAEDA O, 1993, CANCER RES, V53, P2051; MANNERVIK B, 1987, CARCINOGENESIS, V8, P1929, DOI 10.1093/carcin/8.12.1929; MEIJER C, 1990, BRIT J CANCER, V62, P72, DOI 10.1038/bjc.1990.232; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Priebe W, 1998, BIOCHEM BIOPH RES CO, V247, P859, DOI 10.1006/bbrc.1998.8887; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; SABURI Y, 1989, CANCER RES, V49, P7020; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Serafino A, 1998, ANTICANCER RES, V18, P1159; SHIRATORI Y, 1987, CANCER RES, V47, P6806; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; TAN KH, 1986, FEBS LETT, V207, P231, DOI 10.1016/0014-5793(86)81494-6; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WANG YY, 1989, CANCER RES, V49, P6185; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	57	95	101	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2702	2714		10.1096/fj.01-0376com	http://dx.doi.org/10.1096/fj.01-0376com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726546				2022-12-25	WOS:000172964800040
J	Madani, S; Hichami, A; Legrand, A; Belleville, J; Khan, NA				Madani, S; Hichami, A; Legrand, A; Belleville, J; Khan, NA			Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C	FASEB JOURNAL			English	Article						DAG; omega-3/omega-6 fatty acids; PKC isoenzymes	FATTY-ACID COMPOSITION; FISH OIL SUPPLEMENTATION; EICOSAPENTAENOIC ACID; PHORBOL ESTERS; EPITHELIAL-CELLS; PHOSPHOLIPASE-D; RAT-BRAIN; IN-VITRO; N-3; PHOSPHATIDYLSERINE	We synthesized diacylglycerols (DAGs) containing omega -6 or omega -3 polyunsaturated fatty acids [i.e., 1-stearoyl-2-arachidonoyl-sn-glycerol (SAG), 1-stearoyl-2-docosahexaenoyl-sn-glycerol (SDG), and 1-stearoyl-2-eicosapentaenoyl-sn-glycerol (SEG)] and assessed their efficiency on activation of conventional (alpha, betaI, gamma) and novel (epsilon, delta) protein kinase C (PKC). SAG exerted significantly higher stimulatory effects than SDG and SEG on activation of PKC alpha and PKC delta. Activation of PKC betaI by SEG and SDG was higher than that by SAG. Activation of PKC gamma did not differ significantly among DAG molecular species. Addition of SAG to assays containing SEG and SDG exerted additive effects on activation of alpha and epsilon, but not on betaI and gamma, isoforms of PKC. SDG- and SEG-induced activation of PKC delta was significantly curtailed by the addition of SAG. Three DAG species significantly curtailed the PMA-induced activation of betaI, gamma, and delta, but not of alpha and epsilon, isoforms of PKC. Our study demonstrates for the first time that in vitro activation of different PKC isoenzymes vary in response to different DAG species, and one can envisage that this differential regulation may be responsible for their in vivo effects on target organs.	Univ Bourgogne, Fac Sci, UPRES Lipides & Nutr, EA 2422, F-21000 Dijon, France; Univ Rennes 1, Fac Pharm, Mol Pharmacol Lab, F-35014 Rennes, France	Universite de Bourgogne; Universite de Rennes	Khan, NA (corresponding author), Univ Bourgogne, Fac Sci, UPRES Lipides & Nutr, EA 2422, F-21000 Dijon, France.	naim.khan@u-bourgogne.fr		hichami, aziz/0000-0003-4331-5152				Alpert SE, 1999, AM J PHYSIOL-LUNG C, V277, pL457, DOI 10.1152/ajplung.1999.277.3.L457; BELL MV, 1987, COMP BIOCHEM PHYS B, V86, P227, DOI 10.1016/0305-0491(87)90282-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bordoni A, 1992, Cardiologia, V37, P631; GALLOWAY JH, 1985, CLIN SCI, V68, P449, DOI 10.1042/cs0680449; GOLDBERG EM, 1995, BIOPHYS J, V69, P965, DOI 10.1016/S0006-3495(95)79970-2; GOLDBERG EM, 1994, BIOPHYS J, V66, P382, DOI 10.1016/S0006-3495(94)80788-X; Harbige LS, 1998, P NUTR SOC, V57, P555, DOI 10.1079/PNS19980081; HARDY SJ, 1994, J NEUROCHEM, V62, P1546; HOLIAN O, 1992, ANTICANCER RES, V12, P975; Huang MC, 1996, J NUTR, V126, P2199, DOI 10.1093/jn/126.9.2199; KHAN NA, 1990, BIOCHEM PHARMACOL, V40, pR1, DOI 10.1016/0006-2952(90)90340-Q; KHAN NA, 1991, EXP CELL RES, V194, P248, DOI 10.1016/0014-4827(91)90361-W; Khan NA, 1999, BIOCHEM J, V344, P199, DOI 10.1042/0264-6021:3440199; KHAN NA, 2001, IN PRESS RECENT ADV; Kuroki T, 1998, BIOCHEM BIOPH RES CO, V247, P473, DOI 10.1006/bbrc.1998.8814; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; Mantzioris E, 2000, AM J CLIN NUTR, V72, P42; Marignani PA, 1996, J NUTR, V126, P2738; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; McMurray DN, 2000, J INFECT DIS, V182, pS103, DOI 10.1086/315909; MORI TA, 1987, LIPIDS, V22, P744, DOI 10.1007/BF02533975; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PHILBRICK DJ, 1987, J NUTR, V117, P1663, DOI 10.1093/jn/117.10.1663; RANDO RR, 1984, BIOCHEM BIOPH RES CO, V122, P818, DOI 10.1016/S0006-291X(84)80107-2; Rise P, 1999, PROSTAG LEUKOTR ESS, V60, P367, DOI 10.1016/S0952-3278(99)80014-3; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sebaldt RJ, 1997, ADV EXP MED BIOL, V400, P937; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; TERANO T, 1996, LIPIDS, V31, P301; Vernhet L, 1996, J LIPID MEDIAT CELL, V13, P233, DOI 10.1016/0929-7855(95)00050-X; VONSCHACKY C, 1985, J LIPID RES, V26, P457; Ziboh VA, 2000, AM J CLIN NUTR, V71, p361S, DOI 10.1093/ajcn/71.1.361s	39	82	83	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2595	2601		10.1096/fj.01-0753int	http://dx.doi.org/10.1096/fj.01-0753int			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726535				2022-12-25	WOS:000172964800029
J	Bader, AG; Schneider, ML; Bister, K; Hartl, M				Bader, AG; Schneider, ML; Bister, K; Hartl, M			TOJ3, a target of the v-jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1)	ONCOGENE			English	Article						jun oncogene; signal transduction; transcription factor AP-1; gene expression; target gene; nucleolar protein	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-JUN; FHA DOMAIN; STRUCTURAL-ANALYSIS; EMBRYO FIBROBLASTS; MOLECULAR-CLONING; GENE-EXPRESSION; AP-1 FUNCTION; FOS	Using the established quail cell line Q/d3 conditionally transformed by the v-jun oncogene, cDNA clones (TOJ2, TOJ3, TOJ5, TOJ6) were isolated by representational difference analysis (RDA) that correspond to genes which were induced immediately upon conditional activation of v-jun. One of these genes, TOJ3, is immediately and specifically activated after doxycycline-mediated v-jun induction, with kinetics similar to the induction of well characterized direct AP-I target genes. TOJ3 is neither activated upon conditional activation of v-myc, nor in cells or cell lines non-conditionally transformed by oncogenes other than v-jun. Sequence analysis revealed that the TOJ3-specific cDNA encodes a 530-amino acid protein with significant sequence similarities to the murine or human microspherule protein 1 (MCRS1, MSP58), a nucleolar protein that directly interacts with the ICP22 regulatory protein from herpes simplex virus 1 or with p120, a proliferation-related protein expressed at high levels in most human malignant tumor cells. Similar to its mammalian counterparts, the TOJ3 protein contains a bipartite nuclear localization motif and a forkhead associated domain (FHA). Using polyclonal antibodies directed against a recombinant amino-terminal TOJ3 protein segment, the activation of TOJ3 in jun-transformed fibroblasts was also demonstrated at the protein level by specific detection of a polypeptide with an apparent M-r of 65000. Retroviral expression of the TOJ3 gene in quail or chicken embryo fibroblasts induces anchor age-independent growth, indicating that the immediate activation of TOJ3 in fibroblasts transformed by the v-jun oncogene contributes to cell transformation.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at; markus.hartl@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1987, ONCOGENE, V1, P97; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; CURRAN T, 1991, TRANSCRIPTIONAL REGU, P797; Dang CV, 1999, MOL CELL BIOL, V19, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FREEMAN JW, 1988, CANCER RES, V48, P1244; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GROSSI M, 1991, ONCOGENE, V6, P1767; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOZAK P, 1995, EXP CELL RES, V216, P285, DOI 10.1006/excr.1995.1036; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JURDIC P, 1995, ONCOGENE, V11, P1699; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li J, 2000, J CELL SCI, V113, P4143; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MOLDERS H, 1987, ONCOGENE, V1, P377; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SU HY, 1991, ONCOGENE, V6, P1759; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WONG WY, 1992, ONCOGENE, V7, P2077; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	69	50	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7524	7535		10.1038/sj.onc.1204938	http://dx.doi.org/10.1038/sj.onc.1204938			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709724				2022-12-25	WOS:000171976900009
J	De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A				De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A			The gene for a new brain specific RhoA exchange factor maps to the highly unstable chromosomal region 1p36.2-1p36.3.	ONCOGENE			English	Article						Rho GTPase; Dbl exchange factor; transformation; 1p36; chromosome 1	HETEROTRIMERIC G-PROTEINS; NEUROBLASTOMA CELL-LINE; GTP-BINDING PROTEIN; SIGNALING PATHWAYS; ACTIVATION; FAMILY; IDENTIFICATION; GTPASES; DELETION; RAC1	Guanine nucleotide exchange factors from the Dbl family are proto-oncogenic proteins that activate small GTPases of the Rho family. Here we report the characterization of GEF720, a novel Dbl-like protein related to p115Rho-GEF. GEF720 activated RhoA both in our recently developed Yeast Exchange Assay and in biochemical in vitro exchange assays. GEF720 induced RhoA dependent assembly of actin stress fibers in REF52 fibroblastic cells. In NIH3T3 cells this Dbl-like protein elicited formation of transformation foci with a morphology similar to RhoA-V14 induced foci. In the PC12 neuron-like cell line, expression of GEF720, whose mRNA is brain specific, inhibited NGF-induced neurite outgrowth. Finally, GEF720 gene is located on human chromosome 1 on band 1p36, between Tumor Protein 73 and Tumor Necrosis Factor Receptor 12, two genes rearranged in many neuroblastoma cell lines. Together, these results show that this new Dbl related protein, GEF720, is an exchange factor that can directly activate RhoA in vivo and is potentially involved in the control of neuronal cell differentiation. GEF720 is also a new candidate gene involved in the progression of neuroblastoma and developmental abnormalities associated with rearrangements in the 1p36 chromosomal region.	Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, F-34293 Montpellier 5, France; Inst Genet Mol Montpellier, CNRS IFR24 UMR 5535, F-34293 Montpellier 5, France	Universite de Montpellier	Blangy, A (corresponding author), Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	blangy@crbm.cnrs-mop.fr	Coulon, Vincent/AFF-7934-2022; Coulon, Vincent/B-2437-2009; Fort, Philippe/M-9498-2015	Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755; Fort, Philippe/0000-0001-5997-8722; BLANGY, Anne/0000-0001-7043-0784				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Aman AK, 2000, GENE CHROMOSOME CANC, V29, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1038>3.0.CO;2-C; Amler LC, 2000, GENOMICS, V64, P195, DOI 10.1006/geno.1999.6097; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Blangy A, 2000, J CELL SCI, V113, P729; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Cho JH, 2000, HUM MOL GENET, V9, P1425, DOI 10.1093/hmg/9.9.1425; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; De Toledo M, 2000, FEBS LETT, V480, P287, DOI 10.1016/S0014-5793(00)01953-0; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima S, 2000, EXP HEMATOL, V28, P391, DOI 10.1016/S0301-472X(00)00129-6; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Heilstedt HA, 1999, CLIN GENET, V56, P123, DOI 10.1034/j.1399-0004.1999.560205.x; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Janssen JWG, 1999, INT J CANCER, V80, P857; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Knight-Jones E, 2000, DEV MED CHILD NEUROL, V42, P201, DOI 10.1017/S0012162200000347; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NOGUCHI T, 1988, ONCOGENE, V3, P709; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Slavotinek A, 1999, J MED GENET, V36, P657; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759	66	37	38	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7307	7317		10.1038/sj.onc.1204921	http://dx.doi.org/10.1038/sj.onc.1204921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704860				2022-12-25	WOS:000171894200003
J	Deneen, B; Denny, CT				Deneen, B; Denny, CT			Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation	ONCOGENE			English	Article						EWS/FLI1; P16(INK4a); p19(ARF); SV40 large T antigen; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; J DOMAIN; P53; FAMILY; GENES; DIFFERENTIATION; INACTIVATION; FIBROBLASTS	Ewings sarcoma and primitive neuroectodermal tumors (ES/PNET) are characterized by the fusion of the N-terminus of the EWS gene to the C-terminus of a member of the ETS family of transcription factors. While such fusion proteins are thought to play dominant oncogenic roles, it is unlikely that a single genetic alteration by itself will support cellular transformation. Given that EWS/FLI1 is only able to transform immortalized 3T3 fibroblasts and that 30% of ES/PNET tumors contain a homozygous deletion of the p16 focus, it is likely that other genetic events are required for EWS/FLI1 oncogenesis. Here we describe a complementary mechanism utilized in the establishment ES/PNET tumors. EWS/FLI1 has the capacity to induce apoptosis. and growth arrest in normal MEFs. Such effects prevent the establishment of stable expression of the protein in these cells. When expressed in p16, p19(ARF), or p53 deficient MEFs, the apoptotic and growth arrest effects are attenuated, creating a environment permissive for stable expression of the protein. While loss of a single tumor suppressor is sufficient to establish expression of EWS/FLI1, cellular transformation requires further genetic perturbation.	Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Gwynne Hazen Cherry Mem Labs, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA.	cdenny@ucla.edu		Deneen, Benjmain/0000-0002-6335-1081	NCI NIH HHS [CA 87771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Esteller M, 2000, CANCER RES, V60, P129; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fletcher JA, 1998, J CLIN ONCOL, V16, P1241, DOI 10.1200/JCO.1998.16.4.1241; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gjoerup O, 2000, J VIROL, V74, P864, DOI 10.1128/JVI.74.2.864-874.2000; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; JEN J, 1994, CANCER RES, V54, P5523; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1998, CURR OPIN ONCOL, V4, P334; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWRY DR, 1978, J VIROL, V26, P291; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MILLER DG, 1980, CANCER, V46, P1307, DOI 10.1002/1097-0142(19800915)46:6<1307::AID-CNCR2820460602>3.0.CO;2-6; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	38	102	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6731	6741		10.1038/sj.onc.1204875	http://dx.doi.org/10.1038/sj.onc.1204875			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709708				2022-12-25	WOS:000171551600010
J	Merkx, M; Lippard, SJ				Merkx, M; Lippard, SJ			Why OrfY? Characterization of MMOD, a long overlooked component of the soluble methane monooxygenase from Methylococcus capsulatus (Bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; MULTICOMPONENT PHENOL HYDROXYLASE; X-RAY-ABSORPTION; PSEUDOMONAS SP STRAIN-CF600; GENE-CLUSTER; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; CRYSTAL-STRUCTURE; DIIRON CENTER; ACTIVE-SITE	Soluble methane monooxygenase (sMMO) has been studied intensively to understand the mechanism by which it catalyzes the remarkable oxidation of methane to methanol. The cluster of genes that encode for the three characterized protein components of sMMO (MMOH, MMOB, and MMOR) contains an additional open reading frame (orfY) of unknown function. In the present study, MMOD, the protein encoded by orfY, was overexpressed as a fusion protein in Escherichia coli. Pure MMOD was obtained in high yields after proteolytic cleavage and a two-step purification procedure. Western blot analysis of Methylococcus capsulatus (Bath) soluble cell extracts showed that MMOD is expressed in the native organism although at significantly lower levels than the other sMMO proteins. The cofactorless MMOD protein is a potent inhibitor of sMMO activity and binds to the hydroxylase protein (MMOH) with an affinity similar to that of MMOB and MMOR. The addition of up to 2 MMOD per MMOH results in changes in the optical spectrum of the hydroxylase that suggest the formation of a (mu-oxo)diiron(III) center in a fraction of the MMOH-MMOD complexes. Possible functions for MMOD are discussed, including a role in the assembly of the MMOH diiron center similar to that suggested for DmpK, a protein that shares some properties with MMOD.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Rm 18-T122, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Merkx, Maarten/E-7009-2011					Arenghi FLG, 2001, APPL ENVIRON MICROB, V67, P3304, DOI 10.1128/AEM.67.7.3304-3308.2001; Basch H, 1999, J AM CHEM SOC, V121, P7249, DOI 10.1021/ja9906296; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; CARDY DLN, 1991, ARCH MICROBIOL, V156, P477, DOI 10.1007/BF00245395; Chang SL, 1999, BIOCHEMISTRY-US, V38, P5799, DOI 10.1021/bi982992f; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Davydov A, 1997, J BIOL CHEM, V272, P7022, DOI 10.1074/jbc.272.11.7022; Davydov R, 1999, BIOCHEMISTRY-US, V38, P4188, DOI 10.1021/bi982391o; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DEWITT JG, 1995, INORG CHEM, V34, P2505, DOI 10.1021/ic00114a007; Dunietz BD, 2000, J AM CHEM SOC, V122, P2828, DOI 10.1021/ja9920967; Elango N, 1997, PROTEIN SCI, V6, P556; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; Gherman BF, 2001, J AM CHEM SOC, V123, P3836, DOI 10.1021/ja0055108; Grosse S, 1999, APPL ENVIRON MICROB, V65, P3929; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; Horinouchi M, 1999, BIOSCI BIOTECH BIOCH, V63, P1765, DOI 10.1271/bbb.63.1765; Kopp DA, 2001, BIOCHEMISTRY-US, V40, P14932, DOI 10.1021/bi015556t; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; McDonald IR, 1997, APPL ENVIRON MICROB, V63, P1898, DOI 10.1128/AEM.63.5.1898-1904.1997; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Muller J, 2002, BIOCHEMISTRY-US, V41, P42, DOI 10.1021/bi015668k; Murrell JC, 2000, ARCH MICROBIOL, V173, P325, DOI 10.1007/s002030000158; Nakamura K, 2000, J BIOSCI BIOENG, V89, P47, DOI 10.1016/S1389-1723(00)88049-4; Nielsen AK, 1996, MICROBIOL-UK, V142, P1289, DOI 10.1099/13500872-142-5-1289; Nielsen AK, 1997, MOL MICROBIOL, V25, P399, DOI 10.1046/j.1365-2958.1997.4801846.x; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; POWLOWSKI J, 1990, J BACTERIOL, V172, P6834, DOI 10.1128/jb.172.12.6834-6840.1990; Powlowski J, 1997, J BIOL CHEM, V272, P945, DOI 10.1074/jbc.272.2.945; PULVER S, 1993, J AM CHEM SOC, V115, P12409, DOI 10.1021/ja00079a024; Pulver SC, 1997, J AM CHEM SOC, V119, P387, DOI 10.1021/ja962854i; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Shigematsu T, 1999, APPL ENVIRON MICROB, V65, P5198; Shu LJ, 1996, J BIOL INORG CHEM, V1, P297, DOI 10.1007/s007750050057; Siegbahn PEM, 1999, ANNU REV PHYS CHEM, V50, P221, DOI 10.1146/annurev.physchem.50.1.221; Siegbahn PEM, 1999, INORG CHEM, V38, P2880, DOI 10.1021/ic981332w; Siegbahn PEM, 2001, J BIOL INORG CHEM, V6, P27, DOI 10.1007/s007750000184; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; STAINTHORPE AC, 1989, ARCH MICROBIOL, V152, P154, DOI 10.1007/BF00456094; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; WEST CA, 1992, J GEN MICROBIOL, V138, P1301, DOI 10.1099/00221287-138-7-1301; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Whittington DA, 2001, J AM CHEM SOC, V123, P1794, DOI 10.1021/ja0031725; Willems JP, 1998, J AM CHEM SOC, V120, P9410, DOI 10.1021/ja980795y; Yoshizawa K, 2000, J INORG BIOCHEM, V78, P23, DOI 10.1016/S0162-0134(99)00201-9; Yoshizawa K, 1997, CHEM LETT, P587, DOI 10.1246/cl.1997.587; Yoshizawa K, 1998, NIPPON KAGAKU KAISHI, P451, DOI 10.1246/nikkashi.1998.451; Yoshizawa K, 1998, B CHEM SOC JPN, V71, P1899, DOI 10.1246/bcsj.71.1899	61	53	60	2	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5858	5865		10.1074/jbc.M107712200	http://dx.doi.org/10.1074/jbc.M107712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11709550	hybrid			2022-12-25	WOS:000173989200023
J	van Aalten, DMF; Haker, A; Hendriks, J; Hellingwerf, KJ; Joshua-Tor, L; Crielaard, W				van Aalten, DMF; Haker, A; Hendriks, J; Hellingwerf, KJ; Joshua-Tor, L; Crielaard, W			Engineering photocycle dynamics - Crystal structures and kinetics of three photoactive yellow protein hinge-bending mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOTROPHIC BACTERIUM; CONFORMATIONAL-CHANGES; CONCERTED MOTIONS; PRIMARY EVENTS; FLUORESCENCE; PROGRAM; DOMAIN; CRYSTALLOGRAPHY	Crystallographic and spectroscopic analyses of three hinge-bending mutants of the photoactive yellow protein are described. Previous studies have identified Gly(47) and Gly (51) as possible hinge points in the structure of the protein, allowing backbone segments around the chromophore to undergo large concerted motions. We have designed, crystallized, and solved the structures of three mutants: G47S, G51S, and G47S/G51S. The protein dynamics of these mutants are significantly affected. Transitions in the photocycle, measured with laser induced transient absorption spectroscopy, show rates up to 6-fold different from the wild type protein and show an additive effect in the double mutant. Compared with the native structure, no significant conformational differences were observed in the structures of the mutant proteins. We conclude that the structural and dynamic integrity of the region around these mutations is of crucial importance to the photocycle and suggest that the hinge-bending properties of Gly(51) may also play a role in PAS domain proteins where it is one of the few conserved residues.	Univ Dundee, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dundee DD1 5EH, Scotland; Cold Spring Harbor Lab, WM Keck Struct Biol, Cold Spring Harbor, NY 11724 USA; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1018 WV Amsterdam, Netherlands	University of Dundee; Cold Spring Harbor Laboratory; University of Amsterdam	Joshua-Tor, L (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	leemor@cshl.org		Joshua-Tor, Leemor/0000-0001-8185-8049; van Aalten, Daan/0000-0002-1499-6908				Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Changenet P, 1998, CHEM PHYS LETT, V282, P276, DOI 10.1016/S0009-2614(97)01334-1; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hendriks J, 1999, J BIOL CHEM, V274, P17655, DOI 10.1074/jbc.274.25.17655; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; Mello LV, 1997, PROTEIN ENG, V10, P381, DOI 10.1093/protein/10.4.381; Mello LV, 1998, BIOCHEMISTRY-US, V37, P3137, DOI 10.1021/bi971402v; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MILLER A, 1998, BIOCHIM BIOPHYS ACTA, V1141, P190; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; van Aalten DMF, 1998, PROTEIN ENG, V11, P873, DOI 10.1093/protein/11.10.873; Van Aalten DMF, 2000, PROTEIN SCI, V9, P64; VANAALTEN DMF, 1995, PROTEINS, V22, P45, DOI 10.1002/prot.340220107; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; VANAALTEN DMF, 2001, IN PRESS ACTA CRYSTA; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	46	14	14	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6463	6468		10.1074/jbc.M109313200	http://dx.doi.org/10.1074/jbc.M109313200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11714713	hybrid			2022-12-25	WOS:000173989200101
J	Le Gac, NT; Boehmer, PE				Le Gac, NT; Boehmer, PE			Activation of the herpes simplex virus type-1 origin-binding protein (UL9) by heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MOLECULAR CHAPERONE DNAK; ESCHERICHIA-COLI DNAJ; VIRAL ORIGIN; REPLICATION ORIGIN; INITIATOR PROTEIN; CRYSTAL-STRUCTURE; HUMAN HSP70; BOX-I; COMPLEX	Heat shock proteins participate in the initiation of DNA replication of different organisms by facilitating the assembly of initiation complexes. We have examined the effects of human heat shock proteins (Hsp40 and Hsp70) on the interaction of the herpes simplex virus type-1 initiator protein (UL9) with oriS, one of the viral origins of replication. Hsp40 and Hsp70 act substoichiometrically to increase the affinity of UL9 for oriS. The major contributor to this effect is Hsp40. Heat shock proteins also stimulate the ATPase activity of UL9 with oriS and increase opening of the origin. In contrast, heat shock proteins have no effect on the origin-independent activities of UL9 suggesting that their role is not merely in refolding denatured protein. These observations are consistent with a role for heat shock proteins in activating UL9 to efficiently initiate viral origin-dependent DNA replication. The action of heat shock proteins in this capacity is analogous to their role in activating the initiator proteins of other organisms.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Box 016129, Miami, FL 33101 USA.			Boehmer, Paul/0000-0003-4479-0529	NIGMS NIH HHS [GM62643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arana ME, 2001, J BIOL CHEM, V276, P6840, DOI 10.1074/jbc.M007219200; Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; Aslani A, 2001, P NATL ACAD SCI USA, V98, P7194, DOI 10.1073/pnas.121177198; Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; ELIAS P, 1992, J BIOL CHEM, V267, P17424; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Giraldo R, 2001, P NATL ACAD SCI USA, V98, P4938, DOI 10.1073/pnas.081079298; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; Halford WP, 1996, J VIROL, V70, P5051, DOI 10.1128/JVI.70.8.5051-5060.1996; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Khodarev NN, 1999, P NATL ACAD SCI USA, V96, P12062, DOI 10.1073/pnas.96.21.12062; KOBAYASHI K, 1994, MICROBIOL IMMUNOL, V38, P321, DOI 10.1111/j.1348-0421.1994.tb01785.x; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; Konieczny I, 1999, GENET ENG P, V21, P95; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Lee SSK, 1999, J BIOL CHEM, V274, P18613, DOI 10.1074/jbc.274.26.18613; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MALKI A, 1991, MOL GEN GENET, V225, P420, DOI 10.1007/BF00261682; MORIYA A, 1994, ARCH VIROL, V135, P419, DOI 10.1007/BF01310025; PHILLIPS B, 1991, J VIROL, V65, P5680, DOI 10.1128/JVI.65.11.5680-5692.1991; Sampson DA, 2000, J BIOL CHEM, V275, P2931, DOI 10.1074/jbc.275.4.2931; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; WYMAN C, 1993, J BIOL CHEM, V268, P25192; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025	48	32	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5660	5666		10.1074/jbc.M108316200	http://dx.doi.org/10.1074/jbc.M108316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11711536	hybrid			2022-12-25	WOS:000173962900143
J	Yoon, JW; Kita, Y; Frank, DJ; Majewski, RR; Konicek, BA; Nobrega, MA; Jacob, H; Walterhouse, D; Iannaccone, P				Yoon, JW; Kita, Y; Frank, DJ; Majewski, RR; Konicek, BA; Nobrega, MA; Jacob, H; Walterhouse, D; Iannaccone, P			Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING PROTEIN-6; SONIC-HEDGEHOG; IN-VITRO; IMMUNOGLOBULIN SUPERFAMILY; FLOOR PLATE; H19 GENE; GLI; GROWTH; TRANSCRIPTION; OSTEOPONTIN	The zinc finger transcription factor GLI1, which mediates Sonic hedgehog signaling during development, is expressed in several human cancers, including basal cell carcinoma, medulloblastoma, and sarcomas. We identified 147 genes whose levels of expression were significantly altered in RNA obtained from cells demonstrating a transformed phenotype with stable GLI1 expression or stable Ha-ras expression. Comparison of expression profiles from GLI1- and Ha-ras-expressing cells established a set of genes unique to GLI1-induced cell transformation. Thirty genes were altered by stable GLI1 expression, and 124 genes were changed by stable Ha-ras expression. Seven genes had altered expression levels in both GLI1- and Ha-ras-expressing cells. Genes whose expression was altered by GLI1 included cell cycle genes, cell adhesion genes, signal transduction genes, and genes regulating apoptosis. GLI1 consensus DNA-binding sequences were identified in the 5' regions of cyclin D2, IGFBP-6, osteopontin, and plakoglobin, suggesting that these genes represent immediate downstream targets. Gel shift analysis confirmed the ability of the GLI1 protein to bind these sequences. Up-regulation of cyclin D2 and down-regulation of plakoglobin were demonstrated in GLI1-amplified compared with non-amplified hum an rhabdomyosarcoma cells. Many of the GLI1 targets with known function identified in this study increase cell proliferation, indicating that GLI1-induced cell transformation occurs through multiple downstream pathways.	Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA	Northwestern University; Northwestern University; Medical College of Wisconsin	Iannaccone, P (corresponding author), Northwestern Univ, Sch Med, Dept Pediat, 2300 Childrens Plaza 204, Chicago, IL 60614 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES010549] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES10549] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Afshari CA, 1999, CANCER RES, V59, P4759; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dohrmann CE, 1999, MECH DEVELOP, V84, P147, DOI 10.1016/S0925-4773(99)00055-6; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Gabbitas B, 1997, J CELL BIOCHEM, V66, P77, DOI 10.1002/(SICI)1097-4644(19970701)66:1<77::AID-JCB9>3.0.CO;2-V; Gabbitas B, 1996, J CELL PHYSIOL, V169, P15, DOI 10.1002/(SICI)1097-4652(199610)169:1<15::AID-JCP2>3.0.CO;2-H; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Gunnersen JM, 2000, GLIA, V32, P146, DOI 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.3.CO;2-V; Guo QM, 2000, CANCER RES, V60, P5922; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HUANG RP, 1993, DEV BIOL, V155, P307, DOI 10.1006/dbio.1993.1030; Jouvenot Y, 1999, CURR BIOL, V9, P1199, DOI 10.1016/S0960-9822(00)80026-3; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; Muller B, 2000, DEVELOPMENT, V127, P2999; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Ohta S, 1997, BIOCHEM J, V324, P777, DOI 10.1042/bj3240777; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Podlasek CA, 1999, DEV BIOL, V209, P28, DOI 10.1006/dbio.1999.9229; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; SAITOH Y, 1995, LAB INVEST, V72, P55; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sharp JA, 1999, LAB INVEST, V79, P869; Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Tachikui H, 1999, GENE, V240, P325, DOI 10.1016/S0378-1119(99)00445-X; Uchida D, 2000, LAB INVEST, V80, P955, DOI 10.1038/labinvest.3780098; Uzawa K, 1999, J BONE MINER RES, V14, P1272, DOI 10.1359/jbmr.1999.14.8.1272; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Yang JT, 1997, MOL MED, V3, P826, DOI 10.1007/BF03401719; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	45	270	278	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5548	5555		10.1074/jbc.M105708200	http://dx.doi.org/10.1074/jbc.M105708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719506	hybrid			2022-12-25	WOS:000173962900128
J	Banumathy, G; Singh, V; Tatu, U				Banumathy, G; Singh, V; Tatu, U			Host chaperones are recruited in membrane-bound complexes by Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-LIKE PROTEIN; MOLECULAR CHARACTERIZATION; HEAT; MALARIA; PARASITE; ANTIGEN; SURFACE; GENE; IDENTIFICATION; TRANSPORT	The ability of malarial parasite to deploy proteins at the surface of infected erythrocytes is well known. After their synthesis within the parasite, the cargo proteins are exported from the parasite and carried across the erythrocyte cytoplasm to be delivered at the erythrocyte surface. Our knowledge about the mechanisms involved in this complex trafficking path is limited. We have addressed the involvement of chaperones in traffic across erythrocyte cytoplasm. Our analyses of the chaperones available to the parasite indicated that none of the reported chaperones of the parasite origin are present in the erythrocyte cytoplasm. The chaperones of the host (Hsp70, Hsp90, Hop60), on the other hand, were readily detected in the erythrocyte cytosol. Hypotonic lysis and detergent solubilization experiments indicated that unlike their soluble nature in normal erythrocytes, host chaperones are recruited in membrane-bound, detergent-resistant complexes in infected cells. The association of host-Hsp70 with detergent-resistant complexes was ATP-dependent. Importantly, host chaperones could be detected in knob-enriched fractions and could be cross-linked to the knob subunit, PfHRP1, in a large complex at the surface of the infected erythrocytes. Our results implicate host chaperones in the assembly of parasite proteins such as knob subunits at the erythrocyte surface.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Tatu, U (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	tatu@biochem.iisc.ernet.in		Tatu, Utpal/0000-0003-0404-8872				Agarraberes FA, 2001, J CELL SCI, V114, P2491; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BANTING G, 1995, TRENDS CELL BIOL, V5, P340, DOI 10.1016/S0962-8924(00)89060-1; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; BIANCO AE, 1986, P NATL ACAD SCI USA, V83, P8713, DOI 10.1073/pnas.83.22.8713; Blisnick T, 2000, MOL BIOCHEM PARASIT, V111, P107, DOI 10.1016/S0166-6851(00)00301-7; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; BONNEFOY S, 1994, MOL BIOCHEM PARASIT, V67, P157, DOI 10.1016/0166-6851(94)90105-8; CELIS JE, 1994, CELL BIOL LAB HDB, V2, P26; CHISHTI AH, 1992, MOL BIOCHEM PARASIT, V52, P283, DOI 10.1016/0166-6851(92)90062-O; CRANDALL I, 1994, METHOD CELL BIOL, V45, P193; Das A, 1997, MOL BIOCHEM PARASIT, V88, P95, DOI 10.1016/S0166-6851(97)00081-9; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; ELMENDORF HG, 1992, MOL BIOCHEM PARASIT, V52, P215, DOI 10.1016/0166-6851(92)90054-N; FANDEUR T, 1984, J IMMUNOL, V132, P432; GETHING MJ, 1997, GUIDEBOOK MOL CHAPER, P22; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Goodyer ID, 1997, MOL BIOCHEM PARASIT, V87, P13, DOI 10.1016/S0166-6851(97)00039-X; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; GROMOV PS, 1991, EXP CELL RES, V195, P556, DOI 10.1016/0014-4827(91)90412-N; GUDI T, 1993, J BIOL CHEM, V268, P21344; HINTERBERG K, 1994, EXP PARASITOL, V79, P279, DOI 10.1006/expr.1994.1091; JENDOUBI M, 1985, J IMMUNOL, V134, P1941; JENDOUBI M, 1988, NUCLEIC ACIDS RES, V16, P10928, DOI 10.1093/nar/16.22.10928; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; KUMAR N, 1988, P NATL ACAD SCI USA, V85, P6277, DOI 10.1073/pnas.85.17.6277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; Martinez SL, 1998, MOL BIOCHEM PARASIT, V91, P273, DOI 10.1016/S0166-6851(97)00206-5; MATTEI D, 1989, EUR J IMMUNOL, V19, P1823, DOI 10.1002/eji.1830191010; MATTEI D, 1988, NUCLEIC ACIDS RES, V16, P5204, DOI 10.1093/nar/16.11.5204; Mattei D, 1999, PARASITOL TODAY, V15, P235, DOI 10.1016/S0169-4758(99)01450-7; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PANYIM S, 1985, APPL ENV RES TROPICA, P407; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; SCHLESINGER M, 2000, MODERN ELECTROPLATIN, P11; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Wiser Mark F., 1999, Novartis Foundation Symposium, V226, P199; Wiser MF, 1996, MOL BIOCHEM PARASIT, V83, P25, DOI 10.1016/S0166-6851(96)02743-0; Wiser MF, 1999, PARASITOL TODAY, V15, P194, DOI 10.1016/S0169-4758(99)01440-4	50	77	80	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3902	3912		10.1074/jbc.M110513200	http://dx.doi.org/10.1074/jbc.M110513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11711553	hybrid			2022-12-25	WOS:000173813900016
J	Furst, J; Ritter, M; Rudzki, J; Danzl, J; Gschwentner, M; Scandella, E; Jakab, M; Konig, M; Oehl, B; Lang, F; Deetjen, P; Paulmichl, M				Furst, J; Ritter, M; Rudzki, J; Danzl, J; Gschwentner, M; Scandella, E; Jakab, M; Konig, M; Oehl, B; Lang, F; Deetjen, P; Paulmichl, M			ICln ion channel splice variants in Caenorhabditis elegans - Voltage dependence and interaction with an operon partner protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; I-CLN; EXPRESSION; PI(CLN); CELL; INACTIVATION; MECHANISMS; MEMBRANES; BILAYERS; CLONING	ICln is an ion channel identified by expression cloning using a cDNA library from Madin-Darby canine kidney cells. In all organisms tested so far, only one transcript for the ICln protein could be identified. Here we show that two splice variants of the ICln ion channel can be found in Caenorhabditis elegans. Moreover,, we show that these two splice variants of the ICln channel protein, which we termed IClnN1 and IClnN2, can be functionally reconstituted and tested in an artificial lipid bilayer. In these experiments, the IClnN1-induced currents showed no voltage-dependent inactivation, whereas the IClnN2-induced currents fully inactivated at positive potentials. The molecular entity responsible for the voltage-dependent inactivation of IClnN2 is a cluster of positively charged amino acids encoded by exon 2a, which is absent in IClnN1. Our experiments suggest a mechanism of channel inactivation that is similar to the "ball and chain" model proposed for the Shaker potassium channel, i.e. a cluster of positively charged amino acids hinders ion permeation through the channel by a molecular and voltage-dependent interaction at the inner vestibulum of the pore. This hypothesis is supported by the finding that synthetic peptides with the same amino acid sequence as the positive cluster can transform the IClnN1-induced current to the current observed after reconstitution of IClnN2. Furthermore, we show that the nematode ICln gene is embedded in an operon harboring two additional genes, which we termed Nx and Ny. Co-reconstitution of Nx and IClnN2 and functional analysis of the related currents revealed a functional interaction between the two proteins, as evidenced by the fact that the IClnN2-induced current in the presence of Nx was no longer voltage-sensitive. The experiments described indicate that the genome organization in nematodes allows an effective approach for the identification of functional partner proteins of ion channels.	Univ Milan, Dept Biochem & Physiol, I-20133 Milan, Italy; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Innsbruck, Dept Physiol, Inst Physiol & Balneol, A-6020 Innsbruck, Austria	University of Milan; Eberhard Karls University of Tubingen; University of Innsbruck	Paulmichl, M (corresponding author), Univ Innsbruck, Dept Physiol, Inst Physiol & Balneol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	markus.paulmichl@unimi.it	Ritter, Markus/AAG-4987-2020; Danzl, Johann Georg/AGX-2475-2022; Danzl, Johann/N-9987-2015	Ritter, Markus/0000-0001-7346-7750; Danzl, Johann Georg/0000-0001-8559-3973; Danzl, Johann/0000-0001-8559-3973				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BENZ R, 1992, BIOL CHEM H-S, V373, P295, DOI 10.1515/bchm3.1992.373.1.295; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; Chen LX, 1999, AM J PHYSIOL-CELL PH, V276, pC182, DOI 10.1152/ajpcell.1999.276.1.C182; Clapham DE, 1998, J GEN PHYSIOL, V111, P623, DOI 10.1085/jgp.111.5.623; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; EHRLICH BE, 1992, METHOD ENZYMOL, V207, P463; Ferguson KC, 1999, MOL CELL BIOL, V19, P1892; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; GARAVAGLIA L, 2002, IN PRESS PFLUEGERS A; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; GSCHWENTNER M, 1998, CELL VOLUME REGULATI; GSCHWENTNER M, 1996, J ALLERGY CLIN IMMUN, V98, P98; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hubert MD, 2000, BBA-BIOMEMBRANES, V1466, P105, DOI 10.1016/S0005-2736(00)00177-2; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Maniatis T., 1982, MOL CLONING LAB MANU; MEYER G, 1995, BIOELECTROCH BIOENER, V36, P23, DOI 10.1016/0302-4598(94)01727-I; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Pu WT, 1999, MOL CELL BIOL, V19, P4113; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; Schmarda A, 2001, CELL PHYSIOL BIOCHEM, V11, P55, DOI 10.1159/000047792; Schmarda A, 1997, CELL PHYSIOL BIOCHEM, V7, P298, DOI 10.1159/000154885; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Tao GZ, 1998, BIOCHEM BIOPH RES CO, V247, P668, DOI 10.1006/bbrc.1998.8837; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	34	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4435	4445		10.1074/jbc.M107372200	http://dx.doi.org/10.1074/jbc.M107372200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706026	hybrid			2022-12-25	WOS:000173813900086
J	Swaminathan, CP; Sankpal, UT; Rao, DN; Surolia, A				Swaminathan, CP; Sankpal, UT; Rao, DN; Surolia, A			Water-assisted dual mode cofactor recognition by HhaI DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTHALPY-ENTROPY COMPENSATION; ADENOSYL-L-METHIONINE; DIHYDROFOLATE-REDUCTASE; KINETIC MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OSMOTIC-STRESS; BOUND WATER; TARGET BASE; BINDING	Energetically competent binary recognition of the cofactor S-adenoSyl-L-Methionine (AdoMet) and the product S-adenoSyl-L-homocysteine (AdoHcy) by the DNA (cytosine C-5) methyltransferase (M.HhaI) is demonstrated herein. Titration calorimetry reveals a dual mode, involving a primary dominant exothermic reaction followed by a weaker endothermic one, for the recognition of AdoMet and AdoHcy by M.HhaI. Conservation of the bimodal recognition in W41I and W41Y mutants of M.HhaI excludes the cation - pi interaction between the methylsulfonium group of AdoMet and the pi face of the Trp(41) indole ring from a role in its origin. Small magnitude of temperature-independent heat capacity changes upon AdoMet or AdoHcy binding by M.HhaI preclude appreciable conformational alterations in the reacting species. Coupled osmotic-calorimetric analyses of AdoMet and AdoHcy binding by M.HhaI indicate that a net uptake of nearly eight and 10 water molecules, respectively, assists their primary recognition. A change in water activity at constant temperature and pH is sufficient to engender and conserve enthalpy-entropy compensation, consistent with a true osmotic effect. The results implicate solvent reorganization in providing the major contribution to the origin of this isoequilibrium phenomenon in AdoMet and AdoHcy recognition by M.HhaI. The observations provide unequivocal evidence for the binding of AdoMet as well as AdoHcy to M.HhaI in solution state. Isotope partitioning analysis and preincubation studies favor a random mechanism for M.HhaI-catalyzed reaction. Taken together, the results clearly resolve the issue of cofactor recognition by free M.HhaI, specifically in the absence of DNA, leading to the formation of an energetically and catalytically competent binary complex.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009	Sankpal, Umesh/0000-0001-6696-2315				Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BHATTACHARYA S, 1996, J BIOL CHEM, V274, P14743; Billeter M, 1996, CELL, V85, P1057, DOI 10.1016/S0092-8674(00)81306-9; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Gallivan JP, 1999, ORG LETT, V1, P103, DOI 10.1021/ol990577p; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lau EY, 1999, J MOL BIOL, V293, P9, DOI 10.1006/jmbi.1999.3120; Leffler J. E., 1963, RATES EQUILIBRIA ORG, P315; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Niviere V, 1999, J BIOL CHEM, V274, P18252, DOI 10.1074/jbc.274.26.18252; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Rajski SR, 1999, J AM CHEM SOC, V121, P5615, DOI 10.1021/ja9900813; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Rose I A, 1980, Methods Enzymol, V64, P47; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Swaminathan CP, 1999, J BIOL CHEM, V274, P31272, DOI 10.1074/jbc.274.44.31272; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; Weast R. C., 1980, CRC HDB CHEM PHYSICS, pD229; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU JC, 1987, J BIOL CHEM, V262, P4778	49	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4042	4049		10.1074/jbc.M109237200	http://dx.doi.org/10.1074/jbc.M109237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729191	hybrid, Green Accepted			2022-12-25	WOS:000173813900034
J	Chen, F; Bower, J; Leonard, SS; Ding, M; Lu, YJ; Rojanasakul, Y; Kung, HF; Vallyathan, V; Castranova, V; Shi, XL				Chen, F; Bower, J; Leonard, SS; Ding, M; Lu, YJ; Rojanasakul, Y; Kung, HF; Vallyathan, V; Castranova, V; Shi, XL			Protective roles of NF-kappa B for chromium (VI)-induced cytotoxicity is revealed by expression of I kappa B kinase-beta mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; UBIQUITIN-PROTEIN LIGASE; BCL-2 FAMILY PROTEINS; NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; MICE LACKING; T-LYMPHOCYTES; FAS-LIGAND; IKK-ALPHA; APOPTOSIS	To delineate the molecular mechanisms of NF-KE-mediated regulation of chromium (VI)-induced cell death, the signaling pathway leading to the activation of NF-KB was interrupted by stable transfection of a kinase-mutated form of IKB kinase beta (IKKbeta-KM). Here we demonstrate a novel role for the NF-KB transcription factor in inhibiting chromium (VI) -induced cell death. Inhibition of NF-KB by IKKbeta-KM or IKKbeta gene deficiency resulted in a spontaneous cleavage of Bel-xl antiapoptotic protein due to the elevated caspase-3 activity. DNA microarray assay suggested a decreased expression of genes encoding antiapoptotic proteins, cLAP1 and cLAP2, in the cells overexpressing IKKbeta-KM. Chromium(VI) treatment of these NF-KB-inhibited cells induced necrotic-like cell death. Such chromium(VI) -induced cell killing could be partially inhibited by expression of exogenous cLAP1, an inhibitor of caspases, indicating that caspases along with others may be involved in chromium(VI)induced cell death. These results suggest that NF-KB is essential for inhibiting toxic metal-induced cytotoxicity. Such inhibition may involve up-regulation of the expression of anti-death proteins including cLAP1 that prevents spontaneous caspase activation and subsequent cleavage of Bel-xl protein.	NIOSH, PPRB, Hlth Effects Lab Div, Morgantown, WV 26505 USA; W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; University of Hong Kong	Chen, F (corresponding author), NIOSH, PPRB, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Chen, Fei/A-3056-2008; Shi, Xianglin/B-8588-2012	Rojanasakul, Yon/0000-0002-8839-6462				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V338, P165, DOI 10.1006/abbi.1996.9849; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Eguchi Y, 1997, CANCER RES, V57, P1835; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAYANO T, 1995, FEBS LETT, V372, P210, DOI 10.1016/0014-5793(95)00996-M; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang HK, 2000, J BIOL CHEM, V275, P26661; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peters MT, 1999, EXP LUNG RES, V25, P183; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rudolph D, 2000, GENE DEV, V14, P854; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shi XL, 1999, J TOXICOL ENV HEAL B, V2, P87, DOI 10.1080/109374099281241; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Shimizu S, 1996, ONCOGENE, V12, P2045; Shinoura N, 1999, ONCOGENE, V18, P5703, DOI 10.1038/sj.onc.1202966; Shumilla JA, 1999, J BIOL CHEM, V274, P36207, DOI 10.1074/jbc.274.51.36207; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	55	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3342	3349		10.1074/jbc.M101089200	http://dx.doi.org/10.1074/jbc.M101089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11726646	hybrid			2022-12-25	WOS:000173688000039
J	Haqqani, AS; Kelly, JF; Birnboim, HC				Haqqani, AS; Kelly, JF; Birnboim, HC			Selective nitration of histone tyrosine residues in vivo in mutatect tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SURFACTANT PROTEIN-A; REACTIVE OXYGEN; MASS-SPECTROMETRY; OXIDATIVE DAMAGE; PEROXYNITRITE; NITROTYROSINE; EXPRESSION; CANCER; PEPTIDES	Nitric oxide-derived reactive species have been implicated in many disorders. Protein nitrotyrosine is often used as a stable marker of these reactive species. Using immunohistochemistry, we have previously detected nitrotyrosine in murine Mutatect tumors, where neutrophils are the principal source of nitric oxide. We now report on the identification of several prominent nitrotyrosine-containing proteins. Using Western blot analysis, nitrotyrosine in higher molecular mass proteins (>20 kDa) was detected in tumors containing a high number of neutrophils but not in tumors with fewer neutrophils. Staining for nitrotyrosine was consistently seen in low molecular mass proteins (less than or equal to15 kDa), regardless of the level of neutrophils. Protein nitrotyrosine was not seen in Mutatect cells growing in vitro. Treatment with nitric oxide donors produced nitration of less than or equal to15-kDa proteins, but only after extended periods. These small proteins, both from tumors and cultured cells, were identified by mass spectrometry to be his-tones. Only a subset of tyrosine residues was nitrated. Selective nitration may reflect differential accessibility of different tyrosine residues and the influence of neighboring residues within the nucleosome. The prominence of histone nitration may reflect its relative stability, making this post-translational modification a potentially useful marker of extended exposure of cells or tissues to nitric oxide-derived reactive species.	Ottawa Reg Canc Ctr, Ottawa, ON K1H 1C4, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 1C4, Canada; Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Birnboim, HC (corresponding author), Ottawa Reg Canc Ctr, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.			Birnboim, Hyman C./0000-0001-5830-4769				Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BeharCohen FF, 1996, BIOCHEM BIOPH RES CO, V226, P842, DOI 10.1006/bbrc.1996.1438; Buchczyk DP, 2000, BIOL CHEM, V381, P121, DOI 10.1515/BC.2000.017; BUSTIN M, 1971, BIOCHIM BIOPHYS ACTA, V251, P172, DOI 10.1016/0005-2795(71)90100-0; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Garcia-Monzon C, 2000, J HEPATOL, V32, P331, DOI 10.1016/S0168-8278(00)80080-X; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; Goto T, 1999, CLIN CANCER RES, V5, P1411; Greis KD, 1996, ARCH BIOCHEM BIOPHYS, V335, P396, DOI 10.1006/abbi.1996.0522; Hansen PR, 2000, J HEART LUNG TRANSPL, V19, P160, DOI 10.1016/S1053-2498(99)00115-1; Haqqani AS, 1999, ANAL BIOCHEM, V273, P126, DOI 10.1006/abio.1999.4206; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Haqqani AS, 1999, J HISTOCHEM CYTOCHEM, V47, P1563, DOI 10.1177/002215549904701208; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Heeringa P, 2001, J PATHOL, V193, P224; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kojima M, 1999, J SURG ONCOL, V70, P222, DOI 10.1002/(SICI)1096-9098(199904)70:4<222::AID-JSO5>3.0.CO;2-G; Li CQ, 2001, DIGEST DIS SCI, V46, P836, DOI 10.1023/A:1010764720524; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mapp PI, 2001, ARTHRITIS RHEUM, V44, P1534, DOI 10.1002/1529-0131(200107)44:7<1534::AID-ART276>3.0.CO;2-#; Marcondes S, 2001, P NATL ACAD SCI USA, V98, P7146, DOI 10.1073/pnas.141222598; Mendes RV, 2001, HISTOPATHOLOGY, V39, P172, DOI 10.1046/j.1365-2559.2001.01189.x; Mihm MJ, 2001, CARDIOVASC RES, V49, P798, DOI 10.1016/S0008-6363(00)00307-2; Oates JC, 1999, P ASSOC AM PHYSICIAN, V111, P611, DOI 10.1046/j.1525-1381.1999.99110.x; Pignatelli B, 2001, CANCER RES, V61, P778; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PTITSYN L A, 1978, Biokhimiya, V43, P1823; Sakaguchi AA, 1999, FREE RADICAL BIO MED, V27, P781, DOI 10.1016/S0891-5849(99)00124-0; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sandhu JK, 2000, AM J PATHOL, V156, P509, DOI 10.1016/S0002-9440(10)64755-4; Sandhu JK, 1997, MUTAT RES-FUND MOL M, V379, P241, DOI 10.1016/S0027-5107(97)00140-1; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; vanderVliet A, 1996, METHOD ENZYMOL, V269, P175; Vickers SM, 1999, ARCH SURG-CHICAGO, V134, P245, DOI 10.1001/archsurg.134.3.245; Viera L, 1999, METHOD ENZYMOL, V301, P373; WILKINSON D, 1995, BRIT J CANCER, V72, P1234, DOI 10.1038/bjc.1995.492; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Yi DH, 1997, ARCH BIOCHEM BIOPHYS, V344, P253, DOI 10.1006/abbi.1997.0218; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4	57	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3614	3621		10.1074/jbc.M105730200	http://dx.doi.org/10.1074/jbc.M105730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723112	hybrid			2022-12-25	WOS:000173688000074
J	Cadenas, S; Echtay, KS; Harper, JA; Jekabsons, MB; Buckingham, JA; Grau, E; Abuin, A; Chapman, H; Clapham, JC; Brand, MD				Cadenas, S; Echtay, KS; Harper, JA; Jekabsons, MB; Buckingham, JA; Grau, E; Abuin, A; Chapman, H; Clapham, JC; Brand, MD			The basal proton conductance of skeletal muscle mitochondria from transgenic mice overexpressing or lacking uncoupling protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; THYROID-HORMONE; MESSENGER-RNA; EXPRESSION; LEAK; THERMOGENESIS; UCP3; NUCLEOTIDES	The ability of native uncoupling protein-3 (UCP3) to uncouple mitochondrial oxidative phosphorylation is controversial. We measured the expression level of UCP3 and the proton conductance of skeletal muscle mitochondria isolated from transgenic mice overexpressing human UCP3 (UCP3-tg) and from UCP3 knockout (UCP3-KO) mice. The concentration of UCP3 in UCP3-tg mitochondria was similar to3 mug/mg protein, similar to20-fold higher than the wild type value. UCP3-tg mitochondria had increased nonphosphorylating respiration rates, decreased respiratory control, and similar to4-fold increased proton conductance compared with the wild type. However, this increased uncoupling in UCP3-tg mitochondria was not caused by native function of UCP3 because it was not proportional to the increase in UCP3 concentration and was neither activated by superoxide nor inhibited by GDP. UCP3 was undetectable in mitochondria from UCP3-KO mice. Nevertheless, UCP3-KO mitochondria had unchanged respiration rates, respiratory control ratios, and proton conductance compared with the wild type under a variety of assay conditions. We conclude that uncoupling in UCP3-tg mice is an artifact of transgenic expression, and that UCP3 does not catalyze the basal proton conductance of skeletal muscle mitochondria in the absence of activators such as superoxide.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; GlaxoSmithKline, Dept Vasc Biol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept COmparat Genom, Harlow CM19 5AW, Essex, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Cambridge; GlaxoSmithKline; GlaxoSmithKline	Brand, MD (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Brand, Martin D/A-9423-2012; Cadenas, Susana/D-1523-2016; Clapham, John/AAK-4715-2020	Brand, Martin D/0000-0003-4418-6153; Cadenas, Susana/0000-0003-0726-0369				BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; BHATTACHARYA SK, 1991, ANAL BIOCHEM, V192, P344, DOI 10.1016/0003-2697(91)90546-6; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bouillaud F, 1999, INT J OBESITY, V23, pS19, DOI 10.1038/sj.ijo.0800938; Brand M. D., 1995, BIOENERGETICS, V154, P62; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1059, P55, DOI 10.1016/S0005-2728(05)80187-2; Cadenas S, 2000, BIOCHEM J, V348, P209, DOI 10.1042/0264-6021:3480209; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CANNON B, 1985, ESSAYS BIOCHEM, V20, P111; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; CHAPPELL JB, 1954, NATURE, V173, P1094, DOI 10.1038/1731094a0; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2001, BIOCHEM SOC T, V29, P763; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; HEIDKAEMPER D, 2000, FEBS LETT, V2406, P1; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Huppertz C, 2001, J BIOL CHEM, V276, P12520, DOI 10.1074/jbc.M011708200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jekabsons MB, 1999, AM J PHYSIOL-ENDOC M, V277, pE380, DOI 10.1152/ajpendo.1999.277.2.E380; KRAUSS S, 2002, IN PRESS P NATL ACAD; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; ROLFE DFS, 1994, BIOCHIM BIOPHYS ACTA, V1118, P405; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Sheldon JG, 1996, P NATL ACAD SCI USA, V93, P6399, DOI 10.1073/pnas.93.13.6399; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Winkler E, 2001, BIOCHEM BIOPH RES CO, V282, P334, DOI 10.1006/bbrc.2001.4563; Yu XX, 2001, BIOCHEM J, V353, P369, DOI 10.1042/bj3530369; Yu XX, 2000, AM J PHYSIOL-ENDOC M, V279, pE433, DOI 10.1152/ajpendo.2000.279.2.E433; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	58	172	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2773	2778		10.1074/jbc.M109736200	http://dx.doi.org/10.1074/jbc.M109736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707458	hybrid			2022-12-25	WOS:000173421500053
J	Mo, YY; Yu, YN; Shen, ZY; Beck, WT				Mo, YY; Yu, YN; Shen, ZY; Beck, WT			Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; CATALYTIC ACTIVITY; NUCLEAR-BODIES; P53 ACTIVITY; DNA; CELLS; CONJUGATION; BINDING; ENZYME; PML	DNA topoisomerase (topo) I is an essential nuclear protein and a target for anticancer drug camptothecin derivatives. As a nuclear protein, topo I is concentrated in the nucleolus. However, this nucleolar distribution of topo I is dynamic. It has been shown recently that topo I rapidly moves out of the nucleolus (nucleolar delocalization) in response to topo I inhibitors. In the present study, we demonstrated that nucleolar delocalization of topo I is associated with its conjugation by SUMOs (small ubiquitin-like modifiers) in response to the topo I inhibitor topotecan. Time-course experiments revealed that SUMO-topo I conjugation occurred at as early as 5 min after drug treatment, which was earlier than its observed nucleolar delocalization. Furthermore, heat shock blocked sumoylation of topo 1; it also blocked the nucleolar delocalization of topo I fusion proteins. UBC9 is an E2 (ubiquitin carrier protein) -conjugating enzyme essential for sumoylation. Although overexpression of wild-type UBC9 enhanced both sumoylation and nuclear delocalization of topo 1, overexpression of a UBC9 dominant negative mutant attenuated topo I sumoylation and its nucleolar delocalization. Taken together, our results suggest that sumoylation of topo I might serve as an addressing tag for its nucleolar delocalization in response to topo I inhibitors.	Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of New Mexico	Beck, WT (corresponding author), Univ Illinois, Dept Pharmaceut & Pharmacodynam, M-C 865,833 S Wood St, Chicago, IL 60612 USA.		Mo, Yin-Yuan/R-8255-2019	Shen, Zhiyuan/0000-0003-2834-0309	NCI NIH HHS [CA40570, CA30103] Funding Source: Medline; NIEHS NIH HHS [ES08353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353, R29ES008353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Buckwalter CA, 1996, CANCER RES, V56, P1674; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; Danks MK, 1996, CANCER RES, V56, P1664; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kusumoto H, 1996, CANCER RES, V56, P2573; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	47	84	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2958	2964		10.1074/jbc.M108263200	http://dx.doi.org/10.1074/jbc.M108263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11709553	hybrid			2022-12-25	WOS:000173421500077
J	Montagnani, M; Golovchenko, I; Kim, I; Koh, GY; Goalstone, ML; Mundhekar, AN; Johansen, M; Kucik, DF; Quon, MJ; Draznin, B				Montagnani, M; Golovchenko, I; Kim, I; Koh, GY; Goalstone, ML; Mundhekar, AN; Johansen, M; Kucik, DF; Quon, MJ; Draznin, B			Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; GROWTH-FACTOR; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; RESISTANCE; KINASE; RECEPTOR; PROTEIN; FARNESYLTRANSFERASE	The concept of "selective insulin resistance" has emerged as a unifying hypothesis in attempts to reconcile the influence of insulin resistance with that of hyper-insulinemia in the pathogenesis of macrovascular complications of diabetes. To explore this hypothesis in endothelial cells, we designed a set of experiments to mimic the "typical metabolic insulin resistance" by blocking the phosphatidylinositol 3-kinase pathway and exposing the cells to increasing concentrations of insulin ("compensatory hyperinsulinemia"). Inhibition of phosphatidylinositol 3-kinase with wortmannin blocked the ability of insulin to stimulate increased expression of endothelial nitric-oxide synthase, did not affect insulin-induced activation of MAP kinase, and increased the effects of insulin on prenylation of Ras and Rho proteins. At the same time, this experimental paradigm resulted in increased expression of vascular cellular adhesion molecules-1 and E-selectin, as well as increased rolling interactions of monocytes with endothelial cells. We conclude that inhibition of the metabolic branch of insulin signaling leads to an enhanced mitogenic action of insulin in endothelial cells.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; Pohang Univ Sci & Technol, Natl Creat Res Ctr Endothelial Cells, Pohang 790784, South Korea; Univ Alabama Birmingham, Sch Med, Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Univ Calif San Francisco, Program Host Pathogen Interact, San Francisco, CA 94143 USA; Univ Colorado, Sch Med, Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80220 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pohang University of Science & Technology (POSTECH); University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Draznin, B (corresponding author), ACOS, Res & Dev, 1055 Clermont St,151, Denver, CO 80220 USA.	Boris.Draznin@Med.VA.Gov	Quon, Michael/B-1970-2008; Kim, Injune/C-1710-2011; Montagnani, Monica/AAV-2057-2020; Koh, Gou Young/C-1615-2011	Kim, Injune/0000-0001-9244-815X; Montagnani, Monica/0000-0002-5697-8185; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000001, Z01AT000001, Z02AT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Aljada A, 2000, J CLIN ENDOCR METAB, V85, P2572, DOI 10.1210/jc.85.7.2572; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; Chen NG, 1999, J CLIN ENDOCR METAB, V84, P3485, DOI 10.1210/jc.84.10.3485; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; Grenett HE, 1999, THROMB HAEMOSTASIS, V82, P1504; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hsueh WA, 1999, AM J CARDIOL, V84, p21J; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kado S, 1999, DIABETES RES CLIN PR, V46, P143, DOI 10.1016/S0168-8227(99)00083-2; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Montagnani M, 2000, DIABETES OBES METAB, V2, P285, DOI 10.1046/j.1463-1326.2000.00092.x; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nordt TK, 2000, SEMIN THROMB HEMOST, V26, P495, DOI 10.1055/s-2000-13205; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Prescott SM, 2001, J INVEST MED, V49, P104, DOI 10.2310/6650.2001.34106; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHOEMAKER JK, 1995, CAN J APPL PHYSIOL, V20, P127, DOI 10.1139/h95-010; SHYER KG, 1996, CHEST, V109, P1627; Sowers JR, 1997, HYPERTENSION, V29, P691, DOI 10.1161/01.HYP.29.3.691; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Wallen NH, 1999, EUR HEART J, V20, P1039; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	43	271	294	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1794	1799		10.1074/jbc.M103728200	http://dx.doi.org/10.1074/jbc.M103728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707433	hybrid			2022-12-25	WOS:000173421300024
J	Milhiet, PE; Giocondi, MC; Le Grimellec, C				Milhiet, PE; Giocondi, MC; Le Grimellec, C			Cholesterol is not crucial for the existence of microdomains in kidney brush-border membrane models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; GPI-ANCHORED PROTEINS; PHASE-TRANSITIONS; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; MONOLAYERS; DOMAINS; BILAYERS; RAFTS; TRANSPORT	The external membrane leaflet plays a key role in the organization of the cell plasma membrane as a mosaic of ordered microdomains enriched in sphingolipids and cholesterol and of fluid domains. In this study, the thermotropic behavior and the topology of bilayers made of a phosphatidylcholine/sphingomyelin mixture, which mimicks the lipid composition of the external leaflet of renal brush-border membranes, were examined by differential scanning calorimetry and atomic force microscopy. In the absence of cholesterol, a broad phase separation process occurred where ordered gel phase domains of size varying from the mesoscopic to the microscopic scale, enriched in sphingomyelin, occupied half of the bilayer surface at room temperature. Increasing amounts of cholesterol progressively decreased the enthalpy of the transition and modified the topology of membranes domains up to a concentration of 33 mol % for which no membrane domains were detected. These results strongly suggest that, in membranes highly enriched in sphingolipids like renal and intestinal brush borders, there is a threshold close to the physiological concentration above which cholesterol acts as a suppressor rather than as a promoter of membrane domains. They also suggest that cholesterol depletion does not abolish the lateral heterogenity in brush-border membranes.	Univ Montpellier I, INSERM,CNRS UMR 5048, UMR554, CBS, F-34090 Montpellier, France; Univ Paris 12, Lab CRRET, F-94000 Creteil, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Milhiet, PE (corresponding author), Univ Montpellier I, INSERM,CNRS UMR 5048, UMR554, CBS, 29 Rue Navacelles, F-34090 Montpellier, France.	pem@cbs.univ-montp1.fr						Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARMEL G, 1985, BIOCHIM BIOPHYS ACTA, V818, P149, DOI 10.1016/0005-2736(85)90557-7; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V466, P10, DOI 10.1016/0005-2736(77)90204-8; DENKAMP JAF, 1981, NEW COMPREHENSIVE BI, V1, P83; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Dufrene YF, 1997, LANGMUIR, V13, P4779, DOI 10.1021/la970221r; ELYANDOUZI EH, 1993, BIOCHEMISTRY-US, V32, P2047, DOI 10.1021/bi00059a023; Giocondi MC, 2001, LANGMUIR, V17, P1653, DOI 10.1021/la0012135; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; HERNANDEZBORRELL J, 1993, BIOCHIM BIOPHYS ACTA, V1153, P277, DOI 10.1016/0005-2736(93)90416-W; Hollars CW, 1998, BIOPHYS J, V75, P342, DOI 10.1016/S0006-3495(98)77518-6; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOYNOVA R, 1995, BBA-LIPID LIPID MET, V1255, P213, DOI 10.1016/0005-2760(94)00202-A; Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9; LEGRIMELLEC C, 1983, AM J PHYSIOL, V245, pF227, DOI 10.1152/ajprenal.1983.245.2.F227; LEGRIMELLEC C, 1992, KIDNEY INT, V42, P825, DOI 10.1038/ki.1992.357; Maulik PR, 1996, BIOPHYS J, V70, P2256, DOI 10.1016/S0006-3495(96)79791-6; Maulik PR, 1996, BIOCHEMISTRY-US, V35, P8025, DOI 10.1021/bi9528356; MCMULLEN TPW, 1995, BBA-BIOMEMBRANES, V1234, P90, DOI 10.1016/0005-2736(94)00266-R; Milhiet PE, 2001, BIOPHYS J, V81, P547, DOI 10.1016/S0006-3495(01)75721-9; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; Reviakine I, 2000, J STRUCT BIOL, V131, P234, DOI 10.1006/jsbi.2000.4286; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10676, DOI 10.1021/bi00499a015; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shao ZF, 1996, ULTRAMICROSCOPY, V66, P141, DOI 10.1016/S0304-3991(96)00087-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; UNTRACHT SH, 1977, J BIOL CHEM, V252, P4449; VENIEN C, 1988, ANAL BIOCHEM, V174, P325, DOI 10.1016/0003-2697(88)90553-2; Vie V, 1998, LANGMUIR, V14, P4574, DOI 10.1021/la980203p; Worthman LAD, 1997, BIOPHYS J, V72, P2569, DOI 10.1016/S0006-3495(97)78900-8; Yuan CB, 2001, BIOPHYS J, V81, P1059, DOI 10.1016/S0006-3495(01)75763-3	41	72	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					875	878		10.1074/jbc.C100654200	http://dx.doi.org/10.1074/jbc.C100654200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11717303	hybrid			2022-12-25	WOS:000173166800002
J	Albiston, AL; McDowall, SG; Matsacos, D; Sim, P; Clune, E; Mustafa, T; Lee, J; Mendelsohn, FAO; Simpson, RJ; Connolly, LM; Chai, SY				Albiston, AL; McDowall, SG; Matsacos, D; Sim, P; Clune, E; Mustafa, T; Lee, J; Mendelsohn, FAO; Simpson, RJ; Connolly, LM; Chai, SY			Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE AMINOPEPTIDASE; BRAIN; MEMORY; GLUT4; BINDING; SYSTEM; LOCALIZATION; CELLS; RATS	Central infusion of angiotensin IV or its more stable analogues facilitates memory retention and retrieval in normal animals and reverses amnesia induced by scopolamine or by bilateral perforant pathway lesions. These peptides bind with high affinity and specificity to a novel binding site designated the angiotensin AT(4) receptor. Until now, the AT(4) receptor has eluded molecular characterization. Here we identify the AT(4) receptor, by protein purification and peptide sequencing, to be insulin-regulated aminopeptidase (IRAP). HEK 293T cells transfected with IRAP exhibit typical AT(4) receptor binding characteristics; the AT(4) receptor ligands, angiotensin IV and LVV-hemorphin 7, compete for the binding of [I-125]Nle(1)-angiotensin IV with IC50 values of 32 and 140 nM, respectively. The distribution of IRAP and its mRNA in the brain, determined by immunohistochemistry and hybridization histochemistry, parallels that of the AT(4) receptor determined by radioligand binding. We also show that AT(4) receptor ligands dose-dependently inhibit the catalytic activity of IRAP. We have therefore demonstrated that the AT(4) receptor is IRAP and propose that AT(4) receptor ligands may exert their effects by inhibiting the catalytic activity of IRAP thereby extending the half-life of its neuropeptide substrates.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3010, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst, Parkville, Vic 3010, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Chai, SY (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia.			Mustafa, Tomris/0000-0002-0836-2159; Lee, Joohyung/0000-0002-4277-3680; Simpson, Richard/0000-0002-9834-0796; Chai, Siew Yeen/0000-0001-7209-4112				Alescio-Lautier B, 2000, EUR J PHARMACOL, V405, P63, DOI 10.1016/S0014-2999(00)00542-2; Apelt J, 1999, J NEUROSCI RES, V57, P693, DOI 10.1002/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X; BRASZKO JJ, 1988, NEUROSCIENCE, V27, P777, DOI 10.1016/0306-4522(88)90182-0; Chai SY, 2000, J CHEM NEUROANAT, V20, P339, DOI 10.1016/S0891-0618(00)00112-5; DEGASPARO M, 1995, HYPERTENSION, V25, P924, DOI 10.1161/01.HYP.25.5.924; Delorenzi A, 1997, NEUROSCI LETT, V226, P143, DOI 10.1016/S0304-3940(97)00245-0; El Messari S, 1998, J COMP NEUROL, V399, P492, DOI 10.1002/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kramar EA, 2001, BRAIN RES, V897, P114, DOI 10.1016/S0006-8993(01)02100-X; Lee J, 2001, NEUROPHARMACOLOGY, V40, P618, DOI 10.1016/S0028-3908(00)00188-X; Matsumoto H, 2000, EUR J BIOCHEM, V267, P46, DOI 10.1046/j.1432-1327.2000.00949.x; MATSUOKA N, 1995, NEUROSCIENCE, V66, P617, DOI 10.1016/0306-4522(94)00628-I; MILLERWING AV, 1993, J PHARMACOL EXP THER, V266, P1718; Moeller I, 1996, BRAIN RES, V712, P307, DOI 10.1016/0006-8993(95)01482-9; Moeller I, 1997, J NEUROCHEM, V68, P2530; Mustafa T, 2001, J NEUROCHEM, V76, P1679, DOI 10.1046/j.1471-4159.2001.00166.x; Pederson ES, 1998, REGUL PEPTIDES, V74, P97, DOI 10.1016/S0167-0115(98)00028-7; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Simpson RJ, 2000, ELECTROPHORESIS, V21, P1707, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1707::AID-ELPS1707>3.0.CO;2-Q; SWANSON GN, 1992, REGUL PEPTIDES, V40, P409, DOI 10.1016/0167-0115(92)90527-2; Wayner MJ, 2001, PEPTIDES, V22, P1403, DOI 10.1016/S0196-9781(01)00475-2; WRIGHT JW, 1993, BRAIN RES BULL, V32, P497, DOI 10.1016/0361-9230(93)90297-O; Wright JW, 1999, J NEUROSCI, V19, P3952; WRIGHT JW, 1995, FRONT NEUROENDOCRIN, V16, P23, DOI 10.1006/frne.1995.1002	27	379	394	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48623	48626		10.1074/jbc.C100512200	http://dx.doi.org/10.1074/jbc.C100512200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11707427	hybrid			2022-12-25	WOS:000173922100003
J	Birbes, H; El Bawab, S; Hannun, YA; Obeid, LM				Birbes, H; El Bawab, S; Hannun, YA; Obeid, LM			Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis	FASEB JOURNAL			English	Article						targeting; ceramide; mitochondria; apoptosis; Bcl-2; cytochrome c	PERMEABILITY TRANSITION PORE; CERAMIDE-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DISTINCT POOL; CELL-SURFACE; BCL-2; ACTIVATION; MEMBRANES; DEATH	Our previous results have indicated that the major cellular pool of sphingomyelin present on the outer leaflet of the plasma membrane is not involved in the ceramide pathway of apoptosis. Thus, in this study we aimed at defining which intracellular pools of sphingomyelin and ceramide are involved in cell death. The bacterial sphingomyelinase (SMase) gene fused with green fluorescent protein was subcloned into mammalian vectors containing sequences that target the fusion proteins to cytoplasm, plasma membrane, mitochondria, Golgi apparatus, endoplasmic reticulum, or nucleus. Transfection of MCF7 breast cancer cells showed for all constructs an increase in SMase activity ranging from 2- to 60-fold, concomitant with an increase in total cellular ceramide levels (10-100%) as compared with vector-transfected cells. Next, the effect of overexpression of the SMase on cell death was examined. Results demonstrate that only when bacterial SMase was targeted to mitochondria did cells undergo apoptosis; its targeting to the other intracellular compartments was ineffective. Further, the results show that apoptosis induced by mitochondrial targeting of bacterial SMase requires SMase catalytic activity, is prevented by the overexpression of Bcl-2, and is mediated by inducing cytochrome c release. These results demonstrate that ceramide induces cell death specifically when generated in mitochondria. The results highlight the significance of compartment-specific lipid-mediated cell regulation, and they offer a novel general approach for these studies.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,Strom Thurmond Bldg,Room 605, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1995, J LIPID RES, V36, P611; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; COLLEY CM, 1973, BIOCHIM BIOPHYS ACTA, V307, P74, DOI 10.1016/0005-2736(73)90026-6; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAWYLER AJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P130, DOI 10.1016/0005-2736(83)90325-5; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	60	205	212	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2669	2679		10.1096/fj.01-0539com	http://dx.doi.org/10.1096/fj.01-0539com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726543				2022-12-25	WOS:000172964800037
J	Jackson, JG; Zhang, XH; Yoneda, T; Yee, D				Jackson, JG; Zhang, XH; Yoneda, T; Yee, D			Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines	ONCOGENE			English	Article						breast neoplasms; insulin-like growth factors; cell migration; insulin receptor substrate; adhesion	GROWTH-FACTOR-I; IGF-I; EPITHELIAL-CELLS; EXPRESSION; ADHESION; INTEGRINS; MIGRATION; CARCINOMA; PHENOTYPE; PROTEINS	Insulin-like growth factors (IGFs) regulate breast cancer cell proliferation, protect cells from apoptosis, and enhance metastasis. In this study, we examined the IGF signaling pathway in two breast cancer cell lines selected for metastatic behavior. LCC6 was, selected for growth as, an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P). The MDA-231BO cell line was derived from osseous metastases that formed after intracardiac injection of the MDA-MB-231 cell line in athymic mice. Compared to the parental cell Rues, IGF-I treatment enhanced IRS-2 phosphorylation over IRS-I in the metastatic variants. IGF-I stimulated cell migration in the variant cells, but not in the parental cells. To. determine the role for IRS-2 in IGF-mediated motility, we transfected MDA-231BO cells with, an anti-sense IRS-2 construct. Transfected cells had decreased levels of IRS-2. with diminished IGF-mediated motility and anchorage independent growth when compared to control cells. However, adherence to fibronectin was. enhanced in the transfected cells compared to MD A-231BO cells. Our data show that breast cancer cells selected for metastatic behavior in vivo have increased IRS-2 activation and signaling. In these cells, IGF-I enhances cell adhesion and motility suggesting that IRS-2 may mediate these aspects of the malignant phenotype.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA; Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Div Endocrinol, Dept Med, San Antonio, TX 78229 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Yee, D (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA074285, P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA74285, P30CA54174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; CULLEN KJ, 1990, CANCER RES, V50, P48; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; LONG L, 1995, CANCER RES, V55, P1006; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yu GH, 1998, AM J CLIN PATHOL, V109, P315, DOI 10.1093/ajcp/109.3.315; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	32	105	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7318	7325		10.1038/sj.onc.1204920	http://dx.doi.org/10.1038/sj.onc.1204920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704861				2022-12-25	WOS:000171894200004
J	Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP				Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP			The proliferative and apoptotic activities of E2F1 in the mouse retina	ONCOGENE			English	Article						E2F1; p53; RB and retinoblastoma	S-PHASE ENTRY; RETINOBLASTOMA GENE FAMILY; TRANSCRIPTION FACTOR E2F1; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; DEREGULATED EXPRESSION; FIBROBLASTS LEADS; TRANSGENIC MICE; PROTEIN; RB	The E2F1 transcription factor controls cell proliferation and apoptosis. E2F1 activity is negatively regulated by the retinoblastoma (RB) protein. To study how inactivation of Rb and dysregulated E2F1 affects the developing retina, we analysed wild-type and Rb-/- embryonic retinas and retinal transplants and we established transgenic mice expressing human E2F1 in retinal photoreceptor cells under the regulation of the IRBP promoter (TgIRBPE2F1). A marked increase in cell proliferation and apoptosis was observed in the retinas of Rb-/- mice and TgIRBPE2F1 transgenic mice. In the transgenic mice, photoreceptor cells formed rosette-like arrangements at postnatal days 9 through 28. Complete loss of photoreceptors followed in the TgIRBPE2F1 mice but not in the Rb-/- retinal transplants. Both RB-deficient and E2F1-overexpressing photoreceptor cells expressed rhodopsin, a marker of terminal differentiation. Loss of p53 partially reduced the apoptosis and resulted in transient hyperplasia of multiple cell types in the TgIRBPE2F1 retinas at postnatal day 6. Our findings support the concept that cross-talk occurs between different retinal cell types and that multiple genetic pathways must become dysregulated for the full oncogenic transformation of neuronal retinal cells.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Connecticut, Hlth Sci Ctr, Dept Neurosci, Farmington, CT 06030 USA; Med Coll Ohio, Dept Anat & Neurobiol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio; St Jude Children's Research Hospital; University of Connecticut	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	Leee@uthscsa.edu			NCI NIH HHS [P30 CA 54174, CA49649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174, R29CA049649, R37CA049649, R01CA049649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Belliveau MJ, 2000, J NEUROSCI, V20, P2247; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKIN M, 1993, DEV BRAIN RES, V75, P146, DOI 10.1016/0165-3806(93)90075-L; HANKIN MH, 1987, J COMP NEUROL, V263, P455, DOI 10.1002/cne.902630310; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIOU GI, 1990, J BIOL CHEM, V265, P8373; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Skapek SX, 2000, J BIOL CHEM, V275, P7212, DOI 10.1074/jbc.275.10.7212; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Udovichenko IP, 1998, J BIOL CHEM, V273, P7181, DOI 10.1074/jbc.273.13.7181; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1984, CELL, V85, P537; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	64	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7073	7084		10.1038/sj.onc.1204932	http://dx.doi.org/10.1038/sj.onc.1204932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704831				2022-12-25	WOS:000171739300010
J	Kabuta, T; Hakuno, F; Asano, T; Takahashi, SI				Kabuta, T; Hakuno, F; Asano, T; Takahashi, SI			Insulin receptor substrate-3 functions as transcriptional activator in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SUBCELLULAR-LOCALIZATION; PHOSPHOTYROSINE PROTEIN; CELLS; EXPRESSION; 3-KINASE; MEMBER; FAMILY; CAMP; GENE	The family of insulin receptor substrates (IRSs) has been reported to play important roles for signal transduction of various hormones. Four members of the IRS family have been described. Each IRS is believed to have different functions; however, the distinct physiological roles of each IRS are unclear. This study was undertaken to determine the intracellular localization of IRS-3. IRS-3 was expressed in COS-7 cells as fusion with a green fluorescent protein (GFP), and subcellular localization of the chimera protein was analyzed by fluorescent microscopy. Surprisingly, GFP-IRS-3 was localized not only adjacent to the plasma membrane but also in the nucleus. We confirmed by immunostaining with anti-IRS-3 antibody that non-fused IRS-3 protein is also localized in the nucleus of COS-7 cells that were transfected with IRS-3 cDNA. In addition, we detected endogenous IRS-3 in the nucleus of isolated rat adipocytes. We then studied subcellular localization of deletion mutants and fragments of IRS-3 fused with GFP. We found that the region corresponding to amino acid residues 192-223 in the phosphotyrosine binding domain played an important role in nuclear localization. This region includes sequences that are unique to IRS-3. We then investigated intracellular localization of other IRSs fused with GFP. GFP-IRS-1, GFP-IRS-2, and GFP-IRS-4 were mainly localized in the cytosol or plasma membranes. Chimeric protein, Gal4 DNA binding domain fused with IRS-3 C-terminal region, increased transcription of the reporter gene containing Gal4 binding site in human embryonic kidney 293 cells. These results suggest that intracellular localization of IRS-3 is determined by a different mechanism from other IRS proteins, and that IRS-3 possesses a transcription-regulating activity.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Takahashi, SI (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	atkshin@mail.ecc.u-tokyo.ac.jp	Kabuta, Tomohiro/B-2948-2015	Kabuta, Tomohiro/0000-0002-3058-2596; Takahashi, Shin-Ichiro/0000-0002-2323-2010; Hakuno, Fumihiko/0000-0002-4447-6225				Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Ariga M, 2000, BIOCHEM J, V348, P409, DOI 10.1042/0264-6021:3480409; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; KOYAMA H, 1976, J CELL PHYSIOL, V88, P49, DOI 10.1002/jcp.1040880107; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; LYNCH WE, 1970, J BIOL CHEM, V245, P3911; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	24	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6846	6851		10.1074/jbc.M107058200	http://dx.doi.org/10.1074/jbc.M107058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724774	hybrid			2022-12-25	WOS:000174104300014
J	Wobser, H; Dussmann, H; Kogel, D; Wang, HY; Reimertz, C; Wollheim, CB; Byrne, MM; Prehn, JHM				Wobser, H; Dussmann, H; Kogel, D; Wang, HY; Reimertz, C; Wollheim, CB; Byrne, MM; Prehn, JHM			Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; NF-KAPPA-B; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; INSULIN SECRETORY RESPONSES; DEPENDENT DIABETES-MELLITUS; TISSUE-SPECIFIC KNOCKOUT; CYTOCHROME-C RELEASE; TRANSCRIPTION FACTOR; BCL-X; NEURONAL APOPTOSIS	Maturity onset diabetes of the young (MODY) 3 is a monogenic form of diabetes caused by mutations in the transcription factor hepatocyte nuclear factor (HNF)-1. We investigated the involvement of apoptotic events in INS-1alpha insulinoma cells overexpressing wild-type HNF-1alpha (WT-HNF-1alpha) or a dominant-negative mutant (DN-HNF-1alpha) under control of a doxycycline-dependent transcriptional activator. Forty-eight h after induction of DN-HNF-1alpha, INS-1 cells activated caspase-3 and underwent apoptotic cell death, while cells overexpressing WT-HNF-1alpha remained viable. Mitochondrial cytochrome c release and activation of caspase-9 accompanied DN-HNF-1alpha-induced apoptosis, suggesting the involvement of the mitochondrial apoptosis pathway. Activation of caspases was preceded by mitochondrial hyperpolarization and decreased expression of the anti-apoptotic protein Bcl-xL. Transient overexpression of Bcl-xL was sufficient to rescue INS-1 cells from DN-HN-F-1alpha-induced apoptosis. Both WT- and DN-HNF-1alpha-expressing cells demonstrated similar increases in apoptosis when cultured at high glucose (25 mm). In contrast, induction of DN-HNF-1alpha highly sensitized cells to ceramide toxicity. In cells cultured at low glucose, DN-HNF-1alpha induction also caused up-regulation of the cell cycle inhibitor p27(KIP1). Therefore, our data indicate that increased sensitivity to the mitochondrial apoptosis pathway and decreased cell proliferation may account for the progressive loss of beta-cell function seen in MODY 3 subjects.	Westphalian Wilhelms Univ, Fac Med,Dept Pharmacol & Toxicol, Interdisciplinary Ctr Clin Res,IZKF, Res Grp Apoptosis & Cell Death, D-48149 Munster, Germany; Univ Geneva, Med Ctr, Div Clin Biochem & Expt Diabetol, Dept Internal Med, CH-1211 Geneva, Switzerland	University of Munster; University of Geneva	Prehn, JHM (corresponding author), Westphalian Wilhelms Univ, Fac Med,Dept Pharmacol & Toxicol, Interdisciplinary Ctr Clin Res,IZKF, Res Grp Apoptosis & Cell Death, Rontgenstr 21, D-48149 Munster, Germany.	prehn@uni-muenster.de	Prehn, Jochen HM/A-3928-2010; Byrne, Maria/A-8310-2017	Prehn, Jochen HM/0000-0003-3479-7794; Byrne, Maria/0000-0002-9394-8698; Kogel, Donat/0000-0003-1209-0210; Dussmann, Heiko/0000-0002-3582-8057				Bernard C, 1999, FASEB J, V13, P1195, DOI 10.1096/fasebj.13.10.1195; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FAJANS SS, 1994, LIFE SCI, V55, P413, DOI 10.1016/0024-3205(94)90052-3; Finegood DT, 2001, DIABETES, V50, P1021, DOI 10.2337/diabetes.50.5.1021; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hansen T, 1997, DIABETES, V46, P726, DOI 10.2337/diabetes.46.4.726; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200; Koyama M, 1998, AM J PATHOL, V153, P537, DOI 10.1016/S0002-9440(10)65596-4; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LEAHY JL, 1993, DIABETOLOGIA, V36, P1238, DOI 10.1007/BF00400800; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; Ozes ON, 1999, NATURE, V401, P82; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; WARD WK, 1988, DIABETES, V37, P723, DOI 10.2337/diabetes.37.6.723; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamagata K, 1998, DIABETES, V47, P1231, DOI 10.2337/diabetes.47.8.1231; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	48	49	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6413	6421		10.1074/jbc.M108390200	http://dx.doi.org/10.1074/jbc.M108390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11724785	hybrid, Green Published			2022-12-25	WOS:000173989200095
J	Oven, M; Page, JE; Zenk, MH; Kutchan, TM				Oven, M; Page, JE; Zenk, MH; Kutchan, TM			Molecular characterization of the homo-phytochelatin synthase of soybean Glycine max - Relation to phytochelatin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-BINDING PEPTIDES; THIOL PEPTIDES; HIGHER-PLANTS; GLUTATHIONE; CADMIUM; DETOXIFICATION; ARABIDOPSIS; COMPLEXES; YEAST	The phytochelatin homologs homo-phytochelatins are heavy metal-binding peptides present in many legumes. To study the biosynthesis of these compounds, we have isolated and functionally expressed a cDNA GmhPCS1 encoding homo-phytochelatin synthase from Glycine max, a plant known to accumulate homo-phytochelatins rather than phytochelatins upon the exposure to heavy metals. The catalytic properties of GmhPCS1 were compared with the phytochelatin synthase AtPCS1 from Arabidopsis thaliana. When assayed only in the presence of glutathione, both enzymes catalyzed phytochelatin formation. GmhPCS1 accepted homoglutathione as the sole substrate for the synthesis of homo-phytochelatins whereas AtPCS1 did not. Homo-phytochelatin synthesis activity of both recombinant enzymes was significantly higher when glutathione was included in the reaction mixture. The incorporation of both glutathione and homoglutathione into homo-phytochelatin, n = 2, was demonstrated using GmhPCS1 and AtPCS1. In addition to bis(glutathionato)(.)metal complexes, various other metal(.)thiolates were shown to contribute to the activation of phytochelatin synthase. These complexes were not accepted as substrates by the enzyme, thereby suggesting that a recently proposed model of activation cannot fully explain the catalytic mechanism of phytochelatin synthase (Vatamaniuk, O. K., Mari, S., Lu, Y. P., and Rea, P. A. (2000) J. Biol. Chem. 275, 31451-31459).	Leibniz Inst Pflanzenbiochem, D-06120 Halle Saale, Germany; Univ Halle Wittenberg, Biozentrum, D-06120 Halle Saale, Germany	Leibniz Institut fur Pflanzenbiochemie; Martin Luther University Halle Wittenberg	Kutchan, TM (corresponding author), Leibniz Inst Pflanzenbiochem, Weinberg 3, D-06120 Halle Saale, Germany.		Kutchan, Toni/L-4625-2013					Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, PLANT PHYSIOL, V123, P825, DOI 10.1104/pp.123.3.825; FALBE J, 1999, ROMPP LEXIKON CHEM, P4589; GEKELER W, 1989, Z NATURFORSCH C, V44, P361; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GRILL E, 1986, FEBS LETT, V205, P47, DOI 10.1016/0014-5793(86)80863-8; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; GRILL E, 1988, PLANT CELL REP, V7, P375, DOI 10.1007/BF00269516; GRILL E, 1987, P NATL ACAD SCI USA, V84, P439, DOI 10.1073/pnas.84.2.439; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Inouhe M, 2000, PLANT PHYSIOL, V123, P1029, DOI 10.1104/pp.123.3.1029; KADIMA W, 1990, J INORG BIOCHEM, V38, P277, DOI 10.1016/0162-0134(90)80003-G; KLAPHECK S, 1994, PLANT PHYSIOL, V104, P1325, DOI 10.1104/pp.104.4.1325; KLAPHECK S, 1995, PLANT PHYSIOL, V107, P515, DOI 10.1104/pp.107.2.515; Kubota H, 2000, PHYTOCHEMISTRY, V53, P239, DOI 10.1016/S0031-9422(99)00493-8; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; LIPPARD SJ, 1995, BIOINORGNAISCHE CHEM; Loftier S, 1989, FEBS LETT, V258, P42; MEUWLY P, 1995, PLANT J, V7, P391, DOI 10.1046/j.1365-313X.1995.7030391.x; NOSAKA Y, 1995, J PHYS CHEM-US, V99, P8317, DOI 10.1021/j100020a066; Oven M, 2001, PLANT PHYSIOL, V126, P1275, DOI 10.1104/pp.126.3.1275; PRICE CA, 1957, NATURE, V180, P148, DOI 10.1038/180148a0; RAUSER WE, 1990, ANNU REV BIOCHEM, V59, P61, DOI 10.1146/annurev.bi.59.070190.000425; Sambrook J., 2002, MOL CLONING LAB MANU; Sharpe A. G., 1992, INORGANIC CHEM; STEFFENS JC, 1990, ANNU REV PLANT PHYS, V41, P553, DOI 10.1146/annurev.pp.41.060190.003005; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	31	86	94	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4747	4754		10.1074/jbc.M108254200	http://dx.doi.org/10.1074/jbc.M108254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11706029	hybrid			2022-12-25	WOS:000173962900027
J	Richer, JK; Jacobsen, BM; Manning, NG; Abel, MG; Wolf, DM; Horwitz, KB				Richer, JK; Jacobsen, BM; Manning, NG; Abel, MG; Wolf, DM; Horwitz, KB			Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR EXPRESSION; MAMMARY-GLAND DEVELOPMENT; EPIDERMAL-GROWTH-FACTOR; DOWN-REGULATION; B EXPRESSION; C/EBP-BETA; A-FORM; ESTROGEN; PROTEIN; PHOSPHORYLATION	The PR-A and PR-B isoforms of progesterone receptors (PR) have different physiological functions, and their ratio varies widely in breast cancers. To determine whether the two PR regulate different genes, we used human breast cancer cell lines engineered to express one or the other isoform. Cells were treated with progesterone in triplicate, time-separated experiments, allowing statistical analyses of microarray gene expression data. Of 94 progesterone-regulated genes, 65 are uniquely regulated by PR-B, 4 uniquely by PR-A, and only 25 by both. Almost half the genes encode proteins that are membrane-bound or involved in membrane. initiated signaling. We also find an important set of progesterone-regulated genes involved in mammary gland development and/or implicated in breast cancer. This first, large scale study of PR gene regulation has important implications for the measurement of PR in breast cancers and for the many clinical uses of synthetic progestins. It suggests that it is important to distinguish between the two isoforms in breast cancers and that isoform-specific genes can be used to screen for ligands that selectively modulate the activity of PR-A or PR-B. Additionally, use of natural target genes, rather than "consensus" response elements, for transcription studies should improve our understanding of steroid hormone action.	Univ Colorado, Sch Med, Dept Med Endocrinol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Obstet & Gynecol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Richer, JK (corresponding author), Univ Colorado, Sch Med, Dept Med Endocrinol, Box B-151,4200 E 9th Ave, Denver, CO 80262 USA.	jennifer.richer@uchsc.edu		Horwitz, Kathryn/0000-0001-7402-6455; Jacobsen, Britta/0000-0001-8234-1690	NCI NIH HHS [CA26869] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026869, R01CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arcuri F, 1996, ENDOCRINOLOGY, V137, P595, DOI 10.1210/en.137.2.595; BAEZ M, 1987, J BIOL CHEM, V262, P6582; Bamberger AM, 2000, HORM RES, V54, P32; BERGSTRAESSER LM, 1995, AM J PATHOL, V147, P1823; Bethea CL, 1998, ENDOCRINOLOGY, V139, P677, DOI 10.1210/en.139.2.677; BOYDLEINEN PA, 1982, ENDOCRINOLOGY, V111, P30, DOI 10.1210/endo-111-1-30; CLERMONT Y, 1993, ANAT RECORD, V237, P318, DOI 10.1002/ar.1092370304; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; Darnel AD, 1999, J STEROID BIOCHEM, V70, P203, DOI 10.1016/S0960-0760(99)00116-8; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; FEIL PD, 1988, ENDOCRINOLOGY, V123, P2506, DOI 10.1210/endo-123-5-2506; Foster KW, 2000, CANCER RES, V60, P6488; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Friedmann Y, 1996, DEV BIOL, V177, P347, DOI 10.1006/dbio.1996.0168; Fujimoto J, 1997, J STEROID BIOCHEM, V62, P449, DOI 10.1016/S0960-0760(97)00057-5; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; GRAHAM JD, 1995, CANCER RES, V55, P5063; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Horwitz K B, 1985, Recent Prog Horm Res, V41, P249; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HORWITZ KB, 1982, CELL, V28, P633, DOI 10.1016/0092-8674(82)90218-5; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; Howell A, 1998, RECENT RESULTS CANC, V152, P227; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATO J, 1993, J STEROID BIOCHEM, V47, P173, DOI 10.1016/0960-0760(93)90072-5; Kimmick G G, 1998, Cancer Treat Res, V94, P231; Krikun G, 1998, J CLIN ENDOCR METAB, V83, P926, DOI 10.1210/jc.83.3.926; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lo AKF, 2001, CANCER LETT, V163, P117, DOI 10.1016/S0304-3835(00)00683-2; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOCKWOOD CJ, 1993, J CLIN ENDOCR METAB, V76, P231, DOI 10.1210/jc.76.1.231; Lockwood CJ, 2000, J CLIN ENDOCR METAB, V85, P297, DOI 10.1210/jc.85.1.297; Lwaleed BA, 1999, J PATHOL, V187, P291; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mangal RK, 1997, J STEROID BIOCHEM, V63, P195, DOI 10.1016/S0960-0760(97)00119-2; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Mote PA, 2001, J CLIN PATHOL, V54, P624, DOI 10.1136/jcp.54.8.624; Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963; Mote PA, 2000, HUM REPROD, V15, P48, DOI 10.1093/humrep/15.suppl_3.48; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; Nacht M, 1999, CANCER RES, V59, P5464; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SARTORIUS CA, 1994, CANCER RES, V54, P3668; Sato M, 1998, BRAIN DEV-JPN, V20, P50, DOI 10.1016/S0387-7604(97)00099-5; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; SPELSBERG TC, 1980, ENDOCRINOLOGY, V107, P1234, DOI 10.1210/endo-107-4-1234; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; Tung L, 2001, J BIOL CHEM, V276, P39843, DOI 10.1074/jbc.M106843200; Ueno T, 2000, BRIT J CANCER, V83, P164; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Zhang ZP, 2001, MOL CELL ENDOCRINOL, V172, P223, DOI 10.1016/S0303-7207(00)00372-5; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093	73	453	474	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5209	5218		10.1074/jbc.M110090200	http://dx.doi.org/10.1074/jbc.M110090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11717311	hybrid			2022-12-25	WOS:000173962900086
J	Hulme, JT; Ahn, M; Hauschka, SD; Scheuer, T; Catterall, WA				Hulme, JT; Ahn, M; Hauschka, SD; Scheuer, T; Catterall, WA			A novel leucine zipper targets AKAP15 and cyclic AMP-dependent protein kinase to the C terminus of the skeletal muscle Ca2+ channel and modulates its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; CALCIUM CHANNELS; ANCHORING PROTEIN; COILED-COIL; BINDING DOMAIN; AMINO-ACID; PHOSPHORYLATION; SUBUNIT; ALPHA-1; IDENTIFICATION	In skeletal muscle, voltage-dependent potentiation of L-type Ca2+ channel (Ca(V)1.1) activity requires phosphorylation by cyclic AMP-dependent protein kinase (PKA) anchored via an A kinase-anchoring protein (AKAP15). However, the mechanism by which AKAP15 targets PKA to L-type Ca2+ channels has not been elucidated. Here we report that AKAP15 directly interacts with the C-terminal domain of the a, subunit of CaV1.1 via a leucine zipper (LZ) motif. Disruption of the LZ interaction effectively inhibits voltage-dependent potentiation of L-type Ca2+ channels in skeletal muscle cells. Our results reveal a novel mechanism whereby anchoring of PKA to Ca2+ channels via LZ interactions ensures rapid and efficient phosphorylation of Ca2+ channels in response to local signals such as cAMP and depolarization.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	wcatt@u.washington.edu		Ahn, Misol/0000-0002-6088-8481	NHLBI NIH HHS [P01 HL 44948] Funding Source: Medline; NIAMS NIH HHS [R01 AR18860] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; FLEIG A, 1995, J PHYSIOL-LONDON, V489, P41, DOI 10.1113/jphysiol.1995.sp021028; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Hauschka SD, 1979, MUSCLE REGENERATION, P311; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Johnson BD, 1997, J NEUROSCI, V17, P1243; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KERNELL D, 1983, EXP BRAIN RES, V50, P220; LAI Y, 1990, J BIOL CHEM, V265, P20839; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Stone-Hulslander J, 1999, J VIROL, V73, P3630, DOI 10.1128/JVI.73.5.3630-3637.1999; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Yu MS, 1996, J VIROL, V70, P7085, DOI 10.1128/JVI.70.10.7085-7091.1996	36	99	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4079	4087		10.1074/jbc.M109814200	http://dx.doi.org/10.1074/jbc.M109814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11733497	hybrid			2022-12-25	WOS:000173813900039
J	Williams, G; Williams, EJ; Doherty, P				Williams, G; Williams, EJ; Doherty, P			Dimeric versions of two short N-cadherin binding motifs (HAVDI and INPISG) function as N-cadherin agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; RECEPTOR TYROSINE KINASE; FIBROBLAST-GROWTH-FACTOR; NEURITE OUTGROWTH; IN-VIVO; GRANULOSA-CELL; AMINO-ACIDS; FGF; PHOSPHORYLATION; EXPRESSION	N-cadherin is a member of the classical cadherin family of homophilic binding molecules. Peptide competition studies have identified the HAVDI and INPISGQ sequences as functional binding motifs,in extracellular domain I (ECD1) of N-cadherin. Whereas monomeric versions of these motifs function as specific N-cadherin antagonists, we now show that cyclic peptides containing a tandem repeat of the individual motifs function as N-cadherin agonists. In this context, when presented to neurons as soluble molecules, the dimeric versions of the motifs stimulate neurite outgrowth in a similar manner to native N-cadherin. The response to the dimeric agonist peptides was inhibited by monomeric versions of the same motif and also by recombinant N-cadherin ECD1 protein. The responses were also inhibited by antibodies to a fibroblast growth factor receptor (FGFR) binding motif in ECD4 of N-cadherin and by a specific FGFR antagonist (PD17304). These data suggest that the peptides function by binding to and clustering N-cadherin in neurons and thereby activating an N-cadherin/FGFR signaling cascade. The novel agonists will be invaluable for dissecting out those cadherin functions that rely on signaling as opposed to adhesion and clearly have the potential to be developed as therapeutic agents for the promotion of cell survival and axonal regeneration.	Kings Coll London, Ctr Dev Neurobiol, Mol Neurobiol Grp, MRC, London SE1 1UL, England	University of London; King's College London	Doherty, P (corresponding author), Kings Coll London, Ctr Dev Neurobiol, Mol Neurobiol Grp, MRC, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Doherty, Patrick/A-8752-2008; Williams, Gareth/B-3202-2010	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689				Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BARAMI K, 1994, NEURON, V13, P567, DOI 10.1016/0896-6273(94)90026-4; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hamby JM, 1997, J MED CHEM, V40, P2296, DOI 10.1021/jm970367n; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Lom B, 1998, J NEUROBIOL, V37, P633, DOI 10.1002/(SICI)1097-4695(199812)37:4<633::AID-NEU11>3.0.CO;2-L; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Shan WS, 1999, BIOPHYS CHEM, V82, P157, DOI 10.1016/S0301-4622(99)00115-5; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Skaper SD, 2000, J NEUROCHEM, V75, P1520, DOI 10.1046/j.1471-4159.2000.0751520.x; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Williams EJ, 2000, MOL CELL NEUROSCI, V15, P456, DOI 10.1006/mcne.2000.0847; WILLIAMS EJ, 1995, J CELL SCI, V108, P3523; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629	45	50	53	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4361	4367		10.1074/jbc.M109185200	http://dx.doi.org/10.1074/jbc.M109185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726665	hybrid			2022-12-25	WOS:000173813900076
J	Frankel, A; Yadav, N; Lee, JH; Branscombe, TL; Clarke, S; Bedford, MT				Frankel, A; Yadav, N; Lee, JH; Branscombe, TL; Clarke, S; Bedford, MT			The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; S-ADENOSYLMETHIONINE; FISSION YEAST; HUMAN HOMOLOG; METHYLATION; BINDING; INTERACTS; DOMAIN; SKB1; RNA	Protein arginine methylation is a prevalent posttranslational modification in eukaryotic cells that has been implicated in signal transduction, the metabolism of nascent pre-RNA, and the transcriptional activation processes. In searching the human genome for protein arginine N-methyltransferase (PRMT) family members, a novel gene has been found on chromosome I that encodes for an apparent methyltransferase, PRMT6. The polypeptide chain of PRMT6 is 41.9 kDa consisting of a catalytic core sequence common to other PRMT enzymes. Expressed as a glutathione S-transferase fusion protein, PRMT6 demonstrates type I PRMT activity, capable of forming both omega-N(G)-monomethylarginine and asymmetric omega-N(G),N(G)-dimethylarginine derivatives on the recombinant glycine- and arginine-rich substrate in a processive manner with a specific activity of 144 pmol methyl groups transferred min(-1) mg(-1) enzyme. A comparison of substrate specificity reveals that PRMT6 is functionally distinct from two previously characterized type I enzymes, PRMT1 and PRMT4. In addition, PRMT6 displays automethylation activity; it is the first PRMT to do so. This novel human PRMT, which resides solely in the nucleus when fused to the green fluorescent protein, joins a family of enzymes with diverse functions within cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bedford, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	mbedford@sprd1.mdacc.tmc.edu	Bedford, Mark T/E-7856-2011		NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [T32 GM07185, GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, T32GM007185, R01GM026020] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bailey J.L., 1967, TECHNIQUES PROTEIN C; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bao SL, 2001, J BIOL CHEM, V276, P14549, DOI 10.1074/jbc.C100096200; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Belyanskaya LL, 2001, J BIOL CHEM, V276, P18681, DOI 10.1074/jbc.M011446200; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Kzhyshkowska J, 2001, BIOCHEM J, V358, P305, DOI 10.1042/0264-6021:3580305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Nikawa J, 1996, GENE, V171, P107, DOI 10.1016/0378-1119(96)00073-X; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	60	270	275	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3537	3543		10.1074/jbc.M108786200	http://dx.doi.org/10.1074/jbc.M108786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724789	hybrid, Green Published			2022-12-25	WOS:000173688000064
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Analysis of transmembrane segment 10 of the Glut1 glucose transporter by cysteine-scanning mutagenesis and substituted cysteine accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOFACIAL LIGAND-BINDING; SUGAR PERMEATION PATHWAY; HUMAN-ERYTHROCYTE; XENOPUS-OOCYTES; DOMAINS; FAMILY; SYSTEM; HEPG2; SITE	The Glut1 glucose transporter has been proposed to form an aqueous sugar translocation pathway through the lipid bilayer via the clustering of several transmembrane helices (Mueckler, M., Caruso, C., Baldwin, S. A, Panico, M., Blench, I., Morris, H. R., Allard, W. J., Lienhard, G. E., and Lodish, H. F. (1985) Science 229,941-945). The participation of transmembrane helix 10 in the formation of this putative aqueous tunnel was tested using cysteine-scanning mutagenesis in conjunction with the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). A series of 21 mutants was created from a fully functional, cysteine-less, parental Glut1 molecule by changing each residue within putative transmembrane segment 10 to cysteine. Each mutant was then expressed in Xenopus oocytes, and its plasma membrane content, 2-deoxyglucose uptake activity, and sensitivity to pCMBS were measured. Helix 10 exhibited a highly distinctive reaction profile to scanning mutagenesis whereby cysteine substitution at residues within the cytoplasmic N-terminal half of the helix tended to increase specific transport activity, whereas substitution at residues within the exoplasmic C-terminal half of the helix tended to decrease specific transport activity. Four residues within helix 10 were clearly accessible to pCMBS as judged by inhibition or stimulation of transport activity. All four of these residues were clustered along one face of a putative a-helix. These results combined with previously published data suggest that transmembrane segment 10 of Glut1 forms part of the sugar permeation pathway. Two-dimensional models for the conformation of the 12 transmembrane helices and the exofacial glucose-binding site of Glut1 are proposed that are consistent with existing experimental data.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Inukai K, 1994, BIOCHEM J, V291, P861; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Stein W., 2012, TRANSPORT DIFFUSION; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	28	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3498	3503		10.1074/jbc.M109157200	http://dx.doi.org/10.1074/jbc.M109157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11713254	hybrid			2022-12-25	WOS:000173688000059
J	Olland, AM; Underwood, KW; Czerwinski, RM; Lo, MC; Aulabaugh, A; Bard, J; Stahl, ML; Somers, WS; Sullivan, FX; Chopra, R				Olland, AM; Underwood, KW; Czerwinski, RM; Lo, MC; Aulabaugh, A; Bard, J; Stahl, ML; Somers, WS; Sullivan, FX; Chopra, R			Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMN ADENYLYLTRANSFERASE; ENZYMATIC-PROPERTIES; NAD BIOSYNTHESIS; PROTEIN; GENE; CYTIDYLYLTRANSFERASE; PURIFICATION; SYNTHETASE; EXPRESSION	The nadD gene, encoding the enzyme nicotinic acid mononucleotide (NaMN) adenylyltransferase (AT), is essential for the synthesis of NAD and subsequent viability of the cell. The nadD gene in Bacillus subtilis (yqeJ) was identified by sequence homology with other bacterial nadD genes and by biochemical characterization of the gene product. NaMN AT catalyzes the reversible adenylation of both NaMN and the nicotinamide mononucleotide (NAIN) but shows specificity for the nicotinate. In contrast to other known NMN ATs, biophysical characterizations reveal it to be a dimer. The NaMN AT crystal structure was determined for both the apo enzyme and product-bound form, to 2.1 and 3.2 Angstrom, respectively. The structures reveal a "functional" dimer conserved in both crystal forms and a monomer fold common to members of the nucleotidyl-transferase alpha/beta phosphodiesterase superfamily. A structural comparison with family members suggests a new conserved motif (SXXXX(R/K)) at the N terminus of an alpha-helix, which is not part of the shared fold. Interactions of the nicotinic acid with backbone atoms indicate the structural basis for specificity.	Wyeth Ayerst Res, Dept Biol Chem, Cambridge, MA 02140 USA	Pfizer	Chopra, R (corresponding author), Wyeth Ayerst Res, Dept Biol Chem, 35 Cambridge Pk Dr, Cambridge, MA 02140 USA.	rchopra@Genetics.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; BALDUCCI E, 1995, BIOCHEM J, V310, P395, DOI 10.1042/bj3100395; Begley TP, 2001, VITAM HORM, V61, P103; Bell CE, 1997, PROTEIN SCI, V6, P2084; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HUGHES KT, 1983, J BACTERIOL, V155, P213, DOI 10.1128/JB.155.1.213-221.1983; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Mehl RA, 2000, J BACTERIOL, V182, P4372, DOI 10.1128/JB.182.15.4372-4374.2000; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; NATALINI P, 1986, BIOCHEMISTRY-US, V25, P3725, DOI 10.1021/bi00360a037; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, MOL CELL BIOCHEM, V193, P99, DOI 10.1023/A:1006968328186; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x; [No title captured]	38	48	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3698	3707		10.1074/jbc.M109670200	http://dx.doi.org/10.1074/jbc.M109670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11704676	hybrid			2022-12-25	WOS:000173688000084
J	Yang, M; Fong, HKW				Yang, M; Fong, HKW			Synthesis of the all-trans-retinal chromophore of retinal G protein-coupled receptor opsin in cultured pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RGR OPSIN; VITAMIN-A; BINDING PROTEINS; VISUAL PIGMENT; IMMUNOCYTOCHEMICAL LOCALIZATION; BIOCHEMICAL ASPECTS; VERTEBRATE RETINA; BOVINE RETINA; RAT RETINA; REGENERATION	Light-dependent production of 11-cis-retinal by the retinal pigment epithelium (RPE) and normal regeneration of rhodopsin under photic conditions involve the RPE retinal G protein-coupled receptor (RGR) opsin. This microsomal opsin is bound to all-trans-retinal which, upon illumination, isomerizes stereospecifically to the 11-cis isomer. In this paper, we investigate the synthesis of the all-trans-retinal chromophore of RGR in cultured ARPE-hRGR and freshly isolated bovine RPE cells. Exogenous all-trans-[H-3]retinol is incorporated into intact RPE cells and converted mainly into retinyl esters and all-trans-retinal. The intracellular processing of all-trans-[H-3]retinol results in physiological binding to RGR of a radiolabeled retinoid, identified as all-trans-[H-3]retinal. The ARPE-hRGR cells contain a membrane-bound NADPH-dependent retinol dehydrogenase that reacts efficiently with all-trans-retinol but not the 11-cis isomer. The NADPH-dependent all-trans-retinol dehydrogenase activity in isolated RPE microsomal membranes can be linked in vitro to specific binding of the chromophore to RGR. These findings provide confirmation that RGR opsin binds the chromophore, all-transretinal, in the dark. A novel all-trans-retinol dehydrogenase exists in the RPE and performs a critical function in chromophore biosynthesis.	Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Fong, HKW (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.				NEI NIH HHS [EY03040, EY08364] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008364, P30EY003040] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLANER WS, 1987, J BIOL CHEM, V262, P53; BOK D, 1984, INVEST OPHTH VIS SCI, V25, P877; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Chen XN, 1996, HUM GENET, V97, P720; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; EISENFELD AJ, 1985, EXP EYE RES, V41, P299, DOI 10.1016/S0014-4835(85)80020-8; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Hao WS, 2000, METHOD ENZYMOL, V316, P413; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; Jang GF, 2000, J BIOL CHEM, V275, P28128; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; KATO T, 1973, ANAL BIOCHEM, V53, P86, DOI 10.1016/0003-2697(73)90409-0; LANDERS GM, 1990, METHOD ENZYMOL, V189, P70; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; MATA NL, 1992, J BIOL CHEM, V267, P9794; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; MCCORMICK AM, 1982, J BIOL CHEM, V257, P1730; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; OZAKI K, 1983, BIOPHYS J, V44, P127, DOI 10.1016/S0006-3495(83)84285-4; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Qtaishat NM, 1999, INVEST OPHTH VIS SCI, V40, P1040; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1982, J BIOL CHEM, V257, P13329; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246, DOI 10.1164/ajrccm.163.5.2007135; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; Tao L, 1998, Mol Vis, V4, P25; TIMMERS AM, 1991, EXP EYE RES, V52, P129, DOI 10.1016/0014-4835(91)90253-B; WILLIAMS JB, 1984, J LIPID RES, V25, P638; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; Yang M, 2000, MOL VIS, V6, P237; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	51	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3318	3324		10.1074/jbc.M108946200	http://dx.doi.org/10.1074/jbc.M108946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723126	hybrid			2022-12-25	WOS:000173688000036
J	Fladmark, KE; Brustugun, OT; Mellgren, G; Krakstad, C; Boe, R; Vintermyr, OK; Schulman, H; Doskeland, SO				Fladmark, KE; Brustugun, OT; Mellgren, G; Krakstad, C; Boe, R; Vintermyr, OK; Schulman, H; Doskeland, SO			Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; MULTIFUNCTIONAL CAM KINASE; OKADAIC-ACID; PHOSPHATASE INHIBITORS; CATALYTIC ACTIVITY; CALYCULIN-A; CELL-LINE; CALMODULIN; PHOSPHORYLATION; AUTOPHOSPHORYLATION	The potent natural toxins microcystin, nodularin, and okadaic acid act rapidly to induce apoptotie cell death. Here we show that the apoptosis correlates with protein phosphorylation events and can be blocked by protein kinase inhibitors directed against the multifunctional Ca2+/calmodulin-dependent protein kinase 11 (CaMKII). The inhibitors used comprised a battery of cell-permeable protein kinase antagonists and CaMKII-directed peptide inhibitors introduced by microinjection or enforced expression. Furthermore, apoptosis could be induced by enforced expression of active forms of CaMKII but not with inactive CaMKII. It is concluded that the apoptogenic toxins, presumably through their known ability to inhibit serine/threonine protein phosphatases, can cause CaMKII-dependent phosphorylation events leading to cell death.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	University of Bergen; Stanford University	Doskeland, SO (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.		Krakstad, Camilla/AAB-5138-2020; Mellgren, Gunnar/AAG-6573-2020	Krakstad, Camilla/0000-0002-0174-8139; Mellgren, Gunnar/0000-0001-6282-4986; Doskeland, Stein Ove/0000-0002-4009-4756				BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P419; CHAMBERS TC, 1993, INT J CANCER, V53, P323, DOI 10.1002/ijc.2910530225; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; CONNELLY PA, 1987, J BIOL CHEM, V262, P10154; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; DOSKELAND AP, 1992, EUR J BIOCHEM, V206, P161, DOI 10.1111/j.1432-1033.1992.tb16913.x; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; GJERTSEN BT, 1994, J CELL SCI, V107, P3363; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IKEBE M, 1990, J BIOL CHEM, V265, P8975; Ishida A, 2001, J BIOCHEM, V129, P745, DOI 10.1093/oxfordjournals.jbchem.a002915; Ishida A, 1998, FEBS LETT, V427, P115, DOI 10.1016/S0014-5793(98)00405-0; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kawamura T, 1998, BIOCHEM PHARMACOL, V55, P995, DOI 10.1016/S0006-2952(97)00539-X; Kikuchi K, 1999, INT J MOL MED, V4, P395; Krebs EG, 2000, ADV ENZYME REGUL, V40, P441, DOI 10.1016/S0065-2571(99)00030-8; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Mellgren G, 1997, ENDOCRINOLOGY, V138, P4373, DOI 10.1210/en.138.10.4373; MELLGREN G, 1995, J CELL PHYSIOL, V163, P232, DOI 10.1002/jcp.1041630203; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Morimoto Y, 1999, ORAL DIS, V5, P104; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Sandal T, 2001, CELL DEATH DIFFER, V8, P754, DOI 10.1038/sj.cdd.4400873; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; SPASSOVA M, 1995, EUR BIOPHYS J, V24, P69, DOI 10.1007/BF00211401; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VINTERMYR OK, 1993, J CELL PHYSIOL, V156, P160, DOI 10.1002/jcp.1041560122; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; ZHENG B, 1994, J BIOL CHEM, V269, P12332	48	102	108	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2804	2811		10.1074/jbc.M109049200	http://dx.doi.org/10.1074/jbc.M109049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713251	hybrid			2022-12-25	WOS:000173421500058
J	Gilbert, L; He, XF; Farmer, P; Rubin, J; Drissi, H; van Wijnen, AJ; Lian, JB; Stein, GS; Nanes, MS				Gilbert, L; He, XF; Farmer, P; Rubin, J; Drissi, H; van Wijnen, AJ; Lian, JB; Stein, GS; Nanes, MS			Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2 alpha A) is inhibited by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; TRANSCRIPTION FACTOR; 1,25-DIHYDROXYVITAMIN D-3; DEOXYRIBONUCLEIC-ACID; COLLAGEN-SYNTHESIS; CBFA1; RAT; CELLS	The transcription factor RUNX2 (Cbfal/AML3/Pebp-2alphaA) is a critical regulator of osteoblast differentiation. We investigated the effect of the inflammatory cytokine tumor necrosis factor alpha (TNF) on the expression of RUNX2 because TNF is known to inhibit differentiation of ostcoblasts from pluripotent progenitor cells. TNF treatment of fetal calvaria precursor cells or MC3T3-E1 clonal pre-osteoblastic cells caused a dose-dependent suppression of RUNX2 steady state mRNA as measured by reverse transcription-PCR. The IC50 for TNF inhibition was 0.6 ng/ml. TNF suppression of RUNX2 mRNA was confirmed using Northern analysis. The effect of TNF was studied using isoform-specific primers that flanked unique regions of two major RUNX2 isoforms. TNF suppressed expression of the mRNA coding for the shorter MRIPV isoform by >90% while inhibiting expression of the mRNA for the longer MASNS isoform by 50%. RUNX2 nuclear content was evaluated by electrophoretic mobility shift assay using a rat osteocalcin promoter binding sequence as probe and by Western analysis. TNF reduced nuclear RUNX2 protein. Inhibition of new protein synthesis with cycloheximide failed to prevent TNF inhibition of RUNX2 mRNA, suggesting that a newly translated protein did not mediate the TNF effect. RUNX2 mRNA half-life was 1.8 h and reduced to 0.9 h by TNF. The effect of TNF on RUNX2 gene transcription was evaluated using a 0.6.kb RUNX2 promoter-luciferase reporter in MC3T3-E1 cells. TNF caused a dose-dependent inhibition of transcription to 50% of control values. The inhibitory effect of TNF was preserved with deletions to nucleotide -108 upstream of the translational start site; however, localization downstream of nucleotide -108 was obscured by loss of basal activity. Our results indicate that TNF regulates RUNX2 expression at multiple levels including destabilization of mRNA and suppression of transcription. The disproportionate inhibition of RUNX2 nuclear protein suggests that additional post-transcriptional mechanisms may be occurring. Suppression of RUNX2 by TNF may decrease ostcoblast differentiation and inhibit bone formation in TNF excess states.	Altanta Vet Affairs Med Ctr 111, Div Endocrinol & Metab, Atlanta, GA 30033 USA; Emory Univ, Sch Med, Atlanta, GA 30033 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Emory University; University of Massachusetts System; University of Massachusetts Worcester	Nanes, MS (corresponding author), Altanta Vet Affairs Med Ctr 111, Div Endocrinol & Metab, 1670 Clairmont Rd, Atlanta, GA 30033 USA.	mnanes@emory.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; drissi, hicham/0000-0002-3322-281X	NIAMS NIH HHS [R01 AR46452-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046452] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; Aubin Jane E., 1996, P51; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Bae SC, 2001, J BONE JOINT SURG AM, V83A, pS48; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281-200005000-00006; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756-3282(99)00111-8; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KUNO H, 1994, ENDOCRINOLOGY, V134, P2524, DOI 10.1210/en.134.6.2524; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; LIAN JB, 2001, OSTCOPOROSIS; MCCABE LR, 1994, J CELL BIOCHEM, V56, P274, DOI 10.1002/jcb.240560221; NANES MS, 1989, ENDOCRINOLOGY, V124, P339, DOI 10.1210/endo-124-1-339; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Ogawa S, 2000, DNA RES, V7, P181, DOI 10.1093/dnares/7.3.181; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; RALSTON SH, 1990, J BONE MINER RES, V5, P983; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Tsuji K, 2000, BIOCHEM BIOPH RES CO, V274, P171, DOI 10.1006/bbrc.2000.3112; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	49	349	364	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2695	2701		10.1074/jbc.M106339200	http://dx.doi.org/10.1074/jbc.M106339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11723115	hybrid			2022-12-25	WOS:000173421500043
J	Kim, Y; Kim, S; Earnest, TN; Hol, WGJ				Kim, Y; Kim, S; Earnest, TN; Hol, WGJ			Precursor structure of cephalosporin acylase - Insights into autoproteolytic activation in a new N-terminal hydrolase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTARYL-7-AMINOCEPHALOSPORANIC ACID; STRAIN; MECHANISM; PROTEINS; CLASSIFICATION; MOLSCRIPT; SUBUNIT; PROGRAM	Autocatalytic proteolytic cleavage is a frequently observed post-translational modification in proteins. Cephalosporin acylase (CA) is a recently identified member of the N-terminal hydrolase family that is activated from an inactive precursor by autoproteolytic processing, generating a new N-terminal residue, which is either a Ser or a Thr. The N-terminal Ser or Thr becomes a nucleophilic catalytic center for intramolecular and intermolecular amide cleavages. The gene structure of the open reading frame of CAs generally consists of a signal peptide followed by the alpha-subunit, a spacer sequence, and the beta-sub-unit, which are all translated into a single polypeptide chain, the CA precursor. The precursor is post-translationally modified into an active heterodimeric enzyme with alpha- and beta-subunits, first by intramolecular cleavage and second by intermolecular cleavage. We solved the first CA precursor structure (code 1KEH) from a class I CA from Pseudomonas diminuta at a 2.5-Angstrom resolution that provides insight into the mechanism of intramolecular cleavage. A conserved water molecule, stabilized by four hydrogen bonds in unusual pseudotetrahedral geometry, plays a key role to assist the OG atom of Ser(1beta) to generate a strong nucleophile. In addition, the site of the secondary intermolecular cleavage of CA is proposed to be the carbonyl carbon of Gly(158alpha) (Kim, S., and Kim, Y., (2001) J. BioL Chem., 276,48376-48381), which is different from the situation in two other class I CAs.	Yeungnam Univ, Sch Chem Engn, Kyongsan 712749, South Korea; Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley Ctr Struct Biol, Berkeley, CA 94720 USA; Univ Washington, Dept Biochem, Biomol struct Ctr, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	Yeungnam University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Kim, Y (corresponding author), Yeungnam Univ, Sch Chem Engn, Dae Dong, Kyongsan 712749, South Korea.	ykim1@yu.ac.kr	Kim, Youngsoo/D-6046-2012					BINDER R, 1994, APPL ENVIRON MICROB, V60, P1805, DOI 10.1128/AEM.60.6.1805-1809.1994; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DW, 1999, J MICROBIOL, V37, P200; Kim Y, 2001, CHEM BIOL, V8, P1253, DOI 10.1016/S1074-5521(01)00092-8; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwon TH, 2000, J STRUCT BIOL, V131, P79, DOI 10.1006/jsbi.2000.4256; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; Lee YS, 2000, J BIOL CHEM, V275, P39200, DOI 10.1074/jbc.M002504200; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRYER L, 1995, BIOCHEMISTRY-US, P222; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TISCHER W, 1992, ANN NY ACAD SCI, V672, P502; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	32	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2823	2829		10.1074/jbc.M108888200	http://dx.doi.org/10.1074/jbc.M108888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706000	hybrid, Green Submitted			2022-12-25	WOS:000173421500060
J	Matsuo, N; Hoshino, M; Yoshizawa, M; Nabeshima, Y				Matsuo, N; Hoshino, M; Yoshizawa, M; Nabeshima, Y			Characterization of STEF, a guanine nucleotide exchange factor for Rac1, required for neurite growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RHO-FAMILY GTPASES; CELL-MIGRATION; MEMBRANE; PROTEIN; TIAM1; IDENTIFICATION; PROMOTES; KINASE; OUTGROWTH	Accumulating evidence suggests that Rho family GTPases play critical roles in the organization of the nervous system. We previously identified a guanine nucleotide exchange factor of Rac1, STEF (SIF and Tiam 1-like exchange factor), which can induce ruffling membrane in KB cells and is predominantly expressed in the brain during development. Here, we characterize the molecular nature of STEF and its involvement in neurite growth. Deletion analyses revealed distinct roles for individual domains: PHnTSS for membrane association, DH for enzymatic activity, and PHc for promoting catalytic activity. Ectopic expression of STEF in N1E-115 neuroblastoma cells induced neurite-like processes containing F-actin, betaIII tubulin, MAP2, and GAP43 in a Rac1-dependent manner even under the serum-containing neurite-inhibiting conditions. We further found that a PHnTSS STEF fragment specifically inhibited the function of both STEF and Tiam1, a closely related Rac1 guanine nucleotide exchange factor. Suppression of endogenous STEF and Tiam1 activities in N1E-115 cells by ectopically expressed PHnTSS STEF resulted in inhibition of neurite outgrowth in serum-starved conditions, which usually induce neurite formation. Furthermore, these inhibitory effects were rescued by exogenously expressed STEF or Tiam1, suggesting that STEF and Tiam1 are involved in neurite formation through the activation of Rac1 and successive cytoskeletal reorganization of neuronal cells during development.	Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Hoshino, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan.	mikio@lmls.med.kyoto-u.ac.jp	Yoshizawa, Masato/AFD-8467-2022; Yoshizawa, Masato/D-6276-2013; Matsuo, Naoki/B-9929-2008; Yoshizawa, Masato/AAE-9415-2022	Yoshizawa, Masato/0000-0001-8455-8252; Yoshizawa, Masato/0000-0001-9488-2283; Matsuo, Naoki/0000-0003-0988-4706; Yoshizawa, Masato/0000-0001-8455-8252				Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Sone M, 2000, DEVELOPMENT, V127, P4157; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	41	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2860	2868		10.1074/jbc.M106186200	http://dx.doi.org/10.1074/jbc.M106186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707441	hybrid			2022-12-25	WOS:000173421500065
J	Milla, P; Athenstaedt, K; Viola, F; Oliaro-Bosso, S; Kohlwein, SD; Daum, G; Balliano, G				Milla, P; Athenstaedt, K; Viola, F; Oliaro-Bosso, S; Kohlwein, SD; Daum, G; Balliano, G			Yeast oxidosqualene cyclase (Erg7p) is a major component of lipid particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2,3-OXIDOSQUALENE CYCLASE; STEROL BIOSYNTHESIS; SQUALENE-2,3-EPOXIDE CYCLASES; SUBCELLULAR-LOCALIZATION; PARTIAL-PURIFICATION; SQUALENE EPOXIDASE; MOLECULAR-CLONING; CANDIDA-ALBICANS; RAT-LIVER	Oxidosqualene cyclase of the yeast encoded by the ERG7 gene converts oxidosqualene to lanosterol, the first cyclic component of sterol biosynthesis. In a previous study (Athenstaedt, K., Zweytick, D., Jandrositz, A, Kohlwein, S. D., and Daum, G. (1999) J. Bacteriol 181, 6441-6448), Erg7p was identified as a component of yeast lipid particles. Here, we present evidence that Erg7p is almost exclusively associated with this compartment as shown by analysis of enzymatic activity, Western blot analysis, and in vivo localization of Erg7p-GFP. Occurrence of oxidosqualene cyclase in other organelles including the endoplasmic reticulum is negligible. In an erg7 deletion strain or in wild-type cells treated with an inhibitor of oxidosqualene cyclase, the substrate of Erg7p, oxidosqualene, accumulated mostly in lipid particles. Storage in lipid particles of this intermediate produced in excess may provide a possibility to exclude this membrane-perturbing component from other organelles. Thus, our data provide evidence that lipid particles are not only a depot for neutral lipids, but also participate in coordinate sterol metabolism and trafficking and serve as a storage site for compounds that may negatively affect membrane integrity.	Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	University of Turin; Graz University of Technology	Balliano, G (corresponding author), Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farmaco, Corso Raffaello 31, I-10125 Turin, Italy.	balliano@pharm.unito.it	Milla, Paola/H-7596-2012	Milla, Paola/0000-0002-4245-4161; Kohlwein, Sepp Dieter/0000-0002-1030-0598; Athenstaedt, Karin/0000-0001-7198-3989				Abe I, 1996, J AM CHEM SOC, V118, P9180, DOI 10.1021/ja961643a; ABE I, 1989, FEBS LETT, V249, P100, DOI 10.1016/0014-5793(89)80024-9; ABE I, 1992, CHEM PHARM BULL, V40, P1755, DOI 10.1248/cpb.40.1755; ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1992, ARCH BIOCHEM BIOPHYS, V293, P122, DOI 10.1016/0003-9861(92)90374-6; BALLIANO G, 1988, BIOCHIM BIOPHYS ACTA, V959, P9, DOI 10.1016/0005-2760(88)90144-0; Ceruti M, 1998, J MED CHEM, V41, P540, DOI 10.1021/jm970534j; CERUTI M, 1992, J MED CHEM, V35, P3050, DOI 10.1021/jm00094a020; COREY EJ, 1995, J AM CHEM SOC, V117, P11819, DOI 10.1021/ja00152a030; COREY EJ, 1991, J AM CHEM SOC, V113, P8172, DOI 10.1021/ja00021a056; DAUM G, 1982, J BIOL CHEM, V257, P3028; Davis R W, 1980, Methods Enzymol, V65, P404; FIELD RB, 1979, LIPIDS, V14, P741, DOI 10.1007/BF02533900; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GIETZ RD, 1995, METHODS MOL CELL BIO, V43, P177; HOSHINO T, 1991, TETRAHEDRON, V47, P5925, DOI 10.1016/S0040-4020(01)86485-1; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KELLY R, 1990, GENE, V87, P177, DOI 10.1016/0378-1119(90)90299-7; Kohlwein SD, 2000, MICROSC RES TECHNIQ, V51, P511, DOI 10.1002/1097-0029(20001215)51:6<511::AID-JEMT3>3.3.CO;2-P; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEBER R, 1995, BBA-BIOMEMBRANES, V1234, P119, DOI 10.1016/0005-2736(94)00270-Y; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Milla P, 1999, LIPIDS, V34, P681, DOI 10.1007/s11745-999-0413-5; MOORE WR, 1992, J BIOL CHEM, V267, P22003; NES WD, 1990, RECENT ADV PHYTOCHEM, V24, P283; PETRANYI G, 1987, ANTIMICROB AGENTS CH, V31, P1558, DOI 10.1128/AAC.31.10.1558; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; RYDER NS, 1991, BIOCHEM SOC T, V19, P774, DOI 10.1042/bst0190774; SERVOUSE M, 1986, BIOCHEM J, V240, P541, DOI 10.1042/bj2400541; SHECHTER I, 1970, Biochimica et Biophysica Acta, V220, P463, DOI 10.1016/0005-2744(70)90277-9; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	46	70	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2406	2412		10.1074/jbc.M104195200	http://dx.doi.org/10.1074/jbc.M104195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706015	hybrid			2022-12-25	WOS:000173421500007
J	Murillas, R; Simms, KS; Hatakeyama, S; Weissman, AM; Kuehn, MR				Murillas, R; Simms, KS; Hatakeyama, S; Weissman, AM; Kuehn, MR			Identification of developmentally expressed proteins that functionally interact with Nedd4 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WW DOMAINS; FAMILY; DROSOPHILA; PROTEASOME; RECEPTORS; MACHINERY; MODULES; BINDING; NOTCH; GENE	Nedd4 is a HECT domain-containing ubiquitin ligase that mediates ubiquitylation and proteasome degradation of target proteins. The molecular basis for the interaction of Nedd4 with substrates lies in its WW domains, which can bind proline-rich (PY) domains in target proteins. Nedd4 is a developmentally expressed protein and may have a fundamental role to play in embryonic processes. However, whether Nedd4 has such a function is currently unknown, in part because few developmentally regulated ubiquitylation substrates have been identified or characterized. We have carried out a yeast two-hybrid screen and identified four proteins expressed in the mid-gestation embryo that are able to interact with Nedd4. Characterization of their functional interaction with Nedd4 in vitro and in vivo demonstrated that three of the four are bona fide Nedd4 binding partners, and two have the capacity to be ubiquitylation substrates. One of these is the first identified nonviral substrate for Nedd4-mediated monoubiquitylation. Interestingly, neither of these two ubiquitylated proteins interacts with Nedd4 through PY-mediated mechanisms. For one of the three Nedd4 binding partners, there was no discernable evidence of ubiquitylation. However, this protein clearly associates with Nedd4 through its PY domains and can alter the location of Nedd4 in cells, suggesting a role other than as a ubiquitylation substrate.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Regulat Prot Funct Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kuehn, MR (corresponding author), Bldg 10,Rm 4B-36,10 Ctr Dr, Bethesda, MD 20892 USA.		Kuehn, Michael R/A-4573-2014; Hatakeyama, Shigetsugu/C-8333-2012; MURILLAS, RODOLFO/H-8121-2017	Kuehn, Michael R/0000-0002-7703-9160; Hatakeyama, Shigetsugu/0000-0002-2150-9979; MURILLAS, RODOLFO/0000-0001-9813-1006				Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cornell M, 1999, GENETICS, V152, P567; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hamilton MH, 2001, J BIOL CHEM, V276, P26324, DOI 10.1074/jbc.M101205200; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Recalcati S, 2001, J CELL SCI, V114, P1625; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Weston AD, 2000, MECH DEVELOP, V94, P247, DOI 10.1016/S0925-4773(00)00299-9; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	40	58	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2897	2907		10.1074/jbc.M110047200	http://dx.doi.org/10.1074/jbc.M110047200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11717310	hybrid			2022-12-25	WOS:000173421500069
J	Sinclair, JF; O'Brien, AD				Sinclair, JF; O'Brien, AD			Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma of enterohemorrhagic Escherichia coli O157 : H7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O157-H7 REQUIRES INTIMIN; TISSUE-CULTURE CELLS; HEP-2 CELLS; ACTIN CYTOSKELETON; MAMMALIAN-CELLS; BINDING-PROTEIN; MOLECULAR EVOLUTION; NEURITE OUTGROWTH; GENETIC-LOCUS; IN-VITRO	Intimin-gamma is an outer membrane protein of enterohemorrhagic Escherichia coli (EHEC) O157:H7 that is required for the organism to adhere tightly to HEp-2 cells and to colonize experimental animals. Another EHEC O157:H7 protein, the Transferred intimin receptor (Tir), is considered the primary receptor for intimin-gamma. Nevertheless, Tir-independent binding of intimin-gamma to HEp-2 cells has been reported. This observation suggests the existence of a eukaryotic receptor(s) for intimin-gamma. In this study, we sought to identify that receptor(s). First, we determined by equilibrium binding titration that the association of purified intimin-gamma with HEp-2 cells was specific and consistent with a single host cell receptor. Second, we isolated a protein from lysates of HEp-2 cells that bound intimin-gamma and subsequently identified this molecule as nucleolin, a protein involved in cell growth regulation that can be cell surface-expressed. Third, we established that purified intimin-gamma and nucleolin were co-localized on the surface of HEp-2 cells and that the site of EHEC O157:H7 attachment was associated with regions of nucleolin expression. Finally, we demonstrated that mouse anti-nucleolin sera significantly decreased the adherence of EHEC O157:H7 to HEp-2 cells. From this, we conclude that nueleolin is the HEp-2 cell receptor for intimin-gamma expressed by EHEC O157:117.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	O'Brien, AD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aobrien@usuhs.mil		O'Brien, Alison/0000-0002-1315-3204	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020148, R01AI020148, R22AI020148] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20148-16] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adu-Bobie J, 1998, J CLIN MICROBIOL, V36, P662, DOI 10.1128/JCM.36.3.662-668.1998; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Batchelor M, 2000, EMBO J, V19, P2452, DOI 10.1093/emboj/19.11.2452; Brown MD, 2000, J NEUROBIOL, V43, P352, DOI 10.1002/1097-4695(20000615)43:4<352::AID-NEU4>3.0.CO;2-T; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dean-Nystrom EA, 1998, INFECT IMMUN, V66, P4560; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; DeVinney R, 1999, INFECT IMMUN, V67, P2389, DOI 10.1128/IAI.67.5.2389-2398.1999; Dogic D, 1998, J CELL SCI, V111, P793; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1418, DOI 10.1172/JCI116718; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; Frankel G, 1998, MOL MICROBIOL, V29, P559, DOI 10.1046/j.1365-2958.1998.00950.x; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; Gansheroff LJ, 1999, INFECT IMMUN, V67, P6409; Ginisty H, 1999, J CELL SCI, V112, P761; Goosney DL, 1999, TRENDS CELL BIOL, V9, P11, DOI 10.1016/S0962-8924(98)01418-4; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; KAPER JB, 1998, ESCHERICHIA COLI O15, P148; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; Knutton S, 1997, INFECT IMMUN, V65, P1644, DOI 10.1128/IAI.65.5.1644-1652.1997; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; Liu H, 1999, INFECT IMMUN, V67, P2045; Liu H, 1999, MOL MICROBIOL, V34, P67, DOI 10.1046/j.1365-2958.1999.01574.x; LUO Y, 2000, ANTURE, V405, P1073; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; McGraw EA, 1999, MOL BIOL EVOL, V16, P12, DOI 10.1093/oxfordjournals.molbev.a026032; McKee ML, 1996, INFECT IMMUN, V64, P2225, DOI 10.1128/IAI.64.6.2225-2233.1996; MCKEE ML, 1995, INFECT IMMUN, V63, P3739, DOI 10.1128/IAI.63.9.3739-3744.1995; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; Oswald E, 2000, INFECT IMMUN, V68, P64, DOI [10.1128/IAI.68.1.64-71.2000, 10.1128/IAI.68.11.6402-6410.2000]; Perna NT, 1998, INFECT IMMUN, V66, P3810, DOI 10.1128/IAI.66.8.3810-3817.1998; Phillips AD, 2000, MICROBIOL-SGM, V146, P1333, DOI 10.1099/00221287-146-6-1333; Phillips AD, 2000, J INFECT DIS, V181, P1496, DOI 10.1086/315404; Phillips AD, 2000, GUT, V47, P377, DOI 10.1136/gut.47.3.377; Sorokina EA, 1999, J BIOL CHEM, V274, P27491, DOI 10.1074/jbc.274.39.27491; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TZIPORI S, 1995, INFECT IMMUN, V63, P3621, DOI 10.1128/IAI.63.9.3621-3627.1995; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; Wilson BA, 2000, INFECT IMMUN, V68, P4531, DOI 10.1128/IAI.68.8.4531-4538.2000; Yu DH, 1998, BIOCHEM BIOPH RES CO, V247, P186, DOI 10.1006/bbrc.1998.8754; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	71	155	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2876	2885		10.1074/jbc.M110230200	http://dx.doi.org/10.1074/jbc.M110230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704679	Green Submitted, hybrid			2022-12-25	WOS:000173421500067
J	Tarrega, C; Blanco-Aparicio, C; Munoz, JJ; Pulido, R				Tarrega, C; Blanco-Aparicio, C; Munoz, JJ; Pulido, R			Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATION; P38 MAP KINASES; SEE VOL. 292; NUCLEAR TRANSLOCATION; CATALYTIC ACTIVATION; SUBSTRATE SELECTIVITY; IN-VIVO; ERK2; EXPRESSION; SPECIFICITY	Regulated function of mitogen-activated protein (MAP) kinases involves their selective association through docking sites with both activating MAP kinase kinases and inactivating phosphatases, including dual specificity and protein-tyrosine phosphatases (PTP). Site-directed mutagenesis on the mammalian MAP kinases ERK2 and p38alpha identified within their C-terminal docking grooves two clusters of residues important for association with their regulatory PTPs, PTP-SL and STEP. ERK2 and p38alpha mutations that resembled the sevenmaker gain-of-function mutation in the Rolled D. melanogaster ERK2 homologue failed to associate with PTP-SL, were not retained in the cytosol, and were poorly inactivated by this PTP. Additional ERK2 mutations at the docking groove showed deficient association and dephosphorylation by PTP-SL, although their cytosolic retention was unaffected. Other ERK2 mutations, resembling gain-of-function mutations in the FUS3 yeast ERK2 homologue, associated to PTP-SL and were inactivated normally by this PTP. Our results demonstrate that mutations at distinct regions of the docking groove of ERK2 and p38alpha differentially affect their association and regulation by the PTP-SL and STEP PTPs.	Inst Invest Citological Caja Ahorros Valencia, Valencia 46010, Spain		Pulido, R (corresponding author), Inst Invest Citological Caja Ahorros Valencia, Amadeo Saboya 4, Valencia 46010, Spain.	rpulido@ochoa.fib.es	Blanco-Aparicio, Carmen/I-3162-2015	Blanco-Aparicio, Carmen/0000-0002-3249-6595; Pulido, Rafael/0000-0001-9100-248X				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; Augustine KA, 2000, ANAT REC, V258, P221, DOI 10.1002/(SICI)1097-0185(20000301)258:3<221::AID-AR1>3.0.CO;2-W; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KRISHNAN IS, 1994, FEBS LETT, V353, P185, DOI 10.1016/0014-5793(94)01017-X; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lim YM, 1999, GENETICS, V153, P763; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mattison CP, 2000, GENE DEV, V14, P1229; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oellers N, 1996, J BIOL CHEM, V271, P24939, DOI 10.1074/jbc.271.40.24939; Oh-hora M, 1999, J IMMUNOL, V163, P1282; Pettiford SM, 2000, ONCOGENE, V19, P858, DOI 10.1038/sj.onc.1203408; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Raghunathan A, 1996, DEV BRAIN RES, V91, P190, DOI 10.1016/0165-3806(95)00176-X; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Szedlacsek SE, 2001, J MOL BIOL, V311, P557, DOI 10.1006/jmbi.2001.4890; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; van den Maagdenberg AMJM, 1999, EUR J NEUROSCI, V11, P3832, DOI 10.1046/j.1460-9568.1999.00802.x; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Watanabe Y, 1998, MOL BRAIN RES, V58, P83, DOI 10.1016/S0169-328X(98)00100-4; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	71	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2629	2636		10.1074/jbc.M108874200	http://dx.doi.org/10.1074/jbc.M108874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711538	hybrid			2022-12-25	WOS:000173421500034
J	Gampala, SSL; Finkelstein, RR; Sun, SSM; Rock, CD				Gampala, SSL; Finkelstein, RR; Sun, SSM; Rock, CD			ABI5 interacts with abscisic acid signaling effectors in rice protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2C; DNA-BINDING ACTIVITY; ABA RESPONSE LOCI; GUARD-CELL; TRANSCRIPTION FACTORS; GENE-EXPRESSION; BETA-PHASEOLIN; FLOW-CYTOMETRY; DC3 PROMOTER; BZIP FACTOR	Abscisic acid (ABA) regulates seed maturation, germination, and adaptation of vegetative tissues to environmental stresses. The mechanisms of ABA action and the specificity conferred by signaling components in overlapping pathways are not completely understood. The ABI5 gene (ABA insensitive 5) of Arabidopsis encodes a basic leucine zipper factor required for ABA response in the seed and vegetative tissues. Using transient gene expression in rice protoplasts, we provide evidence for the functional interactions of ABI5 with ABA signaling effectors VP1 (viviparous 1) and ABI1 (ABA insensitive 1). Co-transformation experiments with ABI5 cDNA constructs resulted in specific transactivation of the ABA-inducible wheat Em, Arabidopsis AtEm6, bean beta-Phaseolin, and barley HVA1 and HVA22 promoters. Furthermore, ABI5 interacted synergistically with ABA and co-expressed VP1, indicating that ABI5 is involved in ABA-regulated transcription mediated by VP1. ABI5-mediated transactivation was inhibited by overexpression of abi1-1, the dominant-negative allele of the protein phosphatase ABI1, and by 1-butanol, a competitive inhibitor of phospholipase D involved in ABA signaling. Lanthanum, a trivalent ion that acts as an agonist of ABA signaling, potentiated ABI5 transactivation. These results demonstrate that ABI5 is a key target of a conserved ABA signaling pathway in plants.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Chinese Univ Hong Kong, Dept Biol, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; University of California System; University of California Santa Barbara; Chinese University of Hong Kong	Rock, CD (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	borock@ust.hk	Finkelstein, Ruth/Y-3274-2019	, Christopher/0000-0002-2090-0650				Allen GJ, 1999, PLANT CELL, V11, P1785, DOI 10.1105/tpc.11.9.1785; Busk PK, 1997, PLANT CELL, V9, P2261, DOI 10.1105/tpc.9.12.2261; Chak RKF, 2000, PLANTA, V210, P875, DOI 10.1007/s004250050692; Chern MS, 1996, PLANT CELL, V8, P305, DOI 10.1105/tpc.8.2.305; Choi HI, 2000, J BIOL CHEM, V275, P1723, DOI 10.1074/jbc.275.3.1723; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Desikan R, 1999, FEBS LETT, V456, P257, DOI 10.1016/S0014-5793(99)00972-2; FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; FINKELSTEIN RR, 2002, IN PRESS PLANT CELL; Gampala SSL, 2001, J BIOL CHEM, V276, P9855, DOI 10.1074/jbc.M009168200; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Hagenbeek D, 2000, PLANT PHYSIOL, V123, P1553, DOI 10.1104/pp.123.4.1553; Hagenbeek D, 2001, CYTOMETRY, V45, P170, DOI 10.1002/1097-0320(20011101)45:3&lt;170::AID-CYTO1160&gt;3.0.CO;2-Z; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; HOECKER U, 1995, GENE DEV, V9, P2459, DOI 10.1101/gad.9.20.2459; HUANG JWW, 1994, P NATL ACAD SCI USA, V91, P3473, DOI 10.1073/pnas.91.8.3473; Jones HD, 2000, PLANT J, V21, P133, DOI 10.1046/j.1365-313x.2000.00662.x; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Kurup S, 2000, PLANT J, V21, P143, DOI 10.1046/j.1365-313x.2000.00663.x; Leckie CP, 1998, P NATL ACAD SCI USA, V95, P15837, DOI 10.1073/pnas.95.26.15837; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li GF, 1999, P NATL ACAD SCI USA, V96, P7104, DOI 10.1073/pnas.96.12.7104; Liu K, 2001, PLANT CELL, V13, P1453, DOI 10.1105/tpc.13.6.1453; Lopez-Molina L, 2000, PLANT CELL PHYSIOL, V41, P541, DOI 10.1093/pcp/41.5.541; Lopez-Molina L, 2001, P NATL ACAD SCI USA, V98, P4782, DOI 10.1073/pnas.081594298; Lu GH, 1996, PLANT CELL, V8, P847, DOI 10.1105/tpc.8.5.847; Maas C, 1995, METHOD CELL BIOL, V50, P383, DOI 10.1016/S0091-679X(08)61045-6; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakamura S, 2001, PLANT J, V26, P627, DOI 10.1046/j.1365-313x.2001.01069.x; Nantel A, 1996, J BIOL CHEM, V271, P31296, DOI 10.1074/jbc.271.49.31296; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Parcy F, 1997, PLANT CELL, V9, P1265, DOI 10.1105/tpc.9.8.1265; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; RICHIE S, 2000, PLANT PHYSIOL, V124, P693; RICHIE SM, 1998, P NATL ACAD SCI USA, V95, P2697; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Rock CD, 1996, PLANT CELL REP, V15, P371, DOI 10.1007/BF00232374; Rock CD, 2000, NEW PHYTOL, V148, P357, DOI 10.1046/j.1469-8137.2000.00769.x; Rock Christopher D., 1995, P671; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Rohde A, 1999, PLANT CELL ENVIRON, V22, P261, DOI 10.1046/j.1365-3040.1999.00428.x; Sanchez JP, 2001, PLANT CELL, V13, P1143, DOI 10.1105/tpc.13.5.1143; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; Schultz TF, 1996, J BIOL CHEM, V271, P25742, DOI 10.1074/jbc.271.42.25742; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Shen QX, 1997, PHYSIOL PLANTARUM, V101, P653, DOI 10.1111/j.1399-3054.1997.tb01050.x; Shen QX, 2001, PLANT MOL BIOL, V47, P437, DOI 10.1023/A:1011667312754; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; SLIGHTOM JL, 1983, P NATL ACAD SCI-BIOL, V80, P1897, DOI 10.1073/pnas.80.7.1897; Soderman EM, 2000, PLANT PHYSIOL, V124, P1752, DOI 10.1104/pp.124.4.1752; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; SUBRAMANIAN S, 2002, IN PRESS PLANT MOL B; Sutton F, 2000, PLANT PHYSIOL, V124, P223, DOI 10.1104/pp.124.1.223; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255; ZHENG ZW, 1995, PLANT PHYSIOL, V109, P777, DOI 10.1104/pp.109.3.777	73	41	45	5	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1689	1694		10.1074/jbc.M109980200	http://dx.doi.org/10.1074/jbc.M109980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704678	hybrid			2022-12-25	WOS:000173421300011
J	Jung, DJ; Na, SY; Na, DS; Lee, JW				Jung, DJ; Na, SY; Na, DS; Lee, JW			Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RNA-POLYMERASE-II; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; SIGNALING PATHWAYS; N-COR; BINDING; IDENTIFICATION; SPECIFICITY; COREPRESSOR	Transcriptional coactivators either bridge transcription factors and the components of the basal transcription apparatus and/or remodel the chromatin structures. We isolated a novel nuclear protein based on its interaction with the recently described general coactivator activating signal cointegrator-2 (ASC-2). This protein CAPER (for coactivator of activating protein-1 ((AP) over bar -1) and estrogen receptors ((ER) over bars)) selectively bound, among the many transcription factors we tested, the AP-1 component c-Jun and the estradiol-bound ligand binding domains of ERalpha and ERbeta. Interestingly, CAPER exhibited a cryptic autonomous transactivation function that becomes activated only in the presence of estradiol-bound ER. In cotransfections, CAPER stimulated transactivation by ERalpha, ERbeta, and AP-1. Thus, CAPER may represent a more selective transcriptional coactivator molecule that plays a pivotal role for the function of AP-1 and ERs in vivo in conjunction with the general coactivator ASC-2.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Univ Ulsan, Dept Biochem, Coll Med, Seoul 138736, South Korea	Pohang University of Science & Technology (POSTECH); University of Ulsan	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.	jaewoon@postech.ac.kr						Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Greiner EF, 2000, P NATL ACAD SCI USA, V97, P7160, DOI 10.1073/pnas.97.13.7160; Hayes SA, 2001, CANCER RES, V61, P2112; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hirose Y, 2000, GENE DEV, V14, P1415; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	43	77	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1229	1234		10.1074/jbc.M110417200	http://dx.doi.org/10.1074/jbc.M110417200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11704680	hybrid			2022-12-25	WOS:000173166800047
J	Brauer, AU; Savaskan, NE; Kole, MHP; Plaschke, M; Monteggia, LM; Nestler, EJ; Simburger, E; Deisz, RA; Ninnemann, O; Nitsch, R				Brauer, AU; Savaskan, NE; Kole, MHP; Plaschke, M; Monteggia, LM; Nestler, EJ; Simburger, E; Deisz, RA; Ninnemann, O; Nitsch, R			Molecular and functional analysis of hyperpolarization-activated pacemaker channels in the hippocampus after entorhinal cortex lesion	FASEB JOURNAL			English	Article						DDRT-PCR/ECL; HCN; hippocampus; I-h	RAT DENTATE GYRUS; THALAMIC RELAY NEURONS; FASCIA-DENTATA; COMMISSURAL FIBERS; CATION CURRENT; I-H; INDUCED SYNAPTOGENESIS; HISTOCHEMICAL EVIDENCE; ALTERED DEVELOPMENT; CHOLINERGIC FIBERS	Differential display of hippocampal tissue after entorhinal cortex lesion (ECL) revealed decreases in mRNA encoding the neuronal hyperpolarization-activated, cyclic nucleotide-gated channel HCN1. In situ hybridization confirmed that hippocampal transcripts of HCN1, but not HCN2/3/4, are down-regulated after ECL. Expression recovered at similar to 21 days after lesion (dal). Immunohistochemistry demonstrated a corresponding regulation of HCN1 protein expression in CA1-CA3 dendrites, hilar mossy cells and interneurons, and granule cells. Patch-clamp recordings in the early phase after lesion from mossy cells and hilar interneurons revealed an increase in the fast time constant of current activation and a profound negative shift in voltage activation of I-h. Whereas current activation recovered at 30 dal, the voltage activation remained hyperpolarized in mossy cells and hilar interneurons. Granule cells, however, were devoid of any detectable somatic I-h currents. Hence, denervation of the hippocampus decreases HCN1 and concomitantly the I-h activity in hilar neurons, and the recovery of h-current activation kinetics occurs parallel to postlesion sprouting.	Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; German Primate Ctr, Dept Neurobiol, D-37077 Gottingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Deutsches Primatenzentrum (DPZ)	Nitsch, R (corresponding author), Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, Philippstr 12, D-10098 Berlin, Germany.	robert.nitsch@charite.de	Bräuer, Anja/N-3692-2019; Nitsch, Robert/AAI-9129-2021; Braeuer, Anja/K-8339-2013; Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X; Kole, Maarten/0000-0002-3883-5682				ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; Bendotti C, 1996, NEUROREPORT, V7, P2539, DOI 10.1097/00001756-199611040-00027; BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; BRAGIN A, 1995, J NEUROPHYSIOL, V73, P1691, DOI 10.1152/jn.1995.73.4.1691; Brauer AU, 2001, NEUROSCIENCE, V102, P515, DOI 10.1016/S0306-4522(00)00471-1; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; BUCKMASTER PS, 1995, J NEUROSCI, V15, P774; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; DASHEIFF RM, 1982, BRAIN RES, V231, P444, DOI 10.1016/0006-8993(82)90381-X; Deller T, 1999, HIPPOCAMPUS, V9, P314, DOI 10.1002/(SICI)1098-1063(1999)9:3<314::AID-HIPO10>3.3.CO;2-Z; Deller T, 1996, NEUROSCIENCE, V71, P651, DOI 10.1016/0306-4522(95)00475-0; DELLER T, 1995, J COMP NEUROL, V352, P55, DOI 10.1002/cne.903520105; DELLER T, 1995, J NEUROSCI, V15, P6868; Dickson CT, 2000, J NEUROPHYSIOL, V83, P2562, DOI 10.1152/jn.2000.83.5.2562; Franz O, 2000, EUR J NEUROSCI, V12, P2685, DOI 10.1046/j.1460-9568.2000.00151.x; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; FROTSCHER M, 1994, SYNAPSE, V16, P148, DOI 10.1002/syn.890160208; Gasparini S, 1997, PFLUG ARCH EUR J PHY, V435, P99, DOI 10.1007/s004240050488; GOLDEN GT, 1991, NEUROREPORT, V2, P141, DOI 10.1097/00001756-199103000-00008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; KOSAKA T, 1985, J COMP NEUROL, V239, P420, DOI 10.1002/cne.902390408; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIVSEY CT, 1992, NEURON, V8, P745, DOI 10.1016/0896-6273(92)90095-U; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; Monteggia LM, 2000, MOL BRAIN RES, V81, P129, DOI 10.1016/S0169-328X(00)00155-8; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Munsch T, 1999, J PHYSIOL-LONDON, V519, P505, DOI 10.1111/j.1469-7793.1999.0505m.x; NADLER JV, 1977, J COMP NEUROL, V171, P561, DOI 10.1002/cne.901710409; NADLER JV, 1977, J COMP NEUROL, V171, P589, DOI 10.1002/cne.901710410; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NOLAN MF, 2000, SOC NEUR ABSTR, V26, P8032; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PARNAVELAS JG, 1974, NATURE, V248, P71, DOI 10.1038/248071a0; Penttonen M, 1997, HIPPOCAMPUS, V7, P437, DOI 10.1002/(SICI)1098-1063(1997)7:4<437::AID-HIPO9>3.0.CO;2-F; REEVES TM, 1988, EXP NEUROL, V102, P37, DOI 10.1016/0014-4886(88)90076-3; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Savaskan NE, 2000, BRAIN RES, V864, P44, DOI 10.1016/S0006-8993(00)02148-X; SCHARFMAN HE, 1988, J NEUROSCI, V8, P3812; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sciancalepore M, 1998, BRAIN RES, V814, P133, DOI 10.1016/S0006-8993(98)01067-1; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOMOGYI P, 1983, J NEUROSCI, V3, P1450; SORIANO E, 1989, BRAIN RES, V503, P170, DOI 10.1016/0006-8993(89)91722-8; STEWARD O, 1978, BRAIN RES, V149, P216, DOI 10.1016/0006-8993(78)90601-7; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; Strata F, 1997, J NEUROSCI, V17, P1435; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200	70	48	51	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2689	2701		10.1096/fj.01-0235com	http://dx.doi.org/10.1096/fj.01-0235com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726545				2022-12-25	WOS:000172964800039
J	Mirshahi, T; Robillard, L; Zhang, HL; Hebert, TE; Logothetis, DE				Mirshahi, T; Robillard, L; Zhang, HL; Hebert, TE; Logothetis, DE			G beta residues that do not interact with G alpha underlie agonist-independent activity of K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; POTASSIUM CHANNEL; GAMMA-SUBUNITS; INWARD RECTIFIER; CRYSTAL-STRUCTURE; ACTIVATION; IDENTIFICATION; G(BETA-GAMMA); RESOLUTION; INHIBITION	Gbetagamma subunits interact directly and activate G proteingated Inwardly Rectifying K+ (GIRK) channels. Little is known about the identity of functionally important interactions between Gbetagamma and GIRK channels. We tested the effects of all mammalian Gbeta subunits on channel activity and showed that whereas Gbeta1-4 subunits activate heteromeric GIRK channels independently of receptor activation, Gbeta5 does not. Gbeta1 and Gbeta5 both bind the N and C termini of the GIRK1 and GIRK4 channel subunits. Chimeric analysis between the Gbeta1 and Gbeta5 proteins revealed a 90-amino acid stretch that spans blades two and three of the seven-propeller structure and is required for channel activation. Within this region, eight non-conserved amino acids were critical for the activity of Gbeta1, as mutation of each residue to its counterpart in Gbeta5 significantly reduced the ability of Gbeta1 to stimulate channel activity. In particular, mutation of residues Ser-67 and Thr-128 to the corresponding Gbeta5 residues completely abolished Gbeta1 stimulation of GIRK channel activity. Mapping these functionally important residues on the three-dimensional structure of Gbeta1 shows that Ser-67, Ser-98, and Thr-128 are the only surface accessible residues. Galpha(i)1 interacts with Ser-98 but not with Ser-67 and Thr-128 in the heterotrimeric Galphabetagamma structure. Further characterization of the three mutant proteins showed that they fold properly and interact with Ggamma2. Of the three identified functionally important residues, the Ser-67 and Thr-128 Gbeta mutants significantly inhibited basal currents of a channel point mutant that displays Gbetagamma-mediated basal but not agonist-induced currents. Our findings indicate that the presence of GP residues that do not interact with Galpha are involved in Gbetagamma interactions in the absence of agonist stimulation.	NYU, Dept Phys & Biophys, Mt Sinai Sch Med, New York, NY 10029 USA; Univ Montreal, Inst Cardiol Montreal, Ctr Rech, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Anesthesie Reanimat, Montreal, PQ H1T 1C8, Canada	Icahn School of Medicine at Mount Sinai; New York University; Universite de Montreal; Institut de Cardiologie de Montreal; Universite de Montreal	Logothetis, DE (corresponding author), NYU, Dept Phys & Biophys, Mt Sinai Sch Med, New York, NY 10029 USA.				NHLBI NIH HHS [HL 10307, HL 54185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010307, R01HL054185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FIDLERLIM N, 1995, J GEN PHYSIOL, V105, P421; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; HE C, 2002, IN PRESS J BIOL CHEM, V277; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	36	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7348	7355		10.1074/jbc.M109999200	http://dx.doi.org/10.1074/jbc.M109999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11707461	hybrid			2022-12-25	WOS:000174104300078
J	Wang, M; Tan, ZJ; Zhang, R; Kotenko, SV; Liang, P				Wang, M; Tan, ZJ; Zhang, R; Kotenko, SV; Liang, P			Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HUMAN-MELANOMA DIFFERENTIATION; INDUCIBLE FACTOR; FUNCTIONAL-CHARACTERIZATION; IL-TIF; CYTOKINE; IL-10; IDENTIFICATION; CLONING; EXPRESSION	Interleukin 24 (IL-24) encodes a secreted protein that exhibits significant homology to the interleukin 10 (IL-10) family of cytokines. Here we show that the human IL-24 is secreted by activated peripheral blood mononuclear cells and is the ligand for two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. The latter is also the receptor for IL-20. COS cells transfected with either IL-24 receptor heterodimers bind the ligand with similar saturation kinetics. IL-24 binding to either its endogenous receptors on human keratinocytes or to ectopically expressed receptors on baby hamster kidney cells leads to activation of the signal transducers and activators of transcription. Taken together, these results provide compelling evidence for IL-24 being the fourth member of IL-10 family of cytokines to which their specific receptors have been identified.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Vanderbilt University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liang, P (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, 658 MRB 2, Nashville, TN 37232 USA.	peng.liang@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA074067, R01CA076960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485, CA 76960, CA 74067] Funding Source: Medline; NIAID NIH HHS [R01 AI051139, AI 51139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Cleland W W, 1979, Methods Enzymol, V63, P103; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jo H, 2001, METHOD ENZYMOL, V332, P233; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAZAKI I, 1993, J EXP MED, V178, P439, DOI 10.1084/jem.178.2.439; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Schaefer G, 2001, J IMMUNOL, V166, P5859, DOI 10.4049/jimmunol.166.10.5859; Soo C, 1999, J CELL BIOCHEM, V74, P1; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; WANG P, 1994, J IMMUNOL, V153, P811; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	29	218	257	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7341	7347		10.1074/jbc.M106043200	http://dx.doi.org/10.1074/jbc.M106043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11706020	hybrid			2022-12-25	WOS:000174104300077
J	Sbrissa, D; Ikonomov, OC; Shisheva, A				Sbrissa, D; Ikonomov, OC; Shisheva, A			Phosphatidylinositol 3-phosphate-interacting domains in PIKfyve - Binding specificity and role in PIKfyve endomembrane localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE BINDING; FYVE FINGER; ENDOSOMAL LOCALIZATION; PX DOMAINS; KINASE; 3-PHOSPHATE; PROTEIN; IDENTIFICATION; TRANSPORT; CLONING	PIKfyve is a phosphatidylinositol (PtdIns) 3-phosphate (P)-metabolizing enzyme, which, in addition to a C-terminally positioned catalytic domain, harbors several evolutionarily conserved domains, including a FYVE finger. The FYVE finger domains are thought to direct the protein localization to intracellular membrane PtdIns 3-P. Recent studies with several FYVE domain proteins challenge this general concept. Here we have examined the binding of PIKfyve's FYVE domain to PtdIns 3-P in vitro and in vivo and a plausible contribution of this binding mechanism for the intracellular localization of the full-length protein. We document now a specific and high affinity interaction of a recombinantly produced PIKfyve FYVE domain peptide fragment with Ptdlns 3-P-containing liposomes that requires the presence of the conservative core of basic residues within the FYVE domain. PlKfyve localization to membranes of the late endocytic pathway was found to be absolutely dependent on the presence of an intact FYVE finger. Cell treatment with PI 3-kinase inhibitor wortmannin dissociated endosome-bound PlKfyve, indicating that the protein targeted the membrane PtdIns 3-P. An enzymatically inactive peptide fragment of the PlKfyve catalytic domain was found to also specifically bind to Ptdlns 3-P-containing liposomes, with residue Lys-1999 being critical in the interaction. This binding, however, was of relatively low affinity and, in the cellular context, was found ineffective in directing the molecule to Ptdlns 3-P-enriched endosomes. Collectively, these results demonstrate that interaction of the FYVE domain with PtdIns 3-P is absolutely necessary for PIKfyve targeting to the membranes of the late endocytic pathway and determine PlKfyve as a downstream effector of PtdIns 3-P.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ashishev@med.wayne.edu						BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Derubeis AR, 2000, GENE, V255, P195, DOI 10.1016/S0378-1119(00)00303-6; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; IKONOMOV O, 2002, IN PRESS J BIOL CHEM, V277; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Shisheva A, 2001, METHOD ENZYMOL, V329, P39; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SHRISSA D, 2000, BIOCHEMISTRY-US, V39, P15980; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7	37	86	89	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6073	6079		10.1074/jbc.M110194200	http://dx.doi.org/10.1074/jbc.M110194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11706043	hybrid			2022-12-25	WOS:000173989200051
J	Caricasole, A; Bettini, E; Sala, C; Roncarati, R; Kobayashi, N; Caldara, F; Goto, K; Terstappen, GC				Caricasole, A; Bettini, E; Sala, C; Roncarati, R; Kobayashi, N; Caldara, F; Goto, K; Terstappen, GC			Molecular cloning and characterization of the human diacylglycerol kinase beta (DGK beta) gene - Alternative splicing generates DGK beta isotypes with different properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SUBCELLULAR-LOCALIZATION; EXPRESSION; ISOZYME; CELLS; HETEROGENEITY; INVOLVEMENT; PROTEINS; DATABASE; RECEPTOR	Diacylglycerol kinases are key modulators of levels of diacylglycerol, a second messenger involved in a variety of cellular responses to extracellular stimuli. A number of diacylglycerol kinases encoded by separate genes are present in mammalian genomes. We have cloned cDNAs encoding several isoforms of the human homologue of the rat diacylglycerol kinase beta gene and characterized two such isoforms that differ at their carboxyl terminus through alternative splicing and the usage of different polyadenylation signals. Quantitative analysis of gene expression in a panel of human tissue cDNAs revealed that transcripts corresponding to both isoforms are coexpressed in central nervous system tissues and in the uterus, with one variant being expressed at relatively higher levels. As green fluorescent protein fusions, the two isoforms displayed localization to different subcellular compartments, with one variant being associated with the plasma membrane, while the other isoform was predominantly localized within the cytoplasm. Differences were also observed in their subcellular localization in response to phorbol ester stimulation. Enzymatic assays demonstrated that the two isoforms display comparable diacylglycerol kinase activities. Therefore, the human diacylglycerol kinase beta gene can generate several enzyme isoforms, which can display different expression levels and subcellular localization but similar enzymatic activities in vitro.	GlaxoSmithKline, Med Res Ctr, Syst Res Verona, I-37135 Verona, Italy; GlaxoSmithKline, Dept Biol, I-37135 Verona, Italy; Univ Verona, Dept Med & Publ Hlth, Pharmacol Sect, I-37134 Verona, Italy; Yamagata Univ, Sch Med, Dept Anat & Cell Biol, Yamagata 9909585, Japan	GlaxoSmithKline; GlaxoSmithKline; University of Verona; Yamagata University	Bettini, E (corresponding author), GlaxoSmithKline, Med Res Ctr, Syst Res Verona, Via Fleming 4, I-37135 Verona, Italy.							AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Attwood TK, 1999, NUCLEIC ACIDS RES, V27, P220, DOI 10.1093/nar/27.1.220; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bonhomme N, 1998, J CLIN PSYCHOPHARM, V18, P447, DOI 10.1097/00004714-199812000-00005; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; CARISCASOLE A, 2000, Patent No. 0047723; CHEN Q, 1993, J NEUROCHEM, V60, P1212, DOI 10.1111/j.1471-4159.1993.tb03279.x; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; FUJIKAWA K, 1993, BIOCHEM J, V294, P443, DOI 10.1042/bj2940443; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; Goto K, 1996, J LIPID MEDIAT CELL, V14, P251, DOI 10.1016/0929-7855(96)00533-0; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Houssa B, 1997, J BIOL CHEM, V272, P10422; Hurttia H, 1996, BIOCHEM MOL BIOL INT, V40, P579; KAI M, 1994, J BIOL CHEM, V269, P18492; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; KohyamaKoganeya A, 1997, FEBS LETT, V409, P258, DOI 10.1016/S0014-5793(97)00526-7; MARONEY AC, 1989, J CELL BIOCHEM, V40, P165, DOI 10.1002/jcb.240400205; Martelli AM, 2000, CANCER RES, V60, P815; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nogues X, 1997, PROG NEURO-PSYCHOPH, V21, P507, DOI 10.1016/S0278-5846(97)00015-8; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sambrook J., 2002, MOL CLONING LAB MANU; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098	42	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4790	4796		10.1074/jbc.M110249200	http://dx.doi.org/10.1074/jbc.M110249200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719522	hybrid			2022-12-25	WOS:000173962900033
J	Hansen, M; Kun, JFJ; Schultz, JE; Beitz, E				Hansen, M; Kun, JFJ; Schultz, JE; Beitz, E			A single, bi-functional aquaglyceroporin in blood-stage Plasmodium falciparum malaria parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUAPORIN WATER CHANNELS; CULTURE; CELLS; PATHOPHYSIOLOGY; FACILITATOR; PROTEINS; GROWTH; SERUM	The malaria parasite Plasmodium falciparum faces drastic osmotic changes during kidney passages and is engaged in the massive biosynthesis of glycerolipids during its development in the blood-stage. We identified a single aquaglyceroporin (PfAQP) in the nearly finished genome of P. falciparum with highest similarity to the Escherichia coli glycerol facilitator (50.4%), but both canonical Asn-Pro-Ala (NPA) motifs in the pore region are changed to Asn-Leu-Ala (NLA) and Asn-Pro-Ser (NPS), respectively. Expression in Xenopus oocytes renders them highly permeable for both water and glycerol. Sugar alcohols up to five carbons and urea pass the pore. Mutation analyses of the NLA/NPS motifs showed their structural importance, but the symmetrical pore properties were maintained. PfAQP is expressed in blood-stage parasites throughout the development from rings via trophozoites to schizonts and is localized to the parasite but not to the erythrocyte cytoplasm or membrane. Its unique bi-functionality indicates functions in the protection from osmotic stress and efficiently provides access to the serum glycerol pool for the use in ATP generation and primarily in the phospholipid synthesis.	Univ Tubingen, Dept Pharmaceut Biochem, D-72076 Tubingen, Germany; Univ Tubingen, Dept Parasitol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Beitz, E (corresponding author), Univ Tubingen, Dept Pharmaceut Biochem, Morgenstelle 8, D-72076 Tubingen, Germany.		Kun, Jürgen/C-1280-2010					AGARWAL S, 1988, BIOCHEM PHARMACOL, V37, P4605, DOI 10.1016/0006-2952(88)90327-9; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beitz E, 1999, HEARING RES, V132, P76, DOI 10.1016/S0378-5955(99)00036-2; Beitz E, 2000, BIOINFORMATICS, V16, P1050, DOI 10.1093/bioinformatics/16.11.1050; Bill RM, 2001, J BIOL CHEM, V276, P36543, DOI 10.1074/jbc.M105045200; Binh VQ, 1997, AM J TROP MED HYG, V57, P594, DOI 10.4269/ajtmh.1997.57.594; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Carbrey JM, 2001, P NATL ACAD SCI USA, V98, P1000, DOI 10.1073/pnas.98.3.1000; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; Evans ML, 1998, J CLIN ENDOCR METAB, V83, P2952, DOI 10.1210/jc.83.8.2952; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; Mishra Neerad C., 1994, Indian Journal of Malariology, V31, P77; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PUKRITTAYAKAMEE S, 1994, METABOLISM, V43, P887, DOI 10.1016/0026-0495(94)90272-0; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; Vial Henri J., 1992, V18, P259; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zardoya R, 2001, J MOL EVOL, V52, P391, DOI 10.1007/s002390010169; ZOLG JW, 1984, IN VITRO CELL DEV B, V20, P205, DOI 10.1007/BF02618189	37	123	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4874	4882		10.1074/jbc.M110683200	http://dx.doi.org/10.1074/jbc.M110683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729204	hybrid			2022-12-25	WOS:000173962900044
J	Nishioku, T; Hashimoto, K; Yamashita, K; Liou, SY; Kagamiishi, Y; Maegawa, H; Katsube, N; Peters, C; von Figura, K; Saftig, P; Katunuma, N; Yamamoto, K; Nakanishi, H				Nishioku, T; Hashimoto, K; Yamashita, K; Liou, SY; Kagamiishi, Y; Maegawa, H; Katsube, N; Peters, C; von Figura, K; Saftig, P; Katunuma, N; Yamamoto, K; Nakanishi, H			Involvement of cathepsin E in exogenous antigen processing in primary cultured murine microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; CENTRAL-NERVOUS-SYSTEM; INVARIANT-CHAIN; INCREASED EXPRESSION; ACID PROTEINASE; AFFINITY PURIFICATION; CELL ACTIVATION; DENDRITIC CELLS; RAT SPLEEN; IN-VITRO	We have attempted to elucidate an involvement of cathepsin E (CE) in major histocompatibility complex class II-mediated antigen presentation by microglia. In primary cultured murine microglia, CE was localized mainly in early endosomes and its expression level was markedly increased upon stimulation with interferon-gamma. Pepstatin A, a specific inhibitor of aspartic proteases, significantly inhibited interleukin-2 production from an OVA-(266-281)-specific T helper cell hybridomas upon stimulation with native OVA presented by interferon-gamma-treated microglia. However, pepstatin A failed to inhibit the presentation of OVA-(266-281) peptide. The possible involvement of CE in the processing of native OVA into antigenic peptide was further substantiated by that digested fragments of native OVA by CE could be recognized by OVA-specific Th cells. Cathepsin D also degraded native OVA into antigenic peptide, whereas microglia prepared from cathepsin D-deficient mice retained an ability for antigen presentation. On the other hand, the requirement for cysteine proteases such as cathepsins S and B in the processing of invariant chain (Ii) was confirmed by immunoblot analyses in the presence of their specific inhibitors. In conclusion, CE is required for the generation of an antigenic epitope from OVA but not for the processing of Ii in microglia.	Kyushu Univ, Fac Dent Sci, Lab Oral Aging Sci, Fukuoka 8128582, Japan; Kyushu Univ, Dept Pharmacol, Grad Sch Dent Sci, Fukuoka 8128582, Japan; Nippon Glaxo Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3004247, Japan; Ono Pharmaceut Co Ltd, Minase Res Inst, Osaka 6188585, Japan; Univ Freiburg, Inst Mol Med & Zellforsch, D-79106 Freiburg, Germany; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37037 Gottingen, Germany; Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan	Kyushu University; Kyushu University; Eisai Co Ltd; GlaxoSmithKline; Ono Pharmaceutical Co Ltd; University of Freiburg; University of Gottingen; Tokushima Bunri University	Nakanishi, H (corresponding author), Kyushu Univ, Fac Dent Sci, Lab Oral Aging Sci, Fukuoka 8128582, Japan.	nakandeg@mbox.nc.kyushu-u.ac.jp	Saftig, Paul/A-7966-2010					Aloisi F, 1998, J IMMUNOL, V160, P4671; AMANO T, 1995, EXP NEUROL, V136, P171, DOI 10.1006/exnr.1995.1094; Becher B, 2000, GLIA, V29, P293; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; Collawn JF, 1999, MICROBES INFECT, V1, P893, DOI 10.1016/S1286-4579(99)80533-4; DESIMONE R, 1995, J NEUROPATH EXP NEUR, V54, P175; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; DIMENT S, 1990, J IMMUNOL, V145, P417; Driessen C, 1999, J CELL BIOL, V147, P775, DOI 10.1083/jcb.147.4.775; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gresser O, 2001, EUR J IMMUNOL, V31, P1813, DOI 10.1002/1521-4141(200106)31:6<1813::AID-IMMU1813>3.0.CO;2-8; Hewitt EW, 1997, J IMMUNOL, V159, P4693; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Katunuma N, 1999, FEBS LETT, V458, P6, DOI 10.1016/S0014-5793(99)01107-2; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MATSUMOTO Y, 1992, IMMUNOLOGY, V76, P209; MUTO N, 1988, J BIOCHEM-TOKYO, V103, P629, DOI 10.1093/oxfordjournals.jbchem.a122318; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; NAKANISHI H, 1993, EXP NEUROL, V121, P215, DOI 10.1006/exnr.1993.1088; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Nakanishi H, 1997, J NEUROCHEM, V68, P739; Nishishita K, 1996, ARCH BIOCHEM BIOPHYS, V333, P349, DOI 10.1006/abbi.1996.0401; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAKAI H, 1989, BIOCHIM BIOPHYS ACTA, V991, P367, DOI 10.1016/0304-4165(89)90130-X; SAKU T, 1991, J BIOCHEM-TOKYO, V110, P956, DOI 10.1093/oxfordjournals.jbchem.a123696; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Sastradipura DF, 1998, J NEUROCHEM, V70, P2045; Sealy L, 1996, EUR J IMMUNOL, V26, P1838, DOI 10.1002/eji.1830260826; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; SOLCIA E, 1993, EUR J HISTOCHEM, V37, P19; Tanabe K, 1999, J BIOL CHEM, V274, P15725, DOI 10.1074/jbc.274.22.15725; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P278, DOI 10.1093/oxfordjournals.jbchem.a123194; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; YAMAMOTO K, 1978, EUR J BIOCHEM, V92, P499, DOI 10.1111/j.1432-1033.1978.tb12772.x; YAMAMOTO K, 1985, J BIOCHEM-TOKYO, V97, P821, DOI 10.1093/oxfordjournals.jbchem.a135122; YAMAMOTO K, 1979, EUR J BIOCHEM, V95, P459, DOI 10.1111/j.1432-1033.1979.tb12985.x; YAMAMOTO K, 1983, JPN J ORAL BIOL, V25, P834; Zhang TQ, 2000, BIOCHEM BIOPH RES CO, V276, P693, DOI 10.1006/bbrc.2000.3538	48	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4816	4822		10.1074/jbc.M108382200	http://dx.doi.org/10.1074/jbc.M108382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719510	hybrid			2022-12-25	WOS:000173962900036
J	Ruest, LB; Marcotte, R; Wang, E				Ruest, LB; Marcotte, R; Wang, E			Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; I ALPHA-GENE; UP-REGULATION; S1; FACTOR-1-ALPHA; IDENTIFICATION; MITOCHONDRIA; MICROTUBULE; EF-1-ALPHA; PATHWAYS	Peptide elongation factor eEF1A-2/S1, which shares 92% homology with eEF1A-1/EF-1alpha, is exclusively expressed in brain, heart, and skeletal muscle. In these tissues, eEF1A-2/S1 is the only type 1A elongation factor expressed in adulthood because a transition from eEF1A-1/EF-1alpha to eEF1A-2/S1 occurs in early postnatal development. In this article, we report that the expression of eEF1A-2/S1 protein is activated upon myogenic differentiation. Furthermore, we show that upon serum deprivation-induced apoptosis, eEF1A-2/S1 protein disappears and is replaced by its homolog eEF1A-1/EF-1alpha in dying myotubes; cell death is characterized by the activation of caspase-3. In addition, we show that the continuous expression of eEF1A-2/S1 resulting from adenoviral gene transfer protects differentiated myotubes from apoptosis by delaying their death, thus suggesting a prosurvival function for eEF1A-2/S1 in skeletal muscle. In contrast, myotube death is accelerated by the introduction of the homologous gene, eEF1A-1/EF-1alpha, whereas cells transfected with antisense eEF1A-1/EF-1alpha are protected from apoptosis. These results demonstrate that the two sister genes, eEF1A-1/EF-1alpha and eFIA-2/S1, regulate myotube survival with the former exerting prodeath activity and the latter a prosurvival effect.	Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40202 USA; McGill Univ, Dept Med,Sir Mortimer B Davis Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Louisville; Lady Davis Institute; McGill University	Wang, E (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, Sch Med, 470 S Preston St,Rm 304, Louisville, KY 40202 USA.	Eugenia.wang@louisville.edu		Ruest, L. Bruno/0000-0002-5446-9985	NATIONAL INSTITUTE ON AGING [P01AG010821] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG010821-060005, P01 AG 10821-06] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANN DK, 1991, J BIOL CHEM, V266, P10429; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; Chen E, 2000, EXP CELL RES, V259, P140, DOI 10.1006/excr.2000.4952; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; Duttaroy A, 1998, EXP CELL RES, V238, P168, DOI 10.1006/excr.1997.3819; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; GAMBKE B, 1984, J BIOL CHEM, V259, P2092; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Kato MV, 1999, LEUKEMIA LYMPHOMA, V33, P181, DOI 10.3109/10428199909093740; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Khalyfa A, 1999, DEV DYNAM, V216, P267, DOI 10.1002/(SICI)1097-0177(199911)216:3<267::AID-DVDY5>3.0.CO;2-V; Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200; Kristensen P, 1998, BIOCHEM BIOPH RES CO, V245, P810, DOI 10.1006/bbrc.1998.8510; LEE S, 1995, EXP CELL RES, V219, P589, DOI 10.1006/excr.1995.1268; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE S, 1994, BIOCHEM BIOPH RES CO, V203, P1371, DOI 10.1006/bbrc.1994.2336; LEE S, 1993, J BIOL CHEM, V268, P24453; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Mukasa T, 1999, BIOCHEM BIOPH RES CO, V260, P139, DOI 10.1006/bbrc.1999.0829; Oral HB, 1999, ANAL BIOCHEM, V267, P196, DOI 10.1006/abio.1998.2984; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	34	95	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5418	5425		10.1074/jbc.M110685200	http://dx.doi.org/10.1074/jbc.M110685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724805	Green Accepted, hybrid			2022-12-25	WOS:000173962900111
J	Saitoh, H; Pizzi, MD; Wang, J				Saitoh, H; Pizzi, MD; Wang, J			Perturbation of SUMOlation enzyme Ubc9 by distinct domain within nucleoporin RanBP2/Nup358	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; RAD51 RECOMBINATION PROTEIN; GTPASE-ACTIVATING PROTEIN; COVALENT MODIFICATION; SUMO-1 MODIFICATION; PML; INTERACTS; RANGAP1; P53; DEGRADATION	Ubc9, a conjugation enzyme for the ubiquitin-related modifier SUMO, is present predominantly in the nucleus and at the nuclear pore complex. The functional significance of its subcellular compartmentalization, however, remains to be elucidated. Here, we define a Pro-Glu-Asp-Ser-Thr-rich element containing 129 amino acid residues, designated IR1+2, on the human nucleoporin RanBP2/Nup358, which binds directly to Ubc9 with high affinity both in vitro and in vivo. When IR1+2 tagged with green fluorescence protein at its amino terminus (GFP-IR1+2) was transfected into COS-7 cells, we found that similar to90% of the nuclear Ubc9 was sequestered in the cytoplasm. We also observed that both SUMO-1 and SUMO-2/3 were mislocalized, and promyelocytic leukemia protein PML formed an enlarged aggregate in the nucleus. Moreover, the homologous recombination protein Rad51 mislocalized to the cytoplasm, and Rad51 foci, a hallmark of functional association of Rad51 with damaged DNA, did not form efficiently even in the presence of a DNA strand breaker. These findings emphasize that the IR1+2 domain is a useful tool for manipulating the nuclear localization of Ubc9 and perturbing the subcellular localization of SUMOs and/or SUMOlated proteins, and they emphasize the important role of nuclear Ubc9 in the Rad51-mediated homologous recombination pathway, possibly by modulating intracellular trafficking of Rad51.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	Kyushu University; Northwell Health	Saitoh, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Maidashi 3-1-1, Fukuoka 8128582, Japan.	hisaito@molbiol.med.kyushu-u.ac.jp						ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boddy MN, 1996, ONCOGENE, V13, P971; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KUTZMAN AL, 2001, P NATL ACAD SCI USA, V98, P5602; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Masson M, 1997, GENE, V190, P287, DOI 10.1016/S0378-1119(97)00015-2; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tarsounas M, 1997, MOL BIOL CELL, V8, P1405, DOI 10.1091/mbc.8.8.1405; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	55	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4755	4763		10.1074/jbc.M104453200	http://dx.doi.org/10.1074/jbc.M104453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11709548	hybrid			2022-12-25	WOS:000173962900028
J	Bai, ST; Cao, X				Bai, ST; Cao, X			A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; COOPERATIVE DNA-BINDING; TRANSCRIPTIONAL COREPRESSOR; FAMILY MEMBERS; MESSENGER-RNA; HEXAPEPTIDE; RECEPTOR; ROLES; GENE; DIFFERENTIATION	Inhibitory Smads (I-Smads), including Smad6 and Smad7, were initially characterized as cytoplasmic antagonists in the transforming growth factor-beta signaling pathway. However, I-Smads are also localized in the nucleus. Previously, we have shown that Smad6 can function as a transcriptional co-repressor. In this study, we found both Smad6 and Smad7 interact with histone deacetylases (HDACs). Acetylation state of core histones plays a critical role in gene transcription regulation. An HDAC inhibitor, trichostatin A, released Smad6-mediated transcription repression. Moreover, class I HDACs (HDAC-1 and -3), not class II HDACs (HDAC-4,-5, and -6), were co-immunoprecipitated with Smad6. Endogenous HDAC-1 was also shown to interact with both Smad6 and Hoxc-8. Mapping of the interaction domain indicates Smad6 MH2 domain is mainly involved in recruiting HDAC-1. Most interestingly, Smad6 also binds to DNA through its MH1 domain, and the MH2 domain of Smad6 masks this binding activity, indicating that Smad6 MH1 and MR2 domains associate reciprocally and inhibit each other's function. Hoxc-8 induces Smad6 binding to DNA as a transcriptional complex. Our findings revealed that I-Smads act as antagonists in the nucleus by recruiting HDACs.	Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), Univ Alabama, Sch Med, Dept Pathol, 1670 Univ Blvd,VH G002, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK 53757, DK 57501] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bitzer M, 2000, GENE DEV, V14, P187; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Cao X, 1996, J BIOL CHEM, V271, P20650, DOI 10.1074/jbc.271.34.20650; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Luukko K, 2001, MECH DEVELOP, V101, P209, DOI 10.1016/S0925-4773(00)00556-6; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nakayama T, 2001, MECH DEVELOP, V100, P251, DOI 10.1016/S0925-4773(00)00533-5; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamada M, 1999, DEV BIOL, V215, P48, DOI 10.1006/dbio.1999.9419; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zwijsen A, 2000, DEV DYNAM, V218, P663, DOI 10.1002/1097-0177(200008)218:4<663::AID-DVDY1020>3.0.CO;2-7	51	88	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4176	4182		10.1074/jbc.M105105200	http://dx.doi.org/10.1074/jbc.M105105200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11711531	hybrid			2022-12-25	WOS:000173813900053
J	Ilkaeva, O; Kinch, LN; Paulssen, RH; Ross, EM				Ilkaeva, O; Kinch, LN; Paulssen, RH; Ross, EM			Mutations in the carboxyl-terminal domain of phospholipase C-beta 1 delineate the dimer interface and a potential G alpha(q) interaction site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BETA 1; GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNIT; RECEPTOR; G(Q); IDENTIFICATION; PURIFICATION; HYDROLYSIS	The carboxyl-terminal domain of phospholipase C-beta is required for its stimulation by Galpha(q) and for its Galpha(q)-specific GTPase-activating protein (GAP) activity. We subjected this domain to a combination of deletion and alanine/glycine scanning mutagenesis to detect mutations that would inhibit either responsiveness to G(q) or G(q) GAP activity. Most mutations that altered either response or GAP activity diminished both in parallel. Many of these mutations map at the interface at which the carboxyl-terminal domain was recently shown to form a dimer (Singer, A. U., et al. (2001) Nat. Struct. Biol, 9, 32-36). Most others clustered in an area that is a plausible Galpha(q) binding site. In addition, one mutation that differentially inhibited GAP activity relative to responsiveness to Galpha(q) mapped in this region at a location modeled to be in close contact with the switch II region of Galpha(q). This is the site at which RGS proteins are thought to exert their GAP activity. Last, a deletion mutation differentially inhibited the response of phospholipase C-beta1 to Galpha(q) without blocking GAP activity. Its location in the molecule suggests that moving the attachment point of the catalytic domain can disrupt its ability to be activated by Galpha(q).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ross@utsw.swmed.edu		Kinch, Lisa/0000-0003-3041-2615	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beekman A, 1998, CANCER RES, V58, P910; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BIDDLECOME GH, 1997, THESIS U TEXAS DALLA; BLANK JL, 1991, J BIOL CHEM, V266, P18206; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; LEE CW, 1994, J BIOL CHEM, V269, P25335; Meij JTA, 1996, BIOCHEM BIOPH RES CO, V225, P705, DOI 10.1006/bbrc.1996.1239; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER EM, 1991, J BIOL CHEM, V266, P519; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Ross EM, 1999, CRC METH SIG TRANS, P123; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; WU DQ, 1993, J BIOL CHEM, V268, P3704	27	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4294	4300		10.1074/jbc.M109612200	http://dx.doi.org/10.1074/jbc.M109612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729196	hybrid			2022-12-25	WOS:000173813900068
J	Isogai, Z; Aspberg, A; Keene, DR; Ono, RN; Reinhardt, DP; Sakai, LY				Isogai, Z; Aspberg, A; Keene, DR; Ono, RN; Reinhardt, DP; Sakai, LY			Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; PG-M/VERSICAN; ELASTIC FIBERS; MOLECULAR-CLONING; HUMAN CARTILAGE; LECTIN DOMAINS; TENASCIN-R; COMPONENT; EXPRESSION	Fibrillin-containing microfibrils are polymeric structures that are difficult to extract from connective tissues. Proteolytic digestion of tissues has been utilized to release microfibrils for study. Few of the molecules that connect microfibrils to other elements in the matrix have been identified. In this study, electron microscopic immunolocalization of anti-versican antibodies in tissues and in extracted microfibrils demonstrated that the C-terminal region of versican is found associated with fibrillin microfibrils. Extraction of microfibrils followed by treatment of microfibrils under dissociating conditions suggested that the versican C terminus is covalently bound to microfibrils. Binding assays using recombinant fibrillin-1 polypeptides and recombinant lectican lectin domains indicated that the versican lectin domain binds to specific fibrillin-1 polypeptides. The versican lectin domain also bound to molecules comigrating with authentic fibrillin-1 monomers in anassay using cell culture medium. In assays using microfibrils, the versican lectin domain demonstrated preferential binding compared with other lecticans. Binding was calcium-dependent. The binding site for versican in microfibrils is most likely within a region of fibrillin-1 between calcium-binding epidermal growth factor-like domains 11 and 21. Human mutations irk this region can result in severe forms of the Marfan syndrome ("neonatal" Marfan syndrome). The connection between versican and fibrillin microfibrils may be functionally significant, particularly in cardiovascular tissues.	Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Lund Univ, Sect Connect Tissue Biol, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany	Oregon Health & Science University; Lund University; University of Lubeck	Sakai, LY (corresponding author), Shriners Hosp Children, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Reinhardt, Dieter P/A-3102-2008; Isogai, Zenzo/AAD-3690-2022	Reinhardt, Dieter P/0000-0001-6535-9872; Aspberg, Anders/0000-0002-6588-6944				Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BERNSTEIN EF, 1995, LAB INVEST, V72, P662; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; DAHLBACK K, 1990, J INVEST DERMATOL, V94, P284, DOI 10.1111/1523-1747.ep12874430; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Grassel S, 1999, MATRIX BIOL, V18, P309, DOI 10.1016/S0945-053X(99)00019-0; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; Isogai Z, 1996, CANCER RES, V56, P3902; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KIELTY CM, 1991, J CELL SCI, V99, P797; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; Nara Y, 1997, HISTOCHEM J, V29, P21, DOI 10.1023/A:1026460700592; OIKE Y, 1980, BIOCHEM J, V191, P203, DOI 10.1042/bj1910203; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Perris R, 1996, FASEB J, V10, P293, DOI 10.1096/fasebj.10.2.8641562; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SOBUE M, 1989, HISTOCHEM J, V21, P455, DOI 10.1007/BF01845795; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	50	158	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4565	4572		10.1074/jbc.M110583200	http://dx.doi.org/10.1074/jbc.M110583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726670	Green Published, hybrid			2022-12-25	WOS:000173813900101
J	Mishra, A; Hogan, SP; Brandt, EB; Wagner, N; Crossman, MW; Foster, PS; Rothenberg, ME				Mishra, A; Hogan, SP; Brandt, EB; Wagner, N; Crossman, MW; Foster, PS; Rothenberg, ME			Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; COLONY-STIMULATING FACTOR; TISSUE EOSINOPHILIA; IN-VIVO; GASTROINTESTINAL-TRACT; CHEMOTACTIC CYTOKINES; ADHESION MOLECULES; CHEMOKINE EOTAXIN; EPITHELIAL-CELLS; MUCOSAL TISSUES	Eosinophils accumulate in the gastrointestinal tract in a number of medical disorders, but the mechanisms involved are largely unknown. To understand the significance of cytokine expression by enterocytes, enterocyte transgenic mice that overexpressed the eosinophil-selective cytokines eotaxin and interleukin (IL)-5 were generated. Transgenic mice, generated by utilizing the rat intestinal fatty acid-binding protein promoter (Fabpi), overexpressed the mRNA for these cytokines in the small intestine. Overexpression of IL-5 resulted in marked increases of eosinophils in the bone marrow and blood, whereas eotaxin overexpression resulted in similar levels compared with nontransgenic control mice. In contrast, both IL-5 and eotaxin transgenic mice had significant accumulation of eosinophils in the gastrointestinal mucosa compared with control mice. Eotaxin-induced gastrointestinal eosinophilia was substantially higher than that induced by IL-5 and was especially prominent within the lamina propria of the villi. Interestingly, genetic rescue of eotaxin deficiency (by transgenic overexpression of eotaxin in eotaxin gene-targeted mice) resulted in significant restoration of gastrointestinal eosinophil levels. Finally, the intestinal eosinophilia induced by the eotaxin transgene was 137 integrin-dependent. Taken together, these results demonstrate that expression of eotaxin and IL-5 in intestinal epithelium induces compartmentalized dysregulation of eosinophil trafficking and the important role of the 07 integrin in gastrointestinal allergic responses.	Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cologne, Cologne Inst Genet, D-50931 Cologne, Germany; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Cologne; Australian National University; John Curtin School of Medical Research	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA.	rothenberg@chmcc.org	MISHRA, ANIL/S-7983-2017; Foster, Paul/G-5057-2013	MISHRA, ANIL/0000-0003-4266-4684; , Paul/0000-0002-0827-8299; Brandt, Eric/0000-0003-0617-4100	NIAID NIH HHS [R01 AI45898-02, R01 AI42242-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045898, R01AI042242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andres PG, 2000, J IMMUNOL, V164, P6303, DOI 10.4049/jimmunol.164.12.6303; Artis D, 2000, EUR J IMMUNOL, V30, P1656, DOI 10.1002/1521-4141(200006)30:6&lt;1656::AID-IMMU1656&gt;3.0.CO;2-Z; Bischoff SC, 1996, BAILLIERE CLIN GASTR, V10, P443, DOI 10.1016/S0950-3528(96)90052-4; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; Desreumaux P, 1999, AM J GASTROENTEROL, V94, P3396, DOI 10.1016/S0002-9270(99)00716-9; DISCOMBE G, 1946, LANCET, V250, P195; ERLE DJ, 1994, J IMMUNOL, V153, P517; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; HAMANN A, 1994, J IMMUNOL, V152, P3282; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; Keates S, 1997, AM J PHYSIOL-GASTR L, V273, pG75, DOI 10.1152/ajpgi.1997.273.1.G75; Kitayama J, 1997, J IMMUNOL, V159, P3929; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lowichik A, 1996, MODERN PATHOL, V9, P110; Lundahl J, 2000, ALLERGY, V55, P865, DOI 10.1034/j.1398-9995.2000.00574.x; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MacDermott RP, 1999, J CLIN IMMUNOL, V19, P266, DOI 10.1023/A:1020583306627; MacDermott RP, 1998, INFLAMM BOWEL DIS, V4, P54, DOI 10.1097/00054725-199802000-00009; Matsumoto T, 1999, ANN ALLERG ASTHMA IM, V82, P253, DOI 10.1016/S1081-1206(10)62605-1; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 2000, BLOOD, V96, P1538, DOI 10.1182/blood.V96.4.1538.h8001538_1538_1544; Mishra A, 2001, J BIOL CHEM, V276, P8453, DOI 10.1074/jbc.M009481200; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Papakonstanti EA, 2000, MOL MED, V6, P303, DOI 10.1007/BF03401939; Pascal RR, 1997, MODERN PATHOL, V10, P363; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; Rothenberg ME, 2001, ADV IMMUNOL, V78, P291, DOI 10.1016/S0065-2776(01)78007-8; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; Shaw S K, 1995, Semin Immunol, V7, P335, DOI 10.1016/1044-5323(95)90014-4; Simon HU, 2000, ALLERGY, V55, P791, DOI 10.1034/j.1398-9995.2000.00030.x; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; Van Deventer SJH, 1997, ALIMENT PHARM THERAP, V11, P116; Vandezande LM, 1999, CLIN EXP ALLERGY, V29, P652, DOI [10.1046/j.1365-2222.1999.00514.x, 10.1046/j.1365-2222.1999.00511.x]; Vignola AM, 2000, ALLERGY, V55, P931, DOI 10.1034/j.1398-9995.2000.00239.x; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897	53	71	72	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4406	4412		10.1074/jbc.M110424200	http://dx.doi.org/10.1074/jbc.M110424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11733500	Green Published, hybrid			2022-12-25	WOS:000173813900082
J	Richards, CT; Ogut, O; Brozovich, FV				Richards, CT; Ogut, O; Brozovich, FV			Agonist-induced force enhancement - The role of isoforms and phosphorylation of the myosin-targeting subunit of myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RHO-ASSOCIATED KINASE; CA2+ SENSITIZATION; SIGNAL-TRANSDUCTION; INHIBITION; PHOSPHOPROTEIN; CPI-17	The magnitude of agonist-induced Ca2+ sensitization of force is tissue-dependent, but an explanation for this diversity is unknown. Ca2+ sensitization is thought to involve a G-protein-mediated inhibition of myosin light chain phosphatase activity by phosphorylation of the myosin-targeting subunit (MYPT). The MYPT has two isoforms that differ by a central insert, which lies near this phosphorylation site. Expression of MYPT isoforms is both developmentally regulated and tissue-specific. We hypothesized that the presence or absence of the central insert determines the magnitude of agonist-induced Ca2+ sensitization. Throughout development, the chicken aorta exclusively expresses the splice-in MYPT isoform, and guanosine 5'-O-(thiotriphosphate) (GTPgammas) produces a significant force enhancement. Early during development, the chicken gizzard expresses the splice-in MYPT isoform, and GTPgammaS produced a Ca2+ sensitization. In the gizzard coincident with the shift in expression from the splice-in to splice-out MYPT isoform, GTPgammaS no longer produced force enhancement. In addition, adenosine 5'-O-(thiotriphosphate) (ATPgammaS) phosphorylated only adult gizzard tissue, the only tissue that did not demonstrate a Ca2+ sensitization. These results suggest that the relative expression of splice-in/splice-out MYPT isoforms determines the magnitude of agonist-induced force enhancement and that MYPT phosphorylation is not required for Ca2+ sensitization.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brozovich, FV (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064137] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anabuki J, 2000, PFLUG ARCH EUR J PHY, V441, P189, DOI 10.1007/s004240000425; BROZOVICH FV, 1995, AM J PHYSIOL-CELL PH, V268, pC1202, DOI 10.1152/ajpcell.1995.268.5.C1202; BROZOVICH FV, 1995, AM J PHYSIOL-CELL PH, V268, pC237, DOI 10.1152/ajpcell.1995.268.1.C237; DEFEO TT, 1985, J PHYSIOL-LONDON, V369, P269, DOI 10.1113/jphysiol.1985.sp015900; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Facemire C, 2000, J MUSCLE RES CELL M, V21, P367, DOI 10.1023/A:1005680614296; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fisher SA, 1997, CIRC RES, V80, P885; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, BIOCH CONTRACTILE PR, P432; HATHAWAY DR, 1985, AM J PHYSIOL, V249, pC345; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ikebe M, 1996, BIOCHEM BIOPH RES CO, V225, P370, DOI 10.1006/bbrc.1996.1182; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MORELAND RS, 1992, AM J PHYSIOL, V262, pC862, DOI 10.1152/ajpcell.1992.262.4.C862; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Ogut O, 2000, AM J PHYSIOL-CELL PH, V279, pC1722, DOI 10.1152/ajpcell.2000.279.6.C1722; Pfitzer G, 2001, J PHYSIOL-LONDON, V533, P651, DOI 10.1111/j.1469-7793.2001.t01-2-00651.x; Rhee AY, 2000, BIOPHYS J, V79, P1511, DOI 10.1016/S0006-3495(00)76402-2; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Solaro RJ, 2000, CIRC RES, V87, P173, DOI 10.1161/01.RES.87.3.173; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Sward K, 2000, J PHYSIOL-LONDON, V522, P33, DOI 10.1111/j.1469-7793.2000.0033m.x; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4422	4427		10.1074/jbc.M111047200	http://dx.doi.org/10.1074/jbc.M111047200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726673	hybrid			2022-12-25	WOS:000173813900084
J	Uhl, J; Klan, N; Rose, M; Entian, KD; Werz, O; Steinhilber, D				Uhl, J; Klan, N; Rose, M; Entian, KD; Werz, O; Steinhilber, D			The 5-lipoxygenase promoter is regulated by DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; GENE-TRANSCRIPTION; CELLS; BIOSYNTHESIS; INDUCTION; BINDING; ACID	5-lipoxygenase (5-LO), the key enzyme in leukotriene biosynthesis, is expressed in a tissue- and cell differentiation-specific manner. The 5-LO core promoter required for basal promoter activity has a unique (G+C)-rich sequence that contains five tandem Sp1 consensus sequences. The mechanisms involved in the regulation of cell type-specific 5-LO expression are unknown. Here we show that 5-LO expression is regulated by DNA methylation. Treatment of the 5-LO-negative cell lines U937 and HL-60TB with the demethylating agent 5-aza-2'-deoxycytidine (AdC) up-regulated expression of 5-LO primary transcripts and mature mRNA in a similar fashion, indicating that AdC stimulates 5-LO gene transcription. Analysis of the methylation status of the 5-LO promoter revealed that the core promoter region was methylated in U937 and HL-60TB cells, whereas it was unmethylated in the 5-LO-positive parent HL-60 cell line. Reporter gene assays with 5-LO promoter constructs gave up to 68- and 655-fold repression of 5-LO promoter activity in HeLa and Mono Mac 6 cells by methylation. 1,25-dihydroxyvitamin D-3 and transforming growth factor-beta (TGFbeta), potent inducers of the 5-LO pathway in myeloid cell lines, increased 5-LO RNA expression in HL-60TB and U937 cells, but co-treatment with AdC was required to achieve 5-LO expression levels in HL-60TB cells that were comparable with wild-type HL-60 cells. In reporter gene assays, 1,25-dihydroxyvitamin D-3 and TGFbeta were unable to induce promoter activity when the 5-LO promoter constructs were methylated, which suggests that 5-LO promoter demethylation is a prerequisite for the high level induction of 5-LO gene expression by 1,25-dihydroxyvitamin D-3 and TGFbeta and that the effects of both agents on 5-LO mRNA expression are not related to DNA methylation.	Goethe Univ Frankfurt, Inst Pharmazeut Chem, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Microbiol, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Steinhilber, D (corresponding author), Goethe Univ Frankfurt, Inst Pharmazeut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	steinhilber@em.uni-frankfurt.de	Entian, Karl-Dieter/D-3080-2011; Steinhilber, Dieter/J-3221-2012					ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ATTADIA V, 1993, LEUKEMIA, V7, P9; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRUNGS M, 1994, BIOCHEM BIOPH RES CO, V205, P1572, DOI 10.1006/bbrc.1994.2846; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSON HE, 1993, J LIPID MEDIATOR, V6, P15; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; Harle D, 1998, EUR J BIOCHEM, V254, P275, DOI 10.1046/j.1432-1327.1998.2540275.x; Harle D, 1999, ADV EXP MED BIOL, V469, P105; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; KARGMAN S, 1993, J LIPID MEDIATOR, V7, P31; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; McDonald LE, 1997, BIOTECHNIQUES, V22, P272, DOI 10.2144/97222bm16; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Silverman ES, 2000, AM J RESP CRIT CARE, V161, pS77, DOI 10.1164/ajrccm.161.supplement_1.ltta-16; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; STANKOVA J, 1995, BLOOD, V85, P3719, DOI 10.1182/blood.V85.12.3719.bloodjournal85123719; Steinhilber D, 1999, CURR MED CHEM, V6, P71; Werz O, 1996, PHARMAZIE, V51, P893; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	29	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4374	4379		10.1074/jbc.M107665200	http://dx.doi.org/10.1074/jbc.M107665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706027	hybrid			2022-12-25	WOS:000173813900078
J	Zeng, HY; Zhao, DZ; Mukhopadhyay, D				Zeng, HY; Zhao, DZ; Mukhopadhyay, D			Flt-1-mediated down-regulation of endothelial cell proliferation through pertussis toxin-sensitive G proteins, beta gamma subunits, small GTPase CDC42, and partly by Rac-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; RHO-GTPASES; SIGNAL-TRANSDUCTION; VASCULAR ENDOTHELIUM; TYROSINE KINASE; RECEPTOR; ACTIVATION; MIGRATION; BINDING; IDENTIFICATION	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) promotes its function primarily by activating two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR (VEGFR-2). Recently, it has been shown that KDR is responsible for VPF/VEGF-stimulated endothelial cell (EC) proliferation and migration, whereas Flt-1 activation down-modulates KDR-mediated EC proliferation. Although KDR-mediated EC proliferation and migration have been extensively studied, much less is known about Flt-1-mediated antiproliferation. Here, we demonstrate that Flt-1-mediated antiproliferative activity can be blocked completely by the dominant negative mutant of CDC42 (CDC42-17N) and partially by a Rac1 dominant negative mutant (Rac1- but is not affected by a RhoA dominant negative mutant (RhoA-19N). Both CDC42-17N and Rac1-17N increase the intracellular Ca2+ mobilization in response to VPF/VEGF but have no effect on KDR and MAPK phosphorylation. Using the chimeric-receptor EGLT in which the extracellular domain of epidermal growth factor receptor was fused to the transmembrane and intracellular domains of Flt-1, we also demonstrate! that CDC42 and Rac1 are activated by EGLT. Previously, we showed that phosphatidylinositol 3-kinase is required for Flt-1-mediated antiproliferative activity, but phospholipase C is not required. As expected, CDC42: and Rac1 activation mediated by EGLT can be completely inhibited by PI3K inhibitors, wortmannin and LY294002, and the p85 dominant negative mutant but not by either the phospholipase C inhibitor, U73122, or an intracellular Ca2+ chilator BAPTA/AM. Surprisingly, pertussis toxin and overexpression of the free Gbetagamma-specific sequestering minigene hbetaARK1(495) also inhibit EGLT-mediated CDC42 and Rac1 activation completely. Moreover, pertussis toxin treatment also increases the intracellular Ca2+ mobilization and inhibits the antiproliferation activity, thus suggesting that pertussis toxin-sensitive G proteins and the Gbetagamma subunits are involved in the signaling pathway of Flt-1 that down-regulates EC proliferation. Taken together, these results further expand our understanding of Flt-1-mediated antiproliferative activity in VPF/VEGF-stimulated endothelium.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.				NCI NIH HHS [CA78383] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Puls A, 1999, J CELL SCI, V112, P2983; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	39	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4003	4009		10.1074/jbc.M110842200	http://dx.doi.org/10.1074/jbc.M110842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726672	hybrid			2022-12-25	WOS:000173813900029
J	Zolotukhin, AS; Tan, W; Bear, J; Smulevitch, S; Felber, BK				Zolotukhin, AS; Tan, W; Bear, J; Smulevitch, S; Felber, BK			U2AF Participates in the binding of TAP (NXF1) to mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; CONSTITUTIVE TRANSPORT ELEMENT; RIBONUCLEOPROTEIN AUXILIARY FACTOR; NUCLEAR-PORE COMPLEX; VIRUS TYPE-1 REV; SPLICING FACTOR; POLY(A)(+) RNA; BIOCHEMICAL-CHARACTERIZATION; RAE1 GENE; PROTEIN	TAP/NXF1 is a conserved mRNA export receptor serving as a link between messenger ribonucleoproteins (mRNPs) and the nuclear pore complex. The mechanism by which TAP recognizes its export substrate is unclear. We show here that TAP is added to spliced mRNP in human cells. We identified a distinct region of TAP that targets it to mRNP. Using yeast two-hybrid screens and in vitro binding studies, we found that this, region coincides with a direct binding site for U2AF35, the small subunit of the splicing factor U2AF. This interaction is evolutionarily conserved across metazoa, indicating its significance. We further found in human cells that the exogenously expressed large U2AF subunit, U2AF65, accumulates in spliced mRNP, leading to the recruitment of U2AF35 and TAP. Similarly to TAP, U2AF65 stimulated directly the nuclear export and expression,of an mRNA that is otherwise retained in the nucleus. Together with our finding that U2AF is continuously exported from the nucleus, these data suggest that U2AF participates in nuclear export, by facilitating TAP's addition to its mRNA substrates.	NCI, Human Retrovirus Pathogenesis Sect, Basic Res Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Felber, BK (corresponding author), NCI, Human Retrovirus Pathogenesis Sect, Basic Res Lab, Ctr Canc Res,NIH, Bldg 535,Rm 110, Frederick, MD 21702 USA.	felber@mail.ncifcrf.gov			NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bharathi A, 1997, GENE, V198, P251, DOI 10.1016/S0378-1119(97)00322-3; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; Das BK, 1999, MOL CELL BIOL, V19, P6796; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gama-Carvalho M, 2001, J BIOL CHEM, V276, P13104, DOI 10.1074/jbc.M008759200; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Kramer A, 1999, J CELL BIOL, V145, P1355, DOI 10.1083/jcb.145.7.1355; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LEHIR H, 2000, GENE DEV, V19, P6860; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	57	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3935	3942		10.1074/jbc.M107598200	http://dx.doi.org/10.1074/jbc.M107598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724776	hybrid			2022-12-25	WOS:000173813900020
J	Bourbon, NA; Sandirasegarane, L; Kester, M				Bourbon, NA; Sandirasegarane, L; Kester, M			Ceramide-induced inhibition of Akt is mediated through protein kinase C zeta - Implications for growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE-1; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; PKC-ZETA; B-ALPHA; ACTIVATION; STRESS; PHOSPHORYLATION; TRANSLOCATION	We recently demonstrated that ceramide-coated balloon catheters limit vascular smooth muscle cell (VSMC) growth after stretch injury in vivo. In that study, inhibition of VSMC growth was correlated with a decrease in phosphorylation of the cell survival kinase Akt (protein kinase B). Utilizing cultured A7r5 VSMCs, we have now examined the mechanism by which ceramide inhibits Akt phosphorylation/activation. Our initial studies showed that ceramide-induced inhibition of Akt phosphorylation was not mediated through diminution in phosphoinositide 3-kinase activity. As we have previously demonstrated that protein kinase Czeta (PKCzeta) is a target of ceramide, we proposed an alternative signaling mechanism by which ceramide induces inhibition of Akt through activation of PKCzeta. We demonstrate that C-6-ceramide (but not the inactive analog dihydro-C-6-ceramide) induced PKCzeta activity and also caused a selective increase in the association between Akt and PKCzeta, without affecting PKCepsilon, in A7r5 cells. In addition, the ability of ceramide to significantly decrease platelet-derived growth factor-induced Akt phosphorylation or cell proliferation was abrogated in A7r5 cells overexpressing a dominant-negative mutant of PKCzeta. Taken together, these data suggest that ceramide-mediated activation of PKCzeta leads to diminished Akt activation and consequent growth arrest in VSMCs. The therapeutic potential for ceramide to limit dysregulated VSMC growth has direct applicability to vascular diseases such as restenosis and atherosclerosis.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sandirasegarane, L (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, POB 850, Hershey, PA 17033 USA.				NHLBI NIH HHS [HL66371] Funding Source: Medline; NIDDK NIH HHS [DK53715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053715] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Diez C, 2001, CARDIOVASC RES, V49, P731, DOI 10.1016/S0008-6363(00)00296-0; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hurley JH, 1997, PROTEIN SCI, V6, P477; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; KIM MY, 1991, J BIOL CHEM, V266, P484; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Sandirasegarane L, 2000, AM J PHYSIOL-CELL PH, V279, pC225, DOI 10.1152/ajpcell.2000.279.1.C225; Sawai H, 1999, CHEM PHYS LIPIDS, V102, P141, DOI 10.1016/S0009-3084(99)00082-1; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	60	193	200	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3286	3292		10.1074/jbc.M110541200	http://dx.doi.org/10.1074/jbc.M110541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723139	hybrid			2022-12-25	WOS:000173688000032
J	Darrouzet, E; Valkova-Valchanova, M; Daldal, F				Darrouzet, E; Valkova-Valchanova, M; Daldal, F			The [2Fe-2S] cluster E-m as an indicator of the iron-sulfur subunit position in the ubihydroquinone oxidation site of the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUINONE BINDING-CAPACITY; BOVINE HEART-MITOCHONDRIA; FORMING HYDROGEN-BONDS; ENERGY-CONVERSION SITE; RHODOBACTER-CAPSULATUS; ELECTRON-TRANSFER; DOMAIN MOVEMENT; Q(O) SITE; RHODOPSEUDOMONAS-SPHAEROIDES; C OXIDOREDUCTASE	Recent crystallographic and kinetic data have revealed the crucial role of the large scale domain movement of the iron-sulfur subunit [2Fe-2S] cluster domain during the ubihydroquinone oxidation reaction catalyzed by the cytochrome bc(1) complex. Previously, the electron paramagnetic resonance signature of the [2Fe-2S] cluster and its redox midpoint potential (E-m) value have been used extensively to characterize the interactions of the [2Fe-2S] cluster with the occupants of the ubihydroquinone oxidation (Q(o)) catalytic site. In this work we analyze these interactions in various iron-sulfur subunit mutants that carry mutations in its flexible hinge region. We show that the E-m increases of the iron-sulfur subunit [2Fe-2S] cluster induced either by these mutations or by the addition of stigmatellin do not act synergistically. Moreover, the E-m increases disappear in the presence of class I inhibitors like myxothiazol. Because various inhibitors are known to affect the location of the iron-sulfur subunit cluster domain, the measured E-m value of the [2Fe-2S] cluster therefore reflects its equilibrium position in the Q(o) site. We also demonstrate the existence in this site of a location where the E-m of the cluster is increased by about 150 mV and discuss its possible implications in term of Q(o) site catalysis and energetics.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Daldal, F (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	fdaldal@sas.upenn.edu			NIGMS NIH HHS [GM 38237, R01 GM038237] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWYER JR, 1982, J BIOL CHEM, V257, P8321; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Brasseur G, 1997, BIOCHEMISTRY-US, V36, P11685, DOI 10.1021/bi970777d; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; CROFTS AR, 1997, PHOTOTROPHIC PROKARY, P229; Darrouzet E, 1999, J BIOENERG BIOMEMBR, V31, P275, DOI 10.1023/A:1005428014548; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dutton P L, 1978, Methods Enzymol, V54, P411; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; Gopta OA, 1998, FEBS LETT, V431, P291, DOI 10.1016/S0014-5793(98)00768-6; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; Gray KA, 1995, ANOXYGENIC PHOTOSYNT, P747; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; Heimann S, 2000, BIOCHEMISTRY-US, V39, P2692, DOI 10.1021/bi9921992; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Liebl U, 1997, BIOCHEMISTRY-US, V36, P11675, DOI 10.1021/bi970776l; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V547, P270, DOI 10.1016/0005-2728(79)90010-0; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; Sharp RE, 1999, BIOCHEMISTRY-US, V38, P3440, DOI 10.1021/bi982639+; Sharp RE, 1998, FEBS LETT, V431, P423, DOI 10.1016/S0014-5793(98)00792-3; Sharp RE, 1999, BIOCHEMISTRY-US, V38, P14973, DOI 10.1021/bi9914863; TAKAMIYA KI, 1979, BIOCHIM BIOPHYS ACTA, V546, P1, DOI 10.1016/0005-2728(79)90166-X; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	60	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3464	3470		10.1074/jbc.M107973200	http://dx.doi.org/10.1074/jbc.M107973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707448	hybrid			2022-12-25	WOS:000173688000055
J	Laine, J; Kunstle, G; Obata, T; Noguchi, M				Laine, J; Kunstle, G; Obata, T; Noguchi, M			Differential regulation of Akt kinase isoforms by the members of TCL1 oncogene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-GAMMA; PROTEIN; PHOSPHORYLATION; ACTIVATION; EXPRESSION; APOPTOSIS; LYMPHOMAS; SURVIVAL; GENE; MICE	The members of the TCL1 proto-oncogene family (TCL1, MTCP1, and TCL1b) bind to Akt1, increasing its phosphorylation status and kinase activity. This is thought to be secondary to the formation of TCL1-Akt oligomers within which Akt is preferentially phosphorylated. Here we show that, in contrast to Akt1 and Akt2, which bind to all members of the TCL1 family, Akt3 specifically interacts with TCL1 but not with MTCP1 or TCL1b. This association is functional, as the presence of TCL1 but not MTCP1 or TCL1b increased Akt3 kinase activity in in vitro kinase assays. Functional specificity is determined by the Akt pleckstrin homology domain as chimeric Akt1, where Akt1 PH domain was replaced by that of Akt3 was no longer able to interact with MTCP1 or TCL1b and its kinase activity was solely enhanced by TCL1 Moreover, we show that, in TCL1-overexpressing SUPT-11 T-cell leukemia and P3HR-1 Burkitt's lymphoma cell lines, TCL1 interacts with endogenous Akt1, Akt2, and Akt3. TCL1 enhanced hetero-oligomerization of Akt1 with Akt3 and as a consequence facilitated transphosphorylation of Akt molecules, which may contribute to Akt activation and TCL1-induced leukemogenesis in vivo.	Beth Israel Deaconess Med Ctr, Dept Med, Dept Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 7708503, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tokushima University	Noguchi, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Dept Immunol, Boston, MA 02215 USA.	mnoguchi@caregroup.harvard.edu						Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brodbeck D, 2001, J BIOL CHEM, V276, P29550, DOI 10.1074/jbc.M104633200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; MATSUYAMA N, 2001, J BIOL CHEM, V276, P32799; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Narducci MG, 2000, CANCER RES, V60, P2095; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STERN MH, 1993, ONCOGENE, V8, P2475; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yang YS, 1998, J BIOMOL NMR, V11, P337, DOI 10.1023/A:1008279616063	40	87	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3743	3751		10.1074/jbc.M107069200	http://dx.doi.org/10.1074/jbc.M107069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707444	hybrid			2022-12-25	WOS:000173688000089
J	Liang, XW; Teng, A; Braun, DM; Felgner, J; Wang, Y; Baker, SI; Chen, SZ; Zelphati, O; Felgner, PL				Liang, XW; Teng, A; Braun, DM; Felgner, J; Wang, Y; Baker, SI; Chen, SZ; Zelphati, O; Felgner, PL			Transcriptionally active polymerase chain reaction (TAP) - High throughput gene expression using genome sequence data	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOLOGY; IN-VIVO; TRANSFECTION; DELIVERY; BINDING; PEPTIDE; CLONING	An approach is described for making (t) under bar ranscriptionally (a) under bar ctive (P) under bar CR (TAP) fragments that were used directly in in vitro and in vivo expression experiments. TAP fragments encoding reporter genes were amplified in 1 day using typical PCR methodology and were expressed in cultured cells and in mice at levels comparable with a widely used cytomegalovirus promoter-based plasmid expression vector. Following intramuscular injection, a TAP fragment encoding hepatitis B surface antigen (HBsAg) induced anti-HBsAg antibody titers comparable with those induced by supercoiled plasmid encoding the same antigen. Epitope-tagged TAP fragments were generated and transfected into cells for rapid, high throughput immunocytochemical analysis of the tagged gene products. TAP fragments were also transferred directly into expression vectors by in vivo homologous recombination without conventional cloning, affording a high throughput cloning approach that does not require restriction enzyme digestion, ligations, or thymidine adenine complementation cloning. The methodology has been adapted to a robotic work station enabling the high throughput generation of transcriptionally active genes at the rate of more than 400 different genes per day. This technology offers a practical approach to directly utilize genome sequence data to generate functional proteomes.	Gene Therapy Syst Inc, San Diego, CA 92121 USA		Felgner, PL (corresponding author), Gene Therapy Syst Inc, 10190 Telesis Ct, San Diego, CA 92121 USA.	pfelgner@gtsproteomics.com			NIAID NIH HHS [AI47641] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI047641, R44AI047641] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cherng JY, 1999, J CONTROL RELEASE, V60, P343, DOI 10.1016/S0168-3659(99)00089-9; EHRLICH R, 1985, EUR J BIOCHEM, V148, P293, DOI 10.1111/j.1432-1033.1985.tb08838.x; Felgner PL, 1999, NAT BIOTECHNOL, V17, P329, DOI 10.1038/7880; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HANAHAN D, 1980, CELL, V21, P127, DOI 10.1016/0092-8674(80)90120-8; Hofman CR, 2001, GENE THER, V8, P71, DOI 10.1038/sj.gt.3301373; *I LAB AN RES NAT, 1996, GUID US CAR LAB AN; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Li S, 1997, GENE THER, V4, P449, DOI 10.1038/sj.gt.3300413; NIMAN HL, 1985, P NATL ACAD SCI USA, V82, P7924, DOI 10.1073/pnas.82.23.7924; OLINER JD, 1993, NUCLEIC ACIDS RES, V21, P5192, DOI 10.1093/nar/21.22.5192; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; Sykes KF, 1999, NAT BIOTECHNOL, V17, P355, DOI 10.1038/7908; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; XIE TD, 1993, BIOPHYS J, V65, P1684, DOI 10.1016/S0006-3495(93)81208-6; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zelphati O, 2000, BIOTECHNIQUES, V28, P304, DOI 10.2144/00282rr01; Zhang YM, 2000, NAT BIOTECHNOL, V18, P1314, DOI 10.1038/82449	19	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3593	3598		10.1074/jbc.M110652200	http://dx.doi.org/10.1074/jbc.M110652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11713261	hybrid			2022-12-25	WOS:000173688000071
J	Pop, O; Martin, U; Abel, C; Muller, JP				Pop, O; Martin, U; Abel, C; Muller, JP			The twin-arginine signal peptide of PhoD and the TatA(d)/C-d proteins of Bacillus subtilis form an autonomous tat translocation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACZ HYBRID PROTEINS; ESCHERICHIA-COLI; GENE REPLACEMENTS; EXPORT SYSTEM; MEMBRANE; PATHWAY; CHLOROPLASTS; COMPONENTS; SECRETION; TRANSPORT	The bacterial twin-arginine translocation (Tat) pathway has been recently described for PhoD of Bacillus subtilis, a phosphodiesterase containing a twin-arginine signal peptide. The expression of phoD is co-regulated with the expression of tatA(d) and tatC(d) genes localized downstream of phoD. To characterize the specificity of PhoD transport further, translocation of PhoD was investigated in Escherichia coli. By using gene fusions, we analyzed the particular role of the signal peptide and the mature region of PhoD in canalizing the transport route. A hybrid protein consisting of the signal peptide of beta-lactamase and mature PhoD was transported in a Sec-dependent manner indicating that the mature part of Phol) does not contain information canalizing the selected translocation route. Pre-PhoD, as well as a fusion protein consisting of the signal peptide of PhoD (SPPhoD) and beta-galactosidase (LacZ), remained cytosolic in the E. coli. Thus, SPPhoD is not recognized by E. coli transport systems. Co-expression of B. subtilis tatA(d)/C-d genes resulted in the processing Of SPPhoD-LacZ and periplasmic localization of LacZ illustrating a close substrate specificity of the TatA(d)/C-d transport system. While blockage of the Sec-dependent transport did not affect the localization Of SPPhoD-LacZ, translocation and processing was dependent on the pH gradient of the cytosolic membrane. Thus, the minimal requirement of a functional Tat-dependent protein translocation system consists of a twin-arginine signal peptide-containing Tat substrate, its specific TatA/C proteins, and the pH gradient across the cytosolic membrane.	Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Jena, Inst Virol, D-07745 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Muller, JP (corresponding author), Univ Jena, Inst Mol Biol, Winzerlaer Str 10, D-07745 Jena, Germany.							BASSFORD PJ, 1979, J BACTERIOL, V139, P19, DOI 10.1128/JB.139.1.19-31.1979; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Blaudeck N, 2001, J BACTERIOL, V183, P604, DOI 10.1128/JB.183.2.604-610.2001; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; ITO K, 1986, J BACTERIOL, V167, P201, DOI 10.1128/jb.167.1.201-204.1986; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; MULLER J, 1992, MOL GEN GENET, V235, P89, DOI 10.1007/BF00286185; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; RASMUSSEN BA, 1984, J BACTERIOL, V160, P612, DOI 10.1128/JB.160.2.612-617.1984; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; TOMMASSEN J, 1985, EMBO J, V4, P1041, DOI 10.1002/j.1460-2075.1985.tb03736.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VOORHOUT W, 1988, J GEN MICROBIOL, V134, P599; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	41	83	91	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3268	3273		10.1074/jbc.M110829200	http://dx.doi.org/10.1074/jbc.M110829200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719524	hybrid			2022-12-25	WOS:000173688000029
J	Sakahira, H; Nagata, S				Sakahira, H; Nagata, S			Co-translational folding of caspase-activated DNase with Hsp70, Hsp40, and inhibitor of caspase-activated DNase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; MOLECULAR CHAPERONES; INDEPENDENT MECHANISMS; FRAGMENTATION FACTOR; IN-VITRO; PROTEIN; APOPTOSIS; CHAINS; ICAD; CELL	CAD (caspase-activated DNase) that causes chromosomal DNA fragmentation during apoptosis exists as a complex with ICAD (inhibitor of CAD) in proliferating cells. Here, we report that denatured CAD is functionally refolded with Hsc70-Hsp40 and ICAD. Hsc70-Hsp40 suppresses the aggregation of the denatured CAD, but cannot restore its enzymatic activity. In contrast, ICAD could not suppress the aggregation of CAD, but supported the CAD's renaturation with Hsc70-Hsp4O, indicating that ICAD recognizes the quasi-native folding state of CAD that is conferred by Hsc70-Hsp4O. Using an in vitro translation system, we then showed that during CAD translation, Hsc70-Hsp40 as well as ICAD bind to the nascent CAD polypeptide, while on ribosomes. These results indicate that ICAD together with Hsc70-Hsp4O assists the folding of CAD during its synthesis, and that the CAD-ICAD heterodimer is formed co-translationally.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamada Oka, Suita, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Otomo T, 2000, NAT STRUCT BIOL, V7, P658, DOI 10.1038/77957; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 2001, ARCH BIOCHEM BIOPHYS, V388, P91, DOI 10.1006/abbi.2000.2266; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Yokoyama H, 2000, J BIOL CHEM, V275, P12978, DOI 10.1074/jbc.275.17.12978; Young JC, 1996, EMBO J, V15, P172, DOI 10.1002/j.1460-2075.1996.tb00345.x; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	38	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3364	3370		10.1074/jbc.M110071200	http://dx.doi.org/10.1074/jbc.M110071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724800	hybrid			2022-12-25	WOS:000173688000042
J	Bornstein, P; Walsh, V; Tullis, J; Stainbrook, E; Bateman, JF; Hormuzdi, SG				Bornstein, P; Walsh, V; Tullis, J; Stainbrook, E; Bateman, JF; Hormuzdi, SG			The globular domain of the pro alpha 1(I) N-propeptide is not required for secretion, processing by procollagen N-proteinase, or fibrillogenesis of type I collagen in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; EHLERS-DANLOS SYNDROME; DIFFERENTIAL EXPRESSION; MOLECULAR CHAPERONE; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; III COLLAGENS; CELLS	The globular domain in the NH2-terminal propeptide (N-propeptide) of the proalphal(1) chain is largely encoded by exon 2 of the Colla1 gene and has been implicated in a number of processes that are involved in the biogenesis, maturation, and function of type I collagen. These include intracellular chain association, transcellular transport and secretion, proteolytic processing of the precursor, feedback regulation of synthesis, and control of fibrillogenesis. However, none of these proposed functions has been firmly established. To evaluate the function of this procollagen domain we have used a targeted mutagenesis approach to generate mice that lack exon 2 in the Colla1 gene. Mouse lines were established on both a mixed 129 OlaHsd/Sv and C57BL/6 background and a pure 129 OlaHsd/Sv background. Adult mice on the mixed background are normal in appearance and are fertile. To the extent that they have been studied, procollagen synthesis, secretion, and proteolytic processing are normal in these mice, and collagen fibrillogenesis is only slightly altered. However, breeding of heterozygous mutant mice on the 129 background generated homozygous mutants at only 64% of the expected frequency. These findings suggest that although the N-propeptide is not essential for collagen biogenesis in mice it may play some essential role during embryonic development.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Royal Childrens Hosp, Parkville, Vic 3052, Australia	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Royal Children's Hospital Melbourne	Bornstein, P (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.			Bateman, John/0000-0001-8542-0730	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR011248, R01AR011248] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR11248] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; FENTON SP, 1996, THESIS U MELBOURNE; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1988, J HISTOCHEM CYTOCHEM, V36, P1425, DOI 10.1177/36.11.3049791; FOUSER L, 1991, P NATL ACAD SCI USA, V88, P10158, DOI 10.1073/pnas.88.22.10158; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; HORLEIN D, 1981, P NATL ACAD SCI-BIOL, V78, P6163, DOI 10.1073/pnas.78.10.6163; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; Hormuzdi SG, 1999, MATRIX BIOL, V18, P287, DOI 10.1016/S0945-053X(99)00017-7; HU G, 1995, J CELL BIOCHEM, V59, P350, DOI 10.1002/jcb.240590307; John DCA, 1999, NAT BIOTECHNOL, V17, P385, DOI 10.1038/7945; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2000, J BIOL CHEM, V275, P27957; Kyriakides TR, 1999, J INVEST DERMATOL, V113, P782, DOI 10.1046/j.1523-1747.1999.00755.x; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Larrain J, 2000, DEVELOPMENT, V127, P821; LEE ST, 1992, J BIOL CHEM, V267, P24126; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; Liu X, 1997, DEV DYNAM, V209, P85; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; Nah HD, 2001, DEV DYNAM, V220, P307, DOI 10.1002/dvdy.1109; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SMITH LT, 1992, AM J HUM GENET, V51, P235; Sun XL, 2000, RNA, V6, P1, DOI 10.1017/S1355838200991660; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WIESTNER M, 1982, EMBO J, V1, P513, DOI 10.1002/j.1460-2075.1982.tb01200.x; WU CH, 1986, J BIOL CHEM, V261, P482; WU CH, 1991, J BIOL CHEM, V266, P2983; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	46	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2605	2613		10.1074/jbc.m106181200	http://dx.doi.org/10.1074/jbc.m106181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705995	hybrid			2022-12-25	WOS:000173421500031
J	Broustas, CG; Grammatikakis, N; Eto, M; Dent, P; Brautigan, DL; Kasid, U				Broustas, CG; Grammatikakis, N; Eto, M; Dent, P; Brautigan, DL; Kasid, U			Phosphorylation of the myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; PROTEIN-KINASE; SMOOTH-MUSCLE; SIGNAL-TRANSDUCTION; TARGETING SUBUNIT; RAS; ACTIVATION; ASSOCIATION; MEMBRANE; GROWTH	Raf-1 serine/threonine protein kinase plays an important role in cell survival, proliferation, and migration; however, the specific targets of Raf-1 in diverse cellular processes are not clearly defined. Myosin phosphatase activity is critical to the regulation of cytoskeletal reorganization, cytokinesis, and cell motility. Here, we describe the association of Raf-1 with myosin phosphatase and phosphorylation of the regulatory myosin-binding subunit (MBS) of myosin phosphatase by Raf-1. Treatment of cells with phorbol 12-myristate 13-acetate has been shown to stimulate Raf-1 protein kinase. To determine the effect of enzymatic activation of Raf-1 on MBS phosphorylation, COS-1 cells were transiently transfected with FLAG-tagged full-length Raf-1. A significantly higher phosphorylation of purified glutathione S-transferase-tagged truncated MBS protein (amino acids 654-880) occurred in the presence of FLAG-Raf-1 immunoprecipitated from phorbol 12-myristate 13-acetate-treated cells compared with untreated cells (similar to3.0-fold). Using a sequential kinase-phosphatase assay and phosphorylated myosin light chain as substrate in the phosphatase reaction, we showed that Raf-1-associated protein phosphatase-specific activity was inhibited (relative phosphatase activity without and with adenosine 5'-O-(3-thiotriphosphate): 100 and similar to30%, respectively). Previously, ionizing radiation has been shown to activate Raf-1 (Kasid, U., Suy, S., Dent, P., Ray, S., Whiteside, T. L., and Sturgill, T. W. (1996) Nature 382, 813-816). Exposure of cells to ionizing radiation resulted in the increased association of Raf-1 with MBS (3-6-fold versus unirradiated control) and inhibition of Raf-1-associated protein phosphatase-specific activity (relative phosphatase activity without and with ionizing radiation: 100 and similar to54%, respectively). Our studies identify MBS as a new substrate of Raf-1 and implicate a role for Raf-1 in the regulation of pathways involving myosin phosphatase activity.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Biochem, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Mol Biol, Washington, DC 20007 USA; Tufts Univ, Dept Physiol, Boston, MA 02111 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Georgetown University; Georgetown University; Georgetown University; Tufts University; University of Virginia; Virginia Commonwealth University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, E208 Res Bldg,3970 Reservoir Rd, Washington, DC 20007 USA.	kasidu@georgetown.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836; Broustas, Constantinos/0000-0001-7169-807X	NATIONAL CANCER INSTITUTE [R55CA068322, P01CA074175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER; NCI NIH HHS [CA68322, CA40042, CA74175] Funding Source: Medline; NIGMS NIH HHS [GM56362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DENT P, 1995, MOL CELL BIOL, V15, P4125; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Inagaki N, 1997, BIOCHEM BIOPH RES CO, V230, P552, DOI 10.1006/bbrc.1996.5986; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Janosch P, 2000, FASEB J, V14, P2008, DOI 10.1096/fj.99-0883com; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Totsukawa G, 1999, J CELL BIOL, V144, P735, DOI 10.1083/jcb.144.4.735; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016	43	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3053	3059		10.1074/jbc.M106343200	http://dx.doi.org/10.1074/jbc.M106343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11719507	hybrid			2022-12-25	WOS:000173421500089
J	Kast, HR; Goodwin, B; Tarr, PT; Jones, SA; Anisfeld, AM; Stoltz, CM; Tontonoz, P; Kliewer, S; Willson, TM; Edwards, PA				Kast, HR; Goodwin, B; Tarr, PT; Jones, SA; Anisfeld, AM; Stoltz, CM; Tontonoz, P; Kliewer, S; Willson, TM; Edwards, PA			Regulation of multidrug resistance-associated protein 2 (ABCC2) by nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISPECIFIC ORGANIC ANION; BILE-ACID BIOSYNTHESIS; SIGNALING PATHWAY; DRUG-INTERACTIONS; RAT HEPATOCYTES; ENHANCER MODULE; GENE-EXPRESSION; CYP2B GENE; IDENTIFICATION; CAR	The multidrug resistance-associated protein 2 (MRP2, ABCC2), mediates the efflux of several conjugated compounds across the apical membrane of the hepatocyte into the bile canaliculi. We identified MRP2 in a screen designed to isolate genes that are regulated by the farnesoid X-activated receptor (FXR, NR1H4). MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands. In addition, we have shown that MRP2 expression is regulated by the pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3). Thus, treatment of rodent hepatocytes with PXR or CAR agonists results in a robust induction of MRP2 mRNA levels. The dexamethasone- and pregnenolone 16alpha-carbonitrile-dependent induction of MRP2 expression was not evident in hepatocytes derived from PXR null mice. In contrast, induction of MRP2 by phenobarbital, an activator of CAR, was comparable in wild-type and PXR null mice. An unusual 26-bp sequence was identified 440 bp upstream of the MRP2 transcription initiation site that contains an everted repeat of the AGTTCA hexad separated by 8 nucleotides (ER-8). PXR, CAR, and FXR bound with high affinity to this element as heterodimers with the retinoid X receptor a (RXRalpha, NR2B1). Luciferase reporter gene constructs containing I kb of the rat MRP2 promoter were prepared and transiently transfected into HepG2 cells. Luciferase activity was induced in a PXR-, CAR-, or FXR-dependent manner. Furthermore, the isolated ER-S element was capable of conferring PXR, CAR, and FXR responsiveness on a heterologous thymidine kinase promoter. Mutation of the ER-8 element abolished the nuclear receptor response. These studies demonstrate that MRP2 is regulated by three distinct nuclear receptor signaling pathways that converge on a common response element in the 5'-flanking region of this gene.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; GlaxoSmithKline, Nucl Recept Discovery Res, Res Triangle Pk, NC 27709 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; GlaxoSmithKline	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	pedwards@mednet.ucla.edu	feinstein, doug/M-9414-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068445, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68445, HL30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BREMMELGAARD A, 1980, J LIPID RES, V21, P1072; Buchler M, 1996, J BIOL CHEM, V271, P15091; Courtois A, 1999, FEBS LETT, V459, P381, DOI 10.1016/S0014-5793(99)01295-8; Cui YH, 1999, MOL PHARMACOL, V55, P929; Demeule M, 1999, FEBS LETT, V442, P208, DOI 10.1016/S0014-5793(98)01663-9; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fromm MF, 2000, AM J PATHOL, V157, P1575, DOI 10.1016/S0002-9440(10)64794-3; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kauffmann HM, 1998, ARCH TOXICOL, V72, P763, DOI 10.1007/s002040050571; Kauffmann HM, 1998, BIOCHEM BIOPH RES CO, V245, P325, DOI 10.1006/bbrc.1998.8340; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; LeCluyse E L, 1996, Pharm Biotechnol, V8, P121; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Moore JT, 2000, TOXICOLOGY, V153, P1, DOI 10.1016/S0300-483X(00)00300-0; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; MULLER M, 1997, AM J PHYSIOL, V272, pG1286; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Paulusma CC, 1997, J MOL MED-JMM, V75, P420, DOI 10.1007/s001090050127; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; Reichel C, 1999, GASTROENTEROLOGY, V117, P688, DOI 10.1016/S0016-5085(99)70463-4; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schrenk D, 2001, TOXICOL LETT, V120, P51, DOI 10.1016/S0378-4274(01)00306-X; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Smirlis D, 2001, J BIOL CHEM, V276, P12822, DOI 10.1074/jbc.M005930200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	63	735	776	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2908	2915		10.1074/jbc.M109326200	http://dx.doi.org/10.1074/jbc.M109326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706036	hybrid			2022-12-25	WOS:000173421500070
J	Westein, E; Denis, CV; Bouma, BN; Lenting, PJ				Westein, E; Denis, CV; Bouma, BN; Lenting, PJ			The alpha-chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; TISSUE FACTOR; BINDING-SITE; CELLULAR INTERNALIZATION; REGULATORY COMPONENT; LIGAND-BINDING; HIGH-AFFINITY; S BINDING; DEGRADATION; PATHWAY	C4b-binding protein (C4BP) is a heparin-binding protein that participates in both the complement and hemostatic system, We investigated the interaction between C4BP and low density lipoprotein receptor-related protein (LRP), an endocytic receptor involved in the catabolism of various heparin-binding proteins. Both plasma-derived C4BP and recombinant C4BP consisting of only its a-chains (rC4BPalpha) bound efficiently to immobilized LRP, as determined by surface plasmon resonance analysis. Complementary, two distinct fragments of LRP, i.e. clusters 11 and IV, both associated to immobilized rC4BPalpha, and binding could be inhibited by the LRP antagonist receptor-associated protein. Further analysis showed that association of rC4BPalpha to LRP was inhibited by heparin or by anti-C4BP antibody RU-3B9, which recognizes the heparin-binding region of the C4BP alpha-chains. In cellular degradation experiments, LRP-expressing fibroblasts effectively degraded I-125-labeled rC4BPalpha, whereas their LRP-deficient counterparts displayed a 4-fold diminished capacity of degrading I-125-rC4BPalpha. Finally, initial clearance of C4BP in mice was significantly delayed upon co-injection with receptor-associated protein. In conclusion, our data demonstrate that the a-chains of C4BP comprise a binding site for LRP. We propose that LRP mediates at least in part the catabolism of C4BP and, as such, may regulate C4BP participation in complement and hemostatic processes.	Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis Haemostasis, NL-3584 CX Utrecht, Netherlands; Hop Bicetre, INSERM, U143, F-94276 Le Kremlin Bicetre, France	Utrecht University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Lenting, PJ (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis Haemostasis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.lenting@lab.azu.nl	Denis, Cecile/A-7649-2011; Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013	Denis, Cecile/0000-0001-5152-9156; Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; Gliemann J, 1998, BIOL CHEM, V379, P951; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1993, J BIOL CHEM, V268, P3993; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HESSING M, 1990, J IMMUNOL, V144, P204; HESSING M, 1991, EUR J IMMUNOL, V21, P2077, DOI 10.1002/eji.1830210916; HESSING M, 1990, J IMMUNOL, V144, P2632; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KOPPELMAN SJ, 1995, BLOOD, V86, P2653, DOI 10.1182/blood.V86.7.2653.bloodjournal8672653; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Meilinger M, 1999, J BIOL CHEM, V274, P38091, DOI 10.1074/jbc.274.53.38091; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Narita M, 1998, BLOOD, V91, P555, DOI 10.1182/blood.V91.2.555.555_555_560; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; SAEKI T, 1989, BIOCHEM BIOPH RES CO, V164, P1446, DOI 10.1016/0006-291X(89)91832-9; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; SANCHEZCORRAL P, 1995, J IMMUNOL, V155, P4030; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; Storm D, 1997, J BIOL CHEM, V272, P31043, DOI 10.1074/jbc.272.49.31043; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; THERN A, 1995, J IMMUNOL, V154, P375; van de Poel RHL, 2000, BIOCHEMISTRY-US, V39, P14543, DOI 10.1021/bi0006058; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, J CELL SCI, V107, P719; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	47	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2511	2516		10.1074/jbc.M102293200	http://dx.doi.org/10.1074/jbc.M102293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705989	hybrid			2022-12-25	WOS:000173421500020
J	Young, PJ; Day, PM; Zhou, J; Androphy, EJ; Morris, GE; Lorson, CL				Young, PJ; Day, PM; Zhou, J; Androphy, EJ; Morris, GE; Lorson, CL			A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE-PRODUCT; SINGLE NUCLEOTIDE; NUCLEAR EXPORT; COILED BODIES; SMN GENE; BINDING; APOPTOSIS; LOCALIZATION; CELLS; MDM2	Mutations in the SMN1 (survival motor neuron 1) gene cause spinal muscular atrophy (SMA). We now show that SMN protein, the SMN1 gene product, interacts directly with the tumor suppressor protein, p53. Pathogenic missense mutations in SMN reduce both self-association and p53 binding by SMN, and the extent of the reductions correlate with disease severity. The inactive, truncated form of SMN produced by the SMN2 gene in SMA patients fails to bind p53 efficiently. SMN and p53 co-localize in nuclear Cajal bodies, but p53 redistributes to the nucleolus in fibroblasts from SMA patients. These results suggest a functional interaction between SMN and p53, and the potential for apoptosis when this interaction is impaired may explain motor neuron death in SMA.	Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; NE Wales Inst, Multidisciplinary Res & Innovat Ctr, Biochem Grp, Wrexham LL11 2AW, Clwyd, Wales	Arizona State University; Arizona State University-Tempe; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Worcester; Glyndwr University	Lorson, CL (corresponding author), Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA.			Androphy, Elliot/0000-0002-8104-0703	NINDS NIH HHS [R01 NS40275, R01 NS41584-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040275, R01NS041584] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; Broccolini A, 1999, NEUROREPORT, V10, P1637, DOI 10.1097/00001756-199906030-00003; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Kerr DA, 2000, P NATL ACAD SCI USA, V97, P13312, DOI 10.1073/pnas.230364197; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V253, P315, DOI 10.1006/excr.1999.4672; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; Lyon CE, 1997, EXP CELL RES, V230, P84, DOI 10.1006/excr.1996.3380; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Schmalbruch H, 2001, BRAIN PATHOL, V11, P231; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Simic G, 2000, J NEUROPATH EXP NEUR, V59, P398, DOI 10.1093/jnen/59.5.398; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	45	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2852	2859		10.1074/jbc.M108769200	http://dx.doi.org/10.1074/jbc.M108769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704667	hybrid			2022-12-25	WOS:000173421500064
J	Perillan, PR; Chen, MK; Potts, EA; Simard, JM				Perillan, PR; Chen, MK; Potts, EA; Simard, JM			Transforming growth factor-beta(1) regulates Kir2.3 inward rectifier K+ channels via phospholipase C and protein kinase C-delta in reactive astrocytes from adult rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; FACTOR-BETA-S; TGF-BETA; FUNCTIONAL EXPRESSION; SENSORY NEURONS; INHIBITION; CURRENTS; TGF-BETA-1; ACTIVATION; ISOFORMS	The multifunctional cytokine, transforming growth factor beta(1) (TGF-beta(1)), exerts complex effects on astrocytes with early signaling events being less well characterized than transcriptional mechanisms. We examined the effect of TGF-beta(1) on the 14-pS Kir2.3 inward rectifier K+ channel in rat primary cultured reactive astrocytes. Immunofluoreseence study showed that cells co-expressed TGF-beta(1) receptors I and 2, Kir2.3, and glial fibrillary acidic protein (GFAP). Patch clamp study showed that TGF-beta(1) (0.1-100 ng/ml) caused a rapid (<5 min) depolarization because of dose-dependent down-regulation of Kir2.3 channels, which was mimicked by the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (10-500 nm) and which was inhibited by the PKC inhibitor calphostin C (100 nm), by PKC desensitization produced by 3 h of exposure to phorbol 12-myristate 13-acetate (100 lam), and by the PKC-delta isoform-specific inhibitor rottlerin (50 pm). Immunoblot analysis and confocal imaging showed that TGF-beta(1) caused PKC-delta translocation to membrane, and co-immunoprecipitation experiments showed that TGF-beta(1) enhanced association between Kir2.3 and PKC-delta. Additional electro-physiological experiments showed that Kir2.3 channel down-regulation was blocked by the phospholipase C inhibitors, neomycin (100 mum) and D609 (200 mum). Given the commonality of signaling involving PLC-PKC-delta, we speculate that TGF-beta(1)-evoked depolarization may be an early signaling event related to gene transcription in astrocytes.	Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St, Baltimore, MD 21201 USA.	msimard@surgery1.umaryland.edu						Ata KA, 1999, ACTA NEUROPATHOL, V97, P447, DOI 10.1007/s004010051013; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Bringmann A, 2000, GLIA, V29, P35, DOI 10.1002/(SICI)1098-1136(20000101)29:1<35::AID-GLIA4>3.0.CO;2-A; Cameron JS, 1999, DEVELOPMENT, V126, P4157; CHEN CC, 1995, J NEUROCHEM, V64, P818; Chin J, 1999, LEARN MEMORY, V6, P317; Chuang HH, 1997, CELL, V89, P1121, DOI 10.1016/S0092-8674(00)80299-8; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; DELBIGIO MR, 1994, NEUROREPORT, V5, P639, DOI 10.1097/00001756-199401000-00027; FALK T, 1995, FEBS LETT, V367, P127, DOI 10.1016/0014-5793(95)00527-G; Farr M, 1999, LEARN MEMORY, V6, P331; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Houzen H, 1997, J NEUROSCI RES, V50, P990, DOI 10.1002/(SICI)1097-4547(19971215)50:6<990::AID-JNR9>3.3.CO;2-8; Ignotz RA, 2000, J CELL BIOCHEM, V78, P588, DOI 10.1002/1097-4644(20000915)78:4<588::AID-JCB8>3.0.CO;2-6; Ishii M, 1997, J NEUROSCI, V17, P7725; Koller H, 1998, NEUROREPORT, V9, P1375; KORN SJ, 1991, METHODS NEUROSCIENCE; Kucich U, 2000, ARCH BIOCHEM BIOPHYS, V374, P313, DOI 10.1006/abbi.1999.1625; Lhuillier L, 1999, J NEUROPHYSIOL, V82, P1627, DOI 10.1152/jn.1999.82.3.1627; Lhuillier L, 2000, J NEUROSCI, V20, P5616, DOI 10.1523/JNEUROSCI.20-15-05616.2000; Macfarlane SN, 2000, GLIA, V30, P39, DOI 10.1002/(SICI)1098-1136(200003)30:1<39::AID-GLIA5>3.0.CO;2-S; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Muscella A, 2000, J NEUROCHEM, V74, P1325; Nietsch HH, 2000, J BIOL CHEM, V275, P20556, DOI 10.1074/jbc.M002535200; Perillan PR, 1999, GLIA, V27, P213, DOI 10.1002/(SICI)1098-1136(199909)27:3<213::AID-GLIA3>3.3.CO;2-T; Perillan PR, 2000, GLIA, V31, P181, DOI 10.1002/1098-1136(200008)31:2<181::AID-GLIA90>3.0.CO;2-8; Poopalasundaram S, 2000, GLIA, V30, P362, DOI 10.1002/(SICI)1098-1136(200006)30:4<362::AID-GLIA50>3.0.CO;2-4; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; SATO R, 1995, J MEMBRANE BIOL, V148, P185; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Schmidt J, 1996, REV PHYSIOL BIOCH P, V127, P251, DOI 10.1007/BFb0048269; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; Slepko N, 1999, J NEUROSCI RES, V57, P33, DOI 10.1002/(SICI)1097-4547(19990701)57:1<33::AID-JNR4>3.0.CO;2-6; Stonehouse AH, 1999, HISTOCHEM CELL BIOL, V112, P457, DOI 10.1007/s004180050429; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; Visser JA, 1998, MOL CELL ENDOCRINOL, V146, P7, DOI 10.1016/S0303-7207(98)00198-1; Vivien D, 1998, J NEUROCHEM, V70, P2296; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; WU T, 1995, NEUROSCI LETT, V184, P121, DOI 10.1016/0304-3940(94)11185-L; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	54	53	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1974	1980		10.1074/jbc.M107984200	http://dx.doi.org/10.1074/jbc.M107984200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11713246	hybrid			2022-12-25	WOS:000173421300050
J	Sugiyama, M; Kumagai, T; Hayashida, M; Maruyama, M; Matoba, Y				Sugiyama, M; Kumagai, T; Hayashida, M; Maruyama, M; Matoba, Y			The 1.6-A crystal structure of the copper(II)-bound bleomycin complexed with the bleomycin-binding protein from bleomycin-producing Streptomyces verticillus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-BLEOMYCIN; DISTANCE GEOMETRY CALCULATIONS; DIMENSIONAL NMR-SPECTROSCOPY; DNA CLEAVAGE; RESISTANCE DETERMINANT; ACTIVATED BLEOMYCIN; ESCHERICHIA-COLI; A2 GREEN; DRUG; SITE	Bleomycin (Bm) in the culture broth of Streptomyces verticillus is complexed with Cu2+ (Cu(II)). In the present study, we determined the x-ray crystal structures of the Cu(II)-bound and the metal-free types of Bm at a high resolution of 1.6 and 1.8 Angstrom, respectively, which are complexed with a Bm resistance determinant from Bm-producing S. verticillus, designated BLMA. In the current model of Cu(II).Bm complexed with BLMA, two Cu(II).Bm molecules bind to the BLMA dimer. The electron density map shows that the copper ion is clearly defined in the metal-binding domain of the Bm molecule. The metal ion is penta-coordinated by a tetragonal monopyramidal cage of nitrogens and binds to the primary amine of the beta-aminoalanine moiety of Bm. The binding experiment between Bm and BLMA showed that each of the two Bm-binding pockets has a different dissociation constant (K-d1 and K-d2). The K-d1 value of 630 nM for the first Bm binding is larger than the Kd2 value of 120 nM, indicating that the first Bm binding gives rise to a cooperative binding of the second Bm to the other pocket.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							Adam E, 1998, MOL MICROBIOL, V28, P15, DOI 10.1046/j.1365-2958.1998.00755.x; AKKERMAN MAJ, 1990, J AM CHEM SOC, V112, P7462, DOI 10.1021/ja00177a003; AKKERMAN MAJ, 1988, EUR J BIOCHEM, V173, P211, DOI 10.1111/j.1432-1033.1988.tb13987.x; BOGER DL, 1995, BIOORGAN MED CHEM, V3, P1281, DOI 10.1016/0968-0896(95)00113-U; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CaceresCortes J, 1997, EUR J BIOCHEM, V244, P818, DOI 10.1111/j.1432-1033.1997.00818.x; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; DUMAS P, 1994, EMBO J, V13, P2483, DOI 10.1002/j.1460-2075.1994.tb06535.x; GATIGNOL A, 1988, FEBS LETT, V230, P171, DOI 10.1016/0014-5793(88)80665-3; HAASNOOT CAG, 1984, J BIOMOL STRUCT DYN, V2, P449, DOI 10.1080/07391102.1984.10507579; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; Hoehn ST, 2001, BIOCHEMISTRY-US, V40, P5894, DOI 10.1021/bi002635g; IITAKA Y, 1978, J ANTIBIOT, V31, P1070, DOI 10.7164/antibiotics.31.1070; KANE SA, 1994, J BIOL CHEM, V269, P10899; Kawano Y, 2000, J MOL BIOL, V295, P915, DOI 10.1006/jmbi.1999.3404; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumagai T, 1998, ACTA CRYSTALLOGR D, V54, P127, DOI 10.1107/S0907444997008871; Kumagai T, 1999, FEBS LETT, V442, P34, DOI 10.1016/S0014-5793(98)01613-5; KURODA R, 1982, NUCLEIC ACIDS RES, V10, P4753, DOI 10.1093/nar/10.15.4753; Lehmann TE, 1997, BIOCHEMISTRY-US, V36, P2807, DOI 10.1021/bi962748t; LIN SY, 1981, BIOCHEMISTRY-US, V20, P7589, DOI 10.1021/bi00529a038; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; Maruyama M, 2001, J BIOL CHEM, V276, P9992, DOI 10.1074/jbc.M009874200; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKAMUA H, 1974, J ANTIBIOT, V27, P352, DOI 10.7164/antibiotics.27.352; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P665, DOI 10.1021/bi00506a034; SAKAI TT, 1981, J MED CHEM, V24, P279, DOI 10.1021/jm00135a008; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA M, 1994, FEMS MICROBIOL LETT, V121, P81, DOI 10.1111/j.1574-6968.1994.tb07079.x; SUGIYAMA M, 1994, GENE, V151, P11; SUGIYAMA M, 1995, FEBS LETT, V362, P80, DOI 10.1016/0014-5793(95)00218-X; SUZUKI T, 1985, BIOCHEMISTRY-US, V24, P4719, DOI 10.1021/bi00339a001; UMEZAWA H, 1974, FED PROC, V33, P2296; Vanderwall DE, 1997, CHEM BIOL, V4, P373, DOI 10.1016/S1074-5521(97)90128-9; Wu W, 1996, J AM CHEM SOC, V118, P1268, DOI 10.1021/ja9524964; Wu W, 1996, J AM CHEM SOC, V118, P1281, DOI 10.1021/ja952497w; XU RX, 1994, BIOCHEMISTRY-US, V33, P907, DOI 10.1021/bi00170a009	45	52	53	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2311	2320		10.1074/jbc.M103278200	http://dx.doi.org/10.1074/jbc.M103278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706014	hybrid			2022-12-25	WOS:000173421300091
J	Wakasugi, M; Kawashima, A; Morioka, H; Linn, S; Sancar, A; Mori, T; Nikaido, O; Matsunaga, T				Wakasugi, M; Kawashima, A; Morioka, H; Linn, S; Sancar, A; Mori, T; Nikaido, O; Matsunaga, T			DDB accumulates at DNA damage sites immediately after UV irradiation and directly stimulates nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; BINDING-PROTEIN; CELLS; P48; RECOGNITION; GENE; PHOTOPRODUCTS; PHENOTYPE	Damaged DNA-binding protein, DDB, is a heterodimer of p127 and p48 with a high specificity for binding to several types of DNA damage. Mutations in the p48 gene that cause the loss of DDB activity were found in a subset of xeroderma pigmentosum. complementation group E (XP-E) patients and have linked to the deficiency in global genomic repair of cyclobutane pyrimidine dimers (CPDs) in these cells. Here we show that with a highly defined system of purified repair factors, DDB can greatly stimulate the excision reaction reconstituted with XPA, RPA, XPC.HR23B, TFIIH, XPF-.ERCC1 and XPG, up to 17-fold for CPDs and similar to2-fold for (6-4) photoproducts (6-4PPs), indicating that no additional factor is required for the stimulation by DDB. Transfection of the p48 cDNA into an SV40-transformed human cell line, WI38VA13, was found to enhance DDB activity and the in vivo removal of CPDs and 6-4PPs. Furthermore, the combined technique of recently developed micropore UV irradiation and immunostaining revealed that p48 (probably in the form of DDB heterodimer) accumulates at locally damaged DNA sites immediately after UV irradiation, and this accumulation is also observed in XP-A and XP-C cells expressing exogenous p48. These results suggest that DDB can rapidly translocate to the damaged DNA sites independent of functional XPA and XPC proteins and directly enhance the excision reaction by core repair factors.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Nara Med Univ, Radioisotope Res Ctr, Nara 6348521, Japan	Kanazawa University; Hokkaido University; University of California System; University of California Berkeley; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Nara Medical University	Matsunaga, T (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		Wakasugi, Mitsuo/D-8417-2015	Wakasugi, Mitsuo/0000-0001-9593-0566; Mori, Toshio/0000-0002-8321-0710				CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; FELDBERG RS, 1980, NUCLEIC ACIDS RES, V8, P1133, DOI 10.1093/nar/8.5.1133; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P633; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Katsumi S, 2001, J INVEST DERMATOL, V117, P1156, DOI 10.1046/j.0022-202x.2001.01540.x; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1997, J CELL SCI, V110, P1159; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	32	180	185	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1637	1640		10.1074/jbc.C100610200	http://dx.doi.org/10.1074/jbc.C100610200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11705987	Green Published, hybrid			2022-12-25	WOS:000173421300003
J	Gasa, R; Clark, C; Yang, RJ; DePaoli-Roach, AA; Newgard, CB				Gasa, R; Clark, C; Yang, RJ; DePaoli-Roach, AA; Newgard, CB			Reversal of diet-induced glucose intolerance by hepatic expression of a variant glycogen-targeting subunit of protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MAGNETIC-RESONANCE; LIVER-GLYCOGEN; BLOOD-GLUCOSE; GLUCOKINASE; OVEREXPRESSION; METABOLISM	Glycogen-targeting subunits of protein phosphatase-1 facilitate interaction of the phosphatase with enzymes of glycogen metabolism. Expression of one family member, PTG, in the liver of normal rats improves glucose tolerance without affecting other plasma variables but leaves animals unable to reduce hepatic glycogen stores in response to fasting. In the current study, we have tested whether expression of other targeting subunit isoforms, such as the liver isoform G(L), the muscle isoform G(M)/R-GI, or a truncated version of G(M)/R-GI termed G(M)DeltaC in liver ameliorates glucose intolerance in rats fed on a high fat diet (HF). HF animals overexpressing G(M)DeltaC, but not G(L) or G(M)/R-GI, exhibited a decline in blood glucose of 35-44 mg/dl relative to control HF animals during an oral glucose tolerance test (OGTT) such that levels were indistinguishable from those of normal rats fed on standard chow at all but one time point. Hepatic glycogen levels were 2.1-2.4-fold greater in G(L)- and G(M)DeltaC-overexpressing HF rats compared with control HF animals following OGTT. In a second set of studies on fed and 20-h fasted HIP animals, G(M)DeltaC-overexpressing rats lowered their liver glycogen levels by 57% (from 402 54 to 173 27 mug of glycogen/mg of protein) in the fasted versus fed states compared with only 44% in G(L)-overexpressing animals (from 740 +/- 35 to 413 +/- 141 mug of glycogen/mg of protein). Since the OGTT studies were performed on 20-h fasted rats, this meant that G(M)DeltaC-overexpressing rats synthesized much more glycogen than GL-overexpressing HIP rats during the OGTT (419 versus 117 mug of glycogen/mg of protein, respectively), helping to explain why G(M)DeltaC preferentially enhanced glucose clearance. We conclude that G(M)DeltaC has a unique combination of glycogenic potency and responsiveness to glycogenolytic signals that allows it to be used to lower blood glucose levels in diabetes.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569, P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK58398, DK36569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUBBARD MJ, 1990, FEBS LETT, V189, P245; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Steinebach J, 1997, METRIKA, V46, P1, DOI 10.1007/BF02717162; TANG PM, 1991, J BIOL CHEM, V266, P15782; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Yang RJ, 2002, J BIOL CHEM, V277, P1514, DOI 10.1074/jbc.M107001200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	33	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1524	1530		10.1074/jbc.M107744200	http://dx.doi.org/10.1074/jbc.M107744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11707447	hybrid			2022-12-25	WOS:000173166800085
J	Ghalayini, AJ; Desai, N; Smith, KR; Holbrook, RM; Elliott, MH; Kawakatsu, H				Ghalayini, AJ; Desai, N; Smith, KR; Holbrook, RM; Elliott, MH; Kawakatsu, H			Light-dependent association of Src with photoreceptor rod outer segment membrane proteins in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; C-SRC; PHOSPHOLIPASE C-GAMMA-1; RECEPTOR; KINASE; PHOSPHATASE; MODULATION; ACTIVATION; TRANSDUCIN; SUBUNIT	In vivo light exposure results in tyrosine phosphorylation of several rod outer segment (ROS) proteins (Ghalayini, A. J., Guo, X. X., Koutz, C. A, and Anderson, R. E. (1998) Exp. Eye Res. 66,817-821). We now report the presence of Src in ROS and its increased association with bleached ROS membranes. Immunoprecipitation with anti-phosphotyrosine revealed that tyrosine kinase activity recovered from light-adapted ROS membranes was twice that recovered from dark-adapted ROS. Other experiments revealed the presence of both bleached rhodopsin and arrestin in immunoprecipitates of LROS, suggesting the formation of a multimeric complex containing Src, arrestin, and bleached rhodopsin. Additionally, when immobilized Src homology domains 2 and 3 (SH2 and SH3, respectively) were used to study the association of Src with ROS membranes, only bleached opsin and arrestin were found to associate with the SH2 domain of Src. These data strongly suggest that Src through its SH2 domain interacts with bleached rhodopsin and arrestin either directly or indirectly. Similar results were also obtained when dark-adapted and light-adapted retinas were used instead of ROS membranes. Our data strongly suggest that light exposure in vivo activates Src and promotes its association through its SH2 domain with a complex containing bleached rhodopsin and arrestin. A hypothesis for the functional significance of this phenomenon is presented.	Univ Oklahoma, Hlth Sci Ctr, Dean McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Ctr Neurosci, Oklahoma City, OK 73104 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of California System; University of California San Francisco	Ghalayini, AJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dean McGee Eye Inst, Dept Ophthalmol, 608 Stanton L Young Blvd,Rm 409, Oklahoma City, OK 73104 USA.	Abboud-Ghalayini@ouhsc.edu			NATIONAL EYE INSTITUTE [P30EY012190, R01EY011504] Funding Source: NIH RePORTER; NEI NIH HHS [EY11504, EY12190] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bell MW, 2000, J NEUROCHEM, V75, P2006, DOI 10.1046/j.1471-4159.2000.0752006.x; Bell MW, 1999, J NEUROCHEM, V73, P2331, DOI 10.1046/j.1471-4159.1999.0732331.x; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Elliott MH, 2001, INVEST OPHTH VIS SCI, V42, pS184; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fontaine V, 1998, J NEUROSCI, V18, P9662; Ghalayini AJ, 1998, J NEUROCHEM, V70, P171; Ghalayini AJ, 1998, EXP EYE RES, V66, P817, DOI 10.1006/exer.1998.0498; GHALAYINI AJ, 1995, INVEST OPHTHALMOL  S, V36, P1234; GHALAYINI AJ, 1998, INVEST OPHTHALMOL  S, V39, P4427; Guo XX, 1997, INVEST OPHTH VIS SCI, V38, P1873; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCGINNIS JF, 1992, J NEUROSCI RES, V31, P584, DOI 10.1002/jnr.490310325; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; Molokanova E, 1999, J NEUROSCI, V19, P4786; Molokanova E, 1997, J NEUROSCI, V17, P9068; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SCHORB W, 1994, J BIOL CHEM, V269, P19626; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E	34	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1469	1476		10.1074/jbc.M011432200	http://dx.doi.org/10.1074/jbc.M011432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11705988	hybrid			2022-12-25	WOS:000173166800078
J	Diviacco, S; Rapozzi, V; Xodo, L; Helene, C; Quadrifoglio, F; Giovannangeli, C				Diviacco, S; Rapozzi, V; Xodo, L; Helene, C; Quadrifoglio, F; Giovannangeli, C			Site-directed inhibition of DNA replication by triple helix formation	FASEB JOURNAL			English	Article						peptide nucleic acid; triplex; PPT/HIV-1	NUCLEIC-ACID PNA; FORMING OLIGONUCLEOTIDES; TRANSCRIPTION ELONGATION; GENE-EXPRESSION; CROSS-LINKING; IN-VITRO; BINDING; CELLS; POLYMERASE	Sequence-specific DNA recognition can be achieved by the use of triplex-forming molecules, namely, oligonucleotides (TFO) and peptide nucleic acids (PNAs). They have been used to regulate transcription or induce genomic DNA modifications at a selected site in cells and, recently, in vivo. We have determined the conditions under which a triplex structure can inhibit DNA replication in cells. An oligopyrimidine.oligopurine sequence suitable for triplex formation was inserted in a plasmid on both sides of the SV40 origin of replication. This insert-containing plasmid was replicated in COS-1 cells together with the parent plasmid, and the ratio between the corresponding replicated DNAs was quantitated. Selective inhibition of replication of the insert-containing plasmid can be ascribed to ligand binding to the oligopyrimidine.oligopurine sequence. Inhibition of DNA replication was observed using triplex-forming molecules that induce either covalent binding at the double-stranded target sequence (with TFO-psoralen conjugate and irradiation) or noncovalent triplex formation after strand displacement (with bis-PNA). In contrast, in the absence of covalent cross-linking, TFOs (which have been shown to arrest transcription elongation) did not act on replication. These results open new perspectives for future design and use of specific inhibitors of intracellular DNA information processing.	Museum Natl Hist Nat, Biophys Lab, INSERM, U201,CNRS,UMR 8646, F-75231 Paris 05, France; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Giovannangeli, C (corresponding author), Museum Natl Hist Nat, Biophys Lab, INSERM, U201,CNRS,UMR 8646, 43 Rue Cuvier, F-75231 Paris 05, France.	giovanna@mnhn.fr	Xodo, Luigi/W-6350-2019	Xodo, Luigi/0000-0003-3344-7207; RAPOZZI, Valentina/0000-0001-7619-5252				Bailey C, 2000, NUCLEIC ACIDS RES, V28, P1154, DOI 10.1093/nar/28.5.1154; Bastide L, 1999, NUCLEIC ACIDS RES, V27, P551, DOI 10.1093/nar/27.2.551; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; COGOI S, 2000, IN PRESS ANTISENSE N; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Faruqi AF, 2000, MOL CELL BIOL, V20, P990, DOI 10.1128/MCB.20.3.990-1000.2000; Faruqi AF, 1997, NUCLEIC ACIDS RES, V25, P633, DOI 10.1093/nar/25.3.633; Faruqi AF, 1998, P NATL ACAD SCI USA, V95, P1398, DOI 10.1073/pnas.95.4.1398; Giovannangeli C, 2000, CURR OPIN MOL THER, V2, P288; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; GIOVANNANGELI C, 1992, NUCLEIC ACIDS RES, V20, P4275, DOI 10.1093/nar/20.16.4275; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GIOVANNANGELI C, 1993, P NATL ACAD SCI USA, V90, P10013, DOI 10.1073/pnas.90.21.10013; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GUIEYSSE AL, 1995, BIOCHEM BIOPH RES CO, V217, P186, DOI 10.1006/bbrc.1995.2762; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P6192, DOI 10.1021/bi00186a019; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; Kuhn H, 1999, J MOL BIOL, V286, P1337, DOI 10.1006/jmbi.1998.2578; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; Luo ZJ, 2000, P NATL ACAD SCI USA, V97, P9003, DOI 10.1073/pnas.160004997; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V204, P1119, DOI 10.1006/bbrc.1994.2578; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; Nielsen PE, 1999, CURR OPIN STRUC BIOL, V9, P353, DOI 10.1016/S0959-440X(99)80047-5; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Porumb H, 1996, CANCER RES, V56, P515; Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; SCAGGIANTE B, 1994, FEBS LETT, V352, P380, DOI 10.1016/0014-5793(94)00995-3; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; VASQUEZ KM, 1999, PERSPECT ANTISEN SCI, P167; Wang G, 1999, NUCLEIC ACIDS RES, V27, P2806, DOI 10.1093/nar/27.13.2806	44	50	55	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2660	2668		10.1096/fj.01-0440com	http://dx.doi.org/10.1096/fj.01-0440com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726542				2022-12-25	WOS:000172964800036
J	Seifalian, AM; El-Desoky, EH; Delpy, DT; Davidson, BR				Seifalian, AM; El-Desoky, EH; Delpy, DT; Davidson, BR			Effect of graded hypoxia on the rat hepatic tissue oxygenation and energy metabolism monitored by near-infrared and P-31 nuclear magnetic resonance spectroscopy	FASEB JOURNAL			English	Article						NIMR; liver hypoxia; beta nucleoside triphosphate	PERFUSED MOUSE-LIVER; CYTOCHROME-OXIDASE; HEMORRHAGIC-SHOCK; BLOOD-FLOW; IN-SITU; ATP; PHOSPHORYLATION; INVIVO; STATE; NMR	Alteration in hepatic cellular adenosine triphosphate (ATP) levels has been shown to be a sensitive index for hypoxic damage. Hepatic ATP metabolism can be monitored by P-31 nuclear magnetic resonance (NMR). Near-infrared spectroscopy (NIRS) can measure tissue oxyhemoglobin (HbO(2)), deoxyhemoglobin (Hb), and cytochrome oxidase (Cyt Ox), which reflect ATP production. In this study, hepatic oxygenation parameters have been correlated with ATP metabolism under graded hypoxia. Sprague-Dawley rats underwent laparotomy for liver exposure. NIRS probes and an NMR coil were placed on the liver and the animal was positioned in the NMR magnet. Graded hypoxia was achieved by a stepwise reduction of the fraction of inspired oxygen (FiO(2)) from 15 to 4%. Recovery between the hypoxic periods was achieved using 30% oxygen. Hepatic tissue oxygenation parameters were measured continuously by NIRS; P-31-NMR spectra obtained at 1 min intervals from energy metabolites and intracellular pH were calculated. All the hypoxic grades produced an immediate reduction in HbO(2) with a simultaneous increase in Hb. Cyt Ox was reduced significantly only with FiO(2) of less than or equal to 10%. P-31-NMR spectra showed a significant decrease in cellular beta nucleoside triphosphate (beta -NTP) only with FiO(2) of less than or equal to 10%. Significant correlation was seen between beta -NTP and HbO(2) (r=0.85), Hb (r=-0.74), and Cyt Ox (r=0.81). Cyt Ox was reduced with intracellular hypoxia and correlated temporally with the reduction of cellular beta -NTP, and therefore could be used as an index for the changes in beta -NTP with hypoxia.	UCL, Royal Free & Univ Coll Med Sch, Dept Surg, Hepat Haemodynam Lab, London NW3 2QG, England; UCL, Dept Med Phys & Bioengn, London, England	University of London; University College London; University of London; University College London	Seifalian, AM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Surg, Hepat Haemodynam Lab, Pond St, London NW3 2QG, England.	a.seifalian@rfc.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013	Seifalian, Alexander M/0000-0002-1180-3322				BOWERS JL, 1992, AM J PHYSIOL, V262, pG636, DOI 10.1152/ajpgi.1992.262.4.G636; BRADFORD BU, 1986, J PHARMACOL EXP THER, V236, P263; Brauer M, 1997, J STUD ALCOHOL, V58, P119, DOI 10.15288/jsa.1997.58.119; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARINI R, 1995, BIOCHEM BIOPH RES CO, V206, P180, DOI 10.1006/bbrc.1995.1025; Chant C, 1997, ANN PHARMACOTHER, V31, P290, DOI 10.1177/106002809703100303; CHAPMAN AG, 1981, J NEUROCHEM, V36, P179, DOI 10.1111/j.1471-4159.1981.tb02393.x; CHAUDRY IH, 1976, CAN J PHYSIOL PHARM, V54, P750, DOI 10.1139/y76-104; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DEGROOT H, 1985, ANESTHESIOLOGY, V62, P44, DOI 10.1097/00000542-198501000-00009; DESMOULIN F, 1987, EUR J BIOCHEM, V162, P151, DOI 10.1111/j.1432-1033.1987.tb10555.x; El-Desoky AE, 2001, LIVER, V21, P37; El-Desoky AEH, 1999, J HEPATOL, V31, P71, DOI 10.1016/S0168-8278(99)80165-2; El-Desoky AEH, 1999, LIVER TRANSPLANT SUR, V5, P219, DOI 10.1002/lt.500050316; El-Desoky AEH, 2000, EUR SURG RES, V32, P207, DOI 10.1159/000008766; ELDESOKY A, 2000, THESIS U LONDON, P70; EVANOCHKO WT, 1984, BIOCHIM BIOPHYS ACTA, V805, P104, DOI 10.1016/0167-4889(84)90042-9; FARBER JL, 1981, AM J PATHOL, V102, P271; Guyton ACHJ., 1999, TXB MED PHYSL; HIGASHI H, 1989, EUR SURG RES, V21, P76, DOI 10.1159/000129006; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HUGHES RL, 1979, PFLUG ARCH EUR J PHY, V381, P151, DOI 10.1007/BF00582346; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; ILES RA, 1982, BIOSCIENCE REP, V2, P735, DOI 10.1007/BF01114837; Jobsis FF, 1992, QUANTITATIVE SPECTRO, P47; JONES DP, 1982, AM J PHYSIOL, V243, pC247, DOI 10.1152/ajpcell.1982.243.5.C247; KAMIIKE W, 1982, J BIOCHEM-TOKYO, V91, P1349, DOI 10.1093/oxfordjournals.jbchem.a133822; LARSEN JA, 1976, ACTA PHYSIOL SCAND, V98, P257, DOI 10.1111/j.1748-1716.1976.tb00244.x; LUTZ J, 1975, PFLUG ARCH EUR J PHY, V360, P7, DOI 10.1007/BF00584322; MALLIKA C, 1986, ELECTROCHIM ACTA, V31, P885, DOI 10.1016/0013-4686(86)85022-8; Matsunaga A, 1998, AM J PHYSIOL-CELL PH, V275, pC1022, DOI 10.1152/ajpcell.1998.275.4.C1022; MCLAUGHLIN AC, 1979, P NATL ACAD SCI USA, V76, P5445, DOI 10.1073/pnas.76.11.5445; NAKAJIMA Y, 1990, J SURG RES, V48, P111, DOI 10.1016/0022-4804(90)90201-C; NICHOLLS DG, 1982, BIOENERGETICS, P107; OSHINO N, 1974, BIOCHIM BIOPHYS ACTA, V368, P298, DOI 10.1016/0005-2728(74)90176-5; PASS LJ, 1982, J TRAUMA, V22, P730, DOI 10.1097/00005373-198209000-00002; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P1619; SUMIMOTO K, 1988, TRANSPLANTATION, V46, P506, DOI 10.1097/00007890-198810000-00007; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; WILLIAMS SR, 1986, Q J EXP PHYSIOL CMS, V71, P335, DOI 10.1113/expphysiol.1986.sp002994; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P485, DOI 10.1016/0003-9861(79)90375-8; WILSON DF, 1977, AM J PHYSIOL, V233, pC135, DOI 10.1152/ajpcell.1977.233.5.C135; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P494, DOI 10.1016/0003-9861(79)90376-X; WINKLER K, 1986, EUR J CLIN INVEST, V16, P106, DOI 10.1111/j.1365-2362.1986.tb01316.x	47	29	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2642	2648		10.1096/fj.01-0308com	http://dx.doi.org/10.1096/fj.01-0308com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726540				2022-12-25	WOS:000172964800034
J	Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R				Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R			Conservation of mononucleotide repeats within 3 ' and 5 ' untranslated regions and their instability in MSI-H colorectal cancer	ONCOGENE			English	Article						5 ' UTR; 3 ' UTR; MSI tumors	MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCE REPEATS; BINDING PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; COLON CANCERS; CELL-LINES; TRANSCRIPTION; RECEPTOR	Messenger RNA contains untranslated 3' and 5' regions (3' and 5' UTRs) with sequence elements that are essential for the regulation of gene expression. A systematic search of GenBank revealed a large number of mononucleotide repeats within these UTRs. We selected 35 such mononucleotide repeats ranging in length from 15 bp to 32 bp and analysed their size in a series of 60 normal individuals. The conservation of repeats correlated inversely to their length, with longer repeats generally being more polymorphic than shorter repeats, irrespective of 3' or 5' location. Several long repeats were identified however to be monomorphic and we postulate that their conservation may be due to selective pressures relating to a possible functional role. We analysed 19 conserved UTR repeats in 117 colorectal cancers (CRC), 43 of which had defective mismatch repair characterized by widespread microsatellite instability (MSI-H). The UTR repeats were very often deleted in MSI-H tumors, with the length of deletion being proportional to the size of the repeat. Because of the high frequency of deletion observed in the conserved UTR repeats of MSI-H tumors, these could serve as a useful model for the study of possible changes in gene expression resulting from such mutations.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia	Hamelin, R (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		Suraweera, Nirosha/E-5912-2012					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AHARONI A, 1993, NUCLEIC ACIDS RES, V21, P5221, DOI 10.1093/nar/21.22.5221; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GOLLER M, 1994, NUCLEIC ACIDS RES, V22, P1885, DOI 10.1093/nar/22.10.1885; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Kashi Y, 1997, TRENDS GENET, V13, P74, DOI 10.1016/S0168-9525(97)01008-1; LEVISON G, 1987, MOL BIOL EVOL, V4, P202; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; Pesole G, 1997, GENE, V205, P95, DOI 10.1016/S0378-1119(97)00407-1; Pesole G, 2000, BIOINFORMATICS, V16, P439, DOI 10.1093/bioinformatics/16.5.439; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sturzeneker R, 2000, HUM MOL GENET, V9, P347, DOI 10.1093/hmg/9.3.347; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; Zhang L, 2001, CANCER RES, V61, P3801; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	31	24	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7472	7477		10.1038/sj.onc.1204952	http://dx.doi.org/10.1038/sj.onc.1204952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709718				2022-12-25	WOS:000171976900003
J	Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA				Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA			Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN	ONCOGENE			English	Article						MMAC/PTEN; glioma; invasion; matrix metalloproteinases-2; tumor suppression	TUMOR-SUPPRESSOR; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; ADHESION MOLECULES; GERMLINE MUTATIONS; TISSUE INHIBITORS; PTEN; BREAST; PROTEINASES; PTEN/MMAC1	Human gliomas are highly invasive, and remain to be a major obstacle for any effective therapeutic remedy. Among many other factors, gliomas express elevated levels of matrix metalloproteinases (MMPs), which have been implicated to play an important role in tumor invasion as well as neovascularization. The tumor suppressor gene mutated in multiple advanced cancers/phosphatase and tensin homologue (MMAC/PTEN) has been shown to inhibit cell migration, spreading, and focal adhesion. In this study, we determined whether MMAC/PTEN inhibits tumor invasion by modulating MMP-2 activity. Our results showed that reintroduction of the MMAC/PTEN gene into human glioma U251 and U87 cells modified their phenotype and growth characteristics. The ability of MMAC/PTEN to induce anoikis in U251 cells was accompanied by a significant inhibition of in vitro invasion (70%). Expression of MMAC/PTEN in U251 and U87 cells inhibited MMP-2 enzymatic activity as determined by zymography. Furthermore, MMAC/PTEN expression strongly decreased MMP-2 mRNA levels, which correlated well with the inhibition of invasion capacity in these cells. Concomitant with MMP-2 expression and activity, MMP-2 promoter activity was also reduced in MMAC/PTEN expressing cells. Our observations suggest that MMAC/PTEN inhibits tumor cell invasion in part by regulating MMP-2 gene transcription and thereby its enzymatic activity. Further characterization of this regulation will facilitate the development of MMAC/PTEN based gene therapy for gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer; University of Alabama System; University of Alabama Birmingham	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 100, Houston, TX 77030 USA.	wyung@mdanderson.org	Davies, Michael/GWV-2527-2022		NATIONAL CANCER INSTITUTE [P30CA016672, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, R01 CA 51148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL C, 1994, CANCER RES, V54, P943; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; APODACA G, 1990, CANCER RES, V50, P2322; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BJERKVIG R, 1986, CANCER RES, V46, P4071; Cairns P, 1997, CANCER RES, V57, P4997; Cheney IW, 1998, CANCER RES, V58, P2331; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COCKETT MI, 1994, BIOCHEM SOC T, V22, P55, DOI 10.1042/bst0220055; DAVIES B, 1993, CANCER RES, V53, P5365; Davies MA, 1998, CANCER RES, V58, P5285; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Guldberg P, 1997, CANCER RES, V57, P3660; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOHANAM S, 1993, CANCER RES, V53, P4143; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; NAKAJIMA M, 1993, CANCER RES, V53, P5802; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Qin HW, 1998, J IMMUNOL, V161, P6664; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Rhei E, 1997, CANCER RES, V57, P3657; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEFTOR REB, 1993, CANCER RES, V53, P3411; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tashiro H, 1997, CANCER RES, V57, P3935; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; Uhm JH, 1997, CAN J NEUROL SCI, V24, P3, DOI 10.1017/S0317167100021028; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang SI, 1997, CANCER RES, V57, P4183; Xuan JW, 1998, ANTICANCER RES, V18, P743; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	60	99	113	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6669	6678		10.1038/sj.onc.1204799	http://dx.doi.org/10.1038/sj.onc.1204799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709701				2022-12-25	WOS:000171551600003
J	Latonen, L; Taya, Y; Laiho, M				Latonen, L; Taya, Y; Laiho, M			UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts	ONCOGENE			English	Article						p53; HDM2; phosphorylation; UV-damage	TUMOR-SUPPRESSOR P53; PROTEASOME-MEDIATED DEGRADATION; DNA-DAMAGE; CELL-CYCLE; MDM2 GENE; ULTRAVIOLET-RADIATION; POTENTIAL MEDIATOR; DOUBLE MINUTE-2; GROWTH ARREST; FEEDBACK LOOP	We address here the effects of increasing fluencies of UV-radiation on stability, modifications, activity and HDM2-interactions of endogenous p53 tumor suppressor and on cellular damage response of human diploid fibroblasts. Low amounts of UVB/C-radiation induced a transient cell cycle arrest of the cells which correlated with rapid but transient increase in p53 levels. In contrast, high UV-fluency caused cell apoptosis and a slower but sustained increase in p53. Regulation of p53 target genes was highly dependent on the radiation dose used. Whereas low doses induced p21/Cip1/Waf1 and HDM2, high doses induced only GADD45 and BAX increasing the BAX:BCL-2 ratio. The levels of HDM2, a negative regulator of p53, increased only by the low dose of UVC and p53-HDM2 association was promoted. In the absence of HDM2-induction after the high dose of UV-radiation p53-HDM2-interaction was promoted, but HDM2 failed to downregulate p53. p53 site-specific modifications (Ser15, Ser33, Ser37, Lys382) varied kinetically and were dependent on the fluency of the radiation used. Maximal phosphorylation of p53 on Ser15 and Ser33 correlated with increased levels of HDM2-free p53. The results suggest that regulation of p53 and HDM2 by UV-radiation is highly dose-dependent and contributes to the outcome of the cellular response.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	University of Helsinki; National Cancer Center - Japan	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 63, FIN-00014 Helsinki, Finland.	Marikki.Laiho@Helsinki.Fi	Latonen, Leena/C-8787-2016	Latonen, Leena/0000-0003-4502-2193				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Buschmann T, 2000, CANCER RES, V60, P896; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JUVEN T, 1993, ONCOGENE, V8, P3411; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhao RB, 2000, GENE DEV, V14, P981	54	105	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6784	6793		10.1038/sj.onc.1204883	http://dx.doi.org/10.1038/sj.onc.1204883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709713				2022-12-25	WOS:000171551600015
J	Wei, S; Wang, MWH; Teitelbaum, SL; Ross, FP				Wei, S; Wang, MWH; Teitelbaum, SL; Ross, FP			Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; MURINE BONE-MARROW; DIFFERENTIATION FACTOR; GENE-EXPRESSION; FACTOR RECEPTOR; OSTEOPROTEGERIN LIGAND; TERMINAL KINASE; ALPHA PROMOTER; MICE	To define the molecular mechanism(s) by which interleukin (IL)-4 reversibly inhibits formation of osteoclasts (OCs) from bone marrow macrophages (BMMs), we examined the capacity of this T cell-derived cytokine to impact signals known to modulate osteoclastogenesis, which include those initiated by macrophage colony-stimulating factor (M-CSF), receptor for activation of NF-kappaB ligand (RANKL), tumor necrosis factor (TNF), and IL-1. We find that although pretreatment of BMMs with IL-4 does not alter M-CSF signaling, it reversibly blocks RANKL-dependent activation of the NF-kappaB, JNK, p38, and ERK signals. IL-4 also selectively inhibits TNF signaling, while enhancing that of IL-1. Contrary to previous reports, we find that MEK inhibitors dose-dependently inhibit OC differentiation. To identify more proximal signals mediating inhibition of OC formation by IL-4, we used mice lacking STAT6 or SHIP1, two adapter proteins that bind the IL-4 receptor. IL-4 fails to inhibit RANKL,/M-CSF-induced osteoclastogenesis by BMMs derived from STAT6-, but not SHIP1-, knockout mice. Consistent with this observation, the inhibitory effects of IL-4 on RANKL-induced NF-kappaB and mitogen-activated protein kinase activation are STAT6-dependent. We conclude that IL-4 reversibly arrests osteoclastogenesis in a STAT6-dependent manner by 1) preventing LkappaB phosphorylation and thus NF-kappaB activation, and 2) blockade of the JNK, p38, and ERK mitogen-activated protein kinase pathways.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Ross, FP (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, MS 90-31-649,216 S Kingshighway, St Louis, MO 63110 USA.	rossf@medicine.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; DROUET C, 1991, J IMMUNOL, V147, P1694; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hamilton TA, 1999, PATHOBIOLOGY, V67, P241, DOI 10.1159/000028101; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014-5793(00)02231-6; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; MCNALLY AK, 1995, AM J PATHOL, V147, P1487; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NAKANO Y, 1994, J BONE MINER RES, V9, P1533, DOI 10.1002/jbmr.5650091005; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Okada Y, 1998, BONE, V22, P361, DOI 10.1016/S8756-3282(97)00296-2; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Ross FP, 2000, J CLIN INVEST, V105, P555, DOI 10.1172/JCI9557; Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHIOI A, 1991, J CELL BIOCHEM, V47, P1; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006-291X(90)91550-C; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	53	154	157	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6622	6630		10.1074/jbc.M104957200	http://dx.doi.org/10.1074/jbc.M104957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11719504	hybrid			2022-12-25	WOS:000173989200122
J	Feldhaus, MJ; Weyrich, AS; Zimmerman, GA; McIntyre, TM				Feldhaus, MJ; Weyrich, AS; Zimmerman, GA; McIntyre, TM			Ceramide generation in situ alters leukocyte cytoskeletal organization and beta(2)-integrin function and causes complete degranulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IGG-DEPENDENT PHAGOCYTOSIS; ACTIVATED PROTEIN-KINASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN NEUTROPHIL ADHERENCE; INTEGRIN FUNCTION; CONFORMATIONAL CHANGE; SIGNAL-TRANSDUCTION; SPHINGOMYELIN CYCLE; SURFACE EXPRESSION	Ceramide levels increase in activated polymorphonuclear neutrophils, and here we show that endogenous ceramide induced degranulation and superoxide generation and increased surface beta2-integrin expression. Ceramide accumulation reveals a bifurcation in integrin function, as it abolished agonist-induced adhesion to planar surfaces, yet had little effect on homotypic aggregation. We increased cellular ceramide content by treating polymorphonuclear neutrophils with sphingomyelinase C and controlled for loss of sphingomyelin by pretreatment with sphingomyelinase D to generate ceramide phosphate, which is not a substrate for sphingomyelinase C. Pretreatment with the latter enzyme blocked all the effects of sphingomyelinase C. Ceramide generation caused a Ca2+ flux and complete degranulation of both primary and secondary granules and increased surface beta2-integrin expression. These integrins were in a nonfunctional state, and subsequent activation with platelet-activating factor or formyl-methionyl-leucyl-phenylalanine induced beta(2)-integrin-dependent homotypic aggregation. However, these cells were completely unable to adhere to surfaces via beta(2)-integrins. This was not due to a defect in the integrins themselves because the active conformation could be achieved by cation switching. Rather, ceramide affected cytoskeletal organization; and inside-out signaling, leading to affinity maturation. Cytochalasin D induced the same disparity between aggregation and surface adhesion. We conclude that ceramide affects F-actin rearrangement, leading to massive degranulation, and reveals differences in beta(2)-integrin-mediated adhesive events.	Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Dept Med, 4130 EIHG, Salt Lake City, UT 84112 USA.			Weyrich, Andrew/0000-0001-9622-4647	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL50153 P50] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1988, BIOCHIM BIOPHYS ACTA, V938, P403, DOI 10.1016/0005-2736(88)90138-1; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALVAREZ V, 1991, KIDNEY INT, V40, P899, DOI 10.1038/ki.1991.291; AMES BN, 1960, J BIOL CHEM, V235, P769; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; BRYANT AE, 1993, FEMS IMMUNOL MED MIC, V7, P321, DOI 10.1111/j.1574-695X.1993.tb00414.x; BUYON JP, 1988, J IMMUNOL, V140, P3156; Cai TQ, 1995, CELL ADHES COMMUN, V3, P399, DOI 10.3109/15419069509081294; CALAFAT J, 1993, BLOOD, V81, P3122; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; FRANCIS JW, 1989, J CELL PHYSIOL, V140, P519, DOI 10.1002/jcp.1041400317; Fuortes M, 1996, J LEUKOCYTE BIOL, V59, P451, DOI 10.1002/jlb.59.3.451; GRIMMINGER F, 1991, J BIOL CHEM, V266, P19276; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1993, ADV LIPID RES, V25, P27; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, P916; HAWKINS D, 1973, J IMMUNOL, V110, P294; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; HENSON PM, 1971, J IMMUNOL, V107, P1547; HENSON PM, 1973, J IMMUNOL, V110, P290; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; Hinkovska-Galcheva V, 1998, BLOOD, V91, P4761, DOI 10.1182/blood.V91.12.4761.412k24_4761_4769; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KARNOVSKY MJ, 1994, HISTOCHEMISTRY, V102, P15, DOI 10.1007/BF00271045; Kitagawa Y, 1997, J APPL PHYSIOL, V82, P1397, DOI 10.1152/jappl.1997.82.5.1397; KUBES P, 1995, FASEB J, V9, P1103; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; Lian JP, 1998, J IMMUNOL, V161, P4375; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Mollby R., 1978, BACTERIAL TOXINS CEL, P367; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Richard A, 1996, BBA-LIPID LIPID MET, V1299, P259, DOI 10.1016/0005-2760(95)00215-4; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SPENCE MW, 1993, ADV LIPID RES, V26, P3; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; Suchard SJ, 1997, J IMMUNOL, V158, P4961; TOPHAM M, 1989, CLIN RES, V37, pA119; van Kooyk Y, 1998, CELL ADHES COMMUN, V6, P247; VOLZ A, 1993, J CELL SCI, V106, P493; WALLIS WJ, 1986, BLOOD, V67, P1007; WARD PD, 1979, J COMP PATHOL, V89, P169, DOI 10.1016/0021-9975(79)90056-2; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	77	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4285	4293		10.1074/jbc.M106653200	http://dx.doi.org/10.1074/jbc.M106653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706024	hybrid			2022-12-25	WOS:000173813900067
J	Li, YH; Spangenberg, O; Paarmann, I; Konrad, M; Lavie, A				Li, YH; Spangenberg, O; Paarmann, I; Konrad, M; Lavie, A			Structural basis for nucleotide-dependent regulation of membrane-associated guanylate kinase-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; DISCS-LARGE; INTRAMOLECULAR INTERACTION; CRYSTAL-STRUCTURE; TIGHT JUNCTION; PDZ DOMAINS; PROTEIN; FAMILY; LOCALIZATION; REFINEMENT	CASK is a member of the membrane-associated guanylate kinases (MAGUK) homologs, a family of proteins that scaffold protein complexes at particular regions of the plasma membrane by utilizing multiple protein-binding domains. The GK domain of MAGUKs, which shares high similarity in amino acid sequence with yeast guanylate kinase (yGMPK), is the least characterized MAGUK domain both in structure and function. In addition to its scaffolding function, the GH domain of hCASK has been shown to be involved in transcription regulation. Here we report the crystal structure of the GK domain of human CASK (hCASK-GK) at 1.3-Angstrom resolution. The structure rationalizes the inability of the GK domain to catalyze phosphoryl transfer and strongly supports its new function as a protein-binding module. Comparison of the hCASK-GK structure with the available crystal structures of yGMPK provides insight into possible conformational changes that occur irk hCASK upon GMP binding. These conformational changes may act to regulate hCASK-GK function in a nucleotide-dependent manner.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Max Planck Inst Biophys Chem, Dept Mol Genet, D-37018 Gottingen, Germany	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Max Planck Society	Lavie, A (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, 1819 W Polk St, Chicago, IL 60612 USA.	lavie@uic.edu	Lavie, Arnon/H-4927-2012	Lavie, Arnon/0000-0001-5591-8722	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Blaszczyk J, 2001, J MOL BIOL, V307, P247, DOI 10.1006/jmbi.2000.4427; Brenman JE, 1998, J NEUROSCI, V18, P8805; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; De Lorenzo C, 1999, CANCER METAST REV, V18, P295, DOI 10.1023/A:1006381526008; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GURUPRASAD L, 1995, J MOL BIOL, V248, P856, DOI 10.1006/jmbi.1995.0266; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Lavie A, 1998, P NATL ACAD SCI USA, V95, P14045, DOI 10.1073/pnas.95.24.14045; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Zhang Y, 2001, FEBS LETT, V497, P99, DOI 10.1016/S0014-5793(01)02450-4	49	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4159	4165		10.1074/jbc.M110792200	http://dx.doi.org/10.1074/jbc.M110792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729206	hybrid, Green Published			2022-12-25	WOS:000173813900051
J	Racape, J; Lecoq, A; Romi-Lebrun, R; Liu, J; Kohler, M; Garcia, ML; Menez, A; Gasparini, S				Racape, J; Lecoq, A; Romi-Lebrun, R; Liu, J; Kohler, M; Garcia, ML; Menez, A; Gasparini, S			Characterization of a novel radiolabeled peptide selective for a subpopulation of voltage-gated potassium channels in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMONE BUNODOSOMA-GRANULIFERA; HETEROMULTIMERIC K+ CHANNELS; AMINO-ACID-SEQUENCE; ALPHA-DENDROTOXIN; BOVINE BRAIN; RAT-BRAIN; BIOLOGICAL-ACTIVITY; SUBUNIT COMPOSITION; BLOCKING TOXINS; XENOPUS-OOCYTES	BgK, a 37-amino acid voltage-gated potassium (Kv) 1 channel blocker isolated from the sea anemone Bunodosoma granulifera, can be modified at certain positions to alter its pharmacological profile (Alessandri-Haber, N., Lecoq, A., Gasparini, S., Grangier-Macmath, G., Jacquet, G., Harvey, A. L., de Medeiros, C., Rowan, E. G., Gola, M., Menez, A., and Crest, M. (1999) J. Biol. Chem. 274, 35653-35661). In the present study, we report the design of two BgK analogs that have been radiolabeled with (INa)-I-125. Whereas BgK(W5Y/Y26F) and its radiolabeled derivative, I-125-BgK(W5Y/Y26F), bind to Kv1.1, Kv1.2, and Kv1.6 channels with potencies similar to those for the parent peptide, BgK, BgK(W5Y/F6A/Y26F) and its monoiodo-tyrosine derivative, I-125-BgK(W5Y/ F6A/Y26F), display a distinctive and unique pharmacological profile; they bind with high affinity to homomultimeric Kv1.1 and Kv1.6 channels, but not to Kv1.2 channels. Interaction of BgK(W5Y/F6A/Y26F) with potassium channels depends on the nature of a residue in the mouth of the channel, at a position that determines channel sensitivity to external tetraethylammonium. In native brain tissue, 125I-BgK(W5Y/F6A/Y26F) binds to a population of Kv1 channels that appear to consist of at least two sensitive (Kv1.1 and/or Kv1.6) subunits, in adjacent position. Given its unique pharmacological properties, I-125-BgK(W5Y/F6A/Y26F) represents a new tool for studying subpopulations of Kv1 channels in native tissues.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Merck & Company	Gasparini, S (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951				Alessandri-Haber N, 1999, J BIOL CHEM, V274, P35653, DOI 10.1074/jbc.274.50.35653; ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Gutman G.A., 1993, SEMIN NEUROSCI, P101; Hanner M, 1999, J BIOL CHEM, V274, P25237, DOI 10.1074/jbc.274.36.25237; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Kaczorowski GJ, 1999, CURR OPIN CHEM BIOL, V3, P448, DOI 10.1016/S1367-5931(99)80066-0; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; KNAUS HG, 1995, BIOCHEMISTRY-US, V34, P13627, DOI 10.1021/bi00041a043; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Pongs O, 1999, FEBS LETT, V452, P31, DOI 10.1016/S0014-5793(99)00535-9; RACAPE J, 2001, THESIS U PARIS SUD P; Robertson B, 1996, FEBS LETT, V383, P26, DOI 10.1016/0014-5793(96)00211-6; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; STRYDOM DJ, 1973, NATURE-NEW BIOL, V243, P88; Suarez-Kurtz G, 1999, J PHARMACOL EXP THER, V289, P1517; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0	36	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3886	3893		10.1074/jbc.M109886200	http://dx.doi.org/10.1074/jbc.M109886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11707459	hybrid			2022-12-25	WOS:000173813900014
J	Darrouzet, E; Daldal, F				Darrouzet, E; Daldal, F			Movement of the iron-sulfur subunit beyond the ef loop of cytochrome b is required for multiple turnovers of the bc1 complex but not for single turnover Q(o) site catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC(1) COMPLEX; ELECTRON-TRANSFER; DOMAIN MOVEMENT; UBIHYDROQUINONE OXIDATION; RHODOBACTER-CAPSULATUS; BOVINE HEART; Q-CYCLE; PROTEIN; SPHAEROIDES; REGION	Recent kinetics experiments using mutants of the bc(1) complex (ubihydroquinone-cytochrome c oxidoreductase) iron-sulfur subunit with modified hinge regions have revealed the crucial role played by the large scale movement of its [2Fe-2S] cluster domain during the activity of this enzyme. In particular, one of these mutants (+1Ala) with an insertion of one alanine residue in the hinge region is partially deficient in performing this movement. We found that this defect can be overcome by the appearance of a second mutation substituting the leucine at position 286 in the ef loop of cytochrome b with a phenylalanine. Detailed studies of these mutants and their derivatives revealed that the ef loop acts as a barrier that needs to be crossed for multiple turnovers of the enzyme but not for a single turnover ubihydroquinone oxidation site catalysis. These findings indicate that the movement of the iron-sulfur subunit is composed of two discrete parts: a "micro-movement" at the cytochrome b interface, during which the [2Fe-2S] cluster interacts with ubihydroquinone oxidation site occupants and catalyzes ubihydroquinone oxidation, and a "macro-movement," during which the cluster domain swings away from cytochrome b interface, crosses the ef loop, and reaches a position close to cytochrome c(1) heme, to which it ultimately transfers an electron.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Daldal, F (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	fdaldal@sas.upenn.edu			NIGMS NIH HHS [GM 38237, R01 GM038237] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brasseur G, 1997, BIOCHEMISTRY-US, V36, P11685, DOI 10.1021/bi970777d; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Dutton P L, 1978, Methods Enzymol, V54, P411; Gray KA, 1995, ANOXYGENIC PHOTOSYNT, P747; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Saribas AS, 1995, BIOCHEMISTRY-US, V34, P16004, DOI 10.1021/bi00049a014; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; Yu CA, 1999, J BIOENERG BIOMEMBR, V31, P167, DOI 10.1023/A:1005418325934; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3471	3476		10.1074/jbc.M107974200	http://dx.doi.org/10.1074/jbc.M107974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707449	hybrid			2022-12-25	WOS:000173688000056
J	Stocco, CO; Lau, LF; Gibori, G				Stocco, CO; Lau, LF; Gibori, G			A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20 alpha-hsd genes by prostaglandin F-2 alpha in ovarian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED KINASE PATHWAY; ORPHAN STEROID-RECEPTOR; NERVE GROWTH-FACTOR; PROTEIN-KINASE; 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; INDUCED APOPTOSIS; TYROSINE KINASE; C-JUN	We have previously demonstrated that prostaglandin F-2alpha (PGF(2alpha)) induces a rapid and transient expression of Nur77 in luteal cells. We have shown that Nur77 plays an important role in ovarian physiology by mediating the PGF(2alpha) induction of 20alpha-HSD, a steroidogenic enzyme involved in the catabolism of progesterone. In this report we established, using luteinized granulosa cells, that PGF(2alpha) stimulates in vitro nur77 expression in a time- and dose-dependent manner. Serial 5'-deletion of the nur77 promoter revealed that the necessary and sufficient elements for PGF(2alpha) induction of Nur77 promoter activity are located between the nueleotides -86 and -33 upstream of the transcription start site, this region containing two AP1 elements. JunD binds to these A-PI sites, but its binding is not stimulated by PGF(2alpha). However, mutation of the AP1 sites as well as a dominant-negative JunD abolished nur77 induction by PGF(2alpha). PGF(2alpha) induces phosphorylation of JunD bound to the nur77 promoter. Stimulation of nur77 expression and JunD phosphorylation were prevented by inhibitors of calcium, calmodulin, or ERK1/2 kinase. PGF2,induced ERK1/2 phosphorylation was prevented by calcium/calmodulin inhibitors. We conclude that activation of JunD through a calmodulim-dependent activation of ERKI/2 mediates nur77 induction by PGF2,. Finally, we demonstrated that this molecular mechanism also mediates 20alpha-hsd induction.	Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gibori, G (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, 835 S Wolcott Ave, Chicago, IL 60612 USA.	ggibori@uic.edu		Lau, Lester/0000-0002-4364-2914	NICHD NIH HHS [HD11119, HD12356] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012356, R37HD011119, R01HD011119] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBARRACIN CT, 1994, ENDOCRINOLOGY, V134, P2453, DOI 10.1210/en.134.6.2453; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DB, 1998, ENDOCRINOLOGY, V139, P3876, DOI 10.1210/en.139.9.3876; Cheng Y, 2000, J BIOL CHEM, V275, P23326, DOI 10.1074/jbc.M001837200; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gibori G., 1993, OVARY, P261; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; Ma R, 2001, J BIOL CHEM, V276, P25759, DOI 10.1074/jbc.M011241200; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Miceli F, 2001, J CLIN ENDOCR METAB, V86, P811, DOI 10.1210/jc.86.2.811; Milvae RA, 2000, REV REPROD, V5, P1; Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1; Ottander U, 1999, MOL HUM REPROD, V5, P391, DOI 10.1093/molehr/5.5.391; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Sola C, 2001, INT J BIOCHEM CELL B, V33, P439, DOI 10.1016/S1357-2725(01)00030-9; Sorin B, 2000, J NEUROENDOCRINOL, V12, P910, DOI 10.1046/j.1365-2826.2000.00546.x; Stocco CO, 2000, J BIOL CHEM, V275, P37202, DOI 10.1074/jbc.M006016200; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tai CJ, 2001, J CLIN ENDOCR METAB, V86, P375, DOI 10.1210/jc.86.1.375; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yazgan O, 2001, CANCER RES, V61, P916; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhong L, 1998, BIOCHEM BIOPH RES CO, V249, P797, DOI 10.1006/bbrc.1998.9229; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	51	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3293	3302		10.1074/jbc.M110936200	http://dx.doi.org/10.1074/jbc.M110936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719525	hybrid			2022-12-25	WOS:000173688000033
J	Ford, E; Hughes, MN; Wardman, P				Ford, E; Hughes, MN; Wardman, P			The reaction of superoxide radicals with S-nitrosoglutathione and the products of its reductive heterolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MEDIATED DECOMPOSITION; CHEMISTRY; PEROXYNITRITE; KINETICS; RELEASE; NITROSO; OXIDATION; DISMUTASE; ACID	Generation of superoxide radicals (0.01-0.1 muM s(-1)) by radiolysis of aqueous solutions containing S-nitrosoglutathione (45-160 mum, pH 3.8-7.3) resulted in loss of this solute at rates varying with solute concentration, radical generation rate, and pH. The results were quantitatively consistent with the loss being attributed to competition between reaction of superoxide with S-nitrosoglutathione (rate constant 300 +/- 100 M-1 s(-1)) and the pH-dependent disproportionation of superoxide/hydroperoxyl. This rate constant is much lower than previous estimates and seven orders of magnitude lower than the rate constants between superoxide and superoxide dismutase or superoxide and nitric oxide. This indicates that interaction between superoxide and S-nitrosoglutathione is unlikely to be biologically important, contrary to previous suggestions that reaction could serve to prevent the rapid reaction between superoxide and nitric oxide. Reductive homolysis of S-nitrosoglutathione by the carbon dioxide radical anion, a model for biological reductants such as disulfide radical anions, occurred with a rate constant of 7.4 X 10(8) M-1 s(-1) and produced nitric oxide stoichiometrically. Thiyl radicals were not produced, indicating the alternative homolysis route to generate nitroxyl did not occur.	Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England; Kings Coll London, Dept Chem, London WC2R 2LS, England	University of Oxford; University of London; King's College London	Wardman, P (corresponding author), Mt Vernon Hosp, Gray Canc Inst, POB 100, Northwood HA6 2JR, Middx, England.	wardman@gci.ac.uk						Aleryani S, 1998, J BIOL CHEM, V273, P6041, DOI 10.1074/jbc.273.11.6041; ASKEW SC, 1995, J CHEM SOC PERK T 2, P741, DOI 10.1039/p29950000741; Atsipapa E., 2000, Nitric Oxide, V4, P278; Atsipapa Eleonora, 1998, Nitric Oxide, V2, P306; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BRADIC Z, 1984, J AM CHEM SOC, V106, P2236, DOI 10.1021/ja00320a002; Butler AR, 1997, ANAL BIOCHEM, V249, P1; BUXTON GV, 1989, RADIAT PHYS CHEM, V34, P699; CANDEIAS LP, 1994, J PHYS CHEM-US, V98, P10131, DOI 10.1021/j100091a031; Dicks AP, 1996, J CHEM SOC PERK T 2, P481, DOI 10.1039/p29960000481; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Hou YC, 1998, BIOORG MED CHEM LETT, V8, P3065, DOI 10.1016/S0960-894X(98)00563-0; Ignarro L., 1995, NITRIC OXIDE BIOCH M; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V361, P323, DOI 10.1006/abbi.1998.1010; Jourd'heuil D, 1998, BIOCHEM BIOPH RES CO, V244, P525, DOI 10.1006/bbrc.1998.8227; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; LOGAGER T, 1993, J PHYS CHEM-US, V97, P10047; Merenyi G, 1999, J PHYS CHEM A, V103, P5685, DOI 10.1021/jp984686h; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Mutus B, 1999, FEBS LETT, V449, P79, DOI 10.1016/S0014-5793(99)00311-7; Noble DR, 2000, NITRIC OXIDE-BIOL CH, V4, P392, DOI 10.1006/niox.2000.0291; ROSS AB, 1998, NDRL NIST SOLUTION K; Scorza G, 1997, FREE RADICAL BIO MED, V22, P633, DOI 10.1016/S0891-5849(96)00378-4; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Soulere L, 2001, TETRAHEDRON, V57, P7173, DOI 10.1016/S0040-4020(01)00694-9; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; Wang K, 2000, CURR MED CHEM, V7, P821; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; Wardman P, 1998, CHEM FREE RADICALS, P155; WARDMAN P, 1991, FREE RADICAL BIO MED, V10, P243, DOI 10.1016/0891-5849(91)90081-D; WARDMAN P, 1991, FREE RADICAL RES COM, V14, P57, DOI 10.3109/10715769109088942; Wardman P, 1992, BJR Suppl, V24, P6; WARDMAN P, 1994, INT J RADIAT BIOL, V65, P35, DOI 10.1080/09553009414550051; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; WOLFENDEN BS, 1982, J CHEM SOC PERK T 2, P805, DOI 10.1039/p29820000805; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983	46	14	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2430	2436		10.1074/jbc.M109310200	http://dx.doi.org/10.1074/jbc.M109310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11709557	hybrid			2022-12-25	WOS:000173421500010
J	Suzuki, T; Futaki, S; Niwa, M; Tanaka, S; Ueda, K; Sugiura, Y				Suzuki, T; Futaki, S; Niwa, M; Tanaka, S; Ueda, K; Sugiura, Y			Possible existence of common internalization mechanisms among arginine-rich peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; ANTENNAPEDIA HOMEODOMAIN; MEDIATED ENDOCYTOSIS; CYTO-TOXICITY; HUMAN-CELLS; HELA-CELLS; 3RD HELIX; PROTEIN; TRANSDUCTION; NUCLEUS	Basic peptides such as human immunodeficiency virus type I (HIV-1) Tat-(48-60) and Drosophila Antennapedia-(43-58) have been reported to have a membrane permeability and a carrier function for intracellular protein delivery. We have shown that not only Tat-(48-60) but many arginine-rich peptides, including HIV-1 Rev-(34-50) and octaarginine (Arg(8)), efficiently translocated through the cell membranes and worked as protein carriers (Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., and Sugiura, Y. (2001) J. Biol. Chem. 276, 5836-5840). Quantification and time course analyses of the cellular uptake of the above peptides by mouse macrophage RAW264.7, human cervical carcinoma HeLa, and simian kidney COS-7 cells revealed that Rev-(34-50) and Arg(8) had a comparable translocation efficiency to Tat.(48-60). Internalization of Tat-(48-60) and Rev-(34-50) was saturable and inhibited by the excess addition of the other peptide. Typical endocytosis and metabolic inhibitors had little effect on the internalization. The uptake of these peptides was significantly inhibited in the presence of heparan sulfate or chondroitin sulfates A, B, and C. Treatment of the cells with the anti-heparan sulfate antibody or heparinase III also lowered the translocation of these peptides. These results strongly suggest that the arginine-rich basic peptides share a certain part of the internalization pathway.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University	Futaki, S (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.			Futaki, Shiroh/0000-0002-0124-4002				Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; BENJAMIN P, 1995, INFECT IMMUN, V63, P3417, DOI 10.1128/IAI.63.9.3417-3421.1995; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dionne MA, 2000, J BIOL CHEM, V275, P12346, DOI 10.1074/jbc.275.16.12346; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 1997, BIOORGAN MED CHEM, V5, P1883, DOI 10.1016/S0968-0896(97)00119-3; Gutierrez JA, 1998, J CELL PHYSIOL, V177, P585, DOI 10.1002/(SICI)1097-4652(199812)177:4<585::AID-JCP9>3.3.CO;2-P; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; Kozak SL, 1999, J BIOL CHEM, V274, P23499, DOI 10.1074/jbc.274.33.23499; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mutoh M, 1999, CANCER RES, V59, P3480; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sjoback R, 1998, BIOPOLYMERS, V46, P445; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; Tamai I, 1997, J PHARMACOL EXP THER, V280, P410; TERASAKI T, 1989, J PHARMACOL EXP THER, V251, P351; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; VIVES E, 2001, PEPTIDES WAVE FUTURE, P942; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	43	409	459	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2437	2443		10.1074/jbc.M110017200	http://dx.doi.org/10.1074/jbc.M110017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711547	hybrid			2022-12-25	WOS:000173421500011
J	Venema, K; Quintero, FJ; Pardo, JM; Donaire, JP				Venema, K; Quintero, FJ; Pardo, JM; Donaire, JP			The Arabidopsis Na+/H+ exchanger AtNHX1 catalyzes low affinity Na+ and K+ transport in reconstituted liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TONOPLAST VESICLES; PLASMA-MEMBRANE; ANTIPORT ACTIVITY; ION-TRANSPORT; NACL STRESS; PLANT-CELLS; H+-ATPASE; PROTON; YEAST	In saline environments, plants accumulate Na+ in vacuoles through the activity of tonoplast Na+/H+ antiporters. The first gene for a putative plant vacuolar Na+/H+ antiporter, AtNHX1, was isolated from Arabidopsis and shown to increase plant tolerance to NaCl. However, AtNHX1 mRNA was up-regulated by Na+ or K+ salts in plants and substituted for the homologous protein of yeast to restore tolerance to several toxic cations. To study the ion selectivity of the AtNHX1 protein, we have purified a histidine-tagged version of the protein from yeast microsomes by Ni2+ affinity chromatography, reconstituted the protein into lipid vesicles, and measured cation-dependent H+ exchange with the fluorescent pH indicator pyranine. The protein catalyzed Na+ and K+ transport with similar affinity in the presence of a pH gradient. Li+ and Cs+ ions were also transported with lower affinity. Ion exchange by AtNHX1 was inhibited 70% by the amiloride analog ethylisopropylamiloride. Our data indicate a role for intracellular antiporters in organelle pH control and osmoregulation.	CSIC, Dept Bioquim Biol Celular & Mol Plantas, Estac Expt Zaidin, E-18080 Granada, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Venema, K (corresponding author), CSIC, Dept Bioquim Biol Celular & Mol Plantas, Estac Expt Zaidin, Apartado 419, E-18080 Granada, Spain.		Pardo, Jose M./B-4652-2009; Pardo, Jose M/AAB-5866-2022; Venema, Kees/G-9558-2015; Quintero, Francisco J/C-3086-2014; Quintero, Francisco J./AAG-2924-2019	Pardo, Jose M./0000-0003-4510-8624; Pardo, Jose M/0000-0003-4510-8624; Venema, Kees/0000-0001-5177-6464; Quintero, Francisco J/0000-0001-8718-2975; Quintero, Francisco J./0000-0001-8718-2975				Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Ballesteros E, 1997, PHYSIOL PLANTARUM, V99, P328, DOI 10.1034/j.1399-3054.1997.990217.x; Barkla BJ, 1996, ANNU REV PLANT PHYS, V47, P159, DOI 10.1146/annurev.arplant.47.1.159; BARKLA BJ, 1995, PLANT PHYSIOL, V109, P549, DOI 10.1104/pp.109.2.549; BLAKE MS, 1984, ANAL BIOCHEM, V128, P302; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Fukada-Tanaka S, 2000, NATURE, V407, P581, DOI 10.1038/35036683; GARBARINO J, 1988, PLANT PHYSIOL, V86, P231, DOI 10.1104/pp.86.1.231; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GIBRAT R, 1983, BIOCHIM BIOPHYS ACTA, V736, P196, DOI 10.1016/0005-2736(83)90284-5; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Montero-Lomeli M, 1999, BIOCHEM CELL BIOL, V77, P25, DOI 10.1139/bcb-77-1-25; NAKAMURA T, 1986, J BIOL CHEM, V261, P678; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pouliquin P, 1999, BIOPHYS J, V76, P360, DOI 10.1016/S0006-3495(99)77203-6; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; SOHMA Y, 2000, J PHYSL, V527, P16; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wells KM, 2001, J BIOL CHEM, V276, P3401, DOI 10.1074/jbc.M001688200; YU FH, 1993, J BIOL CHEM, V268, P25536	44	181	202	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2413	2418		10.1074/jbc.M105043200	http://dx.doi.org/10.1074/jbc.M105043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707435	hybrid			2022-12-25	WOS:000173421500008
J	Wright, CW; Clem, RJ				Wright, CW; Clem, RJ			Sequence requirements for Hid binding and apoptosis regulation in the baculovirus inhibitor of apoptosis Op-IAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CELL-DEATH; BIR MOTIFS; ACTIVATION; CASPASE; SMAC/DIABLO; PROTEINS; REAPER; DOMAIN; GENE	It has been suggested that the Drosophila Hid protein interacts with the baculovirus Op-IAP protein in a manner similar to that of human Smac binding to XIAP, based largely on amino acid sequence homology. However, there is little direct experimental evidence in support of this hypothesis; indeed, evidence exists from previous studies suggesting that the mode of binding is not similar. We have now precisely mapped the interaction between Hid and Op-IAP, and we show clearly for the first time that the biochemical interactions between the amino terminus of Hid and BIR2 of Op-IAP are highly similar to those found between the processed amino terminus of Smac and BIR3 of XIAP. Also similar to Smac, the amino terminus of Hid must be processed to bind Op-IAP. In addition, our data also suggest that a second interaction between Hid and Op-IAP exists that does not involve the amino terminus of Hid, which may explain some of the earlier contradictory results. The evolutionary conservation of this mechanism of binding underscores its importance in apoptotic regulation. Nevertheless, interaction with Hid is not sufficient for Op-IAP to inhibit apoptosis induced by Hid overexpression or by treatment with actinomycin D, indicating that additional sequence elements are required for the antiapoptotic function of Op-IAP.	Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA	Kansas State University	Clem, RJ (corresponding author), Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, 232 Ackert Hall, Manhattan, KS 66506 USA.			Clem, Rollie/0000-0002-2368-720X; Wright, Casey/0000-0002-9512-1264	NATIONAL CANCER INSTITUTE [R29CA078602, T32CA009418] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA78602, T32 CA09418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Silke J, 2001, J CELL SCI, V114, P1821; SRINIVASULA SM, 2001, SCIENCE, V410, P112; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	27	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2454	2462		10.1074/jbc.M110500200	http://dx.doi.org/10.1074/jbc.M110500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11717313	hybrid			2022-12-25	WOS:000173421500013
J	Fraser, E; Young, N; Dajani, R; Franca-Koh, J; Ryves, J; Williams, RSB; Yeo, M; Webster, MT; Richardson, C; Smalley, MJ; Pearl, LH; Harwood, A; Dale, TC				Fraser, E; Young, N; Dajani, R; Franca-Koh, J; Ryves, J; Williams, RSB; Yeo, M; Webster, MT; Richardson, C; Smalley, MJ; Pearl, LH; Harwood, A; Dale, TC			Identification of the Axin and Frat binding region of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FATE SPECIFICATION; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; BETA-CATENIN; XENOPUS EMBRYOS; NUCLEAR EXPORT; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; NEGATIVE REGULATOR; PROTEIN	Glycogen synthase kinase-3 (GSK-3) is a key component of several signaling pathways including those regulated by Wnt and insulin ligands. Specificity in GSK-3 signaling is thought to involve interactions with scaffold proteins that localize GSK-3 regulators and substrates. This report shows that GSK-3 forms a low affinity homodimer that is disrupted by binding to Axin and Frat. Based on the crystal structure of GSK-3, we have used surface-scanning mutagenesis to identify residues that differentially affect GSK-3 interactions. Mutations that disrupt Frat and Axin cluster at the dimer interface explaining their effect on homodimer formation. Loss of the Axin binding site blocks the ability of dominant negative GSK-3 to cause axis duplication in Xenopus embryos. The Axin binding site is conserved within all GSK-3 proteins, and its loss affects both cell motility and gene expression in the nonmetazoan, Dictyostelium. Surprisingly, we find no genetic interaction between a non-Axin-binding GSK-3 mutant and T-cell factor activity, arguing that Axin interactions alone cannot explain the regulation of T-cell factor-mediated gene expression.	Inst Canc Res, Canc Res Campaign Ctr Cell & Mol Biol, London SW3 6JB, England; Inst Canc Res, Sect Struct Biol, London SW3 6JB, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; University of London; University College London	Dale, TC (corresponding author), Inst Canc Res, Canc Res Campaign Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	trevor@icr.ac.uk	Dale, Trevor C/D-3749-2009; Smalley, Matthew J/M-7000-2015; Williams, Robin/G-6807-2011; Fraser, Elizabeth/M-7049-2015; Harwood, Adrian/A-4350-2010	Dale, Trevor C/0000-0002-4880-9963; Smalley, Matthew J/0000-0001-9540-1146; Fraser, Elizabeth/0000-0001-8420-3208; Harwood, Adrian/0000-0003-3124-5169; Pearl, Laurence/0000-0002-6910-1809				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; COATES JC, 1999, THESIS U LONDON; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COHEN P, 1985, MOL BASIS INSULIN AC; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Ginsburg GT, 1997, GENE DEV, V11, P2112, DOI 10.1101/gad.11.16.2112; Grimson MJ, 2000, NATURE, V408, P727, DOI 10.1038/35047099; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hong YR, 2000, BBA-GENE STRUCT EXPR, V1492, P513, DOI 10.1016/S0167-4781(00)00127-5; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1995, DEVELOPMENT, V121, P3979; Itoh K, 1999, GENE DEV, V13, P2328, DOI 10.1101/gad.13.17.2328; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; PIERCE SB, 1995, DEVELOPMENT, V121, P755; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Plyte SE, 1999, DEVELOPMENT, V126, P325; Polakis P, 2000, GENE DEV, V14, P1837; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Townsley FM, 2000, CURR BIOL, V10, P1339, DOI 10.1016/S0960-9822(00)00770-3; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	53	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2176	2185		10.1074/jbc.M109462200	http://dx.doi.org/10.1074/jbc.M109462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707456	hybrid			2022-12-25	WOS:000173421300077
J	Frederich, M; Balschi, JA				Frederich, M; Balschi, JA			The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE; CREATINE-KINASE; PHOSPHORYLATION; INVIVO; TRANSLOCATION; METABOLISM; INHIBITION; SUBFAMILY	The objective of this study was to define the relationship among AMP-activated protein kinase (AMPK) activity, AMP concentration ([AMP]), and [ATP] in perfused rat hearts. Bromo-octanoate, an inhibitor of beta-oxidation, and amino-oxyacetate, an inhibitor of the malate-aspartate shuttle, were used to modify substrate flux and thus increase cytosolic [AMP]. Cytosolic [AMP] was calculated using metabolites measured by P-31 NMR spectroscopy. Rat hearts were perfused with Krebs-Henseleit solution containing glucose and either no inhibitor, the inhibitors, or the inhibitors plus butyrate, a substrate that bypasses the metabolic blocks. In this way, [AMP] changed from 0.2 to 27.9 mum, and [ATP] varied between 11.7 and 6.8 mm. AMPK activity ranged from 7 to 60 pmol(.)min(-1.)mug of protein(-1). The half-maximal AMPK activation (A(0.5)) was 1.8 +/- 0.3 mum AMP. Measurements in vitro have reported similar AMPK A(0.5) at 0.2 mM ATP, but found that A(0.5) increased 10-20-fold at 4 mm ATP. The low An, of this study despite a high [ATP] suggests that in vivo the ATP antagonism of AMPK activation is reduced, and/or other factors besides AMP activate AMPK in the heart.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, NMR Lab Physiol Chem, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Balschi, JA (corresponding author), 221 Longwood Ave,BLI 247, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046033, R29HL046033] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46033] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bak MI, 1998, AM J PHYSIOL-CELL PH, V274, pC992, DOI 10.1152/ajpcell.1998.274.4.C992; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P3123, DOI 10.1006/jmcc.1997.0539; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLE KM, 1988, BIOCHEM BIOPH RES CO, V151, P70, DOI 10.1016/0006-291X(88)90560-8; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dagher Z, 1999, BIOCHEM BIOPH RES CO, V265, P112, DOI 10.1006/bbrc.1999.1635; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Inoue H, 1975, Methods Enzymol, V35, P3, DOI 10.1016/0076-6879(75)35131-8; KIM DK, 1991, AM J PHYSIOL, V260, pH1767, DOI 10.1152/ajpheart.1991.260.6.H1767; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Neubauer S, 1997, CIRCULATION, V96, P2190; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; RAAKA BM, 1979, J BIOL CHEM, V254, P6755; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SAFER B, 1971, J MOL CELL CARDIOL, V2, P111, DOI 10.1016/0022-2828(71)90065-4; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1	33	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1928	1932		10.1074/jbc.M107128200	http://dx.doi.org/10.1074/jbc.M107128200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707445	hybrid			2022-12-25	WOS:000173421300043
J	Bacon, AL; Farrington, SM; Dunlop, MG				Bacon, AL; Farrington, SM; Dunlop, MG			Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue	ONCOGENE			English	Article						TGFBR2; mutation rate; BAX; mismatch repair; colon cancer	GROWTH-FACTOR-BETA; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; INACTIVATION; PROTEIN; BAX; HEREDITARY; EXPRESSION; CANCERS	Repetitive tracts within the coding regions of TGFBR2 and BAX are frequently mutated in mismatch repair deficient tumours and are implicated in tumour progression. However, there has been little study of the balance between selection pressure and inherent instability at sequences within these genes. To determine whether TGFBR2 and BAX are inherently prone to mutations in the presence of MMR defects, we studied MMR deficient cells derived from B-lymphocytes. By analysing cells derived from normal tissue we aimed to minimize the effects of selection pressures that bias the apparent frequency of mutation. We definitively show that certain sequences, usually repaired by MMR, are inherently unstable. Using a small pool PCR technique we confirmed these cells exhibit microsatellite instability. Additionally, we demonstrate that MMR deficiency results in an excess of mutations, specifically at the poly(A)(10) tract compared to other regions of the TGFBR2 gene (P < 0.001). Conversely, an excess of mutations does not appear to arise at the poly(G)(8) tract of the BAX gene. These studies provide insight into the mechanism by which TGFBR2 and BAX genes become mutated during tumorigenesis. These findings invoke the notion of 'unmasking' specific hypermutable sequences in particular genes adding further complexity to the concept of the imitator phenotype.	Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Dunlop, MG (corresponding author), Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Malcolm.Dunlop@hgu.mrc.ac.uk	Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; BACON AL, 2001, IN PRESS NUCL ACIDS; Boland CR, 1998, CANCER RES, V58, P5248; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Carethers JM, 2000, IN VIVO, V14, P13; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grady WM, 1998, CANCER RES, V58, P3101; Grady WM, 1999, CANCER RES, V59, P320; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Lu SL, 1996, CANCER RES, V56, P4595; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mironov N, 1999, CARCINOGENESIS, V20, P2189, DOI 10.1093/carcin/20.11.2189; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; Ouyang H, 1997, CANCER RES, V57, P1851; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Pedroni M, 2001, CANCER RES, V61, P896; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Vilkki S, 2001, CANCER RES, V61, P4541; WANG CY, 1995, CANCER RES, V55, P5101; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhang L, 2001, CANCER RES, V61, P3801	30	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7464	7471		10.1038/sj.onc.1204973	http://dx.doi.org/10.1038/sj.onc.1204973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709717				2022-12-25	WOS:000171976900002
J	Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S				Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S			The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis	ONCOGENE			English	Article						Mad; Myc; wound; epidermis; keratinocyte; psoriasis	GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; MYC ANTAGONIST MAD1; C-MYC; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; MYC/MAX/MAD NETWORK; NUCLEOTIDE-SEQUENCE; CELL-LINE	Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, affects keratinocyte proliferation and differentiation in vitro and in vivo. However, little is known about the mechanisms of activin action in keratinocytes, and its target genes have not been identified. In this study, we demonstrate that activin A and TGF-beta1 directly induce the expression and activity of Mad1, an antagonist of the c-Myc transcription factor, in the human HaCaT keratinocyte cell line. Expression and activity of Mad1 was strongly induced by both factors in keratinocytes, although the intensity of induction was different for activin A and TGF-beta1. To determine a possible role of activin and TGF-beta1 in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair when high levels of these factors are present. Expression of mad1 mRNA and protein, but not of other mad genes, increased significantly after skin injury, particularly in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium. Elevated levels of mad1 mRNA were also detected in the hyperthickened epidermis of psoriatic patients. Since Mad1 regulates proliferation and/or differentiation of various cell types, our results suggest that this transcription factor mediates at least in the part the anti-mitotic and/or differentiation-inducing activities of TGF-beta and activin in keratinocytes.	ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, D-50924 Cologne, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Hannover Medical School	Werner, S (corresponding author), ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Beer, Hans-Dietmar/0000-0002-8085-713X; Werner, Sabine/0000-0001-7397-8710				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RAF, 1996, MOL BIOL WOUND REPAI, P195; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P1; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 2001, MOL CELL BIOL, V21, P703, DOI 10.1128/MCB.21.3.703-712.2001; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; Werner S, 2000, EXP CELL RES, V254, P80, DOI 10.1006/excr.1999.4726; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	51	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7494	7504		10.1038/sj.onc.1204937	http://dx.doi.org/10.1038/sj.onc.1204937			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709721				2022-12-25	WOS:000171976900006
J	Schrager, JA; Minassian, VD; Marsh, JW				Schrager, JA; Minassian, VD; Marsh, JW			HIV Nef increases T cell ERK MAP kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE-2; TERNARY COMPLEX FACTORS; TYPE-1 NEF; ANTIGEN-RECEPTOR; TRANSCRIPTION FACTOR; EFFECTOR FUNCTIONS; ALPHA PROTEOLYSIS	The human immunodeficiency regulatory protein Nef enhances viral replication and is central to viral pathogenesis. Although Nef has displayed a capacity to associate with a diverse assortment of cellular molecules and to increase T cell activity, the biochemical activity of Nef in T cells remains poorly defined. In this report we examine the bioactivity of Nef in primary CD4 T cells and, in particular, focus on the biochemical pathways known to be central to T cell activity. The extracellular signal-regulated kinase (ERK) mitogen-activated protein (ALAP) kinase pathway was dramatically affected by Nef expression with increases in ERK, MEK, and Elk induction. The capacity of Nef to increase the MAP kinase pathway activity was dependent on T cell receptor stimulation. By increasing ERK MAP kinase activity, Nef is functionally associated with a kinase known to affect T cell activity, viral replication, and viral infectivity.	NIMH, LMB, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Marsh, JW (corresponding author), NIMH, LMB, BLdg 36,Rm 1B08,36 Convent Dr,MSC 4034, Bethesda, MD 20892 USA.	jon@codon.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002629, Z01MH002629] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; DE SK, 1994, J BIOL CHEM, V269, P6656; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; GUATELLI JC, 1990, J VIROL, V64, P4093, DOI 10.1128/JVI.64.9.4093-4098.1990; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hodge DR, 1998, J BIOL CHEM, V273, P15727, DOI 10.1074/jbc.273.25.15727; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kempiak SJ, 1999, J IMMUNOL, V162, P3176; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Khoshnan A, 1999, J IMMUNOL, V163, P5444; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu XX, 2001, J BIOL CHEM, V276, P32763, DOI 10.1074/jbc.M101025200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; RHEE SS, 1994, J IMMUNOL, V152, P5128; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sharp BM, 1996, P NATL ACAD SCI USA, V93, P8294, DOI 10.1073/pnas.93.16.8294; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Skowronski J, 1999, COLD SPRING HARB SYM, V64, P453, DOI 10.1101/sqb.1999.64.453; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879	90	55	57	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6137	6142		10.1074/jbc.M107322200	http://dx.doi.org/10.1074/jbc.M107322200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726657	hybrid			2022-12-25	WOS:000173989200060
J	Kasai, T; Iwanaga, Y; Iha, H; Jeang, KT				Kasai, T; Iwanaga, Y; Iha, H; Jeang, KT			Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCERS; VIRUS TYPE-1; P53 FUNCTION; LUNG-CANCER; GENES; LYMPHOMA; MUTATIONS; MECHANISMS; APOPTOSIS; SURVIVAL	Human T-cell leukemia virus type I (HTLV-I) is the causative agent for adult T-cell leukemia (ATL). Molecularly, ATL cells have extensive aneugenic abnormalities that occur, at least in part, from cell cycle dysregulation by the HTLV-I-encoded Tax oncoprotein. Here, we compared six HTLV-I-transformed cells to Jurkat and primary peripheral blood mononuclear cells (PBMC) in their responses to treatment with microtubule inhibitors. We found that both Jurkat and PBMCs arrested efficiently in mitosis when treated with nocodazole. By contrast, all six HTLV-I cells failed to arrest comparably in mitosis, suggesting that ATL cells have a defect in the mitotic spindle assembly checkpoint. Mechanistically, we observed that in HTLV-I Tax-expressing cells human spindle assembly checkpoint factors hsMAD1 and hsMAD2 were mislocated from the nucleus to the cytoplasm. This altered localization of hsMAD1 and hsMAD2 correlated with loss of mitotic checkpoint function and chemoresistance to microtubule inhibitors.	NIAID, Mol Microbiol Lab, Mol Virol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, Mol Virol Sect, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008	Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CESARMAN E, 1992, BLOOD, V80, P3205; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Gillett ES, 2001, DEV CELL, V1, P162, DOI 10.1016/S1534-5807(01)00032-6; HARTWELL L, 1994, SCIENCE, V166, P1821; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kaelin WG, 1999, J CLIN INVEST, V104, P1503, DOI 10.1172/JCI8888; KAMADA N, 1992, CANCER RES, V52, P1481; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Livingston DM, 2001, NATURE, V410, P536, DOI 10.1038/35069185; Matsushita K, 1999, LEUKEMIA LYMPHOMA, V36, P67, DOI 10.3109/10428199909145950; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Ohshima K, 1999, J PATHOL, V189, P539, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;539::AID-PATH465&gt;3.0.CO;2-T; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SAKASHITA A, 1992, BLOOD, V79, P477; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 1999, J MAMMARY GLAND BIOL, V4, P389, DOI 10.1023/A:1018770417964; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; YAMATO K, 1995, ONCOGENE, V11, P1; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	43	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5187	5193		10.1074/jbc.M110295200	http://dx.doi.org/10.1074/jbc.M110295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729202	hybrid			2022-12-25	WOS:000173962900083
J	Kunz, J; Fuelling, A; Kolbe, L; Anderson, RA				Kunz, J; Fuelling, A; Kolbe, L; Anderson, RA			Stereo-specific substrate recognition by phosphatidylinositol phosphate kinases is swapped by changing a single amino acid residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITIDE PHOSPHORYLATION; SIGNALING MOLECULES; LIPID KINASE; FYVE DOMAIN; 5-KINASE; MEMBRANE; 3-PHOSPHATE; ACTIVATION; FAB1P; CYTOSKELETON	Type I and type II phosphatidylinositol phosphate (PIP) kinases generate the lipid second messenger phosphatidylinositol (PtdIns) 4,5-bisphosphate and thus play fundamental roles in the regulation of many cellular processes. Although the two kinase families are highly homologous, they phosphorylate distinct substrates and are functionally non-redundant. Type I PIP kinases phosphorylate PtdIns 4-phosphate at the D-5 hydroxyl group and are consequently PtdIns 4-phosphate 5-kinases. By contrast, type II PIP kinases are PtdIns 5-phosphate 4-kinases that phosphorylate PtdIns 5-phosphate at the D-4 position. Type I PIP kinases, in addition, also phosphorylate other phosphoinositides in vitro and in vivo and thus have the potential to generate multiple lipid second messengers. To understand how these enzymes differentiate between stereoisomeric substrates, we used a site-directed mutagenesis approach. We show that a single amino acid substitution in the activation loop, A381E in IIbeta and the corresponding mutation E362A in Ibeta, is sufficient to swap substrate specificity between these PIP kinases. In addition to its role in substrate specificity, the type I activation loop is also key in subcellular targeting. The Ibeta(E362A) mutant and other mutants with reduced PtdIns 4-phosphate binding affinity were largely cytosolic when expressed in mammalian cells in contrast to wild-type Ibeta which targets to the plasma membrane. These results clearly establish the role of the activation loop in determining both signaling specificity and plasma membrane targeting of type I PIP kinases.	Univ Wisconsin, Med Sch, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Med Sch, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.			Anderson, Richard/0000-0001-6265-8359				Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Halstead JR, 2001, CURR BIOL, V11, P386, DOI 10.1016/S0960-9822(01)00121-X; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 2001, CURR BIOL, V11, pR371, DOI 10.1016/S0960-9822(01)00197-X; Hinchliffe KA, 1999, CURR BIOL, V9, P983, DOI 10.1016/S0960-9822(99)80429-1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Rozenvayn N, 2001, J BIOL CHEM, V276, P22410, DOI 10.1074/jbc.M008184200; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1999, CHEM PHYS LIPIDS, V98, P69, DOI 10.1016/S0009-3084(99)00019-5; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	46	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5611	5619		10.1074/jbc.M110775200	http://dx.doi.org/10.1074/jbc.M110775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11733501	hybrid			2022-12-25	WOS:000173962900137
J	Prouzet-Mauleon, V; Monribot-Espagne, C; Boucherie, H; Lagniel, G; Lopez, S; Labarre, J; Garin, J; Lauquin, GJM				Prouzet-Mauleon, V; Monribot-Espagne, C; Boucherie, H; Lagniel, G; Lopez, S; Labarre, J; Garin, J; Lauquin, GJM			Identification in Saccharomyces cerevisiae of a new stable variant of alkyl hydroperoxide reductase 1 (Ahp1) induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; SUPEROXIDE-DISMUTASE; ENZYME CATALYSIS; ROLES; GENE; PEROXIREDOXIN; PURIFICATION; BIOCHEMISTRY; ANTIOXIDANT; DEFENSE	Yeasts lacking cytoplasmic superoxide dismutase (Cu,Zn-SOD) activity are permanently subjected to oxidative stress. We used two-dimensional PAGE to examine the proteome pattern of Saccharomyces cerevisiae strains lacking Cu,Zn-SOD. We found a new stable form of alkyl hydroperoxide reductase 1 (Ahp1) with a lower isoelectric point. This form was also present in wild type strains after treatment with tent-butyl hydroperoxide. In vitro enzyme assays showed that Ahp1p had lower specific activity in strains lacking Cu,Zn-SOD. We studied three mutants presenting a reduced production of the low pI variant under oxidative stress conditions. Two of the mutants (C62S and S59D) were totally inactive, thus suggesting that the acidic form of Ahp1p may only appear when the enzyme is functional. The other mutant (S59A) was active in vitro and was more resistant to inactivation by tert-butyl hydroperoxide than the wild type enzyme. Furthermore, the inactivation of Ahp1p in vitro is correlated with its conversion to the low pI form. These results suggest that in vivo during some particular oxidative stress (alkyl hydroperoxide treatment or lack of Cu,Zn-SOD activity but not hydrogen peroxide treatment), the catalytic cysteine of Ahp1p is more oxidized than cysteine-sulfenic acid (a natural occurring intermediate of the enzymatic reaction) and that cysteine-sulfinic acid or cysteine-sulfonic acid variant may be inactive.	CNRS, Lab Physiol Mol & Cellulaire, Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France; CNRS, Lab Electrophorese Bidimens Prot Saccharomyces Ce, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CEN G, Lab Chim Prot, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Lauquin, GJM (corresponding author), CNRS, Lab Physiol Mol & Cellulaire, Inst Biochim & Genet Cellulaires, UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	guy.lauquin@ibgc.u-bordeaux2.fr		Prouzet-Mauleon, Valerie/0000-0001-5432-6231				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dean RT, 1997, BIOCHEM J, V324, P1; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; Mates J M, 1999, Front Biosci, V4, pD339; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Sherman F., 1974, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200	36	19	20	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4823	4830		10.1074/jbc.M109614200	http://dx.doi.org/10.1074/jbc.M109614200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719517	hybrid			2022-12-25	WOS:000173962900037
J	Bath, AJ; Milsom, SE; Gormley, NA; Halford, SE				Bath, AJ; Milsom, SE; Gormley, NA; Halford, SE			Many type IIs restriction endonucleases interact with two recognition sites before cleaving DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION; CRYSTAL-STRUCTURE; ENZYMES; FOKI; PURIFICATION; CLEAVAGE; COPIES; SPECIFICITY; BINDING; CLONING	Type Us restriction endonucleases recognize asymmetric DNA sequences and cleave both DNA strands at fixed positions, typically several base pairs away from the recognition site. These enzymes are generally monomers that transiently associate to form dimers to cleave both strands. Their reactions could involve bridging interactions between two copies of their recognition sequence. To examine this possibility, several type Us enzymes were tested against substrates with either one or two target sites. Some of the enzymes cleaved the DNA with two target sites at the same rate as that with one site, but most cut their two-site substrate more rapidly than the one-site DNA. In some cases, the two sites were cut sequentially, at rates that were equal to each other but that exceeded the rate on the one-site DNA. In another case, the DNA with two sites was cleaved rapidly at one site, but the residual site was cleaved at a much slower rate. In a further example, the two sites were cleaved concertedly to give directly the final products cut at both sites. Many type Us enzymes thus interact with two copies of their recognition sequence before cleaving DNA, although via several different mechanisms.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halford, SE (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	s.halford@bris.ac.uk						Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Embleton ML, 2001, J MOL BIOL, V311, P503, DOI 10.1006/jmbi.2001.4892; Friedhoff P, 2001, J BIOL CHEM, V276, P23581, DOI 10.1074/jbc.M101694200; Gormley NA, 2000, J BIOL CHEM, V275, P6928, DOI 10.1074/jbc.275.10.6928; Gormley NA, 2002, J BIOL CHEM, V277, P4034, DOI 10.1074/jbc.M108442200; Halford SE, 2001, BIOCHEM SOC T, V29, P363, DOI 10.1042/BST0290363; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; Higgins LS, 2001, NUCLEIC ACIDS RES, V29, P2492, DOI 10.1093/nar/29.12.2492; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; Huang J, 2001, P NATL ACAD SCI USA, V98, P968, DOI 10.1073/pnas.98.3.968; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; Milsom SE, 2001, J MOL BIOL, V311, P515, DOI 10.1006/jmbi.2001.4893; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; Rao DN, 2000, PROG NUCLEIC ACID RE, V64, P1, DOI 10.1016/S0079-6603(00)64001-1; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts R, 1993, NUCLEASES, P35; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; SEKTAS M, 1992, NUCLEIC ACIDS RES, V20, P433, DOI 10.1093/nar/20.3.433; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Soundararajan M, 2002, J BIOL CHEM, V277, P887, DOI 10.1074/jbc.M109100200; Stanford NP, 2000, EMBO J, V19, P6546, DOI 10.1093/emboj/19.23.6546; STARK WM, 1995, MOBILE GENETIC ELEME, P101; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TUCHOLSKI J, 1995, GENE, V157, P87, DOI 10.1016/0378-1119(94)00787-S; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	49	100	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4024	4033		10.1074/jbc.M108441200	http://dx.doi.org/10.1074/jbc.M108441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729187	hybrid			2022-12-25	WOS:000173813900032
J	Di Lullo, GA; Sweeney, SM; Korkko, J; Ala-Kokko, L; San Antonio, JD				Di Lullo, GA; Sweeney, SM; Korkko, J; Ala-Kokko, L; San Antonio, JD			Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR TYROSINE KINASES; MAMMARY EPITHELIAL-CELLS; TRIPLE-HELICAL COLLAGEN; AMINO-ACID-SEQUENCE; IMPERFECTA TYPE-I; OSTEOGENESIS IMPERFECTA; STAPHYLOCOCCUS-AUREUS; DIRECTED MUTAGENESIS	Type I collagen is the most abundant protein in humans, and it helps to maintain the integrity of many tissues via its interactions with cell surfaces, other extracellular matrix molecules, and growth and differentiation factors. Nearly 50 molecules have been found to interact with type I collagen, and for about half of them, binding sites on this collagen have been elucidated. In addition, over 300 mutations in type I collagen associated with human connective tissue disorders have been described. However, the spatial relationships between the known ligand-binding sites and mutation positions have not been examined. To this end, here we have created a map of type I collagen that includes all of its ligand-binding sites and mutations. The map reveals the existence of several hot spots for ligand interactions on type I collagen and that most of the binding sites locate to its C-terminal half. Moreover, on the collagen fibril some potentially relevant relationships between binding sites were observed including the following: fibronectin- and certain integrin-binding regions are near neighbors, which may mechanistically relate to fibronectin-dependent cell-collagen attachment; proteoglycan binding may potentially impact upon collagen fibrillogenesis, cell-collagen attachment, and collagen glycation seen in diabetes and aging; and mutations associated with osteogenesis imperfecta and other disorders show apparently nonrandom distribution patterns within both the monomer and fibril, implying that mutation positions correlate with disease phenotype. These and other observations presented here may provide novel insights into evaluating type I collagen functions and the relationships between its binding partners and mutations.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70112 USA; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland	Jefferson University; Jefferson University; Jefferson University; Tulane University; Tulane University; University of Oulu; University of Oulu	San Antonio, JD (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Rm 813 Curtis,1015 Walnut St, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053590, R29HL053590] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-53590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITCHISON K, 1988, HUM GENET, V78, P233, DOI 10.1007/BF00291667; [Anonymous], 1991, CELL BIOL EXTRACELLU; ARENCIBIA I, 1990, Tokai Journal of Experimental and Clinical Medicine, V15, P269; AYAD S, 1998, EXTRACELLULAR MATRIX, P45; BACHMANN M, 1995, J NEUROSCI RES, V40, P458, DOI 10.1002/jnr.490400405; Beck K, 2000, P NATL ACAD SCI USA, V97, P4273, DOI 10.1073/pnas.070050097; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; BRENNAN MJ, 1983, CANCER RES, V43, P4302; BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CARSON DD, 1992, DEV BIOL, V149, P307, DOI 10.1016/0012-1606(92)90286-P; CHAPMAN JA, 1974, CONNECT TISSUE RES, V2, P137, DOI 10.3109/03008207409152099; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; Dahl T, 1998, J STRUCT BIOL, V123, P162, DOI 10.1006/jsbi.1998.4025; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; Depraetere H, 1999, THROMB HAEMOSTASIS, V82, P1160; DOYLE BB, 1975, J MOL BIOL, V91, P79, DOI 10.1016/0022-2836(75)90373-3; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; GEBB C, 1986, J BIOL CHEM, V261, P6698; Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650; Grab B, 1996, J BIOL CHEM, V271, P12234, DOI 10.1074/jbc.271.21.12234; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hadley JC, 1998, GLYCOCONJUGATE J, V15, P835, DOI 10.1023/A:1006928403140; Hall DA, 1964, INT REV CONNECTIVE T, V2, P244; Hartford O, 1999, MICROBIOL-SGM, V145, P2497, DOI 10.1099/00221287-145-9-2497; Hay ED., 1991, CELL BIOL EXTRACELLU, P7; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hunzelmann N, 1996, BRIT J DERMATOL, V135, P394; KAPOOR CL, 1975, BIOCHEM J, V147, P199, DOI 10.1042/bj1470199; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KLEINMAN HK, 1976, BIOCHEM BIOPH RES CO, V72, P426, DOI 10.1016/S0006-291X(76)80060-5; KLEINMAN HK, 1978, J BIOL CHEM, V253, P5642; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KODA JE, 1985, J BIOL CHEM, V260, P8157; KODA JE, 1984, J BIOL CHEM, V259, P1763; Korkko J, 1998, AM J HUM GENET, V62, P98, DOI 10.1086/301689; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lawton DM, 1999, J CLIN PATHOL-MOL PA, V52, P92, DOI 10.1136/mp.52.2.92; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P135; LINSENMAYER TF, 1990, ANN NY ACAD SCI, V580, P143, DOI 10.1111/j.1749-6632.1990.tb17926.x; Lira R, 1997, EXP PARASITOL, V85, P149, DOI 10.1006/expr.1996.4127; LIU T, 1990, ORAL MICROBIOL IMMUN, V5, P143, DOI 10.1111/j.1399-302X.1990.tb00412.x; Lund AM, 1998, J CRAN GENET DEV BIO, V18, P30; MAHNKE K, 1995, J LEUKOCYTE BIOL, V57, P63, DOI 10.1002/jlb.57.1.63; Mooney SD, 2001, BIOPOLYMERS, V58, P347, DOI 10.1002/1097-0282(200103)58:3<347::AID-BIP1011>3.0.CO;2-M; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; Pallos D, 2001, ARCH ORAL BIOL, V46, P459, DOI 10.1016/S0003-9969(00)00130-8; PARETI FI, 1986, J BIOL CHEM, V261, P15310; Piez K.A., 1984, EXTRACELLULAR MATRIX; PROBSTMEIER R, 1992, J CELL BIOL, V116, P1063, DOI 10.1083/jcb.116.4.1063; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Razzaque MS, 1998, MODERN PATHOL, V11, P1183; REISER KM, 1992, J BIOL CHEM, V267, P24207; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; ROSALESENCINA JL, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P109; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SCHOEN RC, 1982, HYBRIDOMA, V1, P99, DOI 10.1089/hyb.1.1982.1.99; Scott JE, 1997, CELL BIOCHEM FUNCT, V15, P283, DOI 10.1002/(SICI)1099-0844(199712)15:4<283::AID-CBF752>3.0.CO;2-B; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; Scott John E., 1993, Biochemical Society Transactions, V21, p123S; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SILVER FH, 1980, J BIOL CHEM, V255, P9427; SMITH JW, 1968, NATURE, V219, P157, DOI 10.1038/219157a0; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; Somasundaram R, 2000, J BIOL CHEM, V275, P38170, DOI 10.1074/jbc.M006616200; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TRAUB W, 1992, MATRIX, V12, P197, DOI 10.1016/S0934-8832(11)80062-4; TRUS BL, 1980, NATURE, V286, P300, DOI 10.1038/286300a0; UNDERWOOD PA, 1994, EXP EYE RES, V58, P139, DOI 10.1006/exer.1994.1002; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WALLIS GA, 1993, J MED GENET, V30, P492, DOI 10.1136/jmg.30.6.492; WANG Q, 1993, J BIOL CHEM, V268, P25162; Ward L M, 2001, Hum Mutat, V17, P434, DOI 10.1002/humu.1124; WEINER S, 1986, FEBS LETT, V206, P262, DOI 10.1016/0014-5793(86)80993-0; WESS TJ, 1994, ALCOHOL ALCOHOLISM, V29, P403; Willing MC, 1996, AM J HUM GENET, V59, P799; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; YU L, 1993, DERMATAN SULPHATE PR, P183; ZIMMERMA.BK, 1970, EUR J BIOCHEM, V16, P217, DOI 10.1111/j.1432-1033.1970.tb01074.x	100	623	652	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4223	4231		10.1074/jbc.M110709200	http://dx.doi.org/10.1074/jbc.M110709200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11704682	hybrid			2022-12-25	WOS:000173813900059
J	Kido, M; Shima, F; Satoh, T; Asato, T; Kariya, K; Kataoka, T				Kido, M; Shima, F; Satoh, T; Asato, T; Kariya, K; Kataoka, T			Critical function of the ras-associating domain as a primary ras-binding site for regulation of Saccharomyces cerevisiae adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PHOSPHOLIPASE C-EPSILON; PROTEIN CAP; YEAST; GENE; IDENTIFICATION; HOMOLOGY; GTPASE; KINASE; FAMILY	Mammalian candidate effectors of the small GTPase Ras, such as RalGDS, afadin/AF-6, Rin1, and phospholipase Cc, have been shown to share structurally conserved modules termed Ras-associating (RA) domains at their Ras-binding sites. The Ras-binding domains of Raf-1 and phosphoinositide 3-kinase gamma (other Ras effectors) also share a similar tertiary structure with the RA domains. On the other hand, the primary Ras-binding site of Saccharomyces cerevisiae adenylyl cyclase, the best characterized Ras effector, has been mapped by mutational studies to the leucine-rich repeats (LRR) domain (amino acids 674-1300), whose structure apparently bears no resemblance to the RA domains. By a computer algorithm-based search we have unexpectedly found an RA domain in the N-terminal 81 amino acid residues (676-756) of the LRR domain. The purified RA-domain polypeptide exhibits an ability to bind directly to Ras in a GTP-dependent manner and to competitively inhibit Ras-dependent activation of adenylyl cyclase in vitro, with an affinity comparable with that of the whole LRR domain. The specificity of binding of the RA domain to various Ras effector region mutants is indistinguishable from that of the full-length adenylyl cyclase. The activated RAS2 (RAS2(Val-19))-dependent heat shock sensitivity of yeast cells is suppressed by overexpression of the RA domain polypeptide. Further, mutations of the RA domain abolish its Ras binding activity, and adenylyl cyclase molecules carrying these mutations are rendered unactivatable by Ras in vitro. This RA domain bears highest similarity to the Ras-binding domain of Raf-1 based on comparison of its primary and predicted secondary structures with those of other Ras effectors. These results indicate that the RA domain is a primary Ras-binding site for activation of adenylyl cyclase, implicating RA domains as universal modules for interaction of effectors with Ras, conserved from yeast to mammals.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Ryukyus, Sch Med, Dept Biochem 2, Okinawa 9030215, Japan	Kobe University; University of the Ryukyus	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014					Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MINATO T, 1994, J BIOL CHEM, V269, P20845; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nishida Y, 1998, J BIOL CHEM, V273, P28019, DOI 10.1074/jbc.273.43.28019; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rose MD., 1990, METHODS YEAST GENETI; Rost B, 1996, METHOD ENZYMOL, V266, P525; Russell RB, 1996, J MOL BIOL, V259, P349, DOI 10.1006/jmbi.1996.0325; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Shima F, 2000, MOL CELL BIOL, V20, P26, DOI 10.1128/MCB.20.1.26-33.2000; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	47	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3117	3123		10.1074/jbc.M109526200	http://dx.doi.org/10.1074/jbc.M109526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723130	hybrid			2022-12-25	WOS:000173688000010
J	Cote, JF; Chung, PL; Theberge, JF; Halle, M; Spencer, S; Lasky, LA; Tremblay, ML				Cote, JF; Chung, PL; Theberge, JF; Halle, M; Spencer, S; Lasky, LA; Tremblay, ML			PSTPIP is a substrate of PTP-PEST and serves as a scaffold guiding PTP-PEST toward a specific dephosphorylation of WASP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ALDRICH-SYNDROME PROTEIN; CYTOSKELETAL-ASSOCIATED PROTEIN; FOCAL ADHESION KINASE; SRC FAMILY KINASES; ARP2/3 COMPLEX; N-WASP; CELL-MIGRATION; GROWTH-FACTOR; SH3 DOMAIN	PSTPIP is a tyrosine-phosphorylated protein involved in the organization of the cytoskeleton. Its ectopic expression induces filipodial-like membrane extensions in NIH 3T3 cells. We previously observed a defect in cytokinesis and an increase in the tyrosine phosphorylation of PSTPIP in PTP-PEST-deficient fibroblasts. In this article, we demonstrate that PTP-PEST and PSTPIP are found in the same complexes in vivo and that they interact directly through the CTH domain of PTP-PEST and the coiled-coil domain of PSTPIP. We tested pathways that could regulate the tyrosine phosphorylation of PSTPIP. We found that the activation of the epidermal growth factor and platelet-derived growth factor receptors can induce PSTPIP phosphorylation. With the use of the PP2 inhibitor, we demonstrate that Src kinases are not involved in the epidermal growth factor-mediated phosphorylation of PSTPIP. Together with previous results, this suggests that c-Abl is the critical tyrosine kinase downstream of growth factor receptors responsible for PSTPIP phosphorylation. We also demonstrate that PTP-PEST dephosphorylates PSTPIP at tyrosine 344. Importantly, we identified tyrosine 344 as the main phosphorylation site of PSTPIP by performing tryptic phosphopeptide maps. This is an important finding since tyrosine 367 of PSTPIP was also proposed as a candidate phosphorylation site involved in the negative regulation of the association between PSTPIP and WASP. In this respect, we observed that the PSTPIP-WASP complex is stable in vivo and is not affected by the phosphorylation of PSTPIP. Furthermore, we demonstrate that PSTPIP serves as a scaffold protein between PTP-PEST and WASP and allows PTP-PEST to dephosphorylate WASP. This finding suggests a possible mechanism for PTP-PEST to directly modulate actin remodeling through the PSTPIP-WASP interaction.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	McGill University; McGill University; Roche Holding; Genentech	Cote, JF (corresponding author), McGill Univ, Ctr Canc, 3655 Sir William Osler Promenade,Rm 715,McIntyre, Montreal, PQ H3G 1Y6, Canada.							Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Millard TH, 2001, TRENDS BIOCHEM SCI, V26, P198, DOI 10.1016/S0968-0004(01)01788-1; Modregger J, 2000, J CELL SCI, V113, P4511; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Takenawa T, 2001, J CELL SCI, V114, P1801; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6	57	96	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2973	2986		10.1074/jbc.M106428200	http://dx.doi.org/10.1074/jbc.M106428200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711533	hybrid			2022-12-25	WOS:000173421500079
J	Lacy, DB; Mourez, M; Fouassier, A; Collier, RJ				Lacy, DB; Mourez, M; Fouassier, A; Collier, RJ			Mapping the anthrax protective antigen binding site on the lethal and edema factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; FACTOR CLEAVES; TOXIN; TRANSLOCATION; MACROPHAGES; TERMINUS	Entry of anthrax edema factor (EF) and lethal factor (LF) into the cytosol of eukaryotic cells depends on their ability to translocate across the endosomal membrane in the presence of anthrax protective antigen (PA). Here we report attributes of the N-terminal domains of EF and LF (EFN and LFN, respectively) that are critical for their initial interaction with PA. We found that deletion of the first 36 residues of LFN had no effect on its binding to PA or its ability to be translocated. To map the binding site for PA, we used the three-dimensional structure of LF and sequence similarity between EF and LF to select positions for mutagenesis. We identified seven sites in LFN (Asp-182, Asp-187, Leu-188, Tyr-223, His-229, Leu-235, and Tyr-236) where mutation to Ala produced significant binding defects, with H229A and Y236A almost completely eliminating binding. Homologous mutants of EFN displayed nearly identical defects. Cytotoxicity assays confirmed that the LFN mutations impact intoxication. The seven mutation-sensitive amino acids are clustered on the surface of LF and form a small convoluted patch with both hydrophobic and hydrophilic character. We propose that this patch constitutes the recognition site for PA.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.	jcollier@hms.harvard.edu	Lacy, D. Borden/AFQ-2203-2022	Collier, R John/0000-0002-2427-4239; Lacy, Borden/0000-0003-2273-8121	PHS HHS [R37-A122021] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARORA N, 1993, J BIOL CHEM, V268, P3334; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Gupta P, 2001, BIOCHEM BIOPH RES CO, V280, P158, DOI 10.1006/bbrc.2000.4099; Henikoff JG, 1996, METHOD ENZYMOL, V266, P88; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1991, ANTHRAX TOXIN COMPLE; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; PANNIFER A, 2001, IN PRESS NATURE; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; QUINN CP, 1991, J BIOL CHEM, V266, P20124; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	22	88	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3006	3010		10.1074/jbc.M109997200	http://dx.doi.org/10.1074/jbc.M109997200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714723	hybrid			2022-12-25	WOS:000173421500083
J	McGinness, KE; Joyce, GF				McGinness, KE; Joyce, GF			Substitution of ribonucleotides in the T7 RNA polymerase promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 LATE PROMOTERS; IN-VITRO EVOLUTION; T7-RNA POLYMERASE; KINETIC-ANALYSIS; POINT MUTATIONS; TRANSCRIPTION; DNA; INITIATION; RECOGNITION; SELECTION	A systematic analysis was carried out to examine the effects of ribonucleotide substitution at various locations within the promoter element for T7 RNA polymerase. Ribonucleotides could be introduced at most positions without significantly decreasing transcription efficiency. A critical window of residues that were intolerant of RNA substitution was defined for both the non-template and template strands of the promoter. These residues are involved in important contacts with the AT-rich recognition loop, specificity loop, and beta-intercalating hairpin of the polymerase. These results highlight the malleability of T7 RNA polymerase in recognizing its promoter element and suggest that promoters with altered backbone conformations may be used in molecular biology applications that use T7 RNA polymerase for in vitro transcription.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Joyce, GF (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gjoyce@scripps.edu						Arnaud-Barbe N, 1998, NUCLEIC ACIDS RES, V26, P3550, DOI 10.1093/nar/26.15.3550; BREAKER RR, 1994, BIOCHEMISTRY-US, V33, P11980, DOI 10.1021/bi00205a037; CAZENAVE C, 1994, P NATL ACAD SCI USA, V91, P6972, DOI 10.1073/pnas.91.15.6972; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHAPMAN KA, 1988, NUCLEIC ACIDS RES, V16, P4511, DOI 10.1093/nar/16.10.4511; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DIAZ GA, 1993, J MOL BIOL, V229, P805, DOI 10.1006/jmbi.1993.1086; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Forrer P, 1999, CURR OPIN STRUC BIOL, V9, P514, DOI 10.1016/S0959-440X(99)80073-6; IKEDA RA, 1993, BIOCHEMISTRY-US, V32, P9115, DOI 10.1021/bi00086a016; IKEDA RA, 1992, BIOCHEMISTRY-US, V31, P9073, DOI 10.1021/bi00152a051; IKEDA RA, 1992, NUCLEIC ACIDS RES, V20, P2517, DOI 10.1093/nar/20.10.2517; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Li T, 1996, BIOCHEMISTRY-US, V35, P3722, DOI 10.1021/bi9524373; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4270, DOI 10.1021/bi00067a015; MASLAK M, 1994, BIOCHEMISTRY-US, V33, P6918, DOI 10.1021/bi00188a022; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RASKIN CA, 1993, P NATL ACAD SCI USA, V90, P3147, DOI 10.1073/pnas.90.8.3147; RASKIN CA, 1992, J MOL BIOL, V228, P506, DOI 10.1016/0022-2836(92)90838-B; Roberts RW, 1999, CURR OPIN CHEM BIOL, V3, P268, DOI 10.1016/S1367-5931(99)80042-8; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Rong MQ, 1998, P NATL ACAD SCI USA, V95, P515, DOI 10.1073/pnas.95.2.515; Saenger W., 1984, PRINCIPLES NUCL ACID, P61; SCHICK C, 1995, BIOCHEMISTRY-US, V34, P666, DOI 10.1021/bi00002a034; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Wright MC, 1997, SCIENCE, V276, P614, DOI 10.1126/science.276.5312.614	35	11	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2987	2991		10.1074/jbc.M108820200	http://dx.doi.org/10.1074/jbc.M108820200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704669	hybrid			2022-12-25	WOS:000173421500080
J	Nakamura, Y; Feng, Q; Kumagai, T; Torikai, K; Ohigashi, H; Osawa, T; Noguchi, N; Niki, E; Uchida, K				Nakamura, Y; Feng, Q; Kumagai, T; Torikai, K; Ohigashi, H; Osawa, T; Noguchi, N; Niki, E; Uchida, K			Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant - Implication for inflammation-associated carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; MOUSE SKIN; OXIDATIVE STRESS; TUMOR PROMOTION; PHORBOL ESTER; MULTISTAGE CARCINOGENESIS; CITRUS AURAPTENE; 1'-ACETOXYCHAVICOL ACETATE; LIPID-PEROXIDATION; QUINONE REDUCTASE	Ebselen, a seleno-organic compound showing glutathione peroxidase-like activity, is one of the promising synthetic antioxidants. In the present study, we investigated the antioxidant activities of ebselen using a 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated mouse skin model. Double pretreatments of mouse skin with ebselen significantly inhibited TPA-induced formation of thiobarbituric acid-reacting substance, known as an overall oxidative damage biomarker, in mouse epidermis, suggesting that ebselen indeed acts as an antioxidant in mouse skin. The andoxidative effect of ebselen is attributed to its selective blockade of leukocyte infiltration and activation leading to attenuation of the H2O2 level. In in vitro studies, ebselen inhibited TPA-induced superoxide generation in differentiated HL-60 cells and lipopolysaccharide-induced cyclooxygenase-2 protein expression in RAW 264.7 cells. In addition, we demonstrated for the first time that ebselen potentiated phase II enzyme activities, including NAD(P)H:(quinone-acceptor) oxidoreductasel and glutathione S-transferase in cultured hepatocytes and in mouse skin. These results strongly suggest that ebselen, a multifunctional antioxidant, is a potential chemopreventive agent in inflammation-associated carcinogenesis.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan	Nagoya University; Kyoto University; University of Tokyo	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp		Uchida, Koji/0000-0003-3894-5299				BECKMAN JK, 1994, CARCINOGENESIS, V15, P2937, DOI 10.1093/carcin/15.12.2937; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BERNOFSKY C, 1991, FASEB J, V5, P295, DOI 10.1096/fasebj.5.3.1848195; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COTGREAVE IA, 1989, BIOCHEM PHARMACOL, V38, P649, DOI 10.1016/0006-2952(89)90211-6; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1999, BIOCHEM SOC SYMP, P141; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; HU J, 1995, CARCINOGENESIS, V16, P1815, DOI 10.1093/carcin/16.8.1815; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jang MS, 1998, CANCER LETT, V134, P81, DOI 10.1016/S0304-3835(98)00250-X; JI C, 1992, J BIOL CHEM, V267, P17842; KENSLER TW, 1987, TOXICOL APPL PHARM, V90, P337, DOI 10.1016/0041-008X(87)90341-3; Kensler TW, 1997, ENVIRON HEALTH PERSP, V105, P965, DOI 10.2307/3433311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIORINO M, 1992, ARCH BIOCHEM BIOPHYS, V295, P404, DOI 10.1016/0003-9861(92)90534-4; Marks F, 1998, TOXICOL LETT, V96-7, P111, DOI 10.1016/S0378-4274(98)00057-5; Muller-Decker K, 1998, MOL CARCINOGEN, V23, P36, DOI 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Murakami A, 2000, CANCER RES, V60, P5059; Murakami A, 2000, CARCINOGENESIS, V21, P1843, DOI 10.1093/carcin/21.10.1843; Nakae D, 1998, JPN J CANCER RES, V89, P1118, DOI 10.1111/j.1349-7006.1998.tb00506.x; Nakamura Y, 2000, CANCER RES, V60, P219; Nakamura Y, 1999, CANCER LETT, V140, P37, DOI 10.1016/S0304-3835(99)00048-8; Nakamura Y, 2000, CARCINOGENESIS, V21, P1899, DOI 10.1093/carcin/21.10.1899; Nakamura Y, 1998, CANCER RES, V58, P4832; Nakamura Y, 1998, JPN J CANCER RES, V89, P361, DOI 10.1111/j.1349-7006.1998.tb00572.x; Nakamura Y, 2001, FREE RADICAL BIO MED, V30, P967, DOI 10.1016/S0891-5849(01)00481-6; Nakamura Yoshimasa, 2000, Asian Pac J Cancer Prev, V1, P115; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; ROBERTSON IGC, 1986, CARCINOGENESIS, V7, P295; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sanchez T, 1999, BIOCHEM PHARMACOL, V58, P877, DOI 10.1016/S0006-2952(99)00169-0; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; SCHWARZ M, 1984, CARCINOGENESIS, V5, P1663, DOI 10.1093/carcin/5.12.1663; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; SISSKIN EE, 1982, CARCINOGENESIS, V3, P1459; SOLANKI V, 1981, CARCINOGENESIS, V2, P1141, DOI 10.1093/carcin/2.11.1141; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; Tanaka T, 1997, CARCINOGENESIS, V18, P2155, DOI 10.1093/carcin/18.11.2155; Tanaka T, 1998, CANCER RES, V58, P2550; Tanaka T, 1997, JPN J CANCER RES, V88, P821, DOI 10.1111/j.1349-7006.1997.tb00457.x; THOMPSON BY, 1988, J LEUKOCYTE BIOL, V43, P140, DOI 10.1002/jlb.43.2.140; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WANG JF, 1992, HEPATOLOGY, V15, P1112, DOI 10.1002/hep.1840150623; WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265; WEI HC, 1992, CANCER RES, V52, P2298; WEI HC, 1993, CARCINOGENESIS, V14, P1195, DOI 10.1093/carcin/14.6.1195; WEI HC, 1991, CANCER RES, V51, P4443; YAMADA M, 1987, CELL STRUCT FUNCT, V12, P53, DOI 10.1247/csf.12.53; Yang CF, 2000, CARCINOGENESIS, V21, P2237, DOI 10.1093/carcin/21.12.2237; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200	65	123	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2687	2694		10.1074/jbc.M109641200	http://dx.doi.org/10.1074/jbc.M109641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714717	hybrid			2022-12-25	WOS:000173421500042
J	Meli, M; Vergne, J; Decout, JL; Maurel, MC				Meli, M; Vergne, J; Decout, JL; Maurel, MC			Adenine-aptamer complexes - A bipartite RNA site that binds the adenine nucleic base	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREBIOTIC SYNTHESIS; NUCLEOSIDES; ADENOSINE; CATALYSTS; ANALOG; RESCUE; MOTIF	RNA aptamers that are able to complex free adenine have been isolated by a SELEX (systematic evolution of ligands by exponential enrichment) procedure. The adenine binding site was revealed by sequence alignment for a prevalent cluster of aptamers, and its structure and interactions with adenine were probed by RNase digestion studies, lead cleavage, boundary determination experiments, and truncated sequences studies. A new purine binding motif was functionally and structurally characterized and compared with other RNAs specific to purine or adenylated compounds. The affinity for adenine and the specificity for other related targets were quantified. This work suggests that the adenine binding site is composed of two independent secondary structure elements forming a bipartite binding site that interacts with adenine in a new mode of purine recognition. Such binding is of great interest because the imidazole moiety is not trapped in the binding site, and would easily be available for catalytic activity.	Inst Jacques Monod, Lab Biochim Evolut & Adaptabil Mol, F-75251 Paris 05, France; Univ Grenoble 1, CNRS, UMR 5063, Dept Pharmacochim Lab Chim Bioorgan, F-38706 La Tronche, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Maurel, MC (corresponding author), Inst Jacques Monod, Lab Biochim Evolut & Adaptabil Mol, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.	maurel@ijm.jussieu.fr						ANTONI G, 1983, ANAL BIOCHEM, V129, P60, DOI 10.1016/0003-2697(83)90052-0; Burke DH, 1997, NUCLEIC ACIDS RES, V25, P2020, DOI 10.1093/nar/25.10.2020; Burke DH, 1998, BIOCHEMISTRY-US, V37, P4653, DOI 10.1021/bi972877p; Carnes J, 2000, RNA, V6, P1468, DOI 10.1017/S1355838200001242; CEDERGREN R, 1987, BIOSYSTEMS, V20, P175, DOI 10.1016/0303-2647(87)90043-8; Ciesiolka J, 1996, METHOD ENZYMOL, V267, P315; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; DECOUT JL, 1995, MACROMOL CHEM PHYSIC, V196, P2615, DOI 10.1002/macp.1995.021960814; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; JOYCE GF, 1993, RNA WORLD, P3; Kiga D, 1998, NUCLEIC ACIDS RES, V26, P1755, DOI 10.1093/nar/26.7.1755; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; Koizumi M, 2000, BIOCHEMISTRY-US, V39, P8983, DOI 10.1021/bi000149n; LAAYOUN A, 1994, TETRAHEDRON LETT, V35, P4989, DOI 10.1016/S0040-4039(00)73300-4; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MARTIN RL, 1991, ARCH BIOCHEM BIOPHYS, V284, P26, DOI 10.1016/0003-9861(91)90257-J; MAUREL MC, 1992, J EVOLUTION BIOL, V5, P173, DOI 10.1046/j.1420-9101.1992.5020173.x; MAUREL MC, 1987, BIOCHIMIE, V69, P551, DOI 10.1016/0300-9084(87)90094-0; MAUREL MC, 1990, ORIGINS LIFE EVOL B, V20, P43, DOI 10.1007/BF01808058; MAUREL MC, 1992, J MOL EVOL, V35, P190; Maurel MC, 1999, TETRAHEDRON, V55, P3141, DOI 10.1016/S0040-4020(98)01168-5; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Ricard J, 1996, J MOL EVOL, V43, P315; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; Sutherland JD, 1997, TETRAHEDRON, V53, P11595, DOI 10.1016/S0040-4020(97)00466-3; TREMOLIERES A, 1980, BIOCHIMIE, V62, P493, DOI 10.1016/S0300-9084(80)80068-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468	32	46	55	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2104	2111		10.1074/jbc.M107130200	http://dx.doi.org/10.1074/jbc.M107130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11705996	hybrid			2022-12-25	WOS:000173421300067
J	Deng, GR; Chen, A; Pong, E; Kim, YS				Deng, GR; Chen, A; Pong, E; Kim, YS			Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression	ONCOGENE			English	Article						colorectal cancer; hMLH1 gene; methylation; transcription factor CBF	DNA METHYLATION; NF-Y; MICROSATELLITE INSTABILITY; COLORECTAL-CARCINOMA; COLON-CANCER; HYPERMETHYLATION; INACTIVATION; TUMORS; CELLS; PROTEINS	Microsatellite instability (MSI) is caused by the dysfunction of mismatch repair genes, such as hMLH1, hMSH2. Loss of hMLH1 expression and methylation of CpG sites in hMLH1 promoter are frequently present in sporadic colorectal cancer with MSI. In this study, by transient transfection assay with constructs containing different lengths of hMLH1 promoter and a luciferase reporter gene, we located a proximal region of hMLH1 promoter, which plays a main role in regulating the gene. The fact that luciferase activities were high in all host cell lines regardless of their hMLH1 expression levels indicates that the transcription machinery is intact even in non-expressing cells. When hMLH1 promoter was in vitro methylated before transfection, the luciferase activities in the transfectants were significantly reduced. This observation indicates that methylation causes the inhibition of hMLH1 promoter activity. By electrophoretic mobility shift assay (EMSA), we identified a CCAAT box in this region, which specifically bound transcription factor CBF. Mutations in CCAAT box not only inhibited its binding to CBF factor, but also reduced its ability to drive the expression of luciferase gene. The role of CBF in activating transcription was further substantiated by inhibition of promoter activity with a plasmid expressing a dominant negative CBF-B mutant. Methylation at a CpG site two base pairs upstream of the CCAAT box inhibited the binding of CBF to CCAAT box. We conclude that methylation of an adjacent CpG site inhibits binding of the CBF transcription to the corresponding CCAAT box, and is one of the causes of hMLH1 gene silencing in colon cancer cells.	Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Deng, GR (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA.				NCI NIH HHS [CA 24321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Cunningham JM, 1998, CANCER RES, V58, P3455; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Deng GR, 1999, CANCER RES, V59, P2029; Dobrovic A, 1997, CANCER RES, V57, P3347; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanai Y, 1997, INT J CANCER, V71, P355; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Qian XLC, 1997, CANCER RES, V57, P3672; Sinha S, 1996, MOL CELL BIOL, V16, P328; Stirzaker C, 1997, CANCER RES, V57, P2229; Tanaka H, 1998, CANCER RES, V58, P3429; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	32	66	74	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7120	7127		10.1038/sj.onc.1204891	http://dx.doi.org/10.1038/sj.onc.1204891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704838				2022-12-25	WOS:000171739300017
J	Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G				Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G			Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase C gamma	ONCOGENE			English	Article						c-Kit; daunorubicin; apoptosis; PKC; PLC gamma; ceramide	PROTEIN-KINASE-C; STEM-CELL FACTOR; CERAMIDE-INDUCED APOPTOSIS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; NEUTRAL SPHINGOMYELINASE; TRANSDUCTION PATHWAY; ACTIVATION; EXPRESSION; LIGAND	Previous studies have demonstrated that activation of Kit by stem cell factor (SCF), its natural ligand, or by gain-of-function point mutation in its intracellular domain, confers significant protection against apoptosis induced by growth factor deprivation or radiation. However, the effects of Kit activation on the cellular response to antitumor agents have not been so extensively documented. This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-Kit Delta 27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells. In Ba/F3-wt and in Ba/F3-Kit cells, daunorubicin stimulated within 8-15 min neutral sphingomyelinase and ceramide production but not in SCF-stimulated Ba/F3-Kit or in Ba/F3-Kit Delta 27 whereas all Ba/F3 cells were equally sensitive to exogenous cell-permeant C6-ceramide. In Ba/F3-Kit, SCF-induced Kit activation resulted in a rapid phospholipase C gamma (PLC gamma) tyrosine phosphorylation followed by diacylglycerol release and protein kinase C (PKC) stimulation. U-73122, a PLC gamma inhibitor, not only blocked diacylglycerol production and PKC stimulation but also restored daunorubicin-induced sphingomyelinase stimulation, ceramide production, and apoptosis. These results suggest that Kit activation results in PLC gamma -mediated PKC-dependent sphingomyelinase inhibition which contributes to drug resistance in Kit-related malignancies.	INSERM, Inst Claudius Regaud, E9910, F-31052 Toulouse, France; Inst Natl St & Rech Med, Lab Cancerol Expt, F-13009 Marseille, France; Lab Hematol Cellulaire & Mol, UPRES, EA2509, Fac Pharm, F-75006 Paris, France; Ctr Hosp Univ Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Plo, I (corresponding author), INSERM, Inst Claudius Regaud, E9910, 20,Rue Pont St Pierre, F-31052 Toulouse, France.	plo@icr.fnclcc.fn	dubreuil, patrice/F-5346-2011; Lautier, Dominique/G-3959-2017; Plo, Isabelle/AAT-6742-2021; Dubreuil, Patrice/V-4816-2019; Plo, Isabelle/C-9056-2017	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Plo, Isabelle/0000-0002-5915-6910				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chmura SJ, 1996, CANCER RES, V56, P2711; Cole SR, 1996, LEUKEMIA, V10, P288; Come MG, 1999, INT J CANCER, V81, P580, DOI 10.1002/(SICI)1097-0215(19990517)81:4<580::AID-IJC13>3.0.CO;2-T; De Sepulveda P, 1999, EMBO J, V18, P904; FAN D, 1992, ANTICANCER RES, V12, P661; Feng HL, 1998, MOL REPROD DEV, V49, P317, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;317::AID-MRD12&gt;3.0.CO;2-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; IKEDA H, 1991, BLOOD, V78, P2962; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KOIKE T, 1993, J IMMUNOL, V151, P359; Kozawa O, 1997, EUR J BIOCHEM, V248, P149, DOI 10.1111/j.1432-1033.1997.00149.x; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Mansat V, 1997, CANCER RES, V57, P5300; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; NETA R, 1993, BLOOD, V81, P324; QuilletMary A, 1996, LEUKEMIA, V10, P417; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; REUSSBORST MA, 1994, LEUKEMIA, V8, P258; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIZZO MT, 1991, CELL SIGNAL, V3, P311, DOI 10.1016/0898-6568(91)90060-8; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHUENING FG, 1993, BLOOD, V81, P20; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Yang JM, 1997, BIOCHEM PHARMACOL, V53, P1597, DOI 10.1016/S0006-2952(97)82451-3; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6752	6763		10.1038/sj.onc.1204877	http://dx.doi.org/10.1038/sj.onc.1204877			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709710				2022-12-25	WOS:000171551600012
J	Ikeyama, S; Kokkonen, G; Wang, XT; Holbrook, NJ				Ikeyama, S; Kokkonen, G; Wang, XT; Holbrook, NJ			Effects of aging and calorie restriction on growth factor- and oxidant-induced mitogenesis in rat hepatocytes	FASEB JOURNAL			English	Meeting Abstract									NIA, LMBC, Baltimore, MD 21224 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Yale University									0	107	108	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 22	2002	16	5	2				A1163	A1163		10.1096/fj.01-0409fje	http://dx.doi.org/10.1096/fj.01-0409fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	534PC	11709495				2022-12-25	WOS:000174593902416
J	Steinberg, GR; Dyck, DJ; Calles-Escandon, J; Tandon, NN; Luiken, JJFP; Glatz, JFC; Bonen, A				Steinberg, GR; Dyck, DJ; Calles-Escandon, J; Tandon, NN; Luiken, JJFP; Glatz, JFC; Bonen, A			Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; INSULIN-RESISTANCE; OB/OB MICE; VISCERAL ADIPOSITY; EXPRESSION CLONING; GLUCOSE-TRANSPORT; UP-REGULATION; OBESE OB/OB; TRIGLYCERIDE; PROTEIN	Chronic leptin administration reduces triacylglycerol content in skeletal muscle. We hypothesized that chronic leptin treatment, within physiologic limits, would reduce the fatty acid uptake capacity of red and white skeletal muscle due to a reduction in transport protein expression (fatty acid translocase (FAT/CD36) and plasma membrane-associated fatty acid-binding protein (FABPpm)) at the plasma membrane. Female Sprague-Dawley rats were infused for 2 weeks with leptin (0.5 mg/kg/day) using subcutaneously implanted miniosmotic pumps. Control and pair-fed animals received saline-filled implants. Leptin levels were significantly elevated (similar to4-fold; p < 0.001) in treated animals, whereas pair-fed treated animals had reduced serum leptin levels (approximately - 2-fold; p < 0.01) relative to controls. Palmitate transport rates into giant sarcolemmal vesicles were reduced following leptin treatment in both red (-45%) and white (-84%) skeletal muscle compared with control and pair-fed animals (p < 0.05). Leptin treatment reduced FAT mRNA (red, -70%, p < 0.001; white, -48%, p < 0.01) and FAT/CD36 protein expression (red, -32%; p < 0.05) in whole muscle homogenates, whereas FABPpm mRNA and protein expression were unaltered. However, in leptin-treated animals plasma membrane fractions of both FAT/CD36 and FABPpm protein expression were significantly reduced in red (-28 and -34%, respectively) and white (-44 and -56%, respectively) muscles (p < 0.05). Across all experimental treatments and muscles, palmitate uptake by giant sarcolemmal vesicles was highly correlated with the plasma membrane FAT/CD36 protein (r = 0.88, p < 0.01) and plasma membrane FABPpm protein (r = 0.94, p < 0.01). These studies provide the first evidence that protein-mediated long chain fatty acid transport is subject to long term regulation by leptin.	Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada; Glaxo SmithKline, Miami, FL 33134 USA; Otsuka Maryland Res Inst, Thrombosis Res Lab, Rockville, MD 20850 USA; Maastricht Univ, Dept Physiol, NL-6200 MD Maastricht, Netherlands	University of Waterloo; University of Guelph; GlaxoSmithKline; Maastricht University	Bonen, A (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada.			Steinberg, Gregory/0000-0001-5425-8275				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Barzilai N, 1999, AM J PHYSIOL-ENDOC M, V277, pE291, DOI 10.1152/ajpendo.1999.277.2.E291; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Boden G, 1996, DIABETES CARE, V19, P394, DOI 10.2337/diacare.19.4.394; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Dyck DJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE778, DOI 10.1152/ajpendo.2000.278.5.E778; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FRAYN KN, 1980, J LIPID RES, V21, P139; Han DH, 1997, DIABETES, V46, P1761, DOI 10.2337/diabetes.46.11.1761; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Hevener AL, 2001, DIABETES, V50, P2316, DOI 10.2337/diabetes.50.10.2316; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Kim JK, 1996, DIABETES, V45, P651, DOI 10.2337/diabetes.45.5.651; Luiken JJFP, 2001, J BIOL CHEM, V276, P40567, DOI 10.1074/jbc.M100052200; Luiken JJFP, 1999, J LIPID RES, V40, P1007; MCCULLAGH KJA, 1995, AM J PHYSIOL-REG I, V268, pR884, DOI 10.1152/ajpregu.1995.268.4.R884; McCullagh KJA, 1996, MOL CELL BIOCHEM, V156, P51; MEGENEY LA, 1995, AM J PHYSIOL-REG I, V269, pR1148, DOI 10.1152/ajpregu.1995.269.5.R1148; MEGENEY LA, 1993, AM J PHYSIOL, V264, pE583, DOI 10.1152/ajpendo.1993.264.4.E583; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pelsers MMAL, 1999, BIOCHEM J, V337, P407, DOI 10.1042/0264-6021:3370407; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang JL, 1999, ENDOCRINOLOGY, V140, P2117, DOI 10.1210/en.140.5.2117; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Yaspelkis BB, 1999, METABOLISM, V48, P671, DOI 10.1016/S0026-0495(99)90070-7; Yaspelkis BB, 2001, AM J PHYSIOL-ENDOC M, V280, pE130, DOI 10.1152/ajpendo.2001.280.1.E130; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	49	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8854	8860		10.1074/jbc.M107683200	http://dx.doi.org/10.1074/jbc.M107683200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11729182	hybrid			2022-12-25	WOS:000174400600017
J	Fugere, M; Limperis, PC; Beaulieu-Audy, V; Gagnon, F; Lavigne, P; Klarskov, K; Leduc, R; Day, R				Fugere, M; Limperis, PC; Beaulieu-Audy, V; Gagnon, F; Lavigne, P; Klarskov, K; Leduc, R; Day, R			Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; PROPROTEIN CONVERTASES; PROPEPTIDE CLEAVAGE; FURIN; SUBTILISIN; PRECURSOR; ACTIVATION; ENDOPROTEASE; PATHWAY; DOMAIN	The SPCs (subtilisin-like pro-protein convertases) are a family of enzymes responsible for the proteolytic processing of numerous precursor proteins of the constitutive and regulated secretory pathways. SPCs are themselves synthesized as inactive zymogens. Activation of SPCs occurs via the intramolecular autocatalytic removal of the prodomain. SPC prodomains have been proposed as templates in the development of potent and specific SPC inhibitors. In this study, we investigated the specificity and potency of complete prodomains and short C-terminal prodomain peptides of each SPC on highly purified, soluble enzyme preparations of human SPC1, SPC6, and SPC7. Progress curve kinetic analysis of prodomain peptides and complete prodomains showed competitive inhibitory profiles in the low nano-molar range. Complete prodomains were 5-100 times more potent than C-terminal prodomain peptides, suggesting that N-terminal determinants are involved in the recognition process. However, complete prodomains and prodomain peptides exhibit only a partial specificity toward their cognate enzyme. Ala-scan structure activity studies indicated the importance of basic residues in the P-4, P-5, and P-6 positions for inhibition of SPC1. In contrast, hydrophobic residues in P-6 and P-7, as well as basic residues in P-6 and P-7, were critical for inhibition of SPC7. Our data demonstrated that the use of prodomains as specific inhibitors acting in trans would be of limited usefulness, unless modified into more specific compounds.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, NMR Grp, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Mass Spectrometry Lab, Inst Pharmacol Sherbrooke, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Day, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001,12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.							Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; Denault JB, 2000, PROTEIN EXPRES PURIF, V19, P113, DOI 10.1006/prep.2000.1215; Dong WJ, 1997, J NEUROSCI, V17, P563; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Lipkind GM, 1998, P NATL ACAD SCI USA, V95, P7310, DOI 10.1073/pnas.95.13.7310; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; ODA K, 1992, BIOCHEM BIOPH RES CO, V189, P1353, DOI 10.1016/0006-291X(92)90223-8; Pinnix I, 2001, FASEB J, V15, P1810, DOI 10.1096/fj.00-0891fje; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Ruan B, 1999, BIOCHEMISTRY-US, V38, P8562, DOI 10.1021/bi990362n; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; Tangrea MA, 2001, BIOCHEMISTRY-US, V40, P5488, DOI 10.1021/bi0026472; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; Williams J W, 1979, Methods Enzymol, V63, P437; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	48	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7648	7656		10.1074/jbc.M107467200	http://dx.doi.org/10.1074/jbc.M107467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11723118	hybrid			2022-12-25	WOS:000174268000006
J	Hu, YB; Webb, E; Singh, J; Morgan, BA; Gainor, JA; Gordon, TD; Siahaan, TJ				Hu, YB; Webb, E; Singh, J; Morgan, BA; Gainor, JA; Gordon, TD; Siahaan, TJ			Rapid determination of substrate specificity of Clostridium histolyticum beta-collagenase using an immobilized peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I; PROTEASES; IDENTIFICATION	The molecular basis of the substrate specificity of Clostridium histolyticum beta-collagenase was investigated using a combinatorial method. An immobilized positional peptide library, which contains 24,000 sequences, was constructed with a 7-hydroxycoumarin-4propanoyl (Cop) fluorescent group attached at the N terminus of each sequence. This immobilized peptide library was incubated with C. histolyticum beta-collagenase, releasing fluorogenic fragments in the solution phase. The relative substrate specificity (k(cat)/K-m) for each member of the library was determined by measuring fluorescence intensity in the solution phase. Edman sequencing was used to assign structure to subsites of active substrate mixtures. Collectively, the substrate preference for subsites (P-3-P-4') of C. histolyticum,B-collagenase was determined. The last position on the C-terminal side in which the identity of the amino acids affects the activity of the enzyme is P-4', and an aromatic side chain is preferred in this position. The optimal P-1'-P-3' extended substrate sequence is P-1'-Gly/Ala, P-2'-Pro/Xaa, and P-3'-Lys/Arg/Pro/Thr/Ser. The Cop group in either the P-2 or P-3 position is required for a high substrate activity with C. histolyticum beta-collagenase. S-2 and S. sites of the protease play a dominant role in fixing the substrate specificity. The immobilized peptide library proved to be a powerful approach for assessing the substrate specificity of C histolyticum beta-collagenase, so it may be applied to the study of other proteases of interest.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA; Sterling Winthrop Res Inst, Collegeville, PA 19426 USA	University of Kansas	Siahaan, TJ (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.		Hu, Ruogu/B-2203-2008					ATOR M, 1994, PEPTIDES CHEM STRUCT, P1012; Dekker N, 2001, BIOCHEMISTRY-US, V40, P1694, DOI 10.1021/bi0014195; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Isalan M, 2001, BIOCHEMISTRY-US, V40, P830, DOI 10.1021/bi001728v; Klock G, 1996, CELL TRANSPLANT, V5, P543, DOI 10.1016/0963-6897(96)00023-1; MALLYA SK, 1992, J PROTEIN CHEM, V11, P99, DOI 10.1007/BF01025096; Matsushita O, 2001, J BIOL CHEM, V276, P8761, DOI 10.1074/jbc.M003450200; Mookhtiar K A, 1992, Matrix Suppl, V1, P116; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nishi N, 1998, P NATL ACAD SCI USA, V95, P7018, DOI 10.1073/pnas.95.12.7018; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Rosse G, 2000, J COMB CHEM, V2, P461, DOI 10.1021/cc000019y; SINGH J, 1995, J MED CHEM, V38, P217, DOI 10.1021/jm00002a001; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; St Hilaire PM, 1999, J COMB CHEM, V1, P509, DOI 10.1021/cc990031u; STEINBRINK DR, 1985, J BIOL CHEM, V260, P2771; Tolstrup AB, 2001, GENE, V263, P77; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; WOLTERS GHJ, 1995, DIABETES, V44, P227, DOI 10.2337/diabetes.44.2.227; YIOTAKIS A, 1988, EUR J BIOCHEM, V172, P761, DOI 10.1111/j.1432-1033.1988.tb13954.x	21	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8366	8371		10.1074/jbc.M111042200	http://dx.doi.org/10.1074/jbc.M111042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11724807	hybrid			2022-12-25	WOS:000174268000095
J	Matsumura, ME; Lobe, DR; McNamara, CA				Matsumura, ME; Lobe, DR; McNamara, CA			Contribution of the helix-loop-helix factor Id2 to regulation of vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RAT CAROTID-ARTERY; G(1) PROGRESSION; PROTEINS; P21; EXPRESSION; GROWTH; INJURY; CYCLE; ANGIOPLASTY	Smooth muscle cell (SMC) proliferation plays a key role in vascular proliferative disorders. The molecular mechanisms that control cell cycle entry of SMCs in response to vascular injury are not well understood. Id2 (inhibitor of DNA binding) is a member of the helix-loop-helix (HLH) family of transcription regulators that are known to promote cell cycle progression. Thus, we investigated the role of Id2 in SMC growth and cell cycle regulation. The results demonstrated that overexpression of Id2 resulted in a significant enhancement of SMC growth via increased S-phase entry. A possible mechanism of Id2-enchanced SMC growth is via regulation of p21 expression, as overexpression of Id2-inhibited transcriptional activity of a 2.3-kb p21 promoter/luciferase reporter construct as well as p21 protein levels. Id2 enhancement of SMC growth and inhibition of p21 expression were dependent on phosphorylation of Id2 by cyclin E/cdk2, as an Id2 cDNA containing a mutation in the cdk2 phosphorylation site (serine 5) failed to regulate SMC cell cycle progression or p21 promoter activity. The mechanism of cyclin E/cdk2 control of the Id2 effect may in part involve regulation of nuclear transport; unlike wild-type Id2, the Id2 mutant was not transported to the nucleus. Finally, in a rat carotid model of arterial injury, 142 was expressed in a temporal pattern that parallels the kinetics of cellular proliferation. In summary, these results provide evidence that the Id2 protein is integrated into the cell cycle regulatory cascade that results in SMC proliferation following vascular injury and suggest that this effect is at least in part via a cdk2-dependent inhibition of p21 gene expression.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Matsumura, ME (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, MR-4,Rm 6012,Lane Rd, Charlottesville, VA 22908 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062522, K08HL004431] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL 04431, R01 HL 62522] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CLOWES AW, 1983, LAB INVEST, V49, P327; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Matsumura ME, 2001, ARTERIOSCL THROM VAS, V21, P752, DOI 10.1161/01.ATV.21.5.752; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Suzuki JI, 1997, NAT MED, V3, P900, DOI 10.1038/nm0897-900; THYBERG J, 1995, CELL TISSUE RES, V281, P421; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1998, CIRC RES, V82, P147; YOSHIDA Y, 1988, ARCH PATHOL LAB MED, V112, P987	18	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7293	7297		10.1074/jbc.M108986200	http://dx.doi.org/10.1074/jbc.M108986200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11706002	hybrid			2022-12-25	WOS:000174104300071
J	Knight, D; Harris, R; McAlister, MSB; Phelan, JP; Geddes, S; Moss, SJ; Driscoll, PC; Keep, NH				Knight, D; Harris, R; McAlister, MSB; Phelan, JP; Geddes, S; Moss, SJ; Driscoll, PC; Keep, NH			The X-ray crystal structure and putative ligand-derived peptide binding properties of gamma-aminobutyric acid receptor type A receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 RESONANCE ASSIGNMENTS; MOLECULAR-MOTION; BACKBONE H-1; GABARAP; TRANSPORT; SENSITIVITY; GEPHYRIN; DYNAMICS; INSIGHTS; PROGRAM	The gamma-aminobutyric acid receptor type A (GABA(A)) receptor-associated protein (GABARAP) has been reported to mediate the interaction between the GABA(A) receptor and microtubules. We present the three-dimensional structure of GABARAP obtained by x-ray diffraction at 1.75 Angstrom resolution. The structure was determined by molecular replacement using the structure of the homologous protein GATE-16. NMR spectroscopy of isotope-labeled GABARAP showed the structure in solution to be compatible with the overall fold but showed evidence of conformation heterogeneity that is not apparent in the crystal structure. We assessed the binding of GABARAP to peptides derived from reported binding partner proteins, including the M3-M4 loop of the gamma2 subunit of the GABA(A) receptor and the acidic carboxyl-terminal tails of human alpha- and beta-tubulin. There is a small area of concentrated positive charge on one surface of GABARAP, which we found interacts weakly with all peptides tested, but we found no evidence for specific binding to the proposed physiological target peptides. These results are compatible with a more general role in membrane targeting and transportation for the GABARAP family of proteins.	Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England; UCL, Bloomsbury Ctr Struct Biol, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Ludwig Inst Canc Res, London W1W 7BS, England	University of London; Birkbeck University London; University of London; Birkbeck University London; University College London; University of London; University College London; University of London; University College London; Ludwig Institute for Cancer Research	Keep, NH (corresponding author), Univ London Birkbeck Coll, Sch Crystallog, Malet St, London WC1E 7HX, England.	n.keep@mail.cryst.bbk.ac.uk	Driscoll, Paul C/B-8007-2010; Keep, N/C-2759-2008; Keep, Nicholas/R-3493-2019	Driscoll, Paul C/0000-0002-4124-6950; Keep, N/0000-0002-5042-1837; Keep, Nicholas/0000-0002-5042-1837; mcalister, mark/0000-0003-3986-1767; Harris, Richard/0000-0001-7459-1745				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; EVANS P, 1997, P CCP4 STUD WEEK 199; Harris R, 2001, J BIOMOL NMR, V21, P185, DOI 10.1023/A:1012473609468; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1993, P CCP4 STUD WEEK DAT, P44; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MANN SS, 1994, J BIOL CHEM, V269, P11492; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Schomaker V, 1998, ACTA CRYSTALLOGR B, V54, P507, DOI 10.1107/S0108768198003243; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Stangler T, 2001, J BIOMOL NMR, V21, P183, DOI 10.1023/A:1012416810974; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vernier-Magnin S, 2001, BIOCHEM BIOPH RES CO, V284, P118, DOI 10.1006/bbrc.2001.4908; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	35	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5556	5561		10.1074/jbc.M109753200	http://dx.doi.org/10.1074/jbc.M109753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729197	hybrid			2022-12-25	WOS:000173962900129
J	Wu, LNY; Genge, BR; Kang, MW; Arsenault, AL; Wuthier, RE				Wu, LNY; Genge, BR; Kang, MW; Arsenault, AL; Wuthier, RE			Changes in phospholipid extractability and composition accompany mineralization of chicken growth plate cartilage matrix vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIPHYSEAL CARTILAGE; MEDIATED MINERALIZATION; ALKALINE-PHOSPHATASE; NUCLEATIONAL CORE; CALCIUM; INVITRO; MEMBRANE; LIPIDS; CALCIFICATION; ACCUMULATION	Matrix vesicles are lipid bilayer-enclosed structures that initiate extracellular mineral formation. Little attention has been given to how newly formed mineral interacts with the lipid constituents and then emerges from the lumen. To explore whether specific lipids bind to the incipient mineral and if breakdown of the membrane is involved, we analyzed changes in lipid composition and extractability during vesicle-induced calcification. Isolated matrix vesicles were incubated in synthetic cartilage lymph to induce mineral formation. At various times, samples of the lipids were taken for analysis, extracted both before and after demineralization to remove deposited mineral. Phosphatidylserine and phosphatidylinositol both rapidly disappeared from extracts made before decalcification, indicating rapid degradation. However, extracts made after demineralization revealed that phosphatidylserine had become complexed with newly forming mineral. Concomitantly, its levels actually increased, apparently by base-exchange with phosphatidylethanolamine. Though partially complexed with the mineral, phosphatidylinositol was nevertheless rapidly broken down. Sphingomyelin and phosphatidylethanolamine also underwent rapid breakdown, but phosphatidylcholine was degraded more slowly, all accompanied by a buildup of free fatty acids. The data indicate that phosphatidylserine forms complexes that accompany mineral formation, while degradation of other membrane phospholipids apparently enables egress of crystalline mineral from the vesicle lumen.	Univ S Carolina, Grad Sci Res Ctr 329, Dept Chem & Biochem, Columbia, SC 29208 USA; McMaster Univ, Dept Pathol, Hamilton, ON L8N 3Z5, Canada	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; McMaster University	Wuthier, RE (corresponding author), Univ S Carolina, Grad Sci Res Ctr 329, Dept Chem & Biochem, Columbia, SC 29208 USA.				NIAMS NIH HHS [AR18983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON MB, 1964, J BIOL CHEM, V239, P70; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; ANDERSON HC, 1992, BONE MINER, V17, P107, DOI 10.1016/0169-6009(92)90718-S; ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; BANERJEE P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P305, DOI 10.1016/0005-2760(90)90074-8; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOSKEY AL, 1976, CALCIF TISSUE RES S, V22, P197; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; EANES ED, 1992, BONE MINER, V17, P269, DOI 10.1016/0169-6009(92)90749-4; EISENBERG E, 1970, CALC TISS RES, V6, P32, DOI 10.1007/BF02196182; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HURST WJ, 1984, J AM OIL CHEM SOC, V61, P1462, DOI 10.1007/BF02636365; IANOTTI JP, 1994, CLIN ORTHOP RELAT R, V306, P222; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1979, CALCIFIED TISSUE INT, V27, P41, DOI 10.1007/BF02441159; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; NASH HA, 1964, P NATL ACAD SCI USA, V51, P476, DOI 10.1073/pnas.51.3.476; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; Sabatini M, 2000, BIOCHEM BIOPH RES CO, V267, P438, DOI 10.1006/bbrc.1999.1983; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SKRTIC D, 1992, CALCIFIED TISSUE INT, V50, P253, DOI 10.1007/BF00296290; Sylvia VL, 2001, BBA-MOL CELL RES, V1499, P209, DOI 10.1016/S0167-4889(00)00120-8; WU LNY, 1993, J BIOL CHEM, V268, P25084; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1978, BIOCHEMISTRY-US, V17, P1431, DOI 10.1021/bi00601a011; WUTHIER RE, 1966, J LIPID RES, V7, P558; WUTHIER RE, 1973, CLIN ORTHOP RELAT R, P191; WUTHIER RE, 1988, ISI ATLAS-BIOCHEM, V1, P231; WUTHIER RE, 1968, J LIPID RES, V9, P68; WUTHIER RE, 1976, FED PROC, V35, P117; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311; Zhang J, 2001, EUR J PHARMACOL, V415, P117, DOI 10.1016/S0014-2999(01)00834-2	37	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5126	5133		10.1074/jbc.M107899200	http://dx.doi.org/10.1074/jbc.M107899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714705	hybrid			2022-12-25	WOS:000173962900076
J	Brocke, L; Bendahan, A; Grunewald, M; Kanner, BI				Brocke, L; Bendahan, A; Grunewald, M; Kanner, BI			Proximity of two oppositely oriented reentrant loops in the glutamate transporter GLT-1 identified by paired cysteine mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; DOPAMINE TRANSPORTER; FUNCTIONAL-ANALYSIS; MEMBRANE-VESICLES; ACID TRANSPORTER; CHLORIDE CHANNEL; BINDING-SITE; EXPRESSION; SUBSTRATE; REVEALS	Sodium- and potassium-coupled transporters clear the excitatory neurotransmitter glutamate from the synaptic cleft. Their function is essential for effective glutamatergic neurotransmission. Glutamate transporters have an unusual topology, containing eight membrane-spanning domains and two reentrant loops of opposite orientation. We have introduced pairwise cysteine substitutions in several structural elements of the GLT-1 transporter. A complete inhibition of transport by Cu(II)(1,10-phenanthroline)(3) is observed in the double mutants A412C/V427C and A364C/S440C, but not in the corresponding single mutants. No inhibition is observed in more then 20 other double cysteine mutants. The Cu(II)(1,10-phenanthroline)(3) inhibition can be partly prevented by the nontransportable glutamate analogue dihydrokainate. Treatment with dithiothreitol. restores much of the transport activity. Moreover, micromolar concentrations of cadmium ions reversibly inhibit transport catalyzed by A412C/V427C and A364C/S440C double mutants, but not by the corresponding single mutants. Inhibition by Cu(II)(1,10-phenanthroline)(3) and by cadmium is only observed when the cysteine pairs are introduced in the same polypeptide. Therefore, in both cases the proximity appears:to be intra- rather than intermolecular. Positions 364 and 440 are located on reentrant loop I and II, respectively. Our results suggest that these two loops, previously shown to be essential for glutamate transport, come in close proximity.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.				NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kim YM, 2001, J BIOL CHEM, V276, P36681, DOI 10.1074/jbc.M106079200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	53	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3985	3992		10.1074/jbc.M107735200	http://dx.doi.org/10.1074/jbc.M107735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724778	hybrid			2022-12-25	WOS:000173813900027
J	Nishi, S; Nakabayashi, K; Kobilka, B; Hsueh, AJW				Nishi, S; Nakabayashi, K; Kobilka, B; Hsueh, AJW			The ectodomain of the luteinizing hormone receptor interacts with exoloop 2 to constrain the transmembrane region - Studies using chimeric human and fly receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LUTROPIN CHORIOGONADOTROPIN RECEPTOR; EXTRACELLULAR DOMAIN; CONSTITUTIVE ACTIVATION; CHORIONIC-GONADOTROPIN; THYROTROPIN RECEPTOR; MAMMALIAN-CELLS; TSH RECEPTOR; MOLECULAR-CLONING; RICH REPEATS	Lutropin (LH) and follitropin (FSH) receptors belong to a group of leucine-rich repeat-containing, G protein-coupled receptors (LGRs) found in vertebrates and flies. We fused the ectodomain of human LH or FSH receptors to the transmembrane region of fly LGR2. The chimeric human/fly receptors, unlike their wild type counterparts, exhibited ligand-independent constitutive activity. Because ectodomains likely interact with exoloops to constrain the receptors, individual exoloops of the chimeric receptor containing the ectodomain of the LH receptor and transmembrane region of fly LGR2 was replaced with LH receptor sequences. Chimeric receptors with the ectodomain and exoloop 2, but not exoloop 1 or 3, from LH receptors showed decreases in constitutive activity, but ligand treatment stimulated cAMP production. Furthermore, substitution of key resides in the hinge region of fly LGR2 with LH receptor sequences led to constitutive receptor activation; however, concomitant substitution of the homologous exoloop 2 of the LH receptor decreased G. coupling. These results suggest that the hinge region of the LH receptor interacts with exoloop 2 to constrain the receptor in an inactive conformation whereas ligand binding relieves this Lutropin (LH) and follitropin (FSH) receptors belong to a group of leucine-rich repeat-containing, G protein-coupled receptors (LGRs) found in vertebrates and flies. We fused the ectodomain of human LH or FSH receptors to the transmembrane region of fly LGR2. The chimeric human/fly receptors, unlike their wild type counterparts, exhibited ligand-independent constitutive activity. Because ectodomains likely interact with exoloops to constrain the receptors, individual exoloops of the chimeric receptor containing the ectodomain of the LH receptor and transmembrane region of fly LGR2 was replaced with LH receptor sequences. Chimeric receptors with the ectodomain and exoloop 2, but not exoloop 1 or 3, from LH receptors showed decreases in constitutive activity, but ligand treatment stimulated cAMP production. Furthermore, substitution of key resides in the hinge region of fly LGR2 with LH receptor sequences led to constitutive receptor activation; however, concomitant substitution of the homologous exoloop 2 of the LH receptor decreased G. coupling. These results suggest that the hinge region of the LH receptor interacts with exoloop 2 to constrain the receptor in an inactive conformation whereas ligand binding relieves this constraint, leading to G. activation.constraint, leading to G. activation.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; Eriksen KK, 2000, GENOME RES, V10, P924, DOI 10.1101/gr.10.7.924; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Kopp P, 1997, J CLIN INVEST, V100, P1634, DOI 10.1172/JCI119687; Kudo M, 2000, MOL ENDOCRINOL, V14, P272, DOI 10.1210/me.14.2.272; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Li SH, 2001, J BIOL CHEM, V276, P7968, DOI 10.1074/jbc.M010482200; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2000, ENDOCRINOLOGY, V141, P4081, DOI 10.1210/en.141.11.4081; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, MOL CELL ENDOCRINOL, V125, P93, DOI 10.1016/S0303-7207(96)03951-2; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tonacchera M, 1996, CLIN ENDOCRINOL, V44, P621, DOI 10.1046/j.1365-2265.1996.746567.x; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514	36	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3958	3964		10.1074/jbc.M109617200	http://dx.doi.org/10.1074/jbc.M109617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723133	hybrid			2022-12-25	WOS:000173813900023
J	Teixeiro, E; Fuentes, P; Galocha, B; Alarcon, B; Bragado, R				Teixeiro, E; Fuentes, P; Galocha, B; Alarcon, B; Bragado, R			T cell receptor-mediated signal transduction controlled by the beta chain transmembrane domain - Apoptosis-deficient cells display unbalanced mitogen-activated protein kinases activities upon T cell receptor engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION; CONSTANT-REGION; CD69 EXPRESSION; ERK ACTIVATION; SELF-PEPTIDE; PKC-THETA; TCR; ZAP-70; VAV; PATHWAY	The bases that support the versatility of the T cell receptor (TCR) to generate distinct T cell responses remain unclear. We have previously shown that mutant cells in the transmembrane domain of TCRbeta chain are impaired in TCR-induced apoptosis but are not affected in other functions. Here we describe the biochemical mechanisms by which this mutant receptor supports some T cell responses but fails to induce apoptosis. Extracellular signal-regulated protein kinase (ERK) is activated at higher and more sustained levels in TCbeta-mutated than in wild type cells. Conversely, activation of both c-Jun N-terminal kinase and p38 mitogen-activated protein kinase is severely reduced in mutant cells. By attempting to link this unbalanced induction to altered upstream events, we found that ZAP-70 is normally activated. However, although SLP-76 phosphorylation is normally induced, TCR engagement of mutant cells results in lower tyrosine phosphorylation of LAT but in higher tyrosine phosphorylation of Vav than in wild type cells. The results suggest that an altered signaling cascade leading to an imbalance in mitogen-activated protein kinase activities is involved in the selective impairment of apoptosis in these mutant cells. Furthermore, they also provide new insights in the contribution of TCR to decipher the signals that mediate apoptosis distinctly from proliferation.	Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain; Hosp Clin San Carlos, Unidad Invest, Madrid 28040, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Hospital Clinico San Carlos; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Bragado, R (corresponding author), Fdn Jimenez Diaz, Dept Immunol, Avenida Reyes Catolicos 2, E-28040 Madrid, Spain.		Alarcon, Balbino/N-9648-2016; Fuentes, Patricia/Y-9921-2019	Alarcon, Balbino/0000-0001-7820-1070; Fuentes, Patricia/0000-0003-4597-1022				Ardouin L, 1999, IMMUNITY, V10, P409, DOI 10.1016/S1074-7613(00)80041-2; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Backstrom BT, 1997, J EXP MED, V186, P1933, DOI 10.1084/jem.186.11.1933; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brossart P, 1996, J EXP MED, V183, P2449, DOI 10.1084/jem.183.6.2449; Cao W, 1996, J MOL MED-JMM, V74, P573, DOI 10.1007/s001090050061; Chau LA, 1999, J IMMUNOL, V163, P1853; Chau LA, 2001, TRANSPLANT P, V33, P528, DOI 10.1016/S0041-1345(00)02125-4; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; Combadiere B, 1998, IMMUNITY, V9, P305, DOI 10.1016/S1074-7613(00)80613-5; Combadiere B, 1998, J EXP MED, V187, P349, DOI 10.1084/jem.187.3.349; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fuller-Espie S, 1998, INT IMMUNOL, V10, P923, DOI 10.1093/intimm/10.7.923; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; HIBL M, 1993, GENE DEV, V7, P2135; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kunjibettu S, 2001, INT IMMUNOL, V13, P211, DOI 10.1093/intimm/13.2.211; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Martelli MP, 2000, BLOOD, V96, P2181; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Puente LG, 2000, J IMMUNOL, V165, P6865, DOI 10.4049/jimmunol.165.12.6865; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Rosette C, 2001, IMMUNITY, V15, P59, DOI 10.1016/S1074-7613(01)00173-X; Sahuquillo AG, 1998, J EXP MED, V187, P1179, DOI 10.1084/jem.187.8.1179; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; Salojin KV, 1999, J IMMUNOL, V163, P844; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; She J, 1998, INT IMMUNOL, V10, P1733, DOI 10.1093/intimm/10.11.1733; SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; TaylorFishwick DA, 1995, EUR J IMMUNOL, V25, P3215, DOI 10.1002/eji.1830251203; Teixeiro E, 1999, EUR J IMMUNOL, V29, P745, DOI 10.1002/(SICI)1521-4141(199903)29:03<745::AID-IMMU745>3.0.CO;2-0; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Wei CH, 1999, J IMMUNOL, V163, P2601; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	57	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3993	4002		10.1074/jbc.M107797200	http://dx.doi.org/10.1074/jbc.M107797200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724779	hybrid			2022-12-25	WOS:000173813900028
J	Montell, E; Lerin, C; Newgard, CB; Gomez-Foix, AM				Montell, E; Lerin, C; Newgard, CB; Gomez-Foix, AM			Effects of modulation of glycerol kinase expression on lipid and carbohydrate metabolism in human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; ADIPOSE-TISSUE; IN-VIVO; GLYCOGEN-SYNTHESIS; GLUCOSE; MECHANISMS; EXERCISE; RAT; TRIACYLGLYCEROL; OVEREXPRESSION	Glycerol is taken up by human muscle in vivo and incorporated into lipids, but little is known about regulation of glycerol metabolism in this tissue. In this study, we have analyzed the role of glycerol kinase (GlK) in the regulation of glycerol metabolism in primary cultured human muscle cells. Isolated human muscle cells exhibited lower GlK activity than fresh muscle explants, but the activity in cultured cells was increased by exposure to insulin. [U-C-14]Glycerol was incorporated into cellular phospholipids and triacylglycerides (TAGs), but little or no increase in TAG content or lactate release was observed in response to changes in the medium glycerol concentration. Adenovirus-mediated delivery of the Escherichia coli GlK gene (AdCMV-GlK) into muscle cells caused a 30-fold increase in GIK activity, which was associated with a marked rise in the labeling of phospholipid or TAG from [U-C-14]glycerol compared with controls. Moreover, GIK overexpression caused [U-C-14] glycerol to be incorporated into glycogen, which was dependent on the activation of glycogen synthase. Coincubation of AdCMV-GlK-treated muscle cells with glycerol and oleate resulted in a large accumulation of TAG and an increase in lactate production. We conclude that GlK is the limiting step in muscle cell glycerol metabolism. Glycerol 3-phosphate is readily used for TAG synthesis but can also be diverted to form glycolytic intermediates that are in turn converted to glycogen or lactate. Given the high levels of glycerol in muscle interstitial fluid, these finding suggest that changes in GIK activity in muscle can exert important influences on fuel deposition in this tissue.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomez-Foix, AM (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti I Franques 1, E-08028 Barcelona, Spain.		Lerin, Carles/AAP-9916-2020	Lerin, Carles/0000-0003-0950-4363				ASKANAS V, 1985, ARCH NEUROL-CHICAGO, V42, P749, DOI 10.1001/archneur.1985.04210090013004; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; BANGSBO J, 1991, J PHYSIOL-LONDON, V434, P423, DOI 10.1113/jphysiol.1991.sp018478; Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Coppack SW, 1999, AM J PHYSIOL-ENDOC M, V276, pE233, DOI 10.1152/ajpendo.1999.276.2.E233; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; EMMISON N, 1988, FEBS LETT, V236, P83, DOI 10.1016/0014-5793(88)80289-8; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; Guo ZK, 1999, J BIOL CHEM, V274, P23702, DOI 10.1074/jbc.274.34.23702; Kiens B, 1998, AM J PHYSIOL-ENDOC M, V275, pE332, DOI 10.1152/ajpendo.1998.275.2.E332; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Lerin C, 2000, J BIOL CHEM, V275, P39991, DOI 10.1074/jbc.M006251200; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; MAGGS DG, 1995, J CLIN INVEST, V96, P370, DOI 10.1172/JCI118043; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; NEWSHOLME EA, 1969, BIOCHEM J, V112, P465, DOI 10.1042/bj1120465; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; Samra JS, 1996, CLIN SCI, V90, P453, DOI 10.1042/cs0900453; SARGENT CA, 1994, HUM MOL GENET, V3, P1317, DOI 10.1093/hmg/3.8.1317; SELTZER WK, 1989, MUSCLE NERVE, V12, P307, DOI 10.1002/mus.880120409; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Watford M, 2000, NUTR REV, V58, P145, DOI 10.1111/j.1753-4887.2000.tb01849.x; Westergaard N, 1998, BBA-MOL CELL RES, V1402, P261, DOI 10.1016/S0167-4889(98)00016-0	28	19	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2682	2686		10.1074/jbc.M107227200	http://dx.doi.org/10.1074/jbc.M107227200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714702	hybrid			2022-12-25	WOS:000173421500041
J	Levy, C; Nechushtan, H; Razin, E				Levy, C; Nechushtan, H; Razin, E			A new role for the STAT3 inhibitor, PIAS3 - A repressor of microphthalmia transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; CULTURED MAST-CELLS; GENE-EXPRESSION; MUTANT MICE; TFE3; FOS	In vitro and in vivo evidence suggest that microphthalmia transcription factor (MITF) plays a key regulatory role in tissue-specific gene regulation in several cell types, including melanocytes, osteoclasts, and mast cells. A yeast two-hybrid search, using a portion of a nonmutated MITF gene as the bait in the screening of a mast cell library, resulted in the isolation of the STAT3 inhibitor, PIAS3. PIAS3 is a transcriptional inhibitor that acts by specifically inhibiting STAT3's DNA binding activity. We found that it can directly associate with MITF using an in vitro pull-down assay. Immunoprecipitation of MITF from rat basophilic leukemic cells or mouse melanocytes resulted in the specific co-immuno-precipitation of PIAS3. Co-transfection of MITF with PIAS3 in NIH 3T3 fibroblasts containing an mMCP-6 promoter-luciferase reporter demonstrated up to 94% inhibition of MITF-mediated transcriptional activation. Using a gel-shift assay, it was shown that PIAS3 can block DNA binding activity. It was also found that STAT3 does not interfere, either in vitro or in vivo, with the interaction between PIAS3 and MITF. These data suggest that PIAS3 functions in vivo as a key molecule in supressing the transcriptional activity of MITF, a role of considerable importance in mast cell and melanocyte development.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	ehudr@cc.huji.ac.il	nechushtan, hovav/Z-3564-2019					BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Goldstein RE, 1999, DEVELOPMENT, V126, P3747; Hallsson JH, 2000, GENETICS, V155, P291; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; Ito A, 1999, BLOOD, V93, P1189, DOI 10.1182/blood.V93.4.1189.404k32_1189_1196; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kitamura Y, 2000, INT J HEMATOL, V71, P197; Kitamura Y, 2001, INT ARCH ALLERGY IMM, V124, P16, DOI 10.1159/000053657; Lewin I, 1996, J BIOL CHEM, V271, P1514, DOI 10.1074/jbc.271.3.1514; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; Morii E, 2001, BLOOD, V98, P2577, DOI 10.1182/blood.V98.8.2577; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Nechushtan H, 1997, BLOOD, V89, P2999, DOI 10.1182/blood.V89.8.2999; Ogihara H, 1999, ONCOGENE, V18, P4632, DOI 10.1038/sj.onc.1202844; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	30	75	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1962	1966		10.1074/jbc.M109236200	http://dx.doi.org/10.1074/jbc.M109236200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11709556	hybrid			2022-12-25	WOS:000173421300048
J	Cursio, R; Mari, B; Louis, K; Rostagno, P; Saint-Paul, MC; Giudicelli, J; Bottero, V; Anglard, P; Yiotakis, A; Dive, V; Gugenheim, J; Auberger, P				Cursio, R; Mari, B; Louis, K; Rostagno, P; Saint-Paul, MC; Giudicelli, J; Bottero, V; Anglard, P; Yiotakis, A; Dive, V; Gugenheim, J; Auberger, P			Rat liver injury following normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor	FASEB JOURNAL			English	Article						matrix metalloproteinases (MMPs); tissue inhibitors of matrix metalloproteinase; (TIMPs); ischemia/reperfusion; necrosis; apoptosis	HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; REPERFUSION INJURY; TISSUE INHIBITOR; TNF-ALPHA; HUMAN STROMELYSIN-3; BASEMENT-MEMBRANE; MMP2 ACTIVATION; FOCAL ISCHEMIA; EXPRESSION	Hepatic ischemia occurs in liver transplantation, hemodynamic or cardiogenic shock, and liver resection associated with trauma or tumor. Ischemia/reperfusion (I/R) injury results in microcirculation failure followed by apoptosis and necrosis. Matrix metalloproteinases (MMPs) are involved in many physiological and pathological processes, but their expression and function during liver I/R remains poorly documented. In this study, we evaluated the expression of nine MMPs and their natural inhibitors, tissue inhibitors of MMPs (TIMPs), in a rat model of liver I/R. Analysis of MMP and TIMP expression show that although most of these genes are not constitutively expressed in the normal liver, they are induced in a specific time-dependent manner following I/R. Stromelysin-1, gelatinase B, and collagenase-3 are induced during the early phase of acute liver injury associated with inflammation and increased necrosis/apoptosis, whereas gelatinase A, membrane type-MMP, stromelysin-3, metalloelastase, TIMP-1, and TIMP-2 are essentially detectable during the recovery phase of liver injury corresponding to hepatocyte regeneration. This observation suggested that MMPs and TIMPs could play both deleterious and beneficial roles following I/R. We thus tested the effect of a specific phosphinic MMP inhibitor on acute liver I/R injury. Inhibition of MMP activity was shown to significantly decrease liver injury in ischemic/reperfused liver tissue as assessed by histological studies and serum hepatic enzyme levels. We therefore propose that MMP inhibitors may be of clinical relevance in liver-associated ischemic diseases or after liver transplantation.	Fac Med Pasteur, INSERM, U526, IFR50, Nice, France; Fac Med Pasteur, IFR50, Lab Rech Chirurg, Nice, France; Ctr Antoine Lacassagne, F-06054 Nice, France; Hop Louis Pasteur, Serv Anat Pathol, Nice, France; Fac Med, Biochim Lab, Nice, France; INSERM, U184, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Univ Athens, Organ Chem Lab, Athens, Greece; CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National & Kapodistrian University of Athens; CEA; UDICE-French Research Universities; Universite Paris Saclay	Mari, B (corresponding author), Fac Med Pasteur, INSERM, U526, IFR50, Nice, France.	bmari@unice.fr	Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022; Anglard, Patrick/M-6618-2019; Mari, Bernard P/D-7445-2015	Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard P/0000-0002-0422-9182				Alvarez J, 2000, J BONE MINER RES, V15, P82, DOI 10.1359/jbmr.2000.15.1.82; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Behrendtsen O, 1997, DEV DYNAM, V208, P255; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boulay A, 2001, CANCER RES, V61, P2189; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833; Clavien PA, 2001, HEPATOLOGY, V33, P1555, DOI 10.1053/jhep.2001.25448; Colletti LM, 1996, HEPATOLOGY, V23, P506; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cursio R, 1998, J SURG RES, V80, P339, DOI 10.1006/jsre.1998.5445; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Dive V, 2000, BIOCHEM SOC T, V28, P455, DOI 10.1042/0300-5127:0280455; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Haro H, 2000, J CLIN INVEST, V105, P133, DOI 10.1172/JCI7090; Haruyama T, 2000, BIOCHEM BIOPH RES CO, V272, P681, DOI 10.1006/bbrc.2000.2837; Herbst H, 1997, AM J PATHOL, V150, P1647; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5; JAESCHKE H, 1991, AM J PHYSIOL, V260, P355; Kim TH, 2000, HEPATOLOGY, V31, P75, DOI 10.1002/hep.510310114; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kohli V, 1999, TRANSPLANTATION, V67, P1099, DOI 10.1097/00007890-199904270-00003; LaFleur M, 1996, J EXP MED, V184, P2311; Leber TM, 1998, BRIT J CANCER, V78, P724, DOI 10.1038/bjc.1998.568; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Okada A, 1997, GENE, V185, P187, DOI 10.1016/S0378-1119(96)00615-4; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Planas AM, 2000, BIOCHEM BIOPH RES CO, V278, P803, DOI 10.1006/bbrc.2000.3881; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SAKR MF, 1993, J HEPATOL, V17, P301, DOI 10.1016/S0168-8278(05)80209-0; Sasaki H, 1996, TRANSPLANT P, V28, P1908; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Soccal PM, 2000, TRANSPLANTATION, V70, P998, DOI 10.1097/00007890-200010150-00002; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Takahara T, 1997, HEPATOLOGY, V26, P1521; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Theret N, 1997, AM J PATHOL, V150, P51; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Upadhya AG, 1997, HEPATOLOGY, V26, P922, DOI 10.1002/hep.510260418; Upadhya GA, 2000, HEPATOLOGY, V31, P1115, DOI 10.1053/he.2000.6780; Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WU E, 2001, IN PRESS J CELL BIOC; Yadav SS, 1999, HEPATOLOGY, V30, P1223, DOI 10.1002/hep.510300513; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521; Zhang YH, 1998, J IMMUNOL, V161, P3071	65	91	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					93	+		10.1096/fj.01-0279fje	http://dx.doi.org/10.1096/fj.01-0279fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709491				2022-12-25	WOS:000172420500036
J	Kim, I; Oh, JL; Ryu, YS; So, JN; Sessa, WC; Walsh, K; Koh, GY				Kim, I; Oh, JL; Ryu, YS; So, JN; Sessa, WC; Walsh, K; Koh, GY			Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells	FASEB JOURNAL			English	Article						vascular endothelial growth factor; TNF-alpha; Akt; phosphatidylinositol 3 '-kinase	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; BLOOD-VESSEL DEVELOPMENT; SERINE-THREONINE KINASE; GROWTH-FACTOR; OVEREXPRESSING ANGIOPOIETIN-1; VASCULAR-PERMEABILITY; TIE2 RECEPTOR; FACTOR GENE	Normally, tissue factor (TF) is not expressed on the surface of endothelial cells, but its expression can be induced by vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-alpha. However, the signaling pathway(s) affecting this induction is unknown. Using human umbilical vein endothelial cells, we found that inhibitors of guanine-cytosine-rich DNA binding protein and nuclear factor (NF)-kappaB suppressed VEGF- and TNF-alpha -induced expression and activity of TF. However, unexpectedly, phosphatidylinositol (PI) 3'-kinase inhibitor enhanced the VEGF- and TNF-alpha -induced expression and activity of TF. Angiopoietin-1 (Ang1), a strong activator of intracellular PI 3'-kinase/Akt, inhibited the induction of TF by VEGF and TNF-alpha, whereas Ang1 itself did not produce any significant effect on TF. Selective activation (or inactivation) of PI 3'-kinase/Akt by using adenoviral transfer reduced (or enhanced) TNF-alpha -induced expression of TF mRNA and protein, regardless of Ang1 treatment. From these results, we conclude that Ang1 inhibits the up-regulation of TF expression, possibly through activation of PI 3'-kinase/Akt in endothelial cells. Ang1 may be useful as an inhibitor of VEGF- and TNF-alpha -induced coagulation, inflammation, and cancer progression.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Woosuk Univ, Dept Biotechnol, Chonju 560180, South Korea; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Woosuk University; Yale University; St. Elizabeth's Medical Center	Koh, GY (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, San 31, Pohang 790784, South Korea.	gykoh@postech.ac.kr	Sessa, William C/B-6844-2011; Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011	Sessa, William C/0000-0001-5759-1938; Kim, Injune/0000-0001-9244-815X				Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; KNOLL J, 1997, J BIOL CHEM, V272, P32521; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NAWROTH PP, 1985, THROMB RES, V40, P677, DOI 10.1016/0049-3848(85)90305-6; NEMERSON Y, 1988, BLOOD, V71, P1; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; RAO LVM, 1992, CANCER METAST REV, V11, P249; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	54	99	103	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					126	+		10.1096/fj.01-0556fje	http://dx.doi.org/10.1096/fj.01-0556fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729102				2022-12-25	WOS:000172420500027
J	David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J				David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J			Induction of the IL-13 receptor alpha 2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways	ONCOGENE			English	Article						keratinocytes; MAP kinase; inhibitors; IL-4; IL-13; cytokine receptor chain; transduction	INTERLEUKIN-13 RECEPTOR; MESSENGER-RNA; KINASE PATHWAY; CELL RESPONSE; ALPHA CHAIN; PROTEIN; GENE; INHIBITOR; CLONING; BINDING	IL-4 and IL-13 are related cytokines which induce both pro- and anti-inflammatory effects depending on the cell type they act upon and the nature of the receptors expressed. The type I receptor complex is composed of the IL-4R alpha and gammac and only binds IL-4, whereas, in the type II receptor, IL-4R alpha dimerizes with IL-13R alpha1 upon either IL-4 or IL-13 binding. Another ligand binding chain potentially implicated in the IL-4/M-13 receptor has been described, the IL-13R alpha2, but the regulation of its expression and its role in IL-4/IL-13 transduction is poorly understood. In this study we report that IL-4 and IL-13 upregulate IL-13R alpha2 at both the mRNA and protein levels in the keratinocyte cell line HaCaT. In these cells, IL-4 or IL-13 were shown to activate the Janus Kinases JAK1 and JAK2, the transcription factor STAT6, and the ERK and p38 mitogen-activated protein kinases. We show that IL-4 or IL-13-induced IL-13R alpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580. Moreover, expression of a constitutive active mutant of STAT6 alone did not modify IL-13R alpha2 mRNA expression, but potentiated the effects of IL-4 or 11-13 on IL-13 alpha2 expression. The constitutive active mutants of MEK1 or MKK6 increased the level of expression of IL-13R alpha2 mRNA even in absence of stimulation. Our findings demonstrate, for the first time, that IL-4 and IL-13 can induce IL-13R alpha2 expression in keratinocytes, and that the ERK and p38 MAPK together with JAK2 and STAT6 play a critical role in this process.	INSERM, Fac Pharm, U461, F-92296 Chatenay Malabry, France; Boston Univ, Sch Med, Roger Williams Med Ctr, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Boston University; Roger Williams Medical Center	Pierre, J (corresponding author), INSERM, Fac Pharm, U461, 5,Rue JB Clement, F-92296 Chatenay Malabry, France.		David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRUNET A, 1994, ONCOGENE, V9, P3379; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COLOTTA F, 1992, CYTOKINE, V4, P24, DOI 10.1016/1043-4666(92)90032-M; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; Ezernieks J, 1996, EUR J BIOCHEM, V240, P667, DOI 10.1111/j.1432-1033.1996.0667h.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng NP, 1998, LAB INVEST, V78, P591; Ford D, 1999, J IMMUNOL, V163, P3185; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; HARELBELLAN A, 1986, J IMMUNOL, V136, P2463; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wang LH, 1999, J IMMUNOL, V162, P3897; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	40	77	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6660	6668		10.1038/sj.onc.1204629	http://dx.doi.org/10.1038/sj.onc.1204629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709700				2022-12-25	WOS:000171551600002
J	Ruban, AV; Pascal, AA; Robert, B; Horton, P				Ruban, AV; Pascal, AA; Robert, B; Horton, P			Activation of zeaxanthin is an obligatory event in the regulation of photosynthetic light harvesting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; CHLOROPHYLL FLUORESCENCE; ABSORPTION-SPECTRA; BETA-CAROTENE; XANTHOPHYLLS; SOLVENT; COMPLEX; ENERGY; BINDING; PLANTS	By dynamic changes in protein structure and function, the photosynthetic membranes of plants are able to regulate the partitioning of absorbed light energy between utilization in photosynthesis and photoprotective non-radiative dissipation of the excess energy. This process is controlled by features of the intact membrane, the transmembrane pH gradient, the organization of the photosystem II antenna proteins and the reversible binding of a specific carotenoid, zeaxanthin. Resonance Raman spectroscopy has been applied for the first time to wild type and mutant Arabidopsis leaves and to intact thylakoid membranes to investigate the nature of the absorption changes obligatorily associated with the energy dissipation process. The observed changes in the carotenoid Resonance Raman spectrum proved that zeaxanthin was involved and indicated a dramatic change in zeaxanthin environment that specifically alters the pigment configuration and red-shifts the absorption spectrum. This activation of zeaxanthin is a key event in the regulation of light harvesting.	Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; CE Saclay, URA 2096 CNRS, Sect Biophys Prot & Membranes, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France	University of Sheffield; CEA; UDICE-French Research Universities; Universite Paris Saclay	Ruban, AV (corresponding author), Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	Horton, Peter/A-3958-2012; pascal, andrew a/B-6186-2014; Robert, Bruno/D-1264-2012	Horton, Peter/0000-0002-6095-1460; pascal, andrew a/0000-0002-1844-6065; Robert, Bruno/0000-0001-5999-4538				ANDERSSON PO, 1991, PHOTOCHEM PHOTOBIOL, V54, P353, DOI 10.1111/j.1751-1097.1991.tb02027.x; ANDERSSON PO, 1995, J PHYS CHEM-US, V99, P16199, DOI 10.1021/j100044a002; Baker NR, 1994, PHOTOINHIBITION PHOT; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; DUNIEC JT, 1977, J BIOENERG BIOMEMBR, V9, P223, DOI 10.1007/BF00743153; Frank HA, 2000, BIOCHEMISTRY-US, V39, P2831, DOI 10.1021/bi9924664; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; GARAB G, 1988, BIOCHEMISTRY-US, V27, P2425, DOI 10.1021/bi00407a027; GOTTFRIED DS, 1991, SCIENCE, V251, P662, DOI 10.1126/science.1992518; Hashimoto H, 1997, JPN J APPL PHYS 2, V36, pL916, DOI 10.1143/JJAP.36.L916; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; LEROSEN AL, 1952, J CHEM PHYS, V20, P233, DOI 10.1063/1.1700384; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; NOCTOR G, 1993, BIOCHIM BIOPHYS ACTA, V1183, P339, DOI 10.1016/0005-2728(93)90237-A; NOCTOR G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P320, DOI 10.1016/S0005-2728(05)80143-4; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; Polivka T, 1999, P NATL ACAD SCI USA, V96, P4914, DOI 10.1073/pnas.96.9.4914; REICH R, 1977, PHOTOCHEM PHOTOBIOL, V26, P11, DOI 10.1111/j.1751-1097.1977.tb07442.x; Renge I, 2000, J PHYS CHEM A, V104, P7452, DOI 10.1021/jp000176n; RIMAI L, 1973, J AM CHEM SOC, V95, P4493, DOI 10.1021/ja00795a005; Robert B, 1999, ADV PHOTOSYNTH, V8, P189; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P39, DOI 10.1016/0167-4838(92)90496-Z; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; RUBAN AV, 1993, J PHOTOCH PHOTOBIO B, V21, P229, DOI 10.1016/1011-1344(93)80188-F; SAITO S, 1983, J RAMAN SPECTROSC, V14, P310, DOI 10.1002/jrs.1250140504; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; TORII H, 1993, J CHEM PHYS, V98, P3697, DOI 10.1063/1.464046; Weesie RJ, 1999, BIOSPECTROSCOPY, V5, P19, DOI 10.1002/(SICI)1520-6343(1999)5:1<19::AID-BSPY4>3.0.CO;2-E	34	93	94	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7785	7789		10.1074/jbc.M110693200	http://dx.doi.org/10.1074/jbc.M110693200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11729205	hybrid			2022-12-25	WOS:000174268000022
J	Hulsmeier, AJ; Gehrig, PM; Geyer, R; Sack, R; Gottstein, B; Deplazes, P; Kohler, P				Hulsmeier, AJ; Gehrig, PM; Geyer, R; Sack, R; Gottstein, B; Deplazes, P; Kohler, P			A major Echinococcus multilocularis antigen is a mucin-type glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EM2 ANTIGEN; METACESTODES; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; CESTODES	The metacestode of Echinococcus multilocularis is surrounded by a carbohydrate-rich laminated layer, which plays a key role in the establishment of the infection in the mammalian host. A major component of the laminated layer is an antigen referred to as Em2(G11). This highly species-specific antigen has been used for serodiagnoses of alveolar echinococcosis and is suggested to contain carbohydrates as major constituents. The results of this work have shown that immunoaffinity-purified Em2(G11) subjected to size-exclusion chromatography eluted mainly in the void volume, indicating a high molecular weight structure of this antigen. Amino acid analysis revealed a large proportion of threonine and proline residues in Em2(G11). The carbohydrate moiety of the antigen was found to be composed of galactose, N-acetylgalactosamine, and N-acetylglucosamine with a ratio of 2.4:1.0:0.5 as determined by gas-chromatography/mass spectrometry. An isotope tag was introduced to the beta-eliminated glycans, and an integrated mass spectrometric O-glycan profiling and sequencing approach was employed to obtain detailed sequence and linkage information of the unseparated glycoform. pool. Novel glycoforms containing mucin-type core Gal1-3GalNAc and branched core structures attached to both serine and threonine residues are described. The data presented reveal that the Em2(G11) antigen is a mucin-type glycosylated protein.	Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Bern, Inst Parasitol, CH-3012 Bern, Switzerland	University of Zurich; University of Zurich; Justus Liebig University Giessen; University of Bern	Kohler, P (corresponding author), Univ Zurich, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.	pkoehler@vetparas.unizh.ch		Hulsmeier, Andreas J./0000-0001-6987-8979; Sack, Ragna/0000-0003-0963-8089				Ammann RW, 1996, GASTROENTEROL CLIN N, V25, P655, DOI 10.1016/S0889-8553(05)70268-5; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dai WJ, 2001, INFECT IMMUN, V69, P6074, DOI 10.1128/IAI.69.10.6074-6083.2001; Dell A, 2001, SCIENCE, V291, P2351, DOI 10.1126/science.1058890; DENNIS RD, 1992, EUR J BIOCHEM, V207, P1053, DOI 10.1111/j.1432-1033.1992.tb17142.x; DEPLAZES P, 1991, PARASITOLOGY, V103, P41, DOI 10.1017/S0031182000059278; Eckert J, 1998, ZOONOSES, P689; FERGUSON MAJ, 1993, GLYCOBIOLOGY, V125, P349; GEYER R, 1994, METHOD ENZYMOL, V230, P86; GOTTSTEIN B, 1985, PARASITE IMMUNOL, V7, P201, DOI 10.1111/j.1365-3024.1985.tb00070.x; GOTTSTEIN B, 1995, PARASITOL TODAY, V11, P320, DOI 10.1016/0169-4758(95)80184-7; GOTTSTEIN B, 1994, CLIN EXP IMMUNOL, V96, P245, DOI 10.1111/j.1365-2249.1994.tb06549.x; KHOO K-H, 1991, Glycobiology, V1, P163, DOI 10.1093/glycob/1.2.163; KILEJIAN A, 1971, COMP BIOCHEM PHYSIOL, V40, P25, DOI 10.1016/0305-0491(71)90058-7; Lawton P, 1997, EXP PARASITOL, V87, P142, DOI 10.1006/expr.1997.4190; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; PERSAT F, 1992, J BIOL CHEM, V267, P8764; Pfister M, 2001, CLIN CHEM LAB MED, V39, P527, DOI 10.1515/CCLM.2001.088; Siles-Lucas M, 1998, MOL BIOCHEM PARASIT, V91, P281, DOI 10.1016/S0166-6851(97)00208-9; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; Tsuboi S, 2001, BIOESSAYS, V23, P46, DOI 10.1002/1521-1878(200101)23:1<46::AID-BIES1006>3.3.CO;2-V; Van den Steen PE, 2000, TRENDS GLYCOSCI GLYC, V12, P35, DOI 10.4052/tigg.12.35; VANHALBEEK H, 1994, GLYCOBIOLOGY, V4, P203, DOI 10.1093/glycob/4.2.203; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	28	65	65	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5742	5748		10.1074/jbc.M107161200	http://dx.doi.org/10.1074/jbc.M107161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11729180	hybrid			2022-12-25	WOS:000173989200009
J	Kidd, JF; Pilkington, MF; Schell, MJ; Fogarty, KE; Skepper, JN; Taylor, CW; Thorn, P				Kidd, JF; Pilkington, MF; Schell, MJ; Fogarty, KE; Skepper, JN; Taylor, CW; Thorn, P			Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR; CA2+ SIGNALS; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CYTOCHROME-C; BCL-2 FAMILY; CELLS; TAXOL; MICROTUBULES; OSCILLATIONS	We have characterized the effects of the antimitotic drug paclitaxel (Taxol(TM)) on the Ca2+ signaling cascade of terminally differentiated mouse pancreatic acinar cells. Using single cell fluorescence techniques and whole-cell patch clamping to record cytosolic Ca2+ and plasma membrane Ca2+-dependent Cl- currents, we find that paclitaxel abolishes cytosolic Ca2+ oscillations and in more than half of the cells it also induces a rapid, transient cytosolic Ca2+ response. This response is not affected by removal of extracellular Ca2+ indicating that paclitaxel releases Ca2+ from an intracellular Ca2+ store. Using saponin-permeabilized cells, we show that paclitaxel does not affect Ca2+ release from an inositol trisphosphate-sensitive store. Furthermore, up to 15 min after paclitaxel application, there is no significant effect on either microtubule organization or on endoplasmic reticulum organization. The data suggest a non-endoplasmic reticulum source for the intracellular Ca2+ response. Using the mitochondrial fluorescent dyes, JC-1 and Rhod-2, we show that paclitaxel evoked a rapid decline in the mitochondrial membrane potential and a loss of mitochondrial Ca2+. Cyclosporin A, a blocker of the mitochondrial permeability transition pore, blocked both the paclitaxel-induced loss of mitochondrial Ca2+ and the effect on Ca2+ spikes. We conclude that paclitaxel exerts rapid effects on the cytosolic Ca2+ signal via the opening of the mitochondrial permeability transition pore. This work indicates that some of the more rapidly developing side effects of chemotherapy might be due to an action of antimitotic drugs on mitochondrial function and an interference with the Ca2+ signal cascade.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Univ Massachusetts, Sch Med, Dept Physiol, Biomed Imaging Grp, Worcester, MA USA; Univ Cambridge, Dept Anat, Cambridge CB2 1QJ, England	University of Cambridge; University of Massachusetts System; University of Massachusetts Worcester; University of Cambridge	Thorn, P (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	pt207@cus.cam.ac.uk	Thorn, Peter/F-7030-2010; Taylor, Colin/G-2447-2010	Thorn, Peter/0000-0002-3228-770X; Schell, Michael/0000-0003-1553-3582; Taylor, Colin/0000-0001-7771-1044				Andre N, 2000, CANCER RES, V60, P5349; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Correa V, 2001, MOL PHARMACOL, V59, P1206, DOI 10.1124/mol.59.5.1206; Fogarty KE, 2000, J BIOL CHEM, V275, P22487, DOI 10.1074/jbc.M909402199; Fogarty KE, 2000, BIOPHYS J, V78, P2298, DOI 10.1016/S0006-3495(00)76776-2; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Haldar S, 1997, CANCER RES, V57, P229; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kidd JF, 1999, J PHYSIOL-LONDON, V520, P187, DOI 10.1111/j.1469-7793.1999.00187.x; Kidd JF, 2001, PFLUG ARCH EUR J PHY, V441, P489, DOI 10.1007/s004240000451; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; LEE C, 1989, J CELL BIOL, V109, P2045, DOI 10.1083/jcb.109.5.2045; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perkins CL, 2000, CANCER RES, V60, P1645; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; POSTMA TJ, 1995, ANN ONCOL, V6, P489, DOI 10.1093/oxfordjournals.annonc.a059220; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; ROWINSKY EK, 1997, SEMIN ONCOL, V24; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Smaili SS, 2001, J BIOL CHEM, V276, P23329, DOI 10.1074/jbc.M100989200; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1993, J GEN PHYSIOL, V66, P185; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Tong AW, 2000, AM J CLIN ONCOL-CANC, V23, P463, DOI 10.1097/00000421-200010000-00007; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; WIERNIK PH, 1987, CANCER RES, V47, P2486; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	42	156	165	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6504	6510		10.1074/jbc.M106802200	http://dx.doi.org/10.1074/jbc.M106802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11724773	hybrid			2022-12-25	WOS:000173989200107
J	Gubitz, AK; Mourelatos, Z; Abel, L; Rappsilber, J; Mann, M; Dreyfuss, G				Gubitz, AK; Mourelatos, Z; Abel, L; Rappsilber, J; Mann, M; Dreyfuss, G			Gemin5, a novel WD repeat protein component of the SMN complex that binds Sm proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DISEASE GENE-PRODUCT; POLYACRYLAMIDE GELS; SNRNP BIOGENESIS; COILED BODIES; SURVIVAL; IDENTIFICATION; POMBE; GEMS; ORTHOLOGUE	The survival of motor neurons (SMN) protein is the product of the disease gene of spinal muscular atrophy and is found both in the cytoplasm and the nucleus, where it is concentrated in gems. SMN is part of a multiprotein complex that includes Gemin2, Gemin3, and Gemin4. The SMN complex plays an important role in the cytoplasmic assembly of small nuclear ribonucleoproteins (snRNPs) and likely other RNPs in pre-mRNA splicing and in the assembly of transcriptosomes. Here, we report the identification of an additional component of the SMN complex, a novel WD repeat protein termed Gemin5. Gemin5 binds SMN directly and is a component of the SMN complex. Furthermore, Gemin5 interacts with several of the snRNP core proteins including SmB, SmD1, SmD2, SmD3, and SmE, suggesting that it participates in the activities of the SMN complex in snRN-P assembly. Immunolocalization studies demonstrate that Gemin5 is found in the cytoplasm and in the nucleus, where it colocalizes with SMN in gems. The presence of 13 W-D repeat domains in the amino-terminal half of Gemin5 and a coiled-coil motif near its carboxyl terminus indicate that it may form a large heteromeric complex and engage in multiple interactions.	Univ Penn, Howard Hughes Med Inst, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ So Denmark, Dept Biochem & Mol Biol, Prot Interact Lab, DK-5230 Odense, Denmark	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Southern Denmark	Dreyfuss, G (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.		Rappsilber, Juri/B-7265-2015; Rappsilber, Juri/ABF-3328-2020; Dreyfuss, Gideon/D-1218-2013; Mann, Matthias/A-3454-2013	Rappsilber, Juri/0000-0001-5999-1310; Dreyfuss, Gideon/0000-0001-8129-8774; Mann, Matthias/0000-0003-1292-4799; Mourelatos, Zissimos/0000-0002-9852-1845	NINDS NIH HHS [K08 NS02199, NS 40575] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040575, K08NS002199] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrade MA, 2000, J MOL BIOL, V298, P521, DOI 10.1006/jmbi.2000.3684; Asano S, 2001, GENES CELLS, V6, P225, DOI 10.1046/j.1365-2443.2001.00416.x; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; Tucker KE, 2001, J CELL BIOL, V154, P293, DOI 10.1083/jcb.200104083; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	47	117	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5631	5636		10.1074/jbc.M109448200	http://dx.doi.org/10.1074/jbc.M109448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714716	hybrid			2022-12-25	WOS:000173962900139
J	Jeanson, L; Mouscadet, JF				Jeanson, L; Mouscadet, JF			Ku represses the HIV-1 transcription - Identification of a putative Ku binding site homologous to the mouse mammary tumor virus Nre1 sequence in the HIV-1 long terminal repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; NF-KAPPA-B; DNA-BINDING; V(D)J RECOMBINATION; T-ANTIGEN; AUTOANTIGEN; ELEMENT; ACTIVATION; PURIFICATION	Ku has been implicated in nuclear processes, including DNA break repair, transcription, V(D)J recombination, and telomere maintenance. Its mode of action involves two distinct mechanisms: one in which a nonspecific binding occurs to DNA ends and a second that involves a specific binding to negative regulatory elements involved in transcription repression. Such elements were identified in mouse mammary tumor virus and human T cell leukemia virus retroviruses. The purpose of this study was to investigate a role for Ku in the regulation of human immunodeficiency virus (HIV)-1 transcription. First, HIV-1 LTR activity was studied in CHO-K1 cells and in CHO-derived xrs-6 cells, which are devoid of Ku80. LTR-driven expression of a reporter gene was significantly increased in xrs-6 cells. This enhancement was suppressed after re-expression of Ku80. Second, transcription of HIV-1 was followed in U1 human cells that were depleted in Ku by using a Ku80 antisense RNA. Ku depletion led to a increase of both HIV-1 mRNA synthesis and viral production compared with the parent cells. These results demonstrate that Ku acts as a transcriptional repressor of HIV-1 expression. Finally, a putative Ku-specific binding site was identified within the negative regulatory region of the HIV-1 long terminal repeat, which may account for this repression of transcription.	Inst Gustave Roussy, CNRS, UMR8532, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Mouscadet, JF (corresponding author), Inst Gustave Roussy, CNRS, UMR8532, PR2,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jfm@igr.fr						Baekelandt V, 2000, J VIROL, V74, P11278, DOI 10.1128/JVI.74.23.11278-11285.2000; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Galande S, 2000, CRIT REV EUKAR GENE, V10, P63; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hoover T, 1996, NUCLEIC ACIDS RES, V24, P1895, DOI 10.1093/nar/24.10.1895; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kameoka M, 1999, BIOCHEM BIOPH RES CO, V262, P285, DOI 10.1006/bbrc.1999.1146; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Liu YZ, 1997, BIOCHEM J, V322, P155, DOI 10.1042/bj3220155; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marangoni E, 2000, CANCER GENE THER, V7, P339, DOI 10.1038/sj.cgt.7700111; MAY G, 1991, J BIOL CHEM, V266, P3052; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Nishishita T, 1998, J BIOL CHEM, V273, P10901, DOI 10.1074/jbc.273.18.10901; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; Pedley J, 1998, MELANOMA RES, V8, P471, DOI 10.1097/00008390-199812000-00001; Petroski MD, 1998, J VIROL, V72, P8181, DOI 10.1128/JVI.72.10.8181-8190.1998; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; Sadji Z, 2000, CELL SIGNAL, V12, P745, DOI 10.1016/S0898-6568(00)00126-1; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2001, P NATL ACAD SCI USA, V98, P9605, DOI 10.1073/pnas.171211398; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662	56	32	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4918	4924		10.1074/jbc.M110830200	http://dx.doi.org/10.1074/jbc.M110830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11733502	hybrid			2022-12-25	WOS:000173962900050
J	Rao, US; Steimle, RE; Balachandran, P				Rao, US; Steimle, RE; Balachandran, P			Activation of large conductance sodium channels upon expression of amiloride-sensitive sodium channel in Sf9 insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; ION CHANNELS; FUNCTIONAL-CHARACTERIZATION; HUMAN-DISEASES; REGULATOR; ENAC; SUBUNITS; MEMBRANE; INHIBITION; TRANSPORT	The amiloride-sensitive epithelial sodium channels (ENaC) mediate Na+ reabsorption in epithelial tissues including distal nephron, colon, lung, and secretory glands and plays a critical role in pathophysiology of hypertension and cystic fibrosis. The ENaC is a multimeric protein composed of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits. To study the biochemical properties of the channel, the subunit cDNAs of rat colon ENaC (rENaC) were subcloned into baculoviruses, and the corresponding proteins were expressed in Sf9 insect cells. The functional characteristics of the expressed rENaC were studied in planar lipid bilayers. The results show that expression of alpha-rENaC and alphabetagamma-rENaC in Sf9 insect cells results in the generation of cation-selective large conductance channels. Although the large conductance channels observed in the alpha-rENaC-containing membranes were unaffected by amiloride, the large conductance channels found in alphabetagamma-rENaC complex-containing membranes exhibited voltage-dependent flickering in the presence of micromolar amiloride. Possible implications of these observations are discussed.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rao, US (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525, Omaha, NE 68198 USA.	usrao@unmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051529, R01DK051529] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Benos DJ, 1996, KIDNEY INT, V49, P1632, DOI 10.1038/ki.1996.237; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chan LN, 2000, BIOCHEM BIOPH RES CO, V276, P40, DOI 10.1006/bbrc.2000.3426; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PARKER EM, 1991, J BIOL CHEM, V266, P519; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rao US, 2000, ANAL BIOCHEM, V286, P206, DOI 10.1006/abio.2000.4861; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; Rossier B C, 1994, Curr Opin Nephrol Hypertens, V3, P487, DOI 10.1097/00041552-199409000-00003; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SARIBANSOHRABY S, 1986, AM J PHYSIOL, V250, pC175, DOI 10.1152/ajpcell.1986.250.2.C175; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Schild L, 1996, NEPHROLOGIE, V17, P395; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TOWNSEND C, 1995, J MEMBRANE BIOL, V147, P121; VOLKMAN LE, 1995, SCIENCE, V269, P1834, DOI 10.1126/science.7569919; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; Yang BX, 1997, BIOCHEMISTRY-US, V36, P7625, DOI 10.1021/bi970231r	55	5	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4900	4905		10.1074/jbc.M108258200	http://dx.doi.org/10.1074/jbc.M108258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11733494	hybrid			2022-12-25	WOS:000173962900047
J	Tisdale, EJ				Tisdale, EJ			Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase c mu lambda and plays a role in microtubule dynamics in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BINDING PROTEIN; MEMBRANE-TRANSPORT; VESICLE FORMATION; IN-VITRO; RAB2; LOCALIZATION; ACTIN; ZETA; IDENTIFICATION	The small GTPase Rab2 immunolocalizes to vesicular tubular clusters (VTCs) that function as transport complexes carrying cargo between the endoplasmic reticulum and the Golgi complex. Our previous studies showed that Rab2 promotes vesicle formation from VTCs and that the released vesicles are enriched in P-coat protein, protein kinase C iota/lambda (PKCiota/lambda), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the recycling protein p53/gp58. Because PKCiota/lambda kinase activity was necessary for vesicle formation, a search was initiated to identify the substrate(s) that potentiate Rab2 function within VTCs. In this study, we found that PKCiota/lambda phosphorylates GAPDH. Moreover, GAPDH interacts directly with the PKCiota/lambda regulatory domain. Based on numerous observations that show (beta-COP) GAPDH associates with cytoskeletal elements, we examined the role of phospho-GAPDH in promoting microtubule (MT) binding to membrane. Using a quantitative microsomal binding assay, we found that membrane association of beta-tubulin was dependent on phosphoGAPDH and was blocked by reagents that interfere with Rab2-dependent GAPDH membrane recruitment or with PKCiota/lambda kinase activity. Furthermore, normal rat kidney cells transfected with a constitutively activated form of Rab2 (Q65L) or with our anti-GAPDH polyclonal antibody displayed a dramatic change in MT organization. These combined results suggest that Rab2 stimulated PKCiota/lambda and GAPDH recruitment to VTCs, and the subsequent PKCiota/lambda phosphorylation of GAPDH ultimately influences MT dynamics in the early secretory pathway.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.							ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BREWER C, 1995, J CELL SCI, V108, P1343; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Duclos-Vallee JC, 1998, J GEN VIROL, V79, P1665, DOI 10.1099/0022-1317-79-7-1665; DURRIEU C, 1987, MOL CELL BIOCHEM, V74, P55; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HARRIS JI, 1976, ENZYMES, V13, P1; Hessler RJ, 1998, J LEUKOCYTE BIOL, V63, P331, DOI 10.1002/jlb.63.3.331; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kaneda M, 1997, J BIOCHEM-TOKYO, V122, P1233; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LUCOCQ J, 1991, J CELL SCI, V100, P753; MACRAE TH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P145, DOI 10.1016/0167-4838(92)90001-T; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Reiss N, 1996, BIOCHEM MOL BIOL INT, V38, P711; Reiss N, 1996, BIOCHEM MOL BIOL INT, V40, P1191; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; TACHIBANA K, 1992, BIOCHEM INT, V28, P181; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; WOLF M, 1986, J BIOL CHEM, V261, P3327	53	125	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3334	3341		10.1074/jbc.M109744200	http://dx.doi.org/10.1074/jbc.M109744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724794	hybrid			2022-12-25	WOS:000173688000038
J	Kruger, JM; Fukushima, T; Cherepanov, V; Borregaard, N; Loeve, C; Shek, C; Sharma, K; Tanswell, AK; Chow, CW; Downey, GP				Kruger, JM; Fukushima, T; Cherepanov, V; Borregaard, N; Loeve, C; Shek, C; Sharma, K; Tanswell, AK; Chow, CW; Downey, GP			Protein-tyrosine phosphatase MEG2 is expressed by human neutrophils - Localization to the phagosome and activation by polyphosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINALDEHYDE-BINDING PROTEIN; RESPIRATORY-DISTRESS SYNDROME; SH2 DOMAINS; SUBCELLULAR-LOCALIZATION; RECEPTOR-BETA; GROWTH-FACTOR; LUNG INJURY; PHOSPHORYLATION; CELLS; PATHWAY	Signaling pathways involving reversible tyrosine phosphorylation are essential for neutrophil antimicrobial responses. Using reverse transcriptase PCR, expression of the protein-tyrosine phosphatase MEG2 by peripheral neutrophilic polymorphonuclear leukocytes (PMN) was identified. Polyclonal antibodies against MEG2 were developed that confirmed expression of MEG2 protein by PMN. Through a combination of immunofluorescence and cell fractionation followed by Immunoblotting, we determined that MEG2 is predominantly cytosolic with components present in secondary and tertiary granules and secretory vesicles. MEG2 activity, as determined by immunoprecipitation and in vitro phosphatase assays, is inhibited after exposure of cells to the particulate stimulant opsonized zymosan or to phorbol 12-myristate 13-acetate but largely unaffected by the chemoattractant N-formyl-methionyl-leucyl-phenyalanine. Studies using bacterially expressed glutathione S-transferase MEG2 fusion protein indicate that cysteine 515 is essential for catalytic activity, whereas the noneatalytic (N-terminal) domain of MEG2 negatively regulates the enzymatic activity of the C-terminal phosphatase domain. The activity of MEG2 is enhanced by specific polyphosphoinositides with the order of potency being phosphatidylinositol (PI) 4,5-diphosphate > PI 3,4,5-triphosphate > PI 4-phosphate. MEG2 associates at an early stage with nascent phagosomes. Taken together, our results indicate that MEG2 is a polyphosphoinositide-activated tyrosine phosphatase that may be involved in signaling events regulating phagocytosis, an essential antimicrobial function in the innate immune response.	Univ Toronto, Div Clin Sci, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Toronto Gen Hosp, Res Inst,Hlth Network, Div Respirol, Toronto, ON M5G 1L7, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Copenhagen Hosp, Ringshosp, Dept Hematol, DK-2100 Copenhagen, Denmark	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Copenhagen	Downey, GP (corresponding author), Univ Toronto, Div Clin Sci, Dept Med, Med Sci Bldg,Rm 6264,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Downey, Gregory P/0000-0003-3253-5862	Canadian Institutes of Health Research [15276] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; BANGA JP, 1984, SCAND J IMMUNOL, V19, P11, DOI 10.1111/j.1365-3083.1984.tb00895.x; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHESTER JF, 1985, AM J PATHOL, V121, P284; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CRABB JW, 1988, J BIOL CHEM, V263, P18678; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; CRABB JW, 1988, J BIOL CHEM, V263, P18688; DALCHAU R, 1980, EUR J IMMUNOL, V10, P737, DOI 10.1002/eji.1830101003; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Dong Q, 1999, J IMMUNOL, V162, P3220; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; EISSMANN G, 1984, INFLAMMATION S, V8, pS3; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FUJISHIMA S, 1995, INTENS CARE MED, V21, P277, DOI 10.1007/BF01701489; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GRINSTEIN S, 1991, AM J PHYSIOL, V260, pC1019, DOI 10.1152/ajpcell.1991.260.5.C1019; GROPPE JC, 1993, ANAL BIOCHEM, V210, P337, DOI 10.1006/abio.1993.1205; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HASLETT C, 1985, AM J PATHOL, V119, P101; Hawkins CL, 1997, BBA-MOL BASIS DIS, V1360, P84, DOI 10.1016/S0925-4439(96)00069-5; Hundt M, 1997, EUR J IMMUNOL, V27, P3532, DOI 10.1002/eji.1830271255; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KLAUSNER JM, 1988, ANN SURG, V208, P761, DOI 10.1097/00000658-198812000-00015; KOBAYASHI K, 1995, J BIOCHEM, V117, P1156, DOI 10.1093/oxfordjournals.jbchem.a124838; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Kurose I, 1997, AM J PHYSIOL-HEART C, V272, pH2976, DOI 10.1152/ajpheart.1997.272.6.H2976; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; MCGREGOR PE, 1994, BIOCHEM BIOPH RES CO, V198, P359, DOI 10.1006/bbrc.1994.1050; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OMARY MB, 1980, J EXP MED, V152, P842, DOI 10.1084/jem.152.4.842; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; SCHMELING DJ, 1989, SURGERY, V106, P195; SEIMIYA H, 1995, ONCOGENE, V11, P2047; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Tidow N, 1999, EXP HEMATOL, V27, P1038, DOI 10.1016/S0301-472X(99)00036-3; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; WANDALL JH, 1985, SCAND J GASTROENTERO, V20, P1151, DOI 10.3109/00365528509088887; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	57	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2620	2628		10.1074/jbc.M104550200	http://dx.doi.org/10.1074/jbc.M104550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711529	hybrid			2022-12-25	WOS:000173421500033
J	Liu, HY; Nefsky, BS; Walworth, NC				Liu, HY; Nefsky, BS; Walworth, NC			The Ded1 DEAD box helicase interacts with Chk1 and Cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; DROSOPHILA-OOGENESIS; PROTEIN-SYNTHESIS; RNA HELICASE; TRANSLATION	Ded1 is a fission yeast DEAD box protein involved in translation. We isolated Ded1 in a screen for multi-copy suppressors of a cold-sensitive, loss-of-function mutant of the cyclin-dependent kinase Cdc2. The checkpoint protein kinase Chk1, required for cell cycle arrest in response to DNA damage, was also isolated in this screen. Ded1 interacts with Chk1 in a two-hybrid screen, and this physical interaction can be recapitulated in Schizosaccharomyces pombe. The Ded1 polypeptide is modified in response to heat shock and depletion of carbon source. These two stressors appear to cause different modifications. Thus, the Ded1 protein appears to respond to particular types of cellular stress and may influence the activity of Cdc2 as a result.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Grad Program Microbiol & Mol Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Walworth, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.	walworna@umdnj.edu		Walworth, Nancy/0000-0001-5940-8236	NIGMS NIH HHS [GM53194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Daga RR, 1999, J CELL SCI, V112, P3137; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; Forbes KC, 1998, GENETICS, V150, P1361; Ghabrial A, 1999, NAT CELL BIOL, V1, P354, DOI 10.1038/14046; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Grallert B, 2000, J CELL SCI, V113, P1447; Harlow E., 1988, ANTIBODIES LAB MANUA; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Kawamukai M, 1999, BBA-GENE STRUCT EXPR, V1446, P93, DOI 10.1016/S0167-4781(99)00071-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Shieh JC, 1998, MOL BIOL CELL, V9, P311, DOI 10.1091/mbc.9.2.311; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; Styhler S, 1998, DEVELOPMENT, V125, P1569; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	27	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2637	2643		10.1074/jbc.M109016200	http://dx.doi.org/10.1074/jbc.M109016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711540	hybrid			2022-12-25	WOS:000173421500035
J	Hihi, AK; Gao, Y; Hekimi, S				Hihi, AK; Gao, Y; Hekimi, S			Ubiquinone is necessary for Caenorhabditis elegans development at mitochondrial and non-mitochondrial sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-Q BIOSYNTHESIS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; IDENTIFICATION; CLK-1; YEAST; COQ3; RESPIRATION; EXPRESSION	Ubiquinone (UQ) is a lipid co-factor that is involved in numerous enzymatic processes and is present in most cellular membranes. In particular, UQ is a crucial electron carrier in the mitochondrial respiratory chain. Recently, it was shown that clk-1 mutants of the nematode worm Caenorhabditis elegans do not synthesize UQ(9) but instead accumulate demethoxyubiquinone (DMQ(9)), a biosynthetic precursor of UQ(9) (the subscript refers to the length of the isoprenoid side chain). DMQ(9) is capable of carrying out the function of UQ(9) in the respiratory chain, as demonstrated by the functional competence of mitochondria isolated from clk-1 mutants, and the ability of DMQ(9) to act as a co-factor for respiratory enzymes in vitro. However, despite the presence of functional mitochondria, clk-1 mutant worms fail to complete development when feeding on bacteria that do not produce UQ(8). Here we show that clk-1 mutants cannot grow on bacteria producing only DMQ(8) and that worm coq-3 mutants, which produce neither UQ(9) nor DMQ(9), arrest development even on bacteria producing UQ(8). These results indicate that UQ is required for nematode development at mitochondrial and non-mitochondrial sites and that DMQ cannot functionally replace UQ at those non-mitochondrial sites.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; BRENNER S, 1974, GENETICS, V77, P71; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gupta S, 2000, FEMS MICROBIOL LETT, V182, P51, DOI 10.1111/j.1574-6968.2000.tb08872.x; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Macinga DR, 1998, J BACTERIOL, V180, P128, DOI 10.1128/JB.180.1.128-135.1998; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Mello C, 1995, METHOD CELL BIOL, V48, P451; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Morre DM, 2000, J EXP BIOL, V203, P1513; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; SIEBERT M, 1994, MICROBIOL-SGM, V140, P897, DOI 10.1099/00221287-140-4-897; Soballe B, 1999, MICROBIOL-SGM, V145, P1817, DOI 10.1099/13500872-145-8-1817; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247; Zeng H, 1998, J BACTERIOL, V180, P3681, DOI 10.1128/JB.180.14.3681-3685.1998; Zhang HT, 2000, J BACTERIOL, V182, P6243, DOI 10.1128/JB.182.21.6243-6246.2000	30	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2202	2206		10.1074/jbc.M109034200	http://dx.doi.org/10.1074/jbc.M109034200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706003	hybrid			2022-12-25	WOS:000173421300080
J	Lu, CR; Li, Y; Zhao, YL; Xing, GC; Tang, F; Wang, QM; Sun, YH; Wei, HD; Yang, XM; Wu, CS; Chen, JG; Guan, KL; Zhang, CG; Chen, HP; He, FC				Lu, CR; Li, Y; Zhao, YL; Xing, GC; Tang, F; Wang, QM; Sun, YH; Wei, HD; Yang, XM; Wu, CS; Chen, JG; Guan, KL; Zhang, CG; Chen, HP; He, FC			Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway	FASEB JOURNAL			English	Article						intracellular signaling; augmenter of liver regeneration	HEPATIC STIMULATOR SUBSTANCE; FIBROBLAST-GROWTH-FACTOR; LIVER-REGENERATION; COP9 SIGNALOSOME; PROTEIN; GENE; KINASE; RECEPTOR; YEAST; TRANSCRIPTION	Many growth factors and cytokines are involved in liver regeneration. Of them, only hepatopoietin (HPO)/ALR (augmenter of liver regeneration) is a specifically hepatotrophic factor originally identified from the cytosol of regenerating or hyperplastic hepatic cells. Previous reports indicate that extracellular HPO triggers the MAPK pathway by binding its specific receptor on the cell surface. However, its function in the cytosol of hepatocytes is unclear. Here we identified that JAB1 (Jun activation domain-binding protein 1), a co-activator of AP-1, which is essential for liver regeneration, specifically interacts with intracellular HPO. JAB1 colocalizes with HPO in nuclei of hepatic cells or COS-7 cells. As an intracrine factor, the intracellular function of HPO is to increase c-Jun phosphorylation independent of c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) -1 and -2, and leads to potentiation of JAB1-mediated AP-1 activation. Amino acids 1-63 of HPO molecule are sufficient to bind to JAB1, but the full-length HPO is necessary for its intracellular signaling. Taken together, these results elucidate a novel mechanism of intracrine cytokine signaling by specifically modulating the AP-1 pathway through JAB1, in a MAPK-independent fashion.	Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Genom & Proteom, Beijing 100850, Peoples R China; Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Academy of Military Medical Sciences - China; Peking University; Chinese Academy of Sciences; Institute of Biophysics, CAS	He, FC (corresponding author), Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Genom & Proteom, 27 Taiping Rd, Beijing 100850, Peoples R China.	hefc@nic.bmi.ac.cn	Zhao, Yanlin/M-2360-2013; Zhang, Chenggang/B-1480-2009	Zhao, Yanlin/0000-0002-0278-7543; Zhang, Chenggang/0000-0002-4521-3304				Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Gandhi CR, 1999, HEPATOLOGY, V29, P1435, DOI 10.1002/hep.510290522; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HE FH, 1993, HEPATOLOGY, V17, P225, DOI 10.1016/0270-9139(93)90081-W; HENRIK D, 1997, EMBO J, V16, P7032; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; KRITEN LP, 2000, P NATL ACAD SCI USA, V97, P1489; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; YANG XM, 1997, ACTA PHYSL SINICA, V49, P599	29	60	69	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					90	92		10.1096/fj.01-0506fje	http://dx.doi.org/10.1096/fj.01-0506fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11709497				2022-12-25	WOS:000173656600024
J	Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T				Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T			Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis	ONCOGENE			English	Article						DNA methylation; lung neoplasms; endothelin-1; serotonin IB receptor; MS-RDA	BRONCHIAL EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROSTATE-CANCER; GROWTH-FACTOR; CPG ISLANDS; GENE; ENDOTHELIN; HYPERMETHYLATION; AMPLIFICATION; PCR	Aberrantly hypermethylated genes in human lung cancers were searched for by a genome scanning technique, methylation-sensitive-representational difference analysis (MS-RDA). A total of 59 DNA fragments were isolated as those methylated more heavily in either/both of two lung squamous cell carcinoma cell lines, EBC-1 and LK-2, than in a primary culture of normal human bronchial epithelium, NHBE. Thirty-four DNA fragments, whose hypermethylation was confirmed in primary squamous cell carcinomas, were sequenced. By database searches, 17 of them were shown to be located within 2 kb of putative CpG islands, and five of the 17 DNA fragments had transcribed regions of known genes in their vicinities. By RT - PCR of the five genes in the carcinoma cell lines and NHBE, decreased expression of HTR1B (5-hydroxytryptamine receptor 1B) and EDN1 (endothelin-1) was observed. Sequencing after bisulfite modification showed that the CpG island in the promoter region of HTR1B was hypermethylated, while that of EDN1 was not. Demethylation and re-expression of HTR1B were observed after treatment of LK-2 cells with 5-aza-2'-deoxycytidine. In primary lung cancers, decreased mRNA expression of HTR1B was observed in 11 of 20 cases, and that of EDN1 was in 16 of 20 cases. Immunohistochemical analysis of endothelin-1 confirmed that its immunoreactivity was reduced in squamous cell carcinoma cells compared with that in normal bronchial epithelial cells. Considering that endothelin-1 induces apoptosis in melanoma cells and that silencing of endothelin receptor B is observed in prostate cancers, its reduced expression was speculated to confer a growth advantage to lung cancer cells. MS-RDA was shown to isolate DNA fragments that are hypermethylated and silenced, such as HTR1B, and those whose expressions are altered and the methylation statuses outside the promoter region are altered, such as EDN1.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; Baylin SB, 1998, ADV CANCER RES, V72, P141; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; Eguchi K, 1997, CANCER RES, V57, P4913; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Jakowlew SB, 1997, BBA-GENE STRUCT EXPR, V1353, P157, DOI 10.1016/S0167-4781(97)00068-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KADOKAMI Y, 1995, ANAL BIOCHEM, V226, P193, DOI 10.1006/abio.1995.1212; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MARKEWITZ BA, 1995, AM J PHYSIOL-LUNG C, V268, pL192, DOI 10.1152/ajplung.1995.268.2.L192; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; McDowell DG, 1998, NUCLEIC ACIDS RES, V26, P3340, DOI 10.1093/nar/26.14.3340; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nelson JB, 1997, CANCER RES, V57, P35; Nelson JB, 1996, CANCER RES, V56, P663; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Sambrook J., 2000, MOL CLONING, V3rd; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	31	50	56	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7505	7513		10.1038/sj.onc.1204940	http://dx.doi.org/10.1038/sj.onc.1204940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709722				2022-12-25	WOS:000171976900007
J	Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR				Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR			Gene expression profiles of pancreatic cancer and stromal desmoplasia	ONCOGENE			English	Article						pancreatic cancer; microarray; expression profiling; desmoplasia	GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; BREAST-CANCER; APOPTOSIS; PROTEINS; DECORIN; TUMORS; CELLS; ADENOCARCINOMA; IDENTIFICATION	Gene expression studies were undertaken in normal pancreas and pancreatic adenocarcinomas to determine new candidate genes that can potentially be used as markers of the disease. The characteristic desmoplastic stromal reaction of pancreatic adenocarcinoma greatly hampers expression studies in this tumour type, and usually necessitates time-consuming tissue microdissection for enrichment of the tumour cell population. We show that fine needle aspiration of cancer provides a fast and efficient way of obtaining samples highly enriched in tumour cells with sufficient yields of RNA. Using Atlas cancer cDNA arrays with 588 cancer-related genes, we describe gene expression profiles of normal pancreas, bulk pancreatic tumour tissues and pancreatic tumour aspirates containing more than 95% tumour cells. Analysis of bulk tissue specimens revealed differentially expressed genes belonging predominantly to the stromal component of the tumour. This contrasted with the results obtained from tumour-cell enriched samples. Several genes already described in pancreatic cancer (caspase 8, TIMP1, CD9, IL-13) were also differentially expressed in our study. Furthermore, we found dysregulated expression of genes not previously associated with pancreatic adenocarcinoma, such as Rac 1, GLG1, NEDD5, RPL-13a, RPS9 and members of the Wnt5A gene family. In summary, we present a panel of genes newly identified in the pathogenesis of pancreatic adenocarcinoma and demonstrate that fine needle aspirates of the tumour mass are a convenient source of material for gene expression studies in tumours accompanied by desmoplastic reactions.	Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, London W12 0NN, England; Oxford Glycosci Proteome Discovery, Abingdon, Oxon, England; Univ Verona, Dept Surg, I-37100 Verona, Italy; Univ Verona, Dept Pathol, I-37100 Verona, Italy	Cancer Research UK; Imperial College London; University of Verona; University of Verona	Lemoine, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, Hammersmith Campus, London W12 0NN, England.		Terris, Benoit/P-1497-2017; scarpa, aldo/K-6832-2016; Capelli, Patrizio/AEJ-5748-2022; Capelli, Patrizio/AAD-5108-2022	scarpa, aldo/0000-0003-1678-739X; Capelli, Patrizio/0000-0001-9434-3984; SALVIA, Roberto/0000-0002-3514-8473				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Asakura S, 1999, HUM PATHOL, V30, P195, DOI 10.1016/S0046-8177(99)90275-7; Aspinall RJ, 1999, ANN ONCOL, V10, P188, DOI 10.1023/A:1008315003875; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Cardone A, 1997, PANMINERVA MED, V39, P174; Chen FW, 1998, MOL GENET METAB, V64, P271, DOI 10.1006/mgme.1998.2718; EMMERTBUCK MR, 1996, SCIENCE, V274, P988; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gress TM, 1998, DIGESTION, V59, P625, DOI 10.1159/000007567; Gress TM, 1996, ONCOGENE, V13, P1819; Gress TM, 1997, GENE CHROMOSOME CANC, V19, P97, DOI 10.1002/(SICI)1098-2264(199706)19:2<97::AID-GCC5>3.0.CO;2-V; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; HALVORSEN TB, 1989, J CLIN PATHOL, V42, P162, DOI 10.1136/jcp.42.2.162; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; IOZZO RV, 1995, CANCER RES, V55, P3495; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kohl R, 2000, J BIOL CHEM, V275, P15741, DOI 10.1074/jbc.M903271199; Kornmann M, 1999, ANTICANCER RES, V19, P125; Lemoine NR, 1997, DIGESTION, V58, P550, DOI 10.1159/000201500; Lohr M, 2001, CANCER RES, V61, P550; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ryu B, 2001, CANCER RES, V61, P1833; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sirivatanauksorn Y, 1999, J PATHOL, V189, P150, DOI 10.1002/(SICI)1096-9896(199910)189:2<150::AID-PATH451>3.0.CO;2-G; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Virkajarvi N, 1998, HISTOPATHOLOGY, V33, P432, DOI 10.1046/j.1365-2559.1998.00553.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	39	153	164	2	17	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7437	7446		10.1038/sj.onc.1204935	http://dx.doi.org/10.1038/sj.onc.1204935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704875				2022-12-25	WOS:000171894200018
J	Atlas, E; Stramwasser, M; Mueller, CR				Atlas, E; Stramwasser, M; Mueller, CR			A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element	ONCOGENE			English	Article						BRCA1; expression; transcription; CREB; sporadic breast cancer	SPORADIC BREAST-CANCER; RESPONSE ELEMENT; BINDING PROTEIN; OVARIAN-CANCER; MESSENGER-RNA; GENE-EXPRESSION; CPG ISLAND; METHYLATION; CELLS; ACTIVATION	Transcriptional regulation of the BRCA1 proximal promoter has been suggested to play a role in the decreased expression of BRCA1 observed in sporadic breast cancer. Computer analysis of the sequence of the proximal promoter reveals the presence of a potential CREB site. We have identified CREB/ATF-1 as the factor interacting with this site in nuclear extracts from MCF-7 and T-47D cells. This site is shown to be important for the constitutive expression of the promoter in these cells, as well as in Hep G2 cells. Despite the presence of this site, the BRCA1 promoter is not responsive to cAMP induction. It appears that CREB acts as a constitutive positive element for BRCA1 expression and that any mechanism inactivating CREB function would have a dramatic effect on BRCA1 expression.	Queens Univ, Dept Biochem, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.	muellerc@post.queensu.ca						Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cui JQ, 1998, ONCOL REP, V5, P591; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Dobrovic A, 1997, CANCER RES, V57, P3347; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Husain A, 1998, CANCER RES, V58, P1120; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7110	7114		10.1038/sj.onc.1204890	http://dx.doi.org/10.1038/sj.onc.1204890			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704836				2022-12-25	WOS:000171739300015
J	Itoh, T; Nichols, A; Linn, S				Itoh, T; Nichols, A; Linn, S			Abnormal regulation of DDB2 gene expression in xeroderma pigmentosum group E strains	ONCOGENE			English	Article						DDB2; xeroderma pigmentosum; damage-specific DNA binding protein unscheduled DNA synthesis; p48; skin carcinogenesis	DNA-BINDING PROTEIN; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; ATAXIA-TELANGIECTASIA; DAMAGED DNA; EXCISION-REPAIR; UV-IRRADIATION; CELLS; P48; PHENOTYPE	A damage-specific DNA binding protein (DDB) activity is absent from a subset (DDB-) of cells from individuals initially classified as group E of xeroderma pigmentosum (XP), a hereditary, photosensitive disease with a high incidence of skin malignancies. In these cases, mutations have been identified in the DDB2 gene (DDB2(-)) that codes for the small subunit, p48, of the DDB heterodimer. In four DDB2(-) strains, neither p48 nor DDB activity were observed before or after UV-irradiation, despite an unusually strong up-regulation of DDB2 mRNA levels after UV-irradiation. In a fifth strain, XP82TO, p48 was detectable and both DDB2 mRNA and p48 levels were more up-regulated after UV-irradiation than in normal primary cells. Moreover, DDB activity also became apparent after irradiation. XP82TO showed very mild clinical manifestations compared with the other DDB- patients. These results, coupled with our findings that most, if not all DDB+ cells classified as XP-E were misclassified, suggests a direct correlation between DDB2 levels and the XP-E phenotype.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Itoh, T (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059424] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES08196] Funding Source: Medline; NIGMS NIH HHS [GM59424] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1970, MUTAT RES, V9, P507, DOI 10.1016/0027-5107(70)90035-7; Borson ND, 1998, BIOTECHNIQUES, V25, P130, DOI 10.2144/98251rr01; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1996, J INVEST DERMATOL, V107, P349, DOI 10.1111/1523-1747.ep12363303; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; ITOH T, 1994, MUTAT RES, V314, P233, DOI 10.1016/0921-8777(94)90068-X; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KLEIJER WJ, 1973, MUTAT RES, V20, P417, DOI 10.1016/0027-5107(73)90062-6; KONDO S, 1988, J INVEST DERMATOL, V90, P152, DOI 10.1111/1523-1747.ep12462130; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037	37	11	11	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7041	7050		10.1038/sj.onc.1204909	http://dx.doi.org/10.1038/sj.onc.1204909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704828				2022-12-25	WOS:000171739300007
J	Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E				Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E			PKC eta enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells	ONCOGENE			English	Article						PKC eta; cell cycle; cyclin E; cyclin D; p21; MCF-7	PROTEIN-KINASE-C; CAPILLARY ENDOTHELIAL-CELLS; METASTATIC MELANOMA-CELLS; BREAST-CANCER CELLS; CDK INHIBITORS; PHORBOL ESTER; RETINOBLASTOMA PROTEIN; ALTERED EXPRESSION; GROWTH-INHIBITION; PHASE-TRANSITION	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, not much is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that the expression of PKC eta in MCF-7 cells, under the control of a tetracycline-responsive inducible promoter, enhanced cell growth and affected the cell cycle at several points. The induced expression of another PKC isoform, PKC delta, in MCF-7 cells had opposite effects and inhibited their growth. PKC eta expression activated cellular pathways in these cells that resulted in the increased expression of the G1 phase cyclins, cyclin D and cyclin E. Expression of the cyclin-dependent kinase inhibitor p21(WAF1) was also specifically elevated in PKC eta expressing cells, but its overall effects were not inhibitory. Although, the protein levels of the cyclin-dependent kinase inhibitor p27(KIP1) were not altered by the induced expression of PK eta the cyclin E associated Cdk2 kinase activity was in correlation with the p27(KIP1) bound to the cyclin E complex and not by p21(WAF1) binding. PK eta expression enhanced the removal of p27(KIP1) from this complex, and its re-association with the cyclin D/Cdk4 complex. Reduced binding of p27(KIP1) to the cyclin D/Cdk4 complex at early time points of the cell cycle also enhanced the activity of this complex, while at later time points the decrease in bound p21WAF1 correlated with its increased activity in PKC eta -expressing cells. Thus, PKC eta induces altered expression of several cell cycle functions, which may contribute to its ability to affect cell growth.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel	Ben Gurion University	Livneh, E (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.							AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Downward J, 1997, CURR BIOL, V7, P258; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Livneh E, 1996, ONCOGENE, V12, P1545; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MICHIELI P, 1994, CANCER RES, V54, P3391; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHOU W, 1993, J BIOL CHEM, V268, P23041	63	55	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6794	6804		10.1038/sj.onc.1204885	http://dx.doi.org/10.1038/sj.onc.1204885			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709714	Bronze			2022-12-25	WOS:000171551600016
J	Jones, DC; Ding, XH; Daynes, RA				Jones, DC; Ding, XH; Daynes, RA			Nuclear receptor peroxisome proliferator-activated receptor a (PPAR alpha) is expressed in resting murine lymphocytes - The PPAR alpha in T and B lymphocytes is both transactivation and transrepression competent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR VIRUS TEMPLATES; SMOOTH-MUSCLE CELLS; DIFFERENTIAL EXPRESSION; GAMMA AGONISTS; FATTY-ACIDS; TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; GENE; MOUSE	Peroxisome proliferator-activated receptors (PPARs) are transcription factors that belong to the nuclear hormone receptor superfamily. PPARalpha and PPARgamma ligands have been demonstrated to exert anti-inflammatory activities in macrophages by repressing the activities of several transcription factors. PPARgamma is expressed in T lymphocytes and may play a role in cytokine production, cellular proliferation, and susceptibility to apoptosis. Herein, we demonstrate that T and B lymphocytes constitutively express PPARalpha. PPARalpha represents the predominant isoform expressed in lymphocytes, whereas PPARgamma dominates in all cell types of the myeloid lineage. PPARalpha expression was down-regulated following T-cell activation while PPARgamma expression increased under the same activating conditions. PPARalpha expression in T cells may be regulated by microenvironmental factors, because Peyer's patch T cells expressed far greater levels of PPARalpha than T cells isolated from peripheral lymphoid organs. Exposure to specific ligand determined that PPARalpha in lymphocytes can effectively transactivate a peroxisome proliferator response element reporter construct. PPARalpha's ability to regulate endogenous genes, however, required treatment with histone deacetylase inhibitors. Finally, ligand activation of lymphocyte PPARalpha antagonized NF-kappaB. Our observation that a functional PPARalpha exists within T cells and B lymphocytes suggests an expanding role for this nuclear receptor in cells of the immune system.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Daynes, RA (corresponding author), Univ Utah, Sch Med, Dept Pathol, 30 North 1900 East, Salt Lake City, UT 84132 USA.	daynes.office@path.utah.edu			NCI NIH HHS [CA 25917] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07115, DK 55491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA025917, R01CA025917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115, R01DK055491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601; CACERESDITTMAR G, 1995, PHOTOCHEM PHOTOBIOL, V62, P176, DOI 10.1111/j.1751-1097.1995.tb05255.x; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Diep QN, 2000, HYPERTENSION, V36, P851, DOI 10.1161/01.HYP.36.5.851; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; Gerlag DM, 2000, J IMMUNOL, V165, P1652, DOI 10.4049/jimmunol.165.3.1652; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Harris SG, 2001, EUR J IMMUNOL, V31, P1098, DOI 10.1002/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I; Hennebold JD, 1996, AM J PHYSIOL-REG I, V270, pR1296, DOI 10.1152/ajpregu.1996.270.6.R1296; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; Morrison TB, 1999, J CLIN MICROBIOL, V37, P987, DOI 10.1128/JCM.37.4.987-992.1999; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; ONATE SA, 1995, SCIENCE, V270, P1354; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Peters JM, 1996, MOL PHARMACOL, V50, P67; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, J LIPID RES, V37, P907; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Spencer NFL, 1996, EXP GERONTOL, V31, P393, DOI 10.1016/0531-5565(95)02033-0; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sugiyama H, 2000, EUR J IMMUNOL, V30, P3363, DOI 10.1002/1521-4141(2000012)30:12<3363::AID-IMMU3363>3.0.CO;2-B; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zabel MD, 2000, J IMMUNOL, V165, P4437, DOI 10.4049/jimmunol.165.8.4437	61	129	134	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6838	6845		10.1074/jbc.M106908200	http://dx.doi.org/10.1074/jbc.M106908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11726654	hybrid			2022-12-25	WOS:000174104300013
J	Jopling, LA; Sabroe, I; Andrew, DP; Mitchell, TJ; Li, Y; Hodge, MR; Williams, TJ; Pease, JE				Jopling, LA; Sabroe, I; Andrew, DP; Mitchell, TJ; Li, Y; Hodge, MR; Williams, TJ; Pease, JE			The identification, characterization, and distribution of guinea pig CCR4 and epitope mapping of a blocking antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-DERIVED CHEMOKINE; MOLECULAR-CLONING; T-CELLS; EOSINOPHIL FUNCTION; EOTAXIN RECEPTOR; EPITHELIAL-CELLS; DENDRITIC CELLS; IL-8 RECEPTOR; CUTTING EDGE; EXPRESSION	Th2 lymphocytes play a central role in the control and maintenance of allergic inflammation. The chemokine receptor CCR4 is preferentially expressed on the surface of Th2 lymphocytes polarised in vitro. However, CCR4 is found on the surface of a significant proportion of circulating memory T lymphocytes, some of which are capable of producing the Th1-associated cytokine interferon gamma. To investigate the function of CCR4 on guinea pig (gp) T lymphocytes, we identified the open-reading frame of gpCCR4, which encodes a 361-amino acid protein with 88 and 81% amino acid identity to human and murine CCR4 sequences, respectively. Cells transfected with gpCCR4 migrated toward the human and murine orthologues of the CCR4 ligands, macrophage-derived chemokine and thymus and activation-regulated chemokine. Surface expression of CCR4, using an anti-human CCR4 monoclonal antibody, 10E4, was detected on similar to12% of guinea pig peripheral blood T helper cells, and CCR4(+) guinea pig thymocytes were detected in low numbers. However, CCR4(+) T helper cells constituted similar to9% of the T lymphocyte population within the normal guinea pig lung and 52% of the guinea pig bronchoalveolar lavage fluid, which is consistent with a role for CCR4 in T lymphocyte development and trafficking through normal tissues. Subsequent analysis of chimeric chemokine receptors indicated that 10E4, a functional inhibitor of gpCCR4 responses, recognized the amino terminus of CCR4.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Imperial College London; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	j.pease@ic.ac.uk	Pease, James/X-4521-2018; Sabroe, Ian/I-5981-2013; Sabroe, Ian/AAE-5858-2019	Pease, James/0000-0003-3749-0341; Sabroe, Ian/0000-0001-9750-8975; Jopling, Louise/0000-0002-3130-1194				Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Chantry D, 1999, BLOOD, V94, P1890; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V105, P126, DOI 10.1016/S0091-6749(00)90187-8; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Li L, 1999, J IMMUNOL, V162, P2477; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; Schaniel C, 1999, EUR J IMMUNOL, V29, P2934, DOI 10.1002/(SICI)1521-4141(199909)29:09<2934::AID-IMMU2934>3.3.CO;2-H; Struyf S, 1998, J IMMUNOL, V161, P2672; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6864	6873		10.1074/jbc.M109974200	http://dx.doi.org/10.1074/jbc.M109974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724798	hybrid			2022-12-25	WOS:000174104300017
J	Gorbacheva, VY; Lindner, D; Sen, GC; Vestal, DJ				Gorbacheva, VY; Lindner, D; Sen, GC; Vestal, DJ			The interferon (IFN)-induced GTPase, mGBP-2 - Role in IFN-gamma-induced murine fibroblast proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-BINDING-PROTEIN; INDEPENDENT PATHWAYS; RAS TRANSFORMATION; NUCLEOTIDE-BINDING; MX PROTEINS; ACTIVATION; FAMILY; CELLS; IDENTIFICATION; EXPRESSION	To investigate the function of mGBP-2, a member of the interferon (IFN)-induced guanylate-binding protein family of GTPases, NIH 3T3 fibroblasts were generated that constitutively expressed mGBP-2. mGBP-2 induced a faster growth rate, with the highest expressing clones showing approximately a 50% reduction in doubling time. mGBP-2-expressing cells also grew to higher density and exhibited partial loss of contact growth inhibition, as evidenced by the formation of foci in post-confluent cultures. In addition, mGBP-2-expressing cells showed decreased dependence on serum-derived growth factors. However, they did not lose the requirement for anchorage-dependent growth. Finally, NTH 3T3 cells expressing mGBP-2 formed tumors in athymic mice. An mGBP-2 protein carrying a point mutation (S52N) that reduced GTP binding failed to produce these phenotypes when expressed at the same levels as wild type. The additional finding that IFN-gamma treatment of NIH 3T3 cells resulted in an increase in proliferation similar to that observed for mGBP-2 in the absence of other IFN-induced proteins suggests that mGBP-2 may indeed be important for these growth changes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Vestal, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	vestald@ccf.org						Anderson SL, 1999, J INTERF CYTOK RES, V19, P487, DOI 10.1089/107999099313938; ASUNDI VK, 1994, BBA-GENE STRUCT EXPR, V1217, P257, DOI 10.1016/0167-4781(94)90284-4; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boehm U, 1998, J IMMUNOL, V161, P6715; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; BRINCKERHOFF CE, 1985, J IMMUNOL, V134, P3142; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHENG YSE, 1985, J BIOL CHEM, V260, P5834; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cornelissen AMH, 1999, ARCH ORAL BIOL, V44, P541, DOI 10.1016/S0003-9969(99)00037-0; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; GUPTA SL, 1990, INT J CELL CLONING, V8, P92, DOI 10.1002/stem.5530080709; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Han BH, 1998, BBA-PROTEIN STRUCT M, V1384, P373, DOI 10.1016/S0167-4838(98)00034-X; HUNNINGHAKE GW, 1986, AM REV RESPIR DIS, V134, P1025, DOI 10.1164/arrd.1986.134.5.1025; HUNT JS, 1990, J IMMUNOL, V145, P184; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MELIN M, 1989, CELL MOL BIOL, V35, P97; Nantais DE, 1996, J LEUKOCYTE BIOL, V60, P423, DOI 10.1002/jlb.60.3.423; Neun R, 1996, FEBS LETT, V390, P69, DOI 10.1016/0014-5793(96)00628-X; NICOLET CM, 1994, J IMMUNOL, V152, P153; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; QUI RG, 1997, MOL CELL BIOL, V17, P3449; QUI RG, 1995, NATURE, V374, P457; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; Schwemmle M, 1996, J BIOL CHEM, V271, P10304, DOI 10.1074/jbc.271.17.10304; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stickney JT, 2000, MOL BIOL CELL, V11, P2191, DOI 10.1091/mbc.11.7.2191; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; THORNTON SC, 1990, J LEUKOCYTE BIOL, V47, P312, DOI 10.1002/jlb.47.4.312; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Vestal DJ, 1996, BIOCHEM BIOPH RES CO, V224, P528, DOI 10.1006/bbrc.1996.1060; Vestal DJ, 1998, J INTERF CYTOK RES, V18, P977, DOI 10.1089/jir.1998.18.977; Vestal DJ, 2000, J INTERF CYTOK RES, V20, P991, DOI 10.1089/10799900050198435; WYNN TA, 1991, J IMMUNOL, V147, P4384; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	58	66	68	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6080	6087		10.1074/jbc.M110542200	http://dx.doi.org/10.1074/jbc.M110542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726669	hybrid			2022-12-25	WOS:000173989200052
J	Markus, M; Du, ZM; Benezra, R				Markus, M; Du, ZM; Benezra, R			Enhancer-specific modulation of E protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; HEAVY-CHAIN; GENE-TRANSCRIPTION; E2A GENE; MYOD; ACTIVATION; EXPRESSION	Homodimeric complexes of members of the E protein family of basic helix-loop-helix (bHLH) transcription factors are important for tissue-specific activation of genes in B lymphocytes (Bain, G., Gruenwald, S., and Murre, C. (1993) Mol. Cell Biol. 13,3522-3529; Shen, C. P., and Kadesch, T. (1995) Mol. Cell Biol. 15, 4518-4524; Jacobs, Y., et al. (1994) Mol. Cell Biol. 14,4087-4096; Wilson, R. B., et al. (1991) Mol. Cell Biol. 11, 6185-6191). These homodimers, however, have little activity on myogenic enhancers (Weintraub, H., Genetta, T., and Kadesch, T. (1994) Genes Dev. 8, 2203-2211). We report here the identification of a novel cis-acting transcriptional repression domain in the E protein family of bHLH transcription factors. This domain, the Rep domain, is present in each of the known vertebrate E proteins. Extensive mapping analysis demonstrates that this domain is an acidic region of 30 amino acids with a predicted loop structure. Fusion studies indicate that the Rep domain can repress both of the E protein transactivation domains (AD1 and AD2). Physiologically, the Rep domain plays a key role in maintaining E protein homodimers in an inactive state on myogenic enhancers. In addition, we demonstrate that Rep domain mediated repression of AD1 is a necessary for the function of MyoD-E protein heterodimeric complexes. These studies demonstrate that the Rep domain is important for modulating the transcriptional activity of E proteins and provide key insights into both the selectivity and mechanism of action of E protein containing bHLH protein complexes.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org						ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JACOBS Y, 1994, MOL CELL BIOL, V14, P4087, DOI 10.1128/MCB.14.6.4087; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Massari ME, 1996, MOL CELL BIOL, V16, P121; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARK CW, 1992, J BIOL CHEM, V267, P15642; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	27	28	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6469	6477		10.1074/jbc.M110659200	http://dx.doi.org/10.1074/jbc.M110659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11724804	hybrid			2022-12-25	WOS:000173989200102
J	Chen, KS; Jung, YS; Bonagura, CA; Tilley, GJ; Prasad, GS; Sridhar, V; Armstrong, FA; Stout, CD; Burgess, BK				Chen, KS; Jung, YS; Bonagura, CA; Tilley, GJ; Prasad, GS; Sridhar, V; Armstrong, FA; Stout, CD; Burgess, BK			Azotobacter vinelandii ferredoxin I - A sequence and structure comparison approach to alteration of [4Fe-4S]2(+/+) reduction potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; SITE-DIRECTED MUTAGENESIS; 2 4FE-4S CLUSTERS; REDOX POTENTIALS; CHROMATIUM-VINOSUM; ELECTRON-TRANSFER; MODULATION; METALLOPROTEINS; REARRANGEMENT; RUBREDOXIN	The reduction potential (E-0') of the [4Fe-4S](2+/+) clus- ter of Azotobacter vinelandii ferredoxin I (AvFdI) and related ferredoxins is similar to200 mV more negative than the corresponding clusters of Peptostreptococcus asaccharolyticus ferredoxin and related ferredoxins. Previous studies have shown that these differences in E-0' do not result from the presence or absence of negatively charged surface residues or in differences in the types of hydrophobic residues found close to the [4Fe-4S](2+/+) clusters. Recently, a third, quite distinct class of ferredoxins (represented by the structurally characterized Chromatium vinosum ferredoxin) was shown to have a [4Fe-4S](2+/+) cluster with a very negative E-0' similar to that of AvFdI. The observation that the sequences and structures surrounding the very negative E-0' clusters in quite dissimilar proteins were almost identical inspired the construction of three additional mutations in the region of the [4Fe-4S](2+/+) cluster of AvFdI. The three mutations, V19E, P47S, and L44S, that incorporated residues found in the higher E-0' P. asaccharolyticus ferredoxin all led to increases in E-0' for a total of 130 mV with a 94-mV increase in the case of L44S. The results are interpreted in terms of x-ray structures of the FdI variants and show that the major determinant for the large increase in L44S is the introduction of an OH-S bond between the introduced Ser side chain and the Sgamma atom of Cys ligand 42 and an accompanying movement of water.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Irvine Res Unit Macromol Struct, Irvine, CA 92697 USA; Univ Oxford, Dept Chem, Oxford OX1 3QR, England; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Oxford; Scripps Research Institute	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM-48495, GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495, R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; Bard A. J., 1980, ELECTROCHEMICAL METH; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bertini I, 1997, J BIOL INORG CHEM, V2, P114, DOI 10.1007/s007750050114; Bertini I, 1996, PROG BIOPHYS MOL BIO, V66, P43, DOI 10.1016/S0079-6107(96)00016-8; Bian SM, 1996, BIOCHEMISTRY-US, V35, P14544, DOI 10.1021/bi961658l; Carter Jr C. W., 2001, HDB METALLOPROTEINS, V1, P602; Chen KS, 1999, J BIOL CHEM, V274, P36479, DOI 10.1074/jbc.274.51.36479; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; EDMAN ET, 1976, J BIOL CHEM, V251, P3801; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; FUKUYAMA K, 2001, HDB METALLOPROTEINS, V1, P543; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IWAGAMI SG, 1995, PROTEIN SCI, V4, P2562, DOI 10.1002/pro.5560041213; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; Kummerle R, 2001, J BIOL INORG CHEM, V6, P446; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LANGEN R, 1992, J BIOL CHEM, V267, P25625; Li J, 1998, J PHYS CHEM A, V102, P6311, DOI 10.1021/jp980753w; LUCHINAT C, 1994, BIOCHEM BIOPH RES CO, V203, P436, DOI 10.1006/bbrc.1994.2201; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; Meyer J., 2001, HDB METALLOPROTEINS, V1, P505; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; NaraySzabo G, 1997, J BIOL INORG CHEM, V2, P135, DOI 10.1007/s007750050117; PRZYSIECKI CT, 1985, BIOCHEMISTRY-US, V24, P2542, DOI 10.1021/bi00331a022; REES DC, 1985, P NATL ACAD SCI USA, V82, P3082, DOI 10.1073/pnas.82.10.3082; SCHEJTER A, 1984, BIOCHEMISTRY-US, V23, P1081, DOI 10.1021/bi00301a007; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SIEKER LC, 2001, HDB METALLOPROTEINS, V1, P574; SOLA M, 1989, BIOCHEMISTRY-US, V28, P5261, DOI 10.1021/bi00438a051; Soriano A, 1996, BIOCHEMISTRY-US, V35, P12479, DOI 10.1021/bi960974x; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT CD, 2001, HDB METALLOPROTEINS, V1, P560; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; Xiao ZG, 2000, J BIOL INORG CHEM, V5, P75, DOI 10.1007/PL00010656	51	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5603	5610		10.1074/jbc.M108916200	http://dx.doi.org/10.1074/jbc.M108916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11704670	hybrid			2022-12-25	WOS:000173962900136
J	Hachiya, A; Kobayashi, T; Takema, Y; Imokawa, G				Hachiya, A; Kobayashi, T; Takema, Y; Imokawa, G			Biochemical characterization of endothelin-converting enzyme-1 alpha in cultured skin-derived cells and its postulated role in the stimulation of melanogenesis in human epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT-MELANOMA CELLS; HUMAN MELANOCYTES; HUMAN KERATINOCYTES; MESSENGER-RNA; GROWTH-FACTOR; GLYCOSYLATION INHIBITORS; ULTRAVIOLET-RADIATION; SIGNALING MECHANISMS; BIG ENDOTHELIN-1; ENZYME ECE-1	The vasoconstrictive peptide endothelin-1 (ET-1) is expressed in human epidermis at the gene and protein levels and plays an important role in stimulating pigmentation via its increased secretion by keratinocytes following ultraviolet B (UVB) irradiation. However, one or more biological mechanisms underlying the secretion of ET-1 by keratinocytes in human skin have never been evaluated. In mammalian endothelial cells, a membrane-bound neutral metalloproteinase, termed endothelin-converting enzyme (ECE), catalyzes the specific cleavage of the inactive precursor Big ET to produce mature active ET, which leads in turn to the secretion of ET by those cells. To clarify the potential involvement of ECE in the processing and secretion of ET-1 by human keratinocytes, we synthesized the N-terminal peptide of human ECE-1alpha and generated a rabbit polyclonal antibody (alphaPEPT6) that specifically recognizes ECE-1alpha. Reverse transcription PCR and Western blotting analysis revealed that significant expression of ECE-1 transcripts and ECE-1alpha protein occurs in human keratinocytes. When ECE activity was assayed in extracts of human keratinocytes at pHs ranging from 5.0 to 8.0, the enzymatic profile had an optimal neutral pH of 7.0 and was sharply pH-dependent. Furthermore, when extracts of human keratinocytes were treated with alphaPEPT6, ECE activity was significantly reduced compared with extracts treated with the prebleed serum of alphaPEPT6, which supports the notion that ECE-1alpha is a major metalloproteinase with ECE activity in human keratinocytes. The exogenous addition of the pro-inflammatory cytokine interleukin-1alpha significantly increased expression of ECE-1 transcripts in cultured human keratinocytes, which suggests an association with post-inflammatory hyperpigmentation. Collectively, our results demonstrate for the first time that ECE-1alpha is expressed at significant levels in various types of human skin cells (including keratinocytes) and that it plays a constitutive role in the processing and UVB-inducible secretion of ET-1 by human keratinocytes, which leads to the stimulation of pigmentation in the epidermis.	Kao Biol Sci Labs, Haga, Tochigi 3213497, Japan		Imokawa, G (corresponding author), Kao Biol Sci Labs, 2606 Akabane, Haga, Tochigi 3213497, Japan.			Kobayashi, Takeshi/0000-0002-4372-5285				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CORDER R, 1993, J CARDIOVASC PHARM, V22, pS73, DOI 10.1097/00005344-199322008-00021; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; GAHRING L, 1984, P NATL ACAD SCI-BIOL, V81, P1198, DOI 10.1073/pnas.81.4.1198; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Hedley SJ, 1998, PIGM CELL RES, V11, P45, DOI 10.1111/j.1600-0749.1998.tb00710.x; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; IMOKAWA G, 1986, ARCH DERMATOL RES, V278, P352, DOI 10.1007/BF00418162; IMOKAWA G, 1982, CANCER RES, V42, P1994; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITOU Y, 1988, FEBS LETT, V231, P440; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Kadono S, 2001, J INVEST DERMATOL, V116, P571, DOI 10.1046/j.1523-1747.2001.01296.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; LAPORTE S, 1993, J CARDIOVASC PHARM, V22, pS7, DOI 10.1097/00005344-199322008-00004; MISHIMA Y, 1983, J INVEST DERMATOL, V81, P106, DOI 10.1111/1523-1747.ep12542192; OKAZAKI K, 1976, J INVEST DERMATOL, V67, P541, DOI 10.1111/1523-1747.ep12664554; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; RomeroGraillet C, 1997, J CLIN INVEST, V99, P635, DOI 10.1172/JCI119206; ROSDAHL IK, 1978, J INVEST DERMATOL, V70, P143, DOI 10.1111/1523-1747.ep12258559; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TSUBOI R, 1994, J CELL PHYSIOL, V159, P213, DOI 10.1002/jcp.1041590204; TSUBOI R, 1995, FEBS LETT, V371, P188, DOI 10.1016/0014-5793(95)00912-S; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOHN JJ, 1993, J INVEST DERMATOL, V100, P23, DOI 10.1111/1523-1747.ep12349932	42	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5395	5403		10.1074/jbc.M105874200	http://dx.doi.org/10.1074/jbc.M105874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11723113	hybrid			2022-12-25	WOS:000173962900108
J	Soltyk, AM; MacKenzie, CR; Wolski, VM; Hirama, T; Kitov, PI; Bundle, DR; Brunton, JL				Soltyk, AM; MacKenzie, CR; Wolski, VM; Hirama, T; Kitov, PI; Bundle, DR; Brunton, JL			A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; B-SUBUNIT HOMOPENTAMER; FATTY-ACID CONTENT; SHIGA-LIKE TOXINS; ESCHERICHIA-COLI; GLYCOLIPID BINDING; RECEPTOR-BINDING; HYBRID TOXINS; LOCALIZATION; IDENTIFICATION	Escherichia coli verotoxin, also known as Shiga-like toxin, binds to eukaryotic cell membranes via the glycolipid Gb(3) receptors which present the P-k trisaccharide Galalpha(1-4)Galbeta(1-4)Glcbeta. Crystallographic studies have identified three P-k trisaccharide (P-k-glycoside) binding sites per verotoxin 1B subunit (VT1B) monomer while NMR studies have identified binding of P-k-glycoside only at site 2. To understand the basis for this difference, we studied binding of wild type VT1B and VT1B mutants, defective at one or more of the three sites, to P-k-glycoside and pentavalent P-k trisaccharide (pentaSTARFISH) in solution and Gb(3) presented on liposomal membranes using surface plasmon resonance. Site 2 was the key site in terms of free trisaccharide binding since mutants altered at sites 1 and 3 bound this ligand with wild type affinity. However, effective binding of the pentaSTARFISH molecule also required a functional site 3, suggesting that site 3 promotes pentavalent binding of linked trisaccharides at site 1 and site 2. Optimal binding to membrane-associated Gb(3) involved all three sites. Binding of all single site mutants to liposomal Gb(3) was weaker than wild type VT1B binding. Site 3 mutants behaved as if they had reduced ability to enter into high avidity interactions with Gb(3) in the membrane context. Double mutants at site 1/site 3 and site 2/site 3 were completely inactive in terms of binding to liposomal Gb(3), even though the site 1/site 3 mutant bound trisaccharide with almost wild type affinity. Thus site 2 alone is not sufficient to confer high avidity binding to membrane-localized Gb(3). Cytotoxic activity paralleled membrane glycolipid binding. Our data show that the interaction of verotoxin with the Gb(3) trisaccharide is highly context dependent and that a membrane environment is required for biologically relevant studies of the interaction.	Toronto Gen Hosp, Dept Microbiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Div Clin Sci, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Research Council Canada; University of Alberta	Brunton, JL (corresponding author), Toronto Gen Hosp, Dept Microbiol, 200 Elizabeth St,Norman Urquhart Wing,13th Floor,, Toronto, ON M5G 2C4, Canada.		Kitov, Pavel/J-3714-2014					Bast DJ, 1999, MOL MICROBIOL, V32, P953, DOI 10.1046/j.1365-2958.1999.01405.x; BASTA M, 1989, J CLIN MICROBIOL, V127, P1617; BOYD B, 1991, INFECT IMMUN, V59, P750, DOI 10.1128/IAI.59.3.750-757.1991; Clark C, 1996, MOL MICROBIOL, V19, P891, DOI 10.1046/j.1365-2958.1996.427962.x; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DONOHUEROLFE A, 1989, MOL MICROBIOL, V3, P1231, DOI 10.1111/j.1365-2958.1989.tb00273.x; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FUCHS G, 1986, INFECT IMMUN, V53, P372, DOI 10.1128/IAI.53.2.372-377.1986; HEAD SC, 1991, J BIOL CHEM, V266, P3617; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KHINE AA, 1994, J CELL PHYSIOL, V161, P319, DOI 10.1002/jcp.1041610217; KIARASH A, 1994, J BIOL CHEM, V269, P11138; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Kitova EN, 2001, GLYCOBIOLOGY, V11, P605, DOI 10.1093/glycob/11.7.605; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; LING H, 1999, THESIS U ALBERTA ALB; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; MANGENEY M, 1993, CANCER RES, V53, P5314; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Nakajima H, 2001, J BIOL CHEM, V276, P42915, DOI 10.1074/jbc.M106015200; PELLIZZARI A, 1992, BIOCHEMISTRY-US, V31, P1363, DOI 10.1021/bi00120a011; PETRIC M, 1987, FEMS MICROBIOL LETT, V41, P63; Picking WD, 1999, BIOCHEMISTRY-US, V38, P7177, DOI 10.1021/bi982335n; RAMOTAR K, 1990, BIOCHEM J, V272, P805, DOI 10.1042/bj2720805; Richardson JM, 1997, NAT STRUCT BIOL, V4, P190, DOI 10.1038/nsb0397-190; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; SHARP A, 2000, THESIS U ALBERTA ALB; Shimizu H, 1998, BIOCHEMISTRY-US, V37, P11078, DOI 10.1021/bi980946+; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STOCKBINE NA, 1986, INFECT IMMUN, V53, P135; Thompson GS, 2000, BIOCHEMISTRY-US, V39, P13153, DOI 10.1021/bi001394+; WADELL T, 1990, P NATL ACAD SCI USA, V87, P7898; WEINSTEIN DL, 1989, INFECT IMMUN, V57, P3743, DOI 10.1128/IAI.57.12.3743-3750.1989	38	74	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5351	5359		10.1074/jbc.M107472200	http://dx.doi.org/10.1074/jbc.M107472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11723119	hybrid			2022-12-25	WOS:000173962900103
J	Deakin, S; Leviev, I; Gomaraschi, M; Calabresi, L; Franceschini, G; James, RW				Deakin, S; Leviev, I; Gomaraschi, M; Calabresi, L; Franceschini, G; James, RW			Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; LIPOPROTEIN ASSOCIATED PARAOXONASE; LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; ARTERY DISEASE; DIABETES-MELLITUS; RISK FACTOR; PON1 GENE; POLYMORPHISM	Paraoxonase-1 (PON1) is a high density lipoprotein (HDL)-associated serum enzyme that protects low density lipoproteins from oxidative modifications. There is a relative lack of information on mechanisms implicated in PON1 release from cells. The present study focused on a model derived from stable transfection of CHO cells, to avoid co-secretion of apolipoprotein (apo) A-I and lipids, which could lead to formation of HDL-like complexes. Our results indicate that, in the absence of an appropriate acceptor, little PON1 is released. The results designate HDL as the predominant, physiological acceptor, whose efficiency is influenced by size and composition. Neither lipid-poor apoA-I or apoA-II nor low density lipoproteins could substitute for HDL. Protein-free phospholipid complexes promoted PON1 release. However, the presence of both apolipoprotein and phospholipid were necessary to promote release and stabilize the enzyme. Immunofluorescence studies demonstrated that PON1 was inserted into the external membrane of CHO cells, where it was enzymatically active. Accumulation of PON1 in the cell membrane was not influenced by the ability of the cell to co-secrete of apoA-1. Release appeared to involve desorption by HDL; human and reconstituted HDL promoted PON1 release in a saturable, high affinity manner (apparent affinity 1.59 +/- 0.3 mug of HDL protein/ml). Studies with PON1-transfected hepatocytes (HuH-7) revealed comparable structural features with the peptide located in a punctate pattern at the external membrane and enzymatically active. We hypothesize that release of PON1 involves a docking process whereby HDL transiently associate with the cell membrane and remove the peptide from the external membrane. The secretory process may be of importance for assuring the correct lipoprotein destination of PON1 and thus its functional efficiency.	Univ Hosp Geneva, Div Endocrinol & Diabetol, Clin Diabet Unit, CH-1211 Geneva 14, Switzerland; Univ Milan, Dept Pharmacol Sci, Ctr E Grossi Paoletti, I-20133 Milan, Italy	University of Geneva; University of Milan	James, RW (corresponding author), Univ Hosp Geneva, Div Endocrinol & Diabetol, Clin Diabet Unit, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.	Richard.James@hcuge.ch	Gomaraschi, Monica/A-3601-2014	Gomaraschi, Monica/0000-0003-3082-2120; FRANCESCHINI, GUIDO/0000-0003-2687-1771; Calabresi, Laura/0000-0001-5042-9532				ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812; Antikainen M, 1996, J CLIN INVEST, V98, P883, DOI 10.1172/JCI118869; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BAGDADE JD, 1989, J LAB CLIN MED, V113, P235; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Boemi M, 2001, ATHEROSCLEROSIS, V155, P229, DOI 10.1016/S0021-9150(00)00556-6; Calabresi L, 1997, BIOCHEMISTRY-US, V36, P12428, DOI 10.1021/bi970505a; Gardemann A, 2000, ATHEROSCLEROSIS, V152, P421, DOI 10.1016/S0021-9150(99)00489-X; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; GARIN MCB, 1994, BIOCHEM J, V304, P549, DOI 10.1042/bj3040549; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; James RW, 2000, DIABETES, V49, P1390, DOI 10.2337/diabetes.49.8.1390; JAMES RW, 1988, J LIPID RES, V29, P1557; James RW, 1998, ATHEROSCLEROSIS, V139, P77, DOI 10.1016/S0021-9150(98)00058-6; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Leviev I, 2000, ARTERIOSCL THROM VAS, V20, P516, DOI 10.1161/01.ATV.20.2.516; Leviev I, 2001, J LIPID RES, V42, P528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MILLER RB, 1980, J BIOCHEM BIOPH METH, V3, P345, DOI 10.1016/0165-022X(80)90043-3; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Odawara M, 1997, J CLIN ENDOCR METAB, V82, P2257, DOI 10.1210/jc.82.7.2257; Pfohl M, 1999, DIABETES, V48, P623, DOI 10.2337/diabetes.48.3.623; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; Sanghera DK, 1997, ARTERIOSCL THROM VAS, V17, P1067, DOI 10.1161/01.ATV.17.6.1067; Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; YAMAMOTO T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P49, DOI 10.1016/0005-2760(90)90259-Z	38	180	196	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4301	4308		10.1074/jbc.M107440200	http://dx.doi.org/10.1074/jbc.M107440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726658	hybrid			2022-12-25	WOS:000173813900069
J	Ayabe, T; Wulff, H; Darmoul, D; Cahalan, MD; Chandy, KG; Ouellette, AJ				Ayabe, T; Wulff, H; Darmoul, D; Cahalan, MD; Chandy, KG; Ouellette, AJ			Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE HOST-DEFENSE; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-1; EPITHELIAL-CELLS; GENE-EXPRESSION; K+ CHANNEL; ANTIBIOTICS; ACTIVATION; IKCA1; LUNG	Paneth cells in small intestinal crypts secrete microbicidal alpha-defensins in response to bacteria and bacterial antigens (Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., and Ouellette, A. J. (2000) Nat. Immunol. 1, 113-138). We now report that the Ca2+-activated K+ channel mIKCa1 modulates mouse Paneth cell secretion. mIKCa1 cDNA clones identified in a mouse small intestinal crypt library by hybridization to human IKCa1 cDNA probes were isolated, and DNA sequence analysis showed that they were identical to mIKCa1 cDNAs isolated from erythroid cells and liver. The genomic organization was found to be conserved between mouse and human IKCa1 as shown by comparisons of the respective cDNA and genomic sequences. Reverse transcriptase-PCR experiments using nested primers amplified mIKCa1 from the lower half of bisected crypts and from single Paneth cells, but not from the upper half of bisected crypts, villus epithelium, or undifferentiated crypt epithelial cells, suggesting a lineage-specific role for mIKCa1 in mouse small bowel epithelium. The cloned mIKCa1 channel was calcium-activated and was blocked by ten structurally diverse peptide and nonpeptide inhibitors with potencies spanning 9 orders of magnitude and indistinguishable from that of the human homologue. Consistent with channel blockade, charybdotoxin, clotrimazole, and the highly selective IKCa1 inhibitors, TRAM-34 and TRAM-39, inhibited (similar to50%) Paneth cell secretion stimulated by bacteria or bacterial lipopolysaccharide, measured both as bactericidal activity and secreted cryptdin protein, but the inactive analog, TRAM-7, did not block secretion. These results demonstrate that mIKCa1 is modulator of Paneth cell a-defensin secretion and disclose an involvement in mucosal defense of the intestinal epithelium against ingested bacterial pathogens.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Paris 07, INSERM U410, F-75018 Paris, France	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, D-440 Med Sci 1, Irvine, CA 92697 USA.		Darmoul, Dalila/M-5812-2018; Ayabe, Tokiyoshi/F-5264-2011; wulff, Heike/Z-2056-2019	Darmoul, Dalila/0000-0002-1206-0655; Ayabe, Tokiyoshi/0000-0002-8631-5593; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044632, R55DK044632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44632] Funding Source: Medline; NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; AYUB M, 1990, BIOCHEM PHARMACOL, V40, P1569, DOI 10.1016/0006-2952(90)90456-U; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; Darmoul D, 1997, AM J PHYSIOL-GASTR L, V272, pG197, DOI 10.1152/ajpgi.1997.272.1.G197; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Fowler SM, 2000, BIOCHEMISTRY-US, V39, P4406, DOI 10.1021/bi992372u; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1997, Curr Opin Hematol, V4, P53; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; Quayle AJ, 1998, AM J PATHOL, V152, P1247; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1992, CELL TISSUE RES, V269, P213, DOI 10.1007/BF00319611; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	37	69	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3793	3800		10.1074/jbc.M107507200	http://dx.doi.org/10.1074/jbc.M107507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724775	hybrid, Green Published			2022-12-25	WOS:000173688000095
J	Le Feuvre, RA; Brough, D; Iwakura, Y; Takeda, K; Rothwell, NJ				Le Feuvre, RA; Brough, D; Iwakura, Y; Takeda, K; Rothwell, NJ			Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; MICE DEFICIENT; IL-1-BETA-CONVERTING ENZYME; NUCLEOTIDE RECEPTOR; P2Z PURINORECEPTOR; IL-1-BETA RELEASE; MICROGLIAL CELLS; MATURE IL-1-BETA; ATP; ACTIVATION	ATP stimulation of cell surface P2X7 receptors results in cytolysis and cell death of macrophages. Activation of this receptor in bacterial lipopolysaccharide (LPS)-activated macrophages or monocytes also stimulates processing and release of the cytokine interleukin-1beta (IL-1beta) through activation of caspase-1. The cytokine interleukin 18 (IL-18) is also cleaved by caspase-1 and shares pro-inflammatory characteristics with IL-1beta. The objective of the present study was to test the hypothesis that IL-1beta, IL-18, and/or caspase-1 activation contribute directly to macrophage cell death induced by LPS and ATP. Macrophages were cultured from normal mice or those in which genes for the P2X7 receptor, IL-1beta, IL-1alpha, IL-18, or caspase-1 had been deleted. Our data confirm the importance of the P2X7 receptor in ATP-stimulated cell death and IL-1beta release from LPS-primed macrophages. We demonstrate that prolonged stimulation with ATP leads to cell death, which is partly dependent on LPS priming and caspase-1, but independent of cytokine processing and release. We also provide evidence that LPS priming of macrophages makes them highly susceptible to the toxic effects of brief exposure to ATP, which leads to rapid cell death by a mechanism that is dependent on caspase-1 but, again, independent of cytokine processing and release.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Tokyo 1088639, Japan; Osaka Univ, Hyogo Coll Med, Suita, Osaka 5650871, Japan	University of Manchester; University of Tokyo; Hyogo College of Medicine; Osaka University	Le Feuvre, RA (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Takeda, Kiyoshi/C-9331-2009; Iwakura, Yoichiro/E-5457-2011; Le Feuvre, Rosalind/A-7034-2013	Iwakura, Yoichiro/0000-0002-9934-5775; Brough, David/0000-0002-2250-2381				Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Gabellec MM, 1997, BRAIN RES PROTOC, V1, P145, DOI 10.1016/S1385-299X(96)00023-2; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Mathiak G, 2000, BRIT J PHARMACOL, V131, P383, DOI 10.1038/sj.bjp.0703629; Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200; MILLER BE, 1995, J IMMUNOL, V154, P1331; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NettFiordalisi M, 1995, J LEUKOCYTE BIOL, V58, P717, DOI 10.1002/jlb.58.6.717; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; Schulze-Lohoff E, 1998, AM J PHYSIOL-RENAL, V275, pF962, DOI 10.1152/ajprenal.1998.275.6.F962; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Watanabe N, 1998, CYTOKINE, V10, P645, DOI 10.1006/cyto.1998.0341	37	142	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3210	3218		10.1074/jbc.M104388200	http://dx.doi.org/10.1074/jbc.M104388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11706016	hybrid			2022-12-25	WOS:000173688000021
J	Gusterson, R; Brar, B; Faulkes, D; Giordano, A; Chrivia, J; Latchman, D				Gusterson, R; Brar, B; Faulkes, D; Giordano, A; Chrivia, J; Latchman, D			The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; CREB-BINDING-PROTEIN; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; KINASE; ENDOTHELIN-1; PHOSPHORYLATION; STIMULATION; HYPERTROPHY	The CBP and p300 co-activators play a key role in many aspects of gene regulation being recruited to the DNA via transcription factors that are targets for specific signaling pathways. It has previously been demonstrated that in neuronal cells the ability of CBP and p300 to activate transcription can be directly stimulated by nerve growth factor or calcium-activated signaling pathways. Here we demonstrate that, in cardiac cells, the activity of CBP and p300 is stimulated by phenylephrine (PE) treatment and that they are required for the activation of atrial naturetic factor (ANF) gene expression by PE. Activation of CBP/p300 by PE involves the p42/p44 MAPK pathway and targets primarily the N terminus of p300 and the C terminus of CBP, which are not homologous to one another. To our knowledge, this is the first report of a specific stimulus modulating the activity of CBP and p300 in cardiac cells and it suggests that these factors play an important role in the hypertrophic effect of PE.	UCL, Inst Child Hlth, London WC1N 1EH, England; Thomas Jefferson Univ, Jefferson Canc Inst, Philadelphia, PA 19107 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	University of London; University College London; Jefferson University; Saint Louis University	Latchman, D (corresponding author), UCL, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	d.latchman@ich.ucl.ac.uk	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brar BK, 2001, CARDIOVASC RES, V51, P265, DOI 10.1016/S0008-6363(01)00294-2; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HENNEKAM RCM, 1990, AM J MED GENET, P17; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; LALLI E, 1994, J BIOL CHEM, V269, P17359; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MORIMOTO T, 2000, AM HEART ASS ANN M; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yue TL, 2000, J BIOL CHEM, V275, P37895, DOI 10.1074/jbc.M007037200; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	49	86	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2517	2524		10.1074/jbc.M104626200	http://dx.doi.org/10.1074/jbc.M104626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705990	hybrid			2022-12-25	WOS:000173421500021
J	Satoh, A; Kim, JK; Miyahara, I; Devreese, B; Vandenberghe, I; Hacisalihoglu, A; Okajima, T; Kuroda, S; Adachi, O; Duine, JA; Van Beeumen, J; Tanizawa, K; Hirotsu, K				Satoh, A; Kim, JK; Miyahara, I; Devreese, B; Vandenberghe, I; Hacisalihoglu, A; Okajima, T; Kuroda, S; Adachi, O; Duine, JA; Van Beeumen, J; Tanizawa, K; Hirotsu, K			Crystal structure of quinohemoprotein amine dehydrogenase from Pseudomonas putida - Identification of a novel quinone cofactor encaged by multiple thioether cross-bridges	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLAMINE DEHYDROGENASE; PARACOCCUS-DENITRIFICANS; GALACTOSE-OXIDASE; REFINEMENT; RESOLUTION; AERUGINOSA; MOLSCRIPT; ENZYME	The crystal structure of a quinohemoprotein amine dehydrogenase from Pseudomonas putida has been determined at 1.9-Angstrom resolution. The enzyme comprises three non-identical subunits: a four-domain a-subunit that harbors a di-heme cytochrome c, a seven-bladed beta-propeller beta-subunit that provides part of the active site, and a small gamma-subunit that contains a novel crosslinked, proteinous quinone cofactor, cysteine tryptophylquinone. More surprisingly, the catalytic gamma-subunit contains three additional chemical cross-links that en-cage the cysteine tryptophylquinone cofactor, involving a cysteine side chain bridged to either an Asp or Glu residue all in a hitherto unknown thioether bonding with a methylene carbon atom of acidic amino acid side chains. Thus, the structure of the 79-residue gamma-subunit is quite unusual, containing four internal cross-links in such a short polypeptide chain that would otherwise be difficult to fold into a globular structure.	Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Ibaraki, Osaka 5670047, Japan; Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; State Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Delft Univ Technol, Dept Microbiol & Enzymol, NL-2628 BC Delft, Netherlands; Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Osaka University; Osaka Metropolitan University; Ghent University; Delft University of Technology; Yamaguchi University	Tanizawa, K (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Ibaraki, Osaka 5670047, Japan.		Devreese, Bart/K-2841-2019; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; Okajima, Toshihide/0000-0003-1733-9580				ABRAHAMS JP, 1996, ACTA CRYSTALLOGR D, V52, P32; Adachi O, 1998, BIOSCI BIOTECH BIOCH, V62, P469, DOI 10.1271/bbb.62.469; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; Davidson V. L., 1993, PRINCIPLES APPL QUIN; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; Halcrow MA, 2001, ANGEW CHEM INT EDIT, V40, P346, DOI 10.1002/1521-3773(20010119)40:2<346::AID-ANIE346>3.0.CO;2-R; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadziola A, 1997, STRUCTURE, V5, P203, DOI 10.1016/S0969-2126(97)00179-2; Keitel T, 2000, J MOL BIOL, V297, P961, DOI 10.1006/jmbi.2000.3603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W, 1992, JOINT CCP4 EESF EACM; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Oubrie A, 1999, J MOL BIOL, V289, P319, DOI 10.1006/jmbi.1999.2766; Pettigrew, 1990, CYTOCHROME C EVOLUTI; Rogers MS, 2000, J AM CHEM SOC, V122, P990, DOI 10.1021/ja993385y; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Takagi K, 1999, BIOCHEMISTRY-US, V38, P6935, DOI 10.1021/bi9828268; Takagi K, 2001, EUR J BIOCHEM, V268, P470, DOI 10.1046/j.1432-1033.2001.01912.x; Vandenberghe I, 2001, J BIOL CHEM, V276, P42923, DOI 10.1074/jbc.M107164200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	33	74	76	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2830	2834		10.1074/jbc.M109090200	http://dx.doi.org/10.1074/jbc.M109090200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704672	hybrid			2022-12-25	WOS:000173421500061
J	Savvides, SN; Scheiwein, M; Bohme, CC; Arteel, GE; Karplus, PA; Becker, K; Schirmer, RH				Savvides, SN; Scheiwein, M; Bohme, CC; Arteel, GE; Karplus, PA; Becker, K; Schirmer, RH			Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE PHOSPHORYLATION; PLASMODIUM-FALCIPARUM; SUPEROXIDE-DISMUTASE; OXIDATIVE CHEMISTRY; NITRATION; ACTIVATION; RESONANCE; MECHANISM; CATALYSIS	As part of our studies on the nitric oxide-related pathology of cerebral malaria, we show that the antioxidative enzyme glutathione reductase (GR) is inactivated by peroxynitrite, with GR from the malarial parasite Plasmodium falciparum being more sensitive than human GR. The crystal structure of modified human GR at 1.9-Angstrom resolution provides the first picture of protein inactivation by peroxynitrite and reveals that this is due to the exclusive nitration of 2 Tyr residues (residues 106 and 114) at the glutathione disulfide-binding site. The selective nitration explains the impairment of binding the peptide substrate and thus the nearly 1000-fold decrease in catalytic efficiency (k(cat)/K-m) of glutathione reductase observed at physiologic pH. By oxidizing the catalytic dithiol to a disulfide, peroxynitrite itself can act as a substrate of unmodified and bisnitrated P. falciparum glutathione reductase.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Heidelberg Univ, Biochem Ctr, D-69120 Heidelberg, Germany; Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-4000 Dusseldorf, Germany	Oregon State University; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Heinrich Heine University Dusseldorf	Karplus, PA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS,14853, Corvallis, OR 97331 USA.	andy@odysseus.als.orst.edu; heiner.schirmer@gmx.de	Arteel, Gavin/AAE-2440-2022; Savvides, Savvas/E-1938-2011	Arteel, Gavin/0000-0002-2253-5984; Savvides, Savvas/0000-0003-3420-5947; Karplus, Paul/0000-0001-8725-6292				Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BECKER K, 1999, FLAVINS FLAVOPROT, V13, P853; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Brito C, 1999, J IMMUNOL, V162, P3356; BRUNGER AT, 1992, X PLOR SYSTEM XRYA C; Clark IA, 2000, PARASITOL TODAY, V16, P451, DOI 10.1016/S0169-4758(00)01757-9; CLARK IA, 2000, ACTA PHYSL SCAND S, V167, P14; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Faerman CH, 1996, BIOORGAN MED CHEM, V4, P1247, DOI 10.1016/0968-0896(96)00120-4; Francescutti D, 1996, PROTEIN ENG, V9, P189, DOI 10.1093/protein/9.2.189; FUJII S, 1981, BIOCHEMISTRY-US, V20, P518, DOI 10.1021/bi00506a012; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Hurst JK, 1999, ACCOUNTS CHEM RES, V32, P520, DOI 10.1021/ar9703488; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Knollema S, 1996, J COMP NEUROL, V373, P157, DOI 10.1002/(SICI)1096-9861(19960916)373:2<157::AID-CNE1>3.0.CO;2-2; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; KrauthSiegel RL, 1996, EUR J BIOCHEM, V235, P345, DOI 10.1111/j.1432-1033.1996.00345.x; Kremsner PG, 1996, T ROY SOC TROP MED H, V90, P44, DOI 10.1016/S0035-9203(96)90476-9; Kuwahara H, 2000, INFECT IMMUN, V68, P4378, DOI 10.1128/IAI.68.8.4378-4383.2000; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MOSTAD A, 1990, Z KRISTALLOGR, V193, P127, DOI 10.1524/zkri.1990.193.1-2.127; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1983, J BIOL CHEM, V258, P1752; Perrin D, 2000, ARCH BIOCHEM BIOPHYS, V377, P266, DOI 10.1006/abbi.2000.1787; Quaroni L, 1999, BIOSPECTROSCOPY, V5, pS71, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S71::AID-BSPY8>3.0.CO;2-T; Quijano C, 2001, J BIOL CHEM, V276, P11631, DOI 10.1074/jbc.M009429200; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; SMITH CD, 1992, ARCH BIOCHEM BIOPHYS, V299, P350, DOI 10.1016/0003-9861(92)90286-6; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; White AR, 1999, J NEUROCHEM, V72, P2092, DOI 10.1046/j.1471-4159.1999.0722092.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILLIAMSON TL, 2000, SCIENCE, V288, pA399; Xue J, 2000, ANAL CHEM, V72, P5313, DOI 10.1021/ac000701e	59	106	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2779	2784		10.1074/jbc.M108190200	http://dx.doi.org/10.1074/jbc.M108190200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705998	hybrid			2022-12-25	WOS:000173421500054
J	Tsuji, K; Mizumoto, K; Yamochi, T; Nishimoto, I; Matsuoka, M				Tsuji, K; Mizumoto, K; Yamochi, T; Nishimoto, I; Matsuoka, M			Differential effect of ik3-1/Cables on p53-and p73-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; FUNCTIONAL DOMAIN; INDUCE APOPTOSIS; P53 HOMOLOG; DNA-DAMAGE; IN-VIVO; P73; ADENOVIRUS	ik3-1/Cables is associated with cdk3 in self-replicating cells. In postmitotic neurons, it may serve as an adaptor molecule, functionally connecting c-abl and cdk5, and supporting neurite growth. Here we report that ik3-1 binds to p53 and p73 in vivo. Ectopically expressed ik3-1 potentiates p53-induced cell death but not p73-induced cell death in U2OS cells. On the contrary, coexpression of ik3-1-DeltaC, an ik3-1 deletion mutant lacking the C-terminal 134 amino acids (corresponding to the cyclin box-homologous region), inhibits p73-induced cell death but not p53-induced cell death. ik3-1-DeltaC-mediated inhibition of p73-induced cell death are partially attenuated by overexpression of ik3-1. These data indicate that ik3-1 is not only a regulator for p53-induced cell death but also an essential regulator for p73-induced cell death, and ik3-1-DeltaC competes with ik3-1 only in p73-induced cell death. Furthermore, functional domains of p53 responsible for its interaction with ik3-1 are partially different from those of p73. In conclusion, we found that ik3-1, a putative component of cell cycle regulation, is functionally connected with p53 and p73, but in distinct fashions.	Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1608582, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Biochem, Minato Ku, Tokyo 1088641, Japan	Keio University; Kitasato University	Matsuoka, M (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	sakimatu@mc.med.keio.ac.jp						Agami R, 1999, NATURE, V399, P809; Brand K, 1999, GENE THER, V6, P1054, DOI 10.1038/sj.gt.3300914; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gong JG, 1999, NATURE, V399, P806; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hirose T, 2000, EUR J BIOCHEM, V267, P2113, DOI 10.1046/j.1432-1327.2000.01218.x; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuoka M, 2000, BIOCHEM BIOPH RES CO, V273, P442, DOI 10.1006/bbrc.2000.2965; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OKUDA T, 1992, ONCOGENE, V7, P2249; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yamochi T, 2001, BIOCHEM BIOPH RES CO, V286, P1045, DOI 10.1006/bbrc.2001.5493; YAMOCHI T, 2001, EUR J BIOCHEM, V268, P1; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444; ZHU J, 1998, CANCER RES, V8, P5061; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	39	34	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2951	2957		10.1074/jbc.M108535200	http://dx.doi.org/10.1074/jbc.M108535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706030	hybrid			2022-12-25	WOS:000173421500076
J	Chang, SH; Barbosa-Tessmann, I; Chen, C; Kilberg, MS; Agarwal, A				Chang, SH; Barbosa-Tessmann, I; Chen, C; Kilberg, MS; Agarwal, A			Glucose deprivation induces heme oxygenase-1 gene expression by a pathway independent of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; REGULATED PROTEIN; CARBON-MONOXIDE; ACTIVATION; INDUCTION; CADMIUM; INJURY	Nutrients such as glucose regulate the expression of genes that are involved in plasma membrane transport, metabolic functions, and protein trafficking in the endoplasmic reticulum. Depletion of nutrients results in cellular stress, which evokes adaptive and protective responses, one of which is the induction of heme oxygenase-1 (HO-1), a 32-kDa endoplasmic reticulum enzyme that catalyzes the rate-limiting step in heme degradation. Incubation of HepG2 human hepatoma cells in glucose-free medium resulted in an increased HO-1 mRNA content, reaching a maximum of similar to25-fold over control cells after 12 h. The glucose-dependent induction of HO-1 mRNA was concentration-dependent (k(1/2) similar to0.5 mm) and was attenuated by fructose, galactose, mannose, and 2-deoxyglucose, but not by the non-metabolizable glucose analog, 3-O-methylglucose. Tunicamycin, thapsigargin, or azetidine 2-carboxylate, each of which activates the unfolded protein response pathway, did not induce HO-1 mRNA expression, whereas glucose-regulated protein 78 mRNA was increased. These results demonstrate that glucose availability regulates transcription of the HO-1 gene via a pathway that is different from the unfolded protein response. The induction of HO-1 may serve as a protective response in hypoglycemic circumstances and underscores the importance of understanding nutrient control of the HO-1 gene.	Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Agarwal, A (corresponding author), Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Med, Box 100224 JHMHC,1600 SW Archer Rd, Gainesville, FL 32610 USA.		Barbosa-Tessmann, Ione Parra/H-3856-2012	Barbosa-Tessmann, Ione Parra/0000-0001-9860-378X	NIDDK NIH HHS [R03 DK56279, DK-52064, K08 DK02446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, K08DK002446, R03DK056279] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Alam J, 2000, J BIOL CHEM, V275, P27694; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1989, J BIOL CHEM, V264, P6371; AVERILLBATES DA, 1994, ARCH BIOCHEM BIOPHYS, V312, P52, DOI 10.1006/abbi.1994.1279; BALLA G, 1992, J BIOL CHEM, V267, P18148; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213; LEE AS, 1981, P NATL ACAD SCI-BIOL, V78, P4922, DOI 10.1073/pnas.78.8.4922; Lee J, 1999, J NEUROSCI RES, V57, P48, DOI 10.1002/(SICI)1097-4547(19990701)57:1<48::AID-JNR6>3.0.CO;2-L; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Nath KA, 1998, KIDNEY INT, V53, P100, DOI 10.1046/j.1523-1755.1998.00731.x; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Platt JL, 1998, NAT MED, V4, P1364, DOI 10.1038/3947; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Shiraishi F, 2000, AM J PHYSIOL-RENAL, V278, pF726, DOI 10.1152/ajprenal.2000.278.5.F726; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	40	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1933	1940		10.1074/jbc.M108921200	http://dx.doi.org/10.1074/jbc.M108921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707454	hybrid			2022-12-25	WOS:000173421300044
J	Henningfeld, KA; Friedle, H; Rastegar, S; Knochel, W				Henningfeld, KA; Friedle, H; Rastegar, S; Knochel, W			Autoregulation of Xvent-2B; Direct interaction and functional cooperation of Xvent-2 and Smad1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS HOMEOBOX GENE; TGF-BETA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; MAD PROTEINS; HOMEODOMAIN; MESODERM; BMP-4	Members of the Xvent-2 homeodomain transcription factor family are immediate response genes of BMP-4 signaling. The bone morphogenetic protein response element (BRE) of Xvent-2B was previously identified and characterized with respect to Smad1 and Smad4 binding sites. In this study, we further report on the transcriptional regulation of Xvent-2B. We provide evidence that Xvent-2B (Xvent-2) maintains its own expression through autoregulation. This activity was demonstrated for the endogenous gene by reverse transcriptase-PCR analysis and was found to be insensitive to cycloheximide. Localized by DNase I footprinting were several Xvent-2 binding sites within the proximal upstream region including the BRE. In the early Xenopus embryo, the BRE was shown to be sufficient to drive expression of a green fluorescent protein reporter in a similar pattern compared with the endogenous gene. Furthermore, Xvent-213 was able to activate the BRE in luciferase reporter assays, and in co-injection experiments Xvent-213 and Smad1 were found to synergistically activate the BRE. Moreover, glutathione S-transferase pull-down experiments demonstrated that Xvent-213 directly and specifically interacts with Smad1. This association was mediated by the MH1 domain of Smad1 and required the C-terminal domain of Xvent-2. The failure of an Xvent-2 mutant lacking the C terminus to stimulate the BRE underlines the significance of the C-terminal domain in the described autoregulatory loop.	Univ Ulm, Abt Biochem, D-89081 Ulm, Germany; Univ Gottingen, Abt Entwicklungsbiochem, D-37073 Gottingen, Germany	Ulm University; University of Gottingen	Knochel, W (corresponding author), Univ Ulm, Abt Biochem, Albert Einstein Allee 11, D-89081 Ulm, Germany.		Rastegar, Sepand/E-2324-2015	Rastegar, Sepand/0000-0003-4411-5646				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bateman E, 1998, PROG NUCLEIC ACID RE, V60, P133, DOI 10.1016/S0079-6603(08)60892-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dosch R, 1997, DEVELOPMENT, V124, P2325; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Germain S, 2000, GENE DEV, V14, P435; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imai Y, 2001, DEVELOPMENT, V128, P2407; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladher R, 1996, DEVELOPMENT, V122, P2385; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, GENE DEV, V14, P627; Maxam A M, 1980, Methods Enzymol, V65, P499; Melby AE, 1999, DEV BIOL, V211, P293, DOI 10.1006/dbio.1999.9296; Melby AE, 2000, DEV BIOL, V224, P275, DOI 10.1006/dbio.2000.9780; Nakayama T, 2000, CELL MOL LIFE SCI, V57, P943, DOI 10.1007/PL00000736; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; Schuler-Metz A, 2000, J BIOL CHEM, V275, P34365, DOI 10.1074/jbc.M003915200; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sparrow D B, 2000, Nucleic Acids Res, V28, pE12, DOI 10.1093/nar/28.4.e12; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065	53	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2097	2103		10.1074/jbc.M108524200	http://dx.doi.org/10.1074/jbc.M108524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704665	hybrid			2022-12-25	WOS:000173421300066
J	Maile, LA; Imai, Y; Clarke, JB; Clemmons, DR				Maile, LA; Imai, Y; Clarke, JB; Clemmons, DR			Insulin-like growth factor I increases alpha(v)beta(3) affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ALPHA-V-BETA-3 INTEGRIN; CAVEOLAE MEMBRANE; LIGAND OCCUPANCY; IGF-I; MIGRATION; CHOLESTEROL; BINDING; CD47; REPLICATION	Insulin-like growth factor I (IGF-I) stimulates an increase in alpha(V)beta(3) ligand binding. Stimulation of smooth muscle cells by IGF-I requires alpha(V)beta(3) ligand occupancy, and enhanced alpha(V)beta(3) ligand occupancy augments IGF-I actions. Therefore, IGF-I-induced changes in alpha(V)beta(3) ligand binding may act to further enhance IGF-I actions. Integrin-associated protein (LAP) has been shown to be associated with alpha(V)beta(3) and is required for the binding of alpha(V)beta(3) to vitronectin-coated beads. We therefore investigated whether IGF-I could stimulate IAP-alpha(V)beta(3) association resulting in enhanced ligand binding. IGF-I stimulated an increase in LALP-alpha(V)beta(3) association. This was due, at least in part, to an IGF-I-stimulated redistribution of UP from the Triton-insoluble fraction of the cell to the Triton-soluble fraction of the cell, where most elf the alpha(V)beta(3) was located. Inhibition of the phosphatidylinositol 3-kinase pathway blocked both the redistribution of IAP and the increase in IAP-alpha(V)beta(3) association, providing further evidence that the redistribution of UP is essential for the increase in association. An anti-LAP monoclonal antibody, blocked both the IGF-I-stimulated increase in IAP-alpha(V)beta(3) complex formation and cell migration. IGF-I-stimulated translocation of UP and increase in IAP-alpha(V)beta(3) association represent an important process by which IGF-I modulates alpha(V)beta(3) ligand binding and cellular responses.	Univ N Carolina, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, CB 7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.			Imai, Yumi/0000-0001-5046-4223	NHLBI NIH HHS [HI-56580] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; CLEMMONS DR, 1984, J CELL PHYSIOL, V121, P425, DOI 10.1002/jcp.1041210222; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROSALES C, 1992, J IMMUNOL, V149, P2759; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	24	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1800	1805		10.1074/jbc.M108380200	http://dx.doi.org/10.1074/jbc.M108380200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707450	hybrid			2022-12-25	WOS:000173421300025
J	Tsuboi, S				Tsuboi, S			Calcium integrin-binding protein activates platelet integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TAIL; MYRISTOYL SWITCHES; ALPHA-IIB; MODULATION; ADHESION; DOMAIN; AGGREGATION; INTERACTS; AFFINITY; BETA(3)	alpha(IIb)beta(3), a platelet-specific integrin, plays a critical role in platelet aggregation. The affinity of alpha(IIb)beta(3) for its ligands such as fibrinogen and von Willebrand factor is tightly regulated in an uncharacterized intracellular process termed inside-out signaling. Calcium integrin-binding protein (CIB) has been identified as a protein interacting with the cytoplasmic tail of the alpha(IIb) subunit Of alpha(IIb)beta(3), but its physiological role has not been defined. In the present study, I demonstrate that CIB activates alpha(IIb)beta(3) both in vitro and in vivo. CIB interacts directly with the alpha(IIb) cytoplasmic tail, thereby increasing the affinity of alpha(IIb)beta(3) for fibrinogen in an in vitro fibrinogen-binding assay. The interaction of CIB with the alpha(IIb) cytoplasmic tail is enhanced in a Ca2+-dependent manner. A physiological agonist, ADP, stimulates platelets, activating alpha(IIb)beta(3). When the interaction of CIB with the alpha(IIb) cytoplasmic tail is blocked in native platelets by a permeable competing peptide, alpha(IIb)beta(3) activation is not detected even in the presence of ADP. This result indicates that direct interaction of CIB with the alpha(IIb) cytoplasmic tail converts alpha(IIb)beta(3) from a resting to an active conformation. This suggests that CIB plays an important role in one of the pathways that modulate the affinity of alpha(IIb)beta(3) for its ligand.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Tsuboi, S (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA.				NICHD NIH HHS [HD39187] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD039187] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Parise LV, 1999, CURR OPIN CELL BIOL, V11, P597, DOI 10.1016/S0955-0674(99)00018-6; PURI RN, 1997, CRIT REV BIOCHEM MOL, V3, P437; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197	21	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1919	1923		10.1074/jbc.M110643200	http://dx.doi.org/10.1074/jbc.M110643200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704681	hybrid			2022-12-25	WOS:000173421300041
J	Zhou, ZM; Takaya, N; Nakamura, A; Yamaguchi, M; Takeo, K; Shoun, H				Zhou, ZM; Takaya, N; Nakamura, A; Yamaguchi, M; Takeo, K; Shoun, H			Ammonia fermentation, a novel anoxic metabolism of nitrate by fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-OXYSPORUM; CYTOCHROME P450NOR; NITRITE REDUCTION; DENITRIFICATION; MITOCHONDRION	The induction of fungal denitrification by Fusarium oxysporum requires a minimal amount of O-2, although excess O-2 completely represses this process (Zhou, Z., Takaya, N., Sakairi, M.A. C., and Shoun, H. (2001) Arch. Microbiol. 175, 19-25). Here we describe another metabolic mechanism of nitrate in fungal cells, termed ammonia fermentation, that supports growth under conditions more anoxic than those of denitrification. The novel nitrate metabolism of eukaryotes consists of the reduction of nitrate to ammonium coupled with the catabolic oxidation of electron donors to acetate and substrate-level phosphorylation. F. oxysporum thus has two pathways of dissimilatory nitrate reduction that are alternatively expressed in response to environmental O-2 tension. F. oxysporum prefers O-2 respiration when the O-2 supply is sufficient. We discovered that this fungus is the first eukaryotic, facultative anaerobe known to express one of three distinct metabolic energy mechanisms closely depending on environmental O-2 tension. We also showed that ammonia fermentation occurs in many other fungi that are common in soil, suggesting that facultative anaerobes are widely distributed among fungi that have been considered aerobic organisms.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Chiba Univ, Pathogen Fungi & Microbial Toxicoses Res Ctr, Chiba 2608673, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tokyo; Chiba University; University of Tsukuba	Shoun, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.			Nakamura, Akira/0000-0001-7250-7175				Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; Embley TM, 1998, NATURE, V396, P517, DOI 10.1038/24994; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; HASAN SM, 1975, J GEN MICROBIOL, V87, P120, DOI 10.1099/00221287-87-1-120; ISHIMOTO M, 1974, Z ALLG MIKROBIOL, V14, P115, DOI 10.1002/jobm.3630140206; Klotzsch HR., 1969, METHODS ENZYMOL, V13, P381, DOI [10.1016/0076-6879(69)13065-7, DOI 10.1016/0076-6879(69)13065-7]; Kobayashi M, 1996, J BIOL CHEM, V271, P16263, DOI 10.1074/jbc.271.27.16263; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; NAKANE R, 1963, J MASS SPECTROM SOC, V22, P51; PAGE L, 1990, ARCH MICROBIOL, V154, P349, DOI 10.1007/BF00276530; Ruzicka S, 2000, SOIL BIOL BIOCHEM, V32, P989, DOI 10.1016/S0038-0717(00)00009-2; SEIFRITZ C, 1993, J BACTERIOL, V175, P8008, DOI 10.1128/JB.175.24.8008-8013.1993; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1991, J BIOL CHEM, V266, P11078; SINGH A, 1991, CRIT REV BIOTECHNOL, V11, P129, DOI 10.3109/07388559109040619; Takaya N, 1999, ARCH BIOCHEM BIOPHYS, V372, P340, DOI 10.1006/abbi.1999.1499; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tsuruta S, 1998, FEMS MICROBIOL LETT, V168, P105, DOI 10.1016/S0378-1097(98)00427-3; Zhang L, 2001, EUR J BIOCHEM, V268, P3198, DOI 10.1046/j.1432-1327.2001.02206.x; Zhou ZM, 2001, ARCH MICROBIOL, V175, P19, DOI 10.1007/s002030000231; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997; ZUMFT WG, 1992, PROKARYOTES, P554	22	108	115	4	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1892	1896		10.1074/jbc.M109096200	http://dx.doi.org/10.1074/jbc.M109096200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11713252	hybrid			2022-12-25	WOS:000173421300037
J	Boccaccio, C; Ando, M; Comoglio, PM				Boccaccio, C; Ando, M; Comoglio, PM			A differentiation switch for genetically modified hepatocytes	FASEB JOURNAL			English	Article						hepatocyte growth factor receptor; FKBP; dimerizer; CID; liver	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; SCATTER FACTOR; SIGNAL-TRANSDUCTION; MAP KINASE; ACTIVATION; DIMERIZATION; PURIFICATION; 3-KINASE; CELLS	The hepatocyte growth factor (HGF) receptor mediates a two-sided response-cell proliferation and differentiation. This process, defined as "branching morphogenesis," involves cell scatter and redistribution to form ramified hollow tubules within the extracellular matrix, and protection from apoptosis. We have fused the intracellular domain of the HGF receptor (HGFR) with three FK506-binding protein (FKBP) domains and a membrane-targeting signal. This molecule (FKBP-HGFR) dimerizes after administration of a bifunctional ligand specific for FKBP domains. We show that, in mouse hepatocyte progenitors, FKBP-HGFR dimerization elicits the differentiative side of the HGF response, including cell scatter, morphogenesis, and protection from apoptosis. Surprisingly, FKBP-HGFR does not induce cell proliferation. We could correlate the segregation of the differentiative response with a distinctive signaling kinetic of FKBP-HGFR: a) reduced and prolonged tyrosine kinase activation; and b) low early peak of MAP kinase activation (a log lower than the peak induced by the wild-type receptor), followed by a sustained activation over 6 h. These data show that the biological response triggered by the HGFR can be dissected on the basis of the quantitative signaling profile, and that FKBP-HGFR may be used to control selectively the differentiation of hepatocytes, without promoting cell expansion.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo Torino, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Boccaccio, C (corresponding author), IRCC, Str Prov 142, I-10060 Candiolo Torino, Italy.	cboccaccio@ircc.unito.it	Boccaccio, Carla/AHE-7875-2022	Boccaccio, Carla/0000-0003-2620-9083; Comoglio, Paolo/0000-0002-7056-5328				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Fornoni A, 2001, AM J PATHOL, V158, P275, DOI 10.1016/S0002-9440(10)63966-1; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GOHDA E, 1986, EXP CELL RES, V166, P139, DOI 10.1016/0014-4827(86)90514-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Strain AJ, 1999, HEPATOLOGY, V29, P288, DOI 10.1002/hep.510290131; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZARNEGAR R, 1989, CANCER RES, V49, P3314	53	13	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					120	+		10.1096/fj.01-0537fje	http://dx.doi.org/10.1096/fj.01-0537fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709498				2022-12-25	WOS:000172420500034
J	Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M				Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M			Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis	ONCOGENE			English	Article						anaplastic large cell lymphoma; ALK; tyrosine kinase; chemotherapy; apoptosis	RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA; FACTOR I RECEPTOR; ANAPLASTIC LYMPHOMA; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; POSITIVE LYMPHOMA; LEUKEMIC-CELLS; FRENCH SOCIETY	Anaplastic large cell lymphomas (ALCLs), are frequently associated with, the t(2;5)(p23;q35) translocation, leading to the expression of NPM-ALK, a fusion protein linking nucleophosmin and anaplastic lymphoma kinase, a receptor tyrosine kinase. In ALCLs, dimerization of NPM-ALK leads to constitutive autophosphorylation and activation of the kinase, necessary for NPM-ALK oncogenicity.. To investigate whether NPM-ALK, like other oncogenic tyrosine kinases, can, inhibit drug-induced apoptosis, we permanently transfected NPM-ALK into Jurkat T-cells. As, in ALCLs, NPM-ALK was expressed as, a constitutively kinase-active 80 kDa protein, and could be detected by immunocytochemistry in nucleoli, nuclei and cytoplasm. Doxorubicin-induced apoptosis (assessed by cell morphology and annexin V-FITC binding), was significantly inhibited in two independent NPM-ALK-expressing clones (5.2 +/- 1.8 and 7.5 +/- 0.8%, apoptosis), compared to control vector-transduced cells (36 +/- 6.7%). Similar results were observed with etoposide. In contrast, Fas-induced apoptosis, was not inhibited. Cytochrome c release into the cytosol was delayed in doxorubicin-, but not anti-Fas-treated transfectant cells, indicating that apoptosis inhibition occurred upstream of mitochondrial events. Using NPM-ALK mutants, we demonstrated that inhibition of drug-induced apoptosis: (1) requires functional kinase activity, (2) does not involve phospholipase C-gamma, essential for NPM-ALK-mediated mitogenicity and (3) appears to: be phosphoinositide 3-kinase independent, despite a strong Akt/PKB activation observed in wild type NPM-ALK-expressing cells. These results suggest that the NPM-ALK antiapoptotic and mitogenic pathways are distinct.	CHU Purpan, CNRS UPR2163, UPCM, F-31059 Toulouse 03, France; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-8000 Munich, Germany	CHU de Toulouse; St Jude Children's Research Hospital; Technical University of Munich; University of Munich	Allouche, M (corresponding author), CHU Purpan, CNRS UPR2163, UPCM, Ave Grande Bretagne, F-31059 Toulouse 03, France.	allouche@cict.fr	TOURIOL, Christian/O-8949-2014	TOURIOL, Christian/0000-0003-1219-4693	NCI NIH HHS [CA21765, CA69129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brugieres L, 2000, ANN ONCOL, V11, P53, DOI 10.1023/A:1008352726155; Brugieres L, 1998, BLOOD, V92, P3591; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Collins P, 2000, NAT REV NEUROSCI, V1, P156, DOI 10.1038/35044513; DELSOL G, 1988, AM J PATHOL, V130, P59; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hernandez L, 1999, BLOOD, V94, P3265; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jain SK, 1996, BLOOD, V88, P1542; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lamant L, 1996, BLOOD, V87, P284; Lamant L, 1999, BLOOD, V93, P3088; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Villunger A, 1997, CANCER RES, V57, P3331; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN DX, 1995, CANCER RES, V55, P4922	74	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7386	7397		10.1038/sj.onc.1204870	http://dx.doi.org/10.1038/sj.onc.1204870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704868				2022-12-25	WOS:000171894200011
J	Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC				Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC			LAPSER1: a novel candidate tumor suppressor gene from 10q24.3	ONCOGENE			English	Article						prostate cancer; tumor suppressor; LZTS1; LAPSER1	HUMAN PROSTATE-CANCER; FREQUENT INACTIVATION; ALLELIC LOSS; CELL-LINES; PTEN/MMAC1; CARCINOMAS; REGIONS; 8P22; PTEN; EXPRESSION	Numerous LOH and mutation analysis studies in different tumor tissues, including prostate, indicate that there are multiple tumor suppressor genes (TSGs) present within the human chromosome 8p21-22 and 10q23-24 regions. Recently, we showed that LZTS1 (or FEZ1), a putative TSG located on 8p22, has the potential to function as a cell growth modulator. We report here the cloning, gene organization, cDNA sequence characterization and expression analysis of LAPSER1, an LZTS1-related gene. This gene maps within a subregion of human chromosome 10q24.3 that has been reported to be deleted in various cancers, including prostate tumors, as frequently as the neighboring PTEN locus. The complete LAPSER1 cDNA sequence encodes a predicted protein containing various domains resembling those typically found in transcription factors (P-Box, Q-rich and multiple leucine zippers). LAPSER1 is expressed at the highest levels in normal prostate and testis, where multiple isoforms are seen, some of which are either undetectable or differentially expressed in some prostate tumor tissues and cell lines. Over-expression of LAPSER1 cDNA strongly inhibited cell growth and colony-forming efficiencies of most cancer cells assessed. Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; GRAY IC, 1995, CANCER RES, V55, P4800; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ittmann M, 1996, CANCER RES, V56, P2143; KAGAN J, 1995, ONCOGENE, V11, P2121; KAHN T, 1994, CANCER RES, V54, P1305; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMPARIELLO F, 1994, CYTOMETRY, V15, P294, DOI 10.1002/cyto.990150404; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murakami YS, 1996, CANCER RES, V56, P2157; Narahara K, 1997, J MED GENET, V34, P213, DOI 10.1136/jmg.34.3.213; Orikasa K, 1998, J HUM GENET, V43, P228, DOI 10.1007/s100380050078; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Yokomizo A, 1998, INT J ONCOL, V13, P101	41	38	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6707	6717		10.1038/sj.onc.1204866	http://dx.doi.org/10.1038/sj.onc.1204866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709705				2022-12-25	WOS:000171551600007
J	Lima, APCA; Almeida, PC; Tersariol, ILS; Schmitz, V; Schmaier, AH; Juliano, L; Hirata, IY; Muller-Esterl, W; Chagas, JR; Scharfstein, J				Lima, APCA; Almeida, PC; Tersariol, ILS; Schmitz, V; Schmaier, AH; Juliano, L; Hirata, IY; Muller-Esterl, W; Chagas, JR; Scharfstein, J			Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; AMINO-ACID SEQUENCE; CELL-BINDING-SITE; CYSTEINE-PROTEINASE; ENDOTHELIAL-CELLS; ACTIVATION; RECEPTORS; MECHANISM; INVASION; IDENTIFICATION	Trypanosoma cruzi activates the kinin pathway through the activity of its major cysteine proteinase, cruzipain. Because kininogen molecules may be displayed on cell surfaces by binding to glycosaminoglycans, we examined whether the ability of cruzipain to release kinins from high molecular weight kininogen (HK) is modulated by heparan sulfate (HS). Kinetic assays show that HS reduces the cysteine proteinase inhibitory activity (K-i (app)) of HK about 10-fold. Conversely, the catalytic efficiency of cruzipain on kinin-related synthetic fluorogenic substrates is enhanced up to 6-fold in the presence of HS. Analysis of the HK breakdown products generated by cruzipain indicated that HS changes the pattern of HK cleavage products. Direct measurements of bradykinin demonstrated an up to 35-fold increase in cruzipain-mediated kinin liberation in the presence of HS. Similarly, kinin release by living trypomastigotes increased up to 10-fold in the presence of HS. These studies suggest that the efficiency of T. cruzi to initiate kinin release is potently enhanced by the mutual interactions between cruzipain, HK, and heparan sulfate proteoglyeans.	Univ Brazil, Inst Biofis Carlos Chagas Filho, CCS, BR-21944900 Rio De Janeiro, Brazil; Univ Mogi das Cruzes, Ctr Interdisciplinas Invest Bioquim, Sao Paulo, Brazil; Univ Fed Estado Sao Paulo, Escola Paulista Med, Dept Biofis, Sao Paulo, Brazil; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Goethe Univ Frankfurt, Med Sch, Inst Biochem 2, D-60590 Frankfurt, Germany	Universidade de Mogi das Cruzes; Universidade Estadual Paulista; Universidade Federal de Sao Paulo (UNIFESP); University of Michigan System; University of Michigan; Goethe University Frankfurt	Scharfstein, J (corresponding author), Univ Brazil, Inst Biofis Carlos Chagas Filho, CCS, Bloco G, BR-21944900 Rio De Janeiro, Brazil.	scharf@biof.ufrj.br	Schmitz, Veronica P/D-2458-2013; Schmaier, Alvin/AAM-1063-2020; Chagas, Jair Ribeiro/AFV-6501-2022; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; de Almeida, Paulo C/D-8285-2014; de Almeida, Paulo/D-4794-2012; Chagas, Jair R/A-1701-2012; Juliano, Luiz/D-7204-2012; Lima, Ana Paula CA/G-4122-2012	Schmitz, Veronica P/0000-0002-0865-133X; Schmaier, Alvin/0000-0002-3884-6234; Chagas, Jair Ribeiro/0000-0002-0357-8276; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; de Almeida, Paulo C/0000-0002-5136-5152; Chagas, Jair R/0000-0002-0357-8276; Juliano, Luiz/0000-0002-5589-2822; LIMA, ANA PAULA C. A./0000-0003-4631-2694				Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CADENA RAD, 1991, TRENDS PHARMACOL SCI, V12, P272, DOI 10.1016/0165-6147(91)90569-E; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KELLERMANN J, 1986, EUR J BIOCHEM, V154, P471, DOI 10.1111/j.1432-1033.1986.tb09421.x; Kozik A, 1998, J BIOL CHEM, V273, P33224, DOI 10.1074/jbc.273.50.33224; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; LIMA APCA, 1992, MOL BIOCHEM PARASIT, V56, P335, DOI 10.1016/0166-6851(92)90183-K; Lima APCA, 2001, MOL BIOCHEM PARASIT, V114, P41, DOI 10.1016/S0166-6851(01)00236-5; Maeda H, 1996, MICROBIOL IMMUNOL, V40, P685, DOI 10.1111/j.1348-0421.1996.tb01129.x; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; PARODI AJ, 1995, MOL BIOCHEM PARASIT, V69, P247, DOI 10.1016/0166-6851(94)00213-7; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Renne T, 2001, FEBS LETT, V500, P36, DOI 10.1016/S0014-5793(01)02570-4; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; Sakata Y, 1996, MICROBIOL IMMUNOL, V40, P415, DOI 10.1111/j.1348-0421.1996.tb01088.x; Scharfstein J, 2000, J EXP MED, V192, P1289, DOI 10.1084/jem.192.9.1289; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E; Tchougounova E, 2001, J BIOL CHEM, V276, P3772, DOI 10.1074/jbc.M008434200	39	71	74	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5875	5881		10.1074/jbc.M108518200	http://dx.doi.org/10.1074/jbc.M108518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726662	hybrid			2022-12-25	WOS:000173989200025
J	Molles, BE; Rezai, P; Kline, EF; McArdle, JJ; Sine, SM; Taylor, P				Molles, BE; Rezai, P; Kline, EF; McArdle, JJ; Sine, SM; Taylor, P			Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERESURUS-WAGLERI; PIT VIPER; GAMMA-SUBUNIT; CHOLINERGIC RECEPTOR; MOLECULAR DISSECTION; NUCLEOTIDE-SEQUENCE; LETHAL PEPTIDES; DELTA-SUBUNIT; BETA-SUBUNIT; CELL-LINE	Waglerin-1 (Wtx-1) is a 22-amino acid peptide that is a competitive antagonist of the muscle nicotinic receptor (nAChR). We find that Wtx-1 binds 2100-fold more tightly to the alpha-epsilon than to the alpha-delta binding site interface of the mouse nAChR. Moreover, Wtx-1 binds 100-fold more tightly to the alpha-epsilon interface from mouse nAChR than that from rat or human sources. Site-directed mutagenesis of residues differing in the extracellular domains of rat and mouse a subunits indicates that residues 59 and 115 mediate the species difference in Wtx-1 affinity. Mutation of residues 59 (Asp in mouse, Glu in rat epsilon) and 115 (Tyr in mouse, Ser in rat epsilon) converts Wtx-1 affinity for the alpha-epsilon interface of one species to that of the other species. Studies of different mutations at position 59 indicate both steric and electrostatic contributions to Wtx-1 affinity, whereas at position 115, both aromatic and polar groups contribute to affinity. The human nAChR also has lower affinity for Wtx-1 than mouse nAChR, but unlike rat nAChR, residues in both alpha and epsilon subunits mediate the affinity difference. In human nAChR, polar residues (Ser-187 and Thr-189) confer low affinity, whereas in mouse nAChR aromatic residues (Trp-187 and Phe-189) confer high affinity. The overall results show that non-conserved residues at the nAChR binding site, although not crucial for activation by ACh, govern the potency of neuromuscul toxins.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA; Mayo Clin & Mayo Fdn, Receptor Biol Lab, Dept Physiol & Biophys, Rochester, MN 55905 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; Mayo Clinic	Molles, BE (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	bmolles@ucsd.edu	Rezai, Pouya/J-9718-2018	Rezai, Pouya/0000-0002-5031-8063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07752, GM18360] Funding Source: Medline; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIKEN S P, 1992, Pharmacology and Toxicology, V70, P459; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; BARCHAN D, 1995, BIOCHEMISTRY-US, V34, P9172, DOI 10.1021/bi00028a029; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Chuang LC, 1996, BBA-PROTEIN STRUCT M, V1292, P145, DOI 10.1016/0167-4838(95)00181-6; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Endo T., 1991, P165; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; GROEBE DR, 1995, J BIOL CHEM, V270, P281, DOI 10.1074/jbc.270.1.281; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIN WW, 1995, TOXICON, V33, P111, DOI 10.1016/0041-0101(94)00134-T; McArdle JJ, 1999, J PHARMACOL EXP THER, V289, P543; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; REID HA, 1963, BRIT MED J, P992, DOI 10.1136/bmj.1.5336.992; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SCHMIDT JJ, 1992, TOXICON, V30, P1027, DOI 10.1016/0041-0101(92)90047-9; SCHMIDT JJ, 1995, TOXICON, V33, P1043, DOI 10.1016/0041-0101(95)00043-L; SCHOEPFER R, 1988, FEBS LETT, V226, P235, DOI 10.1016/0014-5793(88)81430-3; Sellin LC, 1996, BIOPHYS J, V70, P3, DOI 10.1016/S0006-3495(96)79559-0; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; TAN NH, 1989, TOXICON, V27, P349; Taylor P, 1998, J PHYSIOL-PARIS, V92, P79, DOI 10.1016/S0928-4257(98)80142-3; TZARTOS SJ, 1991, MOL NEUROBIOL, V5, P1, DOI 10.1007/BF02935610; WEINSTEIN SA, 1991, TOXICON, V29, P227, DOI 10.1016/0041-0101(91)90107-3; WITZEMANN V, 1990, EUR J BIOCHEM, V194, P437, DOI 10.1111/j.1432-1033.1990.tb15637.x; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	43	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5433	5440		10.1074/jbc.M109232200	http://dx.doi.org/10.1074/jbc.M109232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724791	hybrid			2022-12-25	WOS:000173962900113
J	Nohe, A; Hassel, S; Ehrlich, M; Neubauer, F; Sebald, W; Henis, YI; Knaus, P				Nohe, A; Hassel, S; Ehrlich, M; Neubauer, F; Sebald, W; Henis, YI; Knaus, P			The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; I RECEPTORS; C2C12 MYOBLASTS; OSTEOBLASTIC DIFFERENTIATION; LIVE CELLS; FAMILY; INHIBITION; ACTIVATION; COMPLEXES; APOPTOSIS	Bone morphogenetic proteins (BMPs) are multifunctional proteins regulating cell growth, differentiation, and apoptosis. BMP-2 signals via two types of receptors (BRI and BRIT) that are expressed at the cell surface as homomeric as well as heteromeric complexes. Prior to ligand binding, a low but measurable level of BMP-receptors is found in preformed hetero-oligomeric complexes. The major fraction of the receptors is recruited into hetero-oligomeric complexes only after ligand addition. For this, BMP-2 binds first to the high affinity receptor BRI and then recruits BRII into the signaling complex. However, ligand binding to the preformed complex composed of BRII and BRI is still required for signaling, suggesting that it may mediate activating conformational changes. Using several approaches we have addressed the following questions: (i) Are preformed complexes incompetent of signaling in the absence of BMP-2? (ii) Which domains of the BRII receptors are essential for this complex formation? (iii) Are there differences in signals sent from BMP-induced versus preformed receptor complexes? By measuring the activation of Smads, of p38 MAPK and of alkaline phosphatase, we show that the ability of kinase-deficient BRII receptor mutants to inhibit BMP signaling depends on their ability to form heteromeric complexes with BRI. Importantly, a BRII mutant that is incapable in forming preassembled receptor complexes but recruits into a BMP-induced receptor complex does not interfere with the Smad pathway but does inhibit the induction of alkaline phosphatase as well as p38 phosphorylation. These results indicate that signals induced by binding of BMP-2 to preformed receptor complexes activate the Smad pathway, whereas BMP-2-induced recruitment of receptors activates a different, Smad-independent pathway resulting in the induction of alkaline phosphatase activity via p38 MAPK.	Univ Wurzburg, Bioctr, Dept Physiol Chem, D-97074 Wurzburg, Germany; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	University of Wurzburg; Tel Aviv University	Knaus, P (corresponding author), Univ Wurzburg, Bioctr, Dept Physiol Chem, D-97074 Wurzburg, Germany.			Neubauer, Florian/0000-0002-0163-983X; Henis, Yoav/0000-0002-1408-3877; Ehrlich, Marcelo/0000-0002-2352-1808				Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; LIU F, 1995, MOL CELL BIOL, V15, P3479; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006-291X(91)90490-X; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179	44	441	469	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5330	5338		10.1074/jbc.M102750200	http://dx.doi.org/10.1074/jbc.M102750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714695	hybrid			2022-12-25	WOS:000173962900100
J	Obata, Y; Kono, T				Obata, Y; Kono, T			Maternal primary imprinting is established at a specific time for each gene throughout oocyte growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; EPIGENETIC MODIFICATIONS; DNA METHYLTRANSFERASES; MOUSE EMBRYO; GERM-CELLS; METHYLATION; EXPRESSION; H19; EMBRYOGENESIS; MECHANISMS	Primary imprinting during gametogenesis governs the monoallelic expression/repression of imprinted genes in embryogenesis. Previously, we showed that maternal primary imprinting is disrupted in neonate-derived non-growing oocytes. Here, to investigate precisely when and in what order maternal primary imprinting progresses, we produced parthenogenetic embryos containing one genome from a non-growing or growth-stage oocyte from 1- to 20-day-old mice and one from a fully grown oocyte of adult mice. We used these embryos to analyze the expression of eight imprinted genes: Peg1/Mest, Peg3, Snrpn, Znf127, Ndn, Impact, Igf2r, and p57(KIP2). The results showed that the imprinting signals for each gene were not all imposed together at a specific time during oocyte growth but rather occurred throughout the period from primary to antral follicle stage oocytes. The developmental ability of the constructed parthenogenetic embryos was gradually reduced as the nuclear donor oocytes grew. These studies provide the first insight into the process of primary imprinting during oocyte growth.	Tokyo Univ Agr, Dept Biosci, Setagaya Ku, Tokyo 1568502, Japan; Gunma Univ, Ctr Gene Res, Gunma 3718511, Japan	Tokyo University of Agriculture; Gunma University	Kono, T (corresponding author), Tokyo Univ Agr, Dept Biosci, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan.	tomohiro@nodai.ac.jp						Bao SQ, 2000, BIOL REPROD, V62, P616, DOI 10.1095/biolreprod62.3.616; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARR JA, 1995, MAMM GENOME, V6, P405, DOI 10.1007/BF00355641; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kato Y, 1999, DEVELOPMENT, V126, P1823; Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Mertineit C, 1998, DEVELOPMENT, V125, P889; Obata Y, 1998, DEVELOPMENT, V125, P1553; Obata Y, 2000, HUM REPROD, V15, P874, DOI 10.1093/humrep/15.4.874; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; ONEILL GT, 1991, MOL REPROD DEV, V30, P214, DOI 10.1002/mrd.1080300308; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; WASSARMAN PM, 1994, MAMMALIAN OVUM PHYSL, V1, P84; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25	39	220	225	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5285	5289		10.1074/jbc.M108586200	http://dx.doi.org/10.1074/jbc.M108586200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11713250	hybrid			2022-12-25	WOS:000173962900094
J	Delbruck, H; Ziegelin, G; Lanka, E; Heinemann, U				Delbruck, H; Ziegelin, G; Lanka, E; Heinemann, U			An Src homology 3-like domain is responsible for dimerization of the repressor protein KorB encoded by the promiscuous IncP plasmid RP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CONTROL REGION; GLOBAL REGULATOR KORB; CRYSTAL-STRUCTURE; SH3 DOMAIN; NUCLEOTIDE-SEQUENCE; BINDING DOMAIN; RK2; COOPERATIVITY; REPLICATION; REFINEMENT	KorB is a regulatory protein encoded by the conjugative plasmid RP4 and a member of the ParB family of bacterial partitioning proteins. The protein regulates the expression of plasmid genes whose products are involved in replication, transfer, and stable inheritance of RP4 by binding to palindromic 13-bp DNA sequences (5'-TTTAGC(G/C)GCTAAA-3') present 12 times in the 60-kb plasmid. Here we report the crystal structure of KorB-C, the C-terminal domain of KorB comprising residues 297-358. The structure of KorB-C was solved in two crystal forms. Quite unexpectedly, we find that KorB-C shows a fold closely resembling the Src homology 3 (SH3) domain, a fold well known from proteins involved in eukaryotic signal transduction. From the arrangement of molecules in the asymmetric unit., it is concluded that two molecules form a functionally relevant dimer. The detailed analysis of the dimer interface and a chemical cross-linking study suggest that the C-terminal domain is responsible for stabilizing the dimeric form of KorB in solution to facilitate binding to the palindromic operator sequence. The KorB-C crystal structure extends the range of protein-protein interactions known to be promoted by SH3 and SH3-like domains.	Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, D-13125 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Free University of Berlin	Heinemann, U (corresponding author), Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, Robert Roessle Str 10, D-13125 Berlin, Germany.	Heinemann@MDC-Berlin.de	Heinemann, Udo/AAH-4766-2019; Heinemann, Udo/S-3379-2016	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; Holliger P, 1997, STRUCTURE, V5, P265, DOI 10.1016/S0969-2126(97)00184-6; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JAGURA-BURDZY G, 1994, P NATL ACAD SCI USA, V91, P10571, DOI 10.1073/pnas.91.22.10571; Jagura-Burdzy G, 1999, MOL MICROBIOL, V32, P519, DOI 10.1046/j.1365-2958.1999.01365.x; Jagura-Burdzy G, 1999, J BACTERIOL, V181, P2807, DOI 10.1128/JB.181.9.2807-2815.1999; Jagura-Burdzy G, 1997, J MOL BIOL, V265, P507, DOI 10.1006/jmbi.1996.0747; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kishan KVR, 2001, PROTEIN SCI, V10, P1046, DOI 10.1110/ps.50401; Kostelidou K, 2000, J MOL BIOL, V295, P411, DOI 10.1006/jmbi.1999.3359; Kostelidou K, 1999, J MOL BIOL, V289, P211, DOI 10.1006/jmbi.1999.2761; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Macartney DP, 1997, MICROBIOL-UK, V143, P2167, DOI 10.1099/00221287-143-7-2167; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayer KL, 1999, BIOCHEMISTRY-US, V38, P13736, DOI 10.1021/bi9910373; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; MOTALLEBIVESHAREH M, 1992, MOL MICROBIOL, V6, P907, DOI 10.1111/j.1365-2958.1992.tb01541.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; Rosche TM, 2000, J BACTERIOL, V182, P6014, DOI 10.1128/JB.182.21.6014-6026.2000; SAFRO M, 1995, PROTEIN SCI, V4, P2429, DOI 10.1002/pro.5560041122; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMAS CM, 1986, NUCLEIC ACIDS RES, V14, P4453, DOI 10.1093/nar/14.11.4453; THOMSON VJ, 1993, J BACTERIOL, V175, P2423, DOI 10.1128/JB.175.8.2423-2435.1993; Thorsted PA, 1998, J MOL BIOL, V282, P969, DOI 10.1006/jmbi.1998.2060; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; Williams DR, 1998, MICROBIOL-UK, V144, P3369, DOI 10.1099/00221287-144-12-3369; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; WILLIAMS DR, 1993, NUCLEIC ACIDS RES, V21, P1141, DOI 10.1093/nar/21.5.1141; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; Zatyka M, 2001, J BACTERIOL, V183, P1022, DOI 10.1128/JB.183.3.1022-1031.2001; Zatyka M, 1997, J BACTERIOL, V179, P7201, DOI 10.1128/jb.179.23.7201-7209.1997; ZATYKA M, 1997, MICROBIOLOGY, V140, P2981	59	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4191	4198		10.1074/jbc.M110103200	http://dx.doi.org/10.1074/jbc.M110103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11711548	hybrid			2022-12-25	WOS:000173813900055
J	Wissmann, R; Bildl, W; Neumann, H; Rivard, AF; Klocker, N; Weitz, D; Schulte, U; Adelman, JP; Bentrop, D; Fakler, B				Wissmann, R; Bildl, W; Neumann, H; Rivard, AF; Klocker, N; Weitz, D; Schulte, U; Adelman, JP; Bentrop, D; Fakler, B			A helical region in the C terminus of small-conductance Ca2+-activated K+ channels controls assembly with apo-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CALCIUM; RECOGNITION; NEURONS; NMR; PROGRAM; DYNAMICS; COMPLEX; MOTIFS; DOMAIN	Small conductance Ca2+-activated potassium (SK) channels underlie the afterhyperpolarization that follows the action potential in many types of central neurons. SK channels are voltage-independent and gated solely by intracellular Ca2+ in the submicromolar range. This high affinity for Ca2+ results from Ca2+-independent association of the SK a-subunit with calmodulin (CaM), a property unique among the large family of potassium channels. Here we report the solution structure of the calmodulin binding domain (CaMBD, residues 396-487 in rat SK2) of SK channels using NMR spectroscopy. The CaMBD exhibits a helical region between residues 423-437, whereas the rest of the molecule lacks stable overall folding. Disruption of the helical domain abolishes constitutive association of CaMBD with Ca2+ free CaM, and results in SK channels that are no longer gated by Ca2+. The results show that the Ca2+-independent CaM-CaMBD interaction, which is crucial for channel function, is at least in part determined by a region different in sequence and structure from other CaM-interacting proteins.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52452 Julich, Germany	Eberhard Karls University of Tubingen; Oregon Health & Science University; Helmholtz Association; Research Center Julich	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, Ob Himmelreich 7, D-72074 Tubingen, Germany.	bernd.fakler@uni-tuebingen.de	Neumann, Heinz/F-7875-2014; Neumann, Heinz/ABC-7323-2021	Neumann, Heinz/0000-0001-9657-1913; 				Antz C, 1999, NAT STRUCT BIOL, V6, P146; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; ISHIMA R, 1995, BIOCHEMISTRY-US, V34, P3162, DOI 10.1021/bi00010a005; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; Oliver D, 2000, NEURON, V26, P595, DOI 10.1016/S0896-6273(00)81197-6; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; STORM JF, 1990, PROG BRAIN RES, V83, P161; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	37	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4558	4564		10.1074/jbc.M109240200	http://dx.doi.org/10.1074/jbc.M109240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723128	Green Published, hybrid			2022-12-25	WOS:000173813900100
J	Zang, MW; Hayne, C; Luo, ZJ				Zang, MW; Hayne, C; Luo, ZJ			Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; RAS TRANSFORMATION; PLASMA-MEMBRANE; IDENTIFICATION; SERINE-338; PATHWAY; GTPASE; FAMILY	Activation of Raf-1 is a complex process in which phosphorylation of Ser(338)-Tyr(341) is a critical step. Previous studies have shown that Pak1/2 is implicated in both Ras-dependent and -independent activation of Raf-1 by phosphorylating Raf Ser(338). The present, study explores the structural basis of Raf-1 phosphorylation by Pak1. We found that Pak directly, associates with Raf-1 under both physiological and overexpressed conditions. The association is greatly stimulated by 4beta-12-O-tetradecanoylphorbol-13-acetate and nocodazole and by expression of the active mutants of Rac and Ras. The active forms of Pak generated by mutation of Thr(423) to Glu or truncation of the amino-terminal moiety exhibit a greater binding to Raf than the wild type, whereas the kinase-dead mutant Pak barely binds Raf. The extent of binding to Raf-1 is correlated with the ability of Pak to phosphorylate Raf and induce mitogen-activated protein kinase activation. Furthermore, the Raf-1 binding site is defined to the carboxyl terminus of the Pak catalytic domain. In addition, our results suggest that the amino-terminal regulatory region of Raf inhibits the interaction. Taken together, the results indicate that the interaction depends on the active conformations of Pak and Raf. They also argue that Pak1 is a physiological candidate for phosphorylation of Raf Ser(338) during the course of Raf activation.	Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Luo, ZJ (corresponding author), Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, 650 Albany St,RM 820, Boston, MA 02118 USA.	zluo@medicine.bu.edu	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289; Luo, Zhijun/0000-0003-3509-4046; Zang, Mengwei/0000-0002-2502-2586	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57959] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BOS JL, 1989, CANCER RES, V49, P4682; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DENT P, 1995, MOL CELL BIOL, V15, P4125; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565	50	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4395	4405		10.1074/jbc.M110000200	http://dx.doi.org/10.1074/jbc.M110000200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11733498	hybrid			2022-12-25	WOS:000173813900081
J	Fan, J; Frey, RS; Rahman, A; Malik, AB				Fan, J; Frey, RS; Rahman, A; Malik, AB			Role of neutrophil NADPH oxidase in the mechanism of tumor necrosis factor-alpha-induced NF-kappa B activation and intercellular adhesion molecule-1 expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; ICAM-1 EXPRESSION; TNF-ALPHA; PROTEIN; GENE; BINDING; INVOLVEMENT; RECEPTORS	In this study, we explored a novel function of polymorphonuclear neutrophils (PMN) NAD(P)H oxidase in the mechanism of tumor necrosis factor-a (TNFalpha)-induced NF-KB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. Studies were made in mice lacking the p47(phox) subunit of NAD(P)H oxidase as well as in cultured mouse lung vascular endothelial cells (MLVEC) from these mice. In response to TNFa challenge, NTF-K3 activation and ICAM-1 expression were significantly attenuated in lungs of p47(phox-/-)mice as compared with wild-type (V;T) mice. The attenuated NF-KB activation in p47(phox-/-) mice was secondary to inhibition of NIK activity and subsequent IKBalpha degradation. Induction of neutropenia using anti-PMN serum prevented the initial TNFalpha-induced NF-KB activation and ICAM-1 expression in WT mice, indicating the involvement of PMN NAD(P)H oxidase in signaling these responses. Moreover, the responses were restored upon repletion with PMN obtained from WT mice but not with PMN from p47(Phox-/-) mice. These findings were recapitulated in MILVEC co-cultured with PMN, suggesting that NF-KB activation and resultant ICAM-1 expression in endothelial cells occurred secondary to oxidants generated by the PMN NAD(P)H oxidase complex. The functional relevance of the PMN NAD(P)H oxidase in mediating TNFa-induced ICAM-1-dependent endothelial adhesivity was evident by markedly reduced adhesion of p47(Phox-/-) PMN in co-culture experiments. Thus, oxidant signaling by the PMN NAD(P)H oxidase complex is an important determinant of TNFa-induced NF-KB activation and ICAM-1 expression in endothelial cells.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Fan, J (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,Rm F-425 M-C 868, Chicago, IL 60612 USA.	jiefan@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL60678, T32 HL07829, HL27016, HL45638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027016, R01HL045638, T32HL007829, P01HL060678, R37HL027016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Balazovich KJ, 1996, BLOOD, V88, P690, DOI 10.1182/blood.V88.2.690.bloodjournal882690; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARLOS TM, 1994, BLOOD, V84, P2068; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Dusi S, 1996, J IMMUNOL, V157, P4615; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hohler B, 2000, HISTOCHEM CELL BIOL, V114, P29; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685, DOI 10.1165/ajrcmb.22.6.3925; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LO SK, 1993, AM J PHYSIOL, V264, pL406; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; Peng Q, 2000, CELL MOL LIFE SCI, V57, P834, DOI 10.1007/s000180050045; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Rahman A, 1999, MOL PHARMACOL, V55, P575; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHUMANN MA, 1995, J BIOL CHEM, V270, P13124, DOI 10.1074/jbc.270.22.13124; SZUCS S, 1994, J IMMUNOL METHODS, V167, P245, DOI 10.1016/0022-1759(94)90093-0; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514	42	109	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3404	3411		10.1074/jbc.M110054200	http://dx.doi.org/10.1074/jbc.M110054200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11729200	hybrid			2022-12-25	WOS:000173688000047
J	Tagami, S; Inokuchi, J; Kabayama, K; Yoshimura, H; Kitamura, F; Uemura, S; Ogawa, C; Ishii, A; Saito, M; Ohtsuka, Y; Sakaue, S; Igarashi, Y				Tagami, S; Inokuchi, J; Kabayama, K; Yoshimura, H; Kitamura, F; Uemura, S; Ogawa, C; Ishii, A; Saito, M; Ohtsuka, Y; Sakaue, S; Igarashi, Y			Ganglioside GM3 participates in the pathological conditions of insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; THIN-LAYER CHROMATOGRAPHY; GROWTH-FACTOR RECEPTOR; FACTOR-ALPHA; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; INTERMEDIATE FILAMENTS; EXPRESSION CLONING; GENE-EXPRESSION	Gangliosides are known as modulators of transmembrane signaling by regulating various receptor functions. We have found that insulin resistance induced by tumor necrosis factor-alpha (TNF-alpha) in 3T3-L1 adipocytes was accompanied by increased GM3 ganglioside expression caused by elevating GM3 synthase activity and its mRNA. We also demonstrated that TNF-alpha simultaneously produced insulin resistance by uncoupling insulin receptor activity toward insulin receptor substrate-1 (IRS-1) and suppressing insulin-sensitive glucose transport. Pharmacological depletion of GM3 in adipocytes by an inhibitor of glucosylceramide synthase prevented the TNF-alpha-induced defect in insulin-dependent tyrosine phosphorylation of IRS-1 and also counteracted the TNF-alpha-induced serine phosphorylation of IRS-1. Moreover, when the adipocytes were incubated with exogenous GM3, suppression of tyrosine phosphorylation of insulin receptor and IRS-1 and glucose uptake in response to insulin stimulation was observed, demonstrating that GM3 itself is able to mimic the effects of TNF on insulin signaling. We used the obese Zucker fa/fa rat and ob/ob mouse, which are known to overproduce TNF-alpha mRNA in adipose tissues, as typical models of insulin resistance. We found that the levels of GM3 synthase mRNA in adipose tissues of these animals were significantly higher than in their lean counterparts. Taken together, the increased synthesis of cellular GM3 by TNF may participate in the pathological conditions of insulin resistance in type 2 diabetes.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Natl Canc Ctr, Virol & Glycobiol Div, Chuo Ku, Tokyo 1040045, Japan	Hokkaido University; Hokkaido University; National Cancer Center - Japan	Inokuchi, J (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Chome, Sapporo, Hokkaido 0600812, Japan.	inokuchi@kinou02.pharm.hokudai.ac.jp	Inokuchi, Jin-ichi/AAW-9964-2020; Kabayama, Kazuya/ABD-5748-2020	Inokuchi, Jin-ichi/0000-0002-0703-5746; Kabayama, Kazuya/0000-0002-7583-5454; Fuse, Chie/0000-0002-8495-2580				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BREMER EG, 1982, BIOCHEM BIOPH RES CO, V106, P711, DOI 10.1016/0006-291X(82)91769-7; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GILLARD BK, 1992, CELL MOTIL CYTOSKEL, V21, P255, DOI 10.1002/cm.970210402; GILLARD BK, 1993, GLYCOBIOLOGY, V3, P57, DOI 10.1093/glycob/3.1.57; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Jimbo M, 2000, J BIOCHEM-TOKYO, V127, P485, DOI 10.1093/oxfordjournals.jbchem.a022631; KASAHARA K, 1994, ANAL BIOCHEM, V218, P224, DOI 10.1006/abio.1994.1164; Kellerer M, 1997, FEBS LETT, V418, P119, DOI 10.1016/S0014-5793(97)01357-4; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Markotic A, 1999, CARBOHYD RES, V321, P75, DOI 10.1016/S0008-6215(99)00171-8; Meuillet EJ, 2000, EXP CELL RES, V256, P74, DOI 10.1006/excr.1999.4509; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OHASHI M, 1979, LIPIDS, V14, P52, DOI 10.1007/BF02533566; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Qi C, 2000, P SOC EXP BIOL MED, V223, P128, DOI 10.1046/j.1525-1373.2000.22318.x; RADIN NS, 1993, ADV LIPID RES, V26, P183; REED BC, 1980, J BIOL CHEM, V255, P1711; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SAKAKIBARA K, 1981, NATURE, V293, P76, DOI 10.1038/293076a0; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TANAKA T, 1994, P 76 ANN M END SOC, V76, P374; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TSURUOKA T, 1993, J BIOL CHEM, V268, P2211; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VILCEK J, 1991, J BIOL CHEM, V266, P7313; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x	60	283	303	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3085	3092		10.1074/jbc.M103705200	http://dx.doi.org/10.1074/jbc.M103705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707432	hybrid			2022-12-25	WOS:000173688000006
J	von Ballmoos, C; Appoldt, Y; Brunner, J; Granier, T; Vasella, A; Dimroth, P				von Ballmoos, C; Appoldt, Y; Brunner, J; Granier, T; Vasella, A; Dimroth, P			Membrane topography of the coupling ion binding site in Na+-translocating F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-C OLIGOMER; PROPIONIGENIUM-MODESTUM; ENERGY TRANSDUCTION; F-ATPASE; ROTATION; F-0; H+; CARBODIIMIDES; F1F0-ATPASE; COMPLEX	A carbodiimide with a photoactivatable diazirine substituent was synthesized and incubated with the Na+-translocating F1F0 ATP synthase from both Propionigenium modestum and Ilyobacter tartaricus. This caused severe inhibition of ATP hydrolysis activity in the absence of Na+ ions but not in its presence, indicating the specific reaction with the Na+ binding c-Glu(65) residue. Photocross-linking was investigated with the substituted ATP synthase from both bacteria in reconstituted 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC)-containing proteoliposomes. A subunit c/POPC conjugate was found in the illuminated samples but no a-c cross-links were observed, not even after ATP-induced rotation of the c-ring. Our substituted diazirine moiety on c-Glu(65) was therefore in close contact with phospholipid but does not contact subunit a. Na-in(+)/Na-22(out)+ exchange activity of the ATP synthase was not affected by modifying the c-Glu(65) sites with the carbodiimide, but upon photoinduced cross-linking, this activity was abolished. Cross-linking the rotor to lipids apparently arrested rotational mobility required for moving Na+ ions back and forth across the membrane. The site of cross-linking was analyzed by digestions of the substituted POPC using phospolipases C and A(2) and by mass spectroscopy. The substitutions were found exclusively at the fatty acid side chains, which indicates that c-Glu(65) is located within the core of the membrane.	Swiss Fed Inst Technol, ETH Zentrum, Inst Mikrobiol Eidgenoss, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, ETH Zentrum, Inst Biochem, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, ETH Honggerberg, Lab Organ Chem Eidgenoss, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Dimroth, P (corresponding author), Swiss Fed Inst Technol, ETH Zentrum, Inst Mikrobiol Eidgenoss, CH-8092 Zurich, Switzerland.	dimroth@micro.biol.ethz.ch		von Ballmoos, Christoph/0000-0002-4642-6088				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dimroth P, 2000, J BIOENERG BIOMEMBR, V32, P449, DOI 10.1023/A:1005608823087; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; JASZAY ZM, 1987, SYNTHESIS-STUTTGART, P520; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, BIOCHEMISTRY-US, V37, P4626, DOI 10.1021/bi973022f; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kaim G, 1999, EMBO J, V18, P4118, DOI 10.1093/emboj/18.15.4118; KLUGE C, 1992, BIOCHEMISTRY-US, V31, P12665, DOI 10.1021/bi00165a017; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; KLUGE C, 1993, J BIOL CHEM, V268, P14557; KOHN J, 1982, J CHROMATOGR, V240, P262, DOI 10.1016/S0021-9673(01)84035-8; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; Matthey UH, 1997, EUR J BIOCHEM, V247, P820, DOI 10.1111/j.1432-1033.1997.t01-1-00820.x; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MOLINA P, 1994, SYNTHESIS-STUTTGART, P1197; Neumann W, 1998, CRYST RES TECHNOL, V33, P1; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Staudinger H, 1921, HELV CHIM ACTA, V4, P861, DOI 10.1002/hlca.19210040192; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; ZETZSCHE AC, 1940, CHEM BER, V73, P114	45	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3504	3510		10.1074/jbc.M110301200	http://dx.doi.org/10.1074/jbc.M110301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719523	hybrid			2022-12-25	WOS:000173688000060
J	Wilson, MC; Meredith, D; Halestrap, AP				Wilson, MC; Meredith, D; Halestrap, AP			Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; AMINO-ACID-TRANSPORT; IMMUNOGLOBULIN SUPERFAMILY; MONOCARBOXYLATE TRANSPORTER-1; MOUSE BASIGIN; MEMBRANE; PROTEIN; MEMBER; GLYCOPROTEIN; EXPRESSION	The monocarboxylate (lactate) transporters MCTI and MCT4 require the membrane-spanning glycoprotein CD147 for their correct plasma membrane expression and function. We have successfully expressed CD147 and MCTI tagged on their C or N termini with either the cyan (CFP) or yellow (YFP) variants of green fluorescent protein. The tagged proteins were correctly targeted to the plasma membrane of COS-7 cells and were functionally active. Measurements of fluorescence resonance energy transfer (FRET) between all combinations of the tagged proteins were made. FRET was observed when either the C or N terminus of MCT1 (intracellular) is tagged with CFP or YFP and co-expressed with CD147 tagged with YFP or CFP on the C terminus (intracellular) but not the N terminus (extracellular). FRET was also observed between two CD147 molecules when both YFP and CFP were on the C terminus but not when both were on the N terminus or one on either end. No FRET was observed between MCT1-YFP and MCT-CFP in any combination. A wide range of controls including photobleaching were employed to confirm that where FRET was observed, it was not an artifact of direct excitation of YFP by the CFP excitation laser. It was also shown that nonspecific overcrowding of proteins did not induce FRET. Because FRET only occurs between two fluorophores if they are less than 100 A apart and in a suitable orientation, our data provide important information on the topology of CD147 and MCTI within the plasma membrane. The minimum configuration consistent with the data is a dimer of CD147 associating with two MCT1 molecules such that the C terminus of CD147 in the cytosol is close to the C terminus of its partner CD147 and to the C and N termini of an associated MCT1 molecule. FRET may provide a non-invasive technique for measuring changes in these interactions in living cells.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	A.Halestrap@Bristol.ac.uk	Meredith, David/F-3664-2010; Halestrap, Andrew P/G-7275-2011	Wilson, Marieangela/0000-0001-6218-3533; Halestrap, Andrew/0000-0001-5374-2778				Abumrad N, 1998, J LIPID RES, V39, P2309; BISWAS C, 1995, CANCER RES, V55, P434; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BRUCE LJ, 1994, BLOOD, V84, P916; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; Gu C, 2001, CURR BIOL, V11, P185, DOI 10.1016/S0960-9822(01)00044-6; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Harpur AG, 2001, NAT BIOTECHNOL, V19, P167, DOI 10.1038/84443; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Meredith D, 2000, J PHYSIOL-LONDON, V526, p23P; MIYAUCHI T, 1995, J BIOCHEM-TOKYO, V118, P717, DOI 10.1093/oxfordjournals.jbchem.a124971; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Poole RC, 1997, J BIOL CHEM, V272, P14624, DOI 10.1074/jbc.272.23.14624; Rahman B, 1999, BIOCHEMISTRY-US, V38, P11577, DOI 10.1021/bi990973f; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; Shirozu M, 1996, GENOMICS, V37, P273, DOI 10.1006/geno.1996.0560; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	39	141	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3666	3672		10.1074/jbc.M109658200	http://dx.doi.org/10.1074/jbc.M109658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719518	hybrid			2022-12-25	WOS:000173688000080
J	Chuong, SDX; Mullen, RT; Muench, DG				Chuong, SDX; Mullen, RT; Muench, DG			Identification of a rice RNA- and microtubule-binding protein as the multifunctional protein, a peroxisomal enzyme involved in the beta-oxidation of fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOVEMENT PROTEIN; CYTOSKELETON; LOCALIZATION; ASSOCIATION; TRANSLATION; HOMOLOG; DOMAINS; STAUFEN; TUBULIN	The control of subcellular mRNA localization and translation is often mediated by protein factors that are directly or indirectly associated with the cytoskeleton. We report the identification and characterization of a rice seed protein that possesses both RNA and microtubule binding activities. In vitro UV cross-linking assays indicated that this protein binds to all mRNA sequences tested, although there was evidence for preferential binding to RNAs that contained A-C nucleotide sequence motifs. The protein was purified to homogeneity using a two-step procedure, and amino acid sequencing identified it as the multifunctional protein (MFP), a peroxisomal enzyme known to possess a number of activities involved in the beta-oxidation of fatty acids. The recombinant version of this rice MFP binds to RNA in UV cross-linking and gel mobility shift experiments, co-sediments specifically with microtubules, and possesses at least two enzymatic activities involved in peroxisomal fatty acid beta-oxidation. Taken together these data suggest that MFP has an important role in mRNA physiology in the cytoplasm, perhaps in regulating the localization or translation of mRNAs through an interaction with microtubules, in addition to its peroxisomal function.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Guelph, Dept Bot, Guelph, ON N1G 2W1, Canada	University of Calgary; University of Guelph	Muench, DG (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	dmuench@ucalgary.ca		Chuong, Simon/0000-0002-4171-5366				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALABAN N, 1990, EXP CELL RES, V191, P219, DOI 10.1016/0014-4827(90)90008-X; BARBARESE E, 1995, J CELL SCI, V108, P2781; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P161, DOI 10.1016/0003-9861(88)90624-8; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; Black DL, 1998, PRACT APPROACH SER, V192, P109; Boyko V, 2000, NAT CELL BIOL, V2, P826, DOI 10.1038/35041072; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Chan J, 1996, PLANT J, V10, P251, DOI 10.1046/j.1365-313X.1996.10020251.x; Choi SB, 2000, NATURE, V407, P765, DOI 10.1038/35037633; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; Corral-Debrinski M, 2000, MOL CELL BIOL, V20, P7881, DOI 10.1128/MCB.20.21.7881-7892.2000; Davies E, 1998, LOOK BEYOND TRANSCRIPTION, P115; DeFranco C, 1998, MOL BIOL CELL, V9, P1695, DOI 10.1091/mbc.9.7.1695; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; Durso NA, 1996, PROTOPLASMA, V190, P141, DOI 10.1007/BF01281313; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; Gomez G, 2001, MOL PLANT MICROBE IN, V14, P910, DOI 10.1094/MPMI.2001.14.7.910; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; HOWE JG, 1984, CELL, V37, P85; HUGDAHL JD, 1993, PLANT CELL, V5, P1063, DOI 10.1105/tpc.5.9.1063; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; JIANG CJ, 1993, J CELL SCI, V105, P891; Kaminski A, 1998, PRACT APPROACH SER, V192, P137; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; KUENG V, 1989, J BIOL CHEM, V264, P5203; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LI XX, 1993, CELL, V72, P869, DOI 10.1016/0092-8674(93)90576-C; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Lipshitz HD, 2000, CURR OPIN GENET DEV, V10, P476, DOI 10.1016/S0959-437X(00)00116-7; Lockhart A, 1998, J STRUCT BIOL, V124, P303, DOI 10.1006/jsbi.1998.4056; Marion RM, 1999, MOL CELL BIOL, V19, P2212; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MILLER KG, 1991, METHOD ENZYMOL, V196, P303; Muench DG, 1998, PLANT PHYSIOL, V116, P559, DOI 10.1104/pp.116.2.559; Muench DG, 2000, PLANTA, V211, P227, DOI 10.1007/PL00008159; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; Okita TW, 1998, J EXP BOT, V49, P1081, DOI 10.1093/jexbot/49.324.1081; Owens RA, 2001, MOL PLANT MICROBE IN, V14, P905, DOI 10.1094/MPMI.2001.14.7.905; Pratt WB, 2001, TRENDS PLANT SCI, V6, P54, DOI 10.1016/S1360-1385(00)01843-4; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; PREISS T, 1995, FEBS LETT, V367, P291, DOI 10.1016/0014-5793(95)00569-U; Rapp S, 1996, J CELL SCI, V109, P837; Reichel C, 1999, TRENDS PLANT SCI, V4, P458, DOI 10.1016/S1360-1385(99)01490-9; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Ruiz-Medrano R, 2001, CURR OPIN PLANT BIOL, V4, P202, DOI 10.1016/S1369-5266(00)00162-X; SCHELLENBAUM P, 1993, PLANT J, V3, P253, DOI 10.1046/j.1365-313X.1993.t01-17-00999.x; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sloboda RD, 1998, PROTEIN EXPRES PURIF, V13, P205, DOI 10.1006/prep.1998.0902; Smertenko A, 2000, NAT CELL BIOL, V2, P750, DOI 10.1038/35036390; Smith MD, 2001, CELL, V105, P293, DOI 10.1016/S0092-8674(01)00337-3; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; Vayda ME, 1998, LOOK BEYOND TRANSCRIPTION, P102; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Wu YJ, 1998, PLANT CELL PHYSIOL, V39, P1251, DOI 10.1093/oxfordjournals.pcp.a029328; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	74	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2419	2429		10.1074/jbc.M109510200	http://dx.doi.org/10.1074/jbc.M109510200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706039	hybrid			2022-12-25	WOS:000173421500009
J	Jablonka-Shariff, A; Garcia-Campayo, V; Boime, I				Jablonka-Shariff, A; Garcia-Campayo, V; Boime, I			Evolution of lutropin to chorionic gonadotropin generates a specific routing signal for apical release in vivo.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; MDCK CELLS; GLYCOPROTEIN HORMONES; SECRETORY GRANULES; EPITHELIAL-CELLS; SORTING SIGNALS; ALPHA-SUBUNIT; BETA-SUBUNIT; GLYCOSYLATION; LH	One of the fundamental differences among mammals is the mechanism of maintaining the corpus luteum of pregnancy. Placentation in primates is associated with the production of the glycoprotein hormone chorionic gonadotropin (CG), which is secreted into the maternal serum and stimulates progesterone synthesis from the corpus luteum, which is essential for early development of the embryo. CG together with the pituitary hormones lutropin (LH), follitropin, and thyrotropin constitute the family of glycoprotein hormones comprised of a common a subunit and a hormone-specific (3 subunit. The LHbeta and CGbeta subunits share 85% amino acid sequence identity, and functionally LH and CG are interchangeable. CGbeta evolved by a recent gene duplication event from the LHbeta locus, and despite the close relationship between them, their modes of secretion are quite different. CG release from the placenta is apically directed, whereas LH is released from the basal side of the cell, and the determinant(s) for this redirected trafficking are unknown. Here, using the polarized Madin-Darby canine kidney (MDCK) cell line, we provide evidence for the molecular basis of the different secretory patterns of LH and CG in vivo. The apical targeting of CG is programmed by a carboxyl-terminal sequence, which encodes a novel sorting signal. It is also apparent that the presence of the O-linked oligosaccharides in the CTP sequence contributes to this apical routing. The CTP, which is absent in LH, redirects CG to the maternal serum and permits the unique arrangement for primate placentation. Our data also show that the MDCK cells can distinguish the different secretory pathways for the gonadotropins and will be a valuable model for elucidating the determinants associated with the unique sorting of these functionally related hormones.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Boime, I (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid St, St Louis, MO 63110 USA.			Garcia-Campayo, Javier/0000-0002-3797-4218				BLOMQUIST JF, 1992, J BIOL CHEM, V267, P20798; BOYD JD, 1970, HUMAN PLACENTA, P157; BRAUNSTE.GD, 1972, ENDOCRINOLOGY, V91, P1030, DOI 10.1210/endo-91-4-1030; CONN PM, 1987, BIOL REPROD, V36, P17, DOI 10.1095/biolreprod36.1.17; CORLESS CL, 1985, ENDOCRINOLOGY, V117, P1699, DOI 10.1210/endo-117-4-1699; CURRIE RJW, 1995, J ENDOCRINOL, V147, P259, DOI 10.1677/joe.0.1470259; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JAFFE RB, 1978, REPRODUCTIVE ENDOCRI, P521; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LLOYD JM, 1988, ENDOCRINOLOGY, V122, P1282, DOI 10.1210/endo-122-4-1282; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; Muyan M, 1997, PLACENTA, V18, P237, DOI 10.1016/S0143-4004(97)80056-2; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Ogren Linda, 1994, P875; OWEN DM, 1989, J CLIN ENDOCR METAB, V53, P1307; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHOME B, 1973, J CLIN ENDOCR METAB, V36, P618, DOI 10.1210/jcem-36-3-618; Simons K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P101; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; SOWERS JR, 1979, J ENDOCRINOL, V80, P83, DOI 10.1677/joe.0.0800083; SUEMIZU H, 1988, ACTA HISTOCHEM CYTOC, V21, P265, DOI 10.1267/ahc.21.265; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; THIEDE HA, 1963, OBSTET GYNECOL, V22, P433; Thomas SG, 1997, ENDOCRINOLOGY, V138, P1347, DOI 10.1210/en.138.3.1347; WYNN RM, 1972, AM J OBSTET GYNECOL, V114, P339, DOI 10.1016/0002-9378(72)90612-6; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	36	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					879	882		10.1074/jbc.C100402200	http://dx.doi.org/10.1074/jbc.C100402200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11723109	hybrid			2022-12-25	WOS:000173166800003
J	Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F				Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F			RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours	ONCOGENE			English	Article						methylation; 3p tumour suppressor gene; neuroblastoma; phaeochromocytoma	HOMOZYGOUS DELETION; LUNG-CANCER; GENE-EXPRESSION; SHORT ARM; SUPPRESSOR; PHEOCHROMOCYTOMA; HETEROZYGOSITY; IDENTIFICATION; TUMORS; CHROMOSOME-3	Deletions of chromosome 3p are frequent in many types of neoplasia including neural crest tumours such as neuroblastoma (NB) and phaeochromocytoma. Recently we isolated several candidate tumour suppressor genes (TSGs) from a 120 kb critical interval at 3p21.3 defined by overlapping homozygous deletions in lung and breast tumour lines. Although mutation analysis of candidate TSGs in lung and breast cancers revealed only rare mutations, expression of one of the genes (RASSF1A) was absent in the majority of lung tumour cell lines analysed. Subsequently methylation of a CpG island in the promoter region of RASSF1A was demonstrated in a majority of small cell lung carcinomas and to a lesser extent in non-small cell lung carcinomas. To investigate the role of 3p TSGs in neural crest tumours, we (a) analysed phaeochromocytomas for 3p allele loss (n = 41) and RASSF1A methylation (n = 23) and (b) investigated 67 neuroblastomas for RASSF1A inactivation. 46% of phaeochromocytomas showed 3p allele loss (38.5% at 3p21.3). RASSF1A promoter region hypermethylation was found in 22% (5/23) of sporadic phaeochromocytomas and in 55% (37/67) of neuroblastomas analysed but RASSF1A mutations were not identified. In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. As frequent methylation of the CASP8 gene has also been reported in neuroblastoma, we investigated whether RASSF1A and CASP8 methylation were independent or related events. CASP8 methylation was detected in 56% of neuroblastomas with RASSF1A methylation and 17% without RASSF1A methylation (P = 0.0031). These results indicate that (a) RASSF1A inactivation by hypermethylation is a frequent event in neural crest tumorigenesis, particularly neuroblastoma, and that RASSF1A is a candidate 3p21.3 neuroblastoma TSG and (b) a subset of neuroblastomas may be characterized by a CpG island methylator phenotype.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Gothenburg, Sahlgrenska Univ Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Karolinska Inst, Karolinska Hosp, Dept Woman & Child Hlth, Childhood Canc Res Unit, S-17176 Stockholm, Sweden; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Univ Freiburg, Med Klin, D-79106 Freiburg, Germany; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Birmingham; Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; University of Birmingham; University of Freiburg; Kuopio University Hospital; Harvard University; Dana-Farber Cancer Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Cambridge	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		Martinsson, Tommy/J-4140-2013; MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012	Martinsson, Tommy/0000-0002-9403-3123; MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Eng, Charis/0000-0002-3693-5145; Voutilainen, Raimo/0000-0002-7858-665X; Kogner, Per/0000-0002-2202-9694; Cummins, Carole/0000-0001-5464-1944; Astuti, Dewi/0000-0003-4205-6160				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fullwood P, 1999, CANCER RES, V59, P4662; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Hoehner JC, 1998, LAB INVEST, V78, P29; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Lerman MI, 2000, CANCER RES, V60, P6116; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; MOLEY JF, 1991, CANCER RES, V51, P1596; MORRISSEY C, 2001, IN PRESS CANC RES; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303	27	108	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7573	7577		10.1038/sj.onc.1204968	http://dx.doi.org/10.1038/sj.onc.1204968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709729				2022-12-25	WOS:000171976900014
J	Suvas, S; Singh, V; Sahdev, S; Vohra, H; Agrewala, JN				Suvas, S; Singh, V; Sahdev, S; Vohra, H; Agrewala, JN			Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD4(+) T-CELLS; INDUCED APOPTOSIS; SOLUBLE FORM; IN-VIVO; COSTIMULATORY SIGNALS; COUNTER-RECEPTOR; INTERFERON-GAMMA; CYTOPLASMIC TAIL; CD40 LIGAND; BCL-X	To date, not much has been known regarding the role of CD80 and CD86 molecules in signaling of B cells. The CD28/CTLA4 ligands, CD80 (B7-1) and CD86 (B7-2), are expressed on the surface of freshly isolated splenic B cells, and their expression is up-regulated by lipopolysaccharides. In the present study, we have investigated whether signaling via CD80/CD86 could alter the proliferation and immunoglobulin synthesis of B cells. Splenic B cells were stimulated with lipopolysaccharides in the presence of anti-B7-1 (16-10A1) and anti-B7-2 (GL1) monoclonal antibodies (mAbs). Exciting features observed during the study were that cross-linking of CD86 with GL1 enhanced the proliferation and production of IgG1 and IgG2a isotypes. In contrast, anti-B7-1 (16-10A1) mAb could efficiently block the proliferation and production of IgG1 and IgG2a. Furthermore, GL1 mAb could also induce the secretion of IgG isotypes from B cell lymphomas. Importantly, 16-10A1 could retard the growth of lymphomas and favored the up-regulation of pro-apoptotic molecules caspase-3, caspase-8, Fas, FasL, Bak, and Bax and down-regulation of antiapoptotic molecule Bcl-x(L). In contrast, GL1 augmented the level of anti-apoptotic molecules Bcl-w and Bel-x(L) and decreased the levels of pro-apoptotic molecule caspase-8, thereby providing a novel insight into the mechanism whereby triggering through CD80 and CD86 could deliver regulatory signals. Thus, this study is the first demonstration of a distinct signaling event induced by CD80 and CD86 molecules in B cell lymphoma. Finally, the significance of the finding is that CD80 provided negative signal for the proliferation and IgG secretion of normal B cells and B cell lymphomas. In contrast, CD86 encouraged the activity of B cells.	Inst Microbial Technol, Immunol Lab, Chandigarh 160036, India; Postgrad Inst Med Educ & Res, Dept Expt Med, Chandigarh 160036, India; Ctr DNA Fingerprinting & Diagnost, Hyderabad 500076, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Agrewala, JN (corresponding author), Inst Microbial Technol, Immunol Lab, Sector 39A, Chandigarh 160036, India.		Agrewala, Javed Naim/AAS-8449-2021					AGREWALA JN, 1994, EUR J IMMUNOL, V24, P2092, DOI 10.1002/eji.1830240924; Agrewala JN, 1998, J IMMUNOL, V160, P1067; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BAJORATH J, 1994, PROTEIN SCI, V3, P2148, DOI 10.1002/pro.5560031128; Baskar S, 1996, J IMMUNOL, V156, P3821; Bergamo A, 1997, BRIT J HAEMATOL, V97, P652, DOI 10.1046/j.1365-2141.1997.1032919.x; Billian G, 1997, EUR J IMMUNOL, V27, P405, DOI 10.1002/eji.1830270210; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Budd RC, 2001, CURR OPIN IMMUNOL, V13, P356, DOI 10.1016/S0952-7915(00)00227-2; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAMLE NK, 1992, J IMMUNOL, V148, P1985; Doty RT, 1996, J IMMUNOL, V157, P3270; Doty RT, 1998, J IMMUNOL, V161, P2700; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Gajewski TF, 1996, J IMMUNOL, V156, P2909; Goldstein MD, 1996, J IMMUNOL, V157, P2837; GORDON J, 1988, J IMMUNOL, V140, P1425; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; HAN SH, 1995, J IMMUNOL, V155, P556; Hasnain SE, 1999, J BIOSCIENCE, V24, P13, DOI 10.1007/BF02941101; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; Hirokawa M, 1996, IMMUNOL LETT, V50, P95, DOI 10.1016/0165-2478(96)02526-6; HIROKAWA M, 1995, IMMUNOLOGY, V86, P155; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Katz E, 2001, J IMMUNOL, V166, P137, DOI 10.4049/jimmunol.166.1.137; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nakajima A, 1998, J IMMUNOL, V161, P1901; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; *PHARM, 1998, PHARM INSTR MAN AP A, P77; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; RONCHESE F, 1994, J EXP MED, V179, P809, DOI 10.1084/jem.179.3.809; Sah NK, 1999, P NATL ACAD SCI USA, V96, P4838, DOI 10.1073/pnas.96.9.4838; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; SETHNA MP, 1994, IMMUNITY, V1, P415, DOI 10.1016/1074-7613(94)90072-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Thomas A, 2000, LEUKEMIA RES, V24, P813, DOI 10.1016/S0145-2126(00)00051-5	50	171	190	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7766	7775		10.1074/jbc.M105902200	http://dx.doi.org/10.1074/jbc.M105902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11726649	hybrid			2022-12-25	WOS:000174268000020
J	Woods, AJ; Roberts, MS; Choudhary, J; Barry, ST; Mazaki, Y; Sabe, H; Morley, SJ; Critchley, DR; Norman, JC				Woods, AJ; Roberts, MS; Choudhary, J; Barry, ST; Mazaki, Y; Sabe, H; Morley, SJ; Critchley, DR; Norman, JC			Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ACTIN MESSENGER-RNA; BINDING PROTEIN; FOCAL ADHESIONS; LD MOTIFS; LOCALIZATION; RECOGNITION; PAG3/PAP-ALPHA/KIAA0400; RECRUITMENT; COMPARTMENT	Using mass spectrometry we have identified proteins which co-immunoprecipitate with paxillin, an adaptor protein implicated in the integrin-mediated signaling pathways of cell motility. A major component of paxillin immunoprecipitates was poly(A)-binding protein 1, a 70-kDa mRNA-binding protein. Poly(A)-binding protein 1 associated with both the alpha and beta isoforms of paxillin, and this was unaffected by RNase treatment consistent with a protein-protein interaction. The NH2-terminal region of paxillin (residues 54-313) associated directly with poly(A)-binding protein 1 in cell lysates, and with His-poly(A)-binding protein 1 immobilized in microtiter wells. Binding was specific, saturable and of high affinity (K-d of approximate to10 nm). Cell fractionation studies showed that at steady state, the bulk of paxillin and poly(A)-binding protein 1 was present in the "dense" polyribosome-associated endoplasmic reticulum. However, inhibition of nuclear export with leptomycin B caused paxillin and poly(A)-binding protein 1 to accumulate in the nucleus, indicating that they shuttle between the nuclear and cytoplasmic compartments. When cells migrate, poly(A)binding protein 1 colocalized with paxillin-beta at the tips of lamellipodia. Our results suggest a new mechanism whereby a paxillin-poly(A) -binding protein I complex facilitates transport of mRNA from the nucleus to sites of protein synthesis at the endoplasmic reticulum and the leading lamella during cell migration.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Biomol Sequencing Grp, Stevenage SG1 7NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Stevenage SG1 7NY, Herts, England; Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Univ Sussex, Sch Biol Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England	University of Leicester; GlaxoSmithKline; GlaxoSmithKline; University of Sussex	Norman, JC (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	jcn2@le.ac.uk	Sabe, Hisataka/GPF-4385-2022; Choudhary, Jyoti/S-1232-2017; Sabe, Hisataka/A-4066-2012	Choudhary, Jyoti/0000-0003-0881-5477; NORMAN, Jim/0000-0002-0098-3014; Mazaki, Yuichi/0000-0003-4192-0834				Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Bassell GJ, 1998, J NEUROSCI, V18, P251; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Calado A, 2000, J CELL SCI, V113, P2309; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Huttelmaier S, 2001, J CELL BIOL, V155, P775, DOI 10.1083/jcb.200105044; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Latham VM, 2001, CURR BIOL, V11, P1010, DOI 10.1016/S0960-9822(01)00291-3; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; Mohr E, 2001, P NATL ACAD SCI USA, V98, P7072, DOI 10.1073/pnas.111146598; Mohr E, 2001, EUR J NEUROSCI, V13, P1107, DOI 10.1046/j.0953-816x.2001.01477.x; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; NIKOLOPOULOS SN, 2001, J BIOL CHEM, V5, P5; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Plonne D, 1999, ANAL BIOCHEM, V276, P88, DOI 10.1006/abio.1999.4311; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shestakova EA, 2001, P NATL ACAD SCI USA, V98, P7045, DOI 10.1073/pnas.121146098; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2000, J CELL SCI, V113, P4139; Uchida H, 2001, J EXP MED, V193, P955, DOI 10.1084/jem.193.8.955; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7	47	88	91	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6428	6437		10.1074/jbc.M109446200	http://dx.doi.org/10.1074/jbc.M109446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11704675	hybrid			2022-12-25	WOS:000173989200097
J	Fortenberry, Y; Hwang, JR; Apletalina, EV; Lindberg, I				Fortenberry, Y; Hwang, JR; Apletalina, EV; Lindberg, I			Functional characterization of proSAAS - Similarities and differences with 7B2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE POLYPEPTIDE 7B2; PROHORMONE CONVERTASE PC2; ENZYMATIC CHARACTERIZATION; ATT-20 CELLS; CT PEPTIDE; IDENTIFICATION; PROENKEPHALIN; FURIN; PURIFICATION; INHIBITION	Prohormone convertases (PC) 1 and 2, enzymes found primarily in neuroendocrine tissues, are thought to mediate the proteolytic cleavage of many peptide precursors. To date, endogenous binding proteins for both PC2 (7132) and PC1 (proSAAS) have been identified. Although 7132 represents a potent inhibitor of PC2, the most important function of 7132 as regards this enzyme appears to be the absolute requirement of PC2 for 7132 in the generation of active enzyme, recently corroborated through production of a null animal that lacks PC2 activity. The purpose of the present study was to determine whether proSAAS exerts effects on PC1 other than inhibition, and to establish functional similarities and differences between 7112 and proSAAS. We first asked whether the N-terminal domain of proSAAS (proSAAS-(1-180)) could stabilize PC1 activity, similar to the effect of the N-terminal domain of 7132 on PC2. Recombinant His-tagged proSAAS-(1-180) had no effect on PC1 activity in vitro and was unable to protect PC 1 from thermal denaturation. Transient cotransfection of proSAAS-(1225) cDNA with PC1 cDNA into HEK 293 cells reduced the amount of PC1 activity detected in the medium. Surprisingly, cotransfection of proSAAS-(1-180) cDNA, encoding a protein that lacks the inhibitory C-terminal domain peptide, also reduced the activity of PC1 detected in the medium, but the mass of PC1 secreted into the medium was increased, suggesting a proSAAS-mediated inactivation reaction. Similar results were observed in CHO/PC1 cells stably transfected with proSAAS-(1-180). Stable transfection of SAAS cDNAs into AtT-20 cells was used to examine the role of proSAAS in a neuroendocrine setting. Unlike 7132, proSAAS-(1-225) was able to slow convertase-mediated processing of proopiomelanocortin and proenkephalin; however, similarly to 7132, proSAAS expression did not result in any accumulated differences in the content of cellular processed peptide. In summary, although both proSAAS and 7112 potently inhibit PC enzymes via a C-terminal peptide, their intracellular interactions with PCs appear to differ significantly, with each binding protein exhibiting unique properties.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@LSUHSC.edu	Lindberg, Iris/Q-3825-2019		NIDA NIH HHS [DA05084, DA00204, R56 DA005084] Funding Source: Medline; NIDDK NIH HHS [DK49703S2, DK49703] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; Basak A, 2001, J BIOL CHEM, V276, P32720, DOI 10.1074/jbc.M104064200; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Cameron A., 2001, ENZYMES, V22, P291; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Gorham EL, 1996, DNA CELL BIOL, V15, P339, DOI 10.1089/dna.1996.15.339; Hwang JR, 2001, J NEUROCHEM, V79, P437, DOI 10.1046/j.1471-4159.2001.00594.x; Johanning K, 1996, J NEUROCHEM, V66, P898; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LINDBERG I, 1986, BIOCHEM BIOPH RES CO, V139, P1024, DOI 10.1016/S0006-291X(86)80280-7; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Lindberg I., 1995, METH NEUROSCI, V23, P94; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Oliva AA, 2000, BBA-PROTEIN STRUCT M, V1477, P338, DOI 10.1016/S0167-4838(99)00283-6; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; Sayah M, 2001, J NEUROCHEM, V76, P1833, DOI 10.1046/j.1471-4159.2001.00165.x; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	40	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5175	5186		10.1074/jbc.M104531200	http://dx.doi.org/10.1074/jbc.M104531200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719503	hybrid			2022-12-25	WOS:000173962900082
J	Guo, CY; Brautigan, DL; Larner, JM				Guo, CY; Brautigan, DL; Larner, JM			ATM-dependent dissociation of B55 regulatory subunit from nuclear PP2A in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CARBOXYL METHYLATION; MAMMALIAN-CELLS; DNA-REPLICATION; DEPHOSPHORYLATION; ASSOCIATION; PHOSPHORYLATION; EXPRESSION	Ionizing radiation (IR) is known to activate multiple cell cycle checkpoints that are thought to enhance the ability of cells to respond to DNA damage. Protein phosphatase 2A (PP2A) has been implicated in IR-induced activation of checkpoints; therefore, Jurkat cells were exposed to an activating dose of IR or sham treatment as control, and nuclear extracts were analyzed for PP2A by Mono Q anion exchange chromatography and microcystin affinity chromatography. PP2A exists in eukaryotic cells both as a heterodimer consisting of a 65-kDa scaffolding subunit (A) plus a 36-kDa catalytic subunit (C) and as ABC heterotrimers, containing one of a variety of regulatory (B) subunits. Here we show that IR produces a transient and reversible reduction in the amount of nuclear AB55C heterotrimer without affecting the AB'C heterotrimer or AC heterodimer. In ataxia telangiectasia-mutated (ATM)-deficient cells the amount of nuclear PP2A heterotrimer relative to heterodimer was not reduced by radiation, but the radiation response was restored by transfection of these cells with plasmids encoding ATM. Wortmannin, an inhibitor of kinases such as phosphatidylinositol 3-kinase, also prevented the IR-induced reduction in nuclear PP2A heterotrimer. The changes in nuclear PP2A occurred without a noticeable difference in the carboxyl-terminal methylation of the C subunit, which is known to influence association with B subunits. We conclude a novel ATM-dependent mechanism is regulating association of B55 subunits with nuclear PP2A in response to IR.	Univ Virginia, Hlth Sci Syst, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Hlth Sci Syst, Dept Radiat Oncol, Box 800383, Charlottesville, VA 22908 USA.	jml2p@virginia.edu			NCI NIH HHS [CA72622, CA77584] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077584, R29CA072622] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Brautigan DL, 1997, ADV SEC MESS PHOSPH, V31, P113; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Larner JM, 1997, CANCER SURV, V29, P25; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LIU VF, 1995, STEM CELLS, V13, P117; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; MUMBY M, 2001, SCI SIGNAL T KNOWLED, V79, P1; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; Price NE, 2000, BIOCHEMISTRY-US, V39, P11312, DOI 10.1021/bi0008478; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	51	37	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4839	4844		10.1074/jbc.M110092200	http://dx.doi.org/10.1074/jbc.M110092200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11723136	hybrid			2022-12-25	WOS:000173962900039
J	Murata, M; Okimura, Y; Iida, K; Matsumoto, M; Sowa, H; Kaji, H; Kojima, M; Kangawa, K; Chihara, K				Murata, M; Okimura, Y; Iida, K; Matsumoto, M; Sowa, H; Kaji, H; Kojima, M; Kangawa, K; Chihara, K			Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETAGOGUE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; ACTIVATED PROTEIN-KINASE; RECEPTOR SUBSTRATE-1; PEPCK GENE; PHOSPHATIDYLINOSITOL 3'-KINASE; EXPRESSION; TRANSCRIPTION; PITUITARY; RAT	Ghrelin was identified in the stomach as an endogenous ligand specific for the growth hormone secretagogue receptor (GHS-R). GHS-R is found in various tis- sues, but its function is unknown. Here we show that GHS-R is found in hepatoma cells. Exposure of these cells to ghrelin caused up-regulation of several insulin-induced activities including tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1), association of the adapter molecule growth factor receptor-bound protein 2 with IRS-1, mitogen-activated protein kinase activity, and cell proliferation. Unlike insulin, ghrelin inhibited Akt kinase activity as well as up-regulated gluconeogenesis. These findings raise the possibility that ghrelin modulates insulin activities in humans.	Kobe Univ, Sch Med, Dept Basic Allied Med, Kobe, Hyogo 6540142, Japan; Kobe Univ, Sch Med, Div 3, Kobe, Hyogo 6540142, Japan; Kobe Univ, Sch Med, Div 2, Kobe, Hyogo 6540142, Japan; Coll Nursing Art & Sci, Akashi, Hyogo 6738588, Japan; Natl Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan	Kobe University; Kobe University; Kobe University; National Cerebral & Cardiovascular Center - Japan	Okimura, Y (corresponding author), Kobe Univ, Sch Med, Dept Basic Allied Med, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.		Iida, Keiji/ABB-5126-2021	Iida, Keiji/0000-0002-1516-7757				Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Clark RG, 1997, ENDOCRINOLOGY, V138, P4316, DOI 10.1210/en.138.10.4316; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MOMANY FA, 1984, ENDOCRINOLOGY, V114, P1531, DOI 10.1210/endo-114-5-1531; Muller EE, 1999, PHYSIOL REV, V79, P511, DOI 10.1152/physrev.1999.79.2.511; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/pnas.92.15.7001; PERMIS A, 1995, P NATL ACAD SCI USA, V92, P7971; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Skinner MM, 1998, J CLIN ENDOCR METAB, V83, P4314, DOI 10.1210/jc.83.12.4314; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614	33	228	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5667	5674		10.1074/jbc.M103898200	http://dx.doi.org/10.1074/jbc.M103898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724768	hybrid			2022-12-25	WOS:000173962900144
J	Ananthanarayanan, B; Das, S; Rhee, SG; Murray, D; Cho, W				Ananthanarayanan, B; Das, S; Rhee, SG; Murray, D; Cho, W			Membrane targeting of C2 domains of phospholipase C-delta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN INTERACTIONS; DIFFERENTIAL ROLES; BINDING DOMAIN; COMMON FOLD; SYNAPTOTAGMIN; C-DELTA-1; LIGANDS; ALPHA; MOTIF	The C2 domain is a Ca2+-dependent membrane-targeting module found in many cellular proteins involved in signal transduction or membrane trafficking. To understand the mechanisms by which the C2 domain mediates the membrane targeting of PLC-delta isoforms, we measured the in vitro membrane binding of the C2 domains of PLC-delta1, -delta3, and -delta4 by surface plasmon resonance and monolayer techniques and their subcellular localization by time-lapse confocal microscopy. The membrane binding of the PLC-delta1-C2 is driven by nonspecific electrostatic interactions between the Ca2+-induced cationic surface of protein and the anionic membrane and specific interactions involving Ca2+, Asn(647), and phosphatidylserine (PS). The PS selectivity of PLC-delta1-C2 governs its specific Ca2+-dependent subcellular targeting to the plasma membrane. The membrane binding of the PLC-delta3-C2 also involves Ca2+-induced nonspecific electrostatic interactions and PS coordination, and the latter leads to specific subcellular targeting to the plasma membrane. In contrast to PLC-delta1-C2 and PLC-delta3-C2, PLC-delta4-C2 has significant Ca2+-independent membrane affinity and no PS selectivity due to the presence of cationic residues in the Ca2+-binding loops and the substitution of Ser for the Ca2+-coordinating Asp in position 717. Consequently, PLC-delta4-C2 exhibits unique prelocalization to the plasma membrane prior to Ca2+ import and non-selective Ca2+-mediated targeting to various cellular membranes, suggesting that PLC-delta4 might have a novel regulatory mechanism. Together, these results establish the C2 domains of PLC-delta isoforms as Ca2+-dependent membrane targeting domains that have distinct membrane binding properties that control their subcellular localization behaviors.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yang AS, 1999, PROTEINS, P66	37	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3568	3575		10.1074/jbc.M109705200	http://dx.doi.org/10.1074/jbc.M109705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11706040	hybrid			2022-12-25	WOS:000173688000068
J	Robinson, MJ; Tessier, P; Poulsom, R; Hogg, N				Robinson, MJ; Tessier, P; Poulsom, R; Hogg, N			The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RELATED PROTEIN-8; ARACHIDONIC-ACID; ZINC-BINDING; FATTY-ACIDS; MIGRATION; NEUTROPHILS; RECEPTOR; MRP-14; CP-10; MONOCYTES	The S100 family proteins MRP-8 (S100A8) and MRP-14 (S100A9) form a heterodimer that is abundantly expressed in neutrophils, monocytes, and some secretory epithelia. In inflamed tissues, the MRP-8/14 complex is deposited onto the endothelium of venules associated with extravasating leukocytes. To explore the receptor interactions of MRP-8/14, we use a model system in which the purified MRP-8/14 complex binds to the cell surface of an endothelial cell line, HMEC-1. This interaction is mediated by the MRP-14 subunit and is mirrored by recombinant MRP-14 alone. The cell surface binding of MRP-14 was blocked by heparin, heparan sulfate, and chondroitin sulfate B, and the binding sites were sensitive to heparinase I and trypsin treatment but not to chondroitinase ABC. Furthermore MRP-8/14 and MRP-14 did not bind to a glycosaminoglycan-minus cell line. MRP-14 has a high affinity for heparin (K-d = 6.1 +/- 3.4 nm), and this interaction mimicked that with the endothelial cells. We therefore conclude that the MRP-8/14 complex binds to endothelial cells via the MRP-14 subunit interacting chiefly with heparan sulfate proteoglycans. CD36 and RAGE, two other putative receptors for MRP-8/14, were not expressed by HMEC-1 cells. This binding activity may explain the immobilization of the MRP-8/14 complex on endothelium that is observed in vivo.	Imperial Canc Res Fund, Leukocyte Adhes Lab, London WC2A 3PX, England; In Situ Hybridizat Serv, London WC2A 3PX, England; Histopathol Unit, London WC2A 3PX, England	Cancer Research UK	Hogg, N (corresponding author), Imperial Canc Res Fund, Leukocyte Adhes Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	hogg@icrf.icnet.uk	Tessier, Philippe/A-4466-2010	Tessier, Philippe/0000-0001-7177-7763				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Eue I, 2000, INT IMMUNOL, V12, P1593, DOI 10.1093/intimm/12.11.1593; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Newton RA, 1998, J IMMUNOL, V160, P1427; Nishimura E, 1999, J DENT RES, V78, P1251, DOI 10.1177/00220345990780060901; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Robinson MJ, 2000, BIOCHEM BIOPH RES CO, V275, P865, DOI 10.1006/bbrc.2000.3407; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SENIOR PV, 1988, DEVELOPMENT, V104, P431; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; Srikrishna G, 2001, J IMMUNOL, V166, P4678, DOI 10.4049/jimmunol.166.7.4678; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Tanaka Y, 1993, Curr Top Microbiol Immunol, V184, P99; Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821	37	178	194	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3658	3665		10.1074/jbc.M102950200	http://dx.doi.org/10.1074/jbc.M102950200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723110	hybrid			2022-12-25	WOS:000173688000079
J	Scheper, GC; van Kollenburg, B; Hu, JZ; Luo, YJ; Goss, DJ; Proud, CG				Scheper, GC; van Kollenburg, B; Hu, JZ; Luo, YJ; Goss, DJ; Proud, CG			Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BINDING PROTEIN; FACTOR EIF-4E; SIGNALING PATHWAYS; FACTOR EIF4E; FACTOR 4G; TRANSLATION; MNK1; SITE; YEAST	In eukaryotes, a key step in the initiation of translation is the binding of the eukaryotic initiation factor 4E (eIF4E) to the cap structure of the mRNA. Subsequent recruitment of several components, including the small ribosomal subunit, is thought to allow migration of initiation complexes and recognition of the initiation codon. Mitogens and cytokines stimulate the phosphorylation of eIF4E at Ser(209), but the functional consequences of this modification have remained a major unresolved question. Using fluorescence spectroscopy and surface plasmon resonance techniques, we show that phosphorylation of eIF4E markedly reduces its affinity for capped RNA, primarily due to an increased rate of dissociation. Variant e1F4E proteins harboring negatively charged acidic residues at position 209 also showed decreased binding to capped RNA. Furthermore, a basic residue at position 159 was shown to be essential for cap binding. Although eIF4E-binding protein I greatly stabilized binding of phosphorylated eIF4E to capped RNA, in the presence of eIF4E-binding protein 1 the phosphorylated form still dissociated faster compared with nonphopshorylated eIF4E. The implications of our findings for the mechanism of translation initiation are discussed.	Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY Hunter Coll, Grad Ctr, New York, NY 10021 USA	University of Dundee; City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)	Scheper, GC (corresponding author), Univ Dundee, Sch Life Sci, MSI WTB Complex, Dundee DD1 5EH, Scotland.	g.c.scheper@dundee.ac.uk	Hu, Jianzhong/P-6305-2014; Hu, Jianzhong/ABE-4311-2020; Scheper, Gert C/D-7001-2014	Hu, Jianzhong/0000-0001-8546-5111; Hu, Jianzhong/0000-0001-8546-5111; Proud, Christopher/0000-0003-0704-6442	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bi XP, 2000, BIOCHEMISTRY-US, V39, P5758, DOI 10.1021/bi992322p; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kleijn M, 1995, J CELL BIOCHEM, V59, P443, DOI 10.1002/jcb.240590405; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Novoa I, 1999, MOL CELL BIOL, V19, P2445; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Scheper GC, 2001, PROG MOLEC, V27, P39; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schwartz DC, 2000, MOL CELL BIOL, V20, P7933, DOI 10.1128/MCB.20.21.7933-7942.2000; SHA M, 1995, J BIOL CHEM, V270, P29904; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; Vilela C, 2000, EMBO J, V19, P4372, DOI 10.1093/emboj/19.16.4372; von der Haar T, 2000, J BIOL CHEM, V275, P30551, DOI 10.1074/jbc.M004565200; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	33	203	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3303	3309		10.1074/jbc.M103607200	http://dx.doi.org/10.1074/jbc.M103607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723111	hybrid			2022-12-25	WOS:000173688000034
J	Shah, OJ; Iniguez-Lluhi, JA; Romanelli, A; Kimball, SR; Jefferson, LS				Shah, OJ; Iniguez-Lluhi, JA; Romanelli, A; Kimball, SR; Jefferson, LS			The activated glucocorticoid receptor modulates presumptive autoregulation of ribosomal protein S6 protein kinase, p70 S6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; P70(S6K) SIGNALING PATHWAY; SKELETAL-MUSCLE; MESSENGER-RNAS; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ENHANCEMENT; DIFFERENTIAL REGULATION; PHOSPHORYLATION SITE; RESPONSE ELEMENT; DOWN-REGULATION	Protein metabolism in eukaryotic organisms is defined by a synthesis-degradation equilibrium that is subject to regulation by hormonal and nutritional signals. In mammalian tissues such as skeletal muscle, glucocorticoid hormones specify a catabolic response that influences both protein synthetic and protein degradative pathways. With regard to the former, glucocorticoids attenuate mRNA translation at two levels: translational efficiency, i.e. translation initiation, and translational capacity, i.e. ribosome biogenesis. Glucocorticoids may impair translational capacity through the ribosomal S6 protein kinase (p70 S6K), a recognized glucocorticoid target and an effector of ribosomal protein synthesis. We demonstrate here that the reduction in growth factor-activated p70 S6K activity by glucocorticoids depends upon a functional glucocorticoid receptor (GR) and that the GR is both necessary and sufficient to render p70 S6K subject to glucoriticoid regulation. Furthermore, the DNA binding and transcriptional activation but not repression properties of the GR are indispensable for p70 S6K regulation. Finally, a mutational analysis of the p70 S6K carboxyl terminus indicates that this region confers glucocorticoid sensitivity, and thus glucocorticoids may facilitate autoinhibition of the enzyme ultimately reducing the efficiency with which T389 is phosphorylated.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School	Jefferson, LS (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NIDDK NIH HHS [R01 DK061656-01, R01 DK061656, DK-15658] Funding Source: Medline; NIGMS NIH HHS [T32-GM-08619, T32 GM008619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061656, R01DK015658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Mohaisen M, 2000, STEROIDS, V65, P8, DOI 10.1016/S0039-128X(99)00076-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CAIRNS C, 1993, DNA CELL BIOL; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; GARLICK PJ, 1987, BIOCHEM J, V248, P439, DOI 10.1042/bj2480439; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Grammer TC, 1996, CANCER SURV, V27, P271; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KAYALI AG, 1987, AM J PHYSIOL, V252, pE621, DOI 10.1152/ajpendo.1987.252.5.E621; KELLY FJ, 1982, BIOCHEM J, V208, P147, DOI 10.1042/bj2080147; KIM YS, 1975, J BIOL CHEM, V250, P2293; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Kraiss LW, 2000, AM J PHYSIOL-HEART C, V278, pH1537, DOI 10.1152/ajpheart.2000.278.5.H1537; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; LIU W, 1995, MOL CELL BIOL, V15, P1005; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Meyer T, 1997, J BIOL CHEM, V272, P21090, DOI 10.1074/jbc.272.34.21090; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Monfar M, 1996, MOL ENDOCRINOL, V10, P1107, DOI 10.1210/me.10.9.1107; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; ODEDRA BR, 1983, BIOCHEM J, V214, P617, DOI 10.1042/bj2140617; ONATE SA, 1995, SCIENCE, V270, P1354; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rannels D E, 1980, Adv Myocardiol, V1, P493; RANNELS SR, 1978, AM J PHYSIOL, V235, pE134, DOI 10.1152/ajpendo.1978.235.2.E134; RANNELS SR, 1980, AM J PHYSIOL, V238, pE564, DOI 10.1152/ajpendo.1980.238.6.E564; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE76, DOI 10.1152/ajpendo.2000.278.1.E76; Shah OJ, 2000, BIOCHEM J, V347, P389, DOI 10.1042/0264-6021:3470389; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Webster JC, 1997, J BIOL CHEM, V272, P9287; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WERNERMAN J, 1989, CLIN SCI, V77, P611, DOI 10.1042/cs0770611; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355	78	21	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2525	2533		10.1074/jbc.M105935200	http://dx.doi.org/10.1074/jbc.M105935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11705993	hybrid			2022-12-25	WOS:000173421500022
J	Schinner, S; Dellas, C; Schroder, M; Heinlein, CA; Chang, CS; Fischer, J; Knepel, W				Schinner, S; Dellas, C; Schroder, M; Heinlein, CA; Chang, CS; Fischer, J; Knepel, W			Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; CAMP-RESPONSIVE ELEMENT; PPAR-GAMMA; INSULIN-RESISTANCE; MEMBRANE DEPOLARIZATION; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTORS; PROXIMAL PROMOTER; 3T3-L1 ADIPOCYTES; PROGLUCAGON GENE	The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is involved in glucose homeostasis and synthetic PPARgamma ligands, the thiazolidinedioues, a new class of antidiabetic agents that reduce insulin resistance and, as a secondary effect, reduce hepatic glucose output. PPARgamma is highly expressed in normal human pancreatic islet a-cells that produce glucagon. This peptide hormone is a functional antagonist of insulin stimulating hepatic glucose output. Therefore, the effect of PPARgamma and thiazolidinediones on glucagon gene transcription was investigated. After transient transfection of a glucagon-reporter fusion gene into a glucagon-producing pancreatic islet cell line, thiazolidinediones inhibited glucagon gene transcription when PPARgamma was coexpressed. They also reduced glucagon secretion and glucagon tissue levels in primary pancreatic islets. A 5'/3'-deletion and internal mutation analysis indicated that a pancreatic islet cell-specific enhancer sequence (PISCES) motif within the proximal glucagon promoter element G1 was required for PPARgamma responsiveness. This sequence motif binds the paired domain transcription factor Pax6. When the PISCES motif within G1 was mutated into a GAL4 binding site, the expression of GAL4-Pax6 restored glucagon promoter activity and PPARgamma responsiveness. GAL4-Pax6 transcriptional activity was inhibited by PPARgamma in response to thiazolidinedione treatment also at a minimal viral promoter. These results suggest that PPARgamma in a ligand-dependent but DNA binding-independent manner inhibits Pax6 transcriptional activity, resulting in inhibition of glucagon gene transcription. These data thereby define Pax6 as a novel functional target of PPARgamma and suggest that inhibition of glucagon gene expression may be among the multiple mechanisms through which thiazolidinediones improve glycemic control in diabetic subjects.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany; Univ Rochester, Med Ctr, Dept Pathol, Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA	University of Gottingen; University of Rochester; University of Rochester; University of Rochester	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40,Postfach 3742, D-37070 Gottingen, Germany.							Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Dubois M, 2000, DIABETOLOGIA, V43, P1165, DOI 10.1007/s001250051508; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; Freyse EJ, 1997, DIABETES, V46, P824, DOI 10.2337/diabetes.46.5.824; Furstenau U, 1999, J BIOL CHEM, V274, P5851, DOI 10.1074/jbc.274.9.5851; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Glass CK, 2000, GENE DEV, V14, P121; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; Herzig S, 2000, J BIOL CHEM, V275, P27989; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jin TR, 1996, MOL CELL BIOL, V16, P19; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KNEPEL W, 2001, MOL BASIS ENDOCRINE, P67; KREUTTER DK, 1990, DIABETES, V39, P1414, DOI 10.2337/diabetes.39.11.1414; Kruger M, 1997, N-S ARCH PHARMACOL, V356, P433, DOI 10.1007/PL00005073; LEFEBVRE PJ, 1995, DIABETES CARE, V18, P715, DOI 10.2337/diacare.18.5.715; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; Nawa T, 2000, BIOCHEM BIOPH RES CO, V275, P406, DOI 10.1006/bbrc.2000.3332; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Park KS, 1998, J CLIN ENDOCR METAB, V83, P1636, DOI 10.1210/jc.83.5.1636; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Reichardt HM, 2000, BIOL CHEM, V381, P961, DOI 10.1515/BC.2000.118; Reichardt HM, 1998, MOL CELL ENDOCRINOL, V146, P1, DOI 10.1016/S0303-7207(98)00208-1; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Stevenson RW, 1998, DIABETES, V47, P179, DOI 10.2337/diabetes.47.2.179; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; Uchimura K, 2001, HEPATOLOGY, V33, P91, DOI 10.1053/jhep.2001.21145; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wrege Antje, 1995, Gene Expression, V4, P205; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	72	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1941	1948		10.1074/jbc.M109718200	http://dx.doi.org/10.1074/jbc.M109718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707457	hybrid			2022-12-25	WOS:000173421300045
J	Bergami, PL; Scaglione, J; Levin, MJ				Bergami, PL; Scaglione, J; Levin, MJ			Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic	FASEB JOURNAL			English	Article						Chagas disease; beta 1-adrenoreceptor; G-protein-coupled receptors; arrhythmia; supraventricular tachycardia	CHAGAS HEART-DISEASE; HUMORAL AUTOIMMUNE-RESPONSE; AUTOANTIBODIES; MICE; INFECTION; RECEPTOR; EPITOPE; LUPUS; CARDIOMYOPATHY; ANTIGENS	Sera from patients with chronic Chagas heart disease recognize the carboxyl-terminal regions of the Trypanosoma cruzi ribosomal P proteins defined by B cell epitopes P013 (EDDDDDFGMGALF) and R13 (EEEDDDMGFGLFD) corresponding to the T. cruzi ribosomal P0 (TcP0) and P2 beta (TcP2 beta) proteins, respectively. It has been hypothesized that both epitopes may induce antibodies that cross-react and stimulate the beta1-adrenoreceptor. However, no proof as to their pathogenicity has been obtained. We investigated the consequences of immunizing mice with either TcP0 or TcP2 beta proteins. Of 24 immunized animals, 16 generated antibodies against the carboxyl-terminal end of the corresponding protein, 13 of which showed an altered ECG (P<0.001, 81%). Immunization with TcP0 induced anti-P013 antibodies that bind to and stimulate cardiac G-protein-coupled receptors and are linked to the induction of supraventricular arrhythmia, repolarization, and conduction abnormalities as monitored by serial electrocardiographic analysis. In contrast, immunization with TcP2<beta> generated anti-R13 antibodies with an exclusive beta1-adrenergic-stimulating activity whose appearance strictly correlated with the recording of supraventricular tachycardia and death. These findings demonstrate that anti-P antibodies are arrhythmogenic in the setting of a normal heart, since no inflammatory lesions or fibrosis were evident to light microscopic examination.	INGEBI, Lab Biol Mol Enfermedad Chagas, RA-1428 Buenos Aires, DF, Argentina		Levin, MJ (corresponding author), INGEBI, Lab Biol Mol Enfermedad Chagas, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	mlevin@dna.uba.ar						ANDRADE S G, 1987, Memorias do Instituto Oswaldo Cruz, V82, P59, DOI 10.1590/S0074-02761987000100010; AZNAR C, 1995, FEMS IMMUNOL MED MIC, V12, P231, DOI 10.1111/j.1574-695X.1995.tb00197.x; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; Borda ES, 1996, INT J CARDIOL, V54, P149, DOI 10.1016/0167-5273(96)02592-2; BRANDARIZ S, 1995, LANCET, V346, P1370, DOI 10.1016/S0140-6736(95)92388-8; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; Elies R, 1996, J IMMUNOL, V157, P4203; ELIZARI MV, 2000, ARRHYTMIA MANAGEMENT, P95; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Gehrmann J, 2000, J CARDIOVASC ELECTR, V11, P354, DOI 10.1111/j.1540-8167.2000.tb01806.x; GOLDBARG AN, 1968, CARDIOVASC RES, V2, P93, DOI 10.1093/cvr/2.1.93; HALPERIN C, 2000, ARRHYTHMIA MANAGEMEN, P83; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210; KISHIMOTO C, 1984, J AM COLL CARDIOL, V3, P1461, DOI 10.1016/S0735-1097(84)80285-5; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVIN MJ, 1993, FEMS IMMUNOL MED MIC, V7, P205, DOI 10.1111/j.1574-695X.1993.tb00400.x; LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530; LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x; LOPETEGUI R, 1983, COMM BIOL, V2, P195; LOPETEGUI R, 1983, COMM BIOL, V2, P79; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MULLER S, 1985, BIOCHIM BIOPHYS ACTA, V827, P235, DOI 10.1016/0167-4838(85)90208-0; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PILGRIM H I, 1955, Exp Med Surg, V13, P401; POSTAN M, 1987, AM J TROP MED HYG, V37, P541, DOI 10.4269/ajtmh.1987.37.541; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; RUIZ AM, 1985, ACTA TROP, V42, P299; SADIGURSKY M, 1986, BRAZ J MED BIOL RES, V19, P379; Schijman AG, 2000, J HEART LUNG TRANSPL, V19, P1114, DOI 10.1016/S1053-2498(00)00168-6; SCHIJMAN AG, 1992, IMMUNOL LETT, V33, P15, DOI 10.1016/0165-2478(92)90087-5; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; Tarleton RL, 1999, PARASITOL TODAY, V15, P94, DOI 10.1016/S0169-4758(99)01398-8; TEIXEIRA ARL, 1975, AM J PATHOL, V80, P163; Tekiel VS, 1997, PARASITOLOGY, V115, P495, DOI 10.1017/S0031182097001625; TOMITA M, 1991, CIRCULATION, V83, P635, DOI 10.1161/01.CIR.83.2.635	39	45	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2602	2612		10.1096/fj.01-0132com	http://dx.doi.org/10.1096/fj.01-0132com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726536				2022-12-25	WOS:000172964800030
J	Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M				Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M			RET/PTC1 oncogene signaling in PCCl 3 thyroid cells requires the small GTP-binding protein Rho	ONCOGENE			English	Article						RET; tyrosine-kinase; Rho; Ras; Rac; actin; thyroid; apoptosis	RET TYROSINE KINASE; NEOPLASTIC TRANSFORMATION; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; DOCKING SITE; FAMILY; RAS; ACTIVATION; GTPASES; SHC	Thyroid papillary carcinomas are characterized by RET/PTC rearrangements that cause the tyrosine kinase domain of the RET receptor to fuse with N-terminal sequences encoded by heterologous genes. This results in the aberrant expression of a ligand-independent and constitutively active RET kinase. We analysed actin reorganization induced by the RET/PTC1 oncogene in PC Cl 3 rat thyroid epithelial cells. Differently from oncogenes Src, Ras and Raf, RET/PTC1 caused actin filaments to form prominent stress fibers. Moreover, stress fibers were identified in human thyroid papillary carcinoma cell lines harboring RET/PTC1 rearrangements but not in thyroid carcinoma cells negative for RET/PTC rearrangements. RET/MEN 2A, a constitutively active but unrearranged membrane-bound RET oncoprotein, did not induce stress fibers in PC CI 3 cells. Induction of stress fibers by RET/PTC1 was restricted to thyroid cells; it did not occur in NIH3T3 fibroblasts or MCF7 mammary cells. RET/PTC1-mediated stress fiber formation depended on Rho but not Rac small GTPase activity. In addition, inhibition of Rho, but not of Rac, caused apoptosis of RET/PTC1-expressing thyroid cells. We conclude that Rho is implicated in the actin reorganization and cell survival mediated by the chimeric RET/PTC1 oncogene in thyroid epithelial cells, both phenotypes being cell type- and oncogene type-specific.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Sannio, I-82100 Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; University of Sannio	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Tramontano, Donatella/AAS-1740-2020; melillo, rosa marina/O-5255-2015	Fusco, Alfredo/0000-0003-3332-5197; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275; Tramontano, Donatella/0000-0002-9308-034X; BARONE, Maria Vittoria/0000-0001-6190-4917				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Ponder BAJ, 1999, CANCER RES, V59, p1736S; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; VAN AL, 1997, GENE DEV, V11, P2295; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	46	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					6973	6982		10.1038/sj.onc.1204886	http://dx.doi.org/10.1038/sj.onc.1204886			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704822				2022-12-25	WOS:000171739300001
J	Wilkinson, FH; London, FS; Walsh, PN				Wilkinson, FH; London, FS; Walsh, PN			Residues 88-109 of factor IXa are important for assembly of the factor X activating complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION-FACTOR-IX; FACTOR-LIKE DOMAIN; FACTOR-LIKE MODULES; VIIA TISSUE FACTOR; BLOOD-COAGULATION; HEMOPHILIA-B; CHRISTMAS-FACTOR; FACTOR-XIA	Activated platelets and phospholipid vesicles promote assembly of the intrinsic factor X (FX) activating complex by presenting high-affinity binding sites for blood coagulation FIXa, FVIIIa, and FX. Previous reports suggest that the second epidermal growth factor (EGF)-like domain of FIXa mediates assembly of the FX activating complex (Ahmad, S. S., Rawala, R., Cheung, W. F., Stafford, D. W., and Walsh, P. N. (1995) Biochem. J. 310, 427-431; Wong, M. Y., Gurr, J. A., and Walsh, P. N. (1999) Biochemistry 38, 8948-8960). To identify important residues, we prepared several chimeric FIXa proteins using homologous sequences from FVII: FIXa(FVIIEGF2) (FIXDelta88-124,delFVII91-127), FIXa(loop1), (FIXDelta88-99, delFV1191-102), FIXa(loop2), (FIXDelta95-109,delFVII98-112), FIXa(loop3), (FIXDelta111-124,delFVII114-127), and point mutants (FIXaR94D and FIXa(loop1)G94R). In the presence and absence of FVIIIa, a 2- to 10-fold reduced V-max of FX activation (n(M) FXa min(-1)) was observed for FIXa(FVIIEGF2), FIXa(loop1), FIXa(loop2), and FIXa(loop1)G94R, whereas FIXa(loop3) and FIXaR94D were normal. For all of the FIXa proteins, K-m(app) values were normal as were EC50 values for interactions with FVIIIa. However, K,(app) (in n(M)) for the FX activating complex assembled on phospholipid vesicles was increased for FIXa(FVIIGF2) (43.3 +/- 2.70), FIXa(loop1)(10.9 +/- 2.8), FIXa(loop2) (70.5 +/- 1.60), and FIXa(loop1)G94R (17.1 +/- 2.90) relative to FIXa(N) (3.9 +/- 0.11), FIXa(WT) (4.6 +/- 0.17), FIXa(loop3) (4.5 +/- 0.20), and FIXaR94D (2.2 +/- 0.09) suggesting that reduced V-max is a result of impaired complex assembly. These data indicate that residues 88-109 (but not Arg(94)) are important for normal assembly of the FX activating complex on phospholipid vesicles.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.ocis.temple.edu		Wilkinson, Frank/0000-0001-6003-3478	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, P01HL056914, R01HL046213] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad SS, 1998, BIOCHEMISTRY-US, V37, P1671, DOI 10.1021/bi971591h; AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; AHMAD SS, 1989, J BIOL CHEM, V264, P20012; AHMAD SS, 1992, J BIOL CHEM, V267, P8571; AHMAD SS, 1995, BIOCHEM J, V310, P427, DOI 10.1042/bj3100427; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; ASTERMARK J, 1994, J BIOL CHEM, V269, P3690; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHANCE PF, 1983, HUM GENET, V65, P207, DOI 10.1007/BF00286666; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DIXON WJ, 1969, INTRO STATISTICAL AN, P207; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; Hertzberg MS, 1999, BLOOD, V94, P156, DOI 10.1182/blood.V94.1.156.413k15_156_163; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HULTIN MB, 1982, J CLIN INVEST, V69, P950, DOI 10.1172/JCI110534; LIN SW, 1990, J BIOL CHEM, V265, P144; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOZIER JN, 1990, BLOOD, V75, P1097; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MORITA T, 1991, J BIOCHEM, V110, P990, DOI 10.1093/oxfordjournals.jbchem.a123701; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; RAWALASHEIKH R, 1992, BLOOD, V79, P398; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; STENFLO J, 1991, BLOOD, V78, P1637; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; VANDIEIJEN G, 1981, BIOCHEMISTRY-US, V20, P7096, DOI 10.1021/bi00528a007; WALSH PN, 1972, BRIT J HAEMATOL, V22, P743, DOI 10.1111/j.1365-2141.1972.tb05719.x; WALSH PN, 1984, HAEMATOLOGIA, V17, P57; Wilkinson FH, 2002, J BIOL CHEM, V277, P5734, DOI 10.1074/jbc.M107753200; WINER BJ, 1991, STAT PRINCIPLES EXPT, P158; Wong MY, 1999, BIOCHEMISTRY-US, V38, P8948, DOI 10.1021/bi982835g; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	46	23	24	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5725	5733		10.1074/jbc.M107027200	http://dx.doi.org/10.1074/jbc.M107027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726655	hybrid			2022-12-25	WOS:000173989200007
J	Do Carmo, S; Seguin, D; Milne, R; Rassart, E				Do Carmo, S; Seguin, D; Milne, R; Rassart, E			Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; GROSS CYSTIC-DISEASE; BREAST-CANCER CELLS; MESSENGER-RNA LEVELS; C-FOS TRANSCRIPTION; POTENTIAL Z-DNA; HANDED Z-DNA; D GENE; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION	Apolipoprotein D (apoD) and apolipoprotein E (apoE) are co-expressed in many tissues, and, in certain neuropathological situations, their expression appears to be under coordinate regulation. We have previously shown that apoD gene expression in cultured human fibroblasts is up-regulated when the cells undergo growth arrest. Here, we demonstrate that, starting around day 2 of growth arrest, both apoD and apoE mRNA levels increase between 1.5- and 27-fold in other cell types, including mouse primary fibroblasts and fibroblast-like and human astrocytoma cell lines. To understand the regulatory mechanisms of apoD expression, we have used apoD promoter-luciferase reporter constructs to compare gene expression in growing cells and in cells that have undergone growth arrest. Analysis of gene expression in cells transfected with constructs with deletions and mutations in the apoD promoter and constructs with artificial promoters demonstrated that the region between nucleotides -174 and -4 is fully responsible for the basal gene expression, whereas the region from -558 to -179 is implicated in the induction of apoD expression following growth arrest. Within this region, an alternating purine-pyrimidine stretch and a pair of serum-responsive elements (SRE) were found to be major determinants of growth arrest-induced apoD gene expression. Evidence is also presented that SREs in the apoE promoter may contribute to the up-regulation of apoE gene expression following growth arrest.	Univ Quebec, Dept Sci Biol, Mol Biol Lab, Montreal, PQ H3C 3P8, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W79, Canada	University of Quebec; University of Quebec Montreal; University of Ottawa; University of Ottawa Heart Institute	Rassart, E (corresponding author), Univ Quebec, Dept Sci Biol, Mol Biol Lab, CP 8888 Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.		Do Carmo, Sonia/ABC-8874-2021	Do Carmo, Sonia/0000-0002-6152-8613				ALBERS JJ, 1981, ATHEROSCLEROSIS, V39, P395, DOI 10.1016/0021-9150(81)90025-3; ARNDTJOVIN DJ, 1993, BIOCHEMISTRY-US, V32, P4862, DOI 10.1021/bi00069a023; ASPINALL JO, 1995, J UROLOGY, V154, P622, DOI 10.1016/S0022-5347(01)67123-4; ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; AYRAULTJARRIER M, 1963, B SOC CHIM BIOL, V45, P703; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; Benson BA, 1996, CELL IMMUNOL, V170, P245, DOI 10.1006/cimm.1996.0158; BLAIS Y, 1994, INT J CANCER, V59, P400, DOI 10.1002/ijc.2910590319; BOJANOVSKI D, 1980, FEBS LETT, V112, P251, DOI 10.1016/0014-5793(80)80191-8; BOYLES JK, 1990, J LIPID RES, V31, P2243; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CABRAL JHM, 1995, FEBS LETT, V366, P53, DOI 10.1016/0014-5793(95)00484-Q; CAMATO R, 1989, J LIPID RES, V30, P865; Cofer S, 1996, GENE, V171, P261, DOI 10.1016/0378-1119(96)00099-6; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; DIEZITZA I, 1994, AM J PATHOL, V144, P310; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLEY WG, 1990, BREAST CANCER RES TR, V16, P253, DOI 10.1007/BF01806333; Ding W, 1999, CANCER RES, V59, P3795; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; DRAYNA DT, 1987, DNA-J MOLEC CELL BIO, V6, P199, DOI 10.1089/dna.1987.6.199; Eichman BF, 1999, NUCLEIC ACIDS RES, V27, P543, DOI 10.1093/nar/27.2.543; ELLISON MJ, 1986, BIOCHEMISTRY-US, V25, P3648, DOI 10.1021/bi00360a026; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GILMOUR RS, 1984, EMBO J, V3, P1263, DOI 10.1002/j.1460-2075.1984.tb01961.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAGENSEN DE, 1986, DIS BREAST, P250; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herbert A, 1999, GENETICA, V106, P37, DOI 10.1023/A:1003768526018; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERRICK KR, 1993, GENE, V126, P203, DOI 10.1016/0378-1119(93)90368-D; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Kim SY, 1996, MOL CARCINOGEN, V16, P6, DOI 10.1002/(SICI)1098-2744(199605)16:1<6::AID-MC2>3.3.CO;2-W; KRAJEWSKI WA, 1995, FEBS LETT, V358, P13, DOI 10.1016/0014-5793(94)01377-D; Kuramoto N, 1999, JPN J PHARMACOL, V80, P103, DOI 10.1254/jjp.80.103; LAMBERT J, 1993, BIOCHIM BIOPHYS ACTA, V1172, P190, DOI 10.1016/0167-4781(93)90292-L; Lea O A, 1988, Steroids, V52, P337, DOI 10.1016/0039-128X(88)90135-3; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; Montpied P, 1999, EPILEPSY RES, V35, P135, DOI 10.1016/S0920-1211(99)00003-0; MORGAN IM, 1992, CELL PROLIFERAT, V25, P205, DOI 10.1111/j.1365-2184.1992.tb01395.x; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; Nejedly K, 1996, J BIOMOL STRUCT DYN, V13, P1007, DOI 10.1080/07391102.1996.10508915; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Omoike OI, 1999, BIOCHEM BIOPH RES CO, V262, P523, DOI 10.1006/bbrc.1999.1175; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; PECK LJ, 1985, CELL, V40, P129, DOI 10.1016/0092-8674(85)90316-2; Peitsch M C, 1990, New Biol, V2, P197; PROVOST PR, 1991, FEBS LETT, V290, P139, DOI 10.1016/0014-5793(91)81244-3; PROVOST PR, 1995, MOL CELL ENDOCRINOL, V109, P225, DOI 10.1016/0303-7207(95)03506-3; PROVOST PR, 1990, J LIPID RES, V31, P2057; PROVOST PR, 1991, J LIPID RES, V32, P1959; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; RICH A, 1994, ANN NY ACAD SCI, V726, P1, DOI 10.1111/j.1749-6632.1994.tb52792.x; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SANTORO C, 1984, EMBO J, V3, P1553, DOI 10.1002/j.1460-2075.1984.tb02010.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SMITH KM, 1990, J LIPID RES, V31, P995; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; Suresh S, 1998, J NEUROCHEM, V70, P242; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Terrisse L, 1999, MOL BRAIN RES, V70, P26, DOI 10.1016/S0169-328X(99)00123-0; TERRISSE L, 1995, BRAIN RES MOL BRAIN, V30, P242; Thomas EA, 2001, P NATL ACAD SCI USA, V98, P4066, DOI 10.1073/pnas.071056198; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VIEIRA AV, 1995, MOL REPROD DEV, V42, P443, DOI 10.1002/mrd.1080420411; WEECH PK, 1986, J BIOL CHEM, V261, P7941; Wolfl S, 1996, P NATL ACAD SCI USA, V93, P3664, DOI 10.1073/pnas.93.8.3664; ZENG C, 1996, BIOCHEMISTRY-US, V94, P6626	83	48	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5514	5523		10.1074/jbc.M105057200	http://dx.doi.org/10.1074/jbc.M105057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11711530	hybrid			2022-12-25	WOS:000173962900124
J	Izawa, I; Nishizawa, M; Ohtakara, K; Inagaki, M				Izawa, I; Nishizawa, M; Ohtakara, K; Inagaki, M			Densin-180 interacts with delta-catenin/neural plakophilin-related armadillo repeat protein at synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL PDZ PROTEIN; POSTSYNAPTIC DENSITY; KINASE-II; FAMILY; MEMBER; IDENTIFICATION; LOCALIZATION; JUNCTIONS; SYSTEM; BRAIN	Densin-180, a protein purified from the postsynaptic density fraction of the rat forebrain, is the founding member of a newly described family of proteins termed the LAP (leucine-rich repeats and PSD-95/Dlg-A/ZO-1 (PDZ) domains) family that plays essential roles in establishment of cell polarity. To identify Densin-180-binding proteins, we screened a yeast two-hybrid library using the carboxyl-terminal fragment of Densin-180 containing PDZ domain as bait, and we isolated delta-catenin/neural plakophilin-related armadillo repeat protein (NPRAP) as a Densin-180-interacting protein. delta-catenin/NPRAP, a member of the armadillo repeat family, is a nervous system-specific adherens junction protein originally discovered as an interactor with presenilin-1, a protein involved in Alzheimer's disease. Densin-180 PDZ domain binds the COOH terminus of delta-catenin/NPRAP containing the PDZ domain-binding sequence. Endogenous Densin-180 was co-immunoprecipitated with delta-catenin/NPRAP and N-cadherin. Although Densin-180 was reported to be a transmembrane protein, Densin-180 was not accessible to surface biotinylation in dissociated hippocampal neurons; hence Densin-180 may be a cytosolic protein. Densin-180 colocalized with delta-catenin/NPRAP at synapses in dissociated hippocampal neurons. We propose that Densin-180 is associated in vivo with delta-catenin/NPRAP and may be involved in organization of the synaptic cell-cell junction through interaction with the delta-catenin/NPRAP-N-cadherin complex.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 5148507, Japan	Aichi Cancer Center; Mie University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016					Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ho C, 2000, J COMP NEUROL, V420, P261; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Inagaki N, 2000, J BIOL CHEM, V275, P27165; Izawa I, 2000, J BIOL CHEM, V275, P34521, DOI 10.1074/jbc.M003492200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	27	67	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5345	5350		10.1074/jbc.M110052200	http://dx.doi.org/10.1074/jbc.M110052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729199	hybrid			2022-12-25	WOS:000173962900102
J	Mayo, LD; Dixon, JE; Durden, DL; Tonks, NK; Donner, DB				Mayo, LD; Dixon, JE; Durden, DL; Tonks, NK; Donner, DB			PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHOINOSITIDE 3-OH KINASE; TUMOR-SUPPRESSOR GENE; PHOSPHATASE-ACTIVITY; GLIOBLASTOMA CELLS; ONCOPROTEIN MDM2; COWDEN-DISEASE; GROWTH ARREST; AKT; APOPTOSIS	The PTEN tumor suppressor protein inhibits phosphatidylinositol. 3-kinase (PI3K)/Akt signaling that promotes translocation of Mdm2 into the nucleus. When restricted to the cytoplasm, Mdm2 is degraded. The ability of PTEN to inhibit the nuclear entry of Mdm2 increases the cellular content and transactivation of the p53 tumor suppressor protein. Retroviral transduction of PTEN into U87MG (PTEN null) glioblastoma cells increases p53 activity and expression of p53 target genes and induces cell cycle arrest. U87MG/PTEN glioblastoma cells are more sensitive than U87MG/PTEN null cells to death induced by etoposide, a chemotherapeutic agent that induces DNA damage. Previously, tumor suppressor proteins have been supposed to act individually to suppress cancers. Our results establish a direct connection between the activities of two major tumor suppressors and show that they act together to respond to stresses and malignancies. PTEN protects p53 from survival signals, permitting p53 to function as a guardian of the genome. By virtue of its capacity to protect p53, PTEN can sensitize tumor cells to chemotherapy that relies on p53 activity. p53 induces PTEN gene expression, and here it is shown that PTEN protects p53, indicating that a positive feedback loop may amplify the cellular response to stress, damage, and cancer.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Indiana Univ, Sch Med, Sect Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediatr Res, Indianapolis, IN 46202 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Cold Spring Harbor Laboratory	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu			NATIONAL CANCER INSTITUTE [R37CA053840] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Cheney IW, 1998, CANCER RES, V58, P2331; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Furnari FB, 1998, CANCER RES, V58, P5002; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MORNAND J, 1992, CELL, V69, P1237; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ozes ON, 1999, NATURE, V401, P82; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tanaka M, 2000, ONCOGENE, V19, P5406, DOI 10.1038/sj.onc.1203918; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	64	268	305	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5484	5489		10.1074/jbc.M108302200	http://dx.doi.org/10.1074/jbc.M108302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729185	hybrid			2022-12-25	WOS:000173962900120
J	Moreau, S; Thomson, RM; Kaiser, BN; Trevaskis, B; Guerinot, ML; Udvardi, MK; Puppo, A; Day, DA				Moreau, S; Thomson, RM; Kaiser, BN; Trevaskis, B; Guerinot, ML; Udvardi, MK; Puppo, A; Day, DA			GmZIP1 encodes a symbiosis-specific zinc transporter in soybean	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION TRANSPORT; ARABIDOPSIS-THALIANA; MEMBRANE-PROTEINS; HIGH-AFFINITY; SUPEROXIDE-DISMUTASE; MOLECULAR-BIOLOGY; GENE ENCODES; ZIP FAMILY; DEFICIENCY; YEAST	The importance of zinc in organisms is clearly established, and mechanisms involved in zinc acquisition by plants have recently received increased interest. In this report, the identification, characterization and location of GmZIP1, the first soybean member of the ZIP family of metal transporters, are described. GmZIP1 was found to possess eight putative transmembrane domains together with a histidine-rich extra-membrane loop. By functional complementation of zrt1zrt2 yeast cells no longer able to take up zinc, GmZIP1 was found to be highly selective for zinc, with an estimated K-m value of 13.8 muM. Cadmium was the only other metal tested able to inhibit zinc uptake in yeast. An antibody raised against GmZIP1 specifically localized the protein to the peribacteroid membrane, an endosymbiotic membrane in nodules resulting from the interaction of the plant with its microsymbiont. The specific expression of GmZIP1 in nodules was confirmed by Northern blot, with no expression in roots, stems, or leaves of nodulated soybean plants. Antibodies to GmZIP1 inhibited zinc uptake by symbiosomes, indicating that at least some of the zinc uptake observed in isolated symbiosomes could be attributed to GmZIP1. The orientation of the protein in the membrane and its possible role in the symbiosis are discussed.	Univ Nice Sophia Antipolis, CNRS FRE 2294, Lab Biol Vegetale & Microbiol, F-06108 Nice 2, France; Univ Western Australia, Dept Biochem, Nedlands, WA 6009, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany	UDICE-French Research Universities; Universite Cote d'Azur; University of Western Australia; Australian National University; Max Planck Society	Day, DA (corresponding author), Univ Nice Sophia Antipolis, CNRS FRE 2294, Lab Biol Vegetale & Microbiol, Parc Valrose, F-06108 Nice 2, France.	dday@cyllene.uwa.edu.au	Kaiser, Brent N/O-7458-2015; Trevaskis, Ben/B-5350-2011; Kaiser, Brent/L-6092-2019; Udvardi, Michael/GPX-4653-2022; Day, David/F-6325-2011	Kaiser, Brent N/0000-0001-6167-2423; Trevaskis, Ben/0000-0001-7277-4994; Kaiser, Brent/0000-0001-6167-2423; Udvardi, Michael/0000-0001-9850-0828; Day, David/0000-0001-7967-2173; thomson, rowena/0000-0002-4373-6283				Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; Assuncao AGL, 2001, PLANT CELL ENVIRON, V24, P217, DOI 10.1111/j.1365-3040.2001.00666.x; Belouchi A, 1997, PLANT MOL BIOL, V33, P1085, DOI 10.1023/A:1005723304911; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAKMAK I, 1986, PHYSIOL PLANTARUM, V68, P483, DOI 10.1111/j.1399-3054.1986.tb03386.x; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; Curie C, 2000, BIOCHEM J, V347, P749, DOI 10.1042/0264-6021:3470749; Day DA, 2001, AUST J PLANT PHYSIOL, V28, P667, DOI 10.1071/PP01028; DAY DA, 1989, AUST J PLANT PHYSIOL, V16, P69, DOI 10.1071/PP9890069; Eckhardt U, 2001, PLANT MOL BIOL, V45, P437, DOI 10.1023/A:1010620012803; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Fox TC, 1998, ANNU REV PLANT PHYS, V49, P669, DOI 10.1146/annurev.arplant.49.1.669; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gonzalez A, 1999, PHYSIOL PLANTARUM, V106, P203, DOI 10.1034/j.1399-3054.1999.106209.x; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; Hacisalihoglu G, 2001, PLANT PHYSIOL, V125, P456, DOI 10.1104/pp.125.1.456; Hart JJ, 1998, PLANT PHYSIOL, V118, P219, DOI 10.1104/pp.118.1.219; HERRADA G, 1992, BIOCHEM BIOPH RES CO, V184, P1324, DOI 10.1016/S0006-291X(05)80027-0; Huang CY, 2000, PLANT PHYSIOL, V124, P415, DOI 10.1104/pp.124.1.415; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leidi EO, 2000, NEW PHYTOL, V147, P337, DOI 10.1046/j.1469-8137.2000.00703.x; LeVier K, 1996, PLANT PHYSIOL, V111, P893, DOI 10.1104/pp.111.3.893; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MCMAHON RJ, 1998, AM SOC NUTR SCI, V3166, P667; MINET M, 1992, PLANT J, V2, P417; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Pence NS, 2000, P NATL ACAD SCI USA, V97, P4956, DOI 10.1073/pnas.97.9.4956; PUPPO A, 1982, PLANTA, V156, P374, DOI 10.1007/BF00397477; Reid RJ, 1996, PLANTA, V198, P39; ROBERTSON JG, 1984, J CELL SCI, V69, P147; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Roth L.E., 1988, MOL GENETICS PLANT M, P220; Ruel MT, 1998, AM J CLIN NUTR, V68, p488S, DOI 10.1093/ajcn/68.2.488S; Santos R, 2000, MOL MICROBIOL, V38, P750, DOI 10.1046/j.1365-2958.2000.02178.x; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Smith J.A., 2000, CURRENT PROTOCOLS MO; Summers ML, 2000, J BACTERIOL, V182, P2551, DOI 10.1128/JB.182.9.2551-2558.2000; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Udvardi MK, 1997, ANNU REV PLANT PHYS, V48, P493, DOI 10.1146/annurev.arplant.48.1.493; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; WEBB MJ, 1988, SOIL SCI SOC AM J, V52, P1676, DOI 10.2136/sssaj1988.03615995005200060032x; Whitehead LF, 1997, PHYSIOL PLANTARUM, V100, P30, DOI 10.1034/j.1399-3054.1997.1000103.x; YANG LJO, 1990, PLANTA, V182, P437, DOI 10.1007/BF02411397; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	57	110	119	4	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4738	4746		10.1074/jbc.M106754200	http://dx.doi.org/10.1074/jbc.M106754200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11706025	hybrid			2022-12-25	WOS:000173962900026
J	Gormley, NA; Hillberg, AL; Halford, SE				Gormley, NA; Hillberg, AL; Halford, SE			The type IIs restriction endonuclease BspMI is a tetramer that acts concertedly at two copies of an asymmetric DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION SITES; CRYSTAL-STRUCTURE; CLEAVAGE; FOKI; ENZYMES; BINDING	Type IN endonucleases recognize asymmetric DNA sequences and cleave both strands at fixed positions downstream of the sequence. Many type IIs enzymes, including BspMI, cleave substrates with two sites more rapidly than those with one site. They usually act sequentially on DNA with two sites, but BspMI converted such a substrate directly to the final products cut at both sites. The BspMI endonuclease was found to be a tetramer, in contrast to the monomeric structures for many type Hs enzymes. No change in subunit association occurred during the BspMI reaction. Plasmids with two BspMI sites were cleaved in cis, in reactions spanning sites in the same DNA, even when the sites were separated by just 38 bp. Plasmids with one BspMI site were cleaved in trans, with the enzyme bridging sites in separate DNA molecules: these slow reactions could be accelerated by adding a second DNA with the recognition sequence. Thus, whereas many type IIs enzymes dimerize before cleaving DNA, a process facilitated by two recognition sites in cis, the BspMI tetramer binds two copies of its recognition sequence before cleaving the DNA in both strands at both sites.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halford, SE (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	s.halford@bris.ac.uk						Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Cole J L, 1999, J Biomol Tech, V10, P163; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Embleton ML, 2001, J MOL BIOL, V311, P503, DOI 10.1006/jmbi.2001.4892; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; Friedhoff P, 2001, J BIOL CHEM, V276, P23581, DOI 10.1074/jbc.M101694200; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; Gutfreund H, 1995, KINETICS LIFE SCI, P138; Halford SE, 2001, BIOCHEM SOC T, V29, P363, DOI 10.1042/BST0290363; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; Huang J, 2001, P NATL ACAD SCI USA, V98, P968, DOI 10.1073/pnas.98.3.968; Janscak P, 2001, J MOL BIOL, V306, P417, DOI 10.1006/jmbi.2000.4411; Laue T. M., 1991, ANAL ULTRACENTRIFUGA, P90; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Milsom SE, 2001, J MOL BIOL, V311, P515, DOI 10.1006/jmbi.2001.4893; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; Podtelezhnikov AA, 2000, MACROMOLECULES, V33, P2767, DOI 10.1021/ma991781v; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Roberts R, 1993, NUCLEASES, P35; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasnauskas G, 1999, BIOCHEMISTRY-US, V38, P4028, DOI 10.1021/bi982456n; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Szczelkun MD, 1996, EMBO J, V15, P1460, DOI 10.1002/j.1460-2075.1996.tb00488.x; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; Terry B J, 1987, Gene Amplif Anal, V5, P103; Tsodikov OV, 1999, J MOL BIOL, V294, P639, DOI 10.1006/jmbi.1999.3283; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	45	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4034	4041		10.1074/jbc.M108442200	http://dx.doi.org/10.1074/jbc.M108442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729188	hybrid			2022-12-25	WOS:000173813900033
J	Miles, BW; Thoden, JB; Holden, HM; Raushel, FM				Miles, BW; Thoden, JB; Holden, HM; Raushel, FM			Inactivation of the amidotransferase activity of carbamoyl phosphate synthetase by the antibiotic acivicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE BINDING-SITE; ACID AT-125; PHASE-I; METABOLISM; IDENTIFICATION; NSC-163501; HYDROLYSIS; MECHANISM; CYSTEINE; DOMAIN	Carbamoyl phosphate synthetase (CPS) from Escherichia coli catalyzes the formation of carbamoyl phosphate from 2 mol of ATP, bicarbonate, and glutamine. CPS was inactivated by the glutamine analog, acivicin. In the presence of ATP and bicarbonate the second-order rate constant for the inactivation of the glutamine-dependent activities was 4.0 x 10(4) m(-1) s(-1). In the absence of ATP and bicarbonate the second-order rate constant for inactivation of CPS was reduced by a factor of 200. The enzyme was protected against inactivation by the inclusion of glutamine in the reaction mixture. The ammonia-dependent activities were unaffected by the incubation of CPS with acivicin. These results are consistent with the covalent labeling of the glutamine-binding site located within the small amidotransferase subunit. The binding of ATP and bicarbonate to the large subunit of CPS must also induce a conformational change within the amidotransferase domain of the small subunit that enhances the nucleophilic character of the thiol group required for glutamine hydrolysis. The acivicin-inhibited enzyme was crystallized, and the three-dimensional structure was determined by x-ray diffraction techniques. The thiol group of Cys-269 was covalently attached to the dihydroisoxazole ring of acivicin with the displacement of a chloride ion.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK030343, R01DK030343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30343] Funding Source: Medline; NIGMS NIH HHS [GM55513] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER E, 1985, ADV ENZYME REGUL, V24, P225, DOI 10.1016/0065-2571(85)90078-0; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ARDALAN B, 1982, CHEM PHARM, V31, P1509; CASEY CA, 1983, J BIOL CHEM, V258, P8723; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; CHEN MK, 1993, ANN SURG, V217, P655, DOI 10.1097/00000658-199306000-00007; Chittur SV, 2001, BIOCHEMISTRY-US, V40, P876, DOI 10.1021/bi0014047; EARHART RH, 1983, CANCER TREAT REP, V67, P683; EARHART RH, 1985, ADV ENZYME REGUL, V24, P179, DOI 10.1016/0065-2571(85)90076-7; ELLIOTT WL, 1984, BIOCHEM PHARMACOL, V34, P243; HANKA LJ, 1973, ANTIMICROB AGENTS CH, V3, P425, DOI 10.1128/AAC.3.3.425; HANKA LJ, 1973, CANCER CHEMOTH REP 1, V57, P141; JAYARAM HN, 1975, CANCER CHEMOTH REP 1, V59, P481; JAYARAM HN, 1981, CANCER TREAT REP, V65, P491; KASEMAN DS, 1980, FED PROC, V39, P2032; KELLY RC, 1979, J AM CHEM SOC, V101, P1054, DOI 10.1021/ja00498a056; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; LUSTY CJ, 1992, FEBS LETT, V314, P134; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; MARTIN D G, 1973, Tetrahedron Letters, V27, P2549; MARTIN DG, 1986, J ANTIBIOT, V39, P603, DOI 10.7164/antibiotics.39.603; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; Miles BW, 1998, BIOCHEMISTRY-US, V37, P16773, DOI 10.1021/bi982018g; MUKHERJEE T, 1990, BIOCHEM BIOPH RES CO, V170, P426, DOI 10.1016/0006-291X(90)92109-D; MURPHY WK, 1982, P AM SOC CLIN ONCOL, V1, P237; NAKAMURA J, 1995, J BIOL CHEM, V270, P23450, DOI 10.1074/jbc.270.40.23450; NEIL GL, 1979, CANCER RES, V39, P852; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAUSCH J, 1985, EUR J BIOCHEM, V150, P189, DOI 10.1111/j.1432-1033.1985.tb09006.x; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; ROUSSEL A, 1991, SILICON GRAPHICS GEO; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SEBOLT JS, 1985, BIOCHEM PHARMACOL, V34, P97, DOI 10.1016/0006-2952(85)90106-6; SOUBA WW, 1993, ANN SURG, V218, P715, DOI 10.1097/00000658-199312000-00004; SRIDHAR KS, 1983, CANCER TREAT REP, V67, P701; TAYLOR S, 1984, INVEST NEW DRUG, V2, P311; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TSO JY, 1980, J BIOL CHEM, V255, P6734; VYAS DM, 1984, TETRAHEDRON LETT, V25, P487, DOI 10.1016/S0040-4039(00)99918-0; WEISS GR, 1982, CANCER RES, V42, P3892; WELLNER VP, 1975, J BIOL CHEM, V250, P3261	46	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4368	4373		10.1074/jbc.M108582200	http://dx.doi.org/10.1074/jbc.M108582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729189	hybrid			2022-12-25	WOS:000173813900077
J	Pan, MH; Liang, JS; Fisher, EA; Ginsberg, HN				Pan, MH; Liang, JS; Fisher, EA; Ginsberg, HN			The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglycerlide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; APO-B; INTRACELLULAR DEGRADATION; MCA-RH7777 CELLS; APOPROTEIN B100; ABETALIPOPROTEINEMIA; OVEREXPRESSION; INHIBITION; LIPIDATION	Although microsomal triglyceride transfer protein (MTP) and newly synthesized triglyceride (TG) are critical for co-translational targeting of apolipoprotein B (apoB100) to lipoprotein assembly in hepatoma cell lines, their roles in the later stages of lipoprotein assembly remain unclear. Using N-acetyl-Leu-Leu-norleucinal to prevent proteasomal degradation, HepG2 cells! were radiolabeled and chased for 0-90 min (chase I). The medium was changed and cells chased for another 150 min (chase 11) in the absence (control) or presence of Pfizer MTP inhibitor CP-10447 (CP). As chase I was extended, inhibition of apoB100 secretion by CP during chase II decreased from 75.9% to only 15% of control (no CP during chase 11). Additional studies were conducted in which chase I was either 0 or 90 min, and chase 11 was in the presence of [H-3]glycerol and either BSA (control), CP (inhibits both MTP activity and TG synthesis), BMS-1976360-1) (BMS) (inhibits only MTP activity), or triacsin C (TC) (inhibits only TG synthesis). When chase I was 0 min, CP, BMS, and TC reduced apoB100 secretion during chase 11 by 75.3, 73.9, and 53.9%. However, when chase I was 90 min, those agents reduced apoB100 secretion during chase II by only 16.0, 19.2, and 13.9%. Of note, all three inhibited secretion of newly synthesized TG during chase 11 by 80, 80, and 40%, whether chase I was 0 or 90 min. In both HepG2 cells and McA-RH7777 cells, if chase I was at least 60 min, inhibition of TG synthesis and/or MTP activity did not affect the density of secreted apoB100-lipoproteins under basal conditions. Oleic acid increased secretion of TG-enriched apoB100-lipoproteins similarly in the absence or presence of either of CP, BMS, or TC. We conclude that neither MTP nor newly synthesized TG is necessary for the, later stages of apoB100-lipoprotein assembly and secretion in either HepG2 or McA-RH7777 cells.	Columbia Presbyterian Med Ctr, Dept Med, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA	Columbia University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ginsberg, HN (corresponding author), Columbia Presbyterian Med Ctr, Dept Med, 630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu	Fisher, Edward/ABE-7469-2020	Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [T32 HL07343, HL58541] Funding Source: Medline; PHS HHS [L55638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541, T32HL007343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BOREN J, 1994, J BIOL CHEM, V269, P25879; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Haghpassand M, 1996, J LIPID RES, V37, P1468; Hebbachi AM, 1999, J LIPID RES, V40, P1758; IGAI RA, 1997, BIOCHEM J, V324, P529; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Tietge UJF, 1999, J LIPID RES, V40, P2134; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WU XJ, 1994, J LIPID RES, V35, P1200; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	34	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4413	4421		10.1074/jbc.M107460200	http://dx.doi.org/10.1074/jbc.M107460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11704664	hybrid			2022-12-25	WOS:000173813900083
J	Purkiss, AG; Bateman, OA; Goodfellow, JM; Lubsen, NH; Slingsby, C				Purkiss, AG; Bateman, OA; Goodfellow, JM; Lubsen, NH; Slingsby, C			The x-ray crystal structure of human gamma S-crystallin C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CRYSTALLIN; EYE LENS; ALPHA-CRYSTALLIN; PHASE-SEPARATION; TYROSINE CORNER; PROTEIN; BOVINE; DEAMIDATION; EVOLUTION; ASPARAGINE	gammaS-crystallin is a major human lens protein found in the outer region of the eye lens, where the refractive index is low. Because crystallins are not renewed they acquire post-translational modifications that may perturb stability and solubility. In common with other members of the beta,gamma-crystallin superfamily, gammaS-crystallin comprises two similar beta-sheet domains. The crystal structure of the C-terminal domain of human gammaS-crystallin has been solved at 2.4 Angstrom resolution. The structure shows that in the in vitro expressed protein, the buried cysteines remain reduced. The backbone conformation of the "tyrosine corner" differs from that of other betagamma-crystallins because of deviation from the consensus sequence. The two C-terminal domains in the asymmetric unit are organized about a slightly distorted 2-fold axis to form a dimer with similar geometry to full-length two-domain family members. Two glutamines found in lattice contacts may be important for short range interactions in the lens. An asparagine known to be deamidated in human cataract is located in a highly ordered structural region.	Univ London Birkbeck Coll, Sch Cristallog, London WC1E 7HX, England; Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	University of London; Birkbeck University London; Radboud University Nijmegen	Purkiss, AG (corresponding author), Univ London Birkbeck Coll, Sch Cristallog, Malet Sch, London WC1E 7HX, England.	a.purkiss@mail.cryst.bbk.ac.uk	Lubsen, Nicolette H./B-8426-2011					Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; Bagby S, 1998, J MOL BIOL, V276, P669, DOI 10.1006/jmbi.1997.1563; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Basak AK, 1998, PROTEIN ENG, V11, P337, DOI 10.1093/protein/11.5.337; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chirgadze YN, 1996, ACTA CRYSTALLOGR D, V52, P712, DOI 10.1107/S0907444996000352; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; EVANS PR, 1997, P CCP4 STUD WEEK REC, P97; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GEIGER T, 1987, J BIOL CHEM, V262, P785; Hamill SJ, 2000, J MOL BIOL, V295, P641, DOI 10.1006/jmbi.1999.3360; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; Mayr EM, 1997, J MOL BIOL, V269, P260, DOI 10.1006/jmbi.1997.1033; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Norledge BV, 1996, NAT STRUCT BIOL, V3, P267, DOI 10.1038/nsb0396-267; Norledge BV, 1997, EXP EYE RES, V65, P609, DOI 10.1006/exer.1997.0368; Palme S, 1997, PROTEIN SCI, V6, P1529; Palme S, 1998, PROTEIN SCI, V7, P611, DOI 10.1002/pro.5560070310; Palme S, 1998, J MOL BIOL, V279, P1053, DOI 10.1006/jmbi.1998.1850; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Purkiss AG, 2000, PROTEIN PEPTIDE LETT, V7, P211; PURKISS AG, 1999, CONTAX PROTEIN DISTA; Sinha D, 2001, J BIOL CHEM, V276, P9308, DOI 10.1074/jbc.M010583200; Skouri-Panet F, 2001, BIOPHYS CHEM, V89, P65, DOI 10.1016/S0301-4622(00)00216-7; Slingsby C, 1997, PROG RETIN EYE RES, V16, P3, DOI 10.1016/S1350-9462(96)00018-3; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 2000, J BIOL CHEM, V275, P26109, DOI 10.1074/jbc.M002809200; Takemoto L, 2001, EXP EYE RES, V72, P559, DOI 10.1006/exer.2001.0983; TARDIEU A, 1992, EUR BIOPHYS J BIOPHY, V21, P1, DOI 10.1007/BF00195438; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905; Wenk M, 2000, BIOPHYS CHEM, V86, P95, DOI 10.1016/S0301-4622(00)00161-7	48	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4199	4205		10.1074/jbc.M110083200	http://dx.doi.org/10.1074/jbc.M110083200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706012	hybrid			2022-12-25	WOS:000173813900056
J	Yang, XY; Wang, LH; Mihalic, K; Xiao, WH; Chen, TS; Li, P; Wahl, LM; Farrar, WL				Yang, XY; Wang, LH; Mihalic, K; Xiao, WH; Chen, TS; Li, P; Wahl, LM; Farrar, WL			Interleukin (IL-4) indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; HUMAN MONOCYTES; TRANSCRIPTIONAL REPRESSION; INFLAMMATORY CYTOKINES; UP-REGULATION; OXIDIZED LDL; EXPRESSION; CELLS; GENE; PATHWAYS	The respective development of either T helper type 1 (Th1) or Th2 cells is believed to be mediated by the effects of cytokines acting directly on Th precursors (Thp). We have generated evidence for an indirect monocyte-dependent immunoregulatory pathway. Recently, interleukin (IL) 4 has been shown to produce "new" potential peroxisome proliferator-activated receptor gamma (PPARgamma) ligands by inducing macrophage 12/ 15-lipoxygenase (12/15-LO). We have shown previously that the activated PPARgamma is a profound inhibitor of IL-2 transcription in human T lymphocytes. It is hypothetically possible that IL-4 might indirectly affect IL-2 production by Thp cells via macrophage-derived PPARgamma ligands. Using human monocytes and T lymphocytes from same donors, we have found that monocyte 12/15-LO products mediate the indirect inhibitory effect of IL-4 on anti-CD3- or phytohemagglutinin/ phorbol 12-myristate 13-acetate-stimulated IL-2 production by T lymphocytes. We further analyzed which major 12/15-LO metabolites contributed to the above inhibition. 13-Hydroxyoctadecadienoic acid (13-HODE), a 12/15-LO product, markedly blocked IL-2 production by human blood T lymphocytes, but not Jurkat T cells. Moreover, the IL-4-conditioned macrophage medium contained a sufficient amount of 13-HODE and anti-13-HODE antibody indeed neutralized the inhibitory effects of the IL-4-conditional medium on T-cell IL-2 production. Using human: T lymphocytes and the PPARgamma-transfected Jurkat T cells, we demonstrated the specific inhibition by 13-HODE of the transcription factors NFAT (nuclear factor of activated T cells) and nuclear factor kappaB, the IL-2 promoter reporter, and IL-2 production. However, 15-hydroxytetraenoic acid had little inhibitory effect. The potency of such inhibitory effects correlates well with the capability of the above metabolic lipids to activate PPARgamma. These data provide a mechanism whereby IL-4 may indirectly affect Thp function via PPARgamma activated by macrophage products of the 12/15-LO pathway.	NCI, Cytokine Mol Mechanisms Sect, Immunogenet Mol Lab, NIH, Frederick, MD 21702 USA; Sci Applicat Int Corp, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Med Chem Lab, NIH, Frederick, MD 21702 USA; NIDR, Immunopathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Farrar, WL (corresponding author), NCI, Cytokine Mol Mechanisms Sect, Immunogenet Mol Lab, NIH, POB B,Bldg 560,Rm 31-76, Frederick, MD 21702 USA.		Chen, Taosheng/I-6351-2013; Xiao, Weihua/N-2775-2013	Chen, Taosheng/0000-0001-6420-3809; Xiao, Weihua/0000-0001-9102-6326	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000456] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALROY I, 1995, MOL CELL BIOL, V15, P5789; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Conrad DJ, 1999, CLIN REV ALLERG IMMU, V17, P71, DOI 10.1007/BF02737598; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAYA A, 1991, J IMMUNOL, V146, P4209; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; Greene M. E., 1995, Gene Expression, V4, P281; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P3611, DOI 10.1073/pnas.92.8.3611; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; HO JL, 1994, J EXP MED, V180, P1457, DOI 10.1084/jem.180.4.1457; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KAWAKAMI Y, 1989, J IMMUNOL, V142, P3452; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; Mertz PM, 1996, CELL IMMUNOL, V173, P252, DOI 10.1006/cimm.1996.0275; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; Morel PA, 1998, CRIT REV IMMUNOL, V18, P275, DOI 10.1615/CritRevImmunol.v18.i4.10; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Niiro H, 1998, BIOCHEM BIOPH RES CO, V250, P200, DOI 10.1006/bbrc.1998.9287; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roederer M, 1997, J CLIN INVEST, V99, P1555, DOI 10.1172/JCI119318; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Shureiqi I, 2000, CANCER RES, V60, P6846; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Spindler SA, 1996, BIOCHEM BIOPH RES CO, V218, P187, DOI 10.1006/bbrc.1996.0033; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Wang LH, 1999, J IMMUNOL, V162, P3897; Wang LH, 2000, BLOOD, V95, P3816; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	55	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3973	3978		10.1074/jbc.M105619200	http://dx.doi.org/10.1074/jbc.M105619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726648	hybrid			2022-12-25	WOS:000173813900025
J	Lu, PJ; Zhou, XZ; Liou, YC; Noel, JP; Lu, KP				Lu, PJ; Zhou, XZ; Liou, YC; Noel, JP; Lu, KP			Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; MITOSIS; PROTEIN; RECOGNITION; PHOSPHOPROTEINS; REQUIREMENT; INTERPHASE; INTERACTS; MECHANISM	Phosphoserine-binding modules help determine the specificity of signal transduction events. One such module, the group IV WW domain, plays an essential role in targeting the phosphorylation-specific prolyl isomerase Pin 1 to its substrates. These modules require Ser/Thr phosphorylation of their ligands for binding activity. However, phosphorylation of these modules and its functional significance have not been described, nor is it known whether the function of Pin 1 is regulated. Here we show that Pin 1 WW domain is phosphorylated on Ser(16) both in vitro and in vivo. Further, this phosphorylation regulates the ability of the WW domain to mediate Pin 1 substrate interaction and cellular localization. Moreover, both Pin 1 and WW domain mutants refractory to Ser(16) phosphorylation act as dominant-negative mutants to induce mitotic block and apoptosis and increase multinucleated cells with 8 N DNA content. Thus, phosphorylation is a new mechanism critical for regulating WW domain phosphoserine binding activity and Pinl function.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA; Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Sun Yat Sen University; Salk Institute	Lu, KP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Canc Biol Program,Div Hematol Oncol, 330 Brookline Ave,HIM 1047, Boston, MA 02215 USA.	klu@caregroup.harvard.edu	Noel, Joseph P/A-9459-2009		NIGMS NIH HHS [GM58556, R01GM56230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058556, R01GM056230] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert A, 1999, J CELL SCI, V112, P2493; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; SEAMON KB, 1984, P NATL ACAD SCI-BIOL, V81, P5081, DOI 10.1073/pnas.81.16.5081; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 1999, NATURE, V402, P30; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	27	199	205	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2381	2384		10.1074/jbc.C100228200	http://dx.doi.org/10.1074/jbc.C100228200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11723108	hybrid			2022-12-25	WOS:000173421500004
J	Tsuruoka, H; Khovidhunkit, W; Brown, BE; Fluhr, JW; Elias, PM; Feingold, KR				Tsuruoka, H; Khovidhunkit, W; Brown, BE; Fluhr, JW; Elias, PM; Feingold, KR			Scavenger receptor class B type I is expressed in cultured keratinocytes and epidermis - Regulation in response to changes in cholesterol homeostasis and barrier requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; FATTY-ACID DEFICIENCY; MESSENGER-RNA LEVELS; CUTANEOUS PERMEABILITY BARRIER; SR-BI; SPHINGOLIPID SYNTHESIS; ENZYME PREPARATIONS; CERAMIDE SYNTHESIS; LINOLEIC-ACID; A-I	Cholesterol is a key lipid in the stratum corneum, where it is critical for permeability barrier homeostasis. The epidermis is an active site of cholesterol synthesis, but inhibition of epidermal cholesterol synthesis with topically applied statins only modestly affects epidermal permeability barrier function, suggesting a possible compensatory role for extraepidermal cholesterol. Scavenger receptor class B type I (SR-BI) is a recently described cell surface receptor for high density lipoproteins (HDL) that mediates the selective uptake of cholesterol esters from circulating HDL. In the present study, we demonstrate that SR-BI is present in cultured human keratinocytes and that calcium-induced differentiation markedly decreases SR-BI levels. Additionally, the cell association of [H-3]cholesterol-labeled HDL decreased in differentiated versus undifferentiated keratinocytes. Furthermore, the inhibition of cholesterol synthesis with simvastatin resulted in a 3-4-fold increase in both SR-BI mRNA and protein levels, whereas conversely, addition of 25-hydroxycholesterol suppressed SR-BI levels by approximately 50%. SR-BI mRNA is also expressed in murine epidermis, increasing by 50% in parallel with cholesterol requirements following acute barrier disruption. Because the increase is completely blocked by occlusion with a vapor-impermeable membrane, changes in epidermal SR-BI expression are regulated specifically by barrier requirements. Lastly, using immunofluorescence we demonstrated that SR-BI is present in human epidermis predominantly in the basal layer and increases following barrier disruption. In summary, the present study demonstrates first that SR-BI is expressed in keratinocytes and regulated by cellular cholesterol requirements, suggesting that it plays a role in keratinocyte cholesterol homeostasis. Second, the increase in SR-BI following barrier disruption suggests that SR-BI expression increases to facilitate cholesterol uptake leading to barrier restoration.	Dept Vet Affairs Med Ctr, Metab Sect, Serv Dermatol, San Francisco, CA 94121 USA; Dept Vet Affairs Med Ctr, Med Metab Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; POLA Chem Ind Inc, POLA Labs, R&D Dept Dermatol Sci, Totsuka Ku, Yokohama, Kanagawa 2440812, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pola Chemical Industries Inc.	Feingold, KR (corresponding author), Dept Vet Affairs Med Ctr, Metab Sect, Serv Dermatol, 4150 Clement St,Box 111F, San Francisco, CA 94121 USA.	kfngld@itsa.ucsf.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039639] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39639, AR29706] Funding Source: Medline; NICHD NIH HHS [HD29706] Funding Source: Medline; PHS HHS [P0039448] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Azhar S, 1998, J LIPID RES, V39, P1616; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BOWSER PA, 1985, BIOCHIM BIOPHYS ACTA, V834, P419, DOI 10.1016/0005-2760(85)90016-5; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CHAPKIN RS, 1986, J LIPID RES, V27, P945; CHAPKIN RS, 1984, BIOCHEM BIOPH RES CO, V124, P784, DOI 10.1016/0006-291X(84)91026-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; ELIAS PM, 1980, J INVEST DERMATOL, V74, P230, DOI 10.1111/1523-1747.ep12541775; ELIAS PM, 1978, LAB INVEST, V39, P574; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; FEINGOLD KR, 1991, ADV LIPID RES, V24, P57; FEINGOLD KR, 1990, J CLIN INVEST, V86, P1738, DOI 10.1172/JCI114899; FEINGOLD KR, 1991, CRIT REV THER DRUG, V8, P193; FEINGOLD KR, 1986, J INVEST DERMATOL, V87, P588, DOI 10.1111/1523-1747.ep12455835; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GRUBAUER G, 1987, J LIPID RES, V28, P746; Harris IR, 1998, J LIPID RES, V39, P412; Harris IR, 1997, J INVEST DERMATOL, V109, P783, DOI 10.1111/1523-1747.ep12340962; HOLLERAN WM, 1991, J CLIN INVEST, V88, P1338, DOI 10.1172/JCI115439; HOLLERAN WM, 1991, J LIPID RES, V32, P1151; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JACKSON SM, 1992, J LIPID RES, V33, P1307; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MAN MQ, 1993, J INVEST DERMATOL, V101, P185, DOI 10.1111/1523-1747.ep12363729; MAOQIANG M, 1993, J CLIN INVEST, V92, P791, DOI 10.1172/JCI116652; MENON GK, 1992, J INVEST DERMATOL, V98, P279, DOI 10.1111/1523-1747.ep12497866; MENON GK, 1985, J LIPID RES, V26, P418; MOMMAASKIENHUIS AM, 1987, J INVEST DERMATOL, V89, P513, DOI 10.1111/1523-1747.ep12461024; NUGTEREN DH, 1985, BIOCHIM BIOPHYS ACTA, V834, P429, DOI 10.1016/0005-2760(85)90017-7; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; PONEC M, 1992, J INVEST DERMATOL, V98, pS50, DOI 10.1111/1523-1747.ep12462204; PROKSCH E, 1990, J CLIN INVEST, V85, P874, DOI 10.1172/JCI114514; Reaven E, 1999, BBA-MOL CELL BIOL L, V1436, P565, DOI 10.1016/S0005-2760(98)00169-6; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; STEINBERG D, 1967, SCIENCE, V156, P1740, DOI 10.1126/science.156.3783.1740; Sun Y, 1999, J LIPID RES, V40, P1799; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WANG XD, 1993, J BIOL CHEM, V268, P14497; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WILLIAMS ML, 1987, J LIPID RES, V28, P955; WILLIAMS ML, 1987, J CELL PHYSIOL, V132, P428, DOI 10.1002/jcp.1041320305; WOOD LC, 1994, J INVEST DERMATOL, V103, P834, DOI 10.1111/1523-1747.ep12413597	52	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2916	2922		10.1074/jbc.M106445200	http://dx.doi.org/10.1074/jbc.M106445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707442	hybrid			2022-12-25	WOS:000173421500071
J	Bandyopadhyay, A; Lakshmanan, V; Matsumoto, T; Chang, EC; Maitra, U				Bandyopadhyay, A; Lakshmanan, V; Matsumoto, T; Chang, EC; Maitra, U			Moe1 and spInt6, the fission yeast homologues of mammalian translation initiation factor 3 Subunits p66 (eIF3d) and p48 (eIF3e), respectively, are required for stable association of eIF3 Subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; COMPLEX; PURIFICATION; INTERACTS; MUTANT; INT-6; PRT1	The protein encoded by the fission yeast gene, moe1(+) is the homologue of the p66/eIF3d subunit of mammalian translation initiation factor eIF3. In this study, we show that in fission yeast, Moe1 physically associates with eIF3 core subunits as well as with 40 S ribosomal particles as a constituent of the eIF3 protein complex that is similar in size to multisubunit mammalian eIF3. However, strains lacking moe1(+) (Deltamoe1) are viable and show no gross defects in translation initiation, although the rate of translation in the Deltamoe1 cells is about 30-40% slower than wild-type cells. Mutant Deltamoe1 cells are hypersensitive to caffeine and defective in spore formation. These phenotypes of Deltamoe1 cells are similar to those reported previously for deletion of the fission yeast int6(+) gene that encodes the fission yeast homologue of the p48/Int6/eIF3e subunit of mammalian eIF3. Further analysis of eIF3 subunits in Deltamoe1 or Deltaint6 cells shows that in these deletion strains, while all the eIF3 subunits are bound to 40 S particles, dissociation of ribosome-bound eIF3 results in the loss of stable association between the eIF3 subunits. In contrast, eIF3 isolated from ribosomes of wild-type cells are associated with one another in a protein complex. These observations suggest that Moe1 and spInt6 are each required for stable association of eIF3 subunits in fission yeast.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol & Cell Biol, Bronx, NY 10461 USA; NYU, Dept Biol, New York, NY 10003 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York University	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	maitra@aecom.yu.edu	Bandyopadhyay, Amitabha/B-9735-2008	Bandyopadhyay, Amitabha/0000-0002-0429-438X	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; Chen CR, 2000, MOL BIOL CELL, V11, P4067, DOI 10.1091/mbc.11.12.4067; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Huang HK, 1997, MOD CELL B, V17, P147; Humphrey T, 1998, GENETICS, V148, P1731; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Maiti T, 2000, GENE, V244, P109, DOI 10.1016/S0378-1119(99)00570-3; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370	30	33	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2360	2367		10.1074/jbc.M107790200	http://dx.doi.org/10.1074/jbc.M107790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11705997	hybrid			2022-12-25	WOS:000173421300097
J	Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C				Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C			Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells	ONCOGENE			English	Article						HSP70; apoptosis; immunogenicity; tumorigenicity; colon cancer cells	HEAT-SHOCK-PROTEIN; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; IMMUNE-RESPONSE; DIFFERENTIAL EXPRESSION; TUMOR IMMUNOGENICITY; NEGATIVE REGULATION; IN-VITRO; ANTIGEN; DEATH; TUMORIGENICITY	Expression of inducible heat shock protein 70 (HSP70) in tumor cells has been proposed to enhance their immunogenicity. However, HSP70 has also been demonstrated to prevent tumor cell death, a key process for the development of tumor cell immunogenicity. In the present study, we investigated the influence of the HSP70 protein level on PRO colon cancer cell growth and immunogenicity in syngeneic BDIX rats and nude mice. These cells have a basal expression of HSP70 which can be substantially increased by heat shock. When injected subcutaneously in syngeneic animals, PRO cells do not induce any detectable immune response and give rise to progressive, metastatic and lethal tumors. Stable transfection of an anti-sense hsp70 cDNA in PRO cells (PRO-70AS cells) strongly decreased HSP70 expression and sensitized cell-free extracts to cytochrome c/dATP-mediated activation of caspases. Subcutaneous injection of PRO-70AS cells induced tumors that rapidly regressed in syngeneic rats while they grew normally in nude mice. Syngeneic rats injected with PRO-70AS cells became protected against a further challenge with PRO cells. The tumor-specific immune response induced by HSP70-depleted PRO-70AS cells was associated with an increased rate of cell death in viro. These PRO-70AS cells were also more sensitive to NO-mediated, caspase-dependent, macrophage cytotoxicity in vivo. Altogether, these results indicate that reduced level of HSP70 expression in PRO- colon cancer cells results in the generation of a specific immune response by promoting cell death in vivo.	Fac Med, INSERM, U517, IFR 100, F-21033 Dijon, France; Danish Canc Soc, DK-2100 Copenhagen, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Danish Cancer Society	Garrido, C (corresponding author), Fac Med, INSERM, U517, IFR 100, 7 Blvd Jeanne Darc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Jäättelä, Marja/AAT-7932-2021; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018	Jäättelä, Marja/0000-0001-5950-7111; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BELL DA, 1991, CLIN IMMUNOL IMMUNOP, V60, P13, DOI 10.1016/0090-1229(91)90108-M; Blachere NE, 1995, SEMIN CANCER BIOL, V6, P349, DOI 10.1016/1044-579X(95)90004-7; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; BONNOTTE B, 2001, IN PRESS J IMMUNOL; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; CAIGNARD A, 1988, INT J CANCER, V42, P883, DOI 10.1002/ijc.2910420616; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kaur J, 2000, INT J CANCER, V85, P1; Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Melcher A, 1999, J MOL MED-JMM, V77, P824, DOI 10.1007/s001099900066; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Negulyaev YA, 1996, BBA-BIOMEMBRANES, V1282, P156, DOI 10.1016/0005-2736(96)00055-7; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Ralhan R, 1995, CLIN CANCER RES, V1, P1217; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Shrestha A, 1999, LAB INVEST, V79, P1629; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; Todryk S, 1999, J IMMUNOL, V163, P1398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; Wells AD, 1998, INT IMMUNOL, V10, P609, DOI 10.1093/intimm/10.5.609; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643	47	72	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7478	7485		10.1038/sj.onc.1204948	http://dx.doi.org/10.1038/sj.onc.1204948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709719				2022-12-25	WOS:000171976900004
J	Matyash, M; Matyash, V; Nolte, C; Sorrentino, V; Kettenmann, H				Matyash, M; Matyash, V; Nolte, C; Sorrentino, V; Kettenmann, H			Requirement of functional ryanodine receptor type 3 for astrocyte migration	FASEB JOURNAL			English	Article						RyR3 knockout mice; 4-chloro-m-cresol; in vitro wound-healing assay; cell migration	MOUSE SKELETAL-MUSCLE; CA2+ RELEASE CHANNELS; INTRACELLULAR CALCIUM; IN-VITRO; DIFFERENTIAL DISTRIBUTION; ENDOGENOUS EFFECTORS; ACTIN CYTOSKELETON; G-PROTEIN; CONTRACTION; CELLS	Astrocyte motility plays an important role in the response of the brain to injury and during regeneration. We used two in vitro assays, a wound-healing model and a chemotaxis assay, to study mechanisms that control astrocyte motility. Ryanodine receptors (RyR), intracellular calcium-release channels, modulate intracellular Ca2+ levels, and also motility: 1) blocking RyR with antagonizing concentration of ryanodine (200 muM) strongly attenuated motility and 2) motility of astrocytes cultured from homozygous RyR type 3 knockout mice was impaired strongly compared with wild-type. In contrast, MIP-1 alpha -induced chemotaxis was neither impaired in the presence of ryanodine nor in the cells from the knockout animals. Reverse transcription-polymerase chain reaction (RT-PCR) analysis combined with Western blotting and immunocytochemistry confirmed the expression of RyR type 3, but not type 1 or 2 in cultured and acutely isolated astrocytes. RyR in astrocytes are linked to Ca2+ signaling because the RyR agonist 4-chloro-m-cresol induced a release of Ca2+ from intracellular stores. These results indicate that astrocytes express only RyR type 3 and that this receptor is important for controlling astrocyte motility.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Siena, Dept Neurosci, Mol Med Sect, I-53100 Siena, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Siena; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	hketten@mdc-berlin.de	Sorrentino, Vincenzo/A-4793-2014; Kettenmann, Helmut/AAJ-5142-2021	Sorrentino, Vincenzo/0000-0002-8573-8631; Nolte, Christiane/0000-0001-5398-3440; Kettenmann, Helmut/0000-0001-8208-0291	Telethon [1151] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		ALLEN DG, 1995, J PHYSIOL-LONDON, V487, P331, DOI 10.1113/jphysiol.1995.sp020883; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Cotrina ML, 1998, J NEUROSCI, V18, P8794; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fitch MT, 1999, J NEUROSCI, V19, P8182; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Horgan AM, 1998, J NEUROSCI, V18, P4189; Kabbara AA, 1999, CELL CALCIUM, V25, P227, DOI 10.1054/ceca.1999.0023; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; LANGLEY D, 1994, GLIA, V12, P128, DOI 10.1002/glia.440120206; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu LX, 1999, J IMMUNOL, V163, P5649; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; Mandeville JTH, 1997, J CELL PHYSIOL, V171, P168, DOI 10.1002/(SICI)1097-4652(199705)171:2<168::AID-JCP7>3.0.CO;2-M; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCGRAW J, 2001, MODULATING ASTROGLIO, V63, P109; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Nolte C, 2001, GLIA, V33, P72; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Ouyang Y, 1997, BRAIN RES, V775, P52, DOI 10.1016/S0006-8993(97)00840-8; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Simpson PB, 1998, J NEUROSCI RES, V52, P468, DOI 10.1002/(SICI)1097-4547(19980515)52:4<468::AID-JNR11>3.0.CO;2-#; Sorrentino V, 1999, TRENDS CARDIOVAS MED, V9, P54, DOI 10.1016/S1050-1738(99)00003-1; Tanabe S, 1997, J NEUROSCI, V17, P6522; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Westerblad H, 1998, CELL CALCIUM, V24, P105, DOI 10.1016/S0143-4160(98)90078-1; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Yoshikawa N, 1999, LIFE SCI, V65, P2643, DOI 10.1016/S0024-3205(99)00533-0; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1	42	94	95	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					84	+		10.1096/fj.01-0380fje	http://dx.doi.org/10.1096/fj.01-0380fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709492				2022-12-25	WOS:000172420500038
J	Piao, CQ; Zhao, YL; Hei, TK				Piao, CQ; Zhao, YL; Hei, TK			Analysis of p16 and p21(Cip1) expression in tumorigenic human bronchial epithelial cells induced by asbestos	ONCOGENE			English	Article						asbestos; transformation; human bronchial epithelial cells; p16; p21(Cip1)	P21(WAF1/CIP1) EXPRESSION; MALIGNANT-TRANSFORMATION; DIFFERENTIATION; PROTEIN; GENE; P21; CARCINOMAS; INHIBITOR; MUTATIONS; INDUCTION	Although asbestos is carcinogenic to humans, the mechanism(s) by which it induces cancer is unknown. Using tumor cell lines generated previously by asbestos treatment of immortalized human bronchial epithelial (BEP2D) cells, we examined alterations in p16 and p21(Cip1) genes together with their protein levels. Results were compared with untreated BEP2D cells, normal human bronchial epithelial cells (NHBE), as well as nontumorigenic fusion cell lines generated by fusing tumor cells with BEP2D cells. No deletion in the p16 gene was found in any of the tumor cell lines examined. Although p16 protein was expressed at a similar level in tumor and BEP2D cells, there was a fourfold decrease in its expression among NHBE cells. In contrast, both the protein and mRNA expression levels of p21(Cip1) were decreased by about threefold in tumor cell lines when compared with either BEP2D or NHBE cells, which had a similar expression level. Expression of p21(Cip1) mRNA was restored to the control level in all the fusion cell lines examined. The results suggested that down regulation of p21(Cip1) expression is linked to the tumorigenic conversion of BEP2D cells by asbestos.	Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Piao, CQ (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.	cp16@cp16@columbia.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007890] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05786, ES07890] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUTZ K, 1995, ONCOGENE, V10, P927; CHENG JQ, 1994, CANCER RES, V54, P5547; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; GABRIELLE IT, 1999, P NATL ACAD SCI USA, V96, P9089; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; Hei TK, 1999, ADV SPACE RES-SERIES, V22, P1699; HEI TK, 1992, CANCER RES, V52, P6305; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kokunai T, 1998, INT J CANCER, V75, P643, DOI 10.1002/(SICI)1097-0215(19980209)75:4<643::AID-IJC24>3.0.CO;2-8; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LezonGeyda K, 1996, MUTAT RES-ENVIR MUTA, V361, P113, DOI 10.1016/S0165-1161(96)90245-9; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIVINGSTON GK, 1980, J ENVIRON PATHOL TOX, V4, P373; Marchetti A, 1996, ONCOGENE, V12, P1319; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nadal A, 1997, J PATHOL, V183, P156; Nakao Y, 1997, BRIT J CANCER, V75, P1410, DOI 10.1038/bjc.1997.243; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Park SH, 1998, CANCER RES, V58, P1144; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P505; STANTON MF, 1977, J NATL CANCER I, V58, P587, DOI 10.1093/jnci/58.3.587; Takeshima Y, 1998, CARCINOGENESIS, V19, P1755, DOI 10.1093/carcin/19.10.1755; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, ONCOGENE, V11, P511; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	33	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7301	7306		10.1038/sj.onc.1204908	http://dx.doi.org/10.1038/sj.onc.1204908			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704859				2022-12-25	WOS:000171894200002
J	Escrieut, C; Gigoux, V; Archer, E; Verrier, S; Maigret, B; Behrendt, R; Moroder, L; Bignon, E; Silvente-Poirot, S; Pradayrol, L; Fourmy, D				Escrieut, C; Gigoux, V; Archer, E; Verrier, S; Maigret, B; Behrendt, R; Moroder, L; Bignon, E; Silvente-Poirot, S; Pradayrol, L; Fourmy, D			The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor - Evidence for a crucial role of Met-121 in the activation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; A RECEPTOR; CHROMOSOMAL LOCALIZATION; FUNCTIONAL EXPRESSION; DIRECT IDENTIFICATION; ANTAGONIST SR-27897; MOLECULAR-CLONING; RHODOPSIN; INTERACTS; SR-146131	The cholecystokinin (CCK) receptor-1 (CCK1R) is a G protein-coupled receptor, which mediates important central and peripheral cholecystokinin actions. Our aim was to progress in mapping of the CCK1R binding site by identifying residues that interact with the methionine and phenylalanine residues of the C-terminal moiety of CCK because these are crucial for its binding and biological activity, and to determine whether CCK and the selective non-peptide agonist, SR-146,131, share a common binding site. Identification of putative amino acids of the CCK1R binding site was achieved by dynamics-based docking of the ligand CCK in a refined three-dimensional model of the CCK1R using, as constraints, previous results that identified contact points between residues of CCK and CCK1R (Kennedy, K., Gigoux, V., Escrieut, C., Maigret, B., Martinez, J., Moroder, L., Frehel, D., Gully, D., Vaysse, N., and Fourmy, D. (1997) J. Biol. Chem 272, 2920-2926 and Gigoux, V., Escrieut, C., Fehrentz, J. A., Poirot, S., Maigret, B., Moroder, L., Gully, D., Martinez, J., Vaysse, N., and Fourmy, D. (1999) J. Biol. Chem 274, 20457-20464). By this approach, a series of residues forming connected hydrophobic clusters were identified. Pharmacological and functional analysis of mutated receptors indicated that a network of hydrophobic residues including Cys-94, Met-121, Val-125, Phe-218, Ile-329, Phe-330, Trp-326, Ile-352, Leu-356, and Tyr-360, is involved in the binding site for CCK and in the activation process of the CCK1R. Within this hydrophobic network, the physico-chemical nature of residue 121 seems to be essential for CCK1R functioning. Finally, the biological properties of mutants together with dynamic docking of SR-146,131 in the CCK1R binding site demonstrated that SR-146,131 occupies a region of CCK1R binding site which interacts with the C-terminal amidated tripeptide of CCK, i.e. Met-Asp-Phe-NH2. These new and important insights will serve to better understand the activation process of CCK1R and to design or optimize ligands.	CHU Rangueil, INSERM, Unite 531, F-31054 Toulouse, France; Univ Nancy 1, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France; Max Planck Inst Biochem, D-82143 Martinsried, Germany; Sanofi Synthelabo, F-31036 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Max Planck Society; Sanofi-Aventis; Sanofi France	Fourmy, D (corresponding author), CHU Rangueil, INSERM, Unite 531, Bat K3, F-31054 Toulouse, France.		Poirot, Sandrine/D-5448-2017; Gigoux, Véronique/AAE-6090-2020; Fourmy, Daniel/AAE-3703-2019; Verrier, Sophie/AAT-6640-2021	Gigoux, Véronique/0000-0003-1408-5335; Fourmy, Daniel/0000-0001-9910-4827; Moroder, Luis/0000-0001-9570-5713; Silvente-Poirot, Sandrine/0000-0003-2245-9069				Bignon E, 1999, J PHARMACOL EXP THER, V289, P752; Campagne F, 1999, J COMPUT AID MOL DES, V13, P625, DOI 10.1023/A:1008170432484; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Giragossian C, 2001, BIOCHEMISTRY-US, V40, P3804, DOI 10.1021/bi002659n; Gouldson P, 2000, EUR J PHARMACOL, V400, P185, DOI 10.1016/S0014-2999(00)00414-3; Gouldson P, 1999, EUR J PHARMACOL, V383, P339, DOI 10.1016/S0014-2999(99)00612-3; Gripentrog JM, 2000, BIOCHEM J, V352, P399, DOI 10.1042/0264-6021:3520399; GULLY D, 1993, EUR J PHARMACOL, V232, P13, DOI 10.1016/0014-2999(93)90722-T; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; HUANG S, 1994, J BIOL CHEM, V269, P26121; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIGNON MF, 1987, J BIOL CHEM, V262, P7226; MARSEIGNE A, 1988, J MED CHEM, V31, P966; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SPANARKEL M, 1983, J BIOL CHEM, V258, P6746; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VILLANUEVA ML, 1982, AM J PHYSIOL, V242, pG416, DOI 10.1152/ajpgi.1982.242.4.G416; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701	42	55	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7546	7555		10.1074/jbc.M108563200	http://dx.doi.org/10.1074/jbc.M108563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724786	hybrid			2022-12-25	WOS:000174104300101
J	Joseph, P; Lei, YX; Whong, WZ; Ong, TM				Joseph, P; Lei, YX; Whong, WZ; Ong, TM			Oncogenic potential of mouse translation elongation factor-15, a novel cadmium-responsive proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; GAMMA-RELATED SEQUENCE; METAL CARCINOGENESIS; PTI-1 ONCOGENE; EXPRESSION; CANCER; CELLS; CARCINOMA; FIDELITY; BINDING	The molecular mechanisms potentially responsible for cadmium-induced cell transformation and tumorigenesis were investigated using Balb/c-3T3 cells transformed with cadmium chloride. Differential display analysis of gene expression revealed consistent and reproducible overexpression of a transcript in the transformed cells compared with the nontransformed cells. The full-length cDNA corresponding to the differentially expressed transcript was cloned and was identified as mouse translation elongation factor-1delta subunit (TEF-1delta; GenBank(TM) accession number AF304351). Nucleotide sequence analysis of TEF-1delta cDNA revealed an open reading frame encoding the predicted protein of 281 amino acids and exhibited significant conservation with the corresponding protein of human, Xenopus laevis, and Artemia. The presence of a leucine zipper motif, characteristic of translation elongation factor-1delta, was also found in the mouse TEF-1delta. A 31-kDa protein was detected in eukaryotic cells transfected with an expression vector containing the TEF-1delta cDNA. Overexpression of the TEF-1delta protein by transfection was oncogenic in NlH3T3 cells as evidenced by the appearance of transformed foci exhibiting anchorage-independent growth and the potential to grow as tumors in nude mice. Blocking the translation of TEF-1delta with antisense TEF-1delta mRNA resulted in a significant reversal of the oncogenic potential of cadmium-transformed Balb/c-3T3 cells as evidenced from suppression in anchorage-independent growth and tumorigenesis in nude mice. Our findings demonstrate, for the first time, that the cell transformation and tumorigenesis induced by cadmium are due, at least in part, to the overexpression of TEF-1delta, a novel cadmium-responsive proto-oncogene.	NIOSH, CDC, Toxicol & Mol Biol Branch, Mol Epidemiol Lab, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Joseph, P (corresponding author), NIOSH, CDC, Toxicol & Mol Biol Branch, Mol Epidemiol Lab, MS 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	pcj5@cdc.gov						AYLETT BJ, 1979, CHEM BIOCH BIOL CADM; BLOCK C, 1992, J BIOL CHEM, V267, P19824; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHI KF, 1992, GASTROENTEROLOGY, V103, P98, DOI 10.1016/0016-5085(92)91101-9; CHMIELNICKA J, 1986, BIOL TRACE ELEM RES, V10, P243, DOI 10.1007/BF02795623; Edmonds BT, 1996, J CELL SCI, V109, P2705; ENDER B, 1993, MOL CARCINOGEN, V7, P18, DOI 10.1002/mc.2940070104; ENGER MD, 1987, CELL BIOL TOXICOL, V3, P407; Fay RM, 1996, FOOD CHEM TOXICOL, V34, P1175, DOI 10.1016/S0278-6915(97)00094-X; Friberg L., 1986, HDB TOXICOLOGY METAL, P130; Godwin A. K., 1997, P107; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; GRANT AG, 1992, INT J CANCER, V50, P740, DOI 10.1002/ijc.2910500513; International Agency for Research on Cancer Monographs, 1993, BERYLLIUM CADMIUM ME, V58, P119; Joseph P, 2001, TOXICOL SCI, V61, P295, DOI 10.1093/toxsci/61.2.295; Keshava N, 2000, MUTAT RES-FUND MOL M, V448, P23, DOI 10.1016/S0027-5107(99)00226-2; LEW Y, 1992, PANCREAS, V7, P144, DOI 10.1097/00006676-199203000-00003; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; Nanni P, 2000, INT J CANCER, V87, P186, DOI 10.1002/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SAMBROOK J, 1989, MOL CLONING, V2, P9; SANDERS J, 1993, BIOCHIM BIOPHYS ACTA, V1174, P87, DOI 10.1016/0167-4781(93)90097-W; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; SORAHAN T, 1983, BRIT J IND MED, V40, P293; SORAHAN T, 1987, BRIT J IND MED, V44, P803; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73	36	56	66	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6131	6136		10.1074/jbc.M109373200	http://dx.doi.org/10.1074/jbc.M109373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11711542	hybrid			2022-12-25	WOS:000173989200059
J	Lambert, JM; Karnoub, AE; Graves, LM; Campbell, SL; Der, CJ				Lambert, JM; Karnoub, AE; Graves, LM; Campbell, SL; Der, CJ			Role of MLK3-mediated activation of p70 S6 kinase in Rac1 transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK/SAPK SIGNALING PATHWAY; CELL-CYCLE PROGRESSION; BINDING PROTEINS RAC1; N-TERMINAL KINASE; RAS TRANSFORMATION; JUN KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; EPITHELIAL-CELLS; CDC42	The signaling pathways that mediate the transforming activity of the Rac1 GTPase remain to be determined. In the present study, we used effector domain mutants of the constitutively activated Rac(61L) mutant that display differential transforming activities and differential activation of downstream effector pathways to investigate the contribution of p70 S6 kinase (p70(S6K)) to Rac1 transformation and to decipher the signaling pathways leading from Rac1 to p70(S6K). First, we found that Rac1 transforming activity could be dissociated from Rac1 activation of p70(S6K). A weakly transforming Rac1 mutant retained the ability to activate p70(S6K), whereas some potently transforming effector mutants were impaired in their ability to activate p70(S6K). These data suggest that p70(S6K) is not necessary to promote full Rac1 transforming activity. We also found a strong correlation between the ability of the Rac(61L) effector mutants to activate p70(S6K) and their ability to activate the JNK mitogen-activated protein kinase. We found that the MLK3 serine/threonine kinase activated JNK and p70(S6K), whereas activation of p70(S6K) by Rac(61L) was significantly inhibited by dominant-negative MLK3. Additionally, the ability of the Rac(61L) effector mutants to activate MLK3 correlated well with their ability to activate p70(S6K) and JNK. Taken together, these results provide evidence that Rac1 coordinately activates p70(S6K) and JNK via MLK3 activation. Finally, we found that co-expression of wild type, but not kinase-dead, MLK3 significantly inhibited Rac1 transforming activity. These results suggest that MLK3 may be a negative regulator of the growth-promoting and transforming properties of Rac1.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059767] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA42978, CA55008] Funding Source: Medline; NIGMS NIH HHS [GM59767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartkamp J, 1999, CANCER RES, V59, P2195; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN AL, 1997, GENE DEV, V11, P2295; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4770	4777		10.1074/jbc.M109379200	http://dx.doi.org/10.1074/jbc.M109379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11713255	hybrid			2022-12-25	WOS:000173962900030
J	Lobsanov, YD; Vallee, F; Imberty, A; Yoshida, T; Yip, P; Herscovics, A; Howell, PL				Lobsanov, YD; Vallee, F; Imberty, A; Yoshida, T; Yip, P; Herscovics, A; Howell, PL			Structure of Penicillium citrinum alpha 1,2-mannosidase reveals the basis for differences in specificity of the endoplasmic reticulum and golgi class I enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSIDASE-LIKE PROTEIN; N-GLYCAN BIOSYNTHESIS; PROCESSING ALPHA-MANNOSIDASE; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-PROPERTIES; ASPERGILLUS-ORYZAE; CRYSTAL-STRUCTURES; YEAST; DEGRADATION; REFINEMENT	Class I alpha1,2-mannosidases (glycosylhydrolase family 47) are key enzymes in the maturation of N-glycans. This protein family includes two distinct enzymatically active subgroups. Subgroup I includes the yeast and human endoplasmic reticulum (ER) alpha1,2-mannosidases that primarily trim Man(9)GlcNAc(2) to Man(8)GlcNAc(2) isomer B whereas subgroup 2 includes mammalian Golgi alpha1,2-mannosidases IA, Ibeta, and IC that trim Man(9)GlcNAc(2) to Man(5)GlcNAc(2) via Man(8)GlcNAc(2) isomers A and C. The structure of the catalytic domain of the subgroup 2 alpha1,2-mannosidase from Penicillium citrinum has been determined by molecular replacement at 2.2-Angstrom resolution. The fungal alpha1,2-mannosidase is an (alphaalpha)(7)-helix barrel, very similar to the subgroup 1 yeast (Vallee, F., Lipari, F., Yip, P., Sleno, B., Herscovics, A., and Howell, P. L. (2000) EMBO J. 19, 581-588) and human (Vallee, F., Karaveg, K, Herscovics, A., Moremen, K. W., and Howell, P. L. (2000) J. Biol. Chem. 275, 41287-41298) ER enzymes. The location of the conserved acidic residues of the catalytic site and the binding of the inhibitors, kifunensine and 1-deoxymannojirimycin, to the essential calcium ion are conserved in the fungal enzyme. However, there are major structural differences in the oligosaccharide binding site between the two alpha1,2-mannosidase subgroups. In the subgroup 1 enzymes, an arginine residue plays a critical role in stabilizing the oligosaccharide substrate. In the fungal alpha1,2-mannosidase this arginine is replaced by glycine. This replacement and other sequence variations result in a more spacious carbohydrate binding site. Modeling studies of interactions between the yeast, human and fungal enzymes with different Man(8)GlcNAc(2) isomers indicate that there is a greater degree of freedom to bind the oligosaccharide in the active site of the fungal enzyme than in the yeast and human ER alpha1,2-mannosidases.	Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; CNRS, CERMAV, F-38041 Grenoble 9, France; Hirosaki Univ, Dept Biochem & Biotechnol, Aomori 0368560, Japan; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Hirosaki University; McGill University; University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.on.ca	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527	PHS HHS [31265] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Jakob CA, 2001, EMBO REP, V2, P423; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PEREZ S, 1995, JERUS SYM Q, V27, P425; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; ROUSSEL A, 1991, TURBO FRODO GRAPHICS; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; Sokolowski T, 1997, J MOL GRAPH MODEL, V15, P37, DOI 10.1016/S1093-3263(97)00011-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremblay LO, 2000, J BIOL CHEM, V275, P31655, DOI 10.1074/jbc.M004935200; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; YOSHIDA T, 1993, BIOCHEM J, V290, P349, DOI 10.1042/bj2900349; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	45	43	51	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5620	5630		10.1074/jbc.M110243200	http://dx.doi.org/10.1074/jbc.M110243200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714724	hybrid			2022-12-25	WOS:000173962900138
J	Simon, P; Weiss, FU; Sahin-Toth, M; Parry, M; Nayler, O; Lenfers, B; Schnekenburger, J; Mayerle, J; Domschke, W; Lerch, MM				Simon, P; Weiss, FU; Sahin-Toth, M; Parry, M; Nayler, O; Lenfers, B; Schnekenburger, J; Mayerle, J; Domschke, W; Lerch, MM			Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 -> Cys) that alters autoactivation and autodegradation of cationic trypsinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; CATHEPSIN-B; IN-VITRO; ACTIVATION; SITE; GENE; HETEROGENEITY; ZYMOGENS; ECOTIN; ONSET	Hereditary pancreatitis has been found to be associated with germline mutations in the cationic trypsinogen (PRSS1) gene. Here we report a family with hereditary pancreatitis that carries a novel PRSS1 mutation (R122C). This mutation cannot be diagnosed with the conventional screening method using AflIII restriction enzyme digest. We therefore propose a new assay based on restriction enzyme digest with BstUI, a technique that permits detection of the novel R122C mutation in addition to the most common R122H mutation, and even in the presence of a recently reported neutral polymorphism that prevents its detection by the AflIII method. Recombinantly expressed R122C mutant human trypsinogen was found to undergo greatly reduced autoactivation and cathepsin B-induced activation, which is most likely caused by misfolding or disulfide mismatches of the mutant zymogen. The K-m of R122C trypsin was found to be unchanged, but its k(cat) was reduced to 37% of the wild type. After correction for enterokinase activatable activity, and specifically in the absence of calcium, the R122C mutant was more resistant to autolysis than the wild type and autoactivated more rapidly at pH 8. Molecular modeling of the R122C mutant trypsin predicted an unimpaired active site but an altered stability of the calcium binding loop. This previously unknown trypsinogen mutation is associated with hereditary pancreatitis, requires a novel diagnostic screening method, and, for the first time, raises the question whether a gain or a loss of trypsin function participates in the onset of pancreatitis.	Univ Munster, Dept Med B, Med Klin B, D-48129 Munster, Germany; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Actelion Pharmaceut Ltd, Dept Mol Biol, CH-4123 Allschwil, Switzerland; Actelion Pharmaceut Ltd, Dept Biol Struct, CH-4123 Allschwil, Switzerland; Stadt Kliniken Dortmund, Med Klin Mitte, D-44135 Dortmund, Germany	University of Munster; University of California System; University of California Los Angeles; Actelion Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd; Klinikum Dortmund	Lerch, MM (corresponding author), Univ Munster, Dept Med B, Med Klin B, Albert Schweitzer Str 33, D-48129 Munster, Germany.	markus.lerch@uni-muenster.de	Lerch, Markus M./E-2206-2016; Mayerle, Julia/W-7907-2019; Weiss, Frank Ulrich/A-6386-2009	Lerch, Markus M./0000-0002-9643-8263; Weiss, Frank Ulrich/0000-0003-3369-6369; Sahin-Toth, Miklos/0000-0003-4513-9922; Schnekenburger, Juergen/0000-0002-0199-2908	NIDDK NIH HHS [DK58088] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen JM, 2000, J MED GENET, V37, P67, DOI 10.1136/jmg.37.1.67; Chiari H., 1896, ZEITSCHRIFTFURHEILKU, V17, P69; COLOMB E, 1979, BIOCHIM BIOPHYS ACTA, V570, P397, DOI 10.1016/0005-2744(79)90159-1; COMFORT MW, 1952, GASTROENTEROLOGY, V21, P54; Dasouki MJ, 1998, AM J MED GENET, V77, P47, DOI 10.1002/(SICI)1096-8628(19980428)77:1<47::AID-AJMG11>3.0.CO;2-O; Ferec C, 1999, J MED GENET, V36, P228; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; Gaboriaud C, 1996, J MOL BIOL, V259, P995, DOI 10.1006/jmbi.1996.0376; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; HALANGK W, 2001, IN PRESS AM J PHYSL; Howes N, 2001, GUT, V48, P247, DOI 10.1136/gut.48.2.247; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; Kruger B, 2001, BIOCHEM BIOPH RES CO, V282, P159, DOI 10.1006/bbrc.2001.4561; Le Marechal C, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-19; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; Lerch MM, 2000, MED CLIN N AM, V84, P549, DOI 10.1016/S0025-7125(05)70239-X; Lerch MM, 1999, J NATL CANCER I, V91, P723, DOI 10.1093/jnci/91.8.723; Lerch MM, 2000, ADV EXP MED BIOL, V477, P403; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; Pal G, 1996, FEBS LETT, V385, P165, DOI 10.1016/0014-5793(96)00376-6; PAL G, 1994, FEBS LETT, V342, P57, DOI 10.1016/0014-5793(94)80584-9; PFUTZER RH, 2002, IN PRESS GUT; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 1999, J BIOL CHEM, V274, P29699, DOI 10.1074/jbc.274.42.29699; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; Saluja AK, 1997, GASTROENTEROLOGY, V113, P304, DOI 10.1016/S0016-5085(97)70108-2; Scriver CR, 2000, EUR J PEDIATR, V159, pS243, DOI 10.1007/PL00014412; Sossenheimer MJ, 1997, AM J GASTROENTEROL, V92, P1113; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; Whitcomb DC, 1999, GUT, V45, P317, DOI 10.1136/gut.45.3.317; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3	38	92	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5404	5410		10.1074/jbc.M108073200	http://dx.doi.org/10.1074/jbc.M108073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719509	hybrid			2022-12-25	WOS:000173962900109
J	Fulton, D; Fontana, J; Sowa, G; Gratton, JP; Lin, M; Li, KX; Michell, B; Kemp, BE; Rodman, D; Sessa, WC				Fulton, D; Fontana, J; Sowa, G; Gratton, JP; Lin, M; Li, KX; Michell, B; Kemp, BE; Rodman, D; Sessa, WC			Localization of endothelial nitric-oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SHAPE CHANGE; CELLS; PALMITOYLATION; ACTIVATION; CAVEOLAE; TRANSLOCATION; SITES; CA2+; ENOS	The subcellular localization of endothelial nitric-oxide synthase (eNOS) is critical for optimal coupling of extracellular stimulation to nitric oxide production. Because eNOS is activated by Akt-dependent phosphorylation to produce nitric oxide (NO), we determined the subcellular distribution of eNOS phosphorylated on serine 1179 using a variety of methodologies. Based on sucrose gradient fractionation, phosphorylated-eNOS (P-eNOS) was found in both caveolin-l-enriched membranes and intracellular domains. Co-transfection of eNOS with Akt and stimulation of endothelial cells with vascular endothelial growth factor (VEGF) increased the ratio of P-eNOS to total eNOS but did not change the relative intracellular distribution between these domains. The proper localization of eNOS to intracellular membranes was required for agonist-dependent: phosphorylation on serine 1179, since VEGF did not increase eNOS phosphorylation in cells transfected with a nonacylated, mistargeted form of eNOS. Confocal imaging of P-eNOS and total eNOS pools demonstrated co-localization in the Golgi region and plasmalemma of transfected cells and native endothelial cells. Finally,,VEGF stimulated a large increase in NO localized in both the perinuclear region and the plasma membrane of endothelial cells. Thus, activated, phosphorylated eNOS resides in two cellular compartments and both pools are VEGF-regulated to produce NO.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Colorado, Hlth Sci Ctr, St Ctr Genet Lung Dis, Div Pulm Sci & Crit Care Med, Boulder, CO 80309 USA; St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Yale University; Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Kemp, Bruce/G-9602-2019; Sessa, William C/B-6844-2011; Mordwinkin, Nicholas M/A-4347-2010; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Sessa, William C/0000-0001-5759-1938; Kemp, Bruce E/0000-0001-6735-5082; Gratton, Jean-Philippe/0000-0001-9877-8520; Sowa, Grzegorz/0000-0001-8150-1525	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064793, R01HL061371, R01HL048038, R01HL057665, F32HL010183, R37HL061371, R29HL048038] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61371, T32HL10183, HL48038, HL64793, R01 HL57665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Nishimatsu H, 2001, CIRC RES, V89, P63, DOI 10.1161/hh1301.092498; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SAGO H, 1992, THROMB HAEMOSTASIS, V67, P331; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524	39	168	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4277	4284		10.1074/jbc.M106302200	http://dx.doi.org/10.1074/jbc.M106302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729179	hybrid			2022-12-25	WOS:000173813900066
J	Thukkani, AK; Hsu, FF; Crowley, JR; Wysolmerski, RB; Albert, CJ; Ford, DA				Thukkani, AK; Hsu, FF; Crowley, JR; Wysolmerski, RB; Albert, CJ; Ford, DA			Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens - Production of the chemoattractant, 2-chlorohexadecanal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PEROXIDE-CHLORIDE SYSTEM; OXIDANT MEMBRANE INJURY; HYPOCHLOROUS ACID; MYOCARDIAL-ISCHEMIA; HYDROGEN-PEROXIDE; MYELOPEROXIDASE SYSTEM; REPERFUSION INJURY; ARACHIDONIC-ACID; NADPH OXIDASE	Recently alpha-chloro fatty aldehydes have been shown to be products of reactive chlorinating species targeting the vinyl ether bond of plasmalogens utilizing a cell-free system. Accordingly, the present experiments were designed to show that alpha-chloro fatty aldehydes are produced by activated neutrophils and to determine their physiologic effects. A sensitive gas chromatography-mass spectrometry technique was developed to detect pentafluorobenzyl oximes of a-chloro fatty aldehydes utilizing negative ion chemical ionization. Phorbol 12-myristate 13-acetate activation of neutrophils resulted in the production of both 2-chlorohexadecanal and 2-chlorooctadecanal through a myeloperoxidase-dependent mechanism that likely involved the targeting of both 16 and 18 carbon vinyl ether-linked aliphatic groups present in the sn-1 position of neutrophil plasmalogens. 2-Chlorohexadecanal was also produced by fMLP-treated neutrophils. Additionally, reactive chlorinating species released from activated neutrophils targeted endothelial cell plasmalogens resulting in 2-chlorohexadecanal production. Physiologically relevant concentrations of 2-chlorohexadecanal induced neutrophil chemotaxis in vitro suggesting that alpha-chloro fatty aldehydes may have a role in neutrophil recruitment. Taken together, these studies demonstrate for the first time a novel biochemical mechanism that targets the vinyl ether bond of plasmalogens during neutrophil activation resulting in the production of alpha-chloro fatty aldehydes that may enhance the recruitment of neutrophils to areas of active inflammation.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Hlth Sci Ctr, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, Hlth Sci Ctr, St Louis, MO 63104 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Washington University (WUSTL)	Ford, DA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Hlth Sci Ctr, 1402 S Grand Blvd, St Louis, MO 63104 USA.	fordda@slu.edu	; Ford, David/D-1819-2018	Hsu, Fong-Fu/0000-0001-5368-0183; Ford, David/0000-0002-0029-1560	NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [R01 HL 42665-11] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ARTHUR G, 1986, BIOCHEM J, V236, P475, DOI 10.1042/bj2360475; BASS DA, 1978, J IMMUNOL, V121, P172; BELLESIA F, 1992, TETRAHEDRON, V48, P4579, DOI 10.1016/S0040-4020(01)81231-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Caldwell RA, 1998, CIRC RES, V83, P533, DOI 10.1161/01.RES.83.5.533; CURZIO M, 1982, RES COMMUN CHEM PATH, V36, P463; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; GOTTFRIED EL, 1963, BIOCHEMISTRY-US, V2, P646, DOI 10.1021/bi00904a004; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Hsu FF, 1999, INT J MASS SPECTROM, V185, P795, DOI 10.1016/S1387-3806(98)14105-2; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; KAYGANICH KA, 1992, ANAL CHEM, V64, P2965, DOI 10.1021/ac00047a015; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LAMPERT MB, 1983, BLOOD, V62, P645; MANCUSO AJ, 1978, J ORG CHEM, V43, P2480, DOI 10.1021/jo00406a041; MCMASTER CR, 1992, LIPIDS, V27, P945, DOI 10.1007/BF02535569; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; POST JA, 1988, FEBS LETT, V240, P78, DOI 10.1016/0014-5793(88)80343-0; SEPE SM, 1985, J IMMUNOL, V134, P1888; SEPE SM, 1985, J IMMUNOL, V134, P1896; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; Vermeiren GLJ, 2000, RESUSCITATION, V45, P35, DOI 10.1016/S0300-9572(00)00168-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZ G, 1987, BIOCHEM PHARMACOL, V36, P721, DOI 10.1016/0006-2952(87)90725-8; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	45	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3842	3849		10.1074/jbc.M109489200	http://dx.doi.org/10.1074/jbc.M109489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724792	hybrid			2022-12-25	WOS:000173813900008
J	Lee, WS; Rohrer, J; Kornfeld, R; Kornfeld, S				Lee, WS; Rohrer, J; Kornfeld, R; Kornfeld, S			Multiple signals regulate trafficking of the mannose 6-phosphate-uncovering enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; MEDIATE LOCALIZATION; SORTING SIGNALS; PLASMA-MEMBRANE; AMINO-ACIDS; TGN38; INTERNALIZATION	The "uncovering enzyme," which catalyzes the second step in the formation of the mannose 6-phosphate recognition marker on lysosomal enzyme oligosaccharides, resides primarily in the trans-Golgi network and cycles between this compartment and the plasma membrane. An analysis of green fluorescent protein-uncovering enzyme chimeras revealed that the transmembrane segment and the first 11 residues of the 41-residue-cytoplasmic tail are sufficient for retention in the trans-Golgi network. The next eight residues ((486)YAYHPLQE(493)) fa. cilitate exit from this compartment. Kinetic studies demonstrated that the (YHPL491)-Y-488 sequence also mediates rapid internalization at the plasma membrane. This motif binds adaptor protein-2 in glutathione S-transferase-uncovering enzyme-cytoplasmic tail pull-down assays, indicating that the uncovering enzyme is endocytosed via clathrin-coated vesicles. Consistent with this finding, endogenous uncovering enzyme was detected in purified clathrin-coated vesicles. The enzyme with a Y486A mutation is internalized normally but accumulates on the cell surface because of increased recycling to the plasma membrane. This residue is required for efficient return of the enzyme from endosomes to the trans-Golgi network. These findings indicate that the YAYHPLQE motif is recognized at several sorting sites, including the trans-Golgi network, the plasma membrane, and the endosome.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Friedrich Miescher Inst, CH-4059 Basel, Switzerland	Washington University (WUSTL); Friedrich Miescher Institute for Biomedical Research	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.			Rohrer, Jack/0000-0002-2058-490X	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Drake MT, 2000, MOL BIOL CELL, V11, P3723, DOI 10.1091/mbc.11.11.3723; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Moll M, 2001, J BIOL CHEM, V276, P17887, DOI 10.1074/jbc.M010183200; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Peden AA, 2001, J BIOL CHEM, V276, P49183, DOI 10.1074/jbc.M106646200; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WONG SH, 1993, J BIOL CHEM, V268, P22853; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	34	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3544	3551		10.1074/jbc.M108531200	http://dx.doi.org/10.1074/jbc.M108531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723124	hybrid			2022-12-25	WOS:000173688000065
J	Kino, T; Slobodskaya, O; Pavlakis, GN; Chrousos, GP				Kino, T; Slobodskaya, O; Pavlakis, GN; Chrousos, GP			Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; THYROID-HORMONE RECEPTOR; RNA-POLYMERASE-II; FACTOR KAPPA-B; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL COACTIVATORS; GENE-EXPRESSION; P300; ACTIVATION; VPR	We report that p160 nuclear receptor coactivators potentiate the transactivating activity of Tat, the most potent virally encoded transactivator of HIV-1. One of the p160 proteins (GRIP1) is tethered to the HIV-1 long terminal repeat (LTR) through kappaB-responsive elements, most likely via NF-kappaB, with which it also associates through its coactivator motifs (LXXLL motifs, "NR boxes"). Indeed, the Tat-stimulated kappaB-defective HIV-1 LTR had a markedly impaired response to GRIP1, whereas NR box-defective GRIM proteins lost part of their Tat coactivator effect on the HIV-1 LTR. Through its N-terminal basic helix-loop-helix and C-terminal domains, GRIP1 binds to the N-terminal region of Tat and to the host cell protein cyclin T1, respectively, which is normally complexed with CDK9 as P-TEFb. Thus, NF-kappaB is crucial for tethering p160 coactivator molecules to the HIV-1 LTR, allowing full activation of this promoter by Tat. Interestingly, cotransfection of Tat, GRIP1, and cyclin T1 enhanced not only the activity of the HIV-1 LTR, but also the glucocorticoid receptor-mediated stimulation of the mouse mammary tumor virus (MMTV) promoter, suggesting that Tat can also attract the P-TEFb complex to the MMTV LTR through GRIP1. Thus, it appears that the coactivator complexes of the HIV-1 and MMTV LTRs both include p 160 coactivators and use similar coactivator and elongation complexes for their transcription. Tat may function as an adaptor molecule, efficiently stimulating the processes of transcription initiation and elongation through potentiation of the coupling of p160 coactivators and the P-TEFb complex.	NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Human Retrovirus Sect, Canc Res Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kino, T (corresponding author), NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Rm 9D42,10 Ctr Dr MSC 1583, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618, ZIAHD000615] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000618, Z01HD000615] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen SL, 2000, GENE DEV, V14, P1209; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; DESAIYAJNIK V, 1993, T ASSOC AM PHYSICIAN, V106, P13; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kino T, 1999, J STEROID BIOCHEM, V70, P15, DOI 10.1016/S0960-0760(99)00100-4; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; PAVLAKIS GN, 1996, AIDS DIAGNOSIS TREAT, P45; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Recio JA, 2000, FEBS LETT, V469, P118, DOI 10.1016/S0014-5793(00)01249-7; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Tang HL, 1999, ANNU REV GENET, V33, P133, DOI 10.1146/annurev.genet.33.1.133; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2396	2405		10.1074/jbc.M106312200	http://dx.doi.org/10.1074/jbc.M106312200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704662	hybrid			2022-12-25	WOS:000173421500006
J	Kouguchi, H; Watanabe, T; Sagane, Y; Sunagawa, H; Ohyama, T				Kouguchi, H; Watanabe, T; Sagane, Y; Sunagawa, H; Ohyama, T			In vitro reconstitution of the Clostridium botulinum type D progenitor toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTOXIC-NONHEMAGGLUTININ COMPONENTS; GENES-ENCODING COMPONENTS; MOLECULAR COMPOSITION; ORAL TOXICITIES; NEUROTOXIN; PROTEINS; ELECTROPHORESIS; IDENTIFICATION; HEMAGGLUTININ; ORGANIZATION	Clostridium botulinum type D strain 4947 produces two different sizes of progenitor toxins (M and L) as intact forms without proteolytic processing. The M toxin is composed of neurotoxin (NT) and nontoxic-nonhemagglutinin (NTNHA), whereas the L toxin is composed of the M toxin and hemagglutinin (HA) subcomponents (RA-70, HA-17, and HA-33). The RA-70 subcomponent and the HA-33/17 complex were isolated from the L toxin to near homogeneity by chromatography in the presence of denaturing agents. We were able to demonstrate, for the first time, in vitro reconstitution of the L toxin formed by mixing purified M toxin, HA-70, and HA-33/17. The properties of reconstituted and native L toxins are indistinguishable with respect to their gel filtration profiles, native-PAGE profiles, hemagglutination activity, binding activity to erythrocytes, and oral toxicity to mice. M toxin, which contained nicked NTNHA prepared by treatment with trypsin, could no longer be reconstituted to the L toxin with HA subcomponents, whereas the L toxin treated with proteases was not degraded into M toxin and HA subcomponents. We conclude that the M toxin forms first by assembly of NT with NTNHA and is subsequently converted to the L toxin by assembly with HA-70 and HA-33/17.	Tokyo Univ Agr, Fac Bioind, Dept Food Sci & Technol, Abashiri 0992493, Japan; Hokkaido Inst Publ Hlth, Kita Ku, Sapporo, Hokkaido 0600819, Japan	Tokyo University of Agriculture	Ohyama, T (corresponding author), Tokyo Univ Agr, Fac Bioind, Dept Food Sci & Technol, 196 Yasaka, Abashiri 0992493, Japan.	t-oyama@bioindustry.nodai.ac.jp	Sagane, Yoshimasa/C-7635-2013; Sagane, Yoshimasa/AAG-5543-2019	Sagane, Yoshimasa/0000-0002-7815-3141				Cai SO, 1999, BIOCHEMISTRY-US, V38, P6903, DOI 10.1021/bi990086c; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EAST AK, 1994, CURR MICROBIOL, V29, P69, DOI 10.1007/BF01575751; East AK, 1996, INT J SYST BACTERIOL, V46, P1105, DOI 10.1099/00207713-46-4-1105; FUJII N, 1993, J GEN MICROBIOL, V139, P79, DOI 10.1099/00221287-139-1-79; FUJINAGA Y, 1994, BIOCHEM BIOPH RES CO, V205, P1291, DOI 10.1006/bbrc.1994.2805; Fujinaga Y, 2000, FEBS LETT, V467, P179, DOI 10.1016/S0014-5793(00)01147-9; FUJITA R, 1995, FEBS LETT, V376, P41, DOI 10.1016/0014-5793(95)01241-5; HAUSER D, 1994, MOL GEN GENET, V243, P631, DOI 10.1007/BF00279572; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; Inoue K, 1996, INFECT IMMUN, V64, P1589, DOI 10.1128/IAI.64.5.1589-1594.1996; Inoue K, 1999, MICROBIOL-UK, V145, P2533, DOI 10.1099/00221287-145-9-2533; KITAMURA M, 1969, J BACTERIOL, V98, P1173, DOI 10.1128/JB.98.3.1173-1178.1969; Kouguchi H, 2001, EUR J BIOCHEM, V268, P4019, DOI 10.1046/j.1432-1327.2001.02317.x; Kouguchi Hirokazu, 2000, Japanese Journal of Electrophoresis, V44, P27; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li L, 1999, J TOXICOL-TOXIN REV, V18, P95, DOI 10.3109/15569549909036019; Mei G, 1997, BIOCHEMISTRY-US, V36, P10917, DOI 10.1021/bi970614p; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; Nakajima H, 1998, MICROBIOL IMMUNOL, V42, P599, DOI 10.1111/j.1348-0421.1998.tb02330.x; OGUMA K, 1995, MICROBIOL IMMUNOL, V39, P161, DOI 10.1111/j.1348-0421.1995.tb02184.x; Oguma K, 1999, J TOXICOL-TOXIN REV, V18, P17, DOI 10.3109/15569549909036015; OHISHI I, 1980, INFECT IMMUN, V28, P303; OHISHI I, 1977, INFECT IMMUN, V16, P107, DOI 10.1128/IAI.16.1.107-109.1977; OHYAMA T, 1995, MICROBIOL IMMUNOL, V39, P457, DOI 10.1111/j.1348-0421.1995.tb02229.x; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sagane Y, 2000, J PROTEIN CHEM, V19, P575, DOI 10.1023/A:1007198202016; Sagane Y, 1999, J PROTEIN CHEM, V18, P885, DOI 10.1023/A:1020687430927; SAKAGUCHI G, 1984, BACTERIAL PROTEIN TO, P435; SCHANTZ EJ, 1992, MICROBIOL REV, V56, P80, DOI 10.1128/MMBR.56.1.80-99.1992; SOMERS E, 1991, J PROTEIN CHEM, V10, P415, DOI 10.1007/BF01025256; SUGII S, 1977, INFECT IMMUN, V17, P491, DOI 10.1128/IAI.17.3.491-496.1977; SUGIYAMA H, 1980, MICROBIOL REV, V44, P419, DOI 10.1128/MMBR.44.3.419-448.1980; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005	35	50	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2650	2656		10.1074/jbc.M106762200	http://dx.doi.org/10.1074/jbc.M106762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713244	hybrid			2022-12-25	WOS:000173421500037
J	Petre, CE; Wetherill, YB; Danielsen, M; Knudsen, KE				Petre, CE; Wetherill, YB; Danielsen, M; Knudsen, KE			Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; CARBOXYL-TERMINAL REGIONS; HEAT-SHOCK-PROTEIN; LNCAP CELLS; ESTROGEN-RECEPTOR; PROSTATE-CANCER; STEROID-BINDING; TRANSCRIPTIONAL COACTIVATOR; INDEPENDENT ACTIVATION; HISTONE ACETYLATION	Androgen receptor regulation is pivotal for prostate growth and development. Activation of the receptor is dictated by association with androgen (ligand) and through interaction with co-activators and co-repressors. We have shown previously that cyclin D1 functions as a co-repressor to inhibit ligand-dependent androgen receptor activation. We demonstrate that cyclin D1 directly binds the N terminus of the androgen receptor and that this interaction is independent of ligand. Furthermore, we show that the interaction occurs in the nucleus and does not require the LXXLL motif of cyclin D1. Although two distinct transactivation domains exist in the N terminus (AF-1 and AF-5), the data shown support the hypothesis that cyclin 131 targets the AF-1 transactivation function. The constitutively active AF-5 domain was refractory to cyclin D1 inhibition. By contrast, cyclin D1 completely abolished androgen receptor activity, even in the presence of potent androgen receptor co-activators. This action of cyclin 131 at least partially required de-acetylase activity. Finally, we show that transient, ectopic expression of cyclin D I results in reduced cell cycle progression in androgen-dependent LNCaP cells independent of CDK4 association. Collectively, our data support a model wherein cyclin D1 has a mitogenic (CDK4-dependent) function and an anti-mitogenic function (dependent on regulation of the AF-1 domain) that can collectively control the rate of androgen-dependent cellular proliferation. These findings provide insight into the non-cell cycle functions of cyclin 131 and provide the impetus to study its pleiotropic effects in androgen-dependent cells, especially prostatic adenocarcinomas.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	University System of Ohio; University of Cincinnati; Georgetown University	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	danielsen, mark/AAE-9813-2020; Danielsen, Mark/B-1606-2008	danielsen, mark/0000-0002-0923-9945; Danielsen, Mark/0000-0002-0923-9945; Knudsen, Karen/0000-0002-1301-890X	NIEHS NIH HHS [ES07250-13] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aaltomaa S, 1999, PROSTATE, V38, P175; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRINKMANN AO, 1989, UROL RES, V17, P87, DOI 10.1007/BF00262026; Brinkmann AO, 2000, ADV PHARMACOL, V47, P317; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gao TS, 1999, MOL ENDOCRINOL, V13, P1645, DOI 10.1210/me.13.10.1645; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; Han SW, 1998, YONSEI MED J, V39, P13, DOI 10.3349/ymj.1998.39.1.13; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hayward SW, 1997, BRIT J UROL, V79, P18, DOI 10.1111/j.1464-410X.1997.tb16917.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang EY, 2000, GENE DEV, V14, P45; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Knudsen KE, 1999, CANCER RES, V59, P2297; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; List HJ, 1999, EXP CELL RES, V252, P471, DOI 10.1006/excr.1999.4638; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; LUKAS J, 1994, ONCOGENE, V9, P707; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olapade-Alaopa EO, 1999, CLIN CANCER RES, V5, P569; Pettaway C A, 1998, Tech Urol, V4, P35; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shiraishi T, 1998, UROL INT, V61, P90, DOI 10.1159/000030295; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	76	114	119	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2207	2215		10.1074/jbc.M106399200	http://dx.doi.org/10.1074/jbc.M106399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11714699	hybrid			2022-12-25	WOS:000173421300081
J	Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF				Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF			BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells	ONCOGENE			English	Article						cyclin D2; p27(Kip1); proliferation; apoptosis; WEHI 231; PI3-K	ANTIGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT KINASE; LYMPHOMA-CELLS; G(1) CYCLIN; IN-VITRO; ACTIVATION	Cross-linking of the B cell antigen receptor (BCR) on immature WEHI 231 B cells results in GI cell cycle arrest and apoptosis. Here we investigated the, molecular mechanisms that are necessary and sufficient for these changes to occur., We show that BCR stimulation of WEHI 231 cells results in down-regulation of cyclin D2 and up-regulation of p27(Kip1), which are associated with pocket protein hypophosphorylation and E2F inactivation. Ectopic expression of p27(Kip1) by TAT-fusion protein or retroviral transduction is sufficient to cause G1 cell cycle arrest, followed by apoptosis. In contrast, overt expression of cyclin D2 overcomes, the cell cycle arrest and apoptosis induced by anti-IgM, indicating that downregulation of cyclin D2 is necessary for the cell cycle arrest and apoptosis activated by BCR stimulation. Thus, cyclin D2 and p27(Kip1) have opposing roles in these pathways and our data also suggest that cyclin D2 functions upstream of p27(Kip1) and the pRB pathway and therefore plays an essential part in integrating the signals from BCR with the cell cycle machinery. We next investigated which signal transduction pathways triggered by the BCR regulate cell proliferation and apoptosis. via cyclin D2 and p27(Kip1). Inhibition of PI3-K signalling by LY294002 down-regulated cyclin D2 and up-regulated p27(Kip1) expression at both, protein and RNA levels, mimicking the effects of BCR-stimulation. Furthermore, ectopic expression of a constitutively active form of AKT blocked the cell cycle arrest and apoptosis triggered by anti-IgM and also, abrogated downregulation of cyclin D2 and up-regulation of p27(Kip1) expression induced by BCR-engagement. These results indicate that BCR activation targets: p27(Kip1) and cyclin D2 to mediate cell cycle arrest and apoptosis and that down-regulation of PI3-K/AKT activity post BCR stimulation is necessary for these to occur.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Sect Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Guys Kings St Thomas Sch Med, Rayne Inst, Dept Haematol, London, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	Imperial College London; Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; King's College London; MRC National Institute for Medical Research	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Birkeland ML, 1997, CRIT REV IMMUNOL, V17, P353, DOI 10.1615/CritRevImmunol.v17.i3-4.50; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Donjerkovic D, 1999, CELL GROWTH DIFFER, V10, P695; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GOLD MR, 1994, J IMMUNOL, V152, P42; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Padmore L, 1997, CELL IMMUNOL, V177, P119, DOI 10.1006/cimm.1997.1102; PARADA Y, 2001, J BIOL CHEM, V25, P25; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wu M, 1999, J IMMUNOL, V163, P6530	62	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7352	7367		10.1038/sj.onc.1204951	http://dx.doi.org/10.1038/sj.onc.1204951			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704865				2022-12-25	WOS:000171894200008
J	Deryugina, EI; Ratnikov, BI; Postnova, TI; Rozanov, DV; Strongin, AY				Deryugina, EI; Ratnikov, BI; Postnova, TI; Rozanov, DV; Strongin, AY			Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; COLLAGEN MATRIX; ACTIVATION; SURFACE; FURIN; MMP-2; PROTEOLYSIS; INVASION; CLEAVAGE; ALPHA-V-BETA-3	Recently, we have shown that membrane type 1 matrix metalloproteinase (MT1-MMP) exhibits integrin convertase activity. Similar to furin-like proprotein convertases, MT1-MMP directly processes a single chain precursor of alpha(v) integrin subunit (pro-alpha(v)) into the heavy and light alpha-chains connected by a disulfide bridge. To evaluate functionality of MT1-MMP-processed integrins, we examined breast carcinoma MCF7 cells coexpressing alpha(v)beta(3) integrin with either the wild type or mutant MT1-MMP in a variety of migration and adhesion tests. Specific inhibitors of proprotein convertases and MMP were employed in our cell system to attenuate the individual pathways of pro-alpha(v) maturation. We present evidence that MT1-MMP cleavage of pro-alpha(v) in the cells did not affect RGD-ligand binding of the resulting alpha(v)beta(3) integrin but enhanced outside-in signal transduction through a focal adhesion kinase pathway. Enhanced tyrosine phosphorylation of focal adhesion kinase in cells co-expressing MT1-MMP and alpha(v)beta(3) integrin contributed to efficient adhesion and, especially, migration of cells on vitronectin, a ligand of alpha(v)beta(3) integrin. These mechanisms underscore the significance of a coordinated interplay between MT1-MMP and alpha(v)beta(3) integrin in tumor cells and identify downstream signaling pathways resulting from their interactions. Regulation of integrin maturation and functionality may be an important role of MT1-MMP in tumor cells.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Boettiger D, 2001, J BIOL CHEM, V276, P31684, DOI 10.1074/jbc.M103997200; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, EUR J CANCER, V32A, P2423, DOI 10.1016/S0959-8049(96)00381-4; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Coussens LM, 2000, METH MOL B, V151, P149, DOI 10.1385/1-59259-046-2:149; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Eliceiri BP, 2000, CANCER J, V6, pS245; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Holly SP, 2000, EXP CELL RES, V261, P69, DOI 10.1006/excr.2000.5040; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 2000, CELL MOL LIFE SCI, V57, P16, DOI 10.1007/s000180050496; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; LEONG L, 1995, J CELL SCI, V108, P3817; Lin ECK, 1997, J BIOL CHEM, V272, P23912, DOI 10.1074/jbc.272.38.23912; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Liu SC, 2000, J CELL SCI, V113, P3563; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ruoslahti E, 1997, KIDNEY INT, V51, P1413, DOI 10.1038/ki.1997.193; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; SMITH JW, 1994, J BIOL CHEM, V269, P32788; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zheng DQ, 1999, CANCER RES, V59, P1655	57	179	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9749	9756		10.1074/jbc.M110269200	http://dx.doi.org/10.1074/jbc.M110269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11724803	hybrid			2022-12-25	WOS:000174549200022
J	Ikonomov, OC; Sbrissa, D; Mlak, K; Kanzaki, M; Pessin, J; Shisheva, A				Ikonomov, OC; Sbrissa, D; Mlak, K; Kanzaki, M; Pessin, J; Shisheva, A			Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of PtdIns 3,5-P-2 production for endomembrane integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PERMEANT; YEAST; PHOSPHOINOSITIDES; EXPRESSION; INSULIN	PIKfyve enzymatic activity is required in maintaining late endocytic membrane integrity. PIKfyve is a dual specificity enzyme that phosphorylates phosphatidylinositol (PtdIns) and PtdIns 3-P at the 5-hydroxyl and unidentified endogenous protein substrate(s). To determine which of these activities (lipid versus protein kinase activity) is responsible for endomembrane homeostasis we analyzed a double mutant PIKfyve(K1999E/K2000E). These substitutions in the putative lipid-substrate activation loop nearly completely abrogated the lipid kinase activity without any significant effect on the protein kinase activity of PIKfyve(K1999FIC2000E). Expression of PlKfyve(K1999FJK2000E) in COS cells induced a dramatic dominant-negative effect in the form of endomembrane swelling and vacuolation. In addition, the lipid-substrate specificity of PIKfyve was modified by introducing single mutations in Lys-1999 or Lys-2000. This yielded proteins with preferentially abrogated synthesis of PtdIns 5-P (PIKfyve(K2000E)) or PtdIns 3,5-P-2 (PlKfyve(K1999E)), of which only the PIKfyve(K1999E) mutant induced the characteristic endomembrane defects upon cell transfection. Furthermore, phosphoinositide micro-injection into cells demonstrated a selective ability of PtdIns 3.5-P-2 to correct the endomembrane defects induced by the dominant-negative PlKfyve lipid kinase-deficient mutants. Thus, PtdIns 3,5-P-2 production by PlKfyve is crucial for endomembrane integrity, and Lys-1999 most likely directs the PIKfyve interactions with the 3-phosphate group in PtdIns 3-P.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Univ Iowa, Dept Phys & Biophys, Iowa City, IA 52242 USA	Wayne State University; University of Iowa	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.		Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK 58058] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Rudolf MT, 1998, BIOORG MED CHEM LETT, V8, P1857, DOI 10.1016/S0960-894X(98)00322-9; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319	22	92	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9206	9211		10.1074/jbc.M108750200	http://dx.doi.org/10.1074/jbc.M108750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11714711	hybrid			2022-12-25	WOS:000174400600064
J	Gardai, S; Whitlock, BB; Helgason, C; Ambruso, D; Fadok, V; Bratton, D; Henson, PM				Gardai, S; Whitlock, BB; Helgason, C; Ambruso, D; Fadok, V; Bratton, D; Henson, PM			Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITIES; ADHERENT HUMAN NEUTROPHILS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; INOSITOL PHOSPHATASE; AKT ACTIVATION; IN-VITRO; INHIBITION; PHOSPHORYLATION; FAS	Neutrophils undergo rapid spontaneous apoptosis. Multiple antiapoptotic stimuli can inhibit this process via activation of the Akt pathway. However, despite no such effect singly, combined anti- and proapoptotic stimuli inhibit Akt activity, leaving the cells susceptible to accelerated apoptosis. The blockade of Akt activation depended on reduced phosphoinositide 3,4,5-trisphosphate levels but not decreased phosphatidylinositol 3-kinase activity, thus implicating the involvement of an inositol phosphatase. Evidence for SHIP involvement was provided by SHIP localization to membrane receptors and subsequent activation along with the observed inability of SHIP -/- neutrophils to exhibit enhanced apoptosis with the stimulus combination. Activation of SHIP was found to depend on Lyn activation, and this, in turn, required NADPH oxidase. Neutrophils from chronic granulomatous disease patients and Lyn -/- mice no longer responded to the combined stimuli. Thus, we propose a role for oxidants and Lyn in SHIP regulation and suggest a novel mechanism for regulating neutrophil apoptosis.	Natl Jewish Med & Res Ctr, Dept Pediat & Immunol, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; British Columbia Cancer Agency; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat & Immunol, Cell Biol Program, D508,1400 Jackson St, Denver, CO 80206 USA.							Abreu MT, 2001, J BIOL CHEM, V276, P47563, DOI 10.1074/jbc.M106226200; Aikin R, 2000, BIOCHEM BIOPH RES CO, V277, P455, DOI 10.1006/bbrc.2000.3664; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Chacko GW, 1996, J IMMUNOL, V157, P2234; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dalhoff K, 1998, J INFECT DIS, V178, P891, DOI 10.1086/515350; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Driessens MHE, 1996, J LEUKOCYTE BIOL, V60, P758, DOI 10.1002/jlb.60.6.758; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Gulbins E, 1998, J LEUKOCYTE BIOL, V63, P253, DOI 10.1002/jlb.63.2.253; HASLETT C, 1985, AM J PATHOL, V119, P101; HASLETT C, 1992, CLIN SCI, V83, P639, DOI 10.1042/cs0830639; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huber M, 1999, PROG BIOPHYS MOL BIO, V71, P423, DOI 10.1016/S0079-6107(98)00049-2; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KAPPELLER R, 1994, BIOESSAYS, V16, P565; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Krystal G, 1999, INT J BIOCHEM CELL B, V31, P1007, DOI 10.1016/S1357-2725(99)00072-2; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Oishi K, 1997, SCAND J IMMUNOL, V45, P21, DOI 10.1046/j.1365-3083.1997.d01-365.x; Otero DC, 2001, J BIOL CHEM, V276, P1474, DOI 10.1074/jbc.M003918200; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Rey-Ladino JA, 1999, J IMMUNOL, V162, P5792; SAVIGE JA, 1984, CLIN EXP IMMUNOL, V58, P737; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Sweeney JF, 1999, J SURG RES, V81, P108, DOI 10.1006/jsre.1998.5471; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Tudan C, 2000, J IMMUNOL, V165, P5798, DOI 10.4049/jimmunol.165.10.5798; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Watson RWG, 1999, FEBS LETT, V453, P67, DOI 10.1016/S0014-5793(99)00688-2; Watson RWG, 1997, J IMMUNOL, V158, P945; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; Yan SR, 1999, INFLAMMATION, V23, P167, DOI 10.1023/A:1020245129632; ZHANG L, 2001, CELL DEATH DIFFER, V528, P8; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	52	77	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5236	5246		10.1074/jbc.M110005200	http://dx.doi.org/10.1074/jbc.M110005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724799	hybrid			2022-12-25	WOS:000173962900089
J	Reinboth, B; Hanssen, E; Cleary, EG; Gibson, MA				Reinboth, B; Hanssen, E; Cleary, EG; Gibson, MA			Molecular interactions of biglycan and decorin with elastic fiber components - Biglycan forms a ternary complex with tropoelastin and microfibril-associated glycoprotein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLIN-CONTAINING MICROFIBRILS; EXTRACELLULAR MICROFIBRILS; DEVELOPMENTAL EXPRESSION; SULFATE PROTEOGLYCANS; TARGETED DISRUPTION; VI COLLAGEN; PROTEINS; BINDING; CLONING; MAGP-1	The interactions of the dermatan sulfate proteoglycans biglycan and decorin have been investigated with the elastic fiber components, tropoelastin, fibrillin-containing microfibrils, and microfibril-associated glycoproteins (MAGP) 1 and 2. Both proteoglycans were found to bind tropoelastin and fibrillin-containing microfibrils but not MAGPs 1 and 2 in solid phase binding assays. The specificity of the binding of biglycan and decorin to tropoelastin was confirmed by co-immunoprecipitation experiments and by the blocking of the interactions with elastin-derived peptides. Isolated core proteins from biglycan and decorin bound to tropoelastin more strongly than the intact proteoglycans, and there were no differences in the tropoelastin binding characteristics of distinct glucuronate-rich and iduronate-rich glycoforms of biglycan. These findings indicated that the binding sites were contained in the protein cores of the proteoglycans rather than the glycosaminoglycan side chains. Scatchard analysis showed that biglycan bound more avidly than decorin to tropoelastin with K-d values estimated as 1.95 X 10(-7) M and 5.3 X 10(-7) m, respectively. In blocking experiments each proteoglycan showed extensive inhibition of binding of the other to tropoelastin but was most effective at blocking its own binding. This result suggested that biglycan and decorin had closely spaced but distinct binding sites on tropoelastin. Addition of the elastin-binding protein MAGP-1 to the assays enhanced the binding of biglycan to tropoelastin but had no effect on the decorin-tropoelastin interaction. Co-immunoprecipitation experiments showed that MAGP-1 interacted with biglycan but not decorin in the solution phase. The results indicated that biglycan specifically formed a ternary complex with tropoelastin and MAGP-1. Overall the study supports the concept that biglycan may have a specific role in the elastinogenic phase of elastic fiber formation.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		Hanssen, Eric/A-7217-2013	Hanssen, Eric/0000-0002-4064-1844				BACCARANICONTRI M, 1990, EUR J CELL BIOL, V53, P305; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; CLEARY EG, 1978, EXP MOL PATHOL, V28, P227, DOI 10.1016/0014-4800(78)90054-0; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GIBSON MA, 1986, J BIOL CHEM, V26; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; PasqualiRonchetti I, 1997, MICROSC RES TECHNIQ, V38, P428, DOI 10.1002/(SICI)1097-0029(19970815)38:4<428::AID-JEMT10>3.0.CO;2-L; Reinboth BJ, 2000, MATRIX BIOL, V19, P149, DOI 10.1016/S0945-053X(00)00060-3; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	40	133	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3950	3957		10.1074/jbc.M109540200	http://dx.doi.org/10.1074/jbc.M109540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723132	hybrid			2022-12-25	WOS:000173813900022
J	Zaina, S; Pettersson, L; Ahren, B; Branen, L; Hassan, AB; Lindholm, M; Mattsson, R; Thyberg, J; Nilsson, J				Zaina, S; Pettersson, L; Ahren, B; Branen, L; Hassan, AB; Lindholm, M; Mattsson, R; Thyberg, J; Nilsson, J			Insulin-like growth factor II plays it central role in atherosclerosis in a mouse model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; IGF-II; TRANSGENIC MICE; BECKWITH-WIEDEMANN; DIABETES-MELLITUS; OVEREXPRESSION; RECEPTOR; GENE; MECHANISMS; PHENOTYPE	Insulin-like growth factor II is a fetal promoter of cell proliferation that is involved in some forms of cancer and overgrowth syndromes in humans. Here, we provide two sources of genetic evidence for a novel, pivotal role of locally produced insulin-like growth factor II in the development of atherosclerosis. First, we show that homozygosity for a disrupted insulin-like growth factor II allele in mice lacking apolipoprotein E, a widely used animal model of atherosclerosis, results in aortic lesions that are similar to80% smaller and contain similar to50% less proliferating cells compared with mice lacking only apolipoprotein E. Second, targeted expression of an insulin-like growth factor II transgene in smooth muscle cells, but not the mere elevation of circulating levels of the peptide, causes per se aortic focal intimal thickenings. The insulin-like growth factor II transgenics presented here are the first viable mutant mice spontaneously developing intimal masses. These observations provide the first direct evidence for an atherogenic activity of insulinlike growth factor II in vivo.	Lund Univ, Malmo Gen Hosp, Wallenberg Lab, Dept Med, S-20502 Malmo, Sweden; Lund Univ, BMC, Dept Med, S-22184 Lund, Sweden; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Lund Univ, BMC, Lund Transgen Core Facil, S-22362 Lund, Sweden; Karolinska Inst, Dept Mol & Cell Biol, S-17177 Stockholm, Sweden	Lund University; Lund University; University of Oxford; Lund University; Karolinska Institutet	Zaina, S (corresponding author), Lund Univ, Malmo Gen Hosp, Wallenberg Lab, Dept Med, Entrance 46,1st Fl, S-20502 Malmo, Sweden.		Zaina, Silvio/C-5255-2017; Lindholm, Marie W/B-8736-2015	Zaina, Silvio/0000-0001-6589-076X; Lindholm, Marie W/0000-0003-4309-3203; Wikstrom Lindholm, Marie/0000-0002-0975-2394				BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Binoux M, 1995, DIABETES METAB, V21, P330; Branen L, 2001, HISTOCHEM J, V33, P227, DOI 10.1023/A:1017902509083; Carmeliet P, 1998, CARDIOVASC RES, V39, P8, DOI 10.1016/S0008-6363(98)00108-4; Carroll PV, 1998, CLIN ENDOCRINOL, V49, P739, DOI 10.1046/j.1365-2265.1998.00600.x; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Devedjian JC, 2000, J CLIN INVEST, V105, P731, DOI 10.1172/JCI5656; Dimayuga P, 1999, BIOCHEM BIOPH RES CO, V264, P465, DOI 10.1006/bbrc.1999.1278; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Gibson JM, 1996, J CLIN ENDOCR METAB, V81, P860, DOI 10.1210/jc.81.2.860; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hassan AB, 2000, CANCER RES, V60, P1070; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Ikari Y, 1999, ARTERIOSCL THROM VAS, V19, P2036, DOI 10.1161/01.ATV.19.9.2036; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Lopez MF, 1999, ENDOCRINOLOGY, V140, P1442, DOI 10.1210/en.140.3.1442; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Mauras N, 1997, AM J PHYSIOL-ENDOC M, V272, pE628, DOI 10.1152/ajpendo.1997.272.4.E628; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schwartz SM, 1999, CIRC RES, V85, P877; Sperandeo MP, 2000, AM J HUM GENET, V66, P841, DOI 10.1086/302811; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Wang JW, 1998, ENDOCRINOLOGY, V139, P2605, DOI 10.1210/en.139.5.2605; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; Weninger WJ, 1999, CIRC RES, V85, P970; Zaina S, 1998, J BIOL CHEM, V273, P28610, DOI 10.1074/jbc.273.44.28610; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhu BH, 2001, ENDOCRINOLOGY, V142, P3598, DOI 10.1210/en.142.8.3598	42	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4505	4511		10.1074/jbc.M108061200	http://dx.doi.org/10.1074/jbc.M108061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726660	hybrid			2022-12-25	WOS:000173813900093
J	Dave, N; Lorenz-Fonfria, VA; Villaverde, J; Lemonnier, R; Leblanc, G; Padros, E				Dave, N; Lorenz-Fonfria, VA; Villaverde, J; Lemonnier, R; Leblanc, G; Padros, E			Study of amide-proton exchange of Escherichia coli melibiose permease by attenuated total reflection-fourier transform infrared spectroscopy - Evidence of structure modulation by substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-DEUTERIUM EXCHANGE; RESONANCE ENERGY-TRANSFER; CONFORMATIONAL-CHANGES; SUBMOLECULAR LEVEL; MEMBRANE TOPOLOGY; PROTEIN-STRUCTURE; CARRIER; TRANSPORT; SUGAR; NA+	The accessibility of Escherichia coli melibiose permease to aqueous solvent was studied following hydrogen-deuterium. exchange kinetics monitored by attenuated total reflection-Fourier transform infrared spectroscopy under four distinct conditions where MelB forms different complexes with its substrates (H+, Na+, melibiose). Analysis of the amide II band upon (H2O)-H-2 exposure discloses a significant sugar protection of the protein against aqueous solvent, resulting in an 8% less ex. change of the corresponding H+-melibiose(.)MelB complex compared with the protein in the absence of sugar. Investigation of the amide I exchange reveals clear substrate effects on P-sheet accessibility, with the complex H+-melibiose-MelB being the most protected state against exchange, followed by Na(+.)melibiose(.)MelB. Although of smaller magnitude, similar changes in alpha-helices plus nonordered structures are detected. Finally, no differences are observed when analyzing reverse turn structures. The results suggest that sugar binding induces a remarkable compactness of the carrier's structure, affecting mainly beta-sheet domains of the transporter, which, according to secondary structure predictions, may include cytoplasmic loops 4-5 and 10-11. A possible catalytic role of these two loops in the functioning of MelB is hypothesized.	Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain; Univ Nice Sophia Antipolis, CEA, Lab Physiol Membranes Cellulaires, Lab Rech Correspondant, F-06238 Villefranche Sur Mer, France; CNRS, URA 6078, F-06238 Villefranche Sur Mer, France	Autonomous University of Barcelona; University of Barcelona; CEA; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)	Padros, E (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain.		Fonfria, Victor A. Lorenz/AAU-9034-2021; Fonfria, Victor A Lorenz/B-3754-2018	Fonfria, Victor A. Lorenz/0000-0002-8859-8347; Fonfria, Victor A Lorenz/0000-0002-8859-8347				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; Ambroise Y, 2000, BIOCHEMISTRY-US, V39, P1338, DOI 10.1021/bi9916224; BASSILANA M, 1988, J BIOL CHEM, V263, P9663; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; Clarke J, 1998, CURR OPIN STRUC BIOL, V8, P112, DOI 10.1016/S0959-440X(98)80018-3; Cordat E, 1998, J BIOL CHEM, V273, P33198, DOI 10.1074/jbc.273.50.33198; Cordat E, 2000, BIOCHEMISTRY-US, V39, P4493, DOI 10.1021/bi991852i; Craig I. J. D., 1986, INVERSE PROBLEMS AST; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Dave N, 2000, BIOPHYS J, V79, P747, DOI 10.1016/S0006-3495(00)76332-6; deJongh HHJ, 1997, BIOCHEMISTRY-US, V36, P13593, DOI 10.1021/bi971336x; deJongh HHJ, 1997, BIOCHEMISTRY-US, V36, P13603, DOI 10.1021/bi971337p; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; Ding PZ, 2000, J MEMBRANE BIOL, V174, P135, DOI 10.1007/s002320001038; Ding PZ, 2000, BBA-BIOMEMBRANES, V1509, P123, DOI 10.1016/S0005-2736(00)00286-8; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GREGORY RB, 1985, BIOPOLYMERS, V24, P301, DOI 10.1002/bip.360240203; Gwizdek C, 1997, BIOCHEMISTRY-US, V36, P8522, DOI 10.1021/bi970312n; HAMA H, 1993, J BIOL CHEM, V268, P10060; KNOX DG, 1980, BIOPOLYMERS, V19, P1049, DOI 10.1002/bip.1980.360190509; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; Lorenz VA, 2001, BIOCHEMISTRY-US, V40, P8821, DOI 10.1021/bi010091s; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUMRY R, 1995, PROTEIN SOLVENT INTE, P1; Maehrel C, 1998, J BIOL CHEM, V273, P33192, DOI 10.1074/jbc.273.50.33192; MANTSCH HH, 1988, J MOL STRUCT, V173, P285, DOI 10.1016/0022-2860(88)80061-9; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; PRESS WH, 1992, NUMERICAL RECIPES C, P788; Rath P, 1998, BIOPHYS J, V74, P192, DOI 10.1016/S0006-3495(98)77779-3; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Saba RI, 1999, J BIOL CHEM, V274, P15510, DOI 10.1074/jbc.274.22.15510; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Slotboom DJ, 2001, FEBS LETT, V492, P183, DOI 10.1016/S0014-5793(01)02223-2; SUSI H, 1967, J BIOL CHEM, V242, P5460; TIMASHEFF SN, 1967, J BIOL CHEM, V242, P5466; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; WILSON DM, 1994, BBA-BIOMEMBRANES, V1190, P225, DOI 10.1016/0005-2736(94)90078-7; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; YAZU H, 1984, J BIOL CHEM, V259, P4320	53	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3380	3387		10.1074/jbc.M105466200	http://dx.doi.org/10.1074/jbc.M105466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11729178	hybrid			2022-12-25	WOS:000173688000044
J	Hall, MC; Shcherbakova, PV; Kunkel, TA				Hall, MC; Shcherbakova, PV; Kunkel, TA			Differential ATP binding and intrinsic ATP hydrolysis by amino-terminal domains of the yeast Mlh1 and Pms1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; GYRASE-B-PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SHUTTLE VECTORS; IN-VIVO; MUTL; FRAGMENT; MUTATIONS; GENES	MutL homologs belong to a family of proteins that share a conserved ATP binding site. We demonstrate that amino-terminal domains of the yeast MutL homologs Mlh1 and Pms1 required for DNA mismatch repair both possess independent, intrinsic ATPase activities. Amino acid substitutions in the conserved ATP binding sites concomitantly reduce ATP binding, ATP hydrolysis, and DNA mismatch repair in vivo. The ATPase activities are weak consistent with the hypothesis that ATP binding is primarily responsible for modulating interactions with other MMR components. Three approaches, ATP hydrolysis assays, limited proteolysis protection, and equilibrium dialysis, provide evidence that the amino-terminal domain of MIh1 binds ATP with >10-fold higher affinity than does the amino-terminal domain of Pms1. This is consistent with a model wherein ATP may first bind to MIh1, resulting in events that permit ATP binding to Pms1 and later steps in DNA mismatch repair.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Hall, Mark C./D-1698-2011; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Hall, Mark/0000-0001-6429-2506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065089, ZIAES065089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SIKORSKI RS, 1989, GENETICS, V122, P19; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	27	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3673	3679		10.1074/jbc.M106120200	http://dx.doi.org/10.1074/jbc.M106120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11717305	hybrid			2022-12-25	WOS:000173688000081
J	Scheinfeld, MH; Roncarati, R; Vito, P; Lopez, PA; Abdallah, M; D'Adamio, L				Scheinfeld, MH; Roncarati, R; Vito, P; Lopez, PA; Abdallah, M; D'Adamio, L			Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATES TAU-PROTEIN; INSULIN-SECRETING CELLS; N-TERMINAL KINASE; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; INDUCED APOPTOSIS; AXONAL-TRANSPORT; DISEASE; GENE	The familial Alzheimer's disease gene product amyloid beta precursor protein (APP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide. The biochemical pathway leading to Abeta formation has been extensively studied since extracellular aggregates of Abeta peptides are considered the culprit of Alzheimer's disease. Aside from its pathological relevance, the biological role of APP processing is unknown. Cleavage of APP by gamma-secretase releases, together with Abeta, a COOH-terminal APP intracellular domain, termed AID. This peptide has recently been identified in brain tissue of normal control and patients with sporadic Alzheimer's disease. We have previously shown that AID acts as a positive regulator of apoptosis. Nevertheless, the molecular mechanism by which AID regulates this process remains unknown. Hoping to gain clues about the function of APP, we used the yeast two-hybrid system to identify interaction between the AID region of APP and JNK-interacting protein-1 (JIP1). This molecular interaction is confirmed in vitro, in vivo by fluorescence resonance energy transfer (FRET), and in mouse brain lysates. These data provide a link between APP and its processing by gamma-secretase, and stress kinase signaling pathways. These pathways are known regulators of apoptosis and may be involved in the pathogenesis of Alzheimer's disease.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Naples Federico II, BioGeM Consortium, Dept Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Zymed Labs, San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; University of Naples Federico II; Rockefeller University	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu	Lopez, Peter/AAP-7234-2020; vito, pasquale/ABF-5505-2020	Scheinfeld, Meir H/0000-0001-8880-4318; D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; vito, pasquale/0000-0002-5721-7716; roncarati, roberta/0000-0002-2371-3316; Lopez, Peter/0000-0002-8587-7148	NIGMS NIH HHS [T32GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Guo Q, 1997, J NEUROSCI, V17, P4212; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1999, MOL CELL BIOL, V19, P5179; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Matsuda S, 2001, J NEUROSCI, V21, P6597; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	80	133	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3767	3775		10.1074/jbc.M108357200	http://dx.doi.org/10.1074/jbc.M108357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724784	hybrid			2022-12-25	WOS:000173688000092
J	Wolter, S; Mushinski, JF; Saboori, AM; Resch, K; Kracht, M				Wolter, S; Mushinski, JF; Saboori, AM; Resch, K; Kracht, M			Inducible expression of a constitutively active mutant of mitogen-activated protein kinase kinase 7 specifically activates c-JUN NH2-terminal protein kinase, alters expression of at least nine genes, and inhibits cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; LUNG-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; SYNERGISTIC ACTIVATION; GAMMA-RADIATION; MAMMALIAN-CELLS; MAP KINASES; JNK; MKK7; GROWTH	MKK7 is a recently discovered mitogen-activated protein kinase (MAPK) kinase that is unique in that it specifically activates only the c-JUN NH2-terminal protein kinase (JNK) family of enzymes. Very little is known about the biological role of MKK7. We generated inducible cell lines from the human embryonal kidney carcinoma cell line, HEK293, by stable transfection with a constitutively active mutant of MKK7, MKK7(3E), fused to green fluorescent protein (GFP), under the control of an ecdysone-inducible promoter. Treatment of cells with the synthetic ecdysone analog ponasterone A induced expression of GFP-MKK7(3E) and resulted in sustained activation of endogenous JNK, but neither of the other endogenous MAPKs, ERK or p38. Red and green fluorescing cDNA copies of mRNA extracted from cells obtained before and after induction of GFP-MKK7(3E) were hybridized to microarrays containing more than 6,000 cDNAs in eight independent experiments. By selection criteria, 23 genes were differentially regulated after 24 h of induction of GFP-MKK7(3E) and 16 after 48 h. The expression of 9 genes was consistently changed after both 24 and 48 h of induction. These changes included down-regulation of three genes, c-myc, angiopoietin-2, and glucose-regulated protein 58, and up-regulation of 6 genes, tissue factor pathway inhibitor-2, GRP78, autotaxin, PPP1R7, the DKFZ cDNA p434D0818, and I unknown gene. Consistent with previously described roles of several of the altered genes, MKK7(3E) inhibited cell proliferation. These data implicate active MKK7 in the negative regulation of cell proliferation and provide evidence for a new role for this kinase in the regulation of a distinct, hitherto unrecognized set of genes.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; NCI, Canc Res Ctr, Genet Lab, Mol Genet Sect,NIH, Bethesda, MD 20892 USA	Hannover Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Kracht, Michael/0000-0002-8501-043X				Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chen CY, 2000, GENE DEV, V14, P1236; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Finch A, 2001, BIOCHEM J, V353, P275, DOI 10.1042/0264-6021:3530275; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Khan J, 1998, CANCER RES, V58, P5009; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	46	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3576	3584		10.1074/jbc.M105800200	http://dx.doi.org/10.1074/jbc.M105800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714698	hybrid			2022-12-25	WOS:000173688000069
J	Burgess, S; Jaruga, P; Dodson, ML; Dizdaroglu, M; Lloyd, RS				Burgess, S; Jaruga, P; Dodson, ML; Dizdaroglu, M; Lloyd, RS			Determination of active site residues in Escherichia coli endonuclease VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; SUBSTRATE-SPECIFICITY; CATALYTIC MECHANISM; MODIFIED BASES; III NTH; EXCISION; FPG; PROTEIN; ENZYME; REPAIR	Endonuclease VIII from Escherichia coli is a DNA glycosylase/lyase that removes oxidatively damaged bases. EndoVIII is a functional homologue of endonuclease 111, but a sequence homologue of formamidopyrimidine-DNA glycosylase (Fpg). Using multiple sequence alignments, we have identified six target residues in endoVIII that may be involved in the enzyme's glycosylase and/or lyase functions: the N-terminal proline, and five acidic residues that are completely conserved in the endoVIII-Fpg proteins. To investigate the contribution of these residues, site-directed mutagenesis was used to create seven mutants: P2T, E3D, E3Q, E6Q, D129N, D160N, and E174Q. Each mutant was assayed both for lyase activity on abasic (AP) sites and for glycosylase/lyase activity on 5-hydroxyuracil, thymine glycol, and gamma-irradiated DNA with multiple lesions. The P2T mutant did not have lyase or glycosylase/lyase activity but could efficiently form Schiff base intermediates on AP sites. E6Q, D129N, and D160N behaved essentially as endoVIII in all assays. E3D, E3Q, and E174Q retained significant AP lyase activity but had severely diminished or abolished glycosylase/lyase activities on the DNA lesions tested. These studies provide detailed predictions concerning the active site of endoVIII.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institute of Standards & Technology (NIST) - USA	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 5-142 Med Res Bldg, Galveston, TX 77555 USA.	rslloyd@utmb.edu	Jaruga, Pawel/M-4378-2015	Jaruga, Pawel/0000-0001-9192-6084; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, P30ES006676] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06676, ES04091] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; Dizdaroglu M, 2001, BIOCHEMISTRY-US, V40, P12150, DOI 10.1021/bi015552o; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Fuxreiter M, 1999, BIOCHEMISTRY-US, V38, P9577, DOI 10.1021/bi9901937; Garvish JF, 1999, J BIOL CHEM, V274, P9786, DOI 10.1074/jbc.274.14.9786; Hazra TK, 2000, J BIOL CHEM, V275, P27762; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KOW YW, 1985, P NATL ACAD SCI USA, V82, P8354, DOI 10.1073/pnas.82.24.8354; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; McCullough AK, 2001, BIOCHEMISTRY-US, V40, P561, DOI 10.1021/bi002404+; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Rieger RA, 2000, J AM SOC MASS SPECTR, V11, P505, DOI 10.1016/S1044-0305(00)00117-3; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	34	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2938	2944		10.1074/jbc.M110499200	http://dx.doi.org/10.1074/jbc.M110499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711552	hybrid			2022-12-25	WOS:000173421500074
J	Ke, YH; Theil, EC				Ke, YH; Theil, EC			An mRNA loop/bulge in the ferritin iron-responsive element forms in vivo and was detected by radical probing with Cu-1,10-phenantholine and iron regulatory protein footprinting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MITOCHONDRIAL ACONITASE; INTERNAL LOOP/BULGE; BINDING; TRANSLATION; EXPRESSION; COMPLEXES; REGION; LIVER; LOOPS	Messenger RNA (mRNA) regulatory elements often form helices specifically distorted by loops or bulges, which control protein synthesis rates in vitro. Do such three-dimensional RNA structures form in vivo? We now observe formation of the internal loop[bulge (IL/B structure) in the IRE (iron-responsive element) of ferritin mRNA expressed in HeLa cells, using radical cleavage with Cu-phen (Cu-1,10-phenantholine), and protection of the loop/bulge by the regulatory protein (IRP), expressed by cotransfection. Cu-phen, a metal coordination complex (MC selected because of binding and cleavage at the IL/B in solution, recognized the same site in mRNA in HeLa cells. Endogenous reductants apparently substituted for the sulfhydryl activation of Cuphen cleavage in solution. Selective RNA IL/B recognition by Cu-phen in vivo is emphasized by resistance to cleavage of a mutated, IL/B IRE in ferritin mRNA. Development of small MCs even more selective than Cu-phen can exploit three-dimensional mRNA or viral RNA structures in vivo to manipulate RNA function. Formation in vivo of the IL/B in the ferritin IRE, which is associated in vitro with greater repression than single IRE structures in other mRNAs, likely contributes to larger derepression of ferritin synthesis in vivo triggered by signals for the IRE/IRP system.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Theil, EC (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.							Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; BERTRAND E, 1993, P NATL ACAD SCI USA, V90, P3496, DOI 10.1073/pnas.90.8.3496; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Ke YH, 2000, BIOCHEMISTRY-US, V39, P6235, DOI 10.1021/bi9924765; LIM AC, 1993, BIOCHEMISTRY-US, V32, P11029, DOI 10.1021/bi00092a012; MURAKAWA GJ, 1989, NUCLEIC ACIDS RES, V17, P5361, DOI 10.1093/nar/17.13.5361; Muth GW, 1999, NUCLEIC ACIDS RES, V27, P1906, DOI 10.1093/nar/27.8.1906; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740; SHULL GE, 1983, J BIOL CHEM, V258, P7921; SHULL GE, 1982, J BIOL CHEM, V257, P4187; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; THEIL EC, 1994, NEW J CHEM, V18, P435; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463	26	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2373	2376		10.1074/jbc.C100614200	http://dx.doi.org/10.1074/jbc.C100614200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714692	hybrid			2022-12-25	WOS:000173421500002
J	Nesbitt, WS; Kulkarni, S; Giuliano, S; Goncalves, I; Dopheide, SM; Yap, CL; Harper, IS; Salem, HH; Jackson, SP				Nesbitt, WS; Kulkarni, S; Giuliano, S; Goncalves, I; Dopheide, SM; Yap, CL; Harper, IS; Salem, HH; Jackson, SP			Distinct glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3)-dependent calcium signals cooperatively regulate platelet adhesion under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; CA2+ ENTRY; MECHANISMS; IIB; ACTIVATION; FIBRINOGEN; ALPHA-IIB-BETA-3; FIBRONECTIN	We have investigated the calcium signaling relationship between the two major platelet adhesion receptors, glycoprotein Ib/V/IX (GPIb/V/IX) and integrin alpha(IIb)beta(3,) involved in regulating platelet adhesion on von Willebrand factor (vWf) under flow. Our studies demonstrate that GPIb engagement of immobilized vWf elicits a transient calcium spike that may function to promote reversible arrest of translocating platelets. Subsequent integrin alpha(IIb)beta(3) engagement of vWf promotes sustained calcium oscillations that are essential for the maintenance of irreversible adhesion. GPIb-induced calcium spikes appear distinct from those initiated by integrin alpha(IIb)beta(3), in that the former are exclusively mediated through release of intracellular calcium stores via a signaling mechanism independent of PI 3-kinase. In contrast, integrin alpha(IIb)beta(3)-dependent calcium flux involves a PI 3-kinase-dependent signaling mechanism linked to intracellular calcium mobilization and subsequent transmembrane calcium influx. Studies employing the caged calcium chelator (o-nitrophenyl-EGTA) demonstrate that transient calcium spikes initiate a transient phase of platelet arrest that is converted to irreversible adhesion with the development of sustained oscillatory calcium flux. These studies demonstrate the existence of a dual step calcium signaling mechanism utilized by GPIb and integrin alpha(IIb)beta(3), that serves to regulate the dynamics of platelet adhesion under flow.	Monash Univ, Australian Ctr Blood Dis, Box Hill Hosp, Box Hill, Vic 3127, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Monash Univ, Australian Ctr Blood Dis, Box Hill Hosp, Box Hill, Vic 3127, Australia.	jackson@med.monash.edu.au	Goncalves, Isaac/AAO-8371-2020	Harper, Ian/0000-0002-5499-2231; Jackson, Shaun/0000-0002-4750-1991; Nesbitt, Warwick/0000-0001-5644-7053				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BRASS LF, 1985, J BIOL CHEM, V260, P2231; Chang HH, 1999, EXP CELL RES, V250, P387, DOI 10.1006/excr.1999.4547; COOKE BM, 1993, MICROVASC RES, V45, P33, DOI 10.1006/mvre.1993.1004; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRANCESCONI M, 1995, BIOCHEM BIOPH RES CO, V214, P102, DOI 10.1006/bbrc.1995.2262; HEEMSKERK JWM, 1992, BIOCHEM J, V283, P379, DOI 10.1042/bj2830379; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Kuwahara M, 1999, BLOOD, V94, P1149, DOI 10.1182/blood.V94.4.1149.416k18_1149_1155; MOAKE JL, 1988, BLOOD, V71, P1366; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; Rosado JA, 2001, BLOOD, V97, P2648, DOI 10.1182/blood.V97.9.2648; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; SAGE SO, 1993, ADV EXP MED BIOL, V344, P69; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Sjaastad MD, 1996, MOL BIOL CELL, V7, P1025, DOI 10.1091/mbc.7.7.1025; SULTAN C, 1991, J BIOL CHEM, V266, P23554; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; YAP CL, 2002, IN PRESS BLOOD, V99; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241	34	139	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2965	2972		10.1074/jbc.M110070200	http://dx.doi.org/10.1074/jbc.M110070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713259	hybrid			2022-12-25	WOS:000173421500078
J	Yi, M; Tong, GX; Murry, B; Mendelson, CR				Yi, M; Tong, GX; Murry, B; Mendelson, CR			Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonary Surfactant protein-A (SP-A) gene by thyroid transcription factor-1 (TTF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LUNG INVITRO; CREB-BINDING-PROTEIN; HEPATOCYTE NUCLEAR FACTOR-3; FACTOR-I; DNA-BINDING; COACTIVATOR COMPLEXES; HISTONE ACETYLATION; FAMILY MEMBERS; CYCLIC-AMP; EXPRESSION	Surfactant protein-A (SP-A) gene expression is developmentally regulated in fetal lung type 11 cells and is enhanced by cAMP. cAMP stimulation of SP-A gene expression is mediated by protein kinase A (PKA) phosphorylation of thyroid transcription factor 1 (TTF-1), expressed selectively in developing lung epithelium. In this study, we analyzed roles of CREB-binding protein (CBP) and steroid receptor coactivator-1 (SRC-1) in TTF-1 regulation of SP-A expression. Upon differentiation of human fetal lung in culture, nuclear localization of CBP, SRC-1, and TTF-1 increased in ductular epithelium in association with type 11 cell differentiation and induction of SP-A expression. In transient transfections, CBP and SRC-1 acted synergistically with TTF-1 to increase SP-A promoter activity. Overexpression of PKA catalytic subunit enhanced hSP-A promoter activation by SRC-1 plus TTF-1. Adenoviral E1A overexpression reduced TTF-1 +/- SRC-1 induction of SP-A promoter activity, suggesting a role of endogenous CBP/p300. TTF-1 interacted with SRC-1 and CBP in vitro. SRC-1 immunodepletion from type 11 cell nuclear extracts reduced binding to the TTF-1 binding element upstream of SP-A gene. In cultured type If cells, cAMP increased TTF-1 acetylation. This suggests that cAMP-mediated TTF-1 phosphorylation facilitates interaction with CBP and SRC-1, resulting in its hyperacetylation, further enhancing TTF-1 DNA-binding and transcriptional activity.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mendelson, CR (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Mendelson, Carole Ruth/0000-0003-1696-9791	NHLBI NIH HHS [R37HL50022] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL050022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACARREGUI MJ, 1990, ENDOCRINOLOGY, V127, P1105, DOI 10.1210/endo-127-3-1105; ACARREGUI MJ, 1993, AM J PHYSIOL, V264, pL465, DOI 10.1152/ajplung.1993.264.5.L465; Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN Q, 1992, AM J PHYSIOL, V262, pL662, DOI 10.1152/ajplung.1992.262.6.L662; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; FISHER JH, 1988, BIOCHIM BIOPHYS ACTA, V950, P338, DOI 10.1016/0167-4781(88)90130-3; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Goodman RH, 2000, GENE DEV, V14, P1553; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KATYAL SL, 1992, AM J RESP CELL MOL, V6, P446, DOI 10.1165/ajrcmb/6.4.446; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Kumar AR, 1998, AM J PHYSIOL-LUNG C, V274, pL177, DOI 10.1152/ajplung.1998.274.2.L177; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; Kumar AS, 2000, BBA-GENE STRUCT EXPR, V1492, P45, DOI 10.1016/S0167-4781(00)00058-0; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Li JX, 1998, AM J PHYSIOL-LUNG C, V275, pL1078, DOI 10.1152/ajplung.1998.275.6.L1078; MCCORMICK RJ, 1994, AM J PHYSIOL, V266, P354; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL367, DOI 10.1152/ajplung.1994.266.4.L367; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mendelson CR, 1998, BBA-MOL BASIS DIS, V1408, P132, DOI 10.1016/S0925-4439(98)00063-5; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; ODOM MJ, 1987, ENDOCRINOLOGY, V121, P1155, DOI 10.1210/endo-121-3-1155; ONATE SA, 1995, SCIENCE, V270, P1354; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Scaloni A, 1999, BIOCHEMISTRY-US, V38, P64, DOI 10.1021/bi981300k; Seidner SR, 1996, AM J PHYSIOL-LUNG C, V271, pL609, DOI 10.1152/ajplung.1996.271.4.L609; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SNYDER JM, 1981, CELL TISSUE RES, V220, P17; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Young PP, 1996, AM J PHYSIOL-LUNG C, V271, pL287, DOI 10.1152/ajplung.1996.271.2.L287; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082	63	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2997	3005		10.1074/jbc.M109793200	http://dx.doi.org/10.1074/jbc.M109793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713256	hybrid			2022-12-25	WOS:000173421500082
J	Francin, M; Kaminska, M; Kerjan, P; Mirande, M				Francin, M; Kaminska, M; Kerjan, P; Mirande, M			The N-terminal domain of mammalian lysyl-tRNA synthetase is a functional tRNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; METHIONYL-TRANSFER-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-PROTEIN INTERACTIONS; ESCHERICHIA-COLI; MACROMOLECULAR COMPLEXES; POLYPEPTIDE COMPONENTS; CONFORMATIONAL-CHANGES; REVERSE TRANSCRIPTION	Lysyl-tRNA synthetase from higher eukaryotes possesses a lysine-rich N-terminal polypeptide extension appended to a classical prokaryotic-like LysRS domain. Band shift analysis showed that this extra domain provides LysRS with nonspecific tRNA binding properties. A N-terminally truncated derivative of LysRS, LysRS-DeltaN, displayed a 100-fold lower apparent affinity for tRNA(3)(Lys) and a 3-fold increase in K-m for tRNA(3)(Lys) in the aminoacylation reaction, as compared with the native enzyme. The isolated N-domain of LysRS also displayed weak affinity for tRNA, suggesting that the catalytic and N-domains of LysRS act synergistically to provide a high affinity binding site for tRNA. A more detailed analysis revealed that LysRS binds and specifically aminoacylates an RNA minihelix mimicking the amino acid acceptor, stem-loop structure of tRNA 3, whereas LysRS-DeltaN did not. As a consequence, merging an additional RNA-binding domain into a bacterial-like LysRS increases the catalytic efficiency of the enzyme, especially at the low concentration of deacylated tRNA prevailing in vivo. Our results provide new insights into tRNA(Lys), channeling in eukaryotic cells and shed new light on the possible requirement of native LysRS for triggering tRNA(3)(Lys) packaging into human immunodeficiency virus, type I viral particles.	CNRS, Lab Enzymol & Biochim Struct, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	mirande@lebs.cnrs-gif.fr						Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; Beuning PJ, 1999, BIOPOLYMERS, V52, P1; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; Deinert K, 2001, J BIOL CHEM, V276, P6000, DOI 10.1074/jbc.M008682200; Edmonds BT, 1996, J CELL SCI, V109, P2705; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Kaminska M, 2001, BIOCHEMISTRY-US, V40, P14309, DOI 10.1021/bi015670b; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; KHVOROVA AM, 1992, FEBS LETT, V314, P256, DOI 10.1016/0014-5793(92)81483-3; Kim Y, 2000, J BIOL CHEM, V275, P27062; LAZARD M, 1987, J BIOL CHEM, V262, P3982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1056; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; MIRANDE M, 1983, EUR J BIOCHEM, V131, P163, DOI 10.1111/j.1432-1033.1983.tb07244.x; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Onesti S, 2000, BIOCHEMISTRY-US, V39, P12853, DOI 10.1021/bi001487r; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Renault L, 2001, EMBO J, V20, P570, DOI 10.1093/emboj/20.3.570; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; SMITH DE, 1972, BIOCHIM BIOPHYS ACTA, V269, P67, DOI 10.1016/0005-2787(72)90075-5; SMITH DWE, 1975, SCIENCE, V190, P529, DOI 10.1126/science.1103288; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; Wang CC, 2000, J BIOL CHEM, V275, P17180, DOI 10.1074/jbc.M001057200; Wu H, 1995, BIOCHEMISTRY-US, V34, P16327, DOI 10.1021/bi00050a013	49	97	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1762	1769		10.1074/jbc.M109759200	http://dx.doi.org/10.1074/jbc.M109759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706011	hybrid			2022-12-25	WOS:000173421300020
J	Yun, KM; Morimoto, H; Shibayama, N				Yun, KM; Morimoto, H; Shibayama, N			The contribution of the asymmetric alpha 1 beta 1 half-oxygenated intermediate to human hemoglobin cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NI(II)-FE(II) HYBRID HEMOGLOBINS; 82-BETA-2 LYSYL RESIDUES; EQUILIBRIUM PROPERTIES; EXPERIMENTAL RESOLUTION; MOLECULAR CODE; FREE-ENERGIES; STOPPED-FLOW; CONSTANTS; BINDING; (ALPHA(+CN-)BETA(+CN-))(ALPHA-BETA)	Considerable controversy remains as to the functional and structural properties of the asymmetric alpha1beta1 half-oxygenated intermediate of human hemoglobin, consisting of a deoxygenated and an oxygenated dimer. A recent dimer-tetramer equilibrium study using [Zn(II)/Fe(II)-O-2] hybrid hemoglobins, in which Zn-protoporphyrin IX mimics a deoxyheme, showed that the key intermediate, [alpha(Fe-O-2)beta(Fe-O-2)][alpha(Zn)beta(Zn)], exhibited an enhanced tetramer stability relative to the other doubly oxygenated species. This is one of the strongest findings in support of distinctly favorable intra-dimer cooperativity within the tetramer. However, we present here a different conclusion drawn from direct O-2 binding experiments for the same asymmetric hybrid, [alpha(Fe)beta(Fe)][alpha(Zn)beta(Zn)], and those for [alpha(Fe)beta(Zn)](2) and [alpha(Zn)beta(Fe)](2). In this study, the O-2 equilibrium curves for [alpha(Fe)beta(Fe)][alpha(Zn)beta(Zn)] were determined by an O-2-jump stopped-flow technique to circumvent the problem of dimer rearrangement, and those for [alpha(Fe)beta(Zn)](2) and [alpha(Zn)beta(Fe)](2) were measured by using an Imai apparatus. It was shown that the first and second O-2 equilibrium constants for [alpha(Fe)beta(Fe)][alpha(Zn)beta(Zn)] are 0.0209 mmHg(-1) and 0.0276 mmHg-1, respectively, that are almost identical to those for [alpha(Fe)beta(Zn)](2) or [alpha(Zn)beta(Fe)](2). Therefore, we did not observe large difference among the asymmetric and symmetric hybrids. The discrepancy between the present and previous studies is mainly due to previously observed negative cooperativity for [alpha(Fe)beta(Zn)](2) and [alpha(Zn)beta(Fe)](2), which is not the case in our direct O-2 binding study.	Jichi Med Sch, Dept Phys, Minami Kawachi, Tochigi 3290498, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Jichi Medical University; Osaka University	Shibayama, N (corresponding author), Jichi Med Sch, Dept Phys, Yakushiji 3311-1, Minami Kawachi, Tochigi 3290498, Japan.	shibayam@jichi.ac.jp		Shibayama, Naoya/0000-0002-2208-1126				Ackers GK, 2000, PROTEINS, P23; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ADLER AD, 1970, J INORG NUCL CHEM, V32, P2443, DOI 10.1016/0022-1902(70)80535-8; ASTATKE M, 1992, COMP BIOCHEM PHYS B, V101, P683, DOI 10.1016/0305-0491(92)90359-Y; BANERJEE R, 1969, J MOL BIOL, V42, P351, DOI 10.1016/0022-2836(69)90048-5; DAUGHERTY MA, 1991, P NATL ACAD SCI USA, V88, P1110, DOI 10.1073/pnas.88.4.1110; GERACI G, 1969, J BIOL CHEM, V244, P4664; Huang YW, 1996, BIOCHEMISTRY-US, V35, P704, DOI 10.1021/bi952400i; Huang YW, 1996, BIOPHYS J, V71, P2094, DOI 10.1016/S0006-3495(96)79408-0; Huang YW, 1996, P NATL ACAD SCI USA, V93, P4425, DOI 10.1073/pnas.93.9.4425; Imai K., 1982, ALLOSTERIC EFFECTS H; IP SHC, 1977, J BIOL CHEM, V252, P82; LICATA VJ, 1993, PROTEINS, V17, P279, DOI 10.1002/prot.340170306; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; Miyazaki G, 1999, J MOL BIOL, V292, P1121, DOI 10.1006/jmbi.1999.3124; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ORII Y, 1993, BIOCHEMISTRY-US, V32, P11910, DOI 10.1021/bi00095a021; PERRELLA M, 1986, J BIOL CHEM, V261, P8391; Perrella M, 1999, J BIOL CHEM, V274, P2605, DOI 10.1074/jbc.274.5.2605; Perrella M, 1999, BIOPHYS CHEM, V81, P157, DOI 10.1016/S0301-4622(99)00093-9; SHIBAYAMA N, 1993, BIOCHEMISTRY-US, V32, P8792, DOI 10.1021/bi00085a009; Shibayama N, 1998, BIOCHEMISTRY-US, V37, P6221, DOI 10.1021/bi980134d; Shibayama N, 1997, BIOCHEMISTRY-US, V36, P4375, DOI 10.1021/bi970009m; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHIBAYAMA N, 1995, BIOCHEMISTRY-US, V34, P4773, DOI 10.1021/bi00014a035; SHIBAYAMA N, 1991, BIOCHEMISTRY-US, V30, P8158, DOI 10.1021/bi00247a010; SIMOLO K, 1985, J AM CHEM SOC, V107, P2865, DOI 10.1021/ja00296a006; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1987, P NATL ACAD SCI USA, V84, P7089, DOI 10.1073/pnas.84.20.7089; SPEROS PC, 1991, BIOCHEMISTRY-US, V30, P7254, DOI 10.1021/bi00243a030; TACHIIRI Y, 1990, EUR BIOPHYS J, V18, P9; Unzai S, 1996, J BIOL CHEM, V271, P12451, DOI 10.1074/jbc.271.21.12451; Unzai S, 1998, J BIOL CHEM, V273, P23150, DOI 10.1074/jbc.273.36.23150; Venkatesh B, 1998, PROG INORG CHEM, V47, P563; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493	36	15	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1878	1883		10.1074/jbc.M108494200	http://dx.doi.org/10.1074/jbc.M108494200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11714709	hybrid			2022-12-25	WOS:000173421300035
J	Gaspar, LP; Silva, ACB; Gomes, AMO; Freitas, MS; Bom, APDA; Schwarcz, WD; Mestecky, J; Novak, MJ; Foguel, D; Silva, JL				Gaspar, LP; Silva, ACB; Gomes, AMO; Freitas, MS; Bom, APDA; Schwarcz, WD; Mestecky, J; Novak, MJ; Foguel, D; Silva, JL			Hydrostatic pressure induces the fusion-active state of enveloped viruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; VIRAL MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; CONFORMATIONAL-CHANGES; LOW-TEMPERATURE; MOSAIC-VIRUS; COILED-COIL; PROTEIN; PH; MECHANISM	Enveloped animal viruses must undergo membrane fusion to deliver their genome into the host cell. We demonstrate that high pressure inactivates two membrane-enveloped viruses, influenza and Sindbis, by trapping the particles in a fusion-intermediate state. The pressure-induced conformational changes in Sindbis and influenza viruses were followed using intrinsic and extrinsic fluorescence spectroscopy, circular dichroism, and fusion, plaque, and hemagglutination assays. Influenza virus subjected to pressure exposes hydrophobic domains as determined by tryptophan fluorescence and by the binding of bis-8-anilino-1-naphthalenesulfonate, a well established marker of the fusogenic state in influenza virus. Pressure also produced an increase in the fusion activity at neutral pH as monitored by fluorescence resonance energy transfer using lipid vesicles labeled with fluorescence probes. Sindbis virus also underwent conformational changes induced by pressure similar to those in influenza virus, and the increase in fusion activity was followed by pyrene excimer fluorescence of the metabolically labeled virus particles. Overall we show that pressure elicits subtle changes in the whole structure of the enveloped viruses triggering a conformational change that is similar to the change triggered by low pH. Our data strengthen the hypothesis that the native conformation of fusion proteins is metastable, and a cycle of pressure leads to a final state, the fusion-active state, of smaller volume.	Univ Fed Rio de Janeiro, Ctr Nacl Resoonac Magnet Nucl & Macromol, Inst Ciencias Biomed, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, RJ, Brazil; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Universidade Federal do Rio de Janeiro; University of Alabama System; University of Alabama Birmingham	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Ctr Nacl Resoonac Magnet Nucl & Macromol, Inst Ciencias Biomed, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, RJ, Brazil.		Silva, Jerson/J-8984-2014; Gomes, Andre M.O./C-4009-2014; de Freitas, Mônica Santos/E-8540-2015; SILVA, JERSON Lima/GRF-1442-2022	Silva, Jerson/0000-0001-9523-9441; Gomes, Andre M.O./0000-0003-1052-8004; de Freitas, Mônica Santos/0000-0003-3105-7918; SILVA, JERSON Lima/0000-0001-9523-9441; Foguel, Debora/0000-0001-7312-7115	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI028147, U01AI028147] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; de Sousa PC, 1999, J MOL BIOL, V287, P527; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; EDWARDS J, 1983, J VIROL, V45, P1090, DOI 10.1128/JVI.45.3.1090-1097.1983; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; Foguel D, 1996, P NATL ACAD SCI USA, V93, P10642, DOI 10.1073/pnas.93.20.10642; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; Gaspar LP, 2001, J BIOL CHEM, V276, P7415, DOI 10.1074/jbc.M010037200; Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000; Hierholzer JC, 1996, VIROLOGY METHODS MAN, P41; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; JURKIEWICZ E, 1995, P NATL ACAD SCI USA, V92, P6935, DOI 10.1073/pnas.92.15.6935; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; Korte T, 1999, J VIROL, V73, P4567, DOI 10.1128/JVI.73.6.4567-4574.1999; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Leimkuhler M, 2000, J MOL BIOL, V296, P1295, DOI 10.1006/jmbi.2000.3538; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lima LMTR, 2000, P NATL ACAD SCI USA, V97, P14289, DOI 10.1073/pnas.250352197; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Oliveira AC, 1999, BIOPHYS J, V76, P1270, DOI 10.1016/S0006-3495(99)77290-5; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; OTAKE T, 1997, HIGH PRESSURE RES BI, P233; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; ROBINSON CR, 1995, P NATL ACAD SCI USA, V92, P3444, DOI 10.1073/pnas.92.8.3444; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SILVA JL, 1992, J VIROL, V66, P2111, DOI 10.1128/JVI.66.4.2111-2117.1992; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Strauss JH, 2001, CELL, V105, P5, DOI 10.1016/S0092-8674(01)00291-4; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Webb JN, 2001, P NATL ACAD SCI USA, V98, P7259, DOI 10.1073/pnas.131194798; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	54	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8433	8439		10.1074/jbc.M106096200	http://dx.doi.org/10.1074/jbc.M106096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11723114	hybrid			2022-12-25	WOS:000174268000103
J	Lan, ZD; Sever-Chroneos, Z; Strobeck, MW; Park, CH; Baskaran, R; Edelmann, W; Leone, G; Knudsen, ES				Lan, ZD; Sever-Chroneos, Z; Strobeck, MW; Park, CH; Baskaran, R; Edelmann, W; Leone, G; Knudsen, ES			DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT CELLS; MICROSATELLITE INSTABILITY; IONIZING-RADIATION; KINASE-ACTIVITY; TUMOR-CELLS; RB; CISPLATIN; CANCER; PHOSPHORYLATION; MECHANISMS	DNA-damage evokes cell cycle checkpoints, which function to maintain genomic integrity. The retinoblastoma tumor suppressor (RB) and mismatch repair complexes are known to contribute to the appropriate cellular response to specific types of DNA damage. However, the signaling pathways through which these proteins impact the cell cycle machinery have not been explicitly determined. RB-deficient murine embryo fibroblasts continued a high degree of DNA replication following the induction of cisplatin damage, but were inhibited for G(2)/M progression. This damage led to RB dephosphorylation/activation and subsequent RB-dependent attenuation of cyclin A and CDK2 activity. In both Rb+/+ and Rb-/- cells, cyclin D1 expression was attenuated following DNA damage. As cyclin D1 is a critical determinant of RB phosphorylation and cell cycle progression, we probed the pathway through which cyclin D1 degradation occurs in response to DNA damage. We found that attenuation of endogenous cyclin D1 is dependent on multiple mismatch repair proteins. We demonstrate that the mismatch repair-dependent attenuation of endogenous cyclin D1 is critical for attenuation of CDK2 activity and induction of cell cycle checkpoints. Together, these studies couple the activity of the retinoblastoma and mismatch repair tumor suppressor pathways through the degradation of cyclin D1 and dual attenuation of CDK2 activity.	Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45267 USA; Ohio State Univ, Dept Human Canc Genet, Columbus, OH 43210 USA; Univ Pittsburgh, Dept Biochem, Pittsburgh, PA 15261 USA; Albert Einstein Univ, Dept Cell Biol, Bronx, NY 10461 USA	University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yeshiva University	Knudsen, ES (corresponding author), Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45267 USA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BOYER JC, 1995, CANCER RES, V55, P6063; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Buermeyer AB, 1999, CANCER RES, V59, P538; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edelmann W, 2000, CANCER RES, V60, P803; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1997, CANCER RES, V57, P1841; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1994, CELL, V77, P167; Fritzell JA, 1997, CANCER RES, V57, P5143; Gong JG, 1999, NATURE, V399, P806; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lenferink AEG, 2001, CANCER RES, V61, P6583; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nahum A, 2001, ONCOGENE, V20, P3428, DOI 10.1038/sj.onc.1204452; Nehme A, 1999, BRIT J CANCER, V79, P1104, DOI 10.1038/sj.bjc.6690176; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OConnor PM, 1997, CANCER SURV, V29, P151; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wahl GM, 1997, CANCER SURV, V29, P183; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4	47	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8372	8381		10.1074/jbc.M108906200	http://dx.doi.org/10.1074/jbc.M108906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11726663	hybrid			2022-12-25	WOS:000174268000096
J	Verhamme, IM; Olson, ST; Tollefsen, DM; Bock, PE				Verhamme, IM; Olson, ST; Tollefsen, DM; Bock, PE			Binding of exosite ligands to human thrombin - Re-evaluation of allosteric linkage between thrombin exosites I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; HEPARIN-COFACTOR-II; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; HUMAN FACTOR-V; PROTHROMBIN FRAGMENT-2; ANTITHROMBIN-III; TERNARY COMPLEX; FIBRIN MONOMER	The substrate specificity of thrombin is regulated by binding of macromolecular substrates and effectors to exosites I and II. Exosites I and II have been reported to be extremely linked allosterically, such that binding of a ligand to one exosite results in near-total loss of affinity for ligands at the alternative exosite, whereas other studies support the independence of the interactions. An array of fluorescent thrombin derivatives and fluorescein-labeled hirudin(54-65) ([5F]Hir(54-65)(SO3-)) were used as probes in quantitative equilibrium binding studies to resolve whether the affinities of the exosite I-specific ligands, Hir(54-65)(SO3-) and fibrinogen, and of the exosite II-specific ligands, prothrombin fragment 2 and a monoclonal antibody, were affected by alternate exosite occupation. Hir54-65(SO3-) and fibrinogen bound to exosite I with dissociation constants of 16-28 nM and 5-7 muM, respectively, which were changed less than or equal to2-fold by fragment 2 binding. Native thrombin and four thrombin derivatives labeled with different probes bound fragment 2 and the antibody with dissociation constants of 3-12 muM and 1.8 nM, respectively, unaffected by Hir(54-65)(SO3-) The results support a ternary complex binding model in which exosites I and II can be occupied simultaneously. The thrombin catalytic site senses individual and simultaneous binding of exosite I and II ligands differently, resulting in unique active site environments for each thrombin complex. The results indicate significant, ligand-specific allosteric coupling between thrombin exosites I and II and catalytic site perturbations but insignificant inter-exosite thermodynamic linkage.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3311A, Nashville, TN 37232 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Vanderbilt University; Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3311A, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R29HL038779, R01HL039888, R37HL039888, R01HL038779, R01HL055520] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38779, HL 39888, HL 55520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; ARNI RK, 1994, CHEM PHYS LIPIDS, V67-8, P59, DOI 10.1016/0009-3084(94)90124-4; Arocas V, 1996, BIOCHEMISTRY-US, V35, P9083, DOI 10.1021/bi960043l; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; Bouton MC, 1998, THROMB HAEMOSTASIS, V80, P310, DOI 10.1055/s-0037-1615193; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Colwell NS, 1997, BRIT J HAEMATOL, V97, P219, DOI 10.1046/j.1365-2141.1997.d01-2145.x; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; Jacques SL, 2000, J BIOL CHEM, V275, P40671, DOI 10.1074/jbc.M004544200; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1994, J BIOL CHEM, V269, P11807; LIU LW, 1991, J BIOL CHEM, V266, P23632; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; MANN KG, 1981, METHOD ENZYMOL, V80, P286; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	62	63	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6788	6798		10.1074/jbc.M110257200	http://dx.doi.org/10.1074/jbc.M110257200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724802	hybrid			2022-12-25	WOS:000174104300007
J	Strobeck, MW; Reisman, DN; Gunawardena, RW; Betz, BL; Angus, SP; Kundsen, KE; Kowalik, TF; Weissman, BE; Knudsen, ES				Strobeck, MW; Reisman, DN; Gunawardena, RW; Betz, BL; Angus, SP; Kundsen, KE; Kowalik, TF; Weissman, BE; Knudsen, ES			Compensation of BRG-1 function by Brm - Insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATION; HISTONE DEACETYLASE; PRB-FAMILY; S-PHASE; PROTEIN; REQUIRES; PROLIFERATION; MECHANISMS	The BRG-1 subunit of the (SWISNF)-S-. complex is involved in chromatin remodeling and has been implicated in the action of the retinoblastoma tumor suppressor (RB). Given the importance of BRG-1 in RB function, germ line BRG-1 mutations in tumorigenesis may be tantamount to RB inactivation. Therefore, in this study we assessed the behavior of cells harboring discrete BRG-1 alleles for the RB-signaling pathway. Using p16ink4a, an upstream activator of endogenous RB, or a constitutively active RB construct (PSM-RB), we determined that the majority of tumor lines with germ line defects in BRG-1 were sensitive to RB-mediated cell cycle arrest. By contrast, A427 (lung carcinoma) cells were resistant to expression of p16ink4a and PSM-RB. Analysis of the (SWISNF)-S-. subunits in the different tumor lines revealed that A427 are deficient for BRG-1 and its homologue, Brm, whereas RB-sensitive cell lines retained Brm expression. Similarly, the RB-resistant SW13 and C33A cell lines were also deficient for both BRG-1/Brm. Reintroduction of either BRG-1 or Brm into A427 or C33A cells restored RB-mediated signaling to cyclin A to cause cell cycle arrest. Consistent with this compensatory role, we observed that Brm could also drive expression of CD44. We also determined that loss of these core (SWISNF)-S-. subunits renders SW13 cells resistant to activation of the RB pathway by the chemotherapeutic agent cisplatin, since reintroduction of either BRG-1 or Brm into SW13 cells restored the cisplatin DNA-damage checkpoint. Together, these data demonstrate that Brm can compensate for BRG-1 loss as pertains to RB sensitivity.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Massachusetts, Sch Med, Program Immunol & Virol, Worcester, MA 01655 USA	University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Massachusetts System; University of Massachusetts Worcester	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA.	Erik.Knudsen@UC.edu		Knudsen, Karen/0000-0002-1301-890X; Angus, Steven/0000-0002-7655-657X	NATIONAL CANCER INSTITUTE [R01CA086038, T32CA009156, R01CA082525, R01CA063176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012355] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09156, R01-CA82525-S1, CA-82525, CA-63176, CA-86038] Funding Source: Medline; NIDCR NIH HHS [DE-12355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Castillo JP, 2000, J VIROL, V74, P8028, DOI 10.1128/JVI.74.17.8028-8037.2000; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Reed SI, 1997, CANCER SURV, V29, P7; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stirzaker C, 1997, CANCER RES, V57, P2229; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	61	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4782	4789		10.1074/jbc.M109532200	http://dx.doi.org/10.1074/jbc.M109532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11719516	hybrid			2022-12-25	WOS:000173962900032
J	Fink, BD; Hong, YS; Mathahs, MM; Scholz, TD; Dillon, JS; Sivitz, WI				Fink, BD; Hong, YS; Mathahs, MM; Scholz, TD; Dillon, JS; Sivitz, WI			UCP2-dependent proton leak in isolated mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; HUMAN UNCOUPLING PROTEIN-3; SKELETAL-MUSCLE; EXPRESSION; OVEREXPRESSION; TRANSPORT; OBESITY; ACID; MICE; UCP1	A role for uncoupling protein (UCP) homologues in mediating the proton leak in mammalian mitochondria is controversial. We subjected insulinoma (INS-1) cells to adenoviral expression of UCP2 or UCP1 and assessed the proton leak as the kinetic relationship between oxygen use and the inner mitochondrial membrane potential. Cells were infected with different amounts of rat UCP2, and, in other experiments, with either UCP2 or UCP1. The relative molar expression of these subtypes was quantified through comparison with histidine-tagged UCP1 or UCP2 proteins engineered by expression in Escherichia coli. Adenoviral infection with UCP2, compared with beta-galactosidase, resulted in a dose-dependent shift in kinetics indicating increased H+ flux at any given membrane potential. UCP1 also enhanced H+ flux, but, on a relative molar basis, the overexpression of the endogenous protein, UCP2, was more potent than UCP1. These results were not due to nonspecific overexpression of mitochondrial protein since UCP1 activity was inhibited by GDP and because overexpression of another membrane carrier protein, the oxoglutarate malate carrier had no effect. UCP2-mediated H+ conduction was not GDP sensitive. These data suggest that the UCP homologue, UCP2, mediates the proton leak in mitochondria of a mammalian cell wherein UCP2 is the native subtype.	Univ Iowa, Dept Internal Med, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Dept Internal Med, Div Endocrinol, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Dept Internal Med, Div Metab, Iowa City, IA 55246 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Sivitz, WI (corresponding author), Univ Iowa, Dept Internal Med, 3E-17 VA, Iowa City, IA 52246 USA.	William-Sivitz@uiowa.edu		Scholz, Thomas/0000-0003-0759-2486; Sivitz, William/0000-0002-7829-0189; Fink, Brian/0000-0002-1149-7935; Dillon, Joseph/0000-0002-4002-1418	NIA NIH HHS [R01 AG018928] Funding Source: Medline; NICHD NIH HHS [HD29569] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018928] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouillaud F, 1999, INT J OBESITY, V23, pS19, DOI 10.1038/sj.ijo.0800938; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Dawson A., 1987, MITOCHONDRIA PRACTIC, P35; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hagen T, 2000, BIOCHEMISTRY-US, V39, P5845, DOI 10.1021/bi992980+; Hagen T, 1999, FEBS LETT, V454, P201, DOI 10.1016/S0014-5793(99)00811-X; Heidkaemper D, 2000, FEBS LETT, V480, P265, DOI 10.1016/S0014-5793(00)01949-9; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Kageyama H, 1998, FEBS LETT, V440, P450, DOI 10.1016/S0014-5793(98)01506-3; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Lionetti L, 1998, ARCH BIOCHEM BIOPHYS, V352, P240, DOI 10.1006/abbi.1998.0579; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 1997, BIOSCIENCE REP, V17, P251, DOI 10.1023/A:1027376426860; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Porter C, 1999, GENE THER, V6, pS3; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scholz TD, 1998, AM J PHYSIOL-CELL PH, V274, pC780, DOI 10.1152/ajpcell.1998.274.3.C780; Scholz TD, 2000, J MOL CELL CARDIOL, V32, P1, DOI 10.1006/jmcc.1999.1047; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P811, DOI 10.1139/y89-128; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Yoshitomi H, 1998, BIOCHEM BIOPH RES CO, V253, P85, DOI 10.1006/bbrc.1998.9746; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	47	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3918	3925		10.1074/jbc.M107955200	http://dx.doi.org/10.1074/jbc.M107955200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723122	hybrid			2022-12-25	WOS:000173813900018
J	Kwak, BY; Zhang, YM; Yun, M; Heath, RJ; Rock, CO; Jackowski, S; Park, HW				Kwak, BY; Zhang, YM; Yun, M; Heath, RJ; Rock, CO; Jackowski, S; Park, HW			Structure and mechanism of CTP : phosphocholine cytidylyltransferase (LicC) from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; ESCHERICHIA-COLI; CATALYTIC MECHANISM; PHOSPHORYLCHOLINE; BINDING; LIPOPOLYSACCHARIDE; GENE; SENSITIVITY; DECORATION; SOLVENT	Pneumococcal LicC is a member of the nucleoside triphosphate transferase superfamily and catalyzes the transfer of a cytidine monophosphate from CTP to phosphocholine to form CDP-choline. The structures of apo-LicC and the LicC.CDP-choline-Mg2+ ternary complex were determined, and the comparison of these structures reveals a significant conformational change driven by the multivalent coordination of Mg2+. The key event is breaking the Glu(216).Arg(129) salt bridge, which triggers the coalescence of four individual beta-strands into two extended beta-sheets. These movements reorient the side chains of Trp(136) and Tyr1(90) for the optimal binding and alignment of the phosphocholine moiety. Consistent with these conformational changes, LicC operates via a compulsory ordered kinetic mechanism. The structures explain the substrate specificity of LicC for CTP and phosphocholine and implicate a direct role for Mg2+ in aligning phosphocholine for in-line nucleophilic attack and stabilizing the negative charge that develops in the pentacoordinate transition state. These results provide a structural basis for assigning a specific role for magnesium in the catalytic mechanism of pneumococcal LicC.	St Jude Childrens Res Hosp, Dept Infect Dis, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429; Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496, GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; BEAN B, 1977, J BACTERIOL, V130, P571, DOI 10.1128/JB.130.1.571-574.1977; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Lysenko E, 2000, MOL MICROBIOL, V35, P234, DOI 10.1046/j.1365-2958.2000.01707.x; Lysenko ES, 2000, INFECT IMMUN, V68, P1664, DOI 10.1128/IAI.68.3.1664-1671.2000; MCREE DE, 1998, XTALVIEW VERSION 3 2; Nicholls A., 1992, GRASP GRAPHICAL REPR; Novak R, 2000, MOL MICROBIOL, V36, P366, DOI 10.1046/j.1365-2958.2000.01854.x; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; Rock CO, 2001, J BACTERIOL, V183, P4927, DOI 10.1128/JB.183.16.4927-4931.2001; ROSSMANN MG, 1975, EVOLUTIONARY STRUCTU; Segel I.H., 1975, ENZYME KINETICS; Serino L, 2000, MOL MICROBIOL, V35, P1550, DOI 10.1046/j.1365-2958.2000.01825.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; Tuomanen EI, 1997, MICROB DRUG RESIST, V3, P297, DOI 10.1089/mdr.1997.3.297; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631; Weiser JN, 1998, INFECT IMMUN, V66, P4263; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; Whiting GC, 1996, FEMS MICROBIOL LETT, V143, P279, DOI 10.1016/0378-1097(96)00328-X; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang JR, 1999, MOL MICROBIOL, V31, P1477, DOI 10.1046/j.1365-2958.1999.01291.x; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	40	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4343	4350		10.1074/jbc.M109163200	http://dx.doi.org/10.1074/jbc.M109163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706035	hybrid			2022-12-25	WOS:000173813900074
J	Shen, Y; Lookene, A; Nilsson, S; Olivecrona, G				Shen, Y; Lookene, A; Nilsson, S; Olivecrona, G			Functional analyses of human apolipoprotein CII by site-directed mutagenesis - Identification of residues important for activation of lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-II; HEPATIC LIPASE; ESCHERICHIA-COLI; CHIMERIC LIPASE; BINDING; DOMAIN; CHYLOMICRONS; DEFICIENCY; METABOLISM; FRAGMENTS	Apolipoprotein CII (apoCII) activates lipoprotein lipase (LPL). Seven residues, located on one face of a model alpha-helix spanning residues 59-75, are fully conserved in apoCII from ten different animal species. We have mutated these residues one by one. Substitution of Ala(59) by glycine, or Thr(62) and Gly6(5) by alanine did not change the activation, indicating that these residues are outside the LPL-binding site. Replacement of Tyr(63), Ile(66), Asp(69), or Gln(70) by alanine lowered the affinity for LPL and the catalytic activity of the LPL.apoCII compIex. For each residue several additional replacements were made. Most mutants retained some activating ability, but replacement of Tyr(63) by phenylalanine or tryptophan and Gln70 by glutamate caused almost complete loss of activity. All mutants bound to liposomes with similar affinity as wild-type apoCII, and they also bound with similar affinity to LPL in the absence of hydrolyzable lipids. However, the inactive mutants did not compete with wild-type apoCII in the activation assay. Therefore, we conclude that the productive apoCII.LPL interaction may be dependent on substrate molecules. In summary, our data demonstrate that residues 63, 66, 69, and 70 are of special importance for the function of apoCII, but no single amino acid residue is absolutely crucial.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; NICPB, Tallinn, Estonia	Umea University; National Institute of Chemical Physics & Biophysics (NICPB)	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medchem.umu.se						Andersson Y, 1997, J LIPID RES, V38, P2111; APPLEBAUMBOWDEN D, 1979, METABOLISM, V28, P917, DOI 10.1016/0026-0495(79)90091-X; BENGTSSON G, 1982, FEBS LETT, V147, P183, DOI 10.1016/0014-5793(82)81038-7; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BIER DM, 1970, J LIPID RES, V11, P565; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; CHENG Q, 1990, BIOCHEM J, V269, P403, DOI 10.1042/bj2690403; CLARKE AR, 1985, BIOCHIM BIOPHYS ACTA, V827, P358, DOI 10.1016/0167-4838(85)90220-1; DICHEK HL, 1993, J LIPID RES, V34, P1393; Harlow E., 1988, ANTIBODIES LAB MANUA; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; Kuniyoshi A, 1999, INTERNAL MED, V38, P140, DOI 10.2169/internalmedicine.38.140; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; MacPhee CE, 2000, BIOCHEMISTRY-US, V39, P3433, DOI 10.1021/bi992523t; MacPhee CE, 1999, ANAL BIOCHEM, V275, P22, DOI 10.1006/abio.1999.4283; MacRaild CA, 2001, BIOCHEMISTRY-US, V40, P5414, DOI 10.1021/bi002821m; Olivecrona G, 1997, ARTERIOSCL THROM VAS, V17, P1545, DOI 10.1161/01.ATV.17.8.1545; QUINN D, 1983, PROG LIPID RES, V22, P35, DOI 10.1016/0163-7827(83)90003-6; Roosbeek S, 2001, J LIPID RES, V42, P31; Santamarina-Fojo S., 1992, CURR OPIN LIPIDOL, V3, P186; Shen Y, 2000, GENE, V254, P189, DOI 10.1016/S0378-1119(00)00268-7; Smith L C, 1980, Ann N Y Acad Sci, V348, P213; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; VAINIO P, 1983, J BIOL CHEM, V258, P5477; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VOYTA JC, 1983, J BIOL CHEM, V258, P2934; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; WULFING C, 1994, J BIOL CHEM, V269, P2895	29	37	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4334	4342		10.1074/jbc.M105421200	http://dx.doi.org/10.1074/jbc.M105421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11719505	hybrid			2022-12-25	WOS:000173813900073
J	Sterling, H; Lin, DH; Gu, RM; Dong, K; Hebert, SC; Wang, WH				Sterling, H; Lin, DH; Gu, RM; Dong, K; Hebert, SC; Wang, WH			Inhibition of protein-tyrosine phosphatase stimulates the dynamin-dependent endocytosis of ROMK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING TUBULE; APICAL MEMBRANE; K-CHANNELS; RECEPTOR ENDOCYTOSIS; RAT; CELLS; PHOSPHORYLATION; INTERACTS; SECRETION; NUMBER	We have previously shown that inhibiting protein-tyrosine kinase increased whereas inhibiting protein-tyrosine phosphatase (PTP) decreased renal outer medullary potassium channel 1 (ROMK1) channel activity (1). We have now used confocal microscopy, the patch clamp technique, and biotin labeling to further examine the role of tyrosine phosphorylation in regulating ROMK1 trafficking. Human embryonic kidney 293 cells were cotransfected with c-Src and green fluorescent protein-ROMK1, which has the same biophysical properties as, those of ROMK1. Patch clamp studies have shown, that phenylarsine oxide (PAO), an inhibitor of PTP, decreased the activity of ROMK1. Moreover, addition of PAO reduced the cell surface localization of green fluorescent protein-ROMK1 detected by confocal microscopy and diminished the surface ROMK1 density by 65% measured by biotin labeling. Also, PAO treatment significantly increased the phosphorylation of ROMK1. The notion that the effect of PAO is mediated by stimulating tyrosine phosphorylation-induced endocytosis of ROMK1 has also been supported by findings that mutating the tyrosine residue 337 of ROMK1 to alanine abolished the effect of PAO. Finally, the inhibitory effect of PAO on ROMK1 was completely blocked in the cells co-transfected with dominant negative dynamin (dynaminK44A). This indicates that the tyrosine phosphorylation-induced endocytosis of ROMK1 is dynamin-dependent. We conclude that inhibiting PTP increases ROMK1 phosphorylation and results in a dynamin-dependent internalization of the channel.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	New York Medical College; Yale University	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, BSB Rm 537, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu			NIDDK NIH HHS [R01 DK054983-08, R01 DK047402, R01 DK047402-13, DK 47402, DK 54983, R01 DK054983, DK54999] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047402, R01DK054983, R01DK047402, R01DK054999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Frindt G, 1998, AM J PHYSIOL-RENAL, V274, pF525, DOI 10.1152/ajprenal.1998.274.3.F525; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Gu RM, 2001, AM J PHYSIOL-CELL PH, V281, pC1188, DOI 10.1152/ajpcell.2001.281.4.C1188; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUNTER M, 1984, P NATL ACAD SCI-BIOL, V81, P4237, DOI 10.1073/pnas.81.13.4237; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF821, DOI 10.1152/ajprenal.1999.277.6.F821; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Satlin LM, 1997, AM J PHYSIOL-RENAL, V272, pF397, DOI 10.1152/ajprenal.1997.272.3.F397; SCHAFER JA, 1990, AM J PHYSIOL, V258, pF199, DOI 10.1152/ajprenal.1990.258.1.F199; SCHLATTER E, 1992, PFLUG ARCH EUR J PHY, V420, P39, DOI 10.1007/BF00378639; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4317	4323		10.1074/jbc.M109739200	http://dx.doi.org/10.1074/jbc.M109739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11719519	Green Accepted, hybrid			2022-12-25	WOS:000173813900071
J	Fujino, H; West, KA; Regan, JW				Fujino, H; West, KA; Regan, JW			Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; EP(2) SUBTYPE; CLONING; INACTIVATION; MECHANISM; ISOFORMS; AGONIST	Recently we have shown that the FP, prostanoid receptor, a G-protein-coupled receptor that couples to Galpha(q), activates T-cell factor (Tcf)/Iymphoid enhancer factor (Lef)-mediated transcriptional activation (Fujino, H., and Regan, J. W. (2001) J. Biol. Chem. 276, 1248912492). We now report that the EP2 and EP4 prostanoid receptors, which couple to Galpha(s), also activate Tcf/Lef signaling. By using a Tcf/Lef-responsive luciferase reporter gene, transcriptional activity was stimulated similar to10-fold over basal by I h of treatment with prostaglandin E-2 (PGE(2)) in HEK cells that were stably transfected with the human EP2 and EP4 receptors. This stimulation of reporter gene activity was accompanied by a PGE(2)-dependent increase in the phosphorylation of both glycogen synthase kinase-3 (GSK-3) and Akt kinase. H-89, an inhibitor of protein kinase A (PKA), completely blocked the agonist-dependent phosphorylation of GSK-3 in both EP2- and EP4-expressing cells. However, H-89 pretreatment only blocked PGE(2)-stimulated Lef/Tef reporter gene activity by 20% in EP4-expressing cells compared with 65% inhibition in EP2-expressing cells. On the other hand wortmannin, an inhibitor of phosphatidylinositol 3-kinase, had the opposite effect and inhibited PGE(2)-stimulated reporter gene activity to a much greater extent in EP4-expressing cells as compared with EP2-expressing cells. These findings indicate that the activation of Tcf/Lef signaling by EP2 receptors occurs primarily through a PKA-dependent pathway, whereas EP4 receptors activate Tcf/Lef signaling mainly through a phosphatidylinositol 3-kinase-dependent pathway. This is the first indication of a fundamental difference in the signaling potential of EP2 and EP4 prostanoid receptors.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.							Anthony TL, 2000, CURR EYE RES, V20, P394; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Dale TC, 1998, BIOCHEM J, V329, P209; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Fujino H, 2000, MOL PHARMACOL, V57, P353; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hwang D, 2000, ANNU REV NUTR, V20, P431, DOI 10.1146/annurev.nutr.20.1.431; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Zhang LQ, 1997, J VIROL, V71, P1651, DOI 10.1128/JVI.71.2.1651-1656.1997	23	255	268	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2614	2619		10.1074/jbc.M109440200	http://dx.doi.org/10.1074/jbc.M109440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706038	hybrid			2022-12-25	WOS:000173421500032
J	Sweeney, DA; Siddhanta, A; Shields, D				Sweeney, DA; Siddhanta, A; Shields, D			Fragmentation and re-assembly of the Golgi apparatus in vitro - A requirement for phosphatidic acid and phosphatidylinositol 4,5-bisphosphate synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NASCENT SECRETORY VESICLES; CELL-FREE SYSTEM; PHOSPHOLIPASE-D; TRANS-GOLGI; ENDOPLASMIC-RETICULUM; COATED VESICLES; DOWNSTREAM EFFECTOR; SUGAR NUCLEOTIDES; BINDING PROTEINS	Recent work from our laboratory demonstrated that phosphatidic acid (PA) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2), are required to maintain the structural integrity of the Golgi apparatus. To investigate the role of these lipids in regulating Golgi structure and function, we developed a novel assay to follow the release of post-Golgi vesicles. Isolated rat liver Golgi membranes were incubated with [H-3]CMP sialic acid to radiolabel endogenous soluble and membrane glycoproteins present in the late Golgi and trans-Golgi network. The release of post-Golgi secretory vesicles was determined by measuring incorporation of H-3-labeled proteins into a medium speed supernatant. Vesicle budding was dependent on temperature, cytosol, energy and time. Electron microscopy of Golgi fractions prior to and after incubation demonstrated that the stacked Golgi cisternae generated a heterogeneous population of vesicles (50- to 350-nm diameter). Inhibition of phospholipase D-mediated PA synthesis, by incubation with 1-butanol, resulted in the complete fragmentation of the Golgi membranes in vitro into 50- to 100-nm vesicles; this correlated with diminished PtdIns(4,5)P-2 synthesis. Following alcohol washout, PA synthesis resumed and in the presence of cytosol PtdIns(4,5)P-2 synthesis was restored. Most significantly, under these conditions the fragmented Golgi elements reformed into flattened cisternae and the re-assembled Golgi supported vesicle release. These data demonstrate that inositol phospholipid synthesis is essential for the structure and function of the Golgi apparatus.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Shields, D (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, T32DK007513, R37DK021860, R01DK021860] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK07513, DK P30 41296, DK21860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DASCHER C, 1994, J BIOL CHEM, V269, P1437; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dirac-Svejstrup AB, 2000, J CELL BIOL, V150, P475, DOI 10.1083/jcb.150.3.475; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Gonatas NK, 1998, HISTOCHEM CELL BIOL, V109, P591, DOI 10.1007/s004180050257; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Monier S, 1998, J CELL SCI, V111, P3427; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Sesso A, 1999, TISSUE CELL, V31, P357, DOI 10.1054/tice.1999.0042; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; VARKI A, 1994, METHOD ENZYMOL, V230, P16; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	56	49	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3030	3039		10.1074/jbc.M104639200	http://dx.doi.org/10.1074/jbc.M104639200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704660	hybrid			2022-12-25	WOS:000173421500086
J	Bruns, JR; Ellis, MA; Jeromin, A; Weisz, OA				Bruns, JR; Ellis, MA; Jeromin, A; Weisz, OA			Multiple roles for phosphatidylinositol 4-kinase in biosynthetic transport in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; EPITHELIAL-CELLS; GOLGI NETWORK; SECRETORY PATHWAY; TRANSFER PROTEIN; LIPID RAFTS; MEMBRANE; VESICLES; SURFACE; DYNAMICS	Phosphatidylinositols (PI) play important roles in regulating numerous cellular processes including cytoskeletal organization and membrane trafficking. The control of PI metabolism by phosphatidylinositol kinases has been the subject of extensive investigation; however, little is known about how phosphatidylinositol kinases regulate traffic in polarized epithelial cells. Because phosphatidylinositol 4-kinase (PI4K)-mediated phosphatidylinositol 4-phosphate (PI(4)P) production has been suggested to regulate biosynthetic traffic in yeast and mammalian cells, we have examined the role of PI4Kbeta in protein delivery in polarized MDCK cells, at different levels of the biosynthetic pathway. Expression of wild type PI4Kbeta had no effect on the rate of transport of influenza hemagglutinin (HA) through the Golgi complex, but inhibited the rate of trans-Golgi network (TGN)-to-cell surface delivery of this protein. By contrast, expression of dominant-negative, kinase-dead PI4Kbeta (PI4Kbeta(D656A)) inhibited intra-Golgi transport but stimulated TGN-to-cell surface delivery of HA. Moreover, expression of PI4Kbeta(D656A) significantly increased the solubility in cold Triton X-100 of HA staged in the TGN, suggesting that altered association of HA with lipid rafts may be responsible for the enhanced transport rate. Both wild type and kinase-dead PI4Kbeta inhibited basolateral delivery of vesicular stomatitis virus G protein, suggesting an effector function for PI4Kbeta in the regulation of basolateral traffic. Thus, by contrast with the observed requirement for PI4Kbeta activity and PI(4)P for efficient transport in yeast, our data suggest that changes in PI(4)P levels can stimulate and inhibit Golgi to cell surface delivery in mammalian cells.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@msx.dept-med.pitt.edu			NIDDK NIH HHS [R01-DK54407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Thomas CL, 1999, BIOCHEM SOC T, V27, P648, DOI 10.1042/bst0270648; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642	42	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2012	2018		10.1074/jbc.M108571200	http://dx.doi.org/10.1074/jbc.M108571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704666	hybrid			2022-12-25	WOS:000173421300055
J	Manning-Bog, AB; McCormack, AL; Li, J; Uversky, VN; Fink, AL; Di Monte, DA				Manning-Bog, AB; McCormack, AL; Li, J; Uversky, VN; Fink, AL; Di Monte, DA			The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice - Paraquat and alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; MUTATION; GENE; DEMENTIA; TOXICITY; MODEL; VIVO	alpha-Synuclein-containing aggregates represent a feature of a variety of neurodegenerative disorders, including Parkinson's disease (PD). However, mechanisms that promote intraneuronal alpha-synuclein assembly remain poorly understood. Because pesticides, particularly the herbicide paraquat, have been suggested to play a role as PD risk factors, the hypothesis that interactions between alpha-synuclein and these environmental agents may contribute to aggregate formation was tested in this study. Paraquat markedly accelerated the in vitro rate of alpha-synuclein fibril formation in a dose-dependent fashion. When mice were exposed to the herbicide, brain levels of alpha-synuclein were significantly increased. This up-regulation followed a consistent pattern, with higher alpha-synuclein at 2 days after each of three weekly paraquat injections and with protein levels returning to control values by day 7 post-treatment. Paraquat exposure was also accompanied by aggregate formation. Thioflavine S-positive structures accumulated within neurons of the substantia nigra pars compacta, and dual labeling and confocal imaging confirmed that these aggregates contained alpha-synuclein. The results suggest that up-regulation of alpha-synuclein as a consequence of toxicant insult and direct interactions between the protein and environmental agents are potential mechanisms leading to alpha-synuclein pathology in neurodegenerative disorders.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Di Monte, DA (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Di Monte, Donato/0000-0002-8296-836X	NIEHS NIH HHS [ES10806, ES10422] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010806] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baba M, 1998, AM J PATHOL, V152, P879; Brooks AI, 1999, BRAIN RES, V823, P1, DOI 10.1016/S0006-8993(98)01192-5; BURKITT MJ, 1993, MOL PHARMACOL, V43, P257; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Chan P, 1998, NEUROLOGY, V50, P1136, DOI 10.1212/WNL.50.4.1136; Chan P, 1998, NEUROLOGY, V50, P513, DOI 10.1212/WNL.50.2.513; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Corasaniti MT, 1998, PHARMACOL TOXICOL, V83, P1, DOI 10.1111/j.1600-0773.1998.tb01434.x; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; DIMONTE DA, 2001, TOXICOLOGIST, V60, P238; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Forno L.S, 1988, PROG PARKINSON RES, P11; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuoka Y, 2001, NEUROBIOL DIS, V8, P535, DOI 10.1006/nbdi.2001.0392; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SCHMIDT ML, 1995, AM J PATHOL, V147, P503; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Shimizu K, 2001, BRAIN RES, V906, P135, DOI 10.1016/S0006-8993(01)02577-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Widdowson PS, 1996, HUM EXP TOXICOL, V15, P231, DOI 10.1177/096032719601500308	38	487	502	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1641	1644		10.1074/jbc.C100560200	http://dx.doi.org/10.1074/jbc.C100560200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707429	hybrid			2022-12-25	WOS:000173421300004
J	Wilson, DP; Sutherland, C; Walsh, MP				Wilson, DP; Sutherland, C; Walsh, MP			Ca2+ activation of smooth muscle contraction - Evidence for the involvement of calmodulin that is bound to the triton-insoluble fraction even in the absence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; MYOSIN PHOSPHORYLATION; CHICKEN GIZZARD; CALCIUM; BINDING; CELLS; ACTIN; TENSION; SENSITIVITY; INHIBITION	Smooth muscle contraction is activated by phosphorylation of the 20-kDa light chains of myosin catalyzed by Ca2+/calmodulin (CaM)-dependent myosin light chain kinase (MLCK). According to popular current theory, the CaM involved in MLCK regulation is Ca2+-free and dissociated from the kinase at resting cytosolic free Ca2+ concentration ([Ca2+](i)). An increase in [Ca2+](i) saturates the four Ca2+-binding sites of CaM, which then binds to and activates actin-bound MLCK. The results of this study indicate that this theory requires revision. Sufficient CaM was retained after skinning (demembranation) of rat tail arterial smooth muscle in the presence of EGTA to support Ca2+-evoked contraction, as observed previously with other smooth muscle tissues. This tightly bound CaM was released by the CaM antagonist trifluoperazine (TFP) in the presence of Ca2+ . Following removal of the (Ca2+)(4)-CaM-TFP2 complex, Ca2+ no longer induced contraction. The addition of exogenous CaM to TFP-treated tissue at a [Ca2+] subthreshold for contraction or even in the absence of Ca2+ (presence of 5 mm EGTA), followed by washout of unbound CaM, restored Ca2+-induced contraction; this required MLCK activation, since it was blocked by the MLCK inhibitor ML-9. The data suggest, therefore, that a specific pool of cellular CaM, tightly bound to myofilaments at resting [Ca2+](i), or even in the absence of Ca2+, is responsible for activation of contraction following a local increase in [Ca2+]. This mechanism would allow for localized changes in [Ca2+] in regions of the cell distant from the myofilaments to regulate distinct Ca2+-dependent processes without triggering a contractile response. Immobilized CaM, therefore, resembles troponin C, the Ca2+- binding regulatory protein of striated muscle, which is also bound to the thin filament in a Ca2+-independent manner.	Univ Calgary, Fac Med, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Canadian Inst Hlth Res Grp Regulat Vasc Contracti, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Walsh, MP (corresponding author), Univ Calgary, Fac Med, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada.							ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BARRON JT, 1980, J BIOL CHEM, V255, P6238; Brushia R. J., 1999, FRONT BIOSCI, V4, pD618; CASSIDY P, 1980, PFLUG ARCH EUR J PHY, V387, P115, DOI 10.1007/BF00584261; CASSIDY PS, 1981, PFLUG ARCH EUR J PHY, V392, P115, DOI 10.1007/BF00581258; DABROWSKA R, 1982, BIOCHEM BIOPH RES CO, V107, P1524, DOI 10.1016/S0006-291X(82)80172-1; FILO RS, 1965, SCIENCE, V147, P1581, DOI 10.1126/science.147.3665.1581; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GORDON AR, 1978, P NATL ACAD SCI USA, V75, P3527, DOI 10.1073/pnas.75.7.3527; HINCKE MT, 1988, ELECTROPHORESIS, V9, P303, DOI 10.1002/elps.1150090704; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; Hulvershorn J, 2001, AM J PHYSIOL-HEART C, V280, pH1422, DOI 10.1152/ajpheart.2001.280.3.H1422; ISHIKAWA T, 1988, MOL PHARMACOL, V33, P598; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KERRICK WGL, 1981, J GEN PHYSIOL, V77, P177, DOI 10.1085/jgp.77.2.177; KERRICK WGL, 1980, FED PROC, V39, P1558; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Krueger JK, 2001, J BIOL CHEM, V276, P4535, DOI 10.1074/jbc.C000857200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CH, 2001, J PHYSIOL-LONDON, V534, P641, DOI 10.1111/j.1469-7793.2001.t01-1-00641.x; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; Lin PJ, 1999, J BIOL CHEM, V274, P5987, DOI 10.1074/jbc.274.9.5987; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; RUEGG JC, 1984, FEBS LETT, V170, P383, DOI 10.1016/0014-5793(84)81349-6; RUEGG JC, 1983, BASIC RES CARDIOL, V78, P462, DOI 10.1007/BF02070169; Smith L, 1999, J BIOL CHEM, V274, P29433, DOI 10.1074/jbc.274.41.29433; Smith L, 2000, FEBS LETT, V480, P298, DOI 10.1016/S0014-5793(00)01931-1; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPARROW MP, 1981, FEBS LETT, V125, P141, DOI 10.1016/0014-5793(81)80704-1; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; Weber LP, 2000, BIOCHEM J, V352, P573, DOI 10.1042/0264-6021:3520573; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; ZIMMERMANN B, 1995, J BIOL CHEM, V270, P23966, DOI 10.1074/jbc.270.41.23966	46	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2186	2192		10.1074/jbc.M110056200	http://dx.doi.org/10.1074/jbc.M110056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707462	hybrid			2022-12-25	WOS:000173421300078
J	Meyer, GE; Shelden, E; Kim, B; Feldman, EL				Meyer, GE; Shelden, E; Kim, B; Feldman, EL			Insulin-like growth factor I stimulates motility in human neuroblastoma cells	ONCOGENE			English	Article						PI3-K; MAP kinase; insulin receptor substrate; PTEN	KINASE TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYTOSKELETAL REORGANIZATION; DIFFERENTIAL REGULATION; RECEPTOR SUBSTRATE-2; NEURITE OUTGROWTH; SIGNALING SYSTEM; RAC	Motility is an important process that contributes to cancer cell spread. Growth factors are key regulators of motility in many cell types. Insulin-like growth factor I (IGF-I) causes SH-SY5Y human neuroblastoma cells to undergo dynamic morphological changes, leading to the extension of lamellipodia. IGF-I stimulated lamellipodia extension requires signaling through both phosphatidylinositol 3-kinase (P13-K) and MAP kinase pathways. IGF-I, over a period of hours, stimulates SH-SY5Y and SHEP neuroblastoma cells to become more motile. While SH-SY5Y and SHEP cells use different insulin receptor substrate (IRS) isoforms to transduce signals from the IGF-I receptor, IGF-I has the same relative effect on the motility of both cell lines. Blocking the P13-K and MAP kinase pathways attenuates the ability of IGF-I to increase motility. Overexpression of PTEN also attenuates IGF-I mediated motility. These results delineate some of the proximal events in the signaling mechanism utilized by IGF-I to stimulate cell motility.	Univ Michigan, Dept Neurol, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Med Sci Training Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Program Neurosci, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.		, Eric/GWC-7636-2022	Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [5T32 CA 09676] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07863] Funding Source: Medline; NINDS NIH HHS [R01 NS 38849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JACKSON JG, 1999, END SOC 81 ANN M, P479; Keller HU, 2000, CELL MOTIL CYTOSKEL, V46, P247, DOI 10.1002/1097-0169(200008)46:4<247::AID-CM2>3.0.CO;2-8; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; PANAGAKOS FS, 1993, BIOCHIMIE, V75, P991, DOI 10.1016/0300-9084(93)90150-Q; Shelden EA, 2000, J NEUROSCI METH, V102, P143, DOI 10.1016/S0165-0270(00)00286-7; Singleton JR, 1996, CANCER RES, V56, P4522; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	38	53	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7542	7550		10.1038/sj.onc.1204927	http://dx.doi.org/10.1038/sj.onc.1204927			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709726				2022-12-25	WOS:000171976900011
J	McKay, BC; Becerril, C; Ljungman, M				McKay, BC; Becerril, C; Ljungman, M			P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts	ONCOGENE			English	Article						apoptosis; DNA repair; p53; ultraviolet	RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; IRRADIATED HUMAN FIBROBLASTS; LIGHT-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; ULTRAVIOLET-LIGHT; DNA-DAMAGE; HUMAN-CELLS; INHIBITION	We previously reported that transcription-coupled repair (TCR)-deficient human fibroblasts are extremely sensitive to UV-induced apoptosis and this sensitivity correlated with the induction of the p53 tumour suppressor. However, we have also found that p53 can be protective against UV-induced apoptosis. Thus, prior to this study, it was not clear whether the induction of p53 in TCR-deficient fibroblasts contributed to their death. To address this issue, we have expressed human papillomavirus E6 (HPV-E6) in primary fibroblasts derived from patients affected with xeroderma pigmentosum (complementation groups A, B and C) and Cockayne syndrome (complementation group B). We found that TCR-deficient (XP-A, XP-B and CS-B) fibroblasts were more sensitive than TCR-proficient cells (XP-C and normal) to both UV light and cisplatin treatment and this increase in sensitivity was not p53 dependent. Importantly, HPV-E6 expression increased the sensitivity of TCR-proficient normal and XP-C fibroblasts to UV- and cisplatin-induced apoptosis. This increase in sensitivity correlated with a decrease in the capacity of HPV-E6 expressing cells to recover mRNA synthesis following UV-irradiation. Therefore, we propose that p53 protects against UV- and cisplatin-induced apoptosis in a TCR-dependent manner and that p53 does not contribute strongly to the induction of apoptosis. in TCR-deficient fibroblasts.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Michigan System; University of Michigan	McKay, BC (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 1C4, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331	NCI NIH HHS [CA 82376-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAY A, 1993, J BIOL CHEM, V268, P1650; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, AM J PATHOL, V148, P1019; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	36	95	95	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6805	6808		10.1038/sj.onc.1204901	http://dx.doi.org/10.1038/sj.onc.1204901			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709715				2022-12-25	WOS:000171551600017
J	Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP				Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP			Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling	ONCOGENE			English	Article						microarray; prostate cancer; hormone-refractory; androgen-independent; CWR22	MAMMALIAN TARGET; GROWTH-FACTOR; RECEPTOR; XENOGRAFT; EXPRESSION; CWR22; MODEL; RHABDOMYOSARCOMA; INHIBITION; MECHANISM	Androgen deprivation therapy for advanced prostate cancer is often effective, but not curative. Molecular pathways mediating the therapeutic response and those contributing to the subsequent hormone-refractory cell growth remain poorly understood. Here, cDNA microarray analysis of human CWR22 prostate cancer xenografts during the course of androgen deprivation therapy revealed distinct global gene expression profiles in primary, regressing and recurrent tumors. Elucidation of the genes involved in the transition between these states implicated specific molecular mechanisms in therapy failure and tumor progression. First, we identified a set of androgen-responsive genes whose expression decreased during the therapy response, but was then systematically restored in the recurrent tumors. In addition, altered expression of genes that encode known targets of rapamycin or that converge on the PI3K/AKT/FRAP pathway was observed in the recurrent tumors. Further suggestion for the involvement of these genes in hormone-refractory prostate cancer came from the observation that cells established from the recurrent xenografts were strongly inhibited in vitro by rapamycin. The results of this functional genomic analysis suggest that the combined effect of re-expression of androgen-responsive genes as well as the activation of rapamycin-sensitive signaling may drive prostate cancer progression, and contribute to the failure of androgen-deprivation therapy.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; NCI, Med Branch, NIH, Bethesda, MD 20850 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University	Kallioniemi, OP (corresponding author), NHGRI, Canc Genet Branch, NIH, Bldg 49,Rm 4A24, Bethesda, MD 20892 USA.	okalli@nhgri.nih.gov	Kallioniemi, Olli P/H-5111-2011; Bubendorf, Lukas/G-5299-2015; Bubendorfl, Lukas/H-5880-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Bubendorf, Lukas/0000-0001-5970-1803; 	NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Amler LC, 2000, CANCER RES, V60, P6134; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Cheng L, 1996, J NATL CANCER I, V88, P607, DOI 10.1093/jnci/88.9.607; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DILLING MB, 1994, CANCER RES, V54, P903; Gregory CW, 1998, CANCER RES, V58, P5718; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Khan J, 1998, CANCER RES, V58, P5009; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mousses S, 2000, PRACT APPROACH SER, P113; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sekulic A, 2000, CANCER RES, V60, P3504; WAINSTEIN MA, 1994, CANCER RES, V54, P6049	22	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6718	6723		10.1038/sj.onc.1204889	http://dx.doi.org/10.1038/sj.onc.1204889			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709706				2022-12-25	WOS:000171551600008
J	Proenza, C; O'Brien, J; Nakai, J; Mukherjee, S; Allen, PD; Beam, KG				Proenza, C; O'Brien, J; Nakai, J; Mukherjee, S; Allen, PD; Beam, KG			Identification of a region of RyR1 that participates in allosteric coupling with the alpha(1s) (Ca(V)1.1) II-III loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL RYANODINE RECEPTORS; CALCIUM-RELEASE CHANNEL; CA2+ CHANNELS; DOMAIN-III; ACTIVATION; EXPRESSION; SEQUENCE; INVOLVEMENT; SER(687)	In skeletal muscle, excitation-contraction (EC) coupling and retrograde signaling are thought to result from direct interactions between the ryanodine receptor (RyR1) and the a, subunit of the dihydropyridine receptor (alpha(1S)). Previous work has shown that the s53 region of alpha(1S) (residues 720-765 in the II-III loop) and regions R10 (1635-2636) and R9 (2659-3720) of RyR1 are involved in this signaling. Using the yeast two-hybrid system, we here report an interaction between s53 and the sR16 region of RyR1 (1837-2168, within R10), whereas no interaction was seen using upstream residues of the alpha(1S) II-III loop (s31, 666-709). The specificity of the s53-sR16 interaction was tested by using fragments of the cardiac RyR (RyR2) and DHPR (alpha(1C)) that correspond to sR16 and s53, respectively. No interaction was observed for s16 x c53 (alpha(1C) 850-897), but weak interaction was occasionally observed for s53 x cR16 (RyR2 1817-2142). To test the functional significance of the s53 x sR16 interaction, we expressed in dyspedic myotubes a chimeric RyR (chimeraR16) in which sR16 was substituted for the corresponding region of RyR2. ChimeraR16 was found to mediate weak skeletal-type EC coupling. To test the necessity of sR16 sequence for coupling, we used "chimeraR16-rev," in which sR16 and a small upstream region of RyR1 were replaced by RyR2 sequence. ChimeraR16-rev did not differ from RyR1 in its ability to mediate EC coupling. Thus, interaction between residues 720-765 of alpha(1S) and residues 1837-2168 of RyR1 appears to contribute to but is not essential for EC coupling in skeletal muscle.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Physiol, Ft Collins, CO 80523 USA; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	Colorado State University; Colorado State University; Harvard University; Brigham & Women's Hospital	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu	Tuluc, Petronel/C-2527-2011	Proenza, Catherine/0000-0003-4324-6206	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Proenza C, 2000, J BIOL CHEM, V275, P23169, DOI 10.1074/jbc.M003389200; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; Saiki Y, 1999, J BIOL CHEM, V274, P7825, DOI 10.1074/jbc.274.12.7825; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKEKURA H, 1995, J MUSCLE RES CELL M, V16, P465, DOI 10.1007/BF00126431; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	35	74	74	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6530	6535		10.1074/jbc.M106471200	http://dx.doi.org/10.1074/jbc.M106471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726651	hybrid			2022-12-25	WOS:000173989200110
J	Tempel, W; Tschampel, S; Woods, RJ				Tempel, W; Tschampel, S; Woods, RJ			The xenograft antigen bound to Griffonia simplicifolia lectin 1-B-4 - X-ray crystal structure of the complex and molecular dynamics characterization of the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP OLIGOSACCHARIDES; BANDEIRAEA-SIMPLICIFOLIA; GAL ANTIBODIES; XENOTRANSPLANTATION; TRANSPLANTATION; CRYSTALLOGRAPHY; IDENTIFICATION; CONFORMATION; SIMULATIONS; PROTEINS	The shortage of organs for transplantation into human patients continues to be a driving force behind research into the use of tissues from non-human donors, particularly pig. The primary barrier to such xenotransplantation is the reaction between natural antibodies present in humans and Old World monkeys and the Galalpha(1-3)Gal epitope (xenograft antigen, xenoantigen) found on the cell surfaces of the donor organ. This hyperacute immune response leads ultimately to graft rejection. Because of its high specificity for the xenograft antigen, isolectin 1-B-4 from Griffonia simplicifolia (GS-1-B-4) has been used as an immunodiagnostic reagent. Furthermore, haptens that inhibit natural antibodies also inhibit GS-1-B-4 from binding to the xenoantigen. Here we report the first x-ray crystal structure of the xenograft antigen bound to a protein (GS-1-B-4). The three-dimensional structure was determined from orthorhombic crystals at a resolution of 2.3 Angstrom. To probe the influence of binding on ligand properties, we report also the results of molecular dynamics (MD) simulations on this complex as well as on the free ligand. The MD simulations were performed with the AMBER force-field for proteins augmented with the GLYCAM parameters for glycosides and glycoproteins. The simulations were performed for up to 10 ns in the presence of explicit solvent. Through comparison with MD simulations performed for the free ligand, it has been determined that GS-1-B-4 recognizes the lowest energy conformation of the disaccharide. In addition, the x-ray and modeling data provide clear explanations for the reported specificities of the GS-1-B-4 lectin. It is anticipated that a further understanding of the interactions involving the xenograft antigen will help in the development of therapeutic agents for application in the prevention of hyperacute xenograft rejection.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Woods, RJ (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	rwoods@ccrc.uga.edu	Woods, Robert/F-4962-2015	Woods, Robert/0000-0002-2400-6293	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055230, R01GM055230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; *BIOS MSI, 1995, 950300 BIOS MSI; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH CA, 1986, J AM CHEM SOC, V108, P6168, DOI 10.1021/ja00280a010; CASE D, 1997, AMBER 5 0; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P2850; Goldstein I J, 1999, Subcell Biochem, V32, P127; GOOD AH, 1992, TRANSPL P, V24, P559; Greenstein JL, 1997, NAT BIOTECHNOL, V15, P235, DOI 10.1038/nbt0397-235; HAYES CE, 1974, J BIOL CHEM, V249, P1904; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Jeffrey G.A., 1997, INTRO HYDROGEN BONDI; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kirkeby S, 2001, IMMUNOL CELL BIOL, V79, P121, DOI 10.1046/j.1440-1711.2001.00992.x; Kirschner KN, 2001, P NATL ACAD SCI USA, V98, P10541, DOI 10.1073/pnas.191362798; Kooyman DL, 1996, TRANSPLANTATION, V61, P851, DOI 10.1097/00007890-199603270-00001; LAMB JE, 1984, ARCH BIOCHEM BIOPHYS, V229, P15, DOI 10.1016/0003-9861(84)90125-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; Lescar J, 2002, J BIOL CHEM, V277, P6608, DOI 10.1074/jbc.M109867200; Li J, 1999, CARBOHYD RES, V315, P76, DOI 10.1016/S0008-6215(98)00321-8; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MURPHY LA, 1977, J BIOL CHEM, V252, P4739; Otter A, 1999, EUR J BIOCHEM, V259, P295, DOI 10.1046/j.1432-1327.1999.00036.x; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; PLATT JL, 1991, CURR OPIN IMMUNOL, V3, P735, DOI 10.1016/0952-7915(91)90105-A; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sandrin MS, 1997, GLYCOCONJUGATE J, V14, P97, DOI 10.1023/A:1018521217276; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; Tempel W, 2001, ACTA CRYSTALLOGR D, V57, P1639, DOI 10.1107/S0907444901012148; Thall AD, 1996, TRANSPLANT P, V28, P556; Vaughan HA, 1996, XENOTRANSPLANTATION, V3, P18, DOI 10.1111/j.1399-3089.1996.tb00114.x; WOLFE S, 1979, CARBOHYD RES, V69, P1, DOI 10.1016/S0008-6215(00)85747-X; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; WOODS RJ, 1995, J PHYS CHEM-US, V99, P3832, DOI 10.1021/j100011a061; YAN ZY, 1990, BIOPOLYMERS, V29, P799, DOI 10.1002/bip.360290414	46	54	59	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6615	6621		10.1074/jbc.M109919200	http://dx.doi.org/10.1074/jbc.M109919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11714721	Green Accepted, hybrid			2022-12-25	WOS:000173989200121
J	Delerive, P; Wu, YF; Burris, TP; Chin, WW; Suen, CS				Delerive, P; Wu, YF; Burris, TP; Chin, WW; Suen, CS			PGC-1 functions as a transcriptional coactivator for the retinoid X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC COACTIVATOR; GAMMA COACTIVATOR-1; NUCLEAR RECEPTOR; LIGAND-BINDING; ALPHA; GENE; EXPRESSION; MOTIF	Ligand-dependent gene transcription mediated by the nuclear receptors involves the recruitment of transcriptional coactivators to the ligand-binding domain (LBD), which leads to interaction with the basal transcription machinery, and ultimately with RNA polymerase II. Although most of these coactivators are ubiquitously expressed, a tissue-selective coactivator, PGC-1, has recently been characterized. Because PGC-1 and the retinoid X receptors (RXRs) possess an overlapping tissue distribution, we investigated whether PGC-1 is a coactivator for the retinoid X receptors. In a transient transfection assay, PGC-1 augments ligand-stimulated RXR transcription. Furthermore, PGC-1 efficiently enhances the RXR element-driven reporter gene transcription by all three RXR isoforms. An immunoprecipitation assay reveals that PGC-1 and RXRalpha interact in vivo. In addition, a glutathione S-transferase pull-down assay showed that this interaction requires the presence of the LXXLL motif of PGC-1. We demonstrate further, in a mammalian two-hybrid assay, that this physical interaction also requires the presence of the AF-2 region of RXR to interact with the LXXLL motif of PGC-1, which is consistent with our protein-protein interaction results. A time-resolved fluorescence assay shows that a peptide within the NR box of PGC-1 is efficiently recruited by a ligand-bound RXRalpha in vitro. Finally, PGC-1 and TIF2 synergistically enhance ligand-activated RXRalpha transcriptional activity. Taken together, these results indicate that PGC-1 is a bona fide coactivator for RXRalpha.	Lilly Corp Ctr, Eli Lilly Res Labs, Dept Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA	Eli Lilly	Delerive, P (corresponding author), Lilly Corp Ctr, Eli Lilly Res Labs, Dept Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA.		Burris, Thomas/H-5078-2011; Burris, Thomas P/B-3886-2016	Burris, Thomas P/0000-0003-2922-4449				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Greiner EF, 2000, P NATL ACAD SCI USA, V97, P7160, DOI 10.1073/pnas.97.13.7160; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	25	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3913	3917		10.1074/jbc.M109409200	http://dx.doi.org/10.1074/jbc.M109409200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11714715	hybrid			2022-12-25	WOS:000173813900017
J	Misra, UK; Pizzo, SV				Misra, UK; Pizzo, SV			Regulation of cytosolic phospholipase A(2) activity in macrophages stimulated with receptor-recognized forms of alpha(2)-macroglobulin - Role in mitogenesis and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ARACHIDONIC-ACID RELEASE; ALPHA(2)M SIGNALING RECEPTOR; PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR; PERITONEAL-MACROPHAGES; INTRACELLULAR CALCIUM; GENE-EXPRESSION; MESANGIAL CELLS; GROWTH-FACTOR; UP-REGULATION	Macrophages exposed to receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) demonstrate increased DNA synthesis and cell division. In the current study, we have probed the role of cytosolic phospholipase A(2) (cPLA(2)) activity in the cellular response to alpha(2)M*. Ligation of the a2M* signaling receptor by alpha(2)M*, or its receptor binding fragment, increased cPLA(2) activity 2-3-fold in a concentration and time-dependent manner. This activation required a pertussis toxin-insensitive G protein. Cellular binding of alpha(2)M* also induced transient translocation of cPLA(2) activity to nuclei and membrane fractions. Inhibition of protein kinase C activity or chelation of Ca2+ inhibited alpha(2)M*-induced increased cPLA2 activity. Binding of a2M* to macrophages, moreover, increased phosphorylation of MEK 1/2, ERK 1/2, p38 MAPK, and JNK. Incubation of macrophages with inhibitors of MEK 1/2 or p38 MAPK before stimulation with a2M* profoundly decreased phosphorylation of MAPKs, blocking cPLA2 activation. a2M*-induced increase in [3 H]thymidine uptake and cell proliferation was completely abolished if activation of cPLA2 was prevented. The response of macrophages to a2M* requires transcription factors nuclear factor kappaB, and cAMP-responsive element-binding protein as well as expression of the proto-oneogenes c-fos and c-myc. These studies indicate that the activation of cPLA2 plays a crucial role in alpha(2)M*-induced mitogenesis and cell proliferation.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box, Durham, NC 27710 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asplin IR, 2000, ARCH BIOCHEM BIOPHYS, V383, P135, DOI 10.1006/abbi.2000.2052; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EXTON JH, 1990, J BIOL CHEM, V265, P1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1997, J BIOL CHEM, V272, P497; Misra UK, 1999, J BIOL CHEM, V274, P25785, DOI 10.1074/jbc.274.36.25785; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; Misra UK, 1996, J LEUKOCYTE BIOL, V60, P784, DOI 10.1002/jlb.60.6.784; Misra UK, 2001, ARCH BIOCHEM BIOPHYS, V386, P227, DOI 10.1006/abbi.2000.2199; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 2000, CELL SIGNAL, V12, P99, DOI 10.1016/S0898-6568(99)00070-4; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V363, P68, DOI 10.1006/abbi.1998.1074; Misra UK, 2000, ARCH BIOCHEM BIOPHYS, V379, P153, DOI 10.1006/abbi.2000.1878; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5933; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TAY A, 1994, BIOCHEM J, V304, P417, DOI 10.1042/bj3040417; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; WU S, 2001, HEMOSTASIS THROMBOSE, P367; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; YULE DI, 1992, J BIOL CHEM, V267, P13830	68	40	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4069	4078		10.1074/jbc.M109764200	http://dx.doi.org/10.1074/jbc.M109764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11733496	hybrid			2022-12-25	WOS:000173813900038
J	Kaneto, H; Suzuma, K; Sharma, A; Bonner-Weir, S; King, GL; Weir, GC				Kaneto, H; Suzuma, K; Sharma, A; Bonner-Weir, S; King, GL; Weir, GC			Involvement of protein kinase CB2 in c-myc induction by high glucose in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; OXIDATIVE STRESS; DIABETIC-RATS; HEXOSAMINE PATHWAY; ACTIVATION; EXPRESSION; ISOFORM; MODEL; IDENTIFICATION; LOCALIZATION	The expression of the basic helix-loop-helix transcription factor c-Myc is induced in pancreatic islets of several different diabetic model animals and is possibly involved in suppression of the insulin gene transcription. In this study, we found that activity of protein kinase C is increased by high glucose, preceding the induction of c-myc expression and that PKC beta2 specifically regulates c-myc expression in pancreatic beta-cells. Since PKC alpha, beta2, delta, epsilon, and zeta were expressed in rat pancreatic islets, we prepared each wild type (WT) and dominant negative type (DN) PKC isoform (alpha, beta2, delta, epsilon, and zeta)-expressing adenovirus to examine the effect of each KC isoform on c-myc expression. In isolated rat pancreatic islets, adenovirus-mediated overexpression of WT PKC beta2, but not other PKC isoforms, markedly increased c-myc expression. Moreover, c-myc induction by high glucose was suppressed by adenovirus-mediated overexpression of DN PKC beta2 but not by other DN PKC isoforms. Finally, adenovirus-mediated overexpression of WT PKC beta2, but not of other PKC isoforms, leads to suppression of the insulin gene transcription in pancreatic islets. These results suggest that at least some of the reduction of insulin gene transcription found in the diabetic state is mediated by PKC beta2 regulation of c-myc expression.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Joslin Diabet Ctr, Sect Vasc Cell Biol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.	Kaneto, H (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.	kaneto@osb.att.ne.jp		Bonner-Weir, Susan/0000-0003-4682-0656	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449] Funding Source: NIH RePORTER; NEI NIH HHS [EY-5110] Funding Source: Medline; NIDDK NIH HHS [DK-35449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Dang CV, 1999, MOL CELL BIOL, V19, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; ITO A, 1989, DIABETES, V38, P1005, DOI 10.2337/diabetes.38.8.1005; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kaneto H, 2001, DIABETES, V50, pA80; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; KUNISAKI M, 1994, DIABETES, V43, P1372, DOI 10.2337/diabetes.43.11.1372; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	42	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3680	3685		10.1074/jbc.M109647200	http://dx.doi.org/10.1074/jbc.M109647200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714718	hybrid			2022-12-25	WOS:000173688000082
J	Baker, MD; Papageorgiou, AC; Titball, RW; Miller, J; White, S; Lingard, B; Lee, JJ; Cavanagh, D; Kehoe, MA; Robinson, JH; Acharya, KR				Baker, MD; Papageorgiou, AC; Titball, RW; Miller, J; White, S; Lingard, B; Lee, JJ; Cavanagh, D; Kehoe, MA; Robinson, JH; Acharya, KR			Structural and functional role of threonine 112 in a superantigen Staphylococcus aureus enterotoxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA-CHAIN; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; T-CELLS; STIMULATION; IDENTIFICATION; SPECIFICITY; RECOGNITION; MECHANISM; BINDING	Bacterial superantigens are potent T-cell stimulatory protein molecules produced by Staphylococcus aureus and Streptococcus, pyogenes. Their superantigenic activity can be attributed to their ability to cross-link major histocompatibility complex class 11 molecules with T-cell receptors (TCRs) to form a tri-molecular complex. Each superantigen is known to interact with a specific V-beta element of TCR. Staphylococcal enterotoxin B (SEB, a superantigen), a primary cause of food poisoning, is also responsible for a significant percentage of nonmenstrual associated toxic shock syndrome in patients with a variety of staphylococcal infections. Structural studies have elucidated a binding cavity on the toxin molecule essential for TCR binding. To understand the crucial residues involved in binding, mutagenesis analysis was performed. Our analysis suggest that mutation of a conserved residue Thr(112) to Ser (T112S) in the binding cavity induces a selective reduction in the affinity for binding one TCR V-beta family and can be attributed to the structural differences in the native and mutant toxins. We present a detailed comparison of the mutant structure determined at 2.0 Angstrom with the previously reported native SEB and SEB-TCR V-beta complex structures.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; CBS Porton Down, Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England; Univ Newcastle, Med Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Bath; Defence Science & Technology Laboratory; Newcastle University - UK	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Cavanagh, David R/A-1828-2008; Papageorgiou, Anastassios C./AAL-5274-2020; Baker, Matthew/B-4850-2011	Papageorgiou, Anastassios C./0000-0002-7980-1120; Baker, Matthew/0000-0001-6950-204X; Acharya, K. Ravi/0000-0002-3009-4058; Cavanagh, David/0000-0003-4360-2637				Bergdoll M.S., 1983, STAPHYLOCOCCI STAPHY, V2, P559; Betley M. J., 1992, BIOL SIGNIFICANCE SU, P1; Briggs C, 1997, IMMUNOLOGY, V90, P169, DOI 10.1046/j.1365-2567.1997.00151.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Garcia C, 1998, IMMUNOLOGY, V94, P160, DOI 10.1046/j.1365-2567.1998.00493.x; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; HAYBALL JD, 1994, INT IMMUNOL, V6, P199, DOI 10.1093/intimm/6.2.199; Hayball JD, 2000, IMMUNOL CELL BIOL, V78, P13, DOI 10.1046/j.1440-1711.2000.00880.x; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Kotb M, 1998, CURR OPIN MICROBIOL, V1, P56, DOI 10.1016/S1369-5274(98)80143-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lavoie PM, 1999, IMMUNOL REV, V168, P257, DOI 10.1111/j.1600-065X.1999.tb01297.x; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; METZROTH B, 1993, INFECT IMMUN, V61, P2445, DOI 10.1128/IAI.61.6.2445-2452.1993; Munson SH, 1998, INFECT IMMUN, V66, P3337, DOI 10.1128/IAI.66.7.3337-3348.1998; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papageorgiou AC, 2000, TRENDS MICROBIOL, V8, P369, DOI 10.1016/S0966-842X(00)01793-5; Papageorgiou AC, 1997, STRUCTURE, V5, P991, DOI 10.1016/S0969-2126(97)00252-9; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; REN KY, 1994, J EXP MED, V180, P1675, DOI 10.1084/jem.180.5.1675; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SPERO L, 1988, BACTERIAL TOXINS HDB, V14, P131; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; SWAMINATHAN S, 1995, NAT STRUCT BIOL, V2, P680, DOI 10.1038/nsb0895-680; Swaminathan S., 1996, PROTEIN TOXIN STRUCT, P231; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; Zhang SP, 1998, FEMS MICROBIOL LETT, V168, P227, DOI 10.1111/j.1574-6968.1998.tb13278.x	34	13	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2756	2762		10.1074/jbc.M109369200	http://dx.doi.org/10.1074/jbc.M109369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704673	Green Accepted, hybrid			2022-12-25	WOS:000173421500051
J	Beers, SA; Buckland, AG; Koduri, RS; Cho, W; Gelb, MH; Wilton, DC				Beers, SA; Buckland, AG; Koduri, RS; Cho, W; Gelb, MH; Wilton, DC			The antibacterial properties of secreted phospholipases A(2) - A major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASING PROTEIN BPI; GRAM-POSITIVE BACTERIA; INTERFACIAL BINDING; ESCHERICHIA-COLI; ARACHIDONIC-ACID; EXPRESSION; RELEASE; MEMBRANES; DETERMINANTS; TRYPTOPHAN	The antibacterial properties of human group IIA secreted phospholipase A(2) against Gram-positive bacteria as a result of membrane hydrolysis have been reported. Using Micrococcus luteus as a model system, we demonstrate the very high specificity of this human enzyme for such hydrolysis compared with the group IB, IIE, lIF, V, and X human secreted phospholipase A(2)s. A unique feature of the group IIA enzyme is its very high pI due to a large excess of cationic residues on the enzyme surface. The importance of this global positive charge in bacterial cell membrane hydrolysis and bacterial killing has been examined using charge reversal mutagenesis. The global positive charge on the enzyme surface allows penetration through the bacterial cell wall, thus allowing access of this enzyme to the cell membrane. Reduced bacterial killing was associated with the loss of positive charge and reduced cell membrane hydrolysis. All mutants were highly effective in hydrolyzing the bacterial membrane of cells in which the cell wall was permeabilized with lysozyme. These same overall characteristics were also seen with suspensions of Staphylococcus aureus and Listeria innocua, where cell membrane hydrolysis and antibacterial activity of human group IIA enzyme was also lost as a result of charge reversal mutagenesis.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Illinois, Dept Chem, Chicago, IL 60307 USA	University of Southampton; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wilton, DC (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.			gelb, michael/0000-0001-7000-5219; Beers, Stephen/0000-0002-3765-3342	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36236] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; Elsbach P, 1998, J LEUKOCYTE BIOL, V64, P14, DOI 10.1002/jlb.64.1.14; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Foreman-Wykert AK, 2000, INFECT IMMUN, V68, P1259, DOI 10.1128/IAI.68.3.1259-1264.2000; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gronroos JO, 2001, J IMMUNOL, V166, P4029, DOI 10.4049/jimmunol.166.6.4029; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1997, BBA-LIPID LIPID MET, V1346, P185, DOI 10.1016/S0005-2760(97)00034-9; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; WEISS J, 1994, J BIOL CHEM, V269, P26331; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10311, DOI 10.1021/bi970177e; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10301, DOI 10.1021/bi970176m; WILTON DC, 1990, BIOCHEM J, V266, P435, DOI 10.1042/bj2660435; WORRALL AF, 1991, BIOCHEM J, V278, P365, DOI 10.1042/bj2780365	34	108	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1788	1793		10.1074/jbc.M109777200	http://dx.doi.org/10.1074/jbc.M109777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706041	hybrid			2022-12-25	WOS:000173421300023
J	Correia, JD; Ulevitch, RJ				Correia, JD; Ulevitch, RJ			MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TOLL-LIKE RECEPTORS; CD14; BINDING; ACTIVATION; PROTEIN; LIPOPROTEINS; EXPRESSION; LPS; RESPONSIVENESS	The lipopolysaccharide (LPS) receptor is a multi-protein complex that consists of at least three proteins, CD14, TLR4, and MD-2. Because each of these proteins is glycosylated, we have examined the functional role of N-linked carbohydrates of both MD-2 and TLR4. We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites. Site-directed mutagenesis studies showed that cell surface expression of MD-2 did not depend on the presence of either N-linked site, whereas in contrast, TLR4 mutants carrying substitutions in Asn(526) or Asn(575) failed to be transported to the cell surface. Using a UV-activated derivative of Re595 LPS (ASD-Re595 LPS) in cross-linking assays, we demonstrated a critical role of MD-2 and TLR4 carbohydrates in LPS cross-linking to the LPS receptor. The ability of the various glycosylation mutants to support cell activation was also evaluated in transiently transfected HeLa cells. The double mutant of MD-2 failed to support LPS-induced activation of an interleukin-8 (IL-8) promoter-driven luciferase reporter to induce IL-8 secretion or to activate amino-terminal c-Jun kinase (JNK). Similar results were observed with TLR4 mutants lacking three or more N-linked glycosylation sites. Surprisingly, the reduction in activation resulting from expression of the Asn mutants of MD-2 and TLR4 can be partially reversed by co-expression with CD14. This suggests that the functional integrity of the LPS receptor depends both on the surface expression of at least three proteins, CD14, MD-2, and TLR4, and that N-linked sites of both MD-2 and TLR4 are essential in maintaining the functional integrity of this receptor.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ulevitch, RJ (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ulevitch@scripps.edu	Ulevitch, Richard J/Q-3393-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, R37GM028485, P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM28485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; BOEGE F, 1988, J BIOL CHEM, V263, P9040; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; Deslauriers B, 1999, BIOCHEM J, V339, P397, DOI 10.1042/0264-6021:3390397; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; GAMOU S, 1988, J BIOCHEM-TOKYO, V104, P388, DOI 10.1093/oxfordjournals.jbchem.a122478; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Lamping N, 1996, J IMMUNOL, V157, P4648; LASCOLS O, 1989, MOL CELL ENDOCRINOL, V65, P145, DOI 10.1016/0303-7207(89)90175-5; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; Schumann RR, 1997, J IMMUNOL, V159, P5599; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stelter F, 1997, EUR J BIOCHEM, V243, P100, DOI 10.1111/j.1432-1033.1997.00100.x; Stelter F, 1996, EUR J BIOCHEM, V236, P457, DOI 10.1111/j.1432-1033.1996.00457.x; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; THEOFAN G, 1994, J IMMUNOL, V152, P3623; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Wong PMC, 1999, P NATL ACAD SCI USA, V96, P11543, DOI 10.1073/pnas.96.20.11543	46	160	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1845	1854		10.1074/jbc.M109910200	http://dx.doi.org/10.1074/jbc.M109910200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706042	hybrid			2022-12-25	WOS:000173421300031
J	Kim, SH; Creemers, JWM; Chu, S; Thinakaran, G; Sisodia, SS				Kim, SH; Creemers, JWM; Chu, S; Thinakaran, G; Sisodia, SS			Proteolytic processing of familial British dementia-associated BRI variants - Evidence for enhanced intracellular accumulation of amyloidogenic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; PROPROTEIN CONVERTASE; MESSENGER-RNA; CDNA SEQUENCE; RAT-BRAIN; FURIN; GENE; EXPRESSION; PROTEINS; LOCALIZATION	Different mutations in the BRI2 gene cause rare neurodegenerative conditions, termed familial British dementia (FBD) and familial Danish dementia (FDD). The mutant genes encode BRI-L and BRI-D, the precursors of fibrillogenic ABri and ADan peptides, respectively. We previously reported that furin processes both BRI-L and its wild type counterpart, BRI, resulting in the secretion of C-terminal peptides; elevated levels of peptides were generated from BRI-L. In the present study, we show that inducible expression of alpha1-antitrypsin Portland, a furin inhibitor, inhibits the endoproteolysis of BRI and BRI-L in a dose-dependent manner. Moreover, comparison of the activities of several proprotein convertases reveals that furin is most efficient in endoproteolysis of BRI and BRI-L; PACE4, PC6A, PC6B, and LPC show much lower activities. Interestingly, LPC also exhibits enhanced cleavage of BRI-L compared with BRI. Finally, we demonstrate that BRI-D is also processed by furin and, like BRI-L, the cleavage of BRI-D is more efficient than that of BRI. Interestingly, while the ABri peptide is detected both intracellularly and in the medium, the ADan peptide accumulates predominantly in intracellular compartments. We propose that intracellular accumulation of amyloidogenic ADan or ABri peptides results in the neuronal damage leading to FDD and FBD, respectively.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	University of Chicago; KU Leuven	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 501,947 E 58th St,MC0926, Chicago, IL 60637 USA.							Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; DONG W, 1995, J NEUROSCI, V15, P1778, DOI 10.1523/JNEUROSCI.15-03-01778.1995; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2001, BIOCHEMISTRY-US, V40, P3449, DOI 10.1021/bi002287i; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 2001, GENE, V266, P95, DOI 10.1016/S0378-1119(01)00374-2; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3	31	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1872	1877		10.1074/jbc.M108739200	http://dx.doi.org/10.1074/jbc.M108739200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11709554	hybrid			2022-12-25	WOS:000173421300034
J	Manohar, CF; Short, ML; Nguyen, A; Nguyen, NN; Chagnovich, D; Yang, QW; Cohn, SL				Manohar, CF; Short, ML; Nguyen, A; Nguyen, NN; Chagnovich, D; Yang, QW; Cohn, SL			HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; HUMAN NEUROBLASTOMA-CELLS; 3' UNTRANSLATED REGION; MESSENGER-RNA; N-MYC; GENE-EXPRESSION; C-FOS; CHILDHOOD NEUROBLASTOMA; 3'-UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE	MYCN amplification and consequent deregulated expression plays a crucial role in determining the clinical behavior of neuroblastoma. Enhanced expression of MYCN confers growth potential to neuroblastoma cells, and a direct link between MYCN expression and the development of neuroblastoma has been demonstrated in transgenic mice studies. Although the molecular pathways underlying the regulation of MYCN have not been fully elucidated, post-transcriptional mechanisms appear to be important. Previously, we reported that an embryonic lethal abnormal vision-like (ELAV) protein binds with high specificity to at least two AU-rich elements within the MYCN 3'-untranslated region. In this study, we characterized the ability of cis-acting elements within the MYCN 3'-untranslated region to destabilize mRNA in cells and examined the functional consequences of its interactions with the ELAV protein HuD. We show that at least 4 cis-acting elements within the MYCN X-untranslated region are able to signal the degradation of stable heterologous mRNA. Ectopic overexpression of HuD dramatically inhibits RNA decay mediated by the full-length MYCN 3'-untranslated region and cis-acting destabilizing elements that harbor HuD binding sites in vivo. HuD may contribute to the malignant phenotype of neuroblastoma cells by stabilizing MYCN mRNA, thereby enhancing steady-state levels of expression of this oncogene.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University	Cohn, SL (corresponding author), Childrens Mem Hosp, Div Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA.		Cohn, Susan/AAB-6010-2021; Yang, Qiwei/C-6154-2011	Cohn, Susan/0000-0001-5749-7650; , Qiwei Yang/0000-0001-7131-8946	NATIONAL CANCER INSTITUTE [R01CA074824, P30CA060553] Funding Source: NIH RePORTER; NCI NIH HHS [CA74824, 5P30CA60553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Anderson KD, 2001, EXP NEUROL, V168, P250, DOI 10.1006/exnr.2000.7599; Ball NS, 1997, CLIN CANCER RES, V3, P1859; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Bordow SB, 1998, J CLIN ONCOL, V16, P3286, DOI 10.1200/JCO.1998.16.10.3286; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chagnovich D, 1996, J BIOL CHEM, V271, P33587, DOI 10.1074/jbc.271.52.33587; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FOLEY J, 1991, CANCER RES, V51, P6338; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KING PH, 1994, J NEUROSCI, V14, P1943; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LEE SI, 1988, CELL, V54, P599, DOI 10.1016/S0092-8674(88)80004-7; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; Moss TJ, 1999, CANCER METAST REV, V18, P91, DOI 10.1023/A:1006264420822; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Spengler BA, 1997, ONCOL RES, V9, P467; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1967	1973		10.1074/jbc.M106966200	http://dx.doi.org/10.1074/jbc.M106966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11711535	hybrid			2022-12-25	WOS:000173421300049
J	Hermanto, U; Zong, CS; Wang, LH				Hermanto, U; Zong, CS; Wang, LH			ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth	ONCOGENE			English	Article						ErbB2; PI3 kinase; breast cancer; cell growth	NF-KAPPA-B; PROTEIN-KINASE; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; S6 KINASE; ONCOGENE; AKT; OVEREXPRESSION; AMPLIFICATION	The proto-oncogene ErbB2 is known to be amplified and to play an important role in the development of about one-third of human breast cancers. Phosphatidylinositol 3-kinase (PI3K), which is often activated in ErbB2-overexpressing breast cancer cells, is known to regulate cell proliferation and cell survival. Selective inhibitors of the PI3K pathway were used to assess the relevance of PI3K signaling in the anchorage-independent growth of a series of human mammary carcinoma cell lines. Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression. A similar growth inhibition of ErbB2-overexpressing carcinoma lines was observed when a dominant negative p85(PI3K) mutant was introduced into these cells. Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002- and rapamycin-mediated inhibition of colony formation. Furthermore, treatment with LY294002 resulted in the selective increase of cyclin-dependent kinase inhibitors p21(CIP1) or p27(Kipt) and suppression of cyclin E-associated Cdk2 kinase activity in ErbB2-overexpressing lines, which may account for their hypersensitivity toward inhibitors of the PI3K pathway in anchorage-independent growth. Our results indicate that the PI3K/Akt/p70(S6K) pathway plays an enhanced role in the anchorage-independent growth of ErbB2-overexpressing breast cancer cells, therefore providing a molecular basis for the selective targeting of this signaling pathway in the treatment of ErbB2-related human breast malignancies.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	1u-hai.wang@mssm.edu			NCI NIH HHS [CA 29339, CA 55054] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07280] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339, R01CA055054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ozes ON, 1999, NATURE, V401, P82; PIERCE JH, 1991, ONCOGENE, V6, P1189; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; YANO H, 1993, J BIOL CHEM, V268, P25846; YOKOTA J, 1986, LANCET, V1, P765; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	42	55	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7551	7562		10.1038/sj.onc.1204964	http://dx.doi.org/10.1038/sj.onc.1204964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709727				2022-12-25	WOS:000171976900012
J	Wu, CH; Rastegar, M; Gordon, J; Safa, AR				Wu, CH; Rastegar, M; Gordon, J; Safa, AR			beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein	ONCOGENE			English	Article						multidrug resistance; beta(2)-microglobulin; caspases; apoptosis; leukemia	PERMEABILITY TRANSITION PORE; CLASS-I MOLECULES; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE; INDEPENDENT APOPTOSIS; MELANOMA-CELLS; DEATH PATHWAY; GENE; FAS; ACTIVATION	In this study, we examined whether exogenous beta (2)-microglobulin (beta M-2) can induce apoptosis in the drug sensitive HL-60 leukemia cell line and its drug resistant variants and investigated the molecular mechanism of beta (2)m-induced apoptosis. Our data revealed that beta (2)m is very significantly down-regulated in two multidrug resistant variants of the HL-60 cells: (a) the MRP1-bearing, Bax-deficient HL-60/ADR cell line, and (b) the P-glycoprotein (P-gp) overexpressing HL-60/VCR cell line. However, exogenous beta (2)m induced similar levels of apoptosis in HL-60 cells and these drug resistant variants. beta (2)m-induced apoptosis in HL-60 and HL-60/VCR cells was associated with decreased mitochondrial membrane potential (Delta psim) but did not affect Delta psim in HL-60/ADR cells. Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta (2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta (2)m in these cells is not through MPT pore formation. Furthermore, beta (2)m induced the release of cytochrome c and the apoptosis-inducing factor (AIF) from mitochondria in HL-60 and HL-60/VCR cells, but not in HL-60/ADR cells. Additionally, z-VAD-fmk, a general inhibitor of caspases which inhibited cytochrome c release in HL-60 and HL-60/VCR cells, had no effect on AIF release in any of these cell lines, but inhibited beta (2)m-induced apoptosis in all three cell lines. However, Western blot analysis revealed that caspases-1, -3, -6, -8, and -9 are not activated during beta (2)m-induced apoptosis in these cells. Therefore, beta (2)m-induces apoptosis through an unknown caspase-dependent mitochondrial pathway in HL-60 and HL-60/VCR cells and by a Bax-independent, non-mitochodrial, caspase-dependent pathway in HL-60/ADR cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80734] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benitez R, 1998, TISSUE ANTIGENS, V52, P520, DOI 10.1111/j.1399-0039.1998.tb03082.x; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6990690; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO;2-Q; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Chung TDK, 1998, CANCER GENE THER, V5, P344; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DIXON B, 1993, IMMUNOGENETICS, V38, P27, DOI 10.1007/BF00216387; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Genestier L, 1997, BLOOD, V90, P3629, DOI 10.1182/blood.V90.9.3629; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Genestier L, 1997, BLOOD, V90, P726, DOI 10.1182/blood.V90.2.726.726_726_735; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hicklin DJ, 1998, J CLIN INVEST, V101, P2720, DOI 10.1172/JCI498; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Johnstone RW, 2000, LEUKEMIA LYMPHOMA, V38, P1, DOI 10.3109/10428190009060314; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mori M, 1999, BLOOD, V94, P2744; Mori M, 2001, CANCER RES, V61, P4414; Munker R, 1997, HEMATOL CELL THER, V39, P75, DOI 10.1007/s00282-997-0075-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; ROWLEY DR, 1995, CANCER RES, V55, P781; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Skov S, 1997, J IMMUNOL, V158, P3189; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takagi M, 1999, LEUKEMIA, V13, P70, DOI 10.1038/sj.leu.2401247; Takeuchi T, 1996, INT J CANCER, V67, P709, DOI 10.1002/(SICI)1097-0215(19960904)67:5<709::AID-IJC20>3.0.CO;2-Z; Ten Hagen TLM, 2000, INT J CANCER, V87, P829, DOI 10.1002/1097-0215(20000915)87:6<829::AID-IJC12>3.0.CO;2-C; Vitale M, 1998, CANCER RES, V58, P737; WallenOhman M, 1997, INT IMMUNOL, V9, P599, DOI 10.1093/intimm/9.4.599; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woodle ES, 1997, J IMMUNOL, V158, P2156; Yamamoto H, 2001, GASTROENTEROLOGY, V120, P1565, DOI 10.1053/gast.2001.24497	80	25	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7006	7020		10.1038/sj.onc.1204893	http://dx.doi.org/10.1038/sj.onc.1204893			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704825				2022-12-25	WOS:000171739300004
J	Kiemer, AK; Takeuchi, K; Quinlan, MP				Kiemer, AK; Takeuchi, K; Quinlan, MP			Identification of genes involved in epithelial-mesenchymal transition and tumor progression	ONCOGENE			English	Article						differentiation; transformation; immortalization; gene expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; ARGININE-GLYCINE AMIDINOTRANSFERASE; RENAL-CELL CARCINOMAS; GROWTH-FACTOR; ADENOVIRUS E1A; IN-VIVO; SUPPRESSOR GENE; E1A-12S PROTEIN; LYSYL OXIDASE; X-CHROMOSOME	The adenovirus E1A12S gene product (WT12S) immortalizes epithelial cells and they retain their differentiated characteristics, but certain mutants cannot do the latter. Characterization of mutant immortalized epithelial cells indicated that they had undergone epithelial mesenchymal transition (EMT). Coexpression of V12ras with WT12S leads to benign tumors, but to malignant tumors with 12S mutants. Since EMT is critical for tumor progression, identification of the molecular mechanisms involved should elucidate novel therapeutic targets. To this end, representational difference analysis (RDA) was used to identify cDNAs upregulated in the mutant cell line. Thirty-five differentially expressed mRNAs were identified and classified into several functional categories, including nine novel cDNAs. Among the 26 known cDNAs, extracellular matrix and related proteins made up the largest group of differentially expressed genes, followed by growth factors and receptors and transcription factors. There was also an ion transporter, a cytoskeletal protein, glycosylation and amidinotransferase enzymes and proteins with unknown functions. Some of the known genes have previously been associated with EMT and/or tumor progression and thus served to validate the system to obtain the desired target genes, while other cDNAs are newly linked with dedifferentiation/malignancy. Array analyses indicated that the cDNAs were specifically upregulated in invasive or metastatic tumors, especially of breast, uterus and lung, suggesting their involvement in the progression of these tumors.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany	Kyowa Kirin Ltd; University of Munich	Quinlan, MP (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Machi,Machida Shi, Tokyo 1948533, Japan.		Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				Adachi E, 1997, INT REV CYTOL, V173, P73; Allgayer H, 1998, CLIN EXP METASTAS, V16, P62; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brenner W, 2000, CANCER LETT, V155, P199, DOI 10.1016/S0304-3835(00)00429-8; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; Daniel L, 2000, CANCER RES, V60, P80; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P161; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556; Haralson MA, 2000, MATRIX BIOL, V19, P47, DOI 10.1016/S0945-053X(99)00057-8; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; Hay ED, 1995, ACTA ANAT, V154, P8; He ZH, 1999, CANCER RES, V59, P3222; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC441, DOI 10.1152/ajpcell.1999.277.3.C441; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Huber SM, 2000, AM J PHYSIOL-RENAL, V279, pF65, DOI 10.1152/ajprenal.2000.279.1.F65; HUMM A, 1994, FEBS LETT, V339, P101, DOI 10.1016/0014-5793(94)80394-3; Isaac L, 1999, INFLAMM RES, V48, P446, DOI 10.1007/s000110050485; Kanwar YS, 1998, AM J PHYSIOL-RENAL, V275, pF710, DOI 10.1152/ajprenal.1998.275.5.F710; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; Komiya A, 1997, JPN J CANCER RES, V88, P389, DOI 10.1111/j.1349-7006.1997.tb00394.x; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; Lee SMY, 1998, GENE, V216, P163, DOI 10.1016/S0378-1119(98)00302-3; LINDER S, 1992, ONCOGENE, V7, P439; Lipschutz JH, 1998, AM J KIDNEY DIS, V31, P383, DOI 10.1053/ajkd.1998.v31.pm9506676; Lohi J, 1998, HISTOL HISTOPATHOL, V13, P785, DOI 10.14670/HH-13.785; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Lyon MF, 1999, CURR BIOL, V9, pR235, DOI 10.1016/S0960-9822(99)80151-1; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Mitchell MS, 2000, CANCER RES, V60, P6448; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oivula J, 1999, J PATHOL, V187, P455, DOI 10.1002/(SICI)1096-9896(199903)187:4<455::AID-PATH271>3.0.CO;2-C; Okabe-Kado J, 1998, LEUKEMIA LYMPHOMA, V32, P19, DOI 10.3109/10428199809059243; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; Pujuguet P, 2000, J CELL SCI, V113, P849; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; Ramirez F, 1999, INT J BIOCHEM CELL B, V31, P255, DOI 10.1016/S1357-2725(98)00109-5; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Schneider J, 2000, BRIT J CANCER, V82, P1662; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Sterzel RB, 2000, KIDNEY INT, V58, P1588, DOI 10.1046/j.1523-1755.2000.00320.x; Stohr H, 2000, CYTOGENET CELL GENET, V88, P211, DOI 10.1159/000015552; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; van Goor H, 1999, EXP NEPHROL, V7, P35; Wada J, 1997, KIDNEY INT, V51, P1629, DOI 10.1038/ki.1997.225; WEILER SR, 1994, GENOMICS, V22, P243, DOI 10.1006/geno.1994.1374; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang QW, 1999, DEV BIOL, V212, P229, DOI 10.1006/dbio.1999.9331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202	81	67	68	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6679	6688		10.1038/sj.onc.1204872	http://dx.doi.org/10.1038/sj.onc.1204872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709702				2022-12-25	WOS:000171551600004
J	Slama-Schwok, A; Negrerie, M; Berka, V; Lambry, JC; Tsai, AL; Vos, MH; Martin, JL				Slama-Schwok, A; Negrerie, M; Berka, V; Lambry, JC; Tsai, AL; Vos, MH; Martin, JL			Nitric oxide (NO) traffic in endothelial NO synthase - Evidence for a new NO binding site dependent on tetrahydrobiopterin?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; L-ARGININE; HEME-PROTEINS; MYOGLOBIN; OXYGEN; DOMAIN; RECOMBINATION; INHIBITION; DIFFUSION; ISOFORMS	Nitric oxide (NO) traffic within the reduced ferrous-nitrosyl complex of endothelial nitric-oxide synthase (eNOS) has been studied by ultrafast time-resolved absorption spectroscopy. In the presence of tetrahydrobiopterin, the rate of NO rebinding to the heme upon photodissociation depends on the NO concentration. The time scale of this process, picoseconds to nanoseconds, precludes a diffusion from the solution toward the protein medium, and altogether the data point at a new NO binding site within the protein. Comparison of the kinetics of pterin-bound and -depleted eNOS points out that the existence of this new site depends on the presence of tetrahydrobiopterin. The new non-heme site may act as a "doorstep" to the heme pocket and control NO escape from eNOS.	Ecole Polytech, CNRS, UMR 7645, INSERM U451,Lab Opt & Biosci, F-91128 Palaiseau, France; UTHTMC, Sch Med, Div Hematol, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; University of Texas System; University of Texas Health Science Center Houston	Slama-Schwok, A (corresponding author), Ecole Polytech, CNRS, UMR 7645, INSERM U451,Lab Opt & Biosci, F-91128 Palaiseau, France.		Slama Schwok, Anny/AAD-8986-2019; Slama-Schwok, Anny/K-6826-2017; Negrerie, Michel/L-2283-2018	Slama Schwok, Anny/0000-0002-2703-9728; Negrerie, Michel/0000-0001-9918-031X; Lambry, Jean-Christophe/0000-0001-8264-0391; Vos, Marten/0000-0003-0493-4831	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; CARRERO J, 1995, BIOPHYS CHEM, V54, P143, DOI 10.1016/0301-4622(94)00133-5; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; MARDEN MC, 1982, EUR J BIOCHEM, V128, P399; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Perry JM, 2000, J BIOL CHEM, V275, P14070, DOI 10.1074/jbc.275.19.14070; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PRESS WH, 1988, NUMERICAL RECIPIES; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rusche KM, 2001, J BIOL CHEM, V276, P421, DOI 10.1074/jbc.M006860200; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Vos MH, 2001, BIOCHEMISTRY-US, V40, P7806, DOI 10.1021/bi010060x	30	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7581	7586		10.1074/jbc.M108657200	http://dx.doi.org/10.1074/jbc.M108657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11719512	hybrid			2022-12-25	WOS:000174104300105
J	Kessler, SP; Gomos, JB; Scheidemantel, TS; Rowe, TM; Smith, HL; Sen, GC				Kessler, SP; Gomos, JB; Scheidemantel, TS; Rowe, TM; Smith, HL; Sen, GC			The germinal isozyme of angiotensin-converting enzyme can substitute for the somatic isozyme in maintaining normal renal structure and functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PRESSURE; ACTIVE-SITE; EXPRESSION; GENE; CLEAVAGE; DOMAIN; MICE; SOLUBILIZATION; TRANSCRIPTION; FERTILITY	The angiotensin-converting enzyme (ACE) gene encodes two structurally related isozymes, somatic ACE and germinal ACE, that are uniquely expressed in discrete locations in the body. The importance of ACE in these cell types was revealed by generating Ace -/- mice, which exhibit multiple abnormalities including renal structural defects and functions, hypotension, and male sterility. To test the hypothesis that specific physiological functions of ACE are mediated by isozyme-specific and tissue-specific expression patterns, we have used a transgenic approach to develop mouse strains that express just one ACE isoform in the target tissue of Ace -/- mice. The mice described in this report produce germinal ACE in sperm and serum. These mice were as healthy as wild type mice, and the mates were fertile. Interestingly, they had normal kidney structure, fluid homeostasis, and partially restored urine concentration despite having low blood pressure. This result demonstrated that circulating germinal ACE is sufficient for maintaining normal kidney structure and fluid homeostasis but insufficient for restoring blood pressure to normal levels.	Cleveland Clin Fdn, Lerner Res Inst NC20, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; Chappell MC, 1998, HYPERTENSION, V31, P362, DOI 10.1161/01.HYP.31.1.362; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; Esther CR, 1996, LAB INVEST, V74, P953; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; HUBERT C, 1991, J BIOL CHEM, V266, P15377; Isaac RE, 1997, BIOCHEM J, V328, P587, DOI 10.1042/bj3280587; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; SEN GC, 1990, J CARDIOVASC PHARM, V16, pS14, DOI 10.1097/00005344-199016004-00005; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; Sigmund CD, 2001, AM J HYPERTENS, V14, p33S, DOI 10.1016/S0895-7061(01)02067-2; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STRITTMATTER SM, 1987, NEUROSCIENCE, V21, P407, DOI 10.1016/0306-4522(87)90131-X; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430	34	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4271	4276		10.1074/jbc.M109474200	http://dx.doi.org/10.1074/jbc.M109474200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723129	hybrid			2022-12-25	WOS:000173813900065
J	Breazeale, SD; Ribeiro, AA; Raetz, CRH				Breazeale, SD; Ribeiro, AA; Raetz, CRH			Oxidative decarboxylation of UDP-glucuronic acid in extracts of polymyxin-resistant Escherichia coli - Origin of lipid a species modified with 4-amino-4-deoxy-L-arabinose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; NMR-SPECTROSCOPY; C-13 ASSIGNMENTS; DEFICIENT MUTANT; B RESISTANCE; PMRA MUTANTS; A PRECURSORS; LIPOPOLYSACCHARIDE; GENE; BIOSYNTHESIS	Addition of the 4-amino-4-deoxy-L-arabinose (L-Ara4N) moiety to the phosphate groups of lipid A is implicated in bacterial resistance to polymyxin and cationic antimicrobial peptides of the innate immune system. The sequences of the products of the Salmonella typhimurium pmrE andpmrF loci, both of which are required for polymyxin resistance, recently led us to propose a pathway for L-Ara4N biosynthesis from UDP-glucuronic acid (Zhou, Z., Lin, S., Cotter, R. J., and Raetz, C. R. H. (1999) J. Biol. Chem. 274, 18503-18514). We now report that extracts of a polymyxin-resistant mutant of Escherichia coli catalyze the C-4" oxidation and C-6" decarboxylation of [alpha-P-32]UDP-glucuronic acid, followed by transamination to generate [alpha-P-32]UDP-L-Ara4N, when NAD and glutamate are added as co-substrates. In addition, the [alpha-(32)p]UDP-L-Ara4N is formylated when N-10-formyltetrahydrofolate is included. These activities are consistent with the proposed functions of two of the gene products (PmrI and PmrH) of the pmrF operon. PmrI (renamed ArnA) was overexpressed using a T7 construct, and shown by itself to catalyze the unprecedented oxidative decarboxylation of UDP-glucuronic acid to form uridine 5'-(beta-L-threo-pentapyranosyl-4"-ulose diphosphate). A 6-mg sample of the latter was purified, and its structure was validated by NMR studies as the hydrate of the 4" ketone. ArnA resembles UDP-galactose epimerase, dTDP-glucose-4,6-dehydratase, and UDP-xylose synthase in oxidizing the C-4" position of its substrate, but differs in that it releases the NADH product.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.				NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brade H., 1999, ENDOTOXIN HLTH DIS; Burtnick MN, 1999, ANTIMICROB AGENTS CH, V43, P2648, DOI 10.1128/AAC.43.11.2648; DINARELLO CA, 1991, BLOOD, V77, P1627; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GEBB C, 1975, EUR J BIOCHEM, V54, P493, DOI 10.1111/j.1432-1033.1975.tb04161.x; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hallis TM, 1998, BIOCHEMISTRY-US, V37, P4935, DOI 10.1021/bi9725529; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; Hegeman AD, 2001, BIOCHEMISTRY-US, V40, P6598, DOI 10.1021/bi010441a; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KYOSSEV ZN, 1995, EUR J BIOCHEM, V228, P109, DOI 10.1111/j.1432-1033.1995.0109o.x; LEBBAR S, 1994, J BIOL CHEM, V269, P31881; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Miller J.H., 1972, EXPT MOL GENETICS; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; Parrillo J E, 1993, N Engl J Med, V328, P1471; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; SCHUTZBA.JS, 1970, J BIOL CHEM, V245, P2476; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VANHALBEEK H, 1996, ENCY NMR, V2, P1107; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	61	88	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2886	2896		10.1074/jbc.M109377200	http://dx.doi.org/10.1074/jbc.M109377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706007	hybrid			2022-12-25	WOS:000173421500068
J	Godbout, JP; Pesavento, J; Hartman, ME; Manson, SR; Freund, GG				Godbout, JP; Pesavento, J; Hartman, ME; Manson, SR; Freund, GG			Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; DIABETES-MELLITUS; OXIDATIVE STRESS; BLADDER-CANCER; GLYOXALASE SYSTEM; CELL-DEATH; GLUTATHIONE; INHIBITION; CIS-DIAMMINEDICHLOROPLATINUM(II); PHOSPHORYLATION	The cytotoxic side effects of anti-neoplastic drugs are increased in patients with either type 1 or type 2 diabetes mellitus by a mechanism that is not clearly defined. We report that the circulating glucose metabolite, meth. ylglyoxal (MGO), enhances cisplatin-induced apoptosis by activating protein kinase Cdelta (PKCdelta). We found that treatment of myeloma cells with the antioxidant N-acetylcysteine completely blocked cisplatin-dependent intracellular GSH oxidation, reactive oxygen species (ROS) generation, poly(ADP-ribose) polymerase cleavage, and apoptosis. Importantly, co-treatment of cells with the reactive carbonyl MGO and cisplatin increased apoptosis by 90% over the expected additive effect of combined MGO and cisplatin treatment. This same synergism was also observed when ROS generation was examined. MGO and cisplatin increased PKCdelta activity by 4-fold, and this effect was blocked by the PKCdelta inhibitor rottlerin but not by NAC. Furthermore, rottlerin blocked combined MGO and cisplatin-induced ROS generation and apoptosis. Finally, MGO and cisplatin induced c-Abl activation and c-Abl:PKCdelta association. Rottlerin blocked c-Abl activation, but the c-Abl inhibitor STI-571 increased MGO and cisplatin-induced apoptosis by 50%,. Taken together these data indicate that MGO synergistically enhances cisplatin-induced apoptosis through activation of PKCdelta and that PKCdelta is critical to both cell death and cell survival pathways. These findings suggest that in the patient with diabetes mellitus heightened oxidative stress can enhance the cytotoxicity of agents that induce DNA damage.	Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Coll Med, Dept Pathol, 506 S Mathews Ave, Urbana, IL 61801 USA.	freun@uiuc.edu		Hartman, Matt/0000-0002-6238-1887; Pesavento, James/0000-0001-6107-3666	NCI NIH HHS [CA-61931] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA061931] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Buchdunger E, 1996, CANCER RES, V56, P100; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; CHU G, 1994, J BIOL CHEM, V269, P787; Domenicotti C, 2000, FREE RADICAL BIO MED, V29, P1280, DOI 10.1016/S0891-5849(00)00429-9; Godbout JP, 1999, CELL SIGNAL, V11, P15, DOI 10.1016/S0898-6568(98)00024-2; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Gogas H, 1996, GYNECOL ONCOL, V61, P22, DOI 10.1006/gyno.1996.0090; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Ha H, 1999, DIABETES RES CLIN PR, V45, P147, DOI 10.1016/S0168-8227(99)00044-3; Hartmann JT, 1999, DRUGS, V58, P257, DOI 10.2165/00003495-199958020-00004; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ikeda S, 1999, INT J UROL, V6, P245, DOI 10.1046/j.1442-2042.1999.00058.x; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; ISONISHI S, 1990, J BIOL CHEM, V265, P3623; Kapor-Drezgic J, 1999, J AM SOC NEPHROL, V10, P1193; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miyajima A, 1999, JPN J CANCER RES, V90, P565, DOI 10.1111/j.1349-7006.1999.tb00784.x; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; MOLLMAN JE, 1988, CANCER, V61, P2192, DOI 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OZOLS RF, 1991, SEMIN ONCOL, V18, P222; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Poulson J, 1997, J PAIN SYMPTOM MANAG, V13, P339, DOI 10.1016/S0885-3924(96)00326-0; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SheikhHamad D, 1997, J AM SOC NEPHROL, V8, P1640; SIFTIN DW, 2001, PHYSICIANS DESK REFE, P1055; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; STEWART DJ, 1987, J UROLOGY, V138, P302, DOI 10.1016/S0022-5347(17)43128-4; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; Thornalley PJ, 1996, CLIN SCI, V91, P575, DOI 10.1042/cs0910575; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Witjes JA, 1997, DRUGS, V53, P404, DOI 10.2165/00003495-199753030-00005; YOSHIDA K, 1995, DIABETOLOGIA, V38, P201, DOI 10.1007/s001250050271; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457	55	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2554	2561		10.1074/jbc.M100385200	http://dx.doi.org/10.1074/jbc.M100385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707430	hybrid			2022-12-25	WOS:000173421500025
J	Hepbildikler, ST; Sandhoff, R; Kolzer, M; Proia, RL; Sandhoff, K				Hepbildikler, ST; Sandhoff, R; Kolzer, M; Proia, RL; Sandhoff, K			Physiological substrates for human lysosomal beta-hexosaminidase S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM2 ACTIVATOR PROTEIN; ALPHA-SUBUNIT; ACID; GANGLIOSIDOSIS; IDENTIFICATION; STIMULATION; DEGRADATION; ENZYME; OLIGOSACCHARIDES; GLYCOSYLATION	Human lysosomal beta-hexosaminidases remove terminal beta-glycosidically bound N-acetylhexosamine residues from a number of glycoconjugates. Three different isozymes composed of two noncovalently linked sub-units alpha and beta exist: Hex A (alphabeta), Hex B (betabeta), and Hex S (alphaalpha). While the role of Hex A and B for the degradation of several anionic and neutral glycoconjugates has been well established, the physiological significance of labile Hex S has remained unclear. However, the striking accumulation of anionic oligosaccharides in double knockout mice totally deficient in hexosaminidase activity but not in mice expressing Hex S (Sango, K., McDonald, M. P., Crawley, J. N., Mack, M. L., Tifft, C.J., Skop, E., Starr, C. M., Hoffmann, A., Sandhoff, K., Suzuki, K., and Proia, R. L., (1996) Nat. Genet. 14, 348-352) prompted us to reinvestigate the substrate specificity of Hex S. To identify physiological substrates of Hex S, anionic and neutral oligosaccharides excreted in the urine of the double knockout mice were isolated and analyzed. Using ESI-MS/MS and glycosidase digestion the anionic glycans were identified as products of in. complete dermatan sulfate degradation whereas the neutral storage oligosaccharides were found to be fragments of N-glyean degradation. In vitro, recombinant Hex S was highly active on water-soluble and amphiphilic glycoconjugates including artificial substrates, sulfated GAG fragments, and the sulfated glycosphingolipid SM2. Hydrolysis of membrane-bound SM2 by the recombinant Hex S was synergistically stimulated by the GM2 activator protein and the lysosomal anionic phospholipid bis (monoacylglycero) phosphate.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Deutsch Krebsforschungszentrum Heidelberg, Abt Zellulare & Mol Pathol, D-69120 Heidelberg, Germany; NIDDK, Genet Dev & Dis Brnach, NIH, Bethesda, MD 20892 USA	University of Bonn; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sandhoff, K (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	sandhoff@uni-bonn.de	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER E, 1998, THESIS U BONN BONN G; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; GEIGER B, 1977, AM J HUM GENET, V29, P508; GEYER R, 1994, METHOD ENZYMOL, V230, P86; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; HOPWOOD JJ, 1985, BIOCHEM J, V229, P579, DOI 10.1042/bj2290579; HUBBES M, 1989, FEBS LETT, V249, P316, DOI 10.1016/0014-5793(89)80649-0; IKONNE JU, 1975, AM J HUM GENET, V27, P639; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; JENNEMANN R, 1994, J BIOCHEM-TOKYO, V116, P450, DOI 10.1093/oxfordjournals.jbchem.a124545; Klein A, 1998, CLIN CHEM, V44, P2422; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; KRESSE H, 1981, J BIOL CHEM, V256, P2926; KRESSE H, 1985, METHOD ENZYMOL, V83, P559; KUBUSHIRO K, 1992, CANCER RES, V52, P803; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; METZGER K, 1995, ANAL CHEM, V67, P4178, DOI 10.1021/ac00118a022; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; ODOWD BF, 1988, BIOCHEMISTRY-US, V27, P5216, DOI 10.1021/bi00414a041; Petroulakis E, 1998, HUM MUTAT, V11, P432, DOI 10.1002/(SICI)1098-1004(1998)11:6<432::AID-HUMU3>3.3.CO;2-Q; PROIA RL, 1984, J BIOL CHEM, V259, P3350; SAGHERIAN C, 1993, BIOCHEM CELL BIOL, V71, P340, DOI 10.1139/o93-051; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Schuette CG, 2001, GLYCOBIOLOGY, V11, P549, DOI 10.1093/glycob/11.7.549; Schutte CG, 1998, PROTEIN SCI, V7, P1039; STRECKER G, 1977, EUR J BIOCHEM, V81, P165, DOI 10.1111/j.1432-1033.1977.tb11937.x; Suzuki K, 1997, J NEUROPATH EXP NEUR, V56, P693; Towbin H, 1992, Biotechnology, V24, P145; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Werth N, 2001, J BIOL CHEM, V276, P12685, DOI 10.1074/jbc.M007970200; Wilkening G, 2000, J BIOL CHEM, V275, P35814, DOI 10.1074/jbc.M006568200; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Zaia J, 2001, ANAL CHEM, V73, P233, DOI 10.1021/ac000777a	46	62	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2562	2572		10.1074/jbc.M105457200	http://dx.doi.org/10.1074/jbc.M105457200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707436	hybrid			2022-12-25	WOS:000173421500026
J	Hwang, SG; Lee, DY; Kim, JY; Seo, TG; Choe, JH				Hwang, SG; Lee, DY; Kim, JY; Seo, TG; Choe, JH			Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; VIRAL LIFE-CYCLE; GENE-PRODUCT; CELL-CYCLE; FAMILY PROTEINS; NUCLEAR-LOCALIZATION; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; TRANS-ACTIVATION	The human papillomavirus (HPV) E7 oncoprotein can immortalize primary human cells and induce tumor formation. These properties of E7 depend on its ability to inhibit the activity of retinoblastoma protein (pRB), which in turn affects E2F function. E2F proteins control the expression of genes involved in differentiation, development, cell proliferation, and apoptosis. By using genetic and biochemical approaches, the present study shows that E7 binds to E2F1 in vivo and in vitro and that both proteins co-localize in the nucleus. Importantly, the binding of the high risk group HPV E7 to E2F1 is tighter than the binding of the low risk group HPV E7 to E2F1. Although E7 of the high risk group HPVs activates E2F1-dependent transcription strongly in C33A or 293T cells, E7 of the low risk group HPVs activates transcription only weakly. By using electrophoretic mobility shift assay, we also showed that E7 binds to E2F1-DNA complexes. Furthermore, we show that these activities of E7 are independent of pRB by using E7 and E2F1 mutants that cannot bind to pRB. Taken together, these data suggest that E7 contributes to the deregulation of pRB-dependent E2F1 repression and to the further activation of E2F1 independently of pRB.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, JH (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011	Lee, Daeyoup/0000-0003-2006-1823; 				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Armstrong DJ, 1997, VIROLOGY, V239, P238, DOI 10.1006/viro.1997.8885; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CICCOLINI F, 1994, ONCOGENE, V9, P2633; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; deVilliers EM, 1997, CLIN DERMATOL, V15, P199, DOI 10.1016/S0738-081X(96)00164-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; GIRLING R, 1993, BIOCHEM SOC T, V21, P939, DOI 10.1042/bst0210939; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Magae J, 1996, J CELL SCI, V109, P1717; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	71	96	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2923	2930		10.1074/jbc.M109113200	http://dx.doi.org/10.1074/jbc.M109113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713253	hybrid			2022-12-25	WOS:000173421500072
J	Pavlaki, M; Cao, J; Hymowitz, M; Chen, WT; Bahou, W; Zucker, S				Pavlaki, M; Cao, J; Hymowitz, M; Chen, WT; Bahou, W; Zucker, S			A conserved sequence within the propeptide domain of membrane type I matrix metalloproteinase is critical for function as an intramolecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; 1-MATRIX METALLOPROTEINASE; GELATINASE-A; CATALYTIC DOMAIN; CELL-MIGRATION; PRO-GELATINASE; ACTIVATION; SITE; PROGELATINASE; SURFACE	The propeptide domain of secreted matrix metalloproteinases (MMPs) is responsible for maintaining the latency of these proteinases. Recently, the propeptide domain of the prototype membrane type matrix metalloproteinase (MT1-MMP) was demonstrated to act as an intramolecular chaperone (Cao, J., Hymowitz, M., Conner, C., Bahou, W. F., and Zucker, S. (2000) J. Biol. Chem. 275, 29648 -29653). In the current study, the role of an unique four-amino acid sequence in the propeptide domain of MT1-MMP was examined. The sequence (42)YGYL(45) is conserved in the propeptide domain of all six members of the MT-MMP subfamily, but not in secreted MMPs. Mutant MT1-MMP cDNAs coding for alanine substitutions (single and double amino acid sequences) in this conserved propeptide region were transfected into COS-1 cells deficient in endogenous MT1-MMP. As demonstrated by immunofluoreseence, mutant MT1-MMP protein was synthesized and displayed on the plasma membrane of transfected cells. Alanine substitutions within the (42)YGYL(45) sequence proved to be detrimental for enzyme function in terms of activation of proMMP-2 and binding TIMP-2 to the cell surface (MT1-MMP serves as a cell surface receptor for TIMP-2). In contrast to wild-type MT1-MMP-transfected cells, mutant MT1-AMP-transfected cells were incapable of degrading and migrating on a fibronectin substrate. These data indicate that the conserved (42)YGYL(45) sequence within the propeptide domain of MT-MMPs is required for intramolecular chaperone function of these intrinsic membrane proteinases.	Dept Vet Affairs Med Ctr, Northport, NY 11768 USA; SUNY Stony Brook, Sch Med, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), VA Med Ctr, Mail Code 151, Northport, NY 11768 USA.	s_zucker@yahoo.com						Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Cigic B, 2000, BIOCHEMISTRY-US, V39, P12382, DOI 10.1021/bi0008837; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; DMITRY V, 2001, J BIOL CHEM, V276, P25705; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FREIMARK BD, 1994, J BIOL CHEM, V269, P26982; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, J NEUROSURG, V94, P464, DOI 10.3171/jns.2001.94.3.0464; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; PARK AJ, 1991, J BIOL CHEM, V266, P1584; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stanton H, 1998, J CELL SCI, V111, P2789; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; Wiederanders B, 2000, ADV EXP MED BIOL, V477, P261; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	50	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2740	2749		10.1074/jbc.M108987200	http://dx.doi.org/10.1074/jbc.M108987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11704671	hybrid			2022-12-25	WOS:000173421500049
J	Paz, A; Haklai, R; Elad-Sfadia, G; Ballan, E; Kloog, Y				Paz, A; Haklai, R; Elad-Sfadia, G; Ballan, E; Kloog, Y			Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation	ONCOGENE			English	Article						galectin-1; oncogenic Ras; cell transformation; Ras localization	GROWTH-FACTOR; SELECTIVE-INHIBITION; CAVEOLAE MEMBRANE; PROTEIN; APOPTOSIS; EXPRESSION; ADHESION; LOCALIZATION; ACTIVATION; RECEPTOR	Ras genes, frequently mutated in human tumors, promote malignant transformation. Ras transformation requires membrane anchorage, which is promoted by Ras farnesylcysteine carboxymethylester and by a second signal. Previously we showed that the farnesylcysteine mimetic, farnesylthiosaticylic acid (FTS) disrupts Ras membrane anchorage. To understand how this disruption contributes to inhibition of cell transformation we searched, for new Ras-interacting proteins and identified galectin-1, a lectin implicated in human tumors, as a selective binding partner of oncogenic H-Ras(12V). The observed size of H-Ras(12V)-galectin-1 complex, which is equal to the sum of the molecular weights of Ras and galectin-1 indicates a direct binding interaction between the two proteins. FTS disrupted H-Ras(12V)-galectin-1 interactions. Overexpression of galectin-1 increased membrane-associated Ras, Ras-GTP, and active ERK resulting in cell transformation, which was blocked by dominant negative Ras. Galectin-1 antisense RNA inhibited transformation by H-Ras(12V) and abolished membrane anchorage of green fluorescent protein (GFP)-H-Ras(12V) but not of GFP-H-Ras wild-type (wt), GFP-K-Ras(12V), or GFP-N-Ras(13V). H-Ras(12V)galectin-1 interactions establish an essential link between two proteins associated with cell transformation and human malignancies that can be exploited to selectively target oncogenic Ras proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il						Allione A, 1998, J IMMUNOL, V161, P2114; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bresalier RS, 1997, CANCER, V80, P776; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Hadari YR, 2000, J CELL SCI, V113, P2385; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Kloog, 1999, Expert Opin Investig Drugs, V8, P2121, DOI 10.1517/13543784.8.12.2121; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; Vespa GNR, 1999, J IMMUNOL, V162, P799; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yamaoka K, 1996, J BIOCHEM-TOKYO, V119, P878; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H	46	320	332	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7486	7493		10.1038/sj.onc.1204950	http://dx.doi.org/10.1038/sj.onc.1204950			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709720				2022-12-25	WOS:000171976900005
J	Abounader, R; Lal, B; Luddy, C; Koe, G; Davidson, B; Rosen, EM; Laterra, J				Abounader, R; Lal, B; Luddy, C; Koe, G; Davidson, B; Rosen, EM; Laterra, J			In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis	FASEB JOURNAL			English	Article						glioma; scatter factor; hepatocyte growth factor; c-met; U1snRNA/ribozyme	FACTOR SCATTER FACTOR; HUMAN GLIOBLASTOMA; IN-VIVO; FACTOR PROTECTS; FACTOR HGF/SF; HEPATOCYTE; RECEPTOR; CELLS; METASTASIS; RECURRENCE	The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c-met have been implicated in the genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, including gliomas. We examined the antitumor effects of targeting SF/HGF and c-met expression in pre-established glioma xenografts by using novel chimeric U1snRNA/ribozymes. Transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes inhibited SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and anchorage-independent colony formation in vitro. Delivery of U1snRNA/ribozymes to established subcutaneous glioma xenografts via liposome-DNA complexes significantly inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histologic analysis of tumors treated with U1snRNA/ribozymes showed a significant decrease in blood vessel density, an increase in activation of the pro-apoptotic enzyme caspase-3, and an increase in tumor cell apoptosis. Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the transgenes or intravenous injections of U1snRNA/ribozyme-liposome complexes substantially inhibited tumor growth and promoted animal survival. We demonstrate that SF/HGF and/ or c-met expression can be targeted in vivo to inhibit tumor growth. In addition, our findings represent the first in vivo application of chimeric U1snRNA/ribozymes, which have numerous potential therapeutic gene-targeting applications.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Valentis Inc, Burlingame, CA USA; Univ Iowa, Coll Med, Iowa City, IA USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Iowa; Northwell Health; Yeshiva University	Laterra, J (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.	laterra@kennedykrieger.org						Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Beckley SA, 2001, MOL CELL BIOL, V21, P2815, DOI 10.1128/MCB.21.8.2815-2825.2001; Bowers DC, 2000, CANCER RES, V60, P4277; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Dow SW, 1999, J IMMUNOL, V163, P1552; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Koochekpour S, 1997, CANCER RES, V57, P5391; Krieg AM, 1999, BBA-GENE STRUCT EXPR, V1489, P107, DOI 10.1016/S0167-4781(99)00147-5; Kuba K, 2000, CANCER RES, V60, P6737; Lamszus K, 1998, INT J CANCER, V75, P19, DOI 10.1002/(SICI)1097-0215(19980105)75:1<19::AID-IJC4>3.0.CO;2-4; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Laterra J, 1997, LAB INVEST, V76, P565; Liu RT, 2000, J BIOL CHEM, V275, P8711, DOI 10.1074/jbc.275.12.8711; Montevecchi PC, 1997, RRD ORG BIOORG CHEM, V1, P1; Moriyama T, 1998, CANCER LETT, V124, P149, DOI 10.1016/S0304-3835(97)00469-2; Ramirez R, 2000, CLIN ENDOCRINOL, V53, P635, DOI 10.1046/j.1365-2265.2000.01124.x; Rosen E M, 1997, EXS, V79, P193; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149; Wallenius V, 2000, AM J PATHOL, V156, P821, DOI 10.1016/S0002-9440(10)64950-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; YAMASHITA J, 1994, CANCER RES, V54, P1630; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	33	148	170	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					108	+		10.1096/fj.01-0421fje	http://dx.doi.org/10.1096/fj.01-0421fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729097				2022-12-25	WOS:000172420500025
J	Cheng, GJ; Meinkoth, JL				Cheng, GJ; Meinkoth, JL			Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells	ONCOGENE			English	Article						Ras; Rap1A; thyroid; apoptosis	PROTEIN-KINASE-A; EPITHELIAL-CELLS; MUTANT RAS; EXPRESSION; ONCOGENE; PROLIFERATION; GENE; DIFFERENTIATION; ACTIVATION; PATHWAYS	Ras. mutations, occur at high frequency in thyroid cancer. In vitro, the effects of Ras in thyroid cells are pleiotropic in that expression of activated Ras has been reported to, stimulate proliferation and apoptosis. An understanding of the factors that contribute to the survival versus demise of Ras-transformed cells is essential to our understanding, of the contribution of Ras to thyroid neoplasia and other cancers. Constitutive expression of oncogenic H-Ras sensitized Wistar rat thyroid (WRT) cells to apoptosis stimulated by multiple insults. When deprived of matrix attachment, Ras-transformed cells perished by apoptotic cell death at a high frequency. In contrast, parental cells were more resistant to suspension-induced cell death. Ras effects on anchorage-independent cell death were reproduced by a mutant protein that signals selectively to Raf-1, but not by mutant Ras that preferentially binds, to RalGDS. Expression of a Ras mutant that selectively activates PI3K resulted in substantial protection from detachment-induced cell death., MAPK activity was increased in, adherent Ras12V- and Rasl2V35S-expressing cells, but abolished upon detachment. Interestingly, impaired MAPK activity was sufficient to stimulate apoptosis in adherent Ras-transformed cells, but not in parental cells. Treatment with a PI3-K inhibitor also stimulated apoptosis, selectively in Ras-transformed cells. These results, demonstrate that constitutive expression of activated Ras elicits differential effects on the survival of thyroid cells., Moreover, Ras, expression results in a greater dependence of thyroid cells on MAPK and PI3K activity for their survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P1188, DOI 10.1210/jc.85.3.1188; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; JESO BD, 1995, BIOCHEM BIOPH RES CO, V214, P819; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; Lin TH, 1997, J BIOL CHEM, V272, P8849; MALY FE, 1994, J BIOL CHEM, V269, P18743; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	37	19	19	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7334	7341		10.1038/sj.onc.1204928	http://dx.doi.org/10.1038/sj.onc.1204928			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704863				2022-12-25	WOS:000171894200006
J	Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B				Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B			Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells	ONCOGENE			English	Article						CK2; p53; spindle checkpoint; apoptosis	DNA-DAMAGE; P53 PROTEIN; NEUROBLASTOMA-CELLS; SUPPRESSOR PROTEIN; MOUSE FIBROBLASTS; CYCLE CHECKPOINT; G(2) CHECKPOINT; GAMMA-RADIATION; II SITE; PHOSPHORYLATION	p53 undergoes phosphorylation on several residues in response to cellular stresses that include UV and ionizing radiation, however the influence of spindle damage on this parameter is relatively unclear. Consequently, the effect of nocodazole on serine 392 phosphorylation was examined in two epithelial cell lines. We show that this process is dependent upon the stepwise activation of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase casein kinase 2 (CK2). Furthermore, this activation correlated with the biochemical regulation of the maturation-promoting factor (MPF, cdc2/cyclin B), as both DRB and antisense depletion of CK2, as well as SB203580 were associated with an inhibition of its activation in response to nocodazole. Strikingly, when the cell cycle characteristics of nocodazole treated cells were examined, we observed that depletion or inhibition of the catalytic subunit of CK2, in the presence of microtubule inhibitors, resulted in a compromise of the G2 arrest (spindle checkpoint). Furthermore, CK2-depleted, nocodazole treated cells demonstrated a dramatic reduction in the apoptotic cell fraction, confirming that these cells had been endowed with oncogenic properties. These changes were observed in both HeLa cells and HCT116 cells. We also show that this effect is dependent on the presence of functional wild-type p53, as this phenomenon is not apparent in HCT116 p53 /(-) cells. Collectively, our results indicate two novel roles for CK2 in the spindle checkpoint arrest, in concert with p53. Firstly, to maintain increased cyclinB/cdc2 kinase activity, as a component of G2 arrest, and secondly, a role in p53-mediated apoptosis. These findings may have implications for an improved understanding of abnormalities of the spindle checkpoint in human cancers, which is a prerequisite for defining future therapies.	Univ British Columbia, Jack Bell Res Ctr, Dept Expt Med, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of British Columbia; University of British Columbia; Memorial Sloan Kettering Cancer Center	Salh, B (corresponding author), Univ British Columbia, Dept Med, 100-2647 Willow St, Vancouver, BC V5Z 3P1, Canada.			Pelech, Steven/0000-0003-1112-903X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prives C, 1999, J PATHOL, V187, P112; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHICH SY, 1997, CELL, V91, P325; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULLOA L, 1994, CELL MOL NEUROBIOL, V14, P407, DOI 10.1007/BF02088827; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	62	53	57	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6994	7005		10.1038/sj.onc.1204894	http://dx.doi.org/10.1038/sj.onc.1204894			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704824				2022-12-25	WOS:000171739300003
J	Su, HP; Nakada-Tsukui, K; Tosello-Trampont, AC; Li, Y; Bu, G; Henson, PM; Ravichandran, KS				Su, HP; Nakada-Tsukui, K; Tosello-Trampont, AC; Li, Y; Bu, G; Henson, PM; Ravichandran, KS			Interaction of CED-6/GULP, an adapter protein involved in engulfment of apoptotic cells with CED-1 and CD91/low density lipoprotein receptor-related protein (LRP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; NECROTIC TUMOR-CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; HUMAN MACROPHAGES; TYROSINE KINASES; GENETIC-CONTROL; DEATH; PHAGOCYTOSIS; CLEARANCE	The prompt clearance of cells undergoing apoptosis is critical during embryonic development, normal tissue turnover, as well as inflammation and autoimmunity. The molecular details of the engulfment of apoptotic cells are not fully understood. ced-6 and its human homologue gulp, encode an adapter protein, whose function in engulfment is highly evolutionarily conserved; however, the upstream and downstream components of CED-6 mediated signaling are not known. Recently, ced-1 has been shown to encode a transmembrane protein on phagocytic cells, with two functional sequence motifs in its cytoplasmic tail that are important for engulfment. In this study, using a combination of biochemical approaches and yeast two-hybrid analysis, we present evidence for a physical interaction between GULP/CED-6 and one of the two motifs (NPXY motif) in the cytoplasmic tail of CED-1. The phosphotyrosine binding domain of GULP was necessary and sufficient for this interaction. Since the precise mammalian homologue of CED-1 is not known, we undertook a database search for human proteins that contain the motifs shown to be important for CED-1 function and identified CD91/LRP (low density lipoprotein receptor-related protein) as one candidate. Interestingly, recent studies have also identified CD91/LRP as a receptor involved in the phagocytosis of apoptotic cells in mammals. The GULP phosphotyrosine binding domain was able to specifically interact with one specific NPXY motif in the CD91 cytoplasmic tail. During these studies we have also identified the mouse GULP sequence. These studies suggest a physical link between CED-1 or CD91/LRP and the adapter protein CED-6/GULP during engulfment of apoptotic cells and further elucidate the pathway suggested by the genetic studies.	Univ Virginia, Berine Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Virginia; University of Virginia; Washington University (WUSTL); National Jewish Health	Ravichandran, KS (corresponding author), Univ Virginia, Berine Carter Ctr Immunol Res, Bldg MR4,RM4012F, Charlottesville, VA 22908 USA.	kr4h@virginia.edu		Su, Hua-Poo/0000-0003-3808-7837				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076; BUCHER P, 1994, ISMB, V2, P53; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Horvitz HR, 1999, CANCER RES, V59, p1701S; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hubbard T, 2000, NATURE, V403, P825, DOI 10.1038/35002770; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reiter I, 1999, J IMMUNOL, V163, P1730; Ren Y, 2001, J IMMUNOL, V166, P4743, DOI 10.4049/jimmunol.166.7.4743; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	47	191	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11772	11779		10.1074/jbc.M109336200	http://dx.doi.org/10.1074/jbc.M109336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11729193	hybrid			2022-12-25	WOS:000174846400023
J	Uchiumi, T; Honma, S; Nomura, T; Dabbs, ER; Hachimori, A				Uchiumi, T; Honma, S; Nomura, T; Dabbs, ER; Hachimori, A			Translation elongation by a hybrid ribosome in which proteins at the GTPase center of the Escherichia coli ribosome are replaced with rat counterparts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-G; CROSS-LINKING; ANGSTROM-RESOLUTION; RNA AUTOANTIBODY; LIVER RIBOSOME; SUBUNIT; BINDING; DOMAIN; HYDROLYSIS; MOVEMENT	Ribosomal L10.L7/L12 protein complex and L11 bind to a highly conserved RNA region around position 1070 in domain H of 23 S rRNA and constitute a part of the GTPase-associated center in Escherichia coli ribosomes. We replaced these ribosomal proteins in vitro with the rat counterparts P0.P1/P2 complex and RL12, and tested them for ribosomal activities. The core 50 S subunit lacking the proteins on the 1070 RNA domain was prepared under gentle conditions from a mutant deficient in ribosomal protein L11. The rat proteins bound to the core 50 S subunit through their interactions with the 1070 RNA domain. The resultant hybrid ribosome was insensitive to thiostrepton and showed poly(U)-programmed polyphenylalanine synthesis dependent on the actions of both eukaryotic elongation factors 1alpha (eEF-1alpha) and 2 (eEF-2) but not of the prokaryotic equivalent factors EF-Tu and EF-G. The results from replacement of either the L10.L7/L12 complex or L11 with rat protein showed that the P0.P1/P2 complex, and not RL12, was responsible for the specificity of the eukaryotic ribosomes to eukaryotic elongation factors and for the accompanying GTPase activity. The presence of either E. coli L11 or rat RL12 considerably stimulated the polyphenylalanine synthesis by the hybrid ribosome, suggesting that L11/RL12 proteins play an important role in post-GTPase events of translation elongation.	Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan; Univ Witwatersrand, Sch Mol & Cell Biol, ZA-2050 Wits, South Africa	Shinshu University; University of Witwatersrand	Uchiumi, T (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan.							Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P283, DOI 10.1093/oxfordjournals.jbchem.a130570; Ballesta JPG, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P115; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Briones E, 1998, J BIOL CHEM, V273, P31956, DOI 10.1074/jbc.273.48.31956; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; DABBS ER, 1979, J BACTERIOL, V140, P734, DOI 10.1128/JB.140.2.734-737.1979; Dube P, 1998, STRUCTURE, V6, P389, DOI 10.1016/S0969-2126(98)00040-9; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; Gonzalo P, 2001, J BIOL CHEM, V276, P19762, DOI 10.1074/jbc.M101398200; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; HAMEL E, 1972, J BIOL CHEM, V247, P805; Iwasaki K, 1979, Methods Enzymol, V60, P657; KAZIRO Y, 1972, J BIOCHEM, V72, P853, DOI 10.1093/oxfordjournals.jbchem.a129980; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1986, STRUCTURE FUNCTION G, P309; Montesano-Roditis L, 2001, J BIOL CHEM, V276, P14117, DOI 10.1074/jbc.M008430200; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; NATHANS D, 1961, P NATL ACAD SCI USA, V47, P497, DOI 10.1073/pnas.47.4.497; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PARISI B, 1967, J MOL BIOL, V28, P295, DOI 10.1016/S0022-2836(67)80011-1; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; RANDI R, 1962, J BIOL CHEM, V237, P3707; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; SATO T, 1990, BIOCHEM BIOPH RES CO, V172, P1681; Savelsbergh A, 2000, J BIOL CHEM, V275, P890, DOI 10.1074/jbc.275.2.890; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK MJR, 1980, MOL GEN GENET, V180, P11, DOI 10.1007/BF00267346; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; VANAGTHOVEN AJ, 1977, BIOCHEM BIOPH RES CO, V77, P989, DOI 10.1016/S0006-291X(77)80075-2; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Zhang SY, 2001, J BACTERIOL, V183, P2316, DOI 10.1128/JB.183.7.2316-2321.2001	54	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3857	3862		10.1074/jbc.M107730200	http://dx.doi.org/10.1074/jbc.M107730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729183	hybrid			2022-12-25	WOS:000173813900010
J	Arimondo, PB; Boutorine, A; Baldeyrou, B; Bailly, C; Kuwahara, M; Hecht, SM; Sun, JS; Garestier, T; Helene, C				Arimondo, PB; Boutorine, A; Baldeyrou, B; Bailly, C; Kuwahara, M; Hecht, SM; Sun, JS; Garestier, T; Helene, C			Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; STABILIZATION; REBECCAMYCIN; COMPLEXES; DRUGS	To achieve a sequence-specific DNA cleavage by topoisomerase 1, derivatives of the antitumor drug camptothecin have been covalently linked to triple helix-forming oligonucleotides that bind in a sequence-specific manner to the major groove of double-helical DNA. Triplex formation at the target sequence positions the drug selectively at the triplex site, thereby stimulating topoisomerase I-mediated DNA cleavage at this site. In a continuous effort to optimize this strategy, a broad set of conjugates consisting of (i) 16-20-base-long oligonucleotides, (ii) alkyl linkers of variable length, and (iii) camptothecin derivatives substituted on the A or B quinoline ring were designed and synthesized. Analysis of the cleavage sites at nucleotide resolution reveals that the specificity and efficacy of cleavage depends markedly on the length of both the triple-helical structure and the linker between the oligonucleotide and the poison. The optimized hybrid molecules induced strong and highly specific cleavage at a site adjacent to the triplex. Furthermore, the drug-stabilized DNA-topoisomerase I cleavage complexes were shown to be more resistant to salt-induced reversal than the complexes induced by camptothecin alone. Such rationally designed camptothecin conjugates could provide useful antitumor drugs directed selectively against genes bearing the targeted triplex binding site. In addition, they represent a powerful tool to probe the molecular interactions in the DNA-topoisomerase I complex.	Museo Nacl Hist Nat, Biophys Lab, UMR 8646 CNRS, INSERM U201, F-75231 Paris 05, France; Inst Rech Canc Lille, Ctr Oscar Lambret, INSERM U524, F-59045 Lille, France; Inst Rech Canc Lille, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Oscar Lambret; UNICANCER; Centre Oscar Lambret; University of Virginia	Arimondo, PB (corresponding author), Museo Nacl Hist Nat, Biophys Lab, UMR 8646 CNRS, INSERM U201, 43 Rue Cuvier, F-75231 Paris 05, France.		Boutorine, Alexandre/C-2577-2017; Arimondo, Paola B/R-9095-2017; BAILLY, Christian/AAK-2799-2021	Boutorine, Alexandre/0000-0003-4931-9250; Arimondo, Paola B/0000-0001-5175-4396; BAILLY, Christian/0000-0002-2973-9357	NCI NIH HHS [CA78415] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078415] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arimondo PB, 1999, CR ACAD SCI III-VIE, V322, P785, DOI 10.1016/S0764-4469(00)80037-2; Arimondo PB, 2001, ANGEW CHEM INT EDIT, V40, P3045, DOI 10.1002/1521-3773(20010817)40:16<3045::AID-ANIE3045>3.0.CO;2-A; Arimondo PB, 2001, BIOCONJUGATE CHEM, V12, P501, DOI 10.1021/bc000162k; Arimondo PB, 2000, BIOORGAN MED CHEM, V8, P777, DOI 10.1016/S0968-0896(00)00012-2; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; Grimm GN, 2000, NUCLEOS NUCLEOT NUCL, V19, P1943, DOI 10.1080/15257770008045470; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kehrer DFS, 2001, ANTI-CANCER DRUG, V12, P89, DOI 10.1097/00001813-200102000-00002; Kerrigan JE, 2001, BIOCHEMISTRY-US, V40, P9792, DOI 10.1021/bi010913l; Marchand C, 1996, BIOCHEMISTRY-US, V35, P5022, DOI 10.1021/bi952908l; Matteucci M, 1997, J AM CHEM SOC, V119, P6939, DOI 10.1021/ja9702475; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SAWADA S, 1991, CHEM PHARM BULL, V39, P2574; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Wang CCC, 2001, J AM CHEM SOC, V123, P8657, DOI 10.1021/ja010392p; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	22	48	52	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3132	3140		10.1074/jbc.M110181200	http://dx.doi.org/10.1074/jbc.M110181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724801	hybrid			2022-12-25	WOS:000173688000012
J	Moreira, JMA; Horz, W; Holmberg, S				Moreira, JMA; Horz, W; Holmberg, S			Neither Reb1p nor Poly(dA-dT) elements are responsible for the highly specific chromatin organization at the ILV1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ACTIVATES TRANSCRIPTION; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; YEAST PROMOTER; NUCLEOSOME; SITE; GENE; SEQUENCE; POLY(DA).POLY(DT)	Analysis of the chromatin structure at the yeast ILV1 locus revealed highly positioned nucleosomes covering the entire locus except for a hypersensitive site in the promoter region. All previously identified cis-acting elements required for GCN4-independent ILV1 basal level transcription, including a binding site for the REB1 protein (Reb1p), and a poly(dA.dT) element (26 As out of 32 nucleotides) situated 15 base pairs downstream of the Reb1p-binding site, reside within this hypersensitive site. The existence of a second A.T-rich element (25 As out of 33 nucleotides) present six base pairs upstream of the Reb1p-binding site, suggested that nucleosome exclusion from the hypersensitive site in the ILV1 promoter region might be dictated by synergistic action of the two poly(dA.dT) elements. Replacing one or both of them had, however, no effect on the chromatin structure of the ILV1 promoter, although drastically reduced basal transcription. Similarly, deletion of the Reb1p-binding site, albeit affecting ILV1 expression, had no detectable effect on chromatin at the ILV1 promoter. The absence of a good correlation between effects of these elements on gene activity and on chromatin structure at the ILV1 promoter indicates that the chromatin organization present at the ILV1 promoter is independent of the known regulatory elements and most likely dictated directly by the DNA sequence.	Univ Copenhagen, Inst Mol Biol, Dept Genet, DK-1353 Copenhagen K, Denmark; Univ Munich, Inst Physiol Chem, D-80334 Munich, Germany	University of Copenhagen; University of Munich	Holmberg, S (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Genet, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Holmberg, Steen/N-1128-2014	Holmberg, Steen/0000-0002-0262-3207; Moreira, Jose/0000-0002-9944-1214				ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BRANDL CJ, 1992, J BIOL CHEM, V267, P20943; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; GRAHAM IR, 1994, MOL MICROBIOL, V12, P931, DOI 10.1111/j.1365-2958.1994.tb01081.x; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HERRERA JE, 1989, BIOCHEMISTRY-US, V28, P1993, DOI 10.1021/bi00431a006; HOLMBERG S, 1988, CURR GENET, V13, P207, DOI 10.1007/BF00387766; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Moreira JMA, 1998, MOL GEN GENET, V258, P95, DOI 10.1007/s004380050711; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; PUHL HL, 1995, J MOL BIOL, V245, P559, DOI 10.1006/jmbi.1994.0046; PUHL HL, 1991, J MOL BIOL, V222, P1149, DOI 10.1016/0022-2836(91)90598-Z; Reagan MS, 1998, MOL GEN GENET, V259, P142, DOI 10.1007/s004380050799; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; RHODES D, 1979, NUCLEIC ACIDS RES, V6, P1805, DOI 10.1093/nar/6.5.1805; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen CH, 2001, J BIOL CHEM, V276, P35209, DOI 10.1074/jbc.M104733200; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; SVAREN J, 1995, MICROBIAL GENE TECHN; THIRYBLAISE LM, 1990, MOL GEN GENET, V223, P474, DOI 10.1007/BF00264456; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WELLS R D, 1970, Journal of Molecular Biology, V54, P465, DOI 10.1016/0022-2836(70)90121-X; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5	42	11	11	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3202	3209		10.1074/jbc.M108962200	http://dx.doi.org/10.1074/jbc.M108962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11706001	hybrid			2022-12-25	WOS:000173688000020
J	Jensen, PE; Rosgaard, L; Knoetzel, J; Scheller, HV				Jensen, PE; Rosgaard, L; Knoetzel, J; Scheller, HV			Photosystem I activity is increased in the absence of the PSI-G subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HARVESTING COMPLEX-I; HORDEUM-VULGARE L.; ARABIDOPSIS-THALIANA; STATE TRANSITIONS; K SUBUNIT; BARLEY; PROTEINS; IDENTIFICATION; MUTANTS; RECONSTITUTION	PSI-G is a subunit of photosystem I in eukaryotes. The function of PSI-G was characterized in Arabidopsis plants transformed with a psaG cDNA in antisense orientation. Several plants with significantly decreased PSI-G protein content were identified. Plants with reduced PSI-G content were indistinguishable from wild type when grown under optimal conditions, despite a 40% reduction of photosystem 1. This decrease of photosystem I was correlated with a similar reduction in state transitions. Surprisingly, the reduced photosystem I content was compensated for by a more effective photosystem I because the light-dependent reduction of NADP(+) in vitro was 48% higher. Photosystem I antenna size determined from flash-induced P700 absorption changes did not reveal any significant effect on the size of the photosystem I antenna in the absence of PSI-G, whereas a 17% reduction was seen in the absence of PSI-K. However, nondenaturing green gels revealed that the interaction between photosystem I and the light-harvesting complex I was less stable in the absence of PSI-G. Thus, PSI-G plays a role in stabilizing the binding of the peripheral antenna. The increased activity in the absence of PSI-G suggests that PSI-G could have an important role in regulation of photosystem I.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	peje@kvl.dk	Jensen, Poul Erik/A-4862-2014; Scheller, Henrik V/A-8106-2008; Scheller, Henrik/AAH-4770-2020	Jensen, Poul Erik/0000-0001-6524-7723; Scheller, Henrik V/0000-0002-6702-3560; Scheller, Henrik/0000-0002-6702-3560				BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; KNOETZEL J, 1991, PLANTA, V185, P111, DOI 10.1007/BF00194522; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; Knoetzel J, 1998, FEBS LETT, V436, P339, DOI 10.1016/S0014-5793(98)01158-2; LAM E, 1984, FEBS LETT, V168, P10, DOI 10.1016/0014-5793(84)80197-0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Nielsen VS, 1996, PHYSIOL PLANTARUM, V98, P637, DOI 10.1111/j.1399-3054.1996.tb05721.x; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Ort DR, 2001, PLANT PHYSIOL, V125, P29, DOI 10.1104/pp.125.1.29; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	34	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2798	2803		10.1074/jbc.M110448200	http://dx.doi.org/10.1074/jbc.M110448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707465	hybrid			2022-12-25	WOS:000173421500057
J	Ostrovsky, O; Berman, B; Gallagher, J; Mulloy, B; Fernig, DG; Delehedde, M; Ron, D				Ostrovsky, O; Berman, B; Gallagher, J; Mulloy, B; Fernig, DG; Delehedde, M; Ron, D			Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL REQUIREMENTS; SULFATE PROTEOGLYCAN; BIOLOGICAL-ACTIVITY; LIGAND-BINDING; BASIC FGF; EXPRESSION; IDENTIFICATION; DIMERIZATION; ACTIVATION; DIVERSITY	Heparan sulfates (HS) play an important role in the control of cell growth and differentiation by virtue of their ability to modulate the activities of heparin-binding growth factors, an issue that is particularly well studied for fibroblast growth factors (FGFs). HS/heparin co-ordinate the interaction of FGFs with their receptors (FGFRs) and are thought to play a critical role in receptor dimerization. Biochemical and crystallographic studies, conducted mainly with FGF-2 or FGF-1 and FGF receptors 1 and 2, suggests that an octasaccharide is the minimal length required for FGF- and FGFR-induced dimerization and subsequent activation. In addition, 6-O-sulfate groups are thought to be essential for binding of HS to FGFR and for receptor dimerization. We show here that oligosaccharides shorter than 8 sugar units support activation of FGFR2 IIIb by FGF-1 and interaction of FGFR4 with FGF-1. In contrast, only relatively long oligosaccharides supported receptor binding and activation in the FGF-1(.)FGFR1 or FGF-7(.)FGFR2 IIIb setting. In addition, both 6-O- and 2-O-desulfated heparin activated FGF-1 signaling via FGFR2 IIIb, whereas neither one stimulated FGF-1 signaling via FGFR1 or FGF-7 via FGFR2 IIIb. These findings indicate that the structure of HS required for activating FGFs is dictated by the specific FGF and FGFR combination. These different requirements may reflect the differences in the mode by which a given FGFR interacts with the various FGFs.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Univ Manchester, Cristie Canc Res Campaign Res Ctr, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Natl Inst Biol Stand & Controls, Mol Struct Lab, Potters Bar EN6 3QG, Herts, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Technion Israel Institute of Technology; University of Manchester; National Institute for Biological Standards & Control; University of Liverpool	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@techunix.technion.ac.il	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; DELEHEDDE, Maryse/0000-0003-2724-143X				AVIEZER D, 1994, J BIOL CHEM, V269, P114; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Baumann H, 1998, CARBOHYD RES, V308, P381, DOI 10.1016/S0008-6215(98)00097-4; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Fernig D G, 2001, Methods Mol Biol, V171, P505; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GRAY TE, 1995, BIOCHEMISTRY-US, V34, P10325, DOI 10.1021/bi00033a002; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KREUGER J, 2001, J BIOL CHEM; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rubin J S, 1995, EXS, V74, P191; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 2000, J BIOL CHEM, V275, P34881, DOI 10.1074/jbc.M003293200; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; Siegfried S, 1997, CANCER-AM CANCER SOC, V79, P1166, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1166::AID-CNCR15>3.0.CO;2-Y; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0	59	127	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2444	2453		10.1074/jbc.M108540200	http://dx.doi.org/10.1074/jbc.M108540200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714710	hybrid			2022-12-25	WOS:000173421500012
J	Bean, LJH; Stark, GR				Bean, LJH; Stark, GR			Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; TRANSACTIVATION DOMAIN; IONIZING-RADIATION; RNA-POLYMERASE; PROTEIN; KINASE; CHECKPOINT; CHK2; ACTIVATION	The function and stability of the tumor suppressor p53 are tightly controlled by the negative regulator mouse double minute 2 (Mdm2), which binds to p53, blocking DNA binding and targeting p53 for proteosome-mediated degradation. Following DNA damage or cellular stress, p53 is phosphorylated within the Mdm2 binding domain on threonine 18 and serine 20. To analyze the roles of these phosphorylation events, residues IS and 20 were mutated to alanines. Transient transfection into p53-null cells demonstrated that the T18A protein can be expressed stably, but the S20A protein is very unstable, precluding further analysis. When expressed stably at low basal levels in p53-null human fibroblasts or fibrosarcoma cells, the T18A mutant accumulated 5-10-fold less well than wild-type p53 following exposure to UV. Analysis of p53-dependent transcription following UV revealed that the phosphorylation of threonine 18 is required for transactivation of the p21, Hdm2 (the human ortholog of Mdm2), and GADD45 genes. The phosphorylation of serine 33, another early event following DNA damage, is not required for p53 accumulation or p53-dependent transactivation following UV.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44196 USA	Cleveland Clinic Foundation; Case Western Reserve University	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345, T32GM008613] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM08613, GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Prives C, 1999, J PATHOL, V187, P112; Robinson GK., 1991, STAT SCI, V6, P18, DOI DOI 10.1214/SS/1177011926; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	50	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1864	1871		10.1074/jbc.M108881200	http://dx.doi.org/10.1074/jbc.M108881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707453	hybrid			2022-12-25	WOS:000173421300033
J	Lamande, SR; Morgelin, M; Selan, C; Jobsis, GJ; Baas, F; Bateman, JF				Lamande, SR; Morgelin, M; Selan, C; Jobsis, GJ; Baas, F; Bateman, JF			Kinked collagen VI tetramers and reduced microfibril formation as a result of Bethlem myopathy and introduced triple helical glycine mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; VONWILLEBRAND-FACTOR; MUSCULAR-DYSTROPHY; MATRIX DEPOSITION; ALPHA-3(VI) CHAIN; GLOBULAR DOMAINS; PROCOLLAGEN; SECRETION; SITE; BIOSYNTHESIS	Mutations in the genes that code for collagen VI subunits, COL6A1, COL6A2, and COL6A3, are the cause of the dominantly inherited disorder, Bethlem myopathy. Glycine mutations that interrupt the Gly-X-Y repetitive amino acid sequence that forms the characteristic collagen triple helix have been defined in four families; however, the effects of these mutations on collagen VI biosynthesis, assembly, and structure have not been determined. In this study, we examined the consequences of Bethlem. myopathy triple helical glycine mutations in the alpha1(VI) and alpha2(VI) chains, as well as engineered alpha3(VI) triple helical glycine mutations. Although the Bethlem myopathy and introduced mutations that are toward the N terminus of the triple helix did not measurably affect collagen VI intracellular monomer, dimer, or tetramer assembly, or secretion, the introduced mutation toward the C terminus of the helix severely impaired association of the mutant alpha3(VI) chain with alpha1(VI) and alpha2(VI). Association of the three chains was not completely prevented, however; and some non-disulfide bonded tetramers were secreted. Examination of the secreted Bethlem myopathy and engineered mutant collagen VI by negative staining electron microscopy revealed the striking finding that in all the cell lines a significant proportion of the tetramers contained a kink in the supercoiled triple helical region. Collagen VI tetramers from all of the mutant cell lines also showed a reduced ability to form microfibrils. These results provide the first evidence of the biosynthetic consequences of collagen VI triple helical glycine mutations and indicate that Bethlem myopathy results not only from the synthesis of reduced amounts of structurally normal protein but also from the presence of mutant collagen VI in the extracellular matrix.	Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Lund University; University of Amsterdam; Academic Medical Center Amsterdam	Lamande, SR (corresponding author), Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia.		Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; Bateman, John/0000-0001-8542-0730; Lamande, Shireen/0000-0003-2938-2711				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; BRUNS RR, 1984, J ULTRA MOL STRUCT R, V89, P136, DOI 10.1016/S0022-5320(84)80010-6; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; Fitzgerald J, 2001, J BIOL CHEM, V276, P187, DOI 10.1074/jbc.M008173200; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jobsis GJ, 1996, NEUROLOGY, V46, P779, DOI 10.1212/WNL.46.3.779; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Jobsis GJ, 1999, BRAIN, V122, P649, DOI 10.1093/brain/122.4.649; Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Pepe G, 1999, BIOCHEM BIOPH RES CO, V258, P802, DOI 10.1006/bbrc.1999.0680; Pepe G, 1999, NEUROMUSCULAR DISORD, V9, P264, DOI 10.1016/S0960-8966(99)00014-0; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; Speer MC, 1996, HUM MOL GENET, V5, P1043, DOI 10.1093/hmg/5.7.1043; SPISSINGER T, 1994, MATRIX BIOL, V14, P499; STEINMANN B, 1991, BIOCHEM J, V279, P747, DOI 10.1042/bj2790747; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	32	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1949	1956		10.1074/jbc.M109932200	http://dx.doi.org/10.1074/jbc.M109932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707460	hybrid			2022-12-25	WOS:000173421300046
J	Xiao, GH; Beeser, A; Chernoff, J; Testa, JR				Xiao, GH; Beeser, A; Chernoff, J; Testa, JR			p21-activated kinase links Rac/Cdc42 signaling to merlin.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-BINDING SUBUNIT; NEUROFIBROMATOSIS TYPE-2; CELL-MIGRATION; GENE-PRODUCT; ALPHA-PAK; NF2 GENE; ACTIN; PHOSPHORYLATION; PROTEIN; ASSOCIATION	The neurofibromatosis type 2 tumor suppressor gene, NF2, is mutated in the germ line of NF2 patients and predisposes affected individuals to intracranial and spinal tumors. Moreover, somatic mutations of NF2 can occur in the sporadic counterparts of these neurological tumor types as well as in certain neoplasms of non-neuroectodermal origin, such as malignant mesothelioma and melanoma. NF2 encodes a 595-amino acid protein, merlin, which exhibits significant homology to the ezrinradixin-moesin family of proteins. However, the mechanism by which merlin exerts its tumor suppressor activity is not well understood. In this investigation, we show that merlin is phosphorylated in response to expression of activated Rac and activated Cdc42 in mammalian cells. Furthermore, we demonstrate that merlin phosphorylation is mediated by p21-activated kinase (Pak), a common downstream target of both Rac and Cdc42. Both in vivo and in vitro kinase assays demonstrated that Pak can directly phosphorylate merlin at serine 518, a site that affects merlin activity and localization. These biochemical investigations provide insights into the regulation of merlin function and establish a framework for elucidating tumorigenic mechanisms involved in neoplasms associated with merlin inactivation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA45745] Funding Source: Medline; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	27	198	207	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					883	886		10.1074/jbc.C100553200	http://dx.doi.org/10.1074/jbc.C100553200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11719502	hybrid			2022-12-25	WOS:000173166800004
J	De Vrij, FMS; Sluijs, JA; Gregori, L; Fischer, DF; Hermens, WTJMC; Goldgaber, D; Verhaagen, J; Van Leeuwen, FW; Hol, EM				De Vrij, FMS; Sluijs, JA; Gregori, L; Fischer, DF; Hermens, WTJMC; Goldgaber, D; Verhaagen, J; Van Leeuwen, FW; Hol, EM			Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death	FASEB JOURNAL			English	Article						AD; molecular misreading; neurodegeneration; proteasomal degradation	POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; CELL LINE; IN-VITRO; PROTEASOME; APOPTOSIS; SIGNAL; SYSTEM	Ubiquitin-B+1 (UBB+1) is a mutant ubiquitin that accumulates in the neurones of patients with Alzheimer's disease (AD). Here we report on the biochemical and functional differences between ubiquitin and UBB+1 and the effect of the mutant protein on neuronal cells. UBB+1 lacks the capacity to ubiquitinate, and although it is ubiquitinated itself, UBB+1 is not degraded by the ubiquitin-proteasomal system and is quite stable in neuronal cells. Overexpression of UBB+1 in neuroblastoma cells significantly induces nuclear fragmentation and cell death. Our results demonstrate that accumulation of UBB+1 in neurones is detrimental and may contribute to neuronal dysfunction in AD patients.	Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, Res Grp Mol Misreading, NL-1105 AZ Amsterdam, Netherlands; Vet Affairs Res Serv, Mol Neurovirol Unit, Baltimore, MD USA; SUNY Stony Brook, Sch Med, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hol, EM (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, Res Grp Mol Misreading, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	e.hol@nih.knaw.nl	Verhaagen, Joost/G-4773-2012; Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; de Vrij, Femke M.S./O-9706-2019	Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; de Vrij, Femke M.S./0000-0003-0825-3806; Fischer, David/0000-0002-6690-0197				Amerik AY, 1997, EMBO J, V16, P4826; Anderson AJ, 2000, NEUROBIOL AGING, V21, P511, DOI 10.1016/S0197-4580(00)00126-3; BAMEZAI S, 1991, ARCH BIOCHEM BIOPHYS, V289, P343, DOI 10.1016/0003-9861(91)90421-E; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; PICKART CM, 1998, UBIQUITIN BIOL CELL, P40; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; SLACK R, 1992, EXP CELL RES, V202, P17, DOI 10.1016/0014-4827(92)90399-S; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032	30	118	119	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2680	2688		10.1096/fj.01-0438com	http://dx.doi.org/10.1096/fj.01-0438com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726544				2022-12-25	WOS:000172964800038
J	Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX				Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX			Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice	ONCOGENE			English	Article						Brca1; p53; ErbB2; cyclin D1; c-Myc; tumorigenesis	CANCER-SUSCEPTIBILITY GENES; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; BREAST-CANCER; CELL-CYCLE; TRANSGENIC MICE; TUMOR-FORMATION; MEIOTIC CELLS; 5 REGIONS; C-MYC	Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53(+/-) mutation significantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ER alpha and p16 negative. Translocations involving p53 were also identified which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or irradiation, suggesting that these methods would be effective in treatment of this disease.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO;2-Q; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GATEI M, 2001, J BIOL CHEM, V13, P13; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mueller A, 1997, CANCER RES, V57, P5542; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Osborne RJ, 2000, CANCER RES, V60, P3706; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; Robson M, 1998, CANCER RES, V58, P1839; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Walker RA, 1999, J PATHOL, V188, P229, DOI 10.1002/(SICI)1096-9896(199907)188:3<229::AID-PATH341>3.0.CO;2-F; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	63	149	153	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7514	7523		10.1038/sj.onc.1204929	http://dx.doi.org/10.1038/sj.onc.1204929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709723				2022-12-25	WOS:000171976900008
J	Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ				Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ			Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells	ONCOGENE			English	Article						checkpoint; Chk1; p53; Cds1; DNA damage	CHK1 PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; CYCLE CHECKPOINTS; CDK INHIBITORS; HUMAN MYT1; CDC2; ATR; ACTIVATION; EXTRACTS	Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	O'Connell, MJ (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.			Cuddihy, Andrew/0000-0002-9898-0443				Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fattaey A, 1997, Prog Cell Cycle Res, V3, P233; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson JR, 2000, CANCER RES, V60, P566; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KRAKER AJ, 2000, P AM ASSOC CANC RES, V41, P468; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leu JY, 1999, MOL CELL, V4, P805, DOI 10.1016/S1097-2765(00)80390-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Masui Y, 1998, BIOL CELL, V90, P537, DOI 10.1016/S0248-4900(99)80011-2; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Roberge M, 1998, CANCER RES, V58, P5701; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 2000, GENE DEV, V14, P289; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	55	144	152	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7453	7463		10.1038/sj.onc.1204942	http://dx.doi.org/10.1038/sj.onc.1204942			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709716				2022-12-25	WOS:000171976900001
J	Zhuang, SG; Demirs, JT; Kochevar, IE				Zhuang, SG; Demirs, JT; Kochevar, IE			Protein kinase C inhibits singlet oxygen-induced apoptosis by decreasing caspase-8 activation	ONCOGENE			English	Article						protein kinase C; singlet oxygen; caspase-8; Fas; apoptosis; p38	RECEPTOR-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; RADIATION-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; THERAPY-INDUCED APOPTOSIS; PHOTODYNAMIC THERAPY; CYTOCHROME-C; HL-60 CELLS; HYDROGEN-PEROXIDE; MEDIATED APOPTOSIS	Although activation of protein kinase C (PKC) inhibits apoptosis induced by a variety of stimuli including singlet oxygen, the step at which PKC activation interferes with apoptotic signaling is not well defined. We have shown previously that caspase-8 and p38 mediate singlet oxygen-induced apoptosis in HL-60 cells. In this study, we investigated the influence of PKC on regulation of the caspase-8 and p38 pathways initiated by singlet oxygen. Singlet oxygen induced Fas clustering and subsequent recruitment of FADD and caspase-8. Treatment of cells with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a PKC activator, did not affect the binding of caspase-8 to the aggregated Fas. Surprisingly, under the same conditions PKC activation was still able to prevent singlet oxygen-induced activation of caspase-8 and block its downstream signaling events including cleavage of Bid and caspase-3, decrease in mitochondrial transmembrane potential and release of cytochrome c from mitochondria. Inhibition of PKC by GF109203 or H7 counteracted the TPA-mediated effects on the cleavage of caspases -3 and -8. However, neither activation nor inhibition of PKC affected p38 phosphorylation. These data indicate that PKC inhibits singlet oxygen-induced apoptosis by blocking activation of caspase-8.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NIGMS NIH HHS [GM 30755] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Cook SA, 1999, CIRC RES, V85, P940; Dispersyn G, 1999, BBA-GEN SUBJECTS, V1428, P357, DOI 10.1016/S0304-4165(99)00073-2; Dong SM, 2000, CHEM RES TOXICOL, V13, P585, DOI 10.1021/tx990199x; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Krutmann J, 2000, J DERMATOL SCI, V23, pS22, DOI 10.1016/S0923-1811(99)00077-8; Kwon D, 2001, J NEUROIMMUNOL, V113, P1, DOI 10.1016/S0165-5728(00)00321-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOTEM J, 1991, BLOOD, V78, P953; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luo Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P479, DOI 10.1111/j.1751-1097.1997.tb03176.x; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Pae HO, 2000, IMMUNOPHARM IMMUNOT, V22, P61, DOI 10.3109/08923970009016406; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SOLARY E, 1993, BLOOD, V81, P1359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STOKA V, 2000, J BIOL CHEM, V9, P9; Suhara T, 1998, J IMMUNOL, V160, P4042; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TAKANO Y, 1993, PATHOL RES PRACT, V189, P197, DOI 10.1016/S0344-0338(11)80092-0; Umansky V, 2000, INT J ONCOL, V16, P109; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Webber J, 1996, J PHOTOCH PHOTOBIO B, V35, P209, DOI 10.1016/S1011-1344(96)07291-0; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Yabuki M, 2000, FREE RADICAL RES, V32, P507, DOI 10.1080/10715760000300511; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1998, FEBS LETT, V437, P158, DOI 10.1016/S0014-5793(98)01222-8; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	83	43	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6764	6776		10.1038/sj.onc.1204867	http://dx.doi.org/10.1038/sj.onc.1204867			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709711				2022-12-25	WOS:000171551600013
J	Yoshii, T; Fukumori, T; Honjo, Y; Inohara, H; Kim, HRC; Raz, A				Yoshii, T; Fukumori, T; Honjo, Y; Inohara, H; Kim, HRC; Raz, A			Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN GALECTIN-3; CASEIN KINASE-I; BCL2 PHOSPHORYLATION; CANCER-CELLS; METASTASIS; FAMILY; OVEREXPRESSION; EXPRESSION; INHIBITION; ADHESION	Galectin-3, a beta-galactoside-binding protein, is implicated in cell growth, adhesion, differentiation, and tumor progression by interactions with its ligands. Recent studies have revealed that galectin-3 suppresses apoptosis and anoikis that contribute to cell survival during metastatic cascades. Previously, it has been shown that human galectin-3 undergoes post-translational signaling modification of Ser(6) phosphorylation that acts as an "on/off" switch for its sugar-binding capability. We questioned whether galectin-3 phosphorylation is required for its anti-apoptotic function. Serine to alanine (S6A) and serine to glutamic acid (S6E) mutations were produced at the casein kinase I phosphorylation site in galectin-3. The cDNAs were transfected into a breast carcinoma cell line BT-549 that innately expresses no galectin-3. Metabolic labeling revealed that only wild type galectin-3 undergoes phosphorylation in vivo. Expression of Ser(6) mutants of galectin-3 failed to protect cells from cisplatin-induced cell death and poly(ADP-ribose) polymerase from degradation when compared with wild type galectin-3. The non-phosphorylated galectin-3 mutants failed to protect cells from anoikis with G(1) arrest when cells were cultured in suspension. In response to a loss of cell-substrate interactions, only cells expressing wild type galectin-3 down-regulated cyclin A expression and up-regulated cyclin D-1 and cyclin-dependent kinase inhibitors, i.e. p21(WAF1/CIP1) and p27(KIP1) expression levels. These results demonstrate that galectin-3 phosphorylation regulates its anti-apoptotic signaling activity.	Wayne State Univ, Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA; Osaka Univ, Grad Sch Med, Dept Otolaryngol & Sensory Organ Surg, Suita, Osaka 5650871, Japan; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Osaka University; Wayne State University	Raz, A (corresponding author), Wayne State Univ, Karmanos Canc Inst, Tumor Progress & Metastasis Program, 110 E Warren Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA 46120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046120, R37CA046120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahani S, 1997, CANCER RES, V57, P5272; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; COWLES EA, 1990, J BIOL CHEM, V265, P17706; Gong HC, 1999, CANCER RES, V59, P6239; Haldar S, 1998, CANCER RES, V58, P1609; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; Ibrado AM, 1996, CANCER RES, V56, P4743; Inohara H, 1998, EXP CELL RES, V245, P294, DOI 10.1006/excr.1998.4253; INOHARA H, 1995, CANCER RES, V55, P3267; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kim HRC, 1999, CANCER RES, V59, P4148; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Pratesi G, 2001, BIOCHEM PHARMACOL, V61, P381, DOI 10.1016/S0006-2952(00)00538-4; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yokote H, 2000, BRAIN RES, V857, P78, DOI 10.1016/S0006-8993(99)02414-2	35	193	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6852	6857		10.1074/jbc.M107668200	http://dx.doi.org/10.1074/jbc.M107668200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11724777	hybrid			2022-12-25	WOS:000174104300015
J	Olaso, E; Labrador, JP; Wang, LH; Ikeda, K; Eng, FJ; Klein, R; Lovett, DH; Lin, HC; Friedman, SL				Olaso, E; Labrador, JP; Wang, LH; Ikeda, K; Eng, FJ; Klein, R; Lovett, DH; Lin, HC; Friedman, SL			Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; TYROSINE KINASE; GROWTH-FACTOR; GELATINASE-A; I COLLAGEN; EXPRESSION; INTEGRIN; RAT; INDUCTION; TRANSDUCTION	Discoidin domain receptor 2 (DDR2) is a tyrosine kinase receptor expressed in mesenchymal tissues, the ligand of which is fibrillar collagen. We have compared DDR2 signaling in skin fibroblasts derived from DDR2(-/-) and DDR2(+/-) mice. Proliferation of DDR2(-/-) fibroblasts was significantly decreased compared with DDR2(+/-) cells. DDR2(-/-) fibroblasts exhibited markedly impaired capacity to migrate through a reconstituted basement membrane (Matrigel) in response to a chemotactic stimulus, which correlated with diminished matrix metalloproteinase-2 (MMP-2) activity by gelatin zymography and diminished MMP-2 transcription of a minimal MMP-2 promoter. In contrast, a lack of DDR2 had no effect on cell motility or alph-smooth muscle actin or vinculin expression. Additionally, expression of type I collagen was greatly reduced in DDR2(-/-) cells. Stable reconstitution of either wild-type DDR2 or constitutively active chimeric DDR2 in DDR2(-/-) cells by retroviral infection restored cell proliferation, migration through a reconstituted basement membrane (Matrigel), and MMP-2 levels to those of DDR2(+/-) fibroblasts. These data establish a role for DDR2 in critical events during wound repair.	Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; European Mol Biol Lab, Dev Biol Program, D-69117 Heidelberg, Germany; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-280493 Madrid, Spain; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	Icahn School of Medicine at Mount Sinai; European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Regeneron; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, Rm 1170F,1425 Madison Ave,POB 1123, New York, NY 10029 USA.		Olaso, Elvira/AAA-4497-2019; Labrador, Juan Pablo/C-3018-2014; Klein, Ruediger/C-6147-2008	Olaso, Elvira/0000-0001-6597-3530; Labrador, Juan Pablo/0000-0003-3671-848X; Klein, Ruediger/0000-0002-3109-0163	NIDDK NIH HHS [DK56621, DK39776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R56DK039776, R56DK056621, R01DK056621] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; ALVES F, 1995, ONCOGENE, V10, P609; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; BARKER KT, 1995, ONCOGENE, V10, P569; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENWEL P, 1993, LAB INVEST, V69, P210; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MARTI HP, 1994, AM J PATHOL, V144, P82; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McClain SA, 1996, AM J PATHOL, V149, P1257; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Olaso E, 1997, HEPATOLOGY, V26, P634, DOI 10.1053/jhep.1997.v26.pm0009303493; Ornstein DL, 1999, CLIN EXP METASTAS, V17, P205, DOI 10.1023/A:1006562818088; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; SCHELESSINGER J, 1997, CELL, V91, P869; SCHER W, 1987, LAB INVEST, V57, P607; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TURK J, 1996, J BIOL CHEM, V271, P15074; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239	54	183	196	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3606	3613		10.1074/jbc.M107571200	http://dx.doi.org/10.1074/jbc.M107571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723120	hybrid			2022-12-25	WOS:000173688000073
J	Miravet, S; Piedra, J; Miro, F; Itarte, E; de Herreros, AG; Dunach, M				Miravet, S; Piedra, J; Miro, F; Itarte, E; de Herreros, AG; Dunach, M			The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; WNT SIGNALING PATHWAY; CASEIN KINASE-2; COLON-CARCINOMA; CELL-ADHESION; CYCLIN D1; APC; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	beta-Catenin and plakoglobin are two related armadillo proteins necessary for the establishment of adhesion junctions and desmosomes. Moreover, beta-catenin can also act as a transcriptional co-activator through its interaction with the members of Tcf/LEF-1 transcriptional factor family. We show here that Tcf-4 can be phosphorylated in vitro by protein kinase CK2 stoichiometrically in amino acids Ser-58-Ser-59-Ser-60. Phosphorylation of these residues does not modify the interaction of Tcf-4 with beta-catenin but reduces its association to plakoglobin. The binding sites of Tcf-4 for these two proteins were compared; whereas beta-catenin requires the N-terminal first 50 amino acids, plakoglobin interacts mainly with residues 51-80. Tcf-4-(51-80) binds plakoglobin in the region of armadillo repeats 1-6. Ternary complexes composed by beta-catenin/Tcf-4/plakoglobin could be detected in vitro, demonstrating that simultaneous binding of the two armadillo proteins to Tcf-4 is possible. Experiments performed using a Tcf-4 mutant with decreased interaction to plakoglobin demonstrated that binding to this protein negatively affected the transcriptional activity of Tcf-4. These results indicate that Tcf-4 contains two different sites for binding of beta-catenin and plakoglobin, and the interaction of the latter hinders the transcriptional activity of the complex.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, Unitat Bioquim Ciencies, Bellaterra 08193, Spain	Pompeu Fabra University; Autonomous University of Barcelona; Autonomous University of Barcelona	Dunach, M (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Dr Aiguader 80, E-08003 Barcelona, Spain.		Itarte, Emilio/Q-6246-2019; de Herreros, A Garcia/H-3104-2014; Miro-Mur, Francesc A./AAT-3013-2020; Itarte, Emilio/K-5275-2014; Dunach, Mireia/E-3604-2015	de Herreros, A Garcia/0000-0001-5270-0808; Miro-Mur, Francesc A./0000-0003-3936-2693; Itarte, Emilio/0000-0002-9366-5807; Dunach, Mireia/0000-0001-9844-5603				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; FOUQUET B, 1992, DIFFERENTIATION, V51, P187, DOI 10.1111/j.1432-0436.1992.tb00695.x; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gil C, 1996, BIOCHEM BIOPH RES CO, V225, P1052, DOI 10.1006/bbrc.1996.1293; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SOMMERS CL, 1994, CANCER RES, V54, P3544; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sparks AB, 1998, CANCER RES, V58, P1130; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wahl JK, 2000, J CELL SCI, V113, P1737; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	49	96	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1884	1891		10.1074/jbc.M110248200	http://dx.doi.org/10.1074/jbc.M110248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11711551	hybrid			2022-12-25	WOS:000173421300036
J	Nakamaru-Ogiso, E; Yano, T; Ohnishi, T; Yagi, T				Nakamaru-Ogiso, E; Yano, T; Ohnishi, T; Yagi, T			Characterization of the iron-sulfur cluster coordinated by a cysteine cluster motif (CXXCXXXCX27C) in the Nqo3 subunit in the proton-translocating NADH-quinone oxidoreductase (NDH-1) of Thermus thermophilus HB-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; UBIQUINONE OXIDOREDUCTASE; COMPLEX-I; BIOTIN SYNTHASE; FORMATE DEHYDROGENASE; PERIPHERAL SUBUNITS; CRYSTAL-STRUCTURE; FNR PROTEIN; EXPRESSION	The proton-translocating NADH-quinone oxidoreduetase (NDH-1) of Thermus thermophilus HB-8 is composed of 14 subunits (designated Nqo1-14). This NDH-1 houses nine putative iron-sulfur binding sites, eight of which are generally found in bacterial NDH-1 and its mitochondrial counterpart (complex 1). The extra site contains a CXXCXXXCX27C motif and is located in the Nqo3 subunit. This motif was originally found in Escherichia coli NDH-1 and was assigned to a binuclear cluster (g(z, y, x) = 2.00, 1.95, 1.92) and named N1c. In this report, the Thermus Nqo3 fragment containing this motif was heterologously overexpressed, using a glutathione S-transferase fusion system. This fragment contained a small amount of iron-sulfur cluster, whose content was significantly increased by in vitro reconstitution. The LW-visible and EPR spectroscopic properties of this fragment indicate that the ligated iron-sulfur cluster is tetranuclear with nearly axial symmetry (g(parallel to, perpendicular to) = 2.045, similar to 1.94). Site-directed mutants show that all four cysteines participate in the ligation of a [4Fe-4S] cluster. Considering the fact that the same motif coordinates only tetranuclear clusters in other enzymes so far known, we propose that the CXXCXXXCX27C motif in the Nqo3 subunit most likely ligates the [4Fe-4S] cluster.	Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA; Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Pennsylvania; Scripps Research Institute	Yagi, T (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030736] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [R01GM33712, R01GM30736] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; COLLINS MD, 1980, J APPL BACTERIOL, V48, P277, DOI 10.1111/j.1365-2672.1980.tb01227.x; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; Hu YL, 1999, J MOL BIOL, V286, P899, DOI 10.1006/jmbi.1998.2488; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEINHARDT SW, 1990, J BIOL CHEM, V265, P1360; Mendz GL, 2000, ARCH MICROBIOL, V174, P1, DOI 10.1007/s002030000174; Mulholland SE, 1998, J AM CHEM SOC, V120, P10296, DOI 10.1021/ja981279a; Nagata K, 2001, ANTIMICROB AGENTS CH, V45, P1522, DOI 10.1128/AAC.45.5.1522-1527.2001; Oh JI, 1998, J BIOL CHEM, V273, P26349, DOI 10.1074/jbc.273.41.26349; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1988, ADV MEMBRANE BIOCH B, P237; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; RAGAN CI, 1982, BIOCHEMISTRY-US, V21, P590, DOI 10.1021/bi00532a027; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; Steuber J, 2001, J BIOENERG BIOMEMBR, V33, P179, DOI 10.1023/A:1010774701327; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; YAGI T, 1990, BIOCHEMISTRY-US, V29, P5515, DOI 10.1021/bi00475a015; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1988, BIOCHEMISTRY-US, V27, P2008, DOI 10.1021/bi00406a030; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; Yagi T, 2001, J BIOENERG BIOMEMBR, V33, P233, DOI 10.1023/A:1010787004053; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; Yano T, 1999, J BIOL CHEM, V274, P28606, DOI 10.1074/jbc.274.40.28606; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014	63	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1680	1688		10.1074/jbc.M108796200	http://dx.doi.org/10.1074/jbc.M108796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704668	hybrid			2022-12-25	WOS:000173421300010
J	Bae, MK; Ahn, MY; Jeong, JW; Bae, MH; Lee, YM; Bae, SK; Park, JW; Kim, KR; Kim, KW				Bae, MK; Ahn, MY; Jeong, JW; Bae, MH; Lee, YM; Bae, SK; Park, JW; Kim, KR; Kim, KW			Jab1 interacts directly with HIF-1 alpha and regulates its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR PROTEIN; MODULATE AP-1 ACTIVITY; SIGNAL-TRANSDUCTION; HYPOXIA; DEGRADATION; STABILIZATION; COACTIVATORS; RECRUITMENT	Hypoxia-inducible factor-1 (HIF-1) is a master transcription factor that controls transcriptional activation of a number of genes responsive to the low cellular oxygen tension, including vascular endothelial growth factor (VEGF), erythropoietin, and glycolytic enzymes. The stability and activity of HIF-1alpha are regulated by binding to various proteins such as pVHL, p53, and p300/CBP. Here, using the yeast two-hybrid screening system, we found that HIF-1alpha interacts with Jab1 (Jun activation domain-binding protein-1), which is a coactivator of AP-1 transcription factor and fifth subunit of COP9 signalosome complex. The interaction of Jab1 with HIF-1alpha was confirmed by GST pull-down assay and also reproduced in vivo in HER 293 cells, where endogenous Jab1 was coimmunoprecipitated with the overexpressed HIF-1alpha. Moreover, Jab1-enhanced transcriptional activity of HIF-1 under hypoxia led to increase the expression of VEGF, a major HIF-1 target gene. Furthermore, Jab1 increased HIF-1alpha protein levels, which was due to the enhanced HIF-la stability. The binding of HIF-1alpha and p53 tumor suppressor protein, negative regulator of HIF-1alpha stability, was interfered in a Jab1-dependent manner. Taken together, these results indicate that Jab1 should be considered as a novel regulator of HIF-1alpha stability via direct interaction.	Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Pusan Natl Univ, Dept Biol Mol, Pusan 609735, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pusan National University	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.		Park, Jong-Wan/J-2758-2012					An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chun YS, 2000, EUR J BIOCHEM, V267, P4198, DOI 10.1046/j.1432-1327.2000.01453.x; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ravi R, 2000, GENE DEV, V14, P34; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230	24	161	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					9	12		10.1074/jbc.C100442200	http://dx.doi.org/10.1074/jbc.C100442200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11707426	hybrid			2022-12-25	WOS:000173087900003
J	Chilov, D; Hofer, T; Bauer, C; Wenger, RH; Gassmann, M				Chilov, D; Hofer, T; Bauer, C; Wenger, RH; Gassmann, M			Hypoxia affects expression of circadian genes PER1 and CLOCK in mouse brain	FASEB JOURNAL			English	Article						circadian clock; hypoxia; HIF; PAS proteins	SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; INDUCIBLE FACTOR-1-ALPHA; RHYTHMIC EXPRESSION; PERIOD HOMOLOGS; HIF-ALPHA; PROTEIN; SLEEP; CLONING; MPER2	The key elements of circadian clockwork and oxygen homeostasis are the PAS protein family members PER and CLOCK and hypoxia-inducible factor 1 alpha (HIF-1 alpha). The PAS domain serves as an interface for protein-protein interactions. We asked whether a cross-talk exists between the PAS components of hypoxic and circadian pathways. We found several isoforms of PER1 protein that exhibit tissue-specific size differences. In the mouse brain, a predominantly nuclear 48 kDa isoform that followed a daily rhythm was observed. The 48 kDa form was found in the nuclear fractions derived from mouse liver, Swiss3T3 fibroblasts, and N2A neuroblastoma cells. In mouse kidney and human 293 kidney cells, a 55 kDa PER1 form was detected. CLOCK was observed as a predicted 100 kDa protein in rat-1 cells and in all analyzed mouse tissues including brain, liver, kidney, and spleen. In contrast to PER1, CLOCK protein expression was not rhythmic. Exposure to hypoxia led to increased PER1 and CLOCK protein levels in mice. Based on coimmunoprecipitation experiments that showed protein-protein interaction between PER1 and the a subunit of HIF-1, we suggest that these hypoxic effects may be modulated by HIF-1 alpha.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	maxg@access.unizh.ch	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; chilov, dmitri/0000-0002-2279-0854				Akashi M, 2000, GENE DEV, V14, P645; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chavez JC, 2000, J APPL PHYSIOL, V89, P1937, DOI 10.1152/jappl.2000.89.5.1937; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; COOTE JH, 1992, EUR J APPL PHYSIOL O, V64, P178, DOI 10.1007/BF00717957; COOTE JH, 1993, EUR J APPL PHYSIOL O, V66, P249, DOI 10.1007/BF00235102; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 1999, CHRONOBIOL INT, V16, P377, DOI 10.3109/07420529908998716; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Foulkes NS, 1997, TRENDS NEUROSCI, V20, P487, DOI 10.1016/S0166-2236(97)01109-0; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALE B, 1984, J APPL PHYSIOL, V57, P1564, DOI 10.1152/jappl.1984.57.5.1564; Hastings M H, 1999, J Neurosci, V19, pRC11; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maywood ES, 1999, P NATL ACAD SCI USA, V96, P15211, DOI 10.1073/pnas.96.26.15211; MROSOVSKY N, 1991, J BIOL RHYTHM, V6, P167, DOI 10.1177/074873049100600207; Oishi K, 2000, BIOCHEM BIOPH RES CO, V268, P164, DOI 10.1006/bbrc.1999.2054; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; POLLARD MJ, 1987, J APPL PHYSIOL, V63, P2189, DOI 10.1152/jappl.1987.63.6.2189; PROSSER RA, 1989, J NEUROSCI, V9, P1073; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Schibler U, 1999, J SLEEP RES, V8, P1; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Steeves TDL, 1999, GENOMICS, V57, P189, DOI 10.1006/geno.1998.5675; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wager-Smith K, 2000, NAT GENET, V26, P23, DOI 10.1038/79134; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	85	98	101	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2613	2622		10.1096/fj.01-0092com	http://dx.doi.org/10.1096/fj.01-0092com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726537				2022-12-25	WOS:000172964800031
J	Virador, VM; Muller, J; Wu, XF; Abdel-Malek, ZA; Yu, ZX; Ferrans, VJ; Kobayashi, N; Wakamatsu, K; Ito, S; Hammer, JA; Hearing, VJ				Virador, VM; Muller, J; Wu, XF; Abdel-Malek, ZA; Yu, ZX; Ferrans, VJ; Kobayashi, N; Wakamatsu, K; Ito, S; Hammer, JA; Hearing, VJ			Influence of alpha-melanocyte-stimulating hormone and of ultraviolet radiation on the transfer of melanosomes to keratinocytes	FASEB JOURNAL			English	Article						skin color; tanning; melanosome transfer	MOUSE MELANOCYTES; EPIDERMAL-KERATINOCYTES; IN-VITRO; PROTEIN; CELLS; EXOCYTOSIS; SYNTAXIN-4; TRANSPORT; SECRETION; SNAP-23	The epidermal melanin unit in human skin is composed of melanocytes and keratinocytes. Melanocytes, located in the basal layer of the epidermis, manufacture melanin-loaded organelles called melanosomes. Through their dendritic processes, melanocytes distribute melanosomes to neighboring keratinocytes, where their presence confers to the skin its characteristic color and photoprotective properties. In this study, we used murine melanocytes and keratinocytes alone and in coculture to characterize the processes involved in melanosome transfer. Ultraviolet (UV) radiation induced an accumulation of melanosomes in melanocytes, whereas treatment with alpha -melanocyte-stimulating hormone (MSH) induced exocytosis of melanosomes accompanied by ruffling of the melanocyte membrane. We found that keratinocytes phagocytose melanosomes and latex beads equally well and that this phagocytic process was increased by exposure of keratinocytes to UV radiation or to MSH. Coculture of melanocytes and keratinocytes resulted in an increase in MSH released to the medium. Gene array analysis of MSH-treated melanocytes showed up-regulation of many genes associated with exocytosis. In our studies, we never observed cytophagocytosis of melanosome-filled processes. This result, together with the other findings, suggests that a combination of signals that increase melanosome production and release by melanocytes and that stimulate phagocytosis by keratinocytes are the most relevant mechanisms involved in skin tanning.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Cincinnati, Dept Dermatol, Cincinnati, OH 45267 USA; NHLBI, Pathol Sect, Bethesda, MD 20892 USA; Nara Med Univ, Dept Dermatol, Kashihara, Nara 634, Japan; Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi 4701192, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Nara Medical University; Fujita Health University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Virador, Victoria M./A-8173-2009; Wakamatsu, Kazumasa/AAZ-5877-2020	Wakamatsu, Kazumasa/0000-0003-1748-9001; Ito, Shosuke/0000-0001-9182-5144				Abdel-Malek ZA, 2001, J CELL SCI, V114, P1019; Bandorowicz-Pikula J, 2001, BIOESSAYS, V23, P170, DOI 10.1002/1521-1878(200102)23:2<170::AID-BIES1024>3.0.CO;2-#; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Berg EA, 2000, J NEUROSCI RES, V62, P830, DOI 10.1002/1097-4547(20001215)62:6<830::AID-JNR10>3.3.CO;2-5; Bessou-Touya S, 1998, J INVEST DERMATOL, V111, P1103, DOI 10.1046/j.1523-1747.1998.00405.x; BIRBECK MSC, 1956, EXP CELL RES, V10, P505, DOI 10.1016/0014-4827(56)90022-2; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Dillon SR, 2001, J IMMUNOL, V166, P58, DOI 10.4049/jimmunol.166.1.58; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Faigle W, 2000, MOL BIOL CELL, V11, P3485, DOI 10.1091/mbc.11.10.3485; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Golczak M, 2001, FEBS LETT, V496, P49, DOI 10.1016/S0014-5793(01)02402-4; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Hodel A, 2000, BIOCHEM J, V350, P637, DOI 10.1042/0264-6021:3500637; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; Jimbow K., 1998, PIGMENTARY SYSTEM, P107; Kippenberger S, 1997, PIGM CELL RES, V10, P85, DOI 10.1111/j.1600-0749.1997.tb00472.x; Kits KS, 2000, BRAIN RES REV, V33, P78, DOI 10.1016/S0165-0173(00)00023-0; KLAUS SN, 1969, ARCH DERMATOL, V100, P756, DOI 10.1001/archderm.100.6.756; Koh DS, 2000, J GEN PHYSIOL, V116, P507, DOI 10.1085/jgp.116.4.507; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; MINWALLA L, 2001, IN PRESS PIGMENT CEL; MISAKI Y, 1994, J BIOL CHEM, V269, P4240; OKAZAKI K, 1976, J INVEST DERMATOL, V67, P541, DOI 10.1111/1523-1747.ep12664554; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; ORTONNE JP, 1990, J INT MED RES, V18, pC8; Perego L, 1997, MOL REPROD DEV, V47, P370, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;370::AID-MRD3&gt;3.0.CO;2-H; Potterf SB, 1996, J BIOL CHEM, V271, P4002; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Roth D, 1999, FEBS LETT, V460, P411, DOI 10.1016/S0014-5793(99)01383-6; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Scott G, 2001, J INVEST DERMATOL, V116, P296, DOI 10.1046/j.1523-1747.2001.01221.x; SEIBERG M, 2001, IN PRESS PIGMENT CEL; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; Sharlow ER, 2000, J CELL SCI, V113, P3093; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Virador VM, 2000, EXP CELL RES, V259, P54, DOI 10.1006/excr.2000.4975; WOLFF K, 1974, J ULTRA MOL STRUCT R, V47, P400, DOI 10.1016/S0022-5320(74)90017-3; WOLFF K, 1972, J ULTRA MOL STRUCT R, V39, P262, DOI 10.1016/S0022-5320(72)90022-6; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 2000, PIGM CELL RES, V13, P241, DOI 10.1034/j.1600-0749.2000.130405.x; YAMAMOTO O, 1994, PIGM CELL RES, V7, P158, DOI 10.1111/j.1600-0749.1994.tb00044.x; YUSPA SH, 1983, CARCINOGENESIS, V4, P1413, DOI 10.1093/carcin/4.11.1413	53	119	124	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					105	+		10.1096/fj.01-0518fje	http://dx.doi.org/10.1096/fj.01-0518fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729101				2022-12-25	WOS:000172420500031
J	Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL				Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL			Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1	ONCOGENE			English	Article						c-Myc; E2F-1; Bcl-2; Bcl-X-L; myeloid; apoptosis	CELL-CYCLE ARREST; S-PHASE ENTRY; WILD-TYPE P53; MEDIATED APOPTOSIS; P53-DEPENDENT APOPTOSIS; ORNITHINE-DECARBOXYLASE; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; SEPARABLE FUNCTIONS; RAT FIBROBLASTS	Malignant transformation occurs in cells that overexpress c-Myc or that inappropriately activate E2F-1. Transformation occurs after the selection of cells that have acquired resistance to apoptosis that is triggered by these oncogenes, and a key mediator of this cell death process is the p53 tumor suppressor. In IL-3-dependent immortal 32D.3 myeloid cells the ARF/p53 apoptotic pathway is inactivated, as these cells fail to express ARF. Nonetheless, both c-Myc and E2F-1 overexpression accelerated apoptosis when these cells were deprived of IL-3. Here we report that c-Myc or E2F-1 overexpression suppresses Bcl-2 protein and RNA levels, and that restoration of Bcl-2 protein effectively blocks the accelerated apoptosis that occurs when c-Myc- or E2F-1-overexpressing cells are deprived of IL-3. Blocking p53 activity with mutant p53 did not abrogate E2F-1-induced suppression of Bcl-2. Analysis of immortal myeloid cells engineered to overexpress c-Myc and E2F-1 DNA binding mutants revealed that DNA binding activity of these oncoproteins is required to suppress Bcl-2 expression. These results suggest that the targeting of Bcl-2 family members is an important mechanism of oncogene-induced apoptosis, and that this occurs independent of the ARF/p53 pathway.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Southampton Gen Hosp, CRC, Wessex Med Oncol Unit, Southampton SO16 6YD, Hants, England; Unilever Res US, Edgewater, NJ 07020 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Southampton; Unilever; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007; Packham, Graham/0000-0002-9232-5691	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA063260, F32CA081695, R01CA077274, R01CA064140, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [CA81695, CA77274, CA76379, CA64140, CA63260, CA-21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dai HQ, 1999, CANCER RES, V59, P4944; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HSU B, 1995, ONCOGENE, V11, P175; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; KATO J, 1993, GENE DEV, V7, P331; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor L, 2000, CURR OPIN CELL BIOL, V12, P257, DOI 10.1016/S0955-0674(99)00084-8; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	76	128	130	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6983	6993		10.1038/sj.onc.1204892	http://dx.doi.org/10.1038/sj.onc.1204892			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704823				2022-12-25	WOS:000171739300002
J	Herbert, GB; Shi, B; Gartenhaus, RB				Herbert, GB; Shi, B; Gartenhaus, RB			Expression and stabilization of the MCT-1 protein by DNA damaging agents	ONCOGENE			English	Article						MCT-1 expression; stabilization; DNA damage	T-CELL MALIGNANCIES; WILD-TYPE P53; SUBCELLULAR-LOCALIZATION; CANDIDATE ONCOGENE; HTLV-I; GENE; LYMPHOMA; CYCLE; PHOSPHORYLATION; IDENTIFICATION	The contribution of oncogene amplification and/or overexpression to T-cell lymphoid neoplasms has only of late been established with the implication of the TCL1 and MTCP1 genes in T-cell malignancies. Our laboratory has recently discovered a novel oncogene, MCT-1, amplified in a T-cell lymphoma and mapped to chromosome Xq22-24. MCT-1 has been shown to decrease cell-doubling time, dramatically shortening the duration of G(1) transit time and/or G1-S transition, and transforms NIH3T3 fibroblasts. Constitutive expression of MCT-1 results in a strong proliferative signal and is associated with deregulation of protein kinase-mediated G1/S phase checkpoints. In this study we analysed the level and subcellular localization of this novel cell cycle regulatory molecule as a function of cell cycle phase. In human lymphoid tumors expression of MCT-1 is constant throughout the cell cycle and remains cytoplasmic. Cells overexpressing MCT-1 have increased expression of cyclin DI with dysregulation of the GI-S checkpoint. Both cyclin D1 and MCT-1 are involved in regulating passage of cells through the G1 phase of the cell cycle. Since prior work has shown that gamma irradiation induces cyclin DI expression we investigated the induction of MCT-1 to DNA damaging agents. We demonstrate that increases in MCT-1 protein in irradiated human lymphoid cells do not occur at the mRNA level and do not require new protein synthesis.	Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Gartenhaus, RB (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.			Shi, Bo/0000-0002-0780-0372				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; BENYEHUDA D, 1994, BRIT J HAEMATOL, V86, P792, DOI 10.1111/j.1365-2141.1994.tb04831.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; CHUANG LT, 1994, CANCER RES, V54, P1286; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; EPPERLY M, 1995, RADIAT RES, V143, P245, DOI 10.2307/3579210; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Prosniak M, 1998, CANCER RES, V58, P4233; REID RL, 1993, ONCOGENE, V8, P3029; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; STERN MH, 1993, ONCOGENE, V8, P2475; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Werner CA, 1997, AM J PATHOL, V151, P335; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	26	11	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6777	6783		10.1038/sj.onc.1204881	http://dx.doi.org/10.1038/sj.onc.1204881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709712				2022-12-25	WOS:000171551600014
J	Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP				Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP			Persistent expression of cyclin D1 disrupts normal photoreceptor differentiation and retina development	ONCOGENE			English	Article						cyclin D1; retina; RB; photoreceptors; retinoblastoma	RETINOBLASTOMA PROTEIN; CELL-CYCLE; TARGETED DISRUPTION; ECTOPIC EXPRESSION; VERTEBRATE RETINA; MICE DEFICIENT; MOUSE RETINA; MUTANT MICE; GENE; PATHWAY	The differentiation of neuronal cells in the developing mammalian retina is closely coupled to cell cycle arrest and proceeds in a highly organized manner. Cyclin D1, which regulates cell proliferation in many cells, also drives the proliferation of photoreceptor progenitors. In the mouse retina, cyclin D1 protein normally decreases as photoreceptors mature. To study the importance of the down-regulation of cyclin D1 during photoreceptor development, we generated a transgenic mouse in which cyclin D1 was persistently expressed in developing photoreceptor cells. We observed numerous abnormalities in both photoreceptors and other nonphotoreceptor cells in the retina of these transgenic mice. In particular, we observed delayed opsin expression in developing photoreceptors and alterations in their number and morphology in the mature retina. These alterations were accompanied by disorganization of the inner nuclear and plexiform layers. The expression of cyclin D1 caused excess photoreceptor cell proliferation and apoptosis. Loss of the p53 tumor suppressor gene decreased cyclin D1-induced apoptosis and led to microscopic hyperplasia in the retina. These findings are distinct from other mouse models in which the retinoblastoma gene pathway is disrupted and suggest that the IRBP-cyclin D1 mouse model may recapitulate an early step in the development of retinoblastoma.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Tennessee, Dept Ophthalmol, Memphis, TN 38163 USA; Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Texas System; University of Texas Health San Antonio; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Skapek, SX (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	steve.skapek@stjude.org						Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; DIGGLE P, 1994, ANAL LONGITUNDINAL D, P63; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIN SCJ, 2001, IN PRESS ONCOGENE; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; Morrow EM, 1998, J NEUROSCI, V18, P3738; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.3.CO;2-4; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	44	31	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6742	6751		10.1038/sj.onc.1204876	http://dx.doi.org/10.1038/sj.onc.1204876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709709				2022-12-25	WOS:000171551600011
J	Chen, ZG; Dupre, DJ; Le Gouill, C; Rola-Pleszczynski, M; Stankova, J				Chen, ZG; Dupre, DJ; Le Gouill, C; Rola-Pleszczynski, M; Stankova, J			Agonist-induced internalization of the platelet-activating factor receptor is dependent on Arrestins but independent of G-protein activation - Role of the C terminus and the (D/N)PXXY MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; CYTOPLASMIC TAIL PHOSPHORYLATION; CLATHRIN-MEDIATED ENDOCYTOSIS; ANGIOTENSIN-II RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; MOLECULAR-CLONING	As with most G-protein-coupled receptors, repeated agonist stimulation of the platelet-activating factor receptor (PAFR) results in its desensitization, sequestration, and internalization. In this report, we show that agonist-induced PAFR internalization is independent of G-protein activation but is dependent on arrestins and involves the interaction of arrestins with a limited region of the PAFR C terminus. In cotransfected COS-7 cells, both arrestin-2 and arrestin-3 could be coimmunoprecipitated with PAFR, and agonist stimulation of PAFR induced the translocation of both arrestin-2 and arrestin-3. Furthermore, coexpression of arrestin-2 with PAFR potentiated receptor internalization, whereas agonist-induced PAFR internalization was inhibited by a dominant negative mutant of arrestin-2. The coexpression of a minigene encoding the C-terminal segment of the receptor abolished PAF-induced arrestin translocation and inhibited PAFR internalization. Using C terminus deletion mutants, we determined that the association of arrestin-2 with the receptor was dependent on the region between threonine 305 and valine 330 because arrestin-2 could be immunoprecipitated with the mutant PAFRstop330 but not PAFRstop305. Consistently, stop330 could mediate agonist-induced arrestin-2 translocation, whereas stop305 could not. Two other deletion mutants with slightly longer regions of the C terminus, PAFRstop311 and PAFRstop317, also failed to induce arrestin-2 translocation. Finally, the PAFR mutant Y293A, containing a single substitution in the putative internalization motif DPXXY in the seventh transmembrane domain (which we had shown to be able to internalize but not to couple to G-proteins) could efficiently induce arrestin translocation. Taken together, our results indicate that ligand-induced PAFR internalization is dependent on arrestins, that PAFR can associate with both arrestin-2 and -3, and that their translocation involves interaction with the region of residues 318-330 in the PAFR C terminus but is independent of G-protein activation.	Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Stankova, J (corresponding author), Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	stankova@courrier.usherb.ca	Dupre, Denis J/AAI-2631-2021; Chen, Zhangguo/AAW-2032-2021	Dupre, Denis J/0000-0001-6401-6157; Chen, Zhangguo/0000-0002-2741-0080				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; BENYA RV, 1993, J BIOL CHEM, V268, P20285; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hermans E, 1996, MOL PHARMACOL, V49, P365; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Krueger KM, 1997, J BIOL CHEM, V272, P5; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VANKOPPEN CJ, 1995, EUR J BIOCHEM, V234, P536; VOLGA O, 1998, J BIOL CHEM, V273, P12155; VON ZM, 1992, J BIOL CHEM, V267, P3530; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	62	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7356	7362		10.1074/jbc.M110058200	http://dx.doi.org/10.1074/jbc.M110058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11729201	hybrid			2022-12-25	WOS:000174104300079
J	McLaughlin, M; Hale, R; Ellston, D; Gaudet, S; Lue, RA; Viel, A				McLaughlin, M; Hale, R; Ellston, D; Gaudet, S; Lue, RA; Viel, A			The distribution and function of alternatively spliced insertions in hD1g	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; HUMAN HOMOLOG; DISCS LARGE; INTRAMOLECULAR INTERACTION; TYROSINE KINASE; MEMBRANE; IDENTIFICATION; CHANNEL; BINDING; DOMAINS	hDlg is the human homolog of the Drosophila Discs. large tumor suppressor. As a member of the MAGUK (membrane-associated guanylate kinase) family of scaffolding proteins, hDlg is composed of three PDZ (PSD-95, Dlg, and ZO-1) repeats, an SH3 (Src homology 3) motif, and a GUK (guanylate kinase-ne) domain. Additionally, hDlg contains two regions of alternative splicing. Here we identify a novel insertion, I1B, located N-terminal to the PDZ repeats. We further analyze the tissue-specific combinations of insertions and correlate those results with the distribution of protein isoforms. We also identify the functions of the two alternatively spliced regions. The N-terininal alternatively spliced region is capable of binding several SH3 domains and also moderates the level of protein oligomerization. Insertions in the second region are responsible for determining the localization of hDlg, with insertion I3 targeting the protein to the membrane regions of cell-cell contact and insertion 12 targeting the protein to the nucleus.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	Viel, A (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 13th St,Bldg 149, Charlestown, MA 02129 USA.	alain.viel@cbrc2.mgh.harvard.edu		Gaudet, Suzanne/0000-0002-5701-2825	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057314] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Lallena MJ, 1998, J CELL SCI, V111, P1963; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Mori K, 1998, J HUM GENET, V43, P123, DOI 10.1007/s100380050052; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wu HJ, 1998, J CELL SCI, V111, P2365	23	62	63	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6406	6412		10.1074/jbc.M108724200	http://dx.doi.org/10.1074/jbc.M108724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11723125	hybrid			2022-12-25	WOS:000173989200094
J	Funa, N; Ohnishi, Y; Ebizuka, Y; Horinouchi, S				Funa, N; Ohnishi, Y; Ebizuka, Y; Horinouchi, S			Properties and substrate specificity of RppA, a chalcone synthase-related polyketide synthase in Streptomyces griseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; MALONYL-COENZYME-A; PETROSELINUM-HORTENSE; FLAVANONE SYNTHASE; STILBENE SYNTHASE; ACTIVE-SITE; IDENTIFICATION; BIOSYNTHESIS; PURIFICATION; ANTIBIOTICS	RppA, a chalcone synthase-related polyketide synthase (type III polyketide synthase) in the bacterium Streptomyces griseus, catalyzes the formation of 1,3,6,8-tetrahydroxynaphthalene (THN) from five molecules of malonyl-CoA. The K-m value for malonyl-CoA and the k(cat) value for THN synthesis were determined to be 0.93 +/- 0.1 muM and 0.77 +/- 0.04 min(-1), respectively. RppA accepted aliphatic acyl-CoAs with the carbon lengths from C-4 to C-8 as starter substrates and catalyzed sequential condensation of malonyl-CoA to yield alpha-pyrones and phloroglucinols. In addition, RppA yielded a hexaketide, 4-hydroxy-6-(2',4',6'-trioxotridecyl)-2-pyrone, from octanoyl-CoA and five molecules of malonyl-CoA, suggesting that the size of the active site cavity of RppA is larger than any other chalcone synthase-related enzymes found so far in plants and bacteria. RppA was also found to synthesize a C-methylated pyrone, 3,6-dimethyl-4-hydroxy-2-pyrone, by using acetoacetyl-CoA as the starter and methylmalonyl-CoA as an extender. Thus, the broad substrate specificity of RppA yields a wide variety of products.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.			Ohnishi, Yasuo/0000-0001-7633-9236				Abe I, 2001, EUR J BIOCHEM, V268, P3354, DOI 10.1046/j.1432-1327.2001.02255.x; Abe I, 2000, J AM CHEM SOC, V122, P11242, DOI 10.1021/ja0027113; Akiyama T, 1999, EUR J BIOCHEM, V263, P834, DOI 10.1046/j.1432-1327.1999.00562.x; Bangera MG, 1999, J BACTERIOL, V181, P3155, DOI 10.1128/JB.181.10.3155-3163.1999; CHAPPELL J, 1984, NATURE, V311, P76, DOI 10.1038/311076a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Fujii I, 2000, BIOCHEMISTRY-US, V39, P8853, DOI 10.1021/bi000644j; FUJII I, 2000, CHEM BIOL, V65, P1; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; HEATHCOTE ML, 2001, CHEM BIOL, V67, P1; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Jez J. M., 2000, CHEM BIOL, V40, P1; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; LANZ T, 1991, J BIOL CHEM, V266, P9971; Mol J, 1999, CURR OPIN BIOTECH, V10, P198, DOI 10.1016/S0958-1669(99)80035-4; Morita H, 2001, EUR J BIOCHEM, V268, P3759, DOI 10.1046/j.1432-1327.2001.02289.x; Morita H, 2000, BIOCHEM BIOPH RES CO, V279, P190, DOI 10.1006/bbrc.2000.3920; MUSTAFAVAROGLU MH, 2000, J BACTERIOL, V182, P2619; NIXON JE, 1968, J BIOL CHEM, V243, P5471; OHAGEN D, 1991, POLYKETIDE METABOLIT; Paniego NB, 1999, EUR J BIOCHEM, V262, P612, DOI 10.1046/j.1432-1327.1999.00444.x; Pfeifer V, 2001, J BIOL CHEM, V276, P38370, DOI 10.1074/jbc.M106580200; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; Schroder J, 1998, BIOCHEMISTRY-US, V37, P8417, DOI 10.1021/bi980204g; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; Springob K, 2000, EUR J BIOCHEM, V267, P6552, DOI 10.1046/j.1432-1327.2000.01746.x; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; Suh DY, 2000, BIOCHEM J, V350, P229, DOI 10.1042/0264-6021:3500229; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; YALPANI M, 1969, EUR J BIOCHEM, V8, P495, DOI 10.1111/j.1432-1033.1969.tb00554.x; Zuurbier KWM, 1998, PHYTOCHEMISTRY, V49, P1945, DOI 10.1016/S0031-9422(98)00346-X	40	79	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4628	4635		10.1074/jbc.M110357200	http://dx.doi.org/10.1074/jbc.M110357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11723138	hybrid			2022-12-25	WOS:000173962900012
J	Pandey, KN; Nguyen, HT; Sharma, GD; Shi, SJ; Kriegel, AM				Pandey, KN; Nguyen, HT; Sharma, GD; Shi, SJ; Kriegel, AM			Ligand-regulated internalization, trafficking, and down-regulation of guanylyl cyclase/atrial natriuretic peptide receptor-A in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; LEYDIG TUMOR-CELLS; C-RECEPTORS; MEDIATED ENDOCYTOSIS; LIPOPROTEIN RECEPTOR; CLEARANCE FUNCTION; INSULIN-RECEPTOR; BINDING DOMAIN; CYCLASES	We examined the kinetics of internalization, trafficking, and down-regulation of recombinant guanylyl cyclase/natriuretic peptide receptor-A (NPRA) utilizing stably transfected 293 cells expressing a very high density of receptors. After atrial natriuretic peptide (ANP) binding to NPRA, ligand-receptor complexes are internalized, processed intracellularly, and sequestered into subcellular compartments, which provided an approach to examining directly the dynamics of metabolic turnover of NPRA in intact cells. The translocation of ligand-receptor complexes from cell surface to intracellular compartments seems to be linked to ANP-dependent down-regulation of NPRA. Using tryptic proteolysis of cell surface receptors, it was found that similar to40-50% of internalized ligand-receptor complexes recycled back to the plasma membrane with an apparent t(1/2) = 8 min. The recycling of NPRA was blocked by the lysosomotropic agent chloroquine, the energy depleter dinitrophenol, and also by low temperature, suggesting that recycling of the receptor is an energy- and temperature-dependent process. Data suggest that similar to70-80% of internalized I-125-ANP is processed through a lysosomal degradative pathway; however, 20-25% of internalized ligand is released intact into the cell exterior through an alternative mechanism involving an chloroquine-insensitive pathway. It is implied that internalization and processing of bound ANP-NPRA complexes may play an important role in mediating the biological action of hormone and the receptor protein. In retrospect, this could occur at the level of receptor regulation or through the initiation of ANP mediated signals. It is envisioned that the endocytotic pathway of ligand-receptor complexes of ANP-NPRA would lead to termination and/or diminished responsiveness of ANP in target cells.	Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University	Pandey, KN (corresponding author), Tulane Univ, Sch Med, Dept Physiol, 1430 Tulane Ave,SL39, New Orleans, LA 70112 USA.	kpandey@tulane.edu			NHLBI NIH HHS [HL 57531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057531, R56HL057531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anand-Srivastava MB, 2000, BIOCHEMISTRY-US, V39, P6503, DOI 10.1021/bi992660q; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BERHANU P, 1988, J BIOL CHEM, V263, P5961; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; BURWEN SJ, 1984, J CELL BIOL, V99, P1259, DOI 10.1083/jcb.99.4.1259; CAHILL PA, 1990, J BIOL CHEM, V265, P21896; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG TM, 1984, BIOCHIM BIOPHYS ACTA, V805, P268, DOI 10.1016/0167-4889(84)90082-X; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DELPORTE C, 1992, EUR J PHARM-MOLEC PH, V227, P247, DOI 10.1016/0922-4106(92)90002-D; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; Dunn W. A., 1984, J BIOL CHEM, V249, P5153; Espiner Eric A., 1997, P123; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; Hartford J., 1983, J BIOL CHEM, V258, P3191; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V132, P976, DOI 10.1016/0006-291X(85)91903-5; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; KOH GY, 1992, J BIOL CHEM, V267, P11987; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1985, J BIOL CHEM, V260, P3517; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; MURTHY KK, 1989, MOL CELL ENDOCRINOL, V67, P195, DOI 10.1016/0303-7207(89)90210-4; NAPIER MA, 1986, ARCH BIOCHEM BIOPHYS, V248, P516, DOI 10.1016/0003-9861(86)90504-7; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; Pandey Kailash N., 1996, P255; PANDEY KN, 1988, J BIOL CHEM, V263, P13406; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PANDEY KN, 1989, BIOCHEM BIOPH RES CO, V163, P988, DOI 10.1016/0006-291X(89)92319-X; PANDEY KN, 1992, BIOCHEM J, V288, P55, DOI 10.1042/bj2880055; PANDEY KN, 1993, J BIOL CHEM, V268, P4382; Pandey KN, 2000, MOL PHARMACOL, V57, P259; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; RONDEAU JJ, 1995, BIOCHEMISTRY-US, V34, P2130, DOI 10.1021/bi00007a005; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738	64	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4618	4627		10.1074/jbc.M106436200	http://dx.doi.org/10.1074/jbc.M106436200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11704663	hybrid			2022-12-25	WOS:000173962900011
J	Chen, SL; Loffler, KA; Chen, DG; Stallcup, MR; Muscat, GEO				Chen, SL; Loffler, KA; Chen, DG; Stallcup, MR; Muscat, GEO			The coactivator-associated arginine methyltransferase is necessary for muscle differentiation - CARM1 coactivates myocyte enhancer factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLTRANSFERASE; GENE-EXPRESSION; BINDING-FACTOR; BHLH PROTEINS; RECEPTOR; MEF2; ACTIVATION; MYOD; P300; TRANSCRIPTION	Studies with the myogenic basic helix-loop-helix and MADS box factors suggest that efficient transactivation is dependent on the recruitment of the steroid receptor coactivator (SRC) and the cofactors p300 and p300/CBP-associated factor. SRCs have been demonstrated to recruit CARM1 (coactivator-associated arginine methyltransferase-1), a member of the S-adenOSyl-L-methionine-dependent PRMTI-5 (protein-arginine N-methyltransferase-1-5) family, which catalyzes the methylation of arginine residues. This prompted us to investigate the functional role of CARM1/PRMT4 during skeletal myogenesis. We demonstrate that CARM1 and the SRC cofactor GRIP-1 cooperatively stimulate the activity of myocyte enhancer factor-2C (MEF2C). Moreover, there are direct interactions among MEF2C, GRIP-1, and CARM1. Chromatin immunoprecipitation demonstrated the in vivo recruitment of MEF2 and CARM1 to the endogenous muscle creatine kinase promoter in a differentiation-dependent manner. Furthermore, CARM1 is expressed in somites during embryogenesis and in the nuclei of muscle cells. Treatment of myogenic cells with the methylation inhibitor adenosine dialdehyde or tet-regulated CARM1 "antisense" expression did not affect expression of MyoD. However, inhibition of CARM1. inhibited differentiation and abrogated the expression of the key transcription factors (myogenin and MEF2) that initiate the differentiation cascade. This work clearly demonstrates that the arginine methyltransferase CARM1 potentiates myogenesis and supports the positive role of arginine methylation in mammalian differentiation.	Univ Queensland, Inst Mol Biosci, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Queensland; University of Southern California; University of Southern California	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.		Muscat, George/A-6401-2017	Muscat, George/0000-0002-5829-5695; Loffler, Kelly/0000-0003-3302-5995				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SL, 2000, GENE DEV, V14, P1209; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ONATE SA, 1995, SCIENCE, V270, P1354; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	30	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4324	4333		10.1074/jbc.M109835200	http://dx.doi.org/10.1074/jbc.M109835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11713257	hybrid			2022-12-25	WOS:000173813900072
J	Uchimura, K; El-Fasakhany, FM; Hori, M; Hemmerich, S; Blink, SE; Kansas, GS; Kanamori, A; Kumamoto, K; Kannagi, R; Muramatsu, T				Uchimura, K; El-Fasakhany, FM; Hori, M; Hemmerich, S; Blink, SE; Kansas, GS; Kanamori, A; Kumamoto, K; Kannagi, R; Muramatsu, T			Specificities of N-acetylglucosamine-6-O-sulfotransferases in relation to L-selectin ligand synthesis and tumor-associated enzyme expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; HIGH ENDOTHELIAL VENULES; SIALYL-LEWIS-X; MOLECULAR-CLONING; CHONDROITIN 6-SULFOTRANSFERASE; FUCT-VII; CELLS; IDENTIFICATION; TISSUE; SULFOTRANSFERASES	N-Acetylglucosamine-6-O-sulfotransferase (GIcNAc6ST) catalyzes the transfer of sulfate from adenosine 3'-phosphate,5'-phosphosulfate to the C-6 position of the non-reducing GlcNAc. Three human GlcNAc6STs, namely GlcNAc6ST-1, GIcNAc6ST-2 (HEC-GlcNAc6ST), and GlcNAc6ST-3 (I-GlcNAc6ST), were produced as fusion proteins to protein A, and their substrate specificities as well as their enzymological properties were determined. Both GlcNAc6ST-1 and GIcNAc6ST-2: efficiently utilized the following oligosaccharide structures as acceptors: GlcNAcbeta1-6[Galbeta1-3]Ga1NAc-pNP (core 2) GlcNAcbeta1-6ManOMe, and GlcNAcbeta1-2Man. The ratios of activities to these substrates were not significantly different between the two enzymes. However, GlcNAc6ST-2 but not GlcNAc6ST-1 acted on core 3 of GlcNAcbeta1-3GalNAc-pNP. GlcNAc6ST-3 used only the core 2 structure among the above mentioned oligosaccharide structures. The ability of GlcNAc6ST-1 to sulfate core 2 structure as efficiently as GlcNAc6ST-2 is consistent with the view that GIcNAc6ST-1 is also involved in the synthesis of L-selectin ligand. Indeed, cells doubly transfected with GlcNAc6ST-1 and fucosyltransferase VII cDNAs supported the rolling of L-selectin-expressing cells. The activity of GIcNAc6ST-2 on core 3 and its expression in mucinous adenocarcinoma suggested that this enzyme corresponds to the sulfotransferase, which is specifically expressed in mucinous adenocarcinoma.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Thios Biotechnol, Oakland, CA 94609 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Northwestern University; Aichi Cancer Center	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Uchimura, Kenji/C-9635-2014; ELFASAKHANY, Fathy/ABD-2927-2021; Kannagi, Reiji/Q-6459-2018; Uchimura, Kenji/AFV-1802-2022	Uchimura, Kenji/0000-0003-3009-248X; Kannagi, Reiji/0000-0003-4202-2921; Uchimura, Kenji/0000-0003-3009-248X	NHLBI NIH HHS [HL55647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bhakta S, 2000, J BIOL CHEM, V275, P40226, DOI 10.1074/jbc.M006414200; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; Bowman KG, 1998, CHEM BIOL, V5, P447, DOI 10.1016/S1074-5521(98)90161-2; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; IMAI Y, 1993, NATURE, V361, P555; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kumamoto K, 2001, CANCER RES, V61, P4620; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1987, BLOOD, V70, P1284; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Li XA, 1999, GENOMICS, V55, P345, DOI 10.1006/geno.1998.5653; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Muramatsu T, 2000, J BIOCHEM, V127, P171, DOI 10.1093/oxfordjournals.jbchem.a022590; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Seko A, 2000, GLYCOBIOLOGY, V10, P919, DOI 10.1093/glycob/10.9.919; Snapp KR, 2001, BLOOD, V97, P3806, DOI 10.1182/blood.V97.12.3806; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; TOM BH, 1977, J NATL CANCER I, V58, P1507, DOI 10.1093/jnci/58.5.1507; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Varki A., 1999, ESSENTIALS GLYCOBIOL; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4	48	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3979	3984		10.1074/jbc.M106587200	http://dx.doi.org/10.1074/jbc.M106587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726653	hybrid			2022-12-25	WOS:000173813900026
J	Furman, MH; Ploegh, HL; Tortorella, D				Furman, MH; Ploegh, HL; Tortorella, D			Membrane-specific, host-derived factors are required for US2-and US11-mediated degradation of major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; VPU PROTEIN; RAPID DEGRADATION; HEAVY-CHAINS; GENE-PRODUCTS; ER; CYTOSOL; CD4; PROTEASOME	Human cytomegalovirus encodes two glycoproteins, US2 and US11, that target major histocompatibility complex (MHC) class I heavy chains for proteasomal degradation. We have developed a mRNA-dependent cell-free system that recapitulates US2- and US11-mediated degradation of MHC class I heavy chains. Microsomes support the degradation of MHC class I heavy chains in the presence of US2 or US11 in a cytosol-dependent manner. In vitro, the glycosylated heavy chain is exported from the microsomes. A deglycosylated breakdown intermediate of the heavy chain identical to that generated in intact cells accumulates in soluble form in the presence of proteasome inhibitors. Microsomes derived from the U373 astrocytoma cell line are far more effective than canine-derived membranes in supporting this US2- or US11-dependent reaction. In contrast, the HIV-encoded Vpu membrane protein can cause the destruction of CD4 from either human- or canine-derived membranes. Using the in vitro system, we show that a truncation mutant of US2 that lacks the cytosolic domain is unable to catalyze degradation, whereas a similar truncation of US11 continues to catalyze degradation of class I heavy chains. Therefore, US2 requires both transmembrane and cytosolic interactions to trigger dislocation of heavy chains, whereas US11 relies on the transmembrane do. main to target heavy chains. US2 and US11 thus utilize different targeting mechanisms for class I degradation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,Armenise Bldg,Rm 137, Boston, MA 02115 USA.			Tortorella, Domenico/0000-0003-0961-3535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI042257, R37AI033456] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI42257, 5R37-AI33456] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali BRS, 2000, FEBS LETT, V483, P32, DOI 10.1016/S0014-5793(00)02073-1; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; Fujita K, 1997, J GEN VIROL, V78, P619, DOI 10.1099/0022-1317-78-3-619; Furman MH, 2000, HUM IMMUNOL, V61, P1169, DOI 10.1016/S0198-8859(00)00203-2; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gewurz BE, 2001, J VIROL, V75, P5197, DOI 10.1128/JVI.75.11.5197-5204.2001; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; PARHAM P, 1979, J IMMUNOL, V123, P342; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; Schust DJ, 1998, J EXP MED, V188, P497, DOI 10.1084/jem.188.3.497; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3258	3267		10.1074/jbc.M109765200	http://dx.doi.org/10.1074/jbc.M109765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11717308	hybrid			2022-12-25	WOS:000173688000028
J	Imamura, F; Maeda, S; Doi, T; Fujiyoshi, Y				Imamura, F; Maeda, S; Doi, T; Fujiyoshi, Y			Ligand binding of the second PDZ domain regulates clustering of PSD-95 with the Kv1.4 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NITRIC-OXIDE SYNTHASE; KINASE-ASSOCIATED PROTEIN; NMDA RECEPTOR SUBUNITS; EXCITATORY SYNAPSES; K+ CHANNEL; INTRAMOLECULAR INTERACTION; GUANYLATE KINASES; SEPTATE JUNCTIONS	The molecular mechanisms underlying the protein assembly at synaptic junctions are thought to be important for neural functions. PSD-95, one of the major postsynaptic density proteins, is composed of three PDZ domains (PDZ1, PDZ2, and PDZ3), an SH3 domain, and a GK (guanylate kinase) domain. It binds to the N-methyl-D-aspartate glutamate receptor NR2 subunit or to the Shaker-type K+ channel, Kv1.4, via the PDZ1 or PDZ2 domain, whereas PDZ3 binds to distinct partners. The intramolecular interaction of these multiple domains has been implicated in efficient protein clustering. We introduced missense and deletion mutations into PDZ1 (PDZ1mDelta) and/or PDZ2 (PDZ2mDelta) of the full-length PSD-95 to disrupt the association of each domain with the target proteins, while preserving the overall structure. The ion channel clustering activities of the PSD-95 mutants were analyzed in COS-1 cells coexpressing each mutant and Kv1.4. The mutant bearing the dysfunctional PDZ2 (PSD-95:1-2mDelta) showed significantly reduced clustering efficiency, whereas the mutant with the dysfunctional PDZ1 (P`SD-95:1mDelta-2) exhibited activity comparable with the wild-type activity. Furthermore, we also examined the requirements for the position of PDZ2 in full-length PSD-95 by constructing a series of PDZ1-PDZ2 inversion mutants. Surprisingly, the clustering activity of PSD-95:2-1mDelta, was severely defective. Taken together, these findings show that PDZ2, which is endowed with the highest affinity for Kv1.4, is required for efficient ligand binding. In addition, the ligand binding at the position of the second PDZ domain in full-length PSD-95 is prerequisite for efficient and typical cluster formation. This study suggests that the correct placement of the multiple domains in the full-length PSD-95 protein is necessary for the optimal protein activity.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Univ Tokyo, Dept Physiol, Grad Sch Med, Tokyo 1130033, Japan	Kyoto University; University of Tokyo	Doi, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Fujiyoshi, Yoshinori/E-5989-2012; Imamura, Fumiaki/F-5041-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Maeda, Shoji/0000-0002-7762-9793; Imamura, Fumiaki/0000-0003-1410-3126				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Walikonis RS, 2000, J NEUROSCI, V20, P4069; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	54	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3640	3646		10.1074/jbc.M106940200	http://dx.doi.org/10.1074/jbc.M106940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723117	hybrid			2022-12-25	WOS:000173688000077
J	Le, PU; Guay, G; Altschuler, Y; Nabi, IR				Le, PU; Guay, G; Altschuler, Y; Nabi, IR			Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOCRINE MOTILITY FACTOR; ONCOGENICALLY TRANSFORMED-CELLS; COATED VESICLE FORMATION; FACTOR-RECEPTOR; PLASMA-MEMBRANE; CHOLERA-TOXIN; EXPRESSION; CHOLESTEROL; DYNAMIN; INTERNALIZATION	Caveolae are flask-shaped invaginations at the plasma membrane that constitute a subclass of detergent-resistant membrane domains enriched in cholesterol and sphingolipids and that express caveolin, a caveolar coat protein. Autocrine motility factor receptor (AMF-R) is stably localized to caveolae, and the cholesterol extracting reagent, methyl-beta-cyclodextrin, inhibits its internalization to the endoplasmic reticulum implicating caveolae in this distinct receptor-mediated endocytic pathway. Curiously, the rate of methyl-beta-cyclodextrin-sensitive endocytosis of AMF-R to the endoplasmic reticulum is increased in ras- and abl-transformed NIH-3T3 cells that express significantly reduced levels of caveolin and few caveolae. Overexpression of the dynamin K44A dominant negative mutant via an adenovirus expression system induces caveolar invaginations sensitive to methyl-g-cyclodextrin extraction in the transformed cells without increasing caveolin expression. Dynamin K44A expression further inhibits AMF-R-mediated endocytosis to the endoplasmic reticulum. in untransformed and transformed NIH-3T3 cells. Adenoviral expression of caveolin-1 also induces caveolae in the transformed NIH-3T3 cells and reduces AMF-R-mediated endocytosis to the endoplasmic reticulum to levels observed in untransformed NIH-3T3 cells. Cholesterol-rich detergent-resistant membrane domains or glycolipid rafts therefore invaginate independently of caveolin-1 expression to form endocytosis-competent caveolar vesicles via rapid dynamin-dependent detachment from the plasma membrane. Caveolin-1 stabilizes the plasma membrane association of caveolae and thereby acts as a negative regulator of the caveolae-mediated endocytosis of AMF-R to the endoplasmic reticulum.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel	Universite de Montreal; Hebrew University of Jerusalem	Nabi, IR (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP 6128,Succursale A, Montreal, PQ H3C 3J7, Canada.		Nabi, Ivan R/C-5493-2009; Nabi, Ivan/GWZ-5144-2022	Nabi, Ivan/0000-0002-0670-0513				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bendayan M, 1996, J CELL SCI, V109, P1857; Bender FC, 2000, CANCER RES, V60, P5870; BENLIMAME N, 1995, J CELL BIOL, V129, P459, DOI 10.1083/jcb.129.2.459; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BRUNS RR, 1968, J CELL BIOL, V37, P244, DOI 10.1083/jcb.37.2.244; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Gines S, 2001, MOL PHARMACOL, V59, P1314, DOI 10.1124/mol.59.5.1314; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Le PU, 2000, J CELL SCI, V113, P3227; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NABI IR, 1990, CANCER RES, V50, P409; Nagai Y, 1996, DERMATOLOGY, V192, P8, DOI 10.1159/000246304; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; OTTO T, 1994, CANCER RES, V54, P3120; PALADE GE, 1953, J APPL PHYS, V24, P1424; PALADE GE, 1958, ANAT REC, V130, P467; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sandvig K, 1999, FEBS LETT, V452, P67, DOI 10.1016/S0014-5793(99)00529-3; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Verkade P, 2000, J CELL BIOL, V148, P727, DOI 10.1083/jcb.148.4.727; Wang HJ, 2000, J CELL BIOL, V150, P1489, DOI 10.1083/jcb.150.6.1489; Wang HJ, 1997, J CELL SCI, V110, P3043; WATANABE H, 1991, CANCER RES, V51, P2699; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	79	188	193	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3371	3379		10.1074/jbc.M111240200	http://dx.doi.org/10.1074/jbc.M111240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724808	hybrid			2022-12-25	WOS:000173688000043
J	Voziyan, PA; Metz, TO; Baynes, JW; Hudson, BG				Voziyan, PA; Metz, TO; Baynes, JW; Hudson, BG			A post-amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ADVANCED MAILLARD REACTION; IN-VIVO DETERMINATION; CROSS-LINKING; DIABETIC COMPLICATIONS; SKIN COLLAGEN; AUTOXIDATIVE GLYCOSYLATION; DICARBONYL-COMPOUNDS; MECHANISM; METHYLGLYOXAL	Reactive carbonyl compounds are formed during autoxidation of carbohydrates and peroxidation of lipids. These compounds are intermediates in the formation of advanced glycation end products (AGE) and advanced lipoxidation end products (ALE) in tissue proteins during aging and in chronic disease. We studied the reaction of carbonyl compounds glyoxal (GO) and glycolaldehyde (GLA) with pyridoxamine (PM), a potent post-Amadori inhibitor of AGE formation in vitro and of development of renal and retinal pathology in diabetic animals. PM reacted rapidly with GO and GLA in neutral, aqueous buffer, forming a Schiff base intermediate that cyclized to a hemiaminal adduct by intramolecular reaction with the phenolic hydroxyl group of PM. This bicyclic intermediate dimerized to form a five-ring compound with a central piperazine ring, which was characterized by electrospray ionization-liquid chromatography/mass spectrometry, NMR, and x-ray crystallography. PM also inhibited the modification of lysine residues and loss of enzymatic activity of RNase in the presence of GO and GLA and inhibited formation of the AGE/ALE N-epsilon-(carboxymethyl)lysine during reaction of GO and GLA with bovine serum albumin. Our data suggest that the AGE/ALE inhibitory activity and the therapeutic effects of PM observed in diabetic animal models depend, at least in part, on its ability to trap reactive carbonyl intermediates in AGE/ALE formation, thereby inhibiting the chemical modification of tissue proteins.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of Kansas; University of Kansas Medical Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Voziyan, PA (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.			Hudson, Billy/0000-0002-5420-4100; Metz, Tom/0000-0001-6049-3968	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK018381, R37DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R37 DK18381-28, DK-19971] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALDERSON NA, 2001, 2001 AM DIAB ASS 61, P696; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; ATKINS TW, 1989, DIABETES RES CLIN EX, V11, P125; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Booth AA, 1996, BIOCHEM BIOPH RES CO, V220, P113, DOI 10.1006/bbrc.1996.0366; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; *BRUK AN XRAY SYST, 1998, SMART VERS 5 624 SAI; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BUTLER WL, 1979, METHOD ENZYMOL, V56, P505; COLACO CALS, 1994, NEUROREPORT, V5, P859, DOI 10.1097/00001756-199404000-00001; Degenhardt TP, 1999, DIABETES RES CLIN PR, V43, P81, DOI 10.1016/S0168-8227(98)00121-1; DEGENHARDT TP, 2002, IN PRESS KIDNEY INT; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FIELDS R, 1971, BIOCHEM J, V121, P587, DOI 10.1042/bj1210587; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GUSTAFSON RL, 1957, ARCH BIOCHEM BIOPHYS, V68, P485, DOI 10.1016/0003-9861(57)90379-X; HAYASHI T, 1986, AMINO CARBONYL REACT, P29; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; KALNITSKY G, 1959, J BIOL CHEM, V234, P1512; KARTHA G, 1967, NATURE, V213, P862, DOI 10.1038/213862a0; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; LO TWC, 1994, BIOCHEM PHARMACOL, V48, P1865, DOI 10.1016/0006-2952(94)90584-3; Lubec B, 1997, NEPHRON, V75, P213, DOI 10.1159/000189534; MITCHEL REJ, 1977, ANAL BIOCHEM, V81, P47, DOI 10.1016/0003-2697(77)90597-8; Miyata T, 1999, INT J ARTIF ORGANS, V22, P195, DOI 10.1177/039139889902200402; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; Ohmori S, 1989, Prog Clin Biol Res, V290, P397; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; POLLAK A, 1983, CLIN CHIM ACTA, V133, P15, DOI 10.1016/0009-8981(83)90016-5; POLLAK A, 1984, ACTA DIABETOL LAT, V21, P123, DOI 10.1007/BF02591101; Py G, 2001, METABOLISM, V50, P418, DOI 10.1053/meta.2001.21692; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Ruggiero-Lopez D, 1999, BIOCHEM PHARMACOL, V58, P1765, DOI 10.1016/S0006-2952(99)00263-4; Sheldrick G.M., 1997, SHELXTL PC VERSION 5; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; Shoda H, 1997, ENDOCRINOLOGY, V138, P1886, DOI 10.1210/en.138.5.1886; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; THOMPSON DM, 1980, INORG CHIM A-BIOINOR, V46, P199, DOI 10.1016/S0020-1693(00)84191-2; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YAMADA H, 1994, J BIOL CHEM, V269, P20275	59	177	203	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3397	3403		10.1074/jbc.M109935200	http://dx.doi.org/10.1074/jbc.M109935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11729198	hybrid, Green Published			2022-12-25	WOS:000173688000046
J	Cortes, MJ; Wong-Staal, F; Lama, J				Cortes, MJ; Wong-Staal, F; Lama, J			Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN INDUCES DEGRADATION; INDEPENDENT DOWN-REGULATION; VPU-INDUCED DEGRADATION; CYTOPLASMIC DOMAIN; ENVELOPE GLYCOPROTEIN; NEF PROTEIN; MATRIX PROTEIN; EXPRESSION; REQUIREMENT	The CD4 protein is required for the entry of human immunodeficiency virus (HIV) into target cells. Upon expression of the viral genome, three HIV-1 gene products participate in the removal of the primary viral receptor from the cell surface. To investigate the role of surface-CD4 in HIV replication, we have created a set of Jurkat cell lines which constitutively express surface levels of CD4 comparable to those found in peripheral blood lymphocytes and monocytes. Expression of low levels of CD4 on the surface of producer cells exerted an inhibitory effect on the infectivity of HIV-1 particles, whereas no differences in the amount of cell-free p24 antigen were observed. Higher levels of cell surface CD4 exerted a stronger inhibitory effect on infectivity, and also affected the release of free virus in experiments where the viral genomes were delivered by electrotransfection. The CD4-mediated inhibition of HIV-1 infectivity was not observed in experiments where the vesicular stomatitis virus G protein was used to pseudotype viruses, suggesting that an interaction between CD4 and gp120 is required for interference. In contrast, inhibition of particle release by high levels of cell-surface CD4 was not overcome by pseudotyping HIV-1. with foreign envelope proteins. Protein analysis of viral particles released from HIV-infected Jurkat-T cells revealed a CD4-dependent reduction in the incorporation of gp120. These results demonstrate that physiological levels of cell-surface CD4 interfere with HIV-1 replication in T cells by a mechanism that inhibits envelope incorporation into viral membranes, and therefore provide an explanation for the need to down-modulate the viral receptor in infected cells. Our findings have important implications for the spread of HIV in vivo and suggest that the CD4 down-modulation function may be an alternative target for therapeutic intervention.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Lama, J (corresponding author), Univ Calif San Diego, Dept Med, Mail Code 0665,9500 Gilman Dr, La Jolla, CA 92093 USA.	jlama@ucsd.edu			NIAID NIH HHS [P30AI36214-905] Funding Source: Medline; NIDA NIH HHS [DA13866-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013866] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ANDERSON SJ, 1994, J VIROL, V68, P3092, DOI 10.1128/JVI.68.5.3092-3101.1994; BANDRES JC, 1995, VIROLOGY, V207, P338, DOI 10.1006/viro.1995.1089; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; Bour S, 1999, J BIOL CHEM, V274, P33800, DOI 10.1074/jbc.274.47.33800; BOUR S, 1995, MICROBIOL REV, V59, P63, DOI 10.1128/MMBR.59.1.63-93.1995; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; Carl S, 2001, J VIROL, V75, P3657, DOI 10.1128/JVI.75.8.3657-3665.2001; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Harris M, 1999, CURR BIOL, V9, pR459, DOI 10.1016/S0960-9822(99)80282-6; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Lee YM, 1997, J VIROL, V71, P1443, DOI 10.1128/JVI.71.2.1443-1452.1997; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; Luo TC, 2001, J VIROL, V75, P2488, DOI 10.1128/JVI.75.5.2488-2492.2001; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MARSHALL WL, 1992, J VIROL, V66, P5492, DOI 10.1128/JVI.66.9.5492-5499.1992; Millan J, 1999, TISSUE ANTIGENS, V53, P33, DOI 10.1034/j.1399-0039.1999.530104.x; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697; SAGGIORO D, 1993, J BIOL CHEM, V268, P1368; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sorice M, 1997, J LIPID RES, V38, P969; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; TEMIN HM, 1988, REV INFECT DIS, V10, P399; TREMBLAY M, 1994, EMBO J, V13, P774, DOI 10.1002/j.1460-2075.1994.tb06320.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VINCENT MJ, 1993, J VIROL, V67, P5538, DOI 10.1128/JVI.67.9.5538-5549.1993; WANG H, 1992, J BIOL CHEM, V267, P23617; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; WEISS A, 1984, J IMMUNOL, V133, P123; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992	51	64	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1770	1779		10.1074/jbc.M109807200	http://dx.doi.org/10.1074/jbc.M109807200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704677	hybrid			2022-12-25	WOS:000173421300021
J	Kwon, YW; Ueda, S; Ueno, M; Yodoi, J; Masutani, H				Kwon, YW; Ueda, S; Ueno, M; Yodoi, J; Masutani, H			Mechanism of p53-dependent apoptosis induced by 3-methylcholanthrene - Involvement of p53 phosphorylation and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; DAMAGE-INDUCED PHOSPHORYLATION; AH GENE BATTERY; UV-RADIATION; KINASE ACTIVATION; REDOX REGULATION; IN-VIVO; PROTEIN; CELLS; THIOREDOXIN	Polycyclic aromatic hydrocarbons (PAHs) such as 3-methylcholanthrene (MC) cause untoward effects including carcinogenesis. Here we investigated the effect of MC on apoptosis. MC induced apoptosis, preceded by serine 15 phosphorylation and accumulation of p53. MC failed to cause apoptosis in p53-deficient MG63 cells, whereas ectopic expression of p53 in MG63 cells restored the response to MC. Therefore, MC-induced apoptosis was dependent on p53. MC also activated p38 mitogen-activated protein kinase (MAPK) at 16-24 h. Accumulation of p53 and p53 phosphorylated at serine 15 was not changed by SB203580, a specific inhibitor of p38 MAPK or overexpression of a dominant negative mutant of p38 MAPK at 8 It after MC treatment, whereas the accumulation was suppressed at 24 h. These results suggest that MC induces accumulation and phosphorylation of p53 via a p38 MAPK-independent (early) and p38 MAPK-dependent (late) pathway. SB203580 repressed MC-induced apoptosis. MC induced p38 MAPK activation in p53 expressing cells but not in p53-deficient cells, indicating that the p38 MAPK activation was dependent on early p53 activation. The current study shows that both p53 and p38 MAPK activation are required for MC-induced apoptosis and provides a novel model of a functional regulation between p53 and p38 MAPK in chemical stress-induced apoptosis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				ALBOR A, 1994, CANCER RES, V54, P4502; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burczynski ME, 2000, CANCER RES, V60, P908; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; HARRIS CC, 1974, NATURE, V252, P68, DOI 10.1038/252068a0; Harris CC, 1996, ENVIRON HEALTH PERSP, V104, P435, DOI 10.2307/3432799; Hashimoto S, 1999, BIOCHEM BIOPH RES CO, V258, P443, DOI 10.1006/bbrc.1999.0658; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Holsapple MP, 1996, ANNU REV PHARMACOL, V36, P131; HONMA M, 1994, MUTAT RES, V304, P167, DOI 10.1016/0027-5107(94)90208-9; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutz CT, 1998, TOXICOLOGY, V128, P151, DOI 10.1016/S0300-483X(98)00043-2; Maki CG, 1996, CANCER RES, V56, P2649; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; Masutani H, 2000, ANTIOXIDANT REDOX RE, P297; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Ng D, 1998, J IMMUNOL, V161, P942; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PARK JK, 1991, LIFE SCI, V48, P1255; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rorke EA, 1998, INT J ONCOL, V13, P557; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salas VM, 1998, TOXICOL APPL PHARM, V151, P367, DOI 10.1006/taap.1998.8455; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TOTH B, 1968, CANCER RES, V28, P727; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WILHELMSSON A, 1994, J BIOL CHEM, V269, P19028; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	43	72	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1837	1844		10.1074/jbc.M105033200	http://dx.doi.org/10.1074/jbc.M105033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706017	hybrid			2022-12-25	WOS:000173421300030
J	Vazquez, F; Grossman, SR; Takahashi, Y; Rokas, MV; Nakamura, N; Sellers, WR				Vazquez, F; Grossman, SR; Takahashi, Y; Rokas, MV; Nakamura, N; Sellers, WR			Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TYROSINE-PHOSPHATASE; PDZ DOMAIN; BINDING; GENE; STABILITY	PTEN is a tumor suppressor protein that functions, in large part, by dephosphorylating the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate and by doing so antagonizing the action of phosphoinositide 3-kinase. PTEN structural domains include an N-terminal phosphatase domain, a lipid-binding C2 domain, and a 50-amino acid C-terminal tail that contains a PDZ binding sequence. We showed previously that phosphorylation of the PTEN tail negatively regulates PTEN activity. We now show that phosphorylated PTEN exists in a monomeric "closed" conformation and has low affinity for PDZ domain-containing proteins. Conversely, when unphosphorylated, PTEN is in an "open" conformation, is recruited into a high molecular weight complex (PTEN-associated complex), and strongly interacts with PDZ-containing proteins such as MAGI-2. As a consequence, when compared with wild-type PTEN, the phosphorylation-deficient mutant form of PTEN strongly cooperates with MAGI-2 to block Akt activation. These results indicate that phosphorylation of the PTEN tail causes a conformational change that results in the masking of the PDZ binding domain. Consequently, the ability of PTEN to bind to PDZ domain-containing proteins is reduced dramatically. These data suggest that phosphorylation of the PTEN tail suppresses the activity of PTEN by controlling the recruitment of PTEN into the PTEN-associated complex.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Adult Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sellers, WR (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Adult Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA.	William_Sellers@dfci.harvard.edu						Adey NB, 2000, CANCER RES, V60, P35; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Chen HM, 1999, HUM GENET, V105, P399, DOI 10.1007/s004390051122; Georgescu MM, 2000, CANCER RES, V60, P7033; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	21	337	352	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48627	48630		10.1074/jbc.C100556200	http://dx.doi.org/10.1074/jbc.C100556200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11707428	hybrid			2022-12-25	WOS:000173922100004
J	Karymov, MA; Tomschik, M; Leuba, SH; Caiafa, P; Zlatanova, J				Karymov, MA; Tomschik, M; Leuba, SH; Caiafa, P; Zlatanova, J			DNA methylation-dependent chromatin fiber compaction in vivo and in vitro: requirement for linker histone	FASEB JOURNAL			English	Article						histone H1; chromatin fibers; atomic force microscopy	SCANNING FORCE MICROSCOPY; CPG METHYLATION; CORE PARTICLES; H1 HISTONE; RNA GENE; NUCLEOSOME; POLY(ADP-RIBOSYL)ATION; BINDING; TRANSCRIPTION; REPRESSION	Dynamic alterations in chromatin structure mediated by postsynthetic histone modifications and DNA methylation constitute a major regulatory mechanism in DNA functioning. DNA methylation has been implicated in transcriptional silencing, in part by inducing chromatin condensation. To understand the methylation-dependent chromatin structure, we performed atomic force microscope (AFM) studies of fibers isolated from cultured cells containing normal or elevated levels of m(5)C. Chromatin fibers were reconstituted on control or methylated DNA templates in the presence or absence of linker histone. Visual inspection of AFM images, combined with quantitative analysis of fiber structural parameters, suggested that DNA methylation induced fiber compaction only in the presence of linker histones. This conclusion was further substantiated by biochemical results.	Polytech Univ, Dept Chem & Chem Engn, Brooklyn, NY 11201 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, I-00161 Rome, Italy	New York University; Polytechnic University Puerto Rico; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sapienza University Rome	Zlatanova, J (corresponding author), Polytech Univ, Dept Chem & Chem Engn, 6 Metrotech Ctr, Brooklyn, NY 11201 USA.	leuba@nih.gov; jzlatano@duke.poly.edu	, Miroslav/AAD-9416-2020; Zlatanova, Jordanka/B-3273-2009	, Miroslav/0000-0002-0758-6169; Leuba, Sanford/0000-0003-0278-7997				An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAIAFA P, 1986, BIOCHIM BIOPHYS ACTA, V867, P195, DOI 10.1016/0167-4781(86)90034-5; CARTWRIGHT IL, 1989, METHOD ENZYMOL, V170, P359; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; De Capoa A, 1999, FASEB J, V13, P89; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2000, CURR BIOL, V10, pR60, DOI 10.1016/S0960-9822(00)00286-4; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; LEUBA SH, 1994, J MOL BIOL, V235, P871, DOI 10.1006/jmbi.1994.1045; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Leuba SH, 1999, METH MOL B, V119, P143; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Razin Aharon, 1999, Results and Problems in Cell Differentiation, V25, P189; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, BIOL CHEM, V379, P647; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	60	50	55	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2631	2641		10.1096/fj.01-0345com	http://dx.doi.org/10.1096/fj.01-0345com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726539				2022-12-25	WOS:000172964800033
J	Finta, C; Zaphiropoulos, PG				Finta, C; Zaphiropoulos, PG			Intergenic mRNA molecules resulting from trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450; MAMMALIAN-CELLS; EXON REPETITION; RAT-LIVER; GENE; TRANSCRIPTS; LOCUS; IDENTIFICATION; ORGANIZATION; PRECURSORS	Accumulated recent evidence is indicating that alternative splicing represents a generalized process that increases the complexity of human gene expression. Here we show that mRNA production may not necessarily be limited to single genes, as human liver also has the potential to produce a variety of hybrid cytochrome P450 3A mRNA molecules. The four known cytochrome P450 3A genes in humans, CYP3A4, CYP3A5, CYP3A7, and CYP3A43, share a high degree of similarity, consist of 13 exons with conserved exon-intron boundaries, and form a cluster on chromosome 7. The chimeric CYP3A mRNA molecules described herein are characterized by CYP3A43 exon 1 joined at canonical splice sites to distinct sets of CYP3A4 or CYP3A5 exons. Because the CYP3A43 gene is in a head-to-head orientation with the CYP3A4 and CYP3A5 genes, bypassing transcriptional termination can not account for the formation of hybrid CYP3A mRNAs. Thus, the mechanism generating these molecules has to be an RNA processing event that joins exons of independent pre-mRNA molecules, i.e. transsplicing. Using quantitative real-time polymerase chain reaction, the ratio of one CYP3A43/3A4 intergenic combination was estimated to be similar to0.15% that of the CYP3A43 mRNAs. Moreover, trans-splicing has been found not to interfere with polyadenylation. Heterologous expression of the chimeric species composed of CYP3A43 exon 1 joined to exons 2-13 of CYP3A4 revealed catalytic activity toward testosterone.	Karolinska Inst, Dept Biosci, Ctr Nutr & Toxicol, SE-14157 Huddinge, Sweden	Karolinska Institutet	Zaphiropoulos, PG (corresponding author), Karolinska Inst, Dept Biosci, Ctr Nutr & Toxicol, SE-14157 Huddinge, Sweden.	peter.zaphiropoulos@cnt.ki.se		Zaphiropoulos, Peter/0000-0003-4298-3861				Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; Breen MA, 1997, FEBS LETT, V409, P375, DOI 10.1016/S0014-5793(97)00555-3; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; Chao CW, 1998, MOL MED, V4, P614, DOI 10.1007/BF03401761; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; Crawford J, 1999, GENOMICS, V56, P90, DOI 10.1006/geno.1998.5676; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Finta C, 2000, GENOMICS, V63, P433, DOI 10.1006/geno.1999.6063; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; Gellner K, 2001, PHARMACOGENETICS, V11, P111, DOI 10.1097/00008571-200103000-00002; Graessmann M, 1996, FEBS LETT, V394, P233, DOI 10.1016/0014-5793(96)00956-8; GULICK T, 1997, CURRENT PROTOCOLS MO; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirose Y, 2000, GENE DEV, V14, P1415; Kim J, 2000, GENOMICS, V64, P114, DOI 10.1006/geno.1999.6112; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Marcucci G, 1998, CANCER RES, V58, P790; Muller-Enoch D, 2000, Z NATURFORSCH C, V55, P747; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Neve EPA, 2000, J BIOL CHEM, V275, P17130, DOI 10.1074/jbc.M000957200; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Seroussi E, 1999, GENOME RES, V9, P803, DOI 10.1101/gr.9.9.803; SHIMIZU A, 1991, J EXP MED, V173, P1385, DOI 10.1084/jem.173.6.1385; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; Surono A, 1999, HUM MOL GENET, V8, P493, DOI 10.1093/hmg/8.3.493; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; VELLARD M, 1991, ONCOGENE, V6, P505; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; Westlind A, 2001, BIOCHEM BIOPH RES CO, V281, P1349, DOI 10.1006/bbrc.2001.4505; Zaphiropoulos PG, 1997, MOL CELL BIOL, V17, P2985, DOI 10.1128/MCB.17.6.2985; Zaphiropoulos PG, 1996, P NATL ACAD SCI USA, V93, P6536, DOI 10.1073/pnas.93.13.6536; Zaphiropoulos PG, 1999, NUCLEIC ACIDS RES, V27, P2585, DOI 10.1093/nar/27.13.2585	47	116	125	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5882	5890		10.1074/jbc.M109175200	http://dx.doi.org/10.1074/jbc.M109175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11726664	hybrid			2022-12-25	WOS:000173989200026
J	Korchynskyi, O; ten Dijke, P				Korchynskyi, O; ten Dijke, P			Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; SMAD-BINDING-ELEMENT; FACTOR-BETA; DNA-BINDING; MYOGENIC DIFFERENTIATION; FAMILY MEMBERS; ACTIVIN-A; CELLS; GENE; LOOP	Transforming growth factor-beta (TGF-beta) family members, which include bone morphogenetic proteins (BMPs) and TGF-betas, elicit their cellular effects by activating specific Smad proteins, which control the transcription of target genes. BMPs and TGF-betas have overlapping as well as specific effects on mesenchymal cell differentiation for which the mechanisms are incompletely understood. Here we report that Id1, a dominant negative inhibitor of basic helix-loop-helix proteins, is a direct target gene for BMP. BMP, but not TGF-beta, strongly activates the Id1 promoter in an Smad-dependent manner. We identified two BMP-responsive regions in the mouse Id1 promoter, which contain three distinct sequence elements; one region contains two Smad binding elements (SBEs), and the other region contains a GGCGCC palindromic sequence flanked by two CAGC and two CGCC motifs. Whereas SBEs and GGCGCC sequence are critically important, the CAGC and CGCC motifs are needed for efficient BMP-induced Id1 promoter activation. Smads are part of nuclear transcription factor complexes that specifically bind to SBEs and GGCGCC sequence in response to BMP but not TGF-beta. Multimerization of the all three distinct sequence motifs is needed to generate a highly sensitive and BMP/Smad-dependent specific enhancer. Our results provide important new insights into how the BMP/Smad pathway can specifically activate target genes.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	ten Dijke, P (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Korchynskyi, Olexandr/ADA-6398-2022; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Korchynskyi, Olexandr/0000-0002-4557-4003				Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.3.CO;2-K; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Link BA, 1997, EXP CELL RES, V233, P350, DOI 10.1006/excr.1997.3575; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Tournay O, 1996, MOL CELL BIOL, V16, P2418; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	47	697	729	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4883	4891		10.1074/jbc.M111023200	http://dx.doi.org/10.1074/jbc.M111023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11729207	hybrid			2022-12-25	WOS:000173962900045
J	Datta, A; Huber, F; Boettiger, D				Datta, A; Huber, F; Boettiger, D			Phosphorylation of beta(3) integrin controls ligand binding strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; CYTOPLASMIC DOMAIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; TALIN-BINDING; OUTSIDE-IN; FIBRONECTIN; ACTIVATION; TRANSFORMATION; SUBUNIT	The cytoplasmic domain of beta3 integrin contains tyrosines at positions 747 and 759 in domains that have been implicated in regulation of alpha(v)beta(3) function and that serve as potential substrates for Src family kinases. The phosphorylation level of beta(3) integrin was modulated using a temperature-sensitive v-Src kinase. Increased beta(3) phosphorylation abolished alpha(v)beta(3)- but not alpha(5)beta(1)-mediated adhesion to fibronectin. alpha(v)beta(3)-Mediated cell adhesion was restored by the expression of beta(3) containing Y747F or Y759F mutations but not by wild type beta(3) integrin. Thus, phosphorylation of the cytoplasmic domain of beta(3) is a negative regulator of alpha(v)beta(3)-fibronectin binding strength.	Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Boettiger, D (corresponding author), Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.	boettige@mail.med.upenn.edu	Huber, Francois/G-6245-2011		NATIONAL CANCER INSTITUTE [R01CA016502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057388] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; Boettiger D, 2001, J BIOL CHEM, V276, P31684, DOI 10.1074/jbc.M103997200; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Datta A, 2001, MOL CELL BIOL, V21, P7295, DOI 10.1128/MCB.21.21.7295-7306.2001; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; ENOMOTOIWAMOTO M, 1993, CELL ADHES COMMUN, V1, P191, DOI 10.3109/15419069309097253; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142-9612(99)00170-2; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; Garcia AJ, 1997, BIOMATERIALS, V18, P1091, DOI 10.1016/S0142-9612(97)00042-2; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARONEY AC, 1992, ONCOGENE, V7, P1207; Neff S, 1998, J VIROL, V72, P3587, DOI 10.1128/JVI.72.5.3587-3594.1998; Parise LV, 1999, CURR OPIN CELL BIOL, V11, P597, DOI 10.1016/S0955-0674(99)00018-6; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; TAPLEY P, 1989, ONCOGENE, V4, P325; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YLANNE J, 1995, J BIOL CHEM, V270, P9550; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	46	62	63	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3943	3949		10.1074/jbc.M109536200	http://dx.doi.org/10.1074/jbc.M109536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723131	hybrid			2022-12-25	WOS:000173813900021
J	Floyd, ZE; Stephens, JM				Floyd, ZE; Stephens, JM			Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPAR gamma in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPROVED INSULIN-SENSITIVITY; RECEPTOR-GAMMA; PROTEIN-KINASE; ESTROGEN-RECEPTOR; 26S PROTEASOME; PROLIFERATOR; PHOSPHORYLATION; LIGAND; RESISTANCE; EXPRESSION	Interferon-gamma (IFNgamma) treatment of adipocytes results in a down-regulation of the peroxisome proliferator-activated receptor gamma (PPARgamma). The decrease in PPARgamma expression is mediated by inhibition of PPARgamma synthesis and increased degradation of PPARgamma. In this study, we demonstrate that both PPARgamma1 and PPARgamma2 are targeted to the proteasome under basal conditions and that PPARgamma1 is more labile than PPARgamma2. The IFNgamma-induced increase in PPARgamma turnover is blocked by proteasome inhibition and is accompanied by an increase in PPARgamma-polyubiquitin conjugates. In addition, IFNgamma treatment results in the transcriptional activation of PPARgamma. Similar to ligand-dependent activation of PPARgamma, IFNgamma-induced activation was greater in the phosphorylation-deficient S112A form of PPARgamma when compared with wild-type PPARgamma. Moreover, the inhibition of ERKs I and 2 with a MEK inhibitor, U1026, lead to an inhibition in the decay of PPARgamma proteins, indicating that serine phosphorylation influences the degradation of PPARgamma in fat cells. Our results also demonstrate that the proteasome-dependent degradation of PPARgamma does not require nuclear export. Taken together, these results indicate that PPARgamma is targeted to the ubiquitin-proteasome pathway for degradation under basal conditions and that IFNgamma leads to an increased targeting of PPARgamma to the ubiquitin-proteasome system in a process that is affected by ERK-regulated serine phosphorylation of PPARgamma proteins.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.		Stephens, Jacqueline M/R-5217-2018; Floyd, Elizabeth/W-2758-2019; Floyd, Elizabeth/N-1962-2017	Floyd, Elizabeth/0000-0002-3002-6186; Floyd, Elizabeth/0000-0002-3002-6186	NIDDK NIH HHS [R01DK52968-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052968] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berberich SJ, 1999, DIFFERENTIATION, V64, P205, DOI 10.1046/j.1432-0436.1999.6440205.x; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; Egea PF, 2000, FEBS LETT, V476, P62, DOI 10.1016/S0014-5793(00)01672-0; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GREGOIRE F, 1992, J CELL PHYSIOL, V151, P300, DOI 10.1002/jcp.1041510211; Grossberg S E, 1980, Ann N Y Acad Sci, V350, P294, DOI 10.1111/j.1749-6632.1980.tb20629.x; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; Khanna S, 1999, AM J PHYSIOL-REG I, V276, pR1327, DOI 10.1152/ajpregu.1999.276.5.R1327; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Rieusset J, 1999, DIABETES, V48, P699, DOI 10.2337/diabetes.48.4.699; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosenbaum SE, 1998, MOL ENDOCRINOL, V12, P1150, DOI 10.1210/me.12.8.1150; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Shiba T, 1998, DIABETIC MED, V15, P435, DOI 10.1002/(SICI)1096-9136(199805)15:5<435::AID-DIA566>3.0.CO;2-N; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	56	152	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4062	4068		10.1074/jbc.M108473200	http://dx.doi.org/10.1074/jbc.M108473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11733495	hybrid, Green Published			2022-12-25	WOS:000173813900037
J	Hope, RG; Murphy, DJ; McLauchlan, J				Hope, RG; Murphy, DJ; McLauchlan, J			The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; OIL BODIES; STRUCTURAL PROTEINS; SECONDARY STRUCTURE; STORAGE DROPLETS; BODY FORMATION; EXPRESSION; CLEAVAGE; SEQUENCE; CELLS	In mammalian tissue culture cells, the core protein of hepatitis C virus (HCV) is located at the surface of lipid droplets, which are cytoplasmic structures that store lipid. The critical amino acid sequences necessary for this localization are in a region of core protein that is absent in flavi- and pestiviruses, which are related to HCV. From our sequence comparisons, this region in HCV core was present in the corresponding protein of GBV-B, another virus whose genomic sequence has significant similarity to HCV. Expression of the putative GBV-B core protein revealed that it also was directed to lipid droplets. By extending the comparisons to cellular proteins, there were amino acid sequence similarities between the domains for lipid droplet association in HCV core and plant oleosin proteins. To determine whether these similarities were related functionally, an oleosin encoded by the Brassica napus bniii grene was expressed in different mammalian cell lines, where it retained the capacity to bind to lipid droplets. Analysis of deletion mutants indicated that them critical region within the protein required for this localization was the same for both plant and mammalian cells. A common feature in the viral and plant sequences was a motif containing proline residues. Mutagenesis of these, residues in HCV core and plant oleosin abolished lipid droplet association. Finally, the domain within HCV core required for binding to lipid droplets could substitute for the equivalent domain in oleosin, further indicating the functional relatedness between the viral and plant sequences. These studies identify common! features in disparate proteins that are required for lipid droplet localization.	MRC, Virol Unit, Inst Virol, Glasgow G11 5JR, Lanark, Scotland; Univ Glamorgan, Sch Appl Sci, Pontypridd CF37 1DL, M Glam, Wales	University of Glasgow; University of South Wales	McLauchlan, J (corresponding author), MRC, Virol Unit, Inst Virol, Church St, Glasgow G11 5JR, Lanark, Scotland.		Murphy, Denis J/ABC-1734-2020	Murphy, Denis J/0000-0002-5291-2445				Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; Amberg SM, 1999, J VIROL, V73, P8083, DOI 10.1128/JVI.73.10.8083-8094.1999; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Beames B, 2000, J VIROL, V74, P11764, DOI 10.1128/JVI.74.24.11764-11772.2000; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Bukh J, 1999, VIROLOGY, V262, P470, DOI 10.1006/viro.1999.9941; Chen JCF, 1999, PLANT CELL PHYSIOL, V40, P1079, DOI 10.1093/oxfordjournals.pcp.a029490; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KEDDIE JS, 1992, PLANT MOL BIOL, V19, P443, DOI 10.1007/BF00023392; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lacey DJ, 1998, BIOCHEM J, V334, P469, DOI 10.1042/bj3340469; LI M, 1992, J BIOL CHEM, V267, P8245; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MANDL CW, 1988, VIROLOGY, V166, P197, DOI 10.1016/0042-6822(88)90161-4; MCLAUCHLAN J, 1994, J GEN VIROL, V75, P2047, DOI 10.1099/0022-1317-75-8-2047; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Naested H, 2000, PLANT MOL BIOL, V44, P463, DOI 10.1023/A:1026564411918; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Sarmiento C, 1997, PLANT J, V11, P783, DOI 10.1046/j.1365-313X.1997.11040783.x; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ting JTL, 1997, J BIOL CHEM, V272, P3699, DOI 10.1074/jbc.272.6.3699; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	51	136	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4261	4270		10.1074/jbc.M108798200	http://dx.doi.org/10.1074/jbc.M108798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706032	hybrid			2022-12-25	WOS:000173813900064
J	Ross, S; Tienhaara, A; Lee, MS; Tsai, LH; Gill, G				Ross, S; Tienhaara, A; Lee, MS; Tsai, LH; Gill, G			GC box-binding transcription factors control the neuronal specific transcription of the cyclin-dependent kinase 5 regulator p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; CDK5 ACTIVATOR; PROTEIN-KINASE; TAU-PROTEIN; RAT-BRAIN; SILENCER ELEMENT; DNA-BINDING; SP1; EXPRESSION; PHOSPHORYLATION	Cyclin-dependent kinase 5 (cdk5)/p35 kinase activity is highest in post-mitotic neurons of the central nervous system and is critical for development and function of the brain. The neuronal specific activity of the cdk5/p35 kinase is achieved through the regulated expression of p35 mRNA. We have identified a small 200-bp fragment of the p35 promoter that is sufficient for high levels of neuronal specific expression. Mutational analysis of this TATA-less promoter has identified a 17-bp GC-rich element, present twice, that is both required for promoter activity and sufficient for neuronal specific transcription. A GC box within the 17-bp element is critical for both promoter activity and protein-DNA complex formation. The related transcription factors Sp1, Sp3, and Sp4 constitute most of the GC box DNA binding activity in neurons. We have found that both the relative contribution of the Sp family proteins to GC box binding and the transcriptional activity of these proteins is regulated during neuronal differentiation. Thus, our data show that the GC box-binding Sp proteins contribute to the regulation of p35 expression in neurons, suggesting changes in the Sp transcription factors level and activity may contribute to cell type-specific expression of many genes in the central nervous system.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.							Alroy I, 1999, MOL CELL BIOL, V19, P1961; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Delalle I, 1997, J NEUROCYTOL, V26, P283, DOI 10.1023/A:1018500617374; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Gollner H, 2001, GENES CELLS, V6, P689, DOI 10.1046/j.1365-2443.2001.00455.x; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Heicklen-Klein A, 2000, J NEUROCHEM, V75, P1408, DOI 10.1046/j.1471-4159.2000.0751408.x; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HOSOI T, 1995, J BIOCHEM, V117, P741, DOI 10.1093/oxfordjournals.jbchem.a124771; Humbert S, 2000, J CELL SCI, V113, P975; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lewis Susan E., 1996, Methods (Orlando), V10, P301, DOI 10.1006/meth.1996.0107; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Muralikrishna B, 2001, EUR J BIOCHEM, V268, P3736, DOI 10.1046/j.1432-1327.2001.02281.x; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 1996, GENOMICS, V35, P372, DOI 10.1006/geno.1996.0370; Paglini G, 1998, J NEUROSCI, V18, P9858; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sharma M, 1999, J NEUROCHEM, V73, P79, DOI 10.1046/j.1471-4159.1999.0730079.x; Sjottem E, 1996, J VIROL, V70, P188; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi M, 2000, J NEUROL SCI, V172, P63, DOI 10.1016/S0022-510X(99)00291-9; Tanaka T, 2001, J NEUROSCI, V21, P550, DOI 10.1523/JNEUROSCI.21-02-00550.2001; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tintrup H, 2001, BIOCHEM J, V355, P179, DOI 10.1042/0264-6021:3550179; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yang Y, 2000, J BIOL CHEM, V275, P38863, DOI 10.1074/jbc.M007906200; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	78	43	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4455	4464		10.1074/jbc.M110771200	http://dx.doi.org/10.1074/jbc.M110771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724806	hybrid			2022-12-25	WOS:000173813900088
J	Oubrie, A; Rozeboom, HJ; Kalk, KH; Huizinga, EG; Dijkstra, BW				Oubrie, A; Rozeboom, HJ; Kalk, KH; Huizinga, EG; Dijkstra, BW			Crystal structure of quinohemoprotein alcohol dehydrogenase from Comamonas testosteroni - Structural basis for substrate oxidation and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN GLUCOSE-DEHYDROGENASE; METHANOL DEHYDROGENASE; ETHANOL DEHYDROGENASE; PYRROLOQUINOLINE QUINONE; ACTIVE-SITE; METHYLOBACTERIUM-EXTORQUENS; METHYLAMINE DEHYDROGENASE; PSEUDOMONAS-AERUGINOSA; COFACTOR; PURIFICATION	Quinoprotein alcohol dehydrogenases are redox enzymes that participate in distinctive catabolic pathways that enable bacteria to grow on various alcohols as the sole source of carbon and energy. The x-ray structure of the quinohemoprotein alcohol dehydrogenase from Comamonas testosteroni has been determined at 1.44 Angstrom resolution. It comprises two domains. The N-terminal domain has a beta-propeller fold and binds one pyrrolo-quinoliue quinone cofactor and one calcium ion in the active site. A tetrahydrofuran-2-carboxylic acid molecule is present in the substrate-binding cleft. The position of this oxidation product provides valuable information on the amino acid residues involved in the reaction mechanism and their function. The C-terminal domain is an a-helical type I cytochrome c with His(608) and Met(647) as heme-iron ligands. This is the first reported structure of an electron transfer system between a quinoprotein alcohol dehydrogenase and cytochrome c. The shortest distance between pyrroloquinoline quinone and heme c is 12.9 Angstrom, one of the longest physiological edge-to-edge distances yet determined between two redox centers. A highly unusual disulfide bond between two adjacent cysteines bridges the redox centers. It appears essential for electron transfer. A water channel delineates a possible pathway for proton transfer from the active site to the solvent.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Hu, Ruogu/B-2203-2008; Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477; Oubrie, Arthur/0000-0001-6765-9246				ADACHI O, 1978, AGR BIOL CHEM TOKYO, V42, P2045, DOI 10.1080/00021369.1978.10863306; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Anthony C, 2000, Subcell Biochem, V35, P73; AVEZOUX A, 1995, BIOCHEM J, V307, P735, DOI 10.1042/bj3070735; Balabin IA, 2000, SCIENCE, V290, P114, DOI 10.1126/science.290.5489.114; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dai SD, 2000, SCIENCE, V287, P655, DOI 10.1126/science.287.5453.655; DEJONG GAH, 1995, EUR J BIOCHEM, V230, P899; DEJONG GAH, 1995, BIOCHEMISTRY-US, V34, P9451, DOI 10.1021/bi00029a021; Dewanti AR, 2000, BIOCHEMISTRY-US, V39, P9384, DOI 10.1021/bi992810x; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GEERLOF A, 1994, EUR J BIOCHEM, V226, P537, DOI 10.1111/j.1432-1033.1994.tb20078.x; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; GORISCH H, 1989, A VAN LEEUW J MICROB, V56, P35, DOI 10.1007/BF00822582; GROEN B, 1984, BIOCHEM J, V223, P921, DOI 10.1042/bj2230921; GROEN BW, 1986, BIOCHEM J, V234, P611, DOI 10.1042/bj2340611; HARRIS TK, 1993, BIOCHEMISTRY-US, V32, P14145, DOI 10.1021/bi00214a011; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jongejan A, 1998, PROTEIN ENG, V11, P185, DOI 10.1093/protein/11.3.185; Keitel T, 2000, J MOL BIOL, V297, P961, DOI 10.1006/jmbi.2000.3603; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kurnikov Kurnikov IV., 2000, HARLEM COMPUTER PROG; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; Matsushita K, 1999, BIOCHEMISTRY-US, V38, P6111, DOI 10.1021/bi990121f; MATSUSHITA K, 1993, PRINCIPLES APPL QUIN, P47; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oubrie A, 1999, EMBO J, V18, P5187, DOI 10.1093/emboj/18.19.5187; Oubrie A, 1999, P NATL ACAD SCI USA, V96, P11787, DOI 10.1073/pnas.96.21.11787; Oubrie A, 1999, J MOL BIOL, V289, P319, DOI 10.1006/jmbi.1999.2766; Oubrie A, 2001, ACTA CRYSTALLOGR D, V57, P1732, DOI 10.1107/S0907444901013002; Oubrie A, 2000, PROTEIN SCI, V9, P1265, DOI 10.1110/ps.9.7.1265; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; Shimao M, 1996, BIOSCI BIOTECH BIOCH, V60, P1056; Stoorvogel J, 1996, EUR J BIOCHEM, V235, P690, DOI 10.1111/j.1432-1033.1996.00690.x; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; TAYAMA K, 1989, APPL MICROBIOL BIOT, V32, P181, DOI 10.1007/BF00165885; TOYAMA H, 1995, J BACTERIOL, V177, P2442, DOI 10.1128/jb.177.9.2442-2450.1995; Vangnai AS, 2001, MICROBIOL-UK, V147, P745, DOI 10.1099/00221287-147-3-745; VANSCHIE BJ, 1989, A VAN LEEUW J MICROB, V55, P39, DOI 10.1007/BF02309618; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; XIA ZX, 1992, J BIOL CHEM, V267, P22289; Xia ZX, 1996, J MOL BIOL, V259, P480, DOI 10.1006/jmbi.1996.0334; Yasuda M, 1996, FEMS MICROBIOL LETT, V138, P23; Zarnt G, 2001, J BACTERIOL, V183, P1954, DOI 10.1128/JB.183.6.1954-1960.2001; Zarnt G, 1997, APPL ENVIRON MICROB, V63, P4891, DOI 10.1128/AEM.63.12.4891-4898.1997; Zheng YJ, 2001, P NATL ACAD SCI USA, V98, P432, DOI 10.1073/pnas.021547498	58	69	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3727	3732		10.1074/jbc.M109403200	http://dx.doi.org/10.1074/jbc.M109403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714714	hybrid, Green Published			2022-12-25	WOS:000173688000087
J	Pero, R; Lembo, F; Palmieri, EA; Vitiello, C; Fedele, M; Fusco, A; Bruni, CB; Chiariotti, L				Pero, R; Lembo, F; Palmieri, EA; Vitiello, C; Fedele, M; Fusco, A; Bruni, CB; Chiariotti, L			PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; RNF4; GENE; IDENTIFICATION; COREGULATOR; FAMILY; SNURF	PATZ is a transcriptional repressor affecting the basal activity of different promoters, whereas RNF4 is a transcriptional activator. The association of PATZ with RNF4 switches the activation to repression of selected basal promoters. Because RNF4 interacts also with the androgen receptor (AR) functioning as a coactivator and, in turn, RNF4 associates with PATZ, we investigated whether PATZ functions as an AR coregulator. We demonstrate that PATZ does not influence directly the AR response but acts as an AR corepressor in the presence of RNF4. Such repression is not dependent on histone deacetylases. A mutant RNF4 that doe not bind PATZ but enhances AR-dependent transcription is not influenced by PATZ, demonstrating that the repression by PATZ occurs only upon binding to RNF4. We also demonstrate that RNF4, AR, and PATZ belong to the same complex in vivo also in the presence of androgen, suggesting that repression is not mediated by the displacement of RNF4 from AR. Finally, we show that the repression of endogenous PATZ expression by antisense expression plasmids in LNCaP cells results in a stronger androgen response. Our findings demonstrate that PATZ is a novel AR coregulator that acts by modulating the effect of a coactivator. This could represent a novel and more general mechanism to finely tune the androgen response.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale, I-88100 Catanzaro, Italy; Univ Catanzaro Magna Graecia, Clin G Salvatore, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy	Magna Graecia University of Catanzaro; Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Chiariotti, L (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.	chiariot@unina.it	Pero, Raffaela/L-1461-2015; Fedele, Monica/C-1417-2015; Chiariotti, Lorenzo/AAC-5262-2022	Pero, Raffaela/0000-0003-2182-5530; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Galili N, 2000, DEV DYNAM, V218, P102, DOI 10.1002/(SICI)1097-0177(200005)218:1<102::AID-DVDY9>3.3.CO;2-1; Hakli M, 2001, J BIOL CHEM, V276, P23653, DOI 10.1074/jbc.M009891200; Hayes SA, 2001, CANCER RES, V61, P2112; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Knudsen KE, 1999, CANCER RES, V59, P2297; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LINDZEY J, 1994, VITAM HORM, V49, P383; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pero R, 2001, AM J PATHOL, V159, P1225, DOI 10.1016/S0002-9440(10)62508-4; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837	28	29	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3280	3285		10.1074/jbc.M109491200	http://dx.doi.org/10.1074/jbc.M109491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719514	hybrid			2022-12-25	WOS:000173688000031
J	Guerin, J; Sheng, YH; Reddel, S; Iverson, GM; Chapman, MG; Krilis, SA				Guerin, J; Sheng, YH; Reddel, S; Iverson, GM; Chapman, MG; Krilis, SA			Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein - Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-IMMUNOSORBENT-ASSAY; BETA(2) GLYCOPROTEIN-I; ANTIPHOSPHOLIPID SYNDROME; ANTICARDIOLIPIN ANTIBODIES; APOLIPOPROTEIN-H; 5TH DOMAIN; HUMAN-PLATELETS; BETA(2)-GLYCOPROTEIN-I; CARDIOLIPIN; AFFINITY	The phospholipid-binding plasma protein beta2-glycoprotein I (beta2-GPI) is the primary antigen recognized by the circulating autoantibodies in patients with the "anti-phospholipid syndrome" (APS). Although heparin is routinely used in the treatment and prophylaxis of APS patients, the primary heparin-binding site within beta2-GPI has not been identified. More importantly, how heparin exerts its beneficial effects in vivo in APS patients has not been deduced at the molecular level. Using an expression/site-directed mutagenesis approach, we now show that the positively charged site that resides in the first domain of beta2-GPI is not the primary heparin-binding site. Rather it is the second positively charged site located within the fifth domain of the protein that also binds to phospholipids. Lys(284), Lys(286), and Lys(287) in this domain are essential for the interaction of beta2-GPI with heparin. These data indicate that beta2-GPI binds to heparin in a relatively specific manner even though the affinity for the interaction is rather low. Lys(317) resides in the center of the high affinity phospholipid-binding site. Surprisingly, heparin at concentrations that can be achieved in vivo during anticoagulation therapy greatly enhances the plasmin-mediated cleavage of the Lys(317)- Thr(318) site in beta2-GPI. Because the cleaved form cannot bind to phospholipids effectively, the combined actions of heparin and plasmin result in a diminished ability of beta2-GPI to recognize phospholipids. This, in turn, decreases the prothrombotic activity of the endogenous circulating anti-beta2-GPI antibodies in the patients. Thus, heparin exerts its beneficial effects in APS patients by at least two distinct mechanisms.	St George Hosp, Dept Immunol Allergy & Infect Dis, Sydney, NSW 2217, Australia; St George Hosp, Dept Obstet & Gynecol, Sydney, NSW 2217, Australia; Univ New S Wales, Div Med, Dept Immunol, Kensington, NSW 2033, Australia; La Jolla Pharmaceut Co, San Diego, CA 92121 USA	St George Hospital; St George Hospital; University of New South Wales Sydney; La Jolla Pharmaceutical Company	Krilis, SA (corresponding author), St George Hosp, Dept Immunol Allergy & Infect Dis, 2 South St, Kogarah, NSW 2217, Australia.	s.krilis@unsw.edu.au	sheng, yong H/C-5052-2013	sheng, yong H/0000-0002-4623-9098; Reddel, Stephen/0000-0002-0169-3350				CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; Guerin J, 1997, CLIN EXP IMMUNOL, V109, P304, DOI 10.1046/j.1365-2249.1997.4601357.x; HAGIHARA Y, 1995, J BIOCHEM-TOKYO, V118, P129, DOI 10.1093/oxfordjournals.jbchem.a124867; Hasunuma Y, 1997, CLIN EXP IMMUNOL, V107, P569, DOI 10.1046/j.1365-2249.1997.d01-948.x; Horbach DA, 1999, THROMB HAEMOSTASIS, V81, P87; Hoshino M, 2000, J MOL BIOL, V304, P927, DOI 10.1006/jmbi.2000.4243; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUNT J, 1994, J IMMUNOL, V152, P653; Itoh Y, 2000, J BIOCHEM-TOKYO, V128, P1017, DOI 10.1093/oxfordjournals.jbchem.a022829; Iverson GM, 1998, P NATL ACAD SCI USA, V95, P15542, DOI 10.1073/pnas.95.26.15542; Kandiah DA, 1998, ADV IMMUNOL, V70, P507, DOI 10.1016/S0065-2776(08)60393-4; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KOUTS S, 1993, FEBS LETT, V326, P105, DOI 10.1016/0014-5793(93)81771-Q; KROLL J, 1976, BIOCHIM BIOPHYS ACTA, V434, P490, DOI 10.1016/0005-2795(76)90239-7; MARTINUZZO ME, 1995, BRIT J HAEMATOL, V89, P397, DOI 10.1111/j.1365-2141.1995.tb03317.x; MATSUURA E, 1991, INT IMMUNOL, V3, P1217; MCNALLY T, 1994, THROMB HAEMOSTASIS, V72, P578; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; MCNEIL HP, 1988, THROMB RES, V52, P641, DOI 10.1016/0049-3848(88)90136-3; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; NIMPF J, 1987, ATHEROSCLEROSIS, V63, P109, DOI 10.1016/0021-9150(87)90110-9; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; Ohkura N, 1998, BLOOD, V91, P4173, DOI 10.1182/blood.V91.11.4173.411k35_4173_4179; POLZ E, 1979, PROTIDES BIOL FLUIDS, P817; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1606, DOI 10.1002/art.1780390922; SCHOUSBOE I, 1985, BLOOD, V66, P1086; SCHULTZE HE, 1961, NATURWISSENSCHAFTEN, V48, P719, DOI 10.1007/BF00620967; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Sheng YH, 1996, J IMMUNOL, V157, P3744; Sheng YH, 1998, J IMMUNOL, V161, P2038; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	39	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2644	2649		10.1074/jbc.M110176200	http://dx.doi.org/10.1074/jbc.M110176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711550	hybrid, Green Submitted			2022-12-25	WOS:000173421500036
J	Lin, JD; Puigserver, P; Donovan, J; Tarr, P; Spiegelman, BM				Lin, JD; Puigserver, P; Donovan, J; Tarr, P; Spiegelman, BM			Peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC-1 beta), a novel PGC-1-related transcription coactivator associated with host cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; HCF; PROTEIN; VP16; EXPRESSION; ALPHA	Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) plays a critical role in regulating multiple aspects of energy metabolism, including adaptive thermogenesis, mitochondrial biogenesis, and fatty acid beta-oxidation. Recently, this coactivator of nuclear receptors/transcription factors has been shown to control hepatic gluconeogenesis, an important component of the pathogenesis of both type-1 and type-2 diabetes. We described here the cloning of a novel bona fide homologue of PGC-1, PGC-1beta (PGC-1 was renamed as PGC-1alpha), first identified through searches of new data base entries. Despite the fact that PGC-1alpha and -1beta share similar tissue distributions with highest levels of expression in brown fat and heart, their mRNAs are differentially regulated in the brown adipose tissue upon cold exposure and during brown fat cell differentiation. Like PGC-1alpha, PGC-1beta mRNA levels are increased significantly in the liver during fasting, suggesting a possible role for this factor in the regulation of hepatic gluconeogenesis and/or fatty acid oxidation. Consistent with this, PGC-1beta was shown to physically interact and potently coactivate hepatic nuclear factor 4 and peroxisome proliferator-activated receptor a, nuclear receptors that are essential for hepatic adaptation to fasting. Finally, using sequence comparisons between PGC-1alpha and -1beta we have identified a conserved amino acid motif that serves as a docking site for host cell factor, a cellular protein implicated in cell cycle regulation and viral infection. HCF is shown to bind to both PGC-1alpha and -1beta and augment their transcriptional activity.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, Smith Bldg,Rm 958,1 Jimmy Fund Way, Boston, MA 02115 USA.				NIDDK NIH HHS [R37DK31405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Georgiev O, 1996, GENE, V168, P165, DOI 10.1016/0378-1119(95)00764-4; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLAUS S, 1994, J CELL SCI, V107, P313; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	21	393	413	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1645	1648		10.1074/jbc.C100631200	http://dx.doi.org/10.1074/jbc.C100631200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11733490	hybrid, Green Published			2022-12-25	WOS:000173421300005
J	Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B				Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B			The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site	ONCOGENE			English	Article						c-Jun transcription factor; phosphorylation sites; rat embryo fibroblasts; CBP interaction; oncogene cooperation	EMBRYO FIBROBLASTS; DNA-BINDING; IN-VITRO; RAS; ACTIVATION; CBP; COOPERATION; REQUIRES; DOMAIN; GROWTH	Cotransfection of primary rat embryo fibroblasts (REF) with c-Jun and activated Ras leads to oncogenic transformation and this process requires the phosphorylation of the N-terminal domain of c-Jun. Ras augments this phosphorylation and, consequently activates the c-Jun transactivation property of TRE (TPA Responsive Element)-dependent promoters. To analyse the role of the c-Jun C-terminal phosphorylation site in oncogenic cooperation we tested the activities of N-terminal c-Jun Ala(63/73) (named Nt), C-terminal c-Jun Ala(234/242/246/252) (named Ct) and (Nt+Ct)-with both mutations-nonphosphorylatable c-Jun mutants. In cooperation with Ras, the Ct mutant and wt c-Jun display similar oncogenic properties whereas the Nt form was defective in transforming REF cells. Unexpectedly, the Nt+Ct mutant exhibited identical oncogenic properties to wt c-Jun, demonstrating that the Ct mutation rescues in cis the Nt mutation. The transcriptional activity and the capacity to bind the c-Jun coactivator CREB Binding Protein (CBP) were enhanced by Ras for the wt and Ct proteins but not for the Nt mutant. Interestingly, the Nt+Ct mutant presents identical transactivation and CBP binding activities to wt c-Jun. Therefore the rescue in cis of the defective Nt mutation by the Ct mutation seems to be due to the recovery of CBP binding. Our results revealed that the process of oncogenic cooperation can occur between Ras and the Nt+Ct non-phosphorylatable c-Jun protein.	Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, F-06107 Nice, France; ENS Lyon, INSERM U412, F-69364 Lyon, France; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, Av Valombrose, F-06107 Nice, France.		Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AFL-7188-2022; BOST, Frederic/AAN-4691-2020; Caron, Leslie/AAE-3511-2022	Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; METIVIER C, 1993, ONCOGENE, V8, P2311; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495	17	7	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7425	7429		10.1038/sj.onc.1204924	http://dx.doi.org/10.1038/sj.onc.1204924			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704873				2022-12-25	WOS:000171894200016
J	Vilardaga, JP; Krasel, C; Chauvin, S; Bambino, T; Lohse, MJ; Nissenson, RA				Vilardaga, JP; Krasel, C; Chauvin, S; Bambino, T; Lohse, MJ; Nissenson, RA			Internalization determinants of the parathyroid hormone receptor differentially regulate beta-arrestin/receptor association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; CLATHRIN ADAPTER; VISUAL ARRESTIN; BINDING; DOMAIN; ENDOCYTOSIS; KINASE; PHOSPHORYLATION	beta-Arrestins have been implicated in regulating internalization of the parathyroid hormone receptor (PTHR), but the structural features in the receptor required for this effect are unknown. In the present study performed in HEK-293 cells, we demonstrated that different topological domains of PTHR are implicated in agonist-dependent receptor internalization; truncation of the cytoplasmic tail (PTHR-TR), selective mutations of the cytoplasmic tail to remove the sites of parathyroid hormone (PTIP-stimulated phosphorylation (PTHR-PD), and mutations in the third transmembrane helix (N289A) or in the third cytoplasmic loop (K382A) resulted in a 30-60% reduction in I-125-PTH-related protein internalization. To better define the role of these internalization determinants, we have tested the ability of these mutant PTHRs to associate with beta-arrestins by using three different methodological approaches: 1) ability of overexpression of beta-arrestins to restore the internalization of I-125-PTH-related protein for the mutant PTKRs; 2) visualization of PTH-mediated trafficking of beta-arrestin1 and -2 fused to the green fluorescent protein with receptors by confocal microscopy; 3) quantification of beta-arrestin1-green fluorescent protein translocation by Western blot. Our data reveal that the receptor' cytoplasmic tail contains determinants of beta-arrestin interaction that are distinct from the phosphorylation sites and are sufficient for transient association of beta-arrestin2, but stable association requires receptor phosphorylation. Determinants in the receptor's core (Asn-289 and Lys-382) appear to regulate internalization of the receptor/beta-arrestin complex toward early endocytic endosomes during the initial step of endocytosis.	Vet Affairs Med Ctr, Endocrine Res Unit 111N, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94121 USA; Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, D-97078 Wurzburg, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wurzburg	Lohse, MJ (corresponding author), Vet Affairs Med Ctr, Endocrine Res Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lohse@toxi.uni-wuerzburg.de; chicago@itsa.ucsf.edu	Lohse, Martin J/A-7160-2012; soler, martha maricel m gomez/L-6025-2014; Krasel, Cornelius/AAH-7074-2019	Lohse, Martin J/0000-0002-0599-3510; soler, martha maricel m gomez/0000-0002-4412-8108; Krasel, Cornelius/0000-0001-8309-8696; Vilardaga, Jean-Pierre/0000-0002-1217-1435; Chauvin, Stephanie/0000-0002-8439-1453	NIDDK NIH HHS [DK 35323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gardella T J, 2000, Rev Endocr Metab Disord, V1, P317, DOI 10.1023/A:1026522619828; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HUANG ZM, 1995, MOL ENDOCRINOL, V9, P1240, DOI 10.1210/me.9.9.1240; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LI SC, 1994, BIOCHEMISTRY-US, V33, P14333, DOI 10.1021/bi00251a047; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; SCHEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Subtil A, 1998, EUR J BIOCHEM, V253, P525, DOI 10.1046/j.1432-1327.1998.2530525.x; Vilardaga JP, 2001, MOL ENDOCRINOL, V15, P1186, DOI 10.1210/me.15.7.1186; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	43	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8121	8129		10.1074/jbc.M110433200	http://dx.doi.org/10.1074/jbc.M110433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11726668	hybrid			2022-12-25	WOS:000174268000064
J	Bereziat, V; Kasus-Jacobi, A; Perdereau, D; Cariou, B; Girard, J; Burnol, AF				Bereziat, V; Kasus-Jacobi, A; Perdereau, D; Cariou, B; Girard, J; Burnol, AF			Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; SH2 DOMAIN; PLECKSTRIN HOMOLOGY; CRYSTAL-STRUCTURE; BINDING PROTEIN; ACTIVATION LOOP; CELL-MIGRATION	Grb14 belongs to the Grb7 family of adapters and was recently identified as a partner of the insulin receptor (IR). Here we show that Grb14 inhibits in vitro IR substrate phosphorylation. Grb14 does not alter the K-m for ATP and behaves as an uncompetitive inhibitor for the IR substrate. Similar experiments performed with other members of the Grb7 family, Grb7 and Grb10, and with IGF-1 receptor argue in favor of a specific inhibition of the IR catalytic activity by Grb14. The IR-interacting domain of Grb14, the PIR, is sufficient for the inhibitory effect of Grb14, whereas the SH2 domain has no effect on IR catalytic activity. In Chinese hamster ovary (CHO) cells overexpressing both IR and Grb14, Grb14 binds to the IR as early as 1 min after insulin stimulation, and the two proteins remain associated. When interacting with Grb14, the IR is protected against tyrosine phosphatases action and therefore maintained under a phosphorylated state. However, the binding of Grb14 to the IR induces an early delay in the activation of Akt and ERK1/2 in CHO-IR cells, and ERK1/2 are less efficiently phosphorylated. These findings show that Grb14 is a direct inhibitor of the IR catalytic activity and could be considered as a modulator of insulin signaling.	CNRS, UPR 1524, Inst Cochin Genet Mol, F-75674 Paris 14, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Burnol, AF (corresponding author), CNRS, UPR 1524, Inst Cochin Genet Mol, 24 Rue Faubourg St Jacques, F-75674 Paris 14, France.		KASUS-JACOBI, Anne/V-7799-2019; Burnol, Anne-Francoise/P-2181-2017	KASUS-JACOBI, Anne/0000-0003-3844-0450; BEREZIAT, Veronique/0000-0002-9795-549X; Cariou, Bertrand/0000-0002-1580-8040				ADAMO M, 1992, BIOFACTORS, V3, P151; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BURNOL AF, 1990, AM J PHYSIOL, V259, pE828, DOI 10.1152/ajpendo.1990.259.6.E828; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; DUGGLEBY RG, 1988, BIOCHEM MED METAB B, V40, P204, DOI 10.1016/0885-4505(88)90120-X; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hemming R, 2001, BIOCHEM CELL BIOL, V79, P21, DOI 10.1139/bcb-79-1-21; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Morrione A, 2000, INT J MOL MED, V5, P151; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; NEMENOFF RA, 1984, J BIOL CHEM, V259, P5058; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1984, J BIOL CHEM, V259, P255; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	59	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4845	4852		10.1074/jbc.M106574200	http://dx.doi.org/10.1074/jbc.M106574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11726652	hybrid			2022-12-25	WOS:000173962900040
J	Kawaguchi, T; Osatomi, K; Yamashita, H; Kabashima, T; Uyeda, K				Kawaguchi, T; Osatomi, K; Yamashita, H; Kabashima, T; Uyeda, K			Mechanism for fatty acid "sparing" effect on glucose-induced transcription - Regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; PHOSPHORYLATION; METABOLISM; LIVER; FUEL; CELL	Carbohydrate-responsive element-binding protein (ChREBP) is a new transcription factor that binds to the carbohydrate-responsive element of the L-type pyruvate kinase gene (L-PK). The aim of this study was to investigate the mechanism by which feeding high fat diets results in decreased activity of ChREBP in the liver (Yamashita, H., Takenoshita, M., Sakurai, M:, Bruick, R. K., Henzel, W. J., Shillinglaw, W., Arnot; D., and Uyeda, K. (2001) Proc. Natl. Acad. Sci. U.S.A. 98,9116-9121). We cloned the rat liver ChREBP gene for use throughout this study. Acetate, octanoate, and palmitate inhibited the glucose-induced activation of L-PK transcription in ChREBP-overexpressed hepatocytes. In these hepatocytes, the cytosolic AMP concentration increased 30-fold and AMP-activated protein kinase activity was activated 2-fold. Similarly to the fatty acids, 5-amino-4-imidazolecarboxamide ribotide, a specific activator of AMP-activated protein kinase (AMPK) also inhibited the L-PK transcription activity in ChREBP-overexpressed hepatocytes. Using as a substrate a truncated ChREBP consisting of the C-terminal region, we demonstrated that phosphorylation by AMPK resulted in inactivation of the DNA binding activity. AMPK specifically phosphorylated Ser(568) of ChREBP. A S568A mutant of the ChREBP gene showed tight DNA binding and lost its fatty acid sensitivity, whereas a S568D mutant showed weak DNA binding and inhibited L-PK transcription activity even in the absence oaf fatty acid. These results strongly suggested that the fatty acid inhibition of glucose-induced L-PK transcription resulted from AMPK phosphorylation of ChREBP at Ser(568,) which inactivated the DNA binding activity. AMPK was activated by the increased AMP that was generated by the fatty acid activation.	Dallas Vet Affairs Med Ctr, Dept Biochem, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dallas, TX 75223 USA; Nagasaki Univ, Dept Marine Biochem, Nagasaki 852, Japan; Okayama Prefectural Univ, Dept Nutr Sci, Okayama 71911, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Nagasaki University; Okayama Prefectural University	Uyeda, K (corresponding author), Dallas Vet Affairs Med Ctr, Dept Biochem, 4500 S Lancaster Rd, Dallas, TX 75216 USA.	kuyeda6400@aol.com			NIDDK NIH HHS [DK16195] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		de Luis O, 2000, EUR J HUM GENET, V8, P215, DOI 10.1038/sj.ejhg.5200435; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; KATAN KY, 2001, EUR J BIOCHEM, V268, P3108; Kawaguchi T, 2001, J BIOL CHEM, V276, P28554, DOI 10.1074/jbc.M101396200; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kawaguchi T, 2001, HEPATOL RES, V20, P144, DOI 10.1016/S1386-6346(00)00129-7; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PUZENAT N, 1992, BIOCHEM BIOPH RES CO, V189, P1119, DOI 10.1016/0006-291X(92)92320-W; ROSS BD, 1967, BIOCHEM J, V102, P942, DOI 10.1042/bj1020942; STRUCK E, 1965, BIOCHEM Z, V343, P107; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WILLIAMSON J, 1961, BIOCHEM J, V80, P540, DOI 10.1042/bj0800540; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200	25	314	334	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3829	3835		10.1074/jbc.M107895200	http://dx.doi.org/10.1074/jbc.M107895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724780	hybrid			2022-12-25	WOS:000173813900006
J	Podust, VN; Chang, LS; Ott, R; Dianov, GL; Fanning, E				Podust, VN; Chang, LS; Ott, R; Dianov, GL; Fanning, E			Reconstitution of human DNA polymerase delta using recombinant baculoviruses - The p12 subunit potentiates DNA polymerizing activity of the four-subunit enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION-FACTOR-C; DOUBLE-STRANDED DNA; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; CALF THYMUS; SIMIAN VIRUS-40; SCHIZOSACCHAROMYCES-POMBE; IN-VITRO; FUNCTIONAL INTERACTION	Eukaryotic DNA polymerase 5 is thought to consist of three (budding yeast) or four subunits (fission yeast, mammals). Four human genes encoding polypeptides p125, p50, p66, and p12 have been assigned as subunits of DNA polymerase 5. However, rigorous purification of human or bovine DNA polymerase 5 from natural sources has usually yielded two-subunit preparations containing only p125 and p50 polypeptides. To reconstitute an intact DNA polymerase 8, we have constructed recombinant baculoviruses encoding the p125, p50, p66, and p12 subunits. From insect cells infected with four baculoviruses, protein preparations containing the four polypeptides of expected sizes were isolated. The four-subunit DNA polymerase 5 displayed a specific activity comparable with that of the human, bovine, and fission yeast proteins isolated from natural sources. Recombinant DNA polymerase 5 efficiently replicated singly primed M13 DNA in the presence of replication protein A, proliferating cell nuclear antigen, and replication factor C and was active in the SV40 DNA replication system. A three-subunit subcomplex consisting of the p125, p50, and p66 subunits, but lacking the p12 subunit, was also isolated. The p125, p50, and p66 polypeptides formed a stable complex that displayed DNA polymerizing activity 15-fold lower than that of the four-subunit polymerase. p12, expressed and purified individually, stimulated the activity of the three-subunit complex 4-fold on poly(dA)-oligo(dT) template-primer but had no effect on the activity of the four-subunit enzyme. Therefore, the p12 subunit is required to reconstitute fully active recombinant human DNA polymerase 5.	Vanderbilt Univ, Dept Biol Sci, Stevenson Ctr 2325, Nashville, TN 37232 USA; Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN 37232 USA; Ohio State Univ, Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	Vanderbilt University; Vanderbilt University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Podust, VN (corresponding author), Vanderbilt Univ, Dept Biol Sci, Stevenson Ctr 2325, 1161 21st Ave S, Nashville, TN 37232 USA.		Chang, Long-sheng/E-2871-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CHANG LS, 1995, GENOMICS, V28, P411, DOI 10.1006/geno.1995.1169; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; EKI T, 1992, J BIOL CHEM, V267, P7284; FRANCESCONI S, 1993, NUCLEIC ACIDS RES, V21, P3821, DOI 10.1093/nar/21.16.3821; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MELENDY T, 1991, J BIOL CHEM, V266, P1942; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Pospiech H, 1999, NUCLEIC ACIDS RES, V27, P3799, DOI 10.1093/nar/27.19.3799; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; SCHMITT B, 1984, EUR J BIOCHEM, V144, P127, DOI 10.1111/j.1432-1033.1984.tb08440.x; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Suzuki S, 2000, Nagoya J Med Sci, V63, P99; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHANG J, 1995, GENOMICS, V29, P179, DOI 10.1006/geno.1995.1229; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	72	100	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3894	3901		10.1074/jbc.M109684200	http://dx.doi.org/10.1074/jbc.M109684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11711545	hybrid			2022-12-25	WOS:000173813900015
J	Honda, Y; Tojo, M; Matsuzaki, K; Anan, T; Matsumoto, M; Ando, M; Saya, H; Nakao, M				Honda, Y; Tojo, M; Matsuzaki, K; Anan, T; Matsumoto, M; Ando, M; Saya, H; Nakao, M			Cooperation of HECT-domain ubiquitin ligase hHYD and DNA topoisomerase II-binding protein for DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DROSOPHILA-MELANOGASTER; ANGELMAN SYNDROME; BRCA1; E6-AP; GENE; DEGRADATION; FAMILY; P53; PHOSPHORYLATION	Ubiquitin ligases define the substrate specificity of protein ubiquitination and subsequent proteosomal degradation. The catalytic sequence was first characterized in the C terminus of E6-associated protein (E6AP) and referred to as the HECT (homologous to E6AP C terminus) domain. The human homologue of the regulator of cell proliferation hyperplastic discs in Drosophila, designated hHYD, is a HECT-domain ubiquitin ligase. Here we show that hHYD provides a ubiquitin system for a cellular response to DNA damage. A yeast two-hybrid screen showed that DNA topoisomerase IIbeta-binding protein 1 (TopBP1) interacted with hHYD. Endogenous hHYD bound the BRCA1 C-terminus domains of TopBP1 that are highlighted in DNA damage checkpoint proteins and cell cycle regulators. Using an in vitro reconstitution, specific E2 (ubiquitin-conjugating) enzymes (human UbcH4, UbcH5B, and UbcH5C) transferred ubiquitin molecules to hHYD, leading to the ubiquitination of TopBP1. TopBP1 was usually ubiquitinated and degraded by the proteosome, whereas X-irradiation diminished the ubiquitination of TopBP1 probably via the phosphorylation, resulting in the stable colocalization of up-regulated TopBP1 with gamma-H2AX nuclear foci in DNA breaks. These results demonstrated that hHYD coordinated TopBP1 in the DNA damage response.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; MARTIN P, 1977, DEV BIOL, V55, P213, DOI 10.1016/0012-1606(77)90168-3; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Potter T, 2000, RADIAT RES, V154, P151, DOI 10.1667/0033-7587(2000)154[0151:KETURR]2.0.CO;2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	89	94	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3599	3605		10.1074/jbc.M104347200	http://dx.doi.org/10.1074/jbc.M104347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714696	hybrid			2022-12-25	WOS:000173688000072
J	Morimitsu, Y; Nakagawa, Y; Hayashi, K; Fujii, H; Kumagai, T; Nakamura, Y; Osawa, T; Horio, F; Itoh, K; Iida, K; Yamamoto, M; Uchida, K				Morimitsu, Y; Nakagawa, Y; Hayashi, K; Fujii, H; Kumagai, T; Nakamura, Y; Osawa, T; Horio, F; Itoh, K; Iida, K; Yamamoto, M; Uchida, K			A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; PHENETHYL ISOTHIOCYANATE; CHEMICAL CARCINOGENESIS; METABOLIZING-ENZYMES; RESPONSIVE ELEMENT; CANCER; INDUCTION; INHIBITION	Exposure of cells to a wide variety of chemoprotective compounds confers resistance to a broad set of carcinogens. For a subset of the chemoprotective compounds, protection is generated by an increase in the abundance of the protective phase II detoxification enzymes, such as glutathione S-transferase (GST). We have recently developed a cell culture system, using rat liver epithelial RL 34 cells, that potently responds to the phenolic antioxidants resulting in the induction of GST activity (Kawamoto, Y., Nakamura, Y., Naito, Y., Torii, Y., Kumagai, T., Osawa, T., Ohigashi, H., Satoh, K., Imagawa, M., and Uchida, K. (2000) J. Biol. Chem. 275, 11291-11299.) In the present study, we investigated the phase II-inducing potency of an isothiocyanate compound in vitro and in vivo and examined a possible induction mechanism. Based on an extensive screening of vegetable extracts for GST inducer activity in RL34 cells, we found Japanese horseradish, wasabi (Wasabia japonica, syn. Eutrema wasabi), as the richest source and identified 6-methylsulfinylhexyl isothiocyanate (6-HITC), an analogue of sulforaphane (4-methylsulfinylbutyl isothiocyanate) isolated from broccoli, as the major GST inducer in wasabi. 6-HITC potently induced both class alpha GSTA1 and class pi GSTP1 isozymes in RL34 cells. In animal experiments, we found that 6-MSHI was rapidly absorbed into the body and induced hepatic phase 11 detoxification enzymes more potently than sulforaphane. The observations that W 6-HITC activated the antioxidant response element (ARE), (ii) 6-HITC induced nuclear localization of the transcription factor Nrf2 that binds to ARE, and (iii) the induction of phase 11 enzyme genes by 6-HITC was completely abrogated in the nrf2-deficient mice, suggest that 6-HITC is a potential activator of the Nrf2/ARE-dependent detoxification pathway.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Div Biomed, Nagoya, Aichi 4648601, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Nagoya University; Nagoya University; University of Tsukuba; University of Tsukuba	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Uchida, Koji/0000-0003-3894-5299				Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; COLDITZ GA, 1985, AM J CLIN NUTR, V41, P32, DOI 10.1093/ajcn/41.1.32; Depree JA, 1998, FOOD RES INT, V31, P329, DOI 10.1016/S0963-9969(98)00105-7; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; ETOH H, 1990, AGR BIOL CHEM TOKYO, V54, P1587, DOI 10.1080/00021369.1990.10870168; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Fuke Y, 1997, CYTOTECHNOLOGY, V25, P197, DOI 10.1023/A:1007918508115; Fukuda A, 1996, BIOCHEM BIOPH RES CO, V219, P76, DOI 10.1006/bbrc.1996.0184; GRAHAM S, 1983, CANCER RES, V43, P2409; GUO Z, 1993, CARCINOGENESIS, V14, P1167, DOI 10.1093/carcin/14.6.1167; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1991, BIOCHEM J, V279, P385, DOI 10.1042/bj2790385; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HECHT SS, 1995, J CELL BIOCHEM, P195; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INA K, 1989, AGR BIOL CHEM TOKYO, V53, P537, DOI 10.1080/00021369.1989.10869320; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KENNEDY SW, 1993, ANAL BIOCHEM, V211, P102, DOI 10.1006/abio.1993.1239; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LEONARD TB, 1981, CARCINOGENESIS, V2, P473, DOI 10.1093/carcin/2.6.473; MEHTA RG, 1995, CARCINOGENESIS, V16, P399, DOI 10.1093/carcin/16.2.399; Morimitsu Y, 2000, BIOFACTORS, V13, P271, DOI 10.1002/biof.5520130141; MORSE MA, 1993, CANCER LETT, V72, P103, DOI 10.1016/0304-3835(93)90018-5; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Nakae D, 1998, JPN J CANCER RES, V89, P1118, DOI 10.1111/j.1349-7006.1998.tb00506.x; OLSEN GW, 1991, CANCER CAUSE CONTROL, V2, P291, DOI 10.1007/BF00051668; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; PROCHASKA HJ, 1992, P NATL ACAD SCI USA, V89, P2394, DOI 10.1073/pnas.89.6.2394; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SHI MM, 1994, J BIOL CHEM, V269, P26512; SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711; STONER GD, 1991, CANCER RES, V51, P2063; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; WATTENBERG LW, 1989, CANCER RES, V49, P2689; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WATTENBERG LW, 1985, CANCER RES, V45, P1; WATTENBERG LW, 1981, CANCER RES, V41, P2991; YANG CS, 1994, CANCER RES, V54, pS1982; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; ZHANG Y, 1988, CANCER RES, V58, P4632; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	52	210	224	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3456	3463		10.1074/jbc.M110244200	http://dx.doi.org/10.1074/jbc.M110244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11706044	hybrid			2022-12-25	WOS:000173688000054
J	Schaefer, M; Plant, TD; Stresow, N; Albrecht, N; Schultz, G				Schaefer, M; Plant, TD; Stresow, N; Albrecht, N; Schultz, G			Functional differences between TRPC4 splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNELS; CAPACITATIVE CA2+ ENTRY; INTRACELLULAR CA2+; RAT HOMOLOG; EXPRESSION; PROTEIN; CLONING; LOCALIZATION; CALMODULIN; ACTIVATION	Functional characterizations of heterologously expressed TRPC4 have revealed diverse regulatory mechanisms and permeation properties. We aimed to clarify whether these differences result from different species and splice variants used for heterologous expression. Like the murine beta splice variant, rat and human TRPC4beta both formed receptor-regulated cation channels when expressed in HEK293 cells. In contrast, human TRPC4alpha was poorly activated by stimulation of an H, histamine receptor. This was not due to reduced expression or plasma membrane targeting, because fluorescent TRPC4alpha fusion proteins were correctly inserted in the plasma membrane. Furthermore, currents through both human TRPC4alpha and TRPC4beta had similar current-voltage relationships and single channel conductances. To analyze the assembly of transient receptor potential channel subunits in functional pore complexes in living cells, a fluorescence resonance energy transfer (FRET) approach was used. TRPC4alpha and TRPC4beta homomultimers exhibited robust FRET signals. Furthermore, coexpressed TRPC4alpha and TRPC4beta subunits formed heteromultimers exhibiting comparable FRET signals. To promote variable heteromultimer assemblies, TRPC4alpha/TRPC4beta were coexpressed at different molar ratios. TRPC4beta was inhibited in the presence of TRPC4alpha with a cooperativity higher than 2, indicating a dominant negative effect of TRPC4alpha subunits in heteromultimeric TRPC4 channel complexes. Finally, C-terminal truncation of human TRPC4alpha fully restored the channel activity. Thus, TRPC4beta subunits form a receptor-dependently regulated homomultimeric channel across various species, whereas TRPC4alpha contains a C. terminal autoinhibitory domain that may require additional regulatory mechanisms.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schaefer, M (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de						Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heim R, 1999, METHOD ENZYMOL, V302, P408, DOI 10.1016/S0076-6879(99)02036-4; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; INOUE R, 1990, J PHYSIOL-LONDON, V424, P73, DOI 10.1113/jphysiol.1990.sp018056; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; Inoue Ryuji, 1998, Journal of Smooth Muscle Research, V34, P69; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; Zarei MM, 2001, J BIOL CHEM, V276, P16232, DOI 10.1074/jbc.M008852200; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	40	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3752	3759		10.1074/jbc.M109850200	http://dx.doi.org/10.1074/jbc.M109850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11713258	hybrid			2022-12-25	WOS:000173688000090
J	Tan, C; Mui, A; Dedhar, S				Tan, C; Mui, A; Dedhar, S			Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-1 TRANSCRIPTION FACTOR; INTERFERON-GAMMA; PROTEIN-KINASE; MOUSE MACROPHAGES; BACTERIAL LIPOPOLYSACCHARIDE; SIGNALING PATHWAYS; J774 MACROPHAGES; GENE-EXPRESSION; CELL-ADHESION; MESSENGER-RNA	Nitric oxide (NO) and prostaglandins are produced as a result of the stimulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2, respectively, in response to cytokines or lipopolysaccharide (LPS). We demonstrate that the activity of integrin-linked kinase (ILK) is stimulated by LPS activation in J774 macrophages. Inhibition of ILK activity by dominant-negative ILK or a highly selective small molecule ILK inhibitor, in epithelial cells or LPS-stimulated J774 cells and murine macrophages, resulted in inhibition of iNOS expression and NO synthesis. LPS stimulates the phosphorylation of IkappaB on Ser-32 and promotes its degradation. Inhibition of ILK suppressed this LPS-stimulated IkappaB phosphorylation and degradation. Similarly, ILK inhibition suppressed the LPS-stimulated iNOS promoter activity. Mutation of the NF-kappaB sites in the iNOS promoter abolished LPS- and ILK-mediated regulation of iNOS promoter activity. Overexpression of ILK-stimulated NF-kappaB activity and inhibition of ILK or protein kinase B (PKB/Akt) suppressed this activation. We conclude that ILK can regulate NO production in macrophages by regulating iNOS expression through a pathway involving PKB/Akt and NF-kappaB. Furthermore, we also demonstrate that ILK activity is required for LPS stimulated cyclooxygenase-2 expression in murine and human macrophages. These findings implicate ILK as a potential target for anti-inflammatory applications.	Vancouver Gen Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Ctr Hlth Sci, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada	University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.			Dedhar, Shoukat/0000-0003-4355-1657				Abate A, 1998, PROSTAG OTH LIPID M, V56, P277, DOI 10.1016/S0090-6980(98)00061-6; ALLEY EW, 1995, GENE, V158, P247, DOI 10.1016/0378-1119(94)00892-V; Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; Attur MG, 2000, J IMMUNOL, V164, P2684, DOI 10.4049/jimmunol.164.5.2684; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; D'Acquisto F, 2000, BIOCHEM J, V346, P793, DOI 10.1042/0264-6021:3460793; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DING AH, 1988, J IMMUNOL, V141, P2407; Feng X, 2000, J BIOL CHEM, V275, P8331, DOI 10.1074/jbc.275.12.8331; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Hamilton JA, 1999, ARTERIOSCL THROM VAS, V19, P98, DOI 10.1161/01.ATV.19.1.98; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; LIU MK, 1994, J IMMUNOL, V153, P2642; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; Mack KD, 1998, J IMMUNOL METHODS, V211, P79, DOI 10.1016/S0022-1759(97)00194-4; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Mijatovic T, 1997, J BIOL CHEM, V272, P14394, DOI 10.1074/jbc.272.22.14394; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Ozes ON, 1999, NATURE, V401, P82; Paik JH, 2000, J BIOL CHEM, V275, P28173; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097-4636(20010905)56:3<417::AID-JBM1111>3.0.CO;2-K; Sly LM, 2001, J BIOL CHEM, V276, P35482, DOI 10.1074/jbc.M102876200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; TUSHINSKI RJ, 1983, J CELL PHYSIOL, V116, P67, DOI 10.1002/jcp.1041160111; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; von Knethen A, 1999, J IMMUNOL, V163, P2858; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZEVVAS CG, 2001, J CELL BIOL, V152, P1007; Zhang XO, 1996, J LEUKOCYTE BIOL, V59, P575, DOI 10.1002/jlb.59.4.575	62	69	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3109	3116		10.1074/jbc.M108673200	http://dx.doi.org/10.1074/jbc.M108673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724787	hybrid			2022-12-25	WOS:000173688000009
J	Alexandrow, MG; Ritzi, M; Pemov, A; Hamlin, JL				Alexandrow, MG; Ritzi, M; Pemov, A; Hamlin, JL			A potential role for mini-chromosome maintenance (MCM) proteins in initiation at the dihydrofolate reductase replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NUCLEAR-PROTEIN; DNA-REPLICATION; RECOGNITION COMPLEX; HUMAN MEMBER; CELL-CYCLE; CHO-CELLS; YEAST; IDENTIFICATION; TRANSCRIPTION; CHROMATIN	Mini-chromosome maintenance (MCM) proteins were originally identified in yeast, and homologues have been identified in several other eukaryotic organisms, including mammals. These findings suggest that the mechanisms by which eukaryotic cells initiate and regulate DNA replication have been conserved throughout evolution. However, it is clear that many mammalian origins are much more complex than those of yeast. An example is the Chinese hamster dihydrofolate reductase (DHFR) origin, which resides in the spacer between the DHFR and 2BE2121 genes. This origin consists of a broad zone of potential sites scattered throughout the 55-kb spacer, with several subregions (e.g. ori-beta, ori-beta', and ori-gamma) being preferred. We show here that antibodies to human MCMs 2-7 recognize counterparts in extracts prepared from hamster cells; furthermore, co-immuno-precipitation data demonstrate the presence of an MCM2-3-5 subcomplex as observed in other species. To determine whether MCM proteins play a role in initiation and/or elongation in Chinese hamster cells, we have examined in vivo protein-DNA interactions between the MCMs and chromatin in the DHFR locus using a chromatin immunoprecipitation (ChIP) approach. In synchronized cultures, MCM complexes associate preferentially with DNA in the intergenic initiation zone early in S-phase during the time that replication initiates. However, significant amounts of MCMs were also detected over the two genes, in agreement with recent observations that the MCM complex co-purifies with RNA polymerase IL As cells progress through S-phase, the MCMs redistribute throughout the DHFR domain, suggesting a dynamic interaction with DNA. In asynchronous cultures, in which replication forks should be found at any position in the genome, MCM proteins were distributed relatively evenly throughout the DHFR locus. Altogether, these data are consistent with studies in yeast showing that MCM subunits localize to origins during initiation and then migrate outward with the replication forks. This constitutes the first evidence that mammalian MCM complexes perform a critical role during the initiation and elongation phases of replication at the DHFR origin in hamster cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Konstanz, Dept Biochem, D-78434 Constance, Germany	University of Virginia; University of Konstanz	Hamlin, JL (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Box 800733 HSC, Charlottesville, VA 22908 USA.	jlh2d@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019304, R01GM026108] Funding Source: NIH RePORTER; NIGMS NIH HHS [5F32 GM19304-02, R01 GM 26108, F32 GM019304-01A1, F32 GM019304-02, F32 GM019304] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Aranda A, 1999, MOL CELL BIOL, V19, P1251; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; DePamphilis ML, 1997, METHODS, V13, P211, DOI 10.1006/meth.1997.0521; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dijkwel PA, 1996, J CELL BIOCHEM, V62, P210, DOI 10.1002/(SICI)1097-4644(199608)62:2<210::AID-JCB9>3.0.CO;2-V; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOREMAN PK, 1989, MOL CELL BIOL, V9, P1137, DOI 10.1128/MCB.9.3.1137; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; Kornberg A., 1992, DNA REPLICATION; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; LEU TH, 1989, MOL CELL BIOL, V9, P523, DOI 10.1128/MCB.9.2.523; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MA C, 1990, MOL CELL BIOL, V10, P1338, DOI 10.1128/MCB.10.4.1338; MAINE GT, 1984, GENETICS, V106, P365; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; MILBRANDT JD, 1981, P NATL ACAD SCI-BIOL, V78, P6043, DOI 10.1073/pnas.78.10.6043; MOIR D, 1982, GENETICS, V100, P547; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; PEMOV A, 1995, BIOCHEMISTRY-US, V34, P2381, DOI 10.1021/bi00007a034; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; You ZY, 1999, MOL CELL BIOL, V19, P8003	73	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2702	2708		10.1074/jbc.M108118200	http://dx.doi.org/10.1074/jbc.M108118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11723123	hybrid			2022-12-25	WOS:000173421500044
J	Calabro, V; Mansueto, G; Parisi, T; Vivo, M; Calogero, RA; La Mantia, G				Calabro, V; Mansueto, G; Parisi, T; Vivo, M; Calogero, RA; La Mantia, G			The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P73; DEGRADATION; FAMILY; ACTIVATION; P73-ALPHA; P19(ARF); PROMOTER; SIGNALS; LIMB	Genetic alteration of the p53 tumor suppressor gene, which monitors DNA damage and operates cell cycle checkpoints, is a major factor in the development of human malignancies. The p53 protein belongs to a family that also includes two structurally related proteins, p63 and p73. Although all three proteins share similar transcriptional functions and antiproliferative effects, each of them appears to play a distinct role in development and tumor suppression. One of the principal regulators of p53 activity is the MDM2 protein. The interaction of MDM2 with p53 inhibits p53 transcriptional activity and targets p53 for ubiquitin-dependent degradation. The ability of MDM2 to inhibit p53 functions is antagonized by the ARF oncosuppressor protein. We show here that like p53, the p63alpha and p63gamma isoforms are able to associate with human MDM2 (HDM2). Overexpression of HDM2 increased the steady-state level of intracellular p63 and enhanced its transcriptional activity. Both effects appeared to be counteracted by ARF coexpression. These data indicate that p63 can be activated by HDM2 under conditions in which p53 is inhibited. Therefore, HDM2 expression could support p63-specific transcriptional functions on a common set of genes, keeping interference by p53 at a minimum.	Univ Naples Federico II, Dept Genet, I-80134 Naples, Italy; S Luigi Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet, Via Mezzocannone 8, I-80134 Naples, Italy.		Vivo, Maria/S-3390-2017; Calabro, Viola/H-6156-2013; Calogero, Raffaele/K-9428-2019	Vivo, Maria/0000-0003-2458-4226; Calogero, Raffaele/0000-0002-2848-628X; Calabro, Viola/0000-0002-6508-8889				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Calabro V, 1999, ONCOGENE, V18, P2157, DOI 10.1038/sj.onc.1202532; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; EL DW, 1993, CELL, V75, P817; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu JJ, 2001, CANCER RES, V61, P6703; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levrero M, 2000, J CELL SCI, V113, P1661; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Shimada A, 1999, CANCER RES, V59, P2781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	33	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2674	2681		10.1074/jbc.M107173200	http://dx.doi.org/10.1074/jbc.M107173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714701	hybrid			2022-12-25	WOS:000173421500040
J	Galasinski, SC; Louie, DF; Gloor, KK; Resing, KA; Ahn, NG				Galasinski, SC; Louie, DF; Gloor, KK; Resing, KA; Ahn, NG			Global regulation of post-translational modifications on core histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; CHROMOSOME CONDENSATION; H3 PHOSPHORYLATION; MASS-SPECTROMETRY; PROTEIN PHOSPHATASE-1; INDUCTION; MITOSIS; CELLS; IDENTIFICATION; ACETYLATION	Full-length masses of histones were analyzed by mass spectrometry to characterize post-translational modifications of bulk histones and their changes induced by cell stimulation. By matching masses of unique peptides with full-length masses, H4 and the variants H2A.1, H2B.1, and H3.1 were identified as the main histone forms in K562 cells. Mass changes caused by covalent modifications were measured in a dose- and time-dependent manner following inhibition of phosphatases by okadaic acid. Histones H2A, H3, and H4 underwent changes in mass consistent with altered acetylation and phosphorylation, whereas 11213 mass was largely unchanged. Unexpectedly, histone H4 became almost completely deacetylated in a dose-dependent manner that occurred independently of phosphorylation. Okadaic acid also partially blocked H4 hyperacetylation induced by trichostatin-A, suggesting that the mechanism of deacetylation involves inhibition of H4 acetyltransferase activity, following perturbation of cellular phosphatases In addition, mass changes in H3 in response to okadaic acid were consistent with phosphorylation of methylated, acetylated, and phosphorylated forms. Finally, kinetic differences were observed with respect to the rate of phosphorylation of H2A versus H4, suggesting differential regulation of phosphorylation at sites on these proteins, which are highly related by sequence. These results provide novel evidence that global covalent modifications of chromatin-bound histones are regulated through phosphorylation-dependent mechanisms.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.							Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Burligame A.L., 1994, ANAL CHEM, V66, P634; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JACKSON V, 1976, P NATL ACAD SCI USA, V73, P2266, DOI 10.1073/pnas.73.7.2266; JOHNSTON JA, 1994, CELL MOTIL CYTOSKEL, V29, P280, DOI 10.1002/cm.970290311; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Maharizi M, 1999, J OPTOELECTRON ADV M, V1, P65; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Resing KA, 1999, PROG BIOPHYS MOL BIO, V71, P501, DOI 10.1016/S0079-6107(98)00048-0; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; Thompson LJ, 1997, J BIOL CHEM, V272, P29693, DOI 10.1074/jbc.272.47.29693; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; van Holde K.E., 1988, CHROMATIN; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wolffe A., 1995, CHROMATIN STRUCTURE; WOODLAND HR, 1979, DEV BIOL, V68, P360, DOI 10.1016/0012-1606(79)90210-0	35	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2579	2588		10.1074/jbc.M107894200	http://dx.doi.org/10.1074/jbc.M107894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11709551	hybrid			2022-12-25	WOS:000173421500028
J	Unno, M; Christian, JF; Sjodin, T; Benson, DE; Macdonald, IDG; Sligar, SG; Champion, PM				Unno, M; Christian, JF; Sjodin, T; Benson, DE; Macdonald, IDG; Sligar, SG; Champion, PM			Complex formation of cytochrome P450(cam) with putidaredoxin - Evidence for protein-specific interactions involving the proximal thiolate ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN INVESTIGATIONS; O VIBRATIONAL FREQUENCIES; SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER; HEME-PROTEINS; REDUCED PUTIDAREDOXIN; MYOGLOBIN; P-450CAM; BINDING; DETERMINANTS	We have performed resonance Raman studies on ferrous NO- and CO-adducts of cytochrome P450(cam) and investigated the effects of diprotein complex formation with reduced putidaredoxin. We have found that the Fe-NO stretching mode of NO-P450(cam) can be resolved into two peaks at 551 and 561 cm(-1), and the binding of putidaredoxin increases the intensity of the high frequency component. Because the Fe-NO mode has been shown to be more sensitive to the nature of the heme proximal ligand than to the distal pocket environment, such a perturbation upon putidaredoxin binding is suggestive of changes in conformation or electronic structure that affect the proximal iron-eysteine bond. In accordance with this idea, the isotope shifts for the Fe-XO stretching and Fe-X-O bending modes (X = N or C) are insensitive to the presence or absence of putidaredoxin, indicating that the geometry of the Fe-X-O unit is not significantly altered by the complex formation. On the other hand, complex formation does induce a perturbation of the low frequency heme vibrational modes, suggesting that alterations of the heme electronic structure and/or geometry take place when putidaredoxin binds. We also find that cytochrome b(5) minimally affects the heme active site of the enzyme, although both putidaredoxin and cytochrome b(5) bind to the same or similar site on P450(cam). These observations suggest that there is a key specific interaction between P450(cam) and putidaredoxin, and that this interaction increases the population of a protein conformation that exhibits structural and/or electronic distortions of the heme group associated with the proximal side of the heme pocket and the S Fe electron donation. These electronic and structural changes are potentially correlated with H-bonding to the proximal cysteine.	Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Northeastern Univ, Ctr Interdisciplinary Res Complex Syst, Boston, MA 02115 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	Northeastern University; Northeastern University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Champion, PM (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan.			Unno, Masashi/0000-0002-5016-6274	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM031756, R01GM033775] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35090] Funding Source: Medline; NIGMS NIH HHS [GM-31756, GM-33775] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Christian JF, 1997, BIOCHEMISTRY-US, V36, P11198, DOI 10.1021/bi9710075; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HU SZ, 1991, J AM CHEM SOC, V113, P9760, DOI 10.1021/ja00026a008; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; LEGRAND N, 1995, FEBS LETT, V364, P152, DOI 10.1016/0014-5793(95)00377-L; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; Makino R., 1984, Proceedings of the IXth International Conference on Raman Spectroscopy (papers in summary form only received), P492; MORIKIS D, 1991, J PHYS CHEM-US, V95, P3391, DOI 10.1021/j100161a077; Ogliaro F, 2000, J AM CHEM SOC, V122, P12892, DOI 10.1021/ja005619f; Parusel ABJ, 2000, J AM CHEM SOC, V122, P6371, DOI 10.1021/ja000757q; Perret A, 1998, BIOCHEMISTRY-US, V37, P11412, DOI 10.1021/bi980908q; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1988, J BIOL CHEM, V263, P13544; Suzuki N, 1999, J AM CHEM SOC, V121, P11571, DOI 10.1021/ja992511v; Tomita T, 1999, J PHYS CHEM B, V103, P7044, DOI 10.1021/jp991106n; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; Unno M, 1998, J AM CHEM SOC, V120, P2670, DOI 10.1021/ja973293d; UNO T, 1985, J BIOL CHEM, V260, P2023; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Yu N.-T., 1988, RESONANCE RAMAN SPEC, V3, P39	39	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2547	2553		10.1074/jbc.M108917200	http://dx.doi.org/10.1074/jbc.M108917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706033	hybrid			2022-12-25	WOS:000173421500024
J	Bailey, S; Thompson, E; Nixon, PJ; Horton, P; Mullineaux, CW; Robinson, C; Mann, NH				Bailey, S; Thompson, E; Nixon, PJ; Horton, P; Mullineaux, CW; Robinson, C; Mann, NH			A critical role for the Var2 FtsH homologue of Arabidopsis thaliana in the photosystem II repair cycle in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR SIDE MECHANISM; HIGH-LIGHT STRESS; D1 PROTEIN; CHLOROPHYLL FLUORESCENCE; INVIVO DEGRADATION; PEA-CHLOROPLASTS; PCC 6803; PHOTOINHIBITION; TURNOVER; PRODUCT	Using a var2-2 mutant of Arabidopsis thaliana, which lacks a homologue of the zinc-metalloprotease, FtsH, we demonstrate that this protease is required for the efficient turnover of the D1 polypeptide of photosystem II and protection against photoinhibition in vivo. We show that var2-2 leaves are much more susceptible to light-induced photosystem II photoinhibition than wild-type leaves. Furthermore, the rate of photosystem II photoinhibition in untreated var2-2 leaves is equivalent to that of var2-2 and wild-type leaves, which have been treated with lincomycin, an inhibitor of the photosystem II repair cycle at the level of D1 synthesis. This is in contrast to untreated wild-type leaves, which show a much slower rate of photosystem II photoinhibition due to an efficient photosystem II repair cycle. The recovery of var2-2 leaves from photosystem II photoinhibition is also impaired relative to wild-type. Using Western blot analysis in the presence of lincomycin we show that the D1 polypeptide remains stable in leaves of the var2-2 mutant under photoinhibitory conditions that lead to D1 degradation in wild-type leaves and that the abundance of DegP2 is not affected by the var2-2 mutation. We conclude, therefore, that the Var2 FtsH homologue is required for the cleavage of the D1 polypeptide in vivo. In addition, we identify a conserved lumenal domain in Var2 that is unique to FtsH homologues from oxygenic phototrophs.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; UCL, Dept Biol, London WC1E 6BT, England; Imperial Coll Sci Technol & Med, Dept Biochem, London, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Warwick; University of London; University College London; Imperial College London; University of Sheffield	Mann, NH (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	N.H.Mann@warwick.ac.uk	Horton, Peter/A-3958-2012; Thompson, Elinor P/C-6771-2011	Horton, Peter/0000-0002-6095-1460; Thompson, Elinor P/0000-0002-6434-9290; Nixon, Peter/0000-0003-1952-6937				Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; CANOVAS PM, 1993, FEBS LETT, V324, P341, DOI 10.1016/0014-5793(93)80147-M; Chen M, 2000, PLANT J, V22, P303, DOI 10.1046/j.1365-313x.2000.00738.x; DallaChiesa M, 1997, EUR J BIOCHEM, V248, P731, DOI 10.1111/j.1432-1033.1997.00731.x; DEMMIG B, 1987, PLANTA, V171, P171, DOI 10.1007/BF00391092; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; Haussuhl K, 2001, EMBO J, V20, P713, DOI 10.1093/emboj/20.4.713; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1981, BIOCHIM BIOPHYS ACTA, V635, P53, DOI 10.1016/0005-2728(81)90006-2; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; Jansen MAK, 1996, PHOTOCHEM PHOTOBIOL, V63, P814, DOI 10.1111/j.1751-1097.1996.tb09636.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG TY, 1984, PHOTOSYNTH RES, V5, P105, DOI 10.1007/BF00028524; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Lindahl M, 2000, PLANT CELL, V12, P419, DOI 10.1105/tpc.12.3.419; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OQUIST G, 1992, PLANTA, V186, P450, DOI 10.1007/BF00195327; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V972, P163; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; SANTOS D, 1975, J BACTERIOL, V124, P1502, DOI 10.1128/JB.124.3.1502-1507.1975; Schumann W, 1999, FEMS MICROBIOL REV, V23, P1; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Takechi K, 2000, PLANT CELL PHYSIOL, V41, P1334, DOI 10.1093/pcp/pcd067; Thiele A, 1997, J PLANT PHYSIOL, V151, P286, DOI 10.1016/S0176-1617(97)80254-4; TOMAYASU T, 1995, EMBO J, V14, P2551; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307	41	215	226	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2006	2011		10.1074/jbc.M105878200	http://dx.doi.org/10.1074/jbc.M105878200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11717304	hybrid			2022-12-25	WOS:000173421300054
J	Pelled, D; Raveh, T; Riebeling, C; Fridkin, M; Berissi, H; Futerman, AH; Kimchi, A				Pelled, D; Raveh, T; Riebeling, C; Fridkin, M; Berissi, H; Futerman, AH; Kimchi, A			Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ROLES; CELL-DEATH; DOMAIN; GROWTH; IDENTIFICATION; SPHINGOLIPIDS; SURVIVAL	Treatment of cultured hippocampal neurons with high concentrations of short-chain acyl ceramide derivatives, such as N-hexanoyl-D-sphingosine (C-6-Cer), results in apoptotic cell death. We now show that death-associated protein (DAP) kinase plays an important role in mediating this effect. Upon incubation with C-6-Cer, DAP kinase levels are elevated as early as 1 h after treatment, reaching levels 2-3-fold higher than untreated cells after 4 h. Neurons cultured from DAP kinase-deficient mice were significantly less sensitive to apoptosis induced by C-6-Cer or by ceramide generated by high concentrations of nerve growth factor. A peptide corresponding to the 17 amino acids at the C terminus of DAP kinase protected wild type neurons from C-6-Cer-induced death and from death induced by the addition of exogenous bacterial neutral sphingomyelinase, whereas a scrambled peptide had no protective effect, implying that the DAP kinase C-terminal tail inhibits the function of DAP kinase. Together, these data demonstrate that DAP kinase plays a central role in ceramide-induced cell death in neurons, but the pathway in which DAP kinase is involved is not the only one via which ceramide can induce apoptosis.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115; Pelled, Dori/0000-0002-8643-1850; Riebeling, Christian/0000-0003-1991-0170				Ambrosio AF, 2000, EUR J NEUROSCI, V12, P2021, DOI 10.1046/j.1460-9568.2000.00091.x; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Futerman AH, 1998, ACTA BIOCHIM POL, V45, P469, DOI 10.18388/abp.1998_4240; GOSLIN K, 1999, CULTURING NERVE CELL, P339; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	21	125	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1957	1961		10.1074/jbc.M104677200	http://dx.doi.org/10.1074/jbc.M104677200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11709549	hybrid			2022-12-25	WOS:000173421300047
J	Alvarado-Kristensson, M; Porn-Ares, MI; Grethe, S; Smith, D; Zheng, LM; Andersson, T				Alvarado-Kristensson, M; Porn-Ares, MI; Grethe, S; Smith, D; Zheng, LM; Andersson, T			p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis	FASEB JOURNAL			English	Article						caspases; cell death; leukocytes; survival	NF-KAPPA-B; GRANULOCYTE APOPTOSIS; FAS LIGAND; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; INHIBITION; CASPASES; ALPHA; RAS; MODULATION	Neutrophil apoptosis is essential for resolution of inflammatory reactions. Here, we studied the role of two apoptosis/survival-associated protein kinases in this process. We discovered a previously undetected early and transient inhibition of the activity of p38 mitogen-activated protein kinase (p38 MAPK) during both spontaneous and Fas-induced apoptosis. Pharmacological inhibition of this enzyme augmented the activation of caspases and the apoptotic response, which suggests that the p38 MAPK signals survival in neutrophils. Our finding that caspase-3 activity was initiated during the transient inhibition of p38 MAPK suggests that apoptosis is initiated during this inhibition. Furthermore, such transient inhibition was counteracted by granulocyte-macrophage colony-stimulating factor, which elicits survival. We also found that neither this inhibition of p38 MAPK nor the spontaneous apoptotic response depended on Fas. Instead, the early inhibition of p38 MAPK concurred with a Fas-induced activation of phosphatidylinositol 3-kinase, inhibition of which reduced apoptosis. Thus, the Fas-induced augmentation of spontaneous apoptosis can be explained by its activation of phosphatidylinositol 3-kinase. We conclude that p38 MAPK activity represents a survival signal that is inactivated transiently during both spontaneous and Fas-induced apoptosis, whereas Fas-induced phosphatidylinositol 3-kinase activity is a proapoptotic signal in isolated human neutrophils.	Lund Univ, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University	Andersson, T (corresponding author), Lund Univ, Dept Lab Med, U-MAS,Ent 78,Fl 3, SE-20502 Malmo, Sweden.	tommy.andersson@exppat.mas.lu.se	Alvarado-Kristensson, Maria T./C-4543-2014; zheng, limin/HGB-2510-2022	Alvarado Kristensson, Maria Teresa/0000-0003-0598-7986; Zheng, Limin/0000-0002-8281-1450				Aoshiba K, 1999, J IMMUNOL, V162, P1692; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Brown SB, 1999, J IMMUNOL, V162, P480; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dong Q, 1999, J IMMUNOL, V162, P3220; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GRISWOLD DE, 1987, BIOCHEM PHARMACOL, V36, P3463, DOI 10.1016/0006-2952(87)90327-3; Gulbins E, 1998, J LEUKOCYTE BIOL, V63, P253, DOI 10.1002/jlb.63.2.253; Hale KK, 1999, J IMMUNOL, V162, P4246; Haslett C, 1997, BRIT MED BULL, V53, P669; HASLETT C, 1985, AM J PATHOL, V119, P101; HOMBURG CHE, 1995, BLOOD, V85, P532; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KLEMPNER MS, 1980, J CELL BIOL, V86, P21, DOI 10.1083/jcb.86.1.21; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Sen J, 1996, J IMMUNOL, V156, P4535; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villunger A, 2000, J EXP MED, V192, P647, DOI 10.1084/jem.192.5.647; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; Wei S, 1996, J IMMUNOL, V157, P5155; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zheng LM, 1997, J BIOL CHEM, V272, P23448, DOI 10.1074/jbc.272.37.23448; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	42	67	70	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					129	+		10.1096/fj.01-0817fje	http://dx.doi.org/10.1096/fj.01-0817fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729103				2022-12-25	WOS:000172420500029
J	Moro, F; Okamoto, K; Donzeau, M; Neupert, W; Brunner, M				Moro, F; Okamoto, K; Donzeau, M; Neupert, W; Brunner, M			Mitochondrial protein import: Molecular basis of the ATP-dependent interaction of MtHsp70 with Tim44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; INNER MEMBRANE; DNAK CHAPERONE; MATRIX HSP70; REACTION CYCLE; TRANSLOCATION; SYSTEM; PREPROTEINS; COMPLEX; GRPE	Protein translocation across the mitochondrial inner membrane is driven by cycles of binding and release of mitochondrial heat shock protein 70 (mtHsp70) in the matrix. The peripheral inner membrane protein, Tim44, recruits mtHsp70 in an ATP-dependent manner to the import sites. We show that DnaK, the closely related Hsp70 of Escherichia coli, when targeted to the matrix of yeast mitochondria, interacts in a specific manner with Tim44. The interaction is, however, not regulated by ATP, and DnaK cannot support protein translocation. We used truncated mtHsp70s and chimeric proteins consisting of segments of mtHsp70 and DnaK to analyze which portions of mtHsp70 bind and functionally interact with Tim44. We show that Tim44 interacts with the beta-stranded core of the peptide binding domain of mtHsp70 and of DnaK. The alpha-helices A and B of the peptide binding domain of mtHsp70 are required to transmit the nucleotide state of the ATPase domain to the peptide binding domain. Tim44, by interacting in this way with the peptide binding domain, is proposed to coordinate the binding of mtHsp70 to the incoming preprotein and the subsequent release of the mtHsp70-preprotein complex from the TIM23 complex, the translocase of the inner membrane.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Brunner, M (corresponding author), Biochem Zentrum Heidelberg, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany.		Moro Pérez, Fernando/P-3891-2015	Moro Pérez, Fernando/0000-0002-3568-3388; Brunner, Michael/0000-0001-9798-3047; Donzeau, Mariel/0000-0002-1145-9218				Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Geissler A, 2001, MOL CELL BIOL, V21, P7097, DOI 10.1128/MCB.21.20.7097-7104.2001; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; Krimmer T, 2000, MOL CELL BIOL, V20, P5879, DOI 10.1128/MCB.20.16.5879-5887.2000; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lim JH, 2001, EMBO J, V20, P941, DOI 10.1093/emboj/20.5.941; Liu QL, 2001, J BIOL CHEM, V276, P6112, DOI 10.1074/jbc.M009519200; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; RUDIGER S, 1997, NAT STRUCT BIOL, V4, P324; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	32	47	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6874	6880		10.1074/jbc.M107935200	http://dx.doi.org/10.1074/jbc.M107935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11733493	hybrid			2022-12-25	WOS:000174104300018
J	Ton-That, H; Mazmanian, SK; Alksne, L; Schneewind, O				Ton-That, H; Mazmanian, SK; Alksne, L; Schneewind, O			Anchoring of surface proteins to the cell wall of Staphylococcus aureus - Cysteine 184 and histidine 120 of sortase form a thiolate-imidazolium ion pair for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; CRYSTAL-STRUCTURE; LPXTG MOTIF; PAPAIN; PURIFICATION; PROTEASE; PEPTIDE	Surface proteins of Staphylococcus aureus are anchored to the cell wall peptidoglycan by a mechanism requiring a C-terminal sorting signal with a LPXTG motif. Sortase cleaves polypeptides between the threonine and the glycine of the LPXTG motif. The carboxyl group of threonine is subsequently amide-linked to the amino group of peptidoglycan cross-bridges. The three-dimensional structure of sortase revealed the close proximity of the catalytic site residue cysteine 184 with histidine 120; however, no structural evidence for a thiolate-imidazolium ion pair could be detected. We report that alanine substitution of either cysteine 184 or histidine 120 abolishes in vivo and in vitro sorting reactions. Further, alanine substitution of tryptophan 194, a residue that is in close proximity of histidine 120, reduces the transpeptidase activity of sortase. These results suggest a model whereby sortase forms a thiolate-imidazolium ion pair for the catalysis of its transpeptidation reaction and that the position of tryptophan 194 assists in the formation of this ion pair.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Wyeth Ayerst Res, Dept Infect Dis Res, Pearl River, NY 10965 USA	University of Chicago; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pfizer	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.		Ton-That, Hung/AAB-6155-2020; Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07323, AI 33987, AI 38897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Ilangovan U, 2001, J BIOMOL NMR, V19, P379, DOI 10.1023/A:1011299500628; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P764; Somoza JR, 2000, BIOCHEMISTRY-US, V39, P12543, DOI 10.1021/bi000951p; STORER AC, 1994, METHOD ENZYMOL, V244, P487; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2001, TRENDS MICROBIOL, V9, P101, DOI 10.1016/S0966-842X(01)01955-2; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	30	130	135	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7447	7452		10.1074/jbc.M109945200	http://dx.doi.org/10.1074/jbc.M109945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11714722	hybrid, Green Accepted			2022-12-25	WOS:000174104300090
J	Dramsi, S; Scheid, MP; Maiti, A; Hojabrpour, P; Chen, XM; Schubert, K; Goodlett, DR; Aebersold, R; Duronio, V				Dramsi, S; Scheid, MP; Maiti, A; Hojabrpour, P; Chen, XM; Schubert, K; Goodlett, DR; Aebersold, R; Duronio, V			Identification of a novel phosphorylation site, Ser-170, as a regulator of bad pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-B ACTIVATION; CELL-SURVIVAL; PROTEIN-KINASE; BCL-2 FAMILY; BH3 DOMAIN; HEMATOPOIETIC-CELLS; MASS-SPECTROMETRY; DEATH; PATHWAY; DISSOCIATION	Bad is a pro-apoptotic member of the Bcl-2 family of proteins that is thought to exert a death-promoting effect by heterodimerization with Bcl-X-L, nullifying its anti-apoptotic activity. Growth factors may promote cell survival at least partially through phosphorylation of Bad at one or more of Ser-112, -136, or -155. Our previous work showed that Bad is also phosphorylated in response to cytokines at another site, which we now identify as Ser-170. The functional role of this novel phosphorylation site was assessed by site-directed mutagenesis and analysis of the pro-apoptotic function of Bad in transiently transfected HEK293 and COS-7 cells or by stable expression in the cytokine-dependent cell line, MC/9. In general, mutation of Ser-170 to Ala results in a protein with increased ability to induce apoptosis, similar to the S112A mutant. Mutation of Ser-170 to Asp, mimicking a constitutively phosphorylated site, results in a protein that is virtually unable to induce apoptosis. Similarly, the S112A/S170D double mutant does not cause apoptosis in HEK293 and MC/9 cell lines. These data strongly suggest that phosphorylation of Bad at Ser-170 is a critical event in blocking the pro-apoptotic activity of Bad.	Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Inst Syst Biol, Seattle, WA 98105 USA	University of British Columbia; University of British Columbia; Institute for Systems Biology (ISB)	Duronio, V (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada.	vduronio@interchange.ubc.ca			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041109] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFFOLTER M, 1994, ANAL BIOCHEM, V223, P74, DOI 10.1006/abio.1994.1549; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; JACOBSON MD, 1997, CURR BIOL, V7, P277; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	36	71	73	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6399	6405		10.1074/jbc.M109990200	http://dx.doi.org/10.1074/jbc.M109990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11717309	Green Published, hybrid			2022-12-25	WOS:000173989200093
J	Jacobs-Helber, SM; Abutin, RM; Tian, C; Bondurant, M; Wickrema, A; Sawyer, ST				Jacobs-Helber, SM; Abutin, RM; Tian, C; Bondurant, M; Wickrema, A; Sawyer, ST			Role of JunB in erythroid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; C-JUN; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; DNA-BINDING; ERYTHROPOIETIN; P27(KIP1); PROLIFERATION; INHIBITION; KINASE	The role of junB as a regulator of erythroid cell survival, proliferation, and differentiation was tested by controlled expression of Jun Bin the erythropoietin (EPO)-dependent erythroleukemia cell line HCD57. JunB induced erythroid differentiation as evidenced by increased expression of the erythroid-specific proteins beta-globin, spectrin-alpha, and TER-119. Expression of JunB for at least 48 h was required for the differentiated phenotype to emerge. Differentiation was accompanied by a slower rate of proliferation and an increase in the expression of the cell cycle inhibitory protein p27. p27 protein expression increased due to reduced turnover without changes in transcription, indicating global changes in cell physiology following JunB induction. JunB expression was also studied in mouse and human primary erythroid cells. JunB expression increased immediately in both primary mouse cells and HCD57 cells treated with EPO and quickly returned to base-line levels, followed by a secondary rise in JunB in primary erythroid cells, but not in HCD57 cells, 36-48 h later. This result suggested that the initial EPO-dependent JunB induction was not sufficient to induce differentiation, but that the late EPO-independent JunB expression in primary erythroid cells was necessary for differentiation. This study suggests that JunB is an important regulator of erythroid differentiation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, MVC Stn, Richmond, VA 23298 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60607 USA	Virginia Commonwealth University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sawyer, ST (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, MVC Stn, Med Coll Virginia Campus,POB 980613, Richmond, VA 23298 USA.	ssawyer@hsc.vcu.edu			NHLBI NIH HHS [R01HL65906] Funding Source: Medline; NIDDK NIH HHS [DK39781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Ito E, 1999, GENE, V228, P93, DOI 10.1016/S0378-1119(99)00022-0; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Jochum W, 1999, Verh Dtsch Ges Pathol, V83, P216; KASUKABE T, 1994, CANCER RES, V54, P592; KIM TA, 1993, CANCER LETT, V71, P125, DOI 10.1016/0304-3835(93)90107-K; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; KOO AS, 1992, J UROLOGY, V148, P1314, DOI 10.1016/S0022-5347(17)36899-4; KOURY MJ, 1991, AM J KIDNEY DIS, V18, P20; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; OUAAZ F, 1994, BLOOD, V84, P3095; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Turchi L, 2000, EXP CELL RES, V261, P220, DOI 10.1006/excr.2000.5060; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	33	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4859	4866		10.1074/jbc.M107243200	http://dx.doi.org/10.1074/jbc.M107243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11726656	hybrid			2022-12-25	WOS:000173962900042
J	Burgar, HR; Burns, HD; Elsden, JL; Lalioti, MD; Heath, JK				Burgar, HR; Burns, HD; Elsden, JL; Lalioti, MD; Heath, JK			Association of the signaling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; POINT MUTATION; PROTEIN; CLONING; BINDING; IDENTIFICATION; TRANSDUCTION; EXPRESSION; ACTIVATION; FAMILY	Fibroblast growth factor receptors (FGFRs) are a family of transmembrane tyrosine kinases involved in signaling via interactions with the family of fibroblast growth factors. Alternative splicing of the juxtamembrane region of FGFR1-3 leads to the inclusion or exclusion of two amino acids, valine and threonine, the VT site. The presence or absence of VT (VT + or VT -, respectively) affects the signaling potential of the receptor. The VT+ receptor isoform is required for Erk2 phosphorylation, a component of the mitogen-activated protein kinase signaling pathway. FRS2 is an adaptor protein that links FGFRs to the mitogen-activated protein kinase signaling pathway. FRS2 interacts with a region of the juxtamembrane domain of FGFR1 that includes the alternatively spliced VT site. We investigated the interaction of FRS2 with murine Fgfr1 juxtamembrane domain. We showed the alternatively spliced VT motif, at the juxtamembrane domain of Fgfr1 is required for FRS2 interaction with Fgfr1. Activation of signaling pathways from FRS2 is likely to be regulated by controlling the Fgfr1/FRS2 interaction through alternative splicing of the VT motif of Fgfr1.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Heath, JK (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.							BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JOHNSON D, 1991, MOL CELL BIOL, V9, P4627; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KLINT P, 1999, FRONT BIOSCI, V4, P165; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; McCoon PE, 1996, J BIOL CHEM, V271, P20119, DOI 10.1074/jbc.271.33.20119; McDougall K, 2001, MECH DEVELOP, V103, P145, DOI 10.1016/S0925-4773(01)00337-9; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz D.M., 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Paterno GD, 2000, J BIOL CHEM, V275, P9581, DOI 10.1074/jbc.275.13.9581; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; SHIOZAKI C, 1995, GENE, V152, P215, DOI 10.1016/0378-1119(94)00694-N; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; STARK KL, 1991, DEVELOPMENT, V113, P641; Twigg SRF, 1998, HUM MOL GENET, V7, P685, DOI 10.1093/hmg/7.4.685; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKIE AOM, 1995, CURR BIOL, V5, P500; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	47	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4018	4023		10.1074/jbc.M107785200	http://dx.doi.org/10.1074/jbc.M107785200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729184	hybrid			2022-12-25	WOS:000173813900031
J	Machwe, A; Xiao, LR; Theodore, S; Orren, DK				Machwe, A; Xiao, LR; Theodore, S; Orren, DK			DNase I footprinting and enhanced exonuclease function of the bipartite Werner syndrome protein (WRN) bound to partially melted duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; HELICASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; SYNDROME CELLS; REPLICATION; BINDING; SGS1; TRANSCRIPTION; INTERACTS; REPAIR	Werner syndrome is a premature aging and cancer-prone hereditary disorder caused by deficiency of the WRN protein that harbors 3'- 5' exonuclease and RecQ-type 3' --> 5' helicase activities. To assess the possibility that WRN acts on partially melted DNA intermediates, we constructed a substrate containing a 21-nucleotide noncomplementary region asymmetrically positioned within a duplex DNA fragment. Purified WRN shows an extremely efficient exonuclease activity directed at both blunt ends of this substrate, whereas no activity is observed on a fully duplex substrate. High affinity binding of full-length WRN protects an area surrounding the melted region of the substrate from DNase I digestion. ATP binding stimulates but is not required for WRN binding to this region. Thus, binding of WRN to the melted region underlies the efficient exonuclease activity directed at the nearby ends. In contrast, a WRN deletion mutant containing only the functional exonuclease domain does not detectably bind or degrade this substrate. These experiments indicate a bipartite structure and function for WRN, and we propose a model by which its DNA binding, helicase, and exonuclease activities function coordinately in DNA metabolism. These studies also suggest that partially unwound or noncomplementary regions of DNA could be physiological targets for WRN.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Orren, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 326 Bosomworth Hlth Sci Res Bldg,800 Rose St, Lexington, KY 40536 USA.				NINDS NIH HHS [NS-008900] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bennett SE, 1997, CANCER RES, V57, P2956; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TAHARA H, 1997, ONCOGENE, V15, P1913; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4492	4504		10.1074/jbc.M108880200	http://dx.doi.org/10.1074/jbc.M108880200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11717307	hybrid			2022-12-25	WOS:000173813900092
J	Nghiem, P; Park, PK; Kim, YS; Desai, BN; Schreiber, SL				Nghiem, P; Park, PK; Kim, YS; Desai, BN; Schreiber, SL			ATR is not required for p53 activation but synergizes with p53 in the replication check-point	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; EARLY EMBRYONIC LETHALITY; DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; IONIZING-RADIATION; MAMMALIAN-CELLS; KINASE; PROTEIN; GENE	ATR (ataxia telangiectasia and Rad-3-related) is a protein kinase required for survival after DNA damage. A critical role for ATR has been hypothesized to be the regulation of p53 and other cell cycle checkpoints. ATR has been shown to phosphorylate p53 at Ser(15), and this damage-induced phosphorylation is diminished by expression of a catalytically inactive (ATR-kd) mutant. p53 function could not be examined directly in prior studies of ATR, however, because p53 was mutant or because cells expressed the SV40 large T antigen that blocks p53 function. To test the interactions of ATR and p53 directly we generated human U2OS cell lines inducible for either wild-type or kinase-dead ATR that also have an intact p53 pathway. Indeed, ATR-kd expression sensitized these cells to DNA damage and caused a transient decrease in damage-induced serine 15 phosphorylation of p53. However, we found that the effects of ATR-kd expression do not result in blocking the response of p53 to DNA damage. Specifically, prior ATR-kd expression had no effect on DNA damage-induced p53 protein up-regulation, p53-DNA binding, p21 mRNA up-regulation, or G(1) arrest. Instead of promoting survival via p53 regulation, we found that ATR protects cells by delaying the generation of mitotic phosphoproteins and inhibiting premature chromatin condensation after DNA damage or hydroxyurea. Although p53 inhibition (by E6 or MDM2 expression) had little effect on premature chromatin condensation, when combined with ATR-kd expression there was a marked loss of the replication checkpoint. We conclude that ATR and p53 can function independently but that loss of both leads to synergistic disruption of the replication checkpoint.	Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Cutaneous Oncol Unit, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Schreiber, SL (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X; /0000-0002-3928-5854	NIAMS NIH HHS [K08-AR0208703] Funding Source: Medline; NIGMS NIH HHS [GM-52067] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052067] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Brown EJ, 2000, GENE DEV, V14, P397; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Shieh SY, 2000, GENE DEV, V14, P289; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	86	88	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4428	4434		10.1074/jbc.M106113200	http://dx.doi.org/10.1074/jbc.M106113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11711532	Green Published, hybrid			2022-12-25	WOS:000173813900085
J	Arata, Y; Baleja, JD; Forgac, M				Arata, Y; Baleja, JD; Forgac, M			Cysteine-directed cross-linking to subunit B suggests that subunit E forms part of the peripheral stalk of the vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST V-ATPASE; PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI F1-ATPASE; DELTA-SUBUNIT; NEUROSPORA-CRASSA; SACCHAROMYCES-CEREVISIAE; LUMINAL ACIDIFICATION; INTERSUBUNIT ROTATION; ELECTRON-MICROSCOPY; F1F0-ATP SYNTHASE	We have employed a combination of site-directed mutagenesis and covalent cross-linking to identify subunits in close proximity to subunit B in the vacuolar H+-ATPase (V-ATPase) complex. Unique cysteine residues were introduced into a Cys-less form of subunit B, and the V-ATPase complex in isolated vacuolar membranes from each mutant strain was reacted with the bifunctional, photoactivable maleimide reagent 4-(N-maleimido)benzophenone. Photoactivation resulted in crosslinking of the unique sulfhydryl groups on subunit B with other subunits in the complex. Four of the eight mutants constructed containing a unique Cysteine residue at Ala(15), LyS(45), Glu(494), or Thr(501) resulted in the formation of cross-linked products, which were recognized by Western blot analysis using antibodies against both subunits B and E. These products had a molecular mass of 84 kDa, consistent with a cross-linked product of subunits B and E. Molecular modeling of subunit B places Ala(15) and Lys(45) near the top of the V-1 structure (i.e. farthest from the membrane), whereas Glu(494) and Thr(501) are predicted to reside near the bottom of V, with all four residues predicted to be oriented toward the external surface of the complex. A model incorporating these and previous data is presented in which subunit E exists in an extended conformation on the outer surface of the A(3)B(3) hexamer that forms the core of the V-1 domain. This location for subunit E suggests that this subunit forms part of the peripheral stalk of the V-ATPase that links the V-1 and V-0 domains.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Bowman EJ, 2000, J EXP BIOL, V203, P97; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown D, 2000, J EXP BIOL, V203, P137; Capaldi RA, 2000, J EXP BIOL, V203, P29; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; Graham LA, 2000, J EXP BIOL, V203, P61; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HAZARD AL, 1994, J BIOL CHEM, V269, P427; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 2000, J EXP BIOL, V203, P89; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SHIN K, 1992, J BIOL CHEM, V267, P20835; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	70	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3357	3363		10.1074/jbc.M109967200	http://dx.doi.org/10.1074/jbc.M109967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724797	hybrid			2022-12-25	WOS:000173688000041
J	Hoffman, WH; Biade, S; Zilfou, JT; Chen, JD; Murphy, M				Hoffman, WH; Biade, S; Zilfou, JT; Chen, JD; Murphy, M			Transcriptional repression of the anti-apoptotic survivin gene by wild type p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION; FUNCTIONAL DOMAIN; CANCER CELLS; EXPRESSION; PROTEIN; BINDING; GROWTH; DNA; INHIBITION; CHECKPOINT	Survivin is a member of the inhibitor of apoptosis family. This apoptosis inhibitor also has an evolutionarily conserved role as a mitotic spindle checkpoint protein. Previous studies on p53-repressed genes have implicated several genes involved in the G(2)/M transition of the cell cycle as targets of negative regulation by p53. However, few targets of p53 repression that are antiapoptotic have been identified. This study identifies the anti-apoptotic survivin gene as a p53-repressed gene. Notably, Survivin repression by p53 is shown to be distinct from p53-dependent growth arrest. Chromatin immunoprecipitations indicate that p53 binds the survivin promoter in vivo; immunobinding studies indicate that this site overlaps with a binding site for E2F transcription factors and is subtly distinct from a canonical p53-transactivating element. The survivin-binding site contains a 3-nucleotide spacer between the two decamer "half-sites" of the p53 consensus element; deletion of this spacer is sufficient to convert the survivin site into a transactivating element. Finally, we show that overexpression of Survivin in cells sensitive to p53-dependent cell death markedly inhibits apoptosis induced by ultraviolet light. The identification of survivin as a p53 repressed gene should aid in the elucidation of the contribution of transcriptional repression to p53-dependent apoptosis.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA	Fox Chase Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Murphy, M (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [R01CA080854] Funding Source: NIH RePORTER; NCI NIH HHS [CA80854] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Choki I, 1998, ANTICANCER RES, V18, P4213; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kawasaki H, 1998, CANCER RES, V58, P5071; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Olie RA, 2000, CANCER RES, V60, P2805; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Tamm I, 1998, CANCER RES, V58, P5315; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	54	657	713	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3247	3257		10.1074/jbc.M106643200	http://dx.doi.org/10.1074/jbc.M106643200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714700	hybrid			2022-12-25	WOS:000173688000027
J	Liu, SG; Guo, R; Tu, QS; Quarles, LD				Liu, SG; Guo, R; Tu, QS; Quarles, LD			Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; RENAL PHOSPHATE-TRANSPORT; IN-SITU HYBRIDIZATION; PEX GENE; MUTATIONAL ANALYSIS; TISSUE DISTRIBUTION; CDNA CLONING; EXPRESSION; BONE; MICE	Inactivating mutations of Phex, a phosphate-regulating endopeptidase, cause hypophosphatemia and impaired mineralization in X-linked hypophosphatemia (XLH) and its mouse homologue, Hyp. Because Phex is predominantly expressed in bone and cultured osteoblasts from Hyp mice display an apparent intrinsic mineralization defect, it is thought that reduced expression of Phex in mature osteoblasts is the primary cause of XLH. To test this hypothesis, we studied both targeted expression of Phex to osteoblasts in vivo under the control of the mouse osteocalcin (OG2) promoter and retroviral mediated overexpression of Phex in Hyp-derived osteoblasts (TMOb-Hyp) in vitro. Targeted overexpression of Phex to osteoblasts of OG2 Phex transgenic Hyp mice normalized Phex endopeptidase activity in bone but failed to correct the hypophosphatemia, rickets, or osteomalacia. OG2 Phex transgenic Hyp mice did exhibit a small, but significant, increase in bone mineral density and dry ashed weight, suggesting a partial mineralization effect from restoration of Phex function in mature osteoblasts. Similarly, retroviral mediated overexpression of Phex in TMOb-Hyp osteoblasts restored Phex mRNA levels, protein expression, and endopeptidase activity but failed to correct their intrinsic mineralization defect. In addition, we failed to detect the Phex substrate FGF-23 in osteoblasts. Taken together, these in vivo and in vitro data indicate that expression of Phex in osteoblasts is not sufficient to rescue the Hyp phenotype and that other sites of Phex expression and/or additional factors are likely to be important in the pathogenesis of XLH.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3036, Durham, NC 27710 USA.	Quarl001@mc.duke.edu		Tu, Qisheng/0000-0003-0639-8761; Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043468, R01AR037308] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR43468, R01-AR37308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DELVIN EE, 1990, BONE, V11, P87, DOI 10.1016/8756-3282(90)90055-4; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; ECAROT B, 1992, J BONE MINER RES, V7, P523; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; Grieff M, 1997, BIOCHEM BIOPH RES CO, V231, P635, DOI 10.1006/bbrc.1997.6153; GUNDBERG CM, 1992, ENDOCRINOLOGY, V130, P1909, DOI 10.1210/en.130.4.1909; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; Guo R, 2001, AM J PHYSIOL-ENDOC M, V281, pE837, DOI 10.1152/ajpendo.2001.281.4.E837; Halstead LR, 1996, AM J PHYSIOL-ENDOC M, V270, pE141, DOI 10.1152/ajpendo.1996.270.1.E141; Holm IA, 1997, AM J HUM GENET, V60, P790; Holm IA, 2001, J CLIN ENDOCR METAB, V86, P3889, DOI 10.1210/jc.86.8.3889; Howrey RP, 2000, GENE THER, V7, P215, DOI 10.1038/sj.gt.3301064; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; Lajeunesse D, 1996, KIDNEY INT, V50, P1531, DOI 10.1038/ki.1996.468; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; MEYER RA, 1989, J BONE MINER RES, V4, P493; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Miyamura T, 2000, J BONE MINER RES, V15, P1451, DOI 10.1359/jbmr.2000.15.8.1451; NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735; Nesbitt T, 1999, J BONE MINER RES, V14, P2027, DOI 10.1359/jbmr.1999.14.12.2027; Plummer TB, 1998, DIAGN MOL PATHOL, V7, P76, DOI 10.1097/00019606-199804000-00003; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Quarles LD, 2001, J CLIN ENDOCR METAB, V86, P494, DOI 10.1210/jc.86.2.494; Quarles LD, 1997, J CELL BIOCHEM, V65, P11; Rifas L, 1997, CALCIFIED TISSUE INT, V61, P256, DOI 10.1007/s002239900331; Ruchon AF, 2000, J BONE MINER RES, V15, P1440, DOI 10.1359/jbmr.2000.15.8.1440; Sabbagh Y, 2001, HUM MOL GENET, V10, P1539, DOI 10.1093/hmg/10.15.1539; Sabbagh Yves, 2000, Journal of the American Society of Nephrology, V11, p413A; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Sokal R. R., 1981, BIOMETRY; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Strom TM, 1997, HUM MOL GENET, V6, P165, DOI 10.1093/hmg/6.2.165; Thomas R, 1999, J BONE MINER RES, V14, pS189; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yang H, 1999, J HISTOCHEM CYTOCHEM, V47, P431, DOI 10.1177/002215549904700402; Zoidis E, 2000, MOL CELL ENDOCRINOL, V168, P41, DOI 10.1016/S0303-7207(00)00310-5	49	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3686	3697		10.1074/jbc.M107707200	http://dx.doi.org/10.1074/jbc.M107707200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11713245	hybrid			2022-12-25	WOS:000173688000083
J	Paillard, L; Legagneux, V; Maniey, D; Osborne, HB				Paillard, L; Legagneux, V; Maniey, D; Osborne, HB			c-Jun ARE targets mRNA deadenylation by an EDEN-BP (embryo deadenylation element-binding protein)-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; MESSENGER-RNA DEADENYLATION; XENOPUS OOCYTE MATURATION; MYOTONIC-DYSTROPHY; TRANSLATIONAL CONTROL; CIS-ELEMENT; PROTEIN; DEGRADATION; SEQUENCES; EMBRYOS	In mammalian cells, certain mRNAs encoding cytokines or proto-oncogenes are especially unstable, because of the presence of a particular sequence element in their 3'-untranslated region named ARE (A/U-rich element). AREs cause this instability by provoking the rapid shortening of the poly(A) tail of the mRNA. The deadenylation of mRNAs mediated by AREs containing repeats of the AUUUA motif (class I/II AREs) is conserved in Xenopus embryos. Here, we first extend these observations by showing that c-Jun ARE, a representative of class III (non-AUUUA) AREs, also provokes the deadenylation of a reporter RNA in Xenopus embryos. Next, by immunodepletion and immunoneutralization experiments, we show that, in Xenopus, the rapid deadenylation of RNAs that contain the c-Jun ARE, but not an AUUUA ARE, requires EDEN-BP. This RNA-binding protein was previously shown to provoke the rapid deadenylation of certain Xenopus maternal RNAs. Finally, we show that CUG-BP, the human homologue of EDEN-BP, specifically binds to c-Jun ARE. Together, these results identify CUG-BP as a plausible deadenylation factor responsible for the post-transcriptional control of c-Jun proto-oncogene mRNA in mammalian cells.	Univ Rennes 1, Fac Med, CNRS UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Paillard, L (corresponding author), Univ Rennes 1, Fac Med, CNRS UMR 6061, 2 Ave Leon Bernard, F-35043 Rennes, France.		Legagneux, Vincent/I-3409-2015; Paillard, Luc/AAB-2816-2022	Legagneux, Vincent/0000-0002-1417-6678; Paillard, Luc/0000-0002-9290-7616				Audic Y, 1997, BIOTECHNIQUES, V23, P612, DOI 10.2144/97234bm11; Audic Y, 1997, MOL CELL BIOL, V17, P209, DOI 10.1128/MCB.17.1.209; Audic Y, 1998, MOL CELL BIOL, V18, P6879, DOI 10.1128/MCB.18.12.6879; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Legagneux V, 1995, RNA, V1, P1001; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; Takahashi N, 2000, BIOCHEM BIOPH RES CO, V277, P518, DOI 10.1006/bbrc.2000.3694; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; VONDAM H, 2001, GENE DEV, V20, P2453; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	34	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3232	3235		10.1074/jbc.M109362200	http://dx.doi.org/10.1074/jbc.M109362200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707455	hybrid			2022-12-25	WOS:000173688000024
J	Chen, H; Locke, D; Liu, Y; Liu, CD; Kahn, ML				Chen, H; Locke, D; Liu, Y; Liu, CD; Kahn, ML			The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-VI; GAMMA-CHAIN; INDUCED AGGREGATION; ACTIVATION; EXPRESSION; INTEGRIN; PATIENT	The platelet response to collagen is a primary event in hemostasis and thrombosis, but the precise roles of the numerous identified platelet collagen receptors remain incompletely defined. Attention has recently focused on glycoprotein VI (GPVI), a receptor that is expressed on platelets in association with a signaling adapter, the Fc receptor gamma chain (Fc Rgamma). Genetic and pharmacologic loss of GPVI function results in loss of collagen signaling in platelets, but studies to date have failed to demonstrate that GPVI-Fc Rgamma expression is sufficient to confer collagen signaling responses. These results have led to the hypothesis that collagen responses mediated by GPVI-Fc Rgamma may require the collagen-binding integrin alpha2beta1 as a co-receptor, but this model has not been supported by a recent study of mouse platelets lacking alpha2beta1. In the present study we have used a novel anti-GPVI monoclonal antibody to measure the level of GPVI on human platelets and to guide the development of GPVI-expressing cell lines to assess the role of GPVI in mediating platelet collagen responses. GPVI receptor density on human platelets appears tightly regulated, is independent from the level of alpha2beta1 expression, and significantly exceeds that on previously characterized GPVI-expressing RBL-2H3 cells. Using newly generated GPVI-expressing RBL-2H3 cells with receptor densities equivalent to that on human platelets, we demonstrate that GPVI expression confers both adhesive and signaling responses to collagen in a graded fashion that is proportional to the GPVI receptor density. These results resolve some of the conflicting data regarding GPVI-collagen interactions and demonstrate that 1) GPVI-Fc Rgamma expression is sufficient to confer both adhesion and signaling responses to collagen, and 2) GPVI-mediated collagen responses are receptor density-dependent at the receptor levels expressed on human platelets.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kahn, ML (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2-3 Room 952, Philadelphia, PA 19104 USA.	markkahn@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BRAUNSTEIN D, 1994, BIOPHYS J, V66, P1717, DOI 10.1016/S0006-3495(94)80964-6; Carlsson LE, 1999, BLOOD, V93, P3583, DOI 10.1182/blood.V93.11.3583.410k34_3583_3586; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Hynes RO, 1997, J CLIN INVEST, V100, pS11; Jung TS, 2000, FISH SHELLFISH IMMUN, V10, P285, DOI 10.1006/fsim.1999.0259; KEHREL B, 1988, BLOOD, V71, P1074; KUNICKI TJ, 1993, BLOOD, V82, P2693; LIPPINCOTT JB, 1986, HEMOSTASIS THROMBOSI; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POSNER RG, 1995, J IMMUNOL, V155, P3601; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; SPUDICH A, 1995, P NATL ACAD SCI USA, V92, P6976, DOI 10.1073/pnas.92.15.6976; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; WILNER GD, 1968, J CLIN INVEST, V47, P2616, DOI 10.1172/JCI105944; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	27	120	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3011	3019		10.1074/jbc.M109714200	http://dx.doi.org/10.1074/jbc.M109714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11723134	hybrid			2022-12-25	WOS:000173421500084
J	Rezaie, AR				Rezaie, AR			Partial activation of antithrombin without heparin through deletion of a unique sequence on the reactive site loop of the serpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XA; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; BLOOD-COAGULATION; BINDING; THROMBIN; PROTEINASE; COMPLEX; ACCELERATION; INHIBITOR-1	Native antithrombin (AT) has an inactive reactive site loop conformation unless it is activated by a unique pentasaccharide fragment of heparin (H-5). Structural data suggests that this may be due to preinsertion of two N-terminal residues of the reactive site loop of the serpin into the A-P-sheet of the molecule. Relative to a,antitrypsin, the reactive site loop of AT has three additional residues, Arg(399), Val(400), and Thr(401), at the C-terminal P' end of the loop. To determine whether a longer reactive site loop of AT is responsible for loop preinsertion in the native conformation, mutants of the serpin were expressed in which these residues were individually or in combination deleted. Kinetic analysis suggested that deletion of two residues, Val(400) and Thr(401), changed the solution equilibrium of the serpin in favor of the active conformation, thereby enhancing the inhibition of factor Xa by an order of magnitude independent of H-5. Interestingly, the reactivity of this mutant with thrombin was impaired by the same order of magnitude in the absence, but not in the presence of H-5. These results suggest that a longer reactive site loop in AT is responsible for its inactive native conformation toward factor Xa, while at same time AT requires this feature to regulate the activity of thrombin.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NHLBI NIH HHS [R01 HL62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1992, REGULATION THROMBIN, V2, P159; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P13138, DOI 10.1021/bi9808518; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 2001, BLOOD, V97, P2308, DOI 10.1182/blood.V97.8.2308; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798	28	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1235	1239		10.1074/jbc.M108544200	http://dx.doi.org/10.1074/jbc.M108544200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11707451	hybrid			2022-12-25	WOS:000173166800048
J	Catz, SD; Johnson, JL				Catz, SD; Johnson, JL			Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer	ONCOGENE			English	Article						bcl-2; NF-kappa B; prostate; cancer; transcription	TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; SUPPRESSES APOPTOSIS; HIPPOCAMPAL-NEURONS; GENE-EXPRESSION; FAMILY MEMBERS; BINDING-SITES; MICE LACKING	This work presents direct evidence that the, bcl-2 gene is transcriptionally, regulated by nuclear factor-kappaB (NF-kappaB) and directly links the TNF-alpha /NF-kappaB signaling pathway with Bcl-2 expression and its pro-survival response in human prostate carcinoma cells. DNase I footprinting, gel retardation and supershift analysis identified a NF-kappaB site in the bcl-2 p2 promoter. In the context of a minimal promoter, this bcl-2 p2 site 1 increased transcription 10-fold in the presence of the p50/p65, expression vectors, comparable to the increment observed with the consensus NF-kappaB site, while for the full p2 promoter region transcriptional activity was increased sixfold by over-expression of NF-kappaB, an effect eliminated by mutating the bcl-2 p2 site 1. The expression of Bcl-2 has been linked to the hormone-resistant phenotype of advanced prostate cancer. Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappaB. Concomitantly, bcl-2 p2 promoter studies in LNCaP cells, show a 40-fold increase in promoter activity after stimulation with TNF-alpha in the absence of hormone.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, JL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jjohnson@scripps.edu		Catz, Sergio/0000-0002-1873-0277	NIAID NIH HHS [AI44434] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044434] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apakama I, 1996, BRIT J CANCER, V74, P1258, DOI 10.1038/bjc.1996.526; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baltaci S, 2000, BJU INT, V85, P155, DOI 10.1046/j.1464-410x.2000.00388.x; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bubendorf L, 1996, AM J PATHOL, V148, P1557; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Chaudhary KS, 1999, ENVIRON HEALTH PERSP, V107, P49, DOI 10.2307/3434471; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COLOMBEL M, 1993, AM J PATHOL, V143, P390; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HEWITT SM, 1995, CANCER RES, V55, P5386; Huang A, 1998, UROLOGY, V51, P346, DOI 10.1016/S0090-4295(97)00636-5; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; JOHNSON JL, 1994, NUCLEIC ACIDS RES, V22, P5085, DOI 10.1093/nar/22.23.5085; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu S, 1999, ENDOCRINOLOGY, V140, P5054, DOI 10.1210/en.140.11.5054; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; RAFFO AJ, 1995, CANCER RES, V55, P4438; Saeed B, 1997, PROSTATE, V31, P145; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scherr DS, 1999, J UROLOGY, V162, P12, DOI 10.1097/00005392-199907000-00003; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SINHA AA, 1977, CANCER, V40, P2836, DOI 10.1002/1097-0142(197712)40:6<2836::AID-CNCR2820400614>3.0.CO;2-N; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; SORGE J, 1984, MOL CELL BIOL, V4, P1730, DOI 10.1128/MCB.4.9.1730; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZD, 1999, VIROLOGY, V257, P502, DOI 10.1006/viro.1999.9688; Westin P, 1998, CANCER DETECT PREV, V22, P476; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	80	424	447	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7342	7351		10.1038/sj.onc.1204926	http://dx.doi.org/10.1038/sj.onc.1204926			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704864				2022-12-25	WOS:000171894200007
J	Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			EWS-ATF-1 chimeric protein in soft tissue clear cell sarcoma associates with CREB-binding protein and interferes with p53-mediated trans-activation function	ONCOGENE			English	Article						EWS-ATF-1; CBP; p53; Ewing's sarcoma; clear cell sarcoma	ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; EWINGS-SARCOMA; MALIGNANT-MELANOMA; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; GENE FUSION; EWS GENE; MYXOID LIPOSARCOMA	The recurrent t(12;22) (q13;q12) chromosomal translocation associated with soft tissue clear cell sarcoma results in a chimeric protein EWS-ATF-1 that acts as a constitutive transcriptional activator. The CBP/p300 transcriptional coactivator, which links various transcriptional factors to basal transcription apparatus, participates in transcriptional activation, growth and cell cycle control and differentiation. In this study, we show that EWS-ATF-1 associates constitutively with CBP both in vitro and in vivo. Both EWS and ATF-1 fusion domains are needed for this interaction. Here, we demonstrate that EWS-ATF-1 represses p53/CBP-mediated transactivation function. Overexpression of CBP can counteract this repressive effect of EWS-ATF-1. Taken together, these findings suggest that one of the mechanisms by which EWS-ATF-1 may cause tumors is through targeting CBP/p300 resulting in the loss of function of p53. This novel mechanism may be responsible for the development of these and other related solid tumors.	Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Broad & Vine,MS 481, Philadelphia, PA 19102 USA.				NCI NIH HHS [R01 CA58642, R01 CA 85343, CA 57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085343, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; Fujimura Y, 1996, ONCOGENE, V12, P159; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kung AL, 2000, GENE DEV, V14, P272; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	52	28	28	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6653	6659		10.1038/sj.onc.1204684	http://dx.doi.org/10.1038/sj.onc.1204684			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709699				2022-12-25	WOS:000171551600001
J	Miranda, C; Di Virgilio, M; Selleri, S; Zanotti, G; Pagliardini, S; Pierotti, MA; Greco, A				Miranda, C; Di Virgilio, M; Selleri, S; Zanotti, G; Pagliardini, S; Pierotti, MA; Greco, A			Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP TYROSINES; HIGH-AFFINITY RECEPTOR; TRK; DOMAIN; NTRK1; PROTOONCOGENE; BINDING; MUTANTS; MODEL; NGF	Congenital insensitivity to pain with anhidrosis (CIPA) is a rare genetic disease characterized by absence of reaction to noxious stimuli and anhidrosis. The genetic bases of CIPA have remained long unknown. A few years ago, point mutations affecting both coding and noncoding regions of the neurotrophic tyrosine receptor kinase type 1 (NTRK1)/nerve growth factor receptor gene have been detected in CIPA patients, demonstrating the implication of the nerve growth factor/ NTRK1 pathway in the pathogenesis of the disease. We have previously shown that two CIPA mutations, the G571R and the R774P, inactivate the NTRK1 receptor by interfering with the autophosphorylation process. We have extended our functional analysis to seven additional NTRK1 mutations associated with CIPA recently reported by others. Through a combination of biochemical and biological assays, we have identified polymorphisms and pathogenic mutations. In addition to the identification of residues important for NTRK1 activity, our analysis suggests the existence of two novel pathogenic mechanisms in CIPA: one based on the NTRK1 receptor processing and the other acting through the reduction of the receptor activity.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Padua	Greco, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	greco@istitutotumori.mi.it	Di Virgilio, Michela/AAE-9298-2022; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Zanotti, Giuseppe/0000-0002-0945-6501; Di Virgilio, Michela/0000-0001-5189-0793				AXELROD FB, 1984, AM J DIS CHILD, V138, P947, DOI 10.1001/archpedi.1984.02140480049016; AXELROD FB, 1996, PRINCIPLES PRACTICE, P397; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bodzioch M, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<72::AID-HUMU10>3.0.CO;2-X; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Greco A, 1999, AM J HUM GENET, V64, P1207, DOI 10.1086/302319; Greco A, 1996, ONCOGENE, V13, P2463; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 2000, J CELL PHYSIOL, V182, P127, DOI 10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LOEB DM, 1993, J NEUROSCI, V13, P2919; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; Mardy S, 1999, AM J HUM GENET, V64, P1570, DOI 10.1086/302422; Mardy S, 2001, HUM MOL GENET, V10, P179, DOI 10.1093/hmg/10.3.179; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Miura Y, 2000, HUM GENET, V106, P116, DOI 10.1007/s004390051018; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PARODI A, 2000, BIOCHEM J, V15, P1; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; ROSEMBERG S, 1994, PEDIATR NEUROL, V11, P50, DOI 10.1016/0887-8994(94)90091-4; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shatzky S, 2000, AM J MED GENET, V92, P353, DOI 10.1002/1096-8628(20000619)92:5<353::AID-AJMG12>3.0.CO;2-C; Tagliabue E, 1999, INT J BIOL MARKER, V14, P68, DOI 10.1177/172460089901400203; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C; Yotsumoto S, 1999, J INVEST DERMATOL, V112, P810, DOI 10.1046/j.1523-1747.1999.00569.x	43	35	39	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6455	6462		10.1074/jbc.M110016200	http://dx.doi.org/10.1074/jbc.M110016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11719521	hybrid			2022-12-25	WOS:000173989200100
J	Boo, YC; Sorescu, G; Boyd, N; Shiojima, L; Walsh, K; Du, J; Jo, HJ				Boo, YC; Sorescu, G; Boyd, N; Shiojima, L; Walsh, K; Du, J; Jo, HJ			Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser(1179) by Akt-independent mechanisms - Role of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; ACTIVATION; APOPTOSIS; IDENTIFICATION; TRANSLOCATION; SUPPRESSION; CALCIUM; RELEASE	Recently, we have shown that shear stress stimulates NO. production by the protein kinase B/Akt (Akt)-dependent mechanisms in bovine aortic endothelial cells (BAEC) (Go, Y. M., Boo, Y. C., Park, H., Maland, M. C., Patel, R., Pritchard, K. A., Jr., Fujio, Y., Walsh, K., Darley-Usmar, V., and Jo, H. (2001) J. Appl. Physiol. 91,15741581). Akt has been believed to regulate shear-dependent production of NO. by directly phosphorylating endothelial nitric-oxide synthase (eNOS) at the Ser(1179) residue (eNOS-S-1179), but a critical evaluation using specific inhibitors or dominant negative mutants (Akt(AA) or Akt(AAA)) has not been reported. In addition, other kinases, including protein kinase A (PKA) and AMP kinase have also shown to phosphorylate eNOS-S-1179. Here, we show that shear-dependent phosphorylation of eNOSS1179 is mediated by an Akt-independent, but a PKA-dependent, mechanism. Expression of Akt(AA) or Akt(AAA) in BAEC by using recombinant adenoviral constructs inhibited phosphorylation of eNOS-S-1179 if cells were stimulated by vascular endothelial growth factor (VEGF), but not by shear stress. As shown before, expression of Akt(AA) inhibited shear-dependent NO. production, suggesting that Akt is still an important regulator in NO production. Further studies showed that a selective inhibitor of PKA, H89, inhibited shear-dependent phosphorylation of eNOS-S-1179 and NO. production. In contrast, H89 did not inhibit phosphorylation of eNOS-S' 179 induced by expressing a constitutively active Akt mutant (Akt(Myr) in BAEC, showing that the inhibitor did not affect the Akt pathway. S-Bromo-cAMP alone phosphorylated eNOS-S-1179 within 5 min without activating Akt, in an H89-sensitive manner. Collectively, these results demonstrate that shear stimulates phosphorylation of eNOS-S-1179 in a PKA-dependent, but Akt-independent manner, whereas the NO. production is regulated by the mechanisms dependent on both PKA and Akt. A coordinated interaction between Akt and PKA may be an important mechanism by which eNOS activity is regulated in response to physiological stimuli such as shear stress.	Georgia Tech & Emory Univ, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02135 USA; Univ Kansas, Med Ctr, Div Cardiovasc, Kansas City, KS 66160 USA	University System of Georgia; Georgia Institute of Technology; St. Elizabeth's Medical Center; Tufts University; University of Kansas; University of Kansas Medical Center	Jo, HJ (corresponding author), Georgia Tech & Emory Univ, Wallace H Coulter Dept Biomed Engn, 308D WMB, Atlanta, GA 30322 USA.		Jo, Hanjoong/L-6216-2019	Jo, Hanjoong/0000-0003-1833-372X; Boo, Yong Chool/0000-0001-9895-2066	NHLBI NIH HHS [HL60905] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1999, P NATL ACAD SCI USA, V96, P1123, DOI 10.1073/pnas.96.3.1123; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LIU JW, 1994, J BIOL CHEM, V269, P11691; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Tsao PS, 1996, CIRCULATION, V94, P1682, DOI 10.1161/01.CIR.94.7.1682; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; Wang WG, 1997, BIOCHEM BIOPH RES CO, V233, P748, DOI 10.1006/bbrc.1997.6548; Zhang XP, 2001, ARTERIOSCL THROM VAS, V21, P797, DOI 10.1161/01.ATV.21.5.797	41	364	375	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3388	3396		10.1074/jbc.M108789200	http://dx.doi.org/10.1074/jbc.M108789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11729190	hybrid			2022-12-25	WOS:000173688000045
J	Bridges, LC; Tani, PH; Hanson, KR; Roberts, CM; Judkins, MB; Bowditch, RD				Bridges, LC; Tani, PH; Hanson, KR; Roberts, CM; Judkins, MB; Bowditch, RD			The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha(4)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; AMYLOID PRECURSOR PROTEIN; III CONNECTING SEGMENT; NECROSIS-FACTOR-ALPHA; CELL-ADHESION; DISINTEGRIN DOMAIN; MEDIATES ADHESION; FERTILIN BETA; MURINE EGGS; BINDING	The interaction of lymphocytes with other cells is critical for normal immune surveillance and response. MDC-L (ADAM 28), a member of the ADAM (a disintegrin and metalloprotease) protein family, is expressed on the surface of human lymphocytes. ADAMs possess a disintegrin-like domain similar in sequence to small nonenzymatic snake venom peptides that act as integrin antagonists. We report here that the disintegrin domain of MDC-L is recognized by the leukocyte integrin alpha(4)/beta(1). Recombinant Fe fusion proteins possessing the disintegrin domain of MDC-L supported adhesion of the T-lymphoma cell line, Jurkat, in a concentration- and divalent cation-dependent manner. Adhesion of Jurkat cells to the disintegrin domain of MDC-L was inhibited by an anti-MDC-L monoclonal antibody (mAb), Dis1-1. The epitope for mAb Dis1-1 was localized within 59 residues of the disintegrin domain. Recombinant expression of this 59-residue fragment of the disintegrin domain also supported cell adhesion. Adhesion of Jurkat cells to the MDC-L disintegrin domain was specifically inhibited by anti-alpha(4) and anti-beta(1) function-blocking mAbs. Furthermore, adhesion of various cell lines to MDC-L correlated with expression of the integrin alpha(4)-subunit. Transfected K562 cells expressing alpha(4)beta(1), adhered to the disintegrin domain in contrast to non-transfected K562 cells. We further investigated the binding of recombinant MDC-L disintegrin domain (rDis-Fe) in solution. The rDis-Fe was found to bind to Jurkat cells in solution in a concentration-dependent and saturable manner. Both adhesion and solution binding of rDis-Fe was inhibited by the alpha(4)/beta(1) ligand mimetic CS-1 peptide. Additionally, recognition of the MDC-L disintegrin domain required "activation" of lymphocyte beta(1) integrins. The interaction of MDC-L with alpha(4)beta(1) may potentially regulate metalloprotease function by targeting or sequestering the active protease on the cell surface. These results suggest a potential role for the lymphocyte ADAM, MDC-L, in the interaction of lymphocytes with alpha(4)/beta(1)-expressing leukocytes.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Bowditch, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, BRC 456,POB 26901, Oklahoma City, OK 73190 USA.	ron-bowditch@ouhsc.edu			NIAID NIH HHS [AI47314] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047314] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Calabresi PA, 2001, J NEUROIMMUNOL, V115, P161, DOI 10.1016/S0165-5728(01)00253-3; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Giblin PA, 1997, J IMMUNOL, V159, P3498; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1994, J IMMUNOL, V152, P3282; HARLOW E, 1988, ANTIBODIES; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kauf ACW, 2001, BIOCHEMISTRY-US, V40, P9159, DOI 10.1021/bi010503x; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Roberts CM, 1999, J BIOL CHEM, V274, P29251, DOI 10.1074/jbc.274.41.29251; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Spring FA, 2001, BLOOD, V98, P458, DOI 10.1182/blood.V98.2.458; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; Wagner N, 1998, CURR TOP MICROBIOL, V231, P23; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhou M, 2001, BIOCHEM BIOPH RES CO, V280, P574, DOI 10.1006/bbrc.2000.4155; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	59	67	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3784	3792		10.1074/jbc.M109538200	http://dx.doi.org/10.1074/jbc.M109538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724793	hybrid			2022-12-25	WOS:000173688000094
J	Crawford, SE; Qi, C; Misra, P; Stellmach, V; Rao, MS; Engel, JD; Zhu, YJ; Reddy, JK				Crawford, SE; Qi, C; Misra, P; Stellmach, V; Rao, MS; Engel, JD; Zhu, YJ; Reddy, JK			Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; GENE-EXPRESSION; NERVOUS-SYSTEM; ERYTHROID-DIFFERENTIATION; VENTRAL MORPHOGENESIS; COACTIVATOR COMPLEX; TRAP220 COMPONENT; TUBE FORMATION; PPAR-GAMMA; RXR-ALPHA	Peroxisome proliferator activator receptor (PPAR)binding protein (PBP) is an important coactivator for PPARgamma and other nuclear receptors. It has been identified as an integral component of a multiprotein thyroid hormone receptor-associated protein/vitamin D-3 receptor-interacting protein/activator-recruited cofactor complexes required for transcriptional activity. Here, we show that PBP is critical for the development of placenta and for the normal embryonic development of the heart, eye, vascular, and hematopoietic systems. The primary functional cause of embryonic lethality at embryonic day11.5 observed with PBP null mutation was cardiac failure because of noncompaction of the ventricular myocardium and resultant ventricular dilatation. There was a paucity of retinal pigment, defective lens formation, excessive systemic angiogenesis, a deficiency in the number of megakaryocytes, and an arrest in erythrocytic differentiation. Some of these defects involve PPARgamma and retinoid-sensitive sites, whereas others have not been recognized in the PPAR-signaling pathway. Phenotypic changes in four organ systems observed in PBP null mice overlapped with those in mice deficient in members of GATA, a family of transcription factors known to regulate differentiation of megakaryocytes, erythrocytes, and adipocytes. We demonstrate that PBP interacts with all five GATA factors analyzed, GATA-1, GATA-2, GATA-3, GATA-4, and GATA-6, and show that the binding of GATA-1, GATA-4, and GATA-6 to PBP is not dependent on the nuclear receptor recognition sequence motif LXXLL (where L is leucine and X is any amino acid) in PBP. Coexpression of PBP with GATA-3 markedly enhanced transcriptional activity of GATA-3 in nonhematopoietic cells. These observations identify the GATA family of transcription factors as a new interacting partner of PBP and demonstrate that PBP is essential for normal development of vital organ systems.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NCI NIH HHS [CA 88898, CA64239, CA84472] Funding Source: Medline; NIEHS NIH HHS [K08 ES00356] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472, R01CA064239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BOK D, 1993, J CELL SCI, P189; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breier G, 2000, PLACENTA, V21, pS11, DOI 10.1053/plac.1999.0525; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Cross JC, 2000, SEMIN CELL DEV BIOL, V11, P105, DOI 10.1006/scdb.2000.0156; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kastner P, 1997, DEVELOPMENT, V124, P4749; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Macdonald R, 1996, CURR OPIN NEUROBIOL, V6, P49, DOI 10.1016/S0959-4388(96)80008-0; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Mori M, 2001, INVEST OPHTH VIS SCI, V42, P1312; Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEYMAN GA, 1972, INVEST OPHTH VISUAL, V11, P35; Plutzky J, 2000, Curr Atheroscler Rep, V2, P327, DOI 10.1007/s11883-000-0067-3; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ritter M, 1997, MAYO CLIN PROC, V72, P26, DOI 10.4065/72.1.26; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Schaiff WT, 2000, J CLIN ENDOCR METAB, V85, P3874, DOI 10.1210/jc.85.10.3874; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Smith SK, 2000, SEMIN PERINATOL, V24, P82, DOI 10.1016/S0146-0005(00)80063-4; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsai FY, 1998, DEV BIOL, V196, P218, DOI 10.1006/dbio.1997.8842; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TSCHOEPE D, 1993, SEMIN THROMB HEMOST, V19, P122, DOI 10.1055/s-2007-994015; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	65	107	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3585	3592		10.1074/jbc.M107995200	http://dx.doi.org/10.1074/jbc.M107995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724781	hybrid			2022-12-25	WOS:000173688000070
J	Hicks, A; Drager, RG; Higgs, DC; Stern, DB				Hicks, A; Drager, RG; Higgs, DC; Stern, DB			An mRNA 3 ' processing site targets downstream sequences for rapid degradation in Chlamydomonas chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RIBONUCLEASE-E; REINHARDTII; STABILITY; DETERMINANTS; ACCUMULATION; TRANSLATION; POLYADENYLATION; TRANSFORMATION; TRANSCRIPTS	In Chlamydomonas chloroplasts, atpB pre-mRNA matures through a two-step process. Initially, endonuclease cleavage occurs 8-10 nt downstream of the mature 3' end, which itself lies at the end of a stem-loop-forming inverted repeat (IR) sequence. This intermediate product is then trimmed by a 3' --> 5' exonuelease activity. Although the initial endonucleolytic cleavage by definition generates two products, the downstream product of atpB pre-mRNA endonucleolytic processing cannot be detected, even transiently. This product thus appears to be highly unstable, and it can be hypothesized that specific mechanisms exist to prevent its accumulation. In experiments described here, the atpB 3' maturation site was placed upstream of reporter genes in vivo. Constructs containing both the IR and endonuclease cleavage site (ECS) did not accumulate the reporter gene mRNA, whereas constructs containing only the IR did accumulate the reporter mRNA. The ECS alone gave an intermediate result, suggesting that the IR and ECS act synergistically. Additional secondary structures were used to test whether 5' --> 3' and/or 3' --> 5' exonuclease activities mediated degradation. Because these structures did not prevent degradation, rapid endonucleolytic cleavages most likely trigger RNA destruction after ECS cleavage. On the other hand, fragments resulting from cleavage within the endogenous atpB mRNA could occasionally be detected as antisense transcripts of the adjacent reporter genes. Because endonuclease cleavages are also involved in the 5' maturation of chloroplast mRNAs, where only the downstream cleavage product accumulates, it appears that chloroplast endoribonuclease activities have evolved mechanisms to selectively stabilize different ECS products.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Univ Wisconsin Parkside, Dept Biol Sci, Kenosha, WI 53141 USA	Cornell University; Boyce Thompson Institute for Plant Research; University of Wisconsin System; University of Wisconsin Parkside	Stern, DB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	ds28@corne1l.edu						BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BLOWERS AD, 1990, PLANT CELL, V2, P1059; Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Drager RG, 1996, RNA, V2, P652; Drager RG, 1999, PLANT J, V19, P521, DOI 10.1046/j.1365-313X.1999.00546.x; Drager RG, 1998, PLANT J, V13, P85, DOI 10.1046/j.1365-313X.1998.00016.x; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Felder S, 2001, PLANT CELL, V13, P2127, DOI 10.1105/tpc.13.9.2127; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Higgs DC, 1999, MOL CELL BIOL, V19, P8479; HIGGS DC, 1993, PLANT CELL REP, V12, P445, DOI 10.1007/BF00234710; KLEIN U, 1992, P NATL ACAD SCI USA, V89, P3453, DOI 10.1073/pnas.89.8.3453; Komine Y, 2000, RNA, V6, P598, DOI 10.1017/S1355838200992252; KOMINE Y, 2002, IN PRESS P NATL ACAD; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; Rott R, 1996, MOL GEN GENET, V252, P676, DOI 10.1007/BF02173973; Rott R, 1998, PLANT MOL BIOL, V36, P307, DOI 10.1023/A:1005943701253; Rott R, 1999, PLANT MOL BIOL, V40, P679, DOI 10.1023/A:1006252201661; Rott R, 1998, MOL CELL BIOL, V18, P4605, DOI 10.1128/MCB.18.8.4605; SAKAMOTO W, 1994, MOL CELL BIOL, V14, P6180, DOI 10.1128/MCB.14.9.6180; SAKAMOTO W, 1993, P NATL ACAD SCI USA, V90, P497, DOI 10.1073/pnas.90.2.497; SALVADOR ML, 1993, P NATL ACAD SCI USA, V90, P1556, DOI 10.1073/pnas.90.4.1556; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SHEPHERD HS, 1979, P NATL ACAD SCI USA, V76, P1353, DOI 10.1073/pnas.76.3.1353; SIMPSON CL, 2002, IN PRESS PLANT PHYSL; STERN DB, 1993, MOL CELL BIOL, V13, P2277, DOI 10.1128/MCB.13.4.2277; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; Tock MR, 2000, J BIOL CHEM, V275, P8726, DOI 10.1074/jbc.275.12.8726; Vaistij FE, 2000, PLANT J, V21, P469, DOI 10.1046/j.1365-313x.2000.00700.x; Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813; Walsh AP, 2001, NUCLEIC ACIDS RES, V29, P1864, DOI 10.1093/nar/29.9.1864; ZERGES W, 1994, MOL CELL BIOL, V14, P5268, DOI 10.1128/MCB.14.8.5268	43	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3325	3333		10.1074/jbc.M108979200	http://dx.doi.org/10.1074/jbc.M108979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11724790	hybrid			2022-12-25	WOS:000173688000037
J	Kicska, GA; Tyler, PC; Evans, GB; Furneaux, RH; Kim, K; Schramm, VL				Kicska, GA; Tyler, PC; Evans, GB; Furneaux, RH; Kim, K; Schramm, VL			Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS TH-6-2; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MALARIAL PARASITES; GENE; PURIFICATION; CLONING; PNP	Immucillins are logically designed transition-state analogue inhibitors of mammalian purine nucleoside phosphorylase (PNP) that induce purine-less death of Plasmodium falciparum in cultured erythrocytes (Kicska, G. A., Tyler, P. C., Evans, G. B., Furneaux, R. H., Schramm, V. L., and Kim, K. (2002) J. Biol. Chem. 277, 3226-3231). PNP is present at high levels in human erythrocytes and in P. falciparum, but the Plasmodium enzyme has not been characterized. A search of the P. falciparum genome data base yielded an open reading frame similar to the PNP from Escherichia coli. PNP from P. falciparum (P. falciparum PNP) was cloned, overexpressed in E. coli, purified, and characterized. The primary amino acid sequence has 26% identity with E. coli PNP, has 20% identity with human PNP, and is phylogenetically unique among known PNPs with equal genetic distance between PNPs and uridine phosphorylases. Recombinant P. falciparum PNP is catalytically active for inosine and guanosine but is less active for uridine. The immucillins are powerful inhibitors of P. falciparum PNP. Immucillin-H is a slow onset tight binding inhibitor with a K-i* value of 0.6 nM. Eight related immucillins are also powerful inhibitors with dissociation constants from 0.9 to 20 nM. The K-m/K-i* value for immucillin-H is 9000, making this inhibitor the most powerful yet reported for P. falciparum PNP. The PNP from P. falciparum differs from the human enzyme by a lower K-m for inosine, decreased preference for deoxyguanosine, and reduced affinity for the immucillins, with the exception of 5'-deoxy-immucillin-H. These properties of P. falciparum PNP are consistent with a metabolic role in purine salvage and provide an explanation for the antibiotic effect of the immucillins on P. falciparum cultured in human erythrocytes.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Kim, Kami/0000-0003-3384-152X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM041916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41916, GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berman P A, 1991, Adv Exp Med Biol, V309A, P165; BERMAN PA, 1991, J CLIN INVEST, V88, P1848, DOI 10.1172/JCI115506; BZOWSKA A, 1990, Z NATURFORSCH C, V45, P59; BZOWSKA A, 1995, FEBS LETT, V367, P214, DOI 10.1016/0014-5793(95)00540-P; Cacciapuoti G, 1996, EUR J BIOCHEM, V239, P632, DOI 10.1111/j.1432-1033.1996.0632u.x; DADDONA PE, 1986, J BIOL CHEM, V261, P1667; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Evans GB, 2000, TETRAHEDRON, V56, P3053, DOI 10.1016/S0040-4020(00)00194-0; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GERO AM, 1990, BLOOD CELLS, V16, P467; GOLDFARB AR, 1951, J BIOL CHEM, V193, P397; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Hamamoto T, 1997, BIOSCI BIOTECH BIOCH, V61, P276, DOI 10.1271/bbb.61.276; Hamamoto T, 1997, BIOSCI BIOTECH BIOCH, V61, P272, DOI 10.1271/bbb.61.272; HASSAN HF, 1988, FEMS MICROBIOL LETT, V54, P47, DOI 10.1111/j.1574-6968.1988.tb02709.x; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HUGHES BW, 1995, CANCER RES, V55, P3339; JENSEN KF, 1978, BIOCHIM BIOPHYS ACTA, V525, P346, DOI 10.1016/0005-2744(78)90229-2; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; KIM BK, 1968, J BIOL CHEM, V243, P1771; KIM BK, 1968, J BIOL CHEM, V243, P1763; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SEEGER C, 1995, J BACTERIOL, V177, P5506, DOI 10.1128/jb.177.19.5506-5516.1995; Sherman Irwin W., 1998, P177; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; SORSCHER EJ, 1994, GENE THER, V1, P233; STOECKLER JD, 1980, BIOCHEMISTRY-US, V19, P102, DOI 10.1021/bi00542a016; STOOP JW, 1977, NEW ENGL J MED, V296, P651, DOI 10.1056/NEJM197703242961203; Tebbe J, 1999, J MOL BIOL, V294, P1239, DOI 10.1006/jmbi.1999.3327; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WALSH CJ, 1968, J PROTOZOOL, V15, P763, DOI 10.1111/j.1550-7408.1968.tb02209.x; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Wielgus-Kutrowska B, 1998, ADV EXP MED BIOL, V431, P259; Wiesmann W.P., 1984, Progress in Clinical and Biological Research, V165, P325; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779; Xu YM, 1997, BIOCHEMISTRY-US, V36, P3700, DOI 10.1021/bi9616007	51	93	99	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3219	3225		10.1074/jbc.M105905200	http://dx.doi.org/10.1074/jbc.M105905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707439	hybrid			2022-12-25	WOS:000173688000022
J	Rybalkin, SD; Rybalkina, IG; Feil, R; Hofmann, F; Beavo, JA				Rybalkin, SD; Rybalkina, IG; Feil, R; Hofmann, F; Beavo, JA			Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	12th Protein Kinase Symposium	2000	BAD BRUCKENAU, GERMANY				I-DEFICIENT MICE; NUCLEOTIDE PHOSPHODIESTERASE; KINASE; PROTEIN; BINDING; IDENTIFICATION	Nitric oxide and endogenous nitrovasodilators regulate smooth muscle tone by elevation of cGMP and activation of cyclic GMP-dependent protein kinase (PKG). The amplitude and duration of the cGMP signal in smooth muscle is regulated in large part by cGMP-specific cyclic nucleotide phosphodiesterase (PDE5). Previous in vitro data have suggested that both cAMP-dependent protein kinase and PKG can regulate the activity of PDE5. To test if this type of regulation is important in the intact cell, we have generated phospho-PDE5-specific antisera and have utilized isolated smooth muscle cells from mice having a disruption in the PKG I gene as well as cells from normal human smooth muscle. The data show that in human smooth muscle cells, activation of PKG by 8-Br-cGMP led to phosphorylation and activation of PDE5. In the same cells, 8-Br-cAMP had no significant effect on PDE5 phosphorylation. Treatment of wild-type mouse aortic smooth muscle cells with 8-Br-cGMP also induced the phosphorylation of PDE5, whereas no phosphorylation was seen in smooth muscle cells isolated from mice in which the gene for PKG I had been disrupted. As with the human cells, no phosphorylation was seen in the mouse cells in response to 8-Br-cAMP. These results strongly suggest that a major regulatory pathway for control of PDE5 phosphorylation and activity in intact smooth muscle is via PKG-dependent phosphorylation of PDE5. Finally, experiments with calyculin A and okadaic acid suggest that PP1 phosphatase, the catalytic subunit of myosin phosphatase, can regulate PDE5 dephosphorylation. Together, the data suggest that phosphorylation and activation of PDE5 by PKG I and its subsequent dephosphorylation by myosin phosphatase may be key steps in the regulation of relaxation/contraction cycles of smooth muscle.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Washington; University of Washington Seattle; Technical University of Munich	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Feil, Robert/B-8918-2014	Feil, Robert/0000-0002-7335-4841	NHLBI NIH HHS [HL4498, HL60178] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boolell M, 1996, Int J Impot Res, V8, P47; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; DeGaravilla L, 1996, EUR J PHARMACOL, V313, P89, DOI 10.1016/0014-2999(96)00505-5; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Omura T, 2001, CLIN EXP PHARMACOL P, V28, P259, DOI 10.1046/j.1440-1681.2001.03436.x; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Rybalkin SD, 1997, J CLIN INVEST, V100, P2611, DOI 10.1172/JCI119805; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Sonnenburg WK, 1998, METHODS, V14, P3, DOI 10.1006/meth.1997.0561; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Wyatt TA, 1998, AM J PHYSIOL-HEART C, V274, pH448, DOI 10.1152/ajpheart.1998.274.2.H448; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	23	170	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3310	3317		10.1074/jbc.M106562200	http://dx.doi.org/10.1074/jbc.M106562200			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723116	hybrid			2022-12-25	WOS:000173688000035
J	Mochizuki, T; Asai, A; Saito, N; Tanaka, S; Katagiri, H; Asano, T; Nakane, M; Tamura, A; Kuchino, Y; Kitanaka, C; Kirino, T				Mochizuki, T; Asai, A; Saito, N; Tanaka, S; Katagiri, H; Asano, T; Nakane, M; Tamura, A; Kuchino, Y; Kitanaka, C; Kirino, T			Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CASPASE ACTIVATION; BCL-2; ONCOGENE; AMPLIFICATION; COMMITMENT; EXPRESSION; TRANSFORMATION; CARCINOMAS; INDUCTION	A growing body of evidence now suggests that programmed cell death (PCD) occurs via non-apoptotic mechanisms as well as by apoptosis. In contrast to apoptosis, however, the molecular mechanisms involved in the regulation of non-apoptotic PCD remain only poorly understood. Here we show that ceramide induces a nonapoptotic PCD with a necrotic-like morphology in human glioma cells. Characteristically, the cell death was not accompanied by loss of the mitochondrial transmembrane potential, cytosolic release of cytochrome c from mitochondria, or the activation of the caspase cascade. Consistent with these characteristics, this ceramide-induced cell death was inhibited neither by the overexpression of Bel-xL nor by the pan-caspase inhibitor zVAD-ftnk. However, strikingly, the ceramide-induced non-apoptotic cell death was inhibited by the activation of the Akt/protein kinase B pathway through the expression of a constitutively active version of Akt. The results for the first time indicate that the Akt kinase, known to play an essential role in survival factor-mediated inhibition of apoptotic cell death, is also involved in the regulation of non-apoptotic PCD.	Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Fac Med, Lab Neurosci & Neurooncol, Dept Neurosurg,Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Teikyo Univ, Sch Med, Dept Neurosurg, Itabashi Ku, Tokyo 1738605, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; University of Tokyo; University of Tokyo; University of Tokyo; Teikyo University; Japan Science & Technology Agency (JST)	Kitanaka, C (corresponding author), Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Gottschalk AR, 1996, CELL DEATH DIFFER, V3, P113; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mengubas K, 1999, EXP CELL RES, V249, P116, DOI 10.1006/excr.1999.4474; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Shimizu S, 1996, ONCOGENE, V12, P2045; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsujimoto Yoshihide, 1997, Leukemia (Basingstoke), V11, P380; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	50	56	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2790	2797		10.1074/jbc.M106361200	http://dx.doi.org/10.1074/jbc.M106361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706021	hybrid			2022-12-25	WOS:000173421500056
J	Trembley, JH; Hu, DL; Hsu, LC; Yeung, CY; Slaughter, C; Lahti, JM; Kidd, VJ				Trembley, JH; Hu, DL; Hsu, LC; Yeung, CY; Slaughter, C; Lahti, JM; Kidd, VJ			PITSLRE p110 protein kinases associate with transcription complexes and affect their activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; CARBOXY-TERMINAL DOMAIN; IN-VIVO; TAT TRANSACTIVATION; SPLICING FACTORS; FACTOR TFIIH; ELONGATION; PHOSPHORYLATION; EXPRESSION	Although the PITSLRE protein kinases are members of the cyclin-dependent kinase superfamily, their cellular function is unclear. Previously we demonstrated that the general RNA splicing factor RNPS1 is a specific PITSLRE p110 kinase interactor in vivo. This suggests that the PITSLRE family of protein kinases is involved in some aspect of RNA processing or transcription. Here we identify multiple transcriptional elongation factors, including ELL2, TFHF1, TFIIS, and FACT, as PITSLRE kinase-associated proteins. We demonstrate that PITSLRE p110 protein kinases co-immunoprecipitate and/or co-purify with these elongation factors as well as with RNA polymerase II. Antibody-mediated inhibition of PITSLRE kinase specifically suppressed RNA polymerase II-dependent in vitro transcription initiated at a GC-rich (adenosine deaminase) or TATA box-dependent (Ad2ML) promoter, and this suppression was rescued by readdition of purified PITSLRE p110 kinase. Together, these data strongly suggest that PITSLRE protein kinases participate in a signaling pathway that potentially regulates or links transcription and RNA processing events.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	vincent.kidd@stjude.org		Trembley, Janeen/0000-0003-3597-2611; Hsu, Li-Chung/0000-0001-7206-5231	NATIONAL CANCER INSTITUTE [T32CA009346, P30CA021765, R29CA072572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, 5 T32 CA09346, CA72572] Funding Source: Medline; NIGMS NIH HHS [GM44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Loyer P, 1998, J CELL SCI, V111, P1495; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Michael N, 1998, P NATL ACAD SCI USA, V95, P1166, DOI 10.1073/pnas.95.3.1166; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	44	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2589	2596		10.1074/jbc.M109755200	http://dx.doi.org/10.1074/jbc.M109755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11709559	hybrid			2022-12-25	WOS:000173421500029
J	Dame, RT; Wyman, C; Wurm, R; Wagner, R; Goosen, N				Dame, RT; Wyman, C; Wurm, R; Wagner, R; Goosen, N			Structural basis for H-NS-mediated trapping of RNA polymerase in the open initiation complex at the rrnB P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; COLI NUCLEOID PROTEIN; HISTONE-LIKE PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNIT; CURVED DNA; GENE-EXPRESSION; PROMOTER; TRANSCRIPTION; REPRESSION	The Escherichia coli H-NS protein is a nucleoid-associated protein involved in both transcription regulation and DNA compaction. Each of these processes involves H-NS-mediated bridge formation between adjacent DNA helices. With respect to transcription regulation, preferential binding sites in the promoter regions of different genes have been reported, and generally these regions are curved. Often H-NS binding sites overlap with promoter core regions or with binding sites of other regulatory factors. Not in all cases, however, transcriptional repression is the result of preferential binding by H-NS to promoter regions leading to occlusion of the RNA polymerase. In the case of the rrnB P1, H-NS actually stimulates open complex formation by forming a ternary RNAP(.)H-NS(.)DNA complex, while simultaneously stabilizing it to such an extent that promoter clearance cannot occur. To define the mechanism by which H-NS interferes at this step in the initiation pathway, the architecture of the RNAP(.)H-NS(.)DNA complex was analyzed by scanning force microscopy (SFM). The SFM images show that the DNA flanking the RNA polymerase in open initiation complexes is bridged by H-NS. On the basis of these data, we present a model for the specific repression of transcription initation at the rrnB P1 by H-NS.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Lab Mol Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Heinrich Heine University Dusseldorf	Goosen, N (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Lab Mol Genet, POB 9502, NL-2300 RA Leiden, Netherlands.	N.Goosen@chem.Leidenuniv.nl	Dame, Remus/AAT-2989-2020; Dame, Remus/A-8570-2008; Dame, Remus T./E-1941-2014	Dame, Remus/0000-0001-9863-1692; Dame, Remus T./0000-0001-9863-1692				Afflerbach H, 1999, J MOL BIOL, V286, P339, DOI 10.1006/jmbi.1998.2494; Afflerbach H, 1998, MOL MICROBIOL, V28, P641, DOI 10.1046/j.1365-2958.1998.00829.x; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Ceschini S, 2000, J BIOL CHEM, V275, P729, DOI 10.1074/jbc.275.2.729; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; Choy HE, 1997, J MOL BIOL, V272, P293, DOI 10.1006/jmbi.1997.1221; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Dame RT, 2000, NUCLEIC ACIDS RES, V28, P3504, DOI 10.1093/nar/28.18.3504; Dame RT, 2001, BIOCHIMIE, V83, P231; DEFEZ R, 1981, GENETICS, V97, P11; Donato GM, 1997, J BACTERIOL, V179, P6618, DOI 10.1128/jb.179.21.6618-6625.1997; Dorman CJ, 1999, TRENDS MICROBIOL, V7, P124, DOI 10.1016/S0966-842X(99)01455-9; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; Hirvonen CA, 2001, J BACTERIOL, V183, P6305, DOI 10.1128/JB.183.21.6305-6314.2001; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JACQUET M, 1971, BIOCHEM BIOPH RES CO, V45, P1597, DOI 10.1016/0006-291X(71)90204-X; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; McLeod SM, 2001, CURR OPIN MICROBIOL, V4, P152, DOI 10.1016/S1369-5274(00)00181-8; Mojica FJM, 1997, J BACTERIOL, V179, P3528, DOI 10.1128/jb.179.11.3528-3533.1997; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; Rojo F, 2001, CURR OPIN MICROBIOL, V4, P145, DOI 10.1016/S1369-5274(00)00180-6; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Schroder O, 2000, J MOL BIOL, V298, P737, DOI 10.1006/jmbi.2000.3708; Smyth CP, 2000, MOL MICROBIOL, V36, P962, DOI 10.1046/j.1365-2958.2000.01917.x; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TANAKA K, 1991, AGR BIOL CHEM TOKYO, V55, P3139, DOI 10.1080/00021369.1991.10859737; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; TIPPNER D, 1995, J BIOL CHEM, V270, P22243, DOI 10.1074/jbc.270.38.22243; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; vanUlsen P, 1996, MOL MICROBIOL, V21, P567; VARSHAVSKY AJ, 1977, NUCLEIC ACIDS RES, V4, P2725, DOI 10.1093/nar/4.8.2725; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; Yamada M, 1999, J BACTERIOL, V181, P1838, DOI 10.1128/JB.181.6.1838-1846.1999; YOSHIDA T, 1993, MOL GEN GENET, V237, P113, DOI 10.1007/BF00282791; ZACHARIAS M, 1992, BIOCHEMISTRY-US, V31, P2621, DOI 10.1021/bi00124a024; Zhang AX, 1996, EMBO J, V15, P1340, DOI 10.1002/j.1460-2075.1996.tb00476.x; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	51	141	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2146	2150		10.1074/jbc.C100603200	http://dx.doi.org/10.1074/jbc.C100603200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11714691	hybrid, Green Published			2022-12-25	WOS:000173421300073
J	Ivetic, A; Deka, J; Ridley, A; Ager, A				Ivetic, A; Deka, J; Ridley, A; Ager, A			The cytoplasmic tail of L-selectin interacts with members of the ezrin-radixin-moesin (ERM) family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL-ADHESION; BINDING-SITE; IN-VIVO; EZRIN/RADIXIN/MOESIN PROTEINS; LYMPHOCYTE RECIRCULATION; LEUKOCYTE EMIGRATION; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; CLEAVAGE FURROW	L-selectin regulates the recruitment of naive lymphocytes from the bloodstream to secondary lymphoid organs, mediating their initial capture and subsequent rolling along high endothelial cell surface-expressed ligands in peripheral lymph nodes. In vivo, distribution of L-selectin and cell surface levels determine the tethering efficiency and rolling velocity of leukocytes, respectively. Treatment of naive lymphocytes with phorbol myristate acetate (PMA) induces rapid ectodomain proteolytic down-regulation (shedding) of surface L-selectin via a protein kinase C (PKC)-dependent pathway. In an attempt to isolate proteins that are involved in regulating L-selectin expression, an affinity column was constructed using the 17-amino acid cytoplasmic tail of L-selectin. Affinity purification of extracts from lymphocytes, pre-treated with or without PMA, allowed identification of proteins that interact with the affinity column under one condition but not the other. By using this approach, members of the Ezrin-Radixin-Moesin family of proteins were found to interact specifically with the cytoplasmic tail of L-selectin. Moesin from PMA-stimulated lymphocytes, but not from unstimulated lymphocytes, bound to L-selectin tail. In contrast, ezrin from unstimulated or PMA-stimulated lymphocytes associated with L-selectin tail with equal affinity. Furthermore, the PKC inhibitor Ro 31-8220 significantly reduced the interaction of moesin, but not ezrin, with L-selectin. Alanine mutations of membrane-proximal basic amino acid residues in the cytoplasmic domain of L-selectin identified arginine 357 as a critical residue for both ezrin and moesin interaction. Finally, BIAcore affinity analysis confirmed that N-terminal moesin interacts specifically with L-selectin cytoplasmic tail, with relatively high affinity (K-d approximate to40 nM). Based on these findings, although moesin and ezrin bind to a similar region of the cytoplasmic tail of L-selectin, moesin binding is dependent on PKC activation, which suggests that ezrin and moesin are regulated differently in lymphocytes.	UCL Royal Free & Univ Coll Med Sch, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; MRC National Institute for Medical Research; MRC National Institute for Medical Research	Ivetic, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.			Ivetic, Aleksandar/0000-0001-9844-6518; Ager, Ann/0000-0002-5763-8908				AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Evans SS, 1999, J IMMUNOL, V162, P3615; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Po JL, 1999, HAEMATOLOGICA, V84, P785; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	38	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2321	2329		10.1074/jbc.M109460200	http://dx.doi.org/10.1074/jbc.M109460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706008	hybrid			2022-12-25	WOS:000173421300092
J	Scott, C; Green, J				Scott, C; Green, J			Miscoordination of the iron-sulfur clusters of the anaerobic transcription factor, FNR, allows simple repression but not activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI FNR; C-TERMINAL DOMAIN; RECEPTOR PROTEIN; CONTACT SITE; REGION 1; BINDING; IDENTIFICATION; PROMOTERS; REGULATOR; EXPRESSION	The FNR protein of Escherichia coli regulates target genes in response to anaerobiosis. Environmental oxygen is sensed by the acquisition of oxygen-labile [4Fe-4S] clusters that promote dimerization, DNA binding, and productive interactions with RNA polymerase. Three N-terminal cysteine residues (Cys(20), Cys(23), and Cys(29)) and Cys(122) act as ligands for the FNR iron sulfur clusters. An FNR variant, FNR-C20S, that retains only trace activity in vivo can acquire [4Fe-4S] clusters in vitro that enhance site-specific DNA binding. Second site substitutions in activating regions AR1, AR2, and AR3 restore in vivo activity to FNR-C20S, suggesting that the impairment in FNR-C20S activity is due to a failure to communicate with RNA polymerase effectively. Here we show that FNR-C20S can repress a simple FNR-regulated promoter in vivo and that it can form productive heterodimers with an FNR variant with altered DNA binding specificity, FNR-E209V. Transcription studies with FNR-E209V(.)FNR-C20S heterodimers indicate that the presence of a miscoordinated iron-sulfur cluster (FNR-C20S) in the downstream (but not the upstream) subunit of the FNR dimer impairs activation from a class 11 promoter and that this impairment can be overcome by amino acid substitutions known to unmask AR2 or improve AR3 in the affected subunit.	Univ Sheffield, Krebs Inst Biomol Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Green, J (corresponding author), Univ Sheffield, Krebs Inst Biomol Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk	Scott, Colin/A-4682-2009	Scott, Colin/0000-0001-6110-6982				ANTHAMATTEN D, 1992, J BACTERIOL, V174, P2111, DOI 10.1128/JB.174.7.2111-2120.1992; BELL A, 1994, MOL MICROBIOL, V11, P383, DOI 10.1111/j.1365-2958.1994.tb00318.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; DISPENSA M, 1992, J BACTERIOL, V174, P5803, DOI 10.1128/jb.174.18.5803-5813.1992; Govantes F, 2000, MOL MICROBIOL, V37, P1456, DOI 10.1046/j.1365-2958.2000.02100.x; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Green J, 1999, J BIOL CHEM, V274, P10244, DOI 10.1074/jbc.274.15.10244; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Lee DJ, 2000, MOL MICROBIOL, V37, P1032, DOI 10.1046/j.1365-2958.2000.02086.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Li B, 1998, NUCLEIC ACIDS RES, V26, P2075, DOI 10.1093/nar/26.9.2075; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Marshall FA, 2001, MOL MICROBIOL, V39, P747, DOI 10.1046/j.1365-2958.2001.02262.x; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Meng WM, 1997, MICROBIOL-SGM, V143, P1521, DOI 10.1099/00221287-143-5-1521; Miller JH., 1972, EXPT MOL GENETICS; Ralph ET, 2001, MOL MICROBIOL, V39, P1199, DOI 10.1111/j.1365-2958.2001.02326.x; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; Six S, 1996, J INORG BIOCHEM, V62, P89, DOI 10.1016/0162-0134(95)00091-7; SPIRO S, 1988, MOL MICROBIOL, V2, P701, DOI 10.1111/j.1365-2958.1988.tb00080.x; VanSpanning RJM, 1997, MOL MICROBIOL, V23, P893, DOI 10.1046/j.1365-2958.1997.2801638.x; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028; Williams SM, 1998, FEMS MICROBIOL LETT, V163, P203, DOI 10.1111/j.1574-6968.1998.tb13046.x	31	9	9	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1749	1754		10.1074/jbc.M106192200	http://dx.doi.org/10.1074/jbc.M106192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704661	hybrid			2022-12-25	WOS:000173421300018
J	Perroy, J; Richard, S; Nargeot, J; Bockaert, J; Fagni, L				Perroy, J; Richard, S; Nargeot, J; Bockaert, J; Fagni, L			Permissive effect of voltage on mGlu 7 receptor subtype signaling in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE; SYNAPTIC TRANSMISSION; CORONARY MYOCYTES; PRIMARY CULTURES; CA2+ CHANNELS; ADULT-RAT; LOCALIZATION; ACTIVATION	G protein-coupled receptors mobilize neuronal signal. ing cascades which until now have not been shown to depend on the state of membrane depolarization. Thus we have previously shown that the metabotropic glutamate receptor type 7 (mGlu7 receptor) blocks P/Q-type Ca2+ channels via activation of a G(o) protein and PKC, in cerebellar granule cells. We show here that the transient depolarizations used to evoke the studied Ca2+ current were indeed permissive to activate this pathway by a mGlu7 receptor agonist. Indeed, sustained depolarization to 0 mV was sufficient to inhibit P/Q-type Ca2+ channels. This effect involved a conformational change in voltage-gated sodium channel independently of Na+ flux, activation of a pertussis toxin-sensitive G-protein, inositol trisphosphate formation, intracellular Ca2+ release, and PKC activity. Subliminal sustained membrane depolarization became efficient in inducing inositol trisphosphate formation, release of intracellular Ca2+ and in blocking Ca2+ channels, when applied concomitantly with the mGlu7a receptor agonist, D,L-aminophosphonobutyrate. This synergistic effect of membrane depolarization and mGlu7 receptor activation provides a mechanism by which neuronal excitation could control action of the mGlu7 receptor in neurons.	CNRS, UPR 9023, CCIPE, F-34094 Montpellier 05, France; CNRS, UPR 1142, IGH, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Fagni, L (corresponding author), CNRS, UPR 9023, CCIPE, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Richard, Sylvain/C-9695-2016	perroy, julie/0000-0001-6199-0448; Richard, Sylvain/0000-0001-9460-6705; Nargeot, Joel/0000-0003-2893-5636				Ango F, 2000, J NEUROSCI, V20, P8710; Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Anis Y, 1999, J BIOL CHEM, V274, P7431, DOI 10.1074/jbc.274.11.7431; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Boccara G, 1999, CIRC RES, V85, P606, DOI 10.1161/01.RES.85.7.606; Bradley SR, 1996, J NEUROSCI, V16, P2044; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dube GR, 2000, J NEUROPHYSIOL, V83, P1141, DOI 10.1152/jn.2000.83.3.1141; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; GANITKEVICH VY, 1993, J PHYSIOL-LONDON, V470, P35, DOI 10.1113/jphysiol.1993.sp019845; ITOH T, 1992, J PHYSIOL-LONDON, V451, P307, DOI 10.1113/jphysiol.1992.sp019166; Kinoshita A, 1998, J COMP NEUROL, V393, P332; Kinzie JM, 1997, J COMP NEUROL, V385, P372; KINZIE JM, 1995, NEUROSCIENCE, V69, P167, DOI 10.1016/0306-4522(95)00244-D; Lafon-Cazal M, 1999, NEUROPHARMACOLOGY, V38, P1631, DOI 10.1016/S0028-3908(99)00124-0; Lafon-Cazal M, 1999, EUR J NEUROSCI, V11, P663, DOI 10.1046/j.1460-9568.1999.00475.x; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Mahaut-Smith MP, 1999, J PHYSIOL-LONDON, V515, P385, DOI 10.1111/j.1469-7793.1999.385ac.x; Masugi M, 1999, J NEUROSCI, V19, P955; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; Perroy J, 2000, J NEUROSCI, V20, P7896; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; REGEHR WG, 1994, NEURON, V12, P605, DOI 10.1016/0896-6273(94)90216-X; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; ROMEY G, 1987, P NATL ACAD SCI USA, V84, P896, DOI 10.1073/pnas.84.3.896; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352	33	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1223	1228		10.1074/jbc.M109141200	http://dx.doi.org/10.1074/jbc.M109141200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11706005	hybrid			2022-12-25	WOS:000173166800046
J	Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C				Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C			INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; P14(ARF); p16(INK4a); p53; histopathology; prognosis	METHYLATION; CELL; EXPRESSION; FREQUENCY	The INK4a-ARF (CDKN2A)- locus on chromosome 9p21 encodes for two tumour suppressor proteins, P16(INK4a) and p14(ARF), that act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in tumorigenesis of hepatocellular carcinoma (HCC), we analysed the alterations of p14(ARF), p16(INC4a) and p53. After microdissection, DNA of 71 hepatocellular carcinomas was analysed for INK4-ARF inactivation and p53 mutation by DNA sequence analysis, methylation-specific PCR (MSP), restriction-enzyme related polymerase chain reaction (RE-PCR), mRNA expression and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INC4a) were assessed by differential PCR. Inactivation of p14(ARF) was found in 11/71 cases (15%), alterations of p16(INK4a), occurred in 47/71 carcinomas (66%), which correlated with loss of mRNA transcription. Five tumours (7%) had homozygous deletions of the INK4a-ARF locus. We failed to detect specific mutations of both exons. P16(INK4a) methylation with an unmethylated p14(ARF) promotor appeared in 39 cases. Mutations of p53 were found in 30 of 71 HCC (42%), and only one of them harboured p14(ARF) inactivation. We failed to establish alterations of the INK4a-ARF locus or p53 status as independent prognostic factor in these tumours. Our data indicate, that p14(ARF) methylation occurs independently of p16(INK4a) alterations in a subset of HCC together with wild type p53. The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Canc Epidemiol, D-23564 Lubeck, Germany; Univ Leipzig, Dept Abdominal Vasc & Transplantat Surg 2, D-04103 Leipzig, Germany	Leipzig University; University of Lubeck; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.		Katalinic, Alexander/D-2512-2010	Katalinic, Alexander/0000-0003-0490-1554				[Anonymous], 1997, J CLIN PATHOL; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Bradley G, 2001, ONCOGENE, V20, P654, DOI 10.1038/sj.onc.1204131; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Esteller M, 2000, CANCER RES, V60, P129; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Issa JPJ, 2001, CANCER RES, V61, P3573; Jackson PE, 2001, CANCER RES, V61, P33; Kaneto H, 2001, GUT, V48, P372, DOI 10.1136/gut.48.3.372; Kang GH, 2001, CANCER RES, V61, P2847; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Orlow I, 1999, J NATL CANCER I, V91, P73, DOI 10.1093/jnci/91.1.73; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154	21	108	113	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7104	7109		10.1038/sj.onc.1204902	http://dx.doi.org/10.1038/sj.onc.1204902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704835				2022-12-25	WOS:000171739300014
J	Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S				Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S			Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells	ONCOGENE			English	Article						malolactomycin D; Ras-responsive element; MMP; tansformation	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; FACTOR-BINDING-SITES; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; PROMOTER ACTIVITY; HUMAN CANCER; C-FOS; INVASION; ONCOGENES	To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell Hue with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identified as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorage-independent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogen-activated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These findings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis.	Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.							Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Buttice G, 1996, ONCOGENE, V13, P2297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOUSTIN AS, 1986, CANCER RES, V46, P1015; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Johansson N, 2000, J CELL SCI, V113, P227; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Simon C, 1998, CANCER RES, V58, P1135; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Tanaka Y, 1997, J ANTIBIOT, V50, P194, DOI 10.7164/antibiotics.50.194; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	39	14	14	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6724	6730		10.1038/sj.onc.1204878	http://dx.doi.org/10.1038/sj.onc.1204878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709707				2022-12-25	WOS:000171551600009
J	Vazquez, S; Aquilina, JA; Jamie, JF; Sheil, MM; Truscott, RJW				Vazquez, S; Aquilina, JA; Jamie, JF; Sheil, MM; Truscott, RJW			Novel protein modification by kynurenine in human lenses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-PRODUCTS; ALPHA-CRYSTALLIN; ACID; 3-HYDROXYKYNURENINE; IDENTIFICATION; COLORATION; GLUCOSIDE; CYSTEINE; FILTER; MODEL	It is known that human lenses increase in color and fluorescence with age, but the molecular basis for this is not well understood. We demonstrate here that proteins isolated from human lenses contain significant levels of the UV filter kynurenine covalently bound to histidine and lysine residues. Identification was confirmed by synthesis of the kynurenine amino acid adducts and comparison of the chromatographic retention times and mass spectra of these authentic standards with those of corresponding adducts isolated from human lenses following acid hydrolysis. Using calf lens proteins as a model, covalent binding of kynurenine to lens proteins has been shown to proceed via side chain deamination in a manner analogous to that observed for the related UV filter, 3-hydroxykynurenine O-beta-D-glucoside. Levels of histidylkynurenine and lysylkynurenine were low in human lenses in subjects younger than 30, but thereafter increased in concentration with the age of the individual. Post-translational modification of lens proteins by tryptophan metabolites therefore appears to be responsible, at least in part, for the age-dependent increase in coloration and fluorescence of the human lens, and this process may also be important in other tissues in which up-regulation of tryptophan catabolism occurs.	Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia	University of Wollongong	Truscott, RJW (corresponding author), Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, POB 1144, Wollongong, NSW 2522, Australia.	roger_truscott@uow.edu.au	Sheil, Margaret/F-2949-2015; Aquilina, John Andrew/AGF-4013-2022; Aquilina, J. Andrew/A-5366-2013	Jamie, Joanne/0000-0001-5449-2838				Aquilina JA, 2000, BIOCHEM BIOPH RES CO, V276, P216, DOI 10.1006/bbrc.2000.3461; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; Aquilina JA, 2001, BIOCHEM BIOPH RES CO, V285, P1107, DOI 10.1006/bbrc.2001.5288; BANDO M, 1975, EXP EYE RES, V20, P489, DOI 10.1016/0014-4835(75)90089-5; BANDO M, 1985, EXP EYE RES, V40, P813, DOI 10.1016/0014-4835(85)90126-5; Berman ER, 1991, BIOCH EYE PERSPECTIV; BESSEMS GJH, 1987, INVEST OPHTH VIS SCI, V28, P1157; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Bova LM, 1999, INVEST OPHTH VIS SCI, V40, P3237; Bova LM, 2001, INVEST OPHTH VIS SCI, V42, P200; BUTENANDT A, 1962, CHEM NATURAL SYNTHET, P13; COOPER GF, 1969, J PHYSIOL-LONDON, V203, P411, DOI 10.1113/jphysiol.1969.sp008871; Dickerson JE, 1997, EXP EYE RES, V65, P451, DOI 10.1006/exer.1997.0343; Dillon J, 1999, PHOTOCHEM PHOTOBIOL, V69, P248, DOI 10.1562/0031-8655(1999)069<0248:TPAOTG>2.3.CO;2; DILLON J, 1994, DOC OPHTHALMOL, V88, P339, DOI 10.1007/BF01203686; ELLOZY AR, 1994, PHOTOCHEM PHOTOBIOL, V59, P479, DOI 10.1111/j.1751-1097.1994.tb05068.x; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; FRIEDMAN M, 1966, J ORG CHEM, V31, P2888, DOI 10.1021/jo01347a036; FRIEDMAN M, 1964, J AM CHEM SOC, V86, P3735, DOI 10.1021/ja01072a025; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; Garner B, 2000, BBA-PROTEIN STRUCT M, V1476, P265, DOI 10.1016/S0167-4838(99)00234-4; Garner B, 1999, J BIOL CHEM, V274, P20847, DOI 10.1074/jbc.274.30.20847; HARDING JJ, 1970, BIOCHEM J, V117, P957, DOI 10.1042/bj1170957; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; LERMAN S, 1976, OPHTHALMIC RES, V8, P335, DOI 10.1159/000264841; NAKAI T, 1976, BIOCHIM BIOPHYS ACTA, V420, P258, DOI 10.1016/0005-2795(76)90317-2; RATHBUN WB, 1991, EXP EYE RES, V53, P205, DOI 10.1016/0014-4835(91)90075-P; SEN AC, 1992, PHOTOCHEM PHOTOBIOL, V55, P753; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; Takikawa O, 2001, EXP EYE RES, V72, P271, DOI 10.1006/exer.2000.0951; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; TOKUYAMA T, 1958, J CHEM SOC JPN, V79, P752; TOMODA A, 1990, OPHTHALMIC RES, V22, P152, DOI 10.1159/000267016; Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612; TRUSCOTT RJW, 1994, FEBS LETT, V348, P173, DOI 10.1016/0014-5793(94)00601-6; TSAI L, 1995, FREE RADICAL BIO MED, V19, P39, DOI 10.1016/0891-5849(95)00009-M; VANHEYNI.R, 1971, NATURE, V230, P393, DOI 10.1038/230393a0; VANHEYNINGEN R, 1973, EXP EYE RES, V15, P121, DOI 10.1016/0014-4835(73)90196-6; VANHEYNINGEN R, 1973, CIBA F S, V19, P151; Vazquez S, 2000, FREE RADICAL RES, V32, P11, DOI 10.1080/10715760000300021; WANNEMACHER CF, 1968, EXP EYE RES, V7, P623, DOI 10.1016/S0014-4835(68)80018-1; WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935; WOOD AM, 1993, EXP EYE RES, V56, P317, DOI 10.1006/exer.1993.1041; YAMAZAKI F, 1985, BIOCHEM J, V230, P635, DOI 10.1042/bj2300635; YU NT, 1989, EXP EYE RES, V49, P189, DOI 10.1016/0014-4835(89)90089-4; ZIGMAN S, 1988, EXP EYE RES, V47, P819, DOI 10.1016/0014-4835(88)90065-6	48	101	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4867	4873		10.1074/jbc.M107529200	http://dx.doi.org/10.1074/jbc.M107529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11726659	hybrid			2022-12-25	WOS:000173962900043
J	Haudenschild, D; Moseley, T; Rose, L; Reddi, AH				Haudenschild, D; Moseley, T; Rose, L; Reddi, AH			Soluble and transmembrane Isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-ALLOGRAFT REJECTION; NF-KAPPA-B; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; RHEUMATOID SYNOVIUM; EPITHELIAL-CELLS; TNF-ALPHA; IN-VITRO; T-CELL; IL-17	Members of the interleukin-17 cytokine family are present in a variety of tissues (1-3), although the founding member, interleukin-17, is expressed exclusively in T cells and B cells (4-8). The cloning and characterization of a novel single-pass transmembrane protein with limited homology to the interleukin-17 receptor is reported. High mRNA levels were detected in prostate, cartilage, kidney, liver, heart, and muscle, whereas transcripts were barely detected in thymus and leukocytes. At least 11 RNA splice variants were found, transcribed from 19 exons on human chromosome 3p25.3-3p24.1. Differential exon usage was found in different tissues by quantitative reverse transcriptase-PCR. Predicted proteins range from 186 to 720 amino acids. Soluble secreted proteins lacking transmembrane and intracellular domains are predicted from several splice isoforms and may function as extracellular antagonists to cytokine signaling by functioning as soluble decoy receptors. Using antibodies directed at the cytoplasmic and extracellular domains of this protein, we investigated its localization and found that it was expressed in a variety of normal human tissues including prostate and in prostate cancer.	Univ Calif Davis, Sch Med, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Orthopaed Surg, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Reddi, AH (corresponding author), Univ Calif Davis, Sch Med, Ctr Tissue Regenerat & Repair, 4635 2nd Ave, Sacramento, CA 95817 USA.	ahreddi@ucdavis.edu	Haudenschild, Dominik/B-2381-2008	Haudenschild, Dominik/0000-0001-9947-9864; Moseley, Timothy/0000-0003-1352-6610				Aarvak T, 1999, J IMMUNOL, V162, P1246; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; Albanesi C, 1999, J IMMUNOL, V162, P494; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Antonysamy MA, 1999, TRANSPLANT P, V31, P93, DOI 10.1016/S0041-1345(98)01453-5; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Awane M, 1999, J IMMUNOL, V162, P5337; Broxmeyer HE, 1996, J EXP MED, V183, P2411, DOI 10.1084/jem.183.6.2411; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Fossiez F, 1998, Int Rev Immunol, V16, P541, DOI 10.3109/08830189809043008; Kehlen A, 1999, J NEUROIMMUNOL, V101, P1, DOI 10.1016/S0165-5728(99)00111-3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Loong CC, 2000, TRANSPL P, V32, P1773, DOI 10.1016/S0041-1345(00)01382-8; Lubberts E, 2000, ARTHRITIS RHEUM-US, V43, P1300, DOI 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D; Martel-Pelletier J, 1999, ARTHRITIS RHEUM-US, V42, P2399, DOI 10.1002/1529-0131(199911)42:11<2399::AID-ANR19>3.0.CO;2-Y; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miossec P, 2000, CURR OPIN RHEUMATOL, V12, P181, DOI 10.1097/00002281-200005000-00004; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Spriggs MK, 1997, J CLIN IMMUNOL, V17, P366, DOI 10.1023/A:1027360106635; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhou LM, 1998, BIOCHEM MOL BIOL INT, V45, P1113	32	101	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4309	4316		10.1074/jbc.M109372200	http://dx.doi.org/10.1074/jbc.M109372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11706037	hybrid			2022-12-25	WOS:000173813900070
J	Cheng, J; Moyer, BD; Milewski, M; Loffing, J; Ikeda, M; Mickle, JE; Cutting, GR; Li, M; Stanton, BA; Guggino, WB				Cheng, J; Moyer, BD; Milewski, M; Loffing, J; Ikeda, M; Mickle, JE; Cutting, GR; Li, M; Stanton, BA; Guggino, WB			A golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE REGULATOR; KINASE-A; RECEPTOR INTERNALIZATION; INTERACTING DOMAIN; CELL-SURFACE; CYCLIC-AMP; CFTR; GENE; IDENTIFICATION; TRAFFICKING	We identified a novel cystic fibrosis transmembrane conductance regulator (CFTR) -associating, PDZ domain-containing protein, CAL ((C) under bar FTR (a) under bar ssociated (l) under bar igand) containing two predicted coiled-coiled domains and one PDZ domain. The PDZ domain of CAL binds to the C terminus of CFTR. Although CAL does not have any predicted transmembrane domains, CAL is associated with membranes mediated by a region containing the coiled-coil domains. CAL is located primarily at the Golgi apparatus, co-localizing with trans-Golgi markers and is sensitive to Brefeldin A treatment. Immunoprecipitation experiments suggest that CAL exists as a multimer. Overexpression of CAL reduces CFTR chloride currents in mammalian cells and decreases expression, rate of insertion and half-life of CFTR in the plasma membrane. The Na+/H+ exchanger regulatory factor, NHE-RF, a subplasma membrane PDZ domain protein, restores cell surface expression of CFTR and chloride currents. In addition, NHE-RF inhibits the binding of CAL to CFTR. CAL modulates the surface expression of CFTR. CAL favors retention of CFTR within the cell, whereas NHE-RF favors surface expression by competing with CAL for the binding of CFTR. Thus, the regulation of CFTR in the plasma membrane involves the dynamic interaction between at least two PDZ domain proteins.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Dartmouth Coll, Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland	Johns Hopkins University; Johns Hopkins University; Dartmouth College; University of Zurich	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	wguggino@bs.jhmi.edu	Loffing, Johannes/ABG-9973-2020; Milewski, Michał/AAK-4243-2021; Milewski, Michal/C-7144-2012	Milewski, Michał/0000-0001-7982-2565; Milewski, Michal/0000-0001-7982-2565; Ikeda, Masahiro/0000-0003-2539-8812; Loffing, Johannes/0000-0002-9415-6588	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044003, R01DK045881, R37DK044003, P50DK048977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS033324, R01NS033324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47122] Funding Source: Medline; NIDDK NIH HHS [DK-48977, DK-45881, DK-44003] Funding Source: Medline; NIGMS NIH HHS [GM58488] Funding Source: Medline; NINDS NIH HHS [NS33324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ameen NA, 2000, HISTOCHEM CELL BIOL, V114, P219; Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chung HJ, 2000, J NEUROSCI, V20, P7258; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jilling T, 1996, J BIOL CHEM, V271, P4381; Kennedy MB, 2000, P NATL ACAD SCI USA, V97, P11135, DOI 10.1073/pnas.97.21.11135; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Loffing J, 2000, AM J PHYSIOL-CELL PH, V279, pC1016, DOI 10.1152/ajpcell.2000.279.4.C1016; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Tousson A, 1996, J CELL SCI, V109, P1325; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	46	215	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3520	3529		10.1074/jbc.M110177200	http://dx.doi.org/10.1074/jbc.M110177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707463	hybrid			2022-12-25	WOS:000173688000062
J	Duthey, B; Caudron, S; Perroy, J; Bettler, B; Fagni, L; Pin, JP; Prezeau, L				Duthey, B; Caudron, S; Perroy, J; Bettler, B; Fagni, L; Pin, JP; Prezeau, L			A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CEREBELLAR GRANULE CELLS; 3RD INTRACELLULAR LOOPS; PHOSPHOLIPASE-C; COUPLED RECEPTORS; CALCIUM CHANNELS; LIGAND-BINDING; AMINO-ACIDS; DOMAIN; 2ND	Although G-protein-coupled receptors (GPCRs) have been shown to assemble into functional homo or heteromers, the role of each protomer in G-protein activation is not known. Among the GPCRs, the gamma-aminobutyric acid (GABA) type B receptor (GABA(B)R) is the only one known so far that needs two subunits, GB1 and GB2, to function. The GB1 subunit contains the GABA binding site but is unable to activate G-proteins alone. In contrast the GB2 subunit, which does not bind GABA, has an heptahelical domain able to activate G-proteins when assembled into homodimers (Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, G., Bettler, B., Prezeau, L., and Pin, J.-P. (2001) EMBO J. 20, 2152-2159). In the present study, we have examined the role of each subunit within the GB1-GB2 heteromer, in G-protein coupling. To that end, point mutations in the highly conserved third intracellular loop known to prevent G-protein activation of the related Ca-sensing or metabotropic glutamate receptors were introduced into GB1 and GB2. One mutation, L686P introduced in GB2 prevents the formation of a functional receptor, even though the heteromer reaches the cell surface, and even though the mutated subunit still associates with GB1 and increases GABA affinity on GB1. This was observed either in HEK293 cells where the activation of the G-protein was assessed by measurement of inositol phosphate accumulation, or in cultured neurons where the inhibition of the Ca2+ channel current was measured. In contrast, the same mutation when introduced into GB1 does not modify the G-protein coupling properties of the heteromeric GABA(B) receptor either in HEK293 cells or in neurons. Accordingly, whereas in all GPCRs the same protein is responsible for both agonist binding and G-protein activation, these two functions are assumed by two distinct subunits in the GABA(B) heteromer: one sub. unit, GB1, binds the agonists whereas the other, GB2, activates the G-protein. This illustrates the importance of a single subunit for G-protein activation within a dimeric receptor.	CNRS, UPR 9023, CCIPE, INSERM Pharmacol Endocrinol, F-34000 Montpellier, France; Inst Physiol, Pharmazentrum, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Prezeau, L (corresponding author), CNRS, UPR 9023, CCIPE, INSERM Pharmacol Endocrinol, 141 Rue Cardonille, F-34000 Montpellier, France.		bettler, bernhard/AAO-8018-2020; Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Bettler, Bernhard/0000-0003-0842-8207; perroy, julie/0000-0001-6199-0448				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bessis AS, 2000, PROTEIN SCI, V9, P2200, DOI 10.1110/ps.9.11.2200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Calver AR, 2001, J NEUROSCI, V21, P1203; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Filippov AK, 2000, J NEUROSCI, V20, P2867; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Pagano A, 2001, J NEUROSCI, V21, P1189; Perroy J, 2000, J NEUROSCI, V20, P7896; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197	45	162	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3236	3241		10.1074/jbc.M108900200	http://dx.doi.org/10.1074/jbc.M108900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11711539	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000173688000025
J	Jave-Suarez, LF; Winter, H; Langbein, L; Rogers, MA; Schweizer, J				Jave-Suarez, LF; Winter, H; Langbein, L; Rogers, MA; Schweizer, J			HOXC13 is involved in the regulation of human hair keratin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEINS; MUTANT MICE; DNA-BINDING; MEIS1; COMPLEXES; SEQUENCE; DOMAIN	At present, HOXC13 is the only member of the HOX multigene family that produces a fragile hair phenotype when mutated or overexpressed in mice. To determine whether hair keratin genes are targets for this transcription factor, we analyzed the HOXC13 responsiveness of human hair keratin genes, whose expression matched that of nuclear HOXC13, immunologically revealed in cells of the lower hair-forming compartment of the human anagen hair follicle. We show that HOXC13, but not a homeobox-deleted HOXC13, strongly activated the promoters of the genes, with the respective proximal promoter regions being sufficient for optimal activation. The hair keratin promoters contained numerous putative Hox binding core motifs TAAT, TTAT, and TTAC. Electrophoretic mobility shift assays revealed that HOXC13 bound exclusively to distinct TAAT and TTAT core motifs that were clearly concentrated in the proximal promoter regions. A comparison of the sequences flanking HOXC13 binding and nonbinding core motifs, respectively, allowed the deduction of an extended 8-bp HOXC13 consensus binding sequence TT(A/F)ATNPuPu. Thus, the DNA binding conditions for HOXC13 were distinct from those of other members of the paralogous group 13, i.e. murine Hoxb13 and HOXd13, for which previous investigations yielded the consensus binding sequence TTFA(T/C)NPuPu. Collectively, our data speak for a direct involvement of HOXC13 in the control of hair keratin expression during early trichocyte differentiation.	Deutsch Krebsforschungszentrum, Div Tumor Cell Regulat, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Cell Biol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Schweizer, J (corresponding author), Res Program 2, 5th Floor,Rm 522,Neuenheimerfeld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012; Jave-Suarez, Luis Felipe/T-7036-2018	Rogers, Michael A./0000-0002-3728-2107; Jave-Suarez, Luis Felipe/0000-0001-6209-5031				Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; DHOUAILLY D, 1989, EXP CELL RES, V181, P141, DOI 10.1016/0014-4827(89)90189-4; Duboule D, 1998, GENE DEV, V12, P1, DOI 10.1101/gad.12.1.1; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Godwin AR, 1999, J INVEST DERM SYMP P, V4, P244, DOI 10.1038/sj.jidsp.5640221; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; Maconochie M, 1996, ANNU REV GENET, V30, P529, DOI 10.1146/annurev.genet.30.1.529; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Powell CC, 1997, CEA CRITIC, V59, P1; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; STANCHIA E, 2000, J MOL BIOL, V299, P667; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Winter H, 2001, HUM GENET, V108, P37, DOI 10.1007/s004390000439; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134	29	90	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3718	3726		10.1074/jbc.M101616200	http://dx.doi.org/10.1074/jbc.M101616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11714694	hybrid			2022-12-25	WOS:000173688000086
J	Boileau, AJ; Newell, JG; Czajkowski, C				Boileau, AJ; Newell, JG; Czajkowski, C			GABA(A) receptor beta(2) Tyr(97) and Leu(99) line the GABA-binding site - Insights into mechanisms of agonist and antagonist actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; NICOTINIC ACETYLCHOLINE-RECEPTOR; AMINOBUTYRIC ACID(A) RECEPTORS; ALPHA-SUBUNIT; SUBSTITUTED CYSTEINES; BENZODIAZEPINE BINDING; A RECEPTOR; LIGAND; IDENTIFICATION; ACCESSIBILITY	The identification of residues that line neurotransmitter-binding sites and catalyze allosteric transitions that result in channel gating is crucial for understanding ligand-gated ion channel function. In this study, we used the substituted cysteine accessibility method and two-electrode voltage clamp to identify novel gamma-aminobutyric acid (GABA)-binding site residues and to elucidate the secondary structure of the Trp(92)-Asp(101) region of the beta(2) subunit. Each residue was mutated individually to cysteine and expressed with wild-type alpha(1) subunits in Xenopus oocytes. GABA- gated currents (I-GABA) were measured before and after exposure to the sulfhydryl reagent, N-biotinylaminoethyl methanethiosulfonate (MTS). V93C, D95C, Y97C, and L99C are accessible to derivatization. This pattern of accessibility is consistent with beta(2)Val(93)-Leu(99) adopting a beta-strand conformation. Both GABA and SR95531 protect Y97C and L99C from modification, indicating that these two residues line the GABA-binding site. In D95C-containing receptors, application of MTS in the presence of SR95531 causes a greater effect on I-GABA than MTS alone, suggesting that binding of a competitive antagonist can cause movements in the binding site. In addition, we present evidence that beta(2)L99C homomers form spontaneously open channels. Thus, mutation of a binding site residue can alter channel gating, which implies that Leu(99) may be important for coupling agonist binding to channel gating.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave,MSC Rm 197, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727, R56NS034727] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34727] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Barnard EA, 1998, PHARMACOL REV, V50, P291; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Birnir B, 1997, SYNAPSE, V26, P324, DOI 10.1002/(SICI)1098-2396(199707)26:3<324::AID-SYN13>3.0.CO;2-V; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; Boileau AJ, 1999, J NEUROSCI, V19, P10213; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; CHAMBON JP, 1985, P NATL ACAD SCI USA, V82, P1832, DOI 10.1073/pnas.82.6.1832; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOU TC, 1974, MOL PHARMACOL, V10, P235; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies M, 1998, J NEUROCHEM, V70, P2188; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Horenstein J, 1998, MOL PHARMACOL, V53, P870; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Javitch JA, 2000, BIOCHEMISTRY-US, V39, P12190, DOI 10.1021/bi001069m; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Koch SE, 2000, J BIOL CHEM, V275, P34493, DOI 10.1074/jbc.M005569200; Kucken AM, 2000, MOL PHARMACOL, V57, P932; Lambert G, 2001, J GEN PHYSIOL, V117, P533, DOI 10.1085/jgp.117.6.533; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; Uchida I, 1996, EUR J PHARMACOL, V307, P89, DOI 10.1016/0014-2999(96)00156-2; Ueno S, 1997, J NEUROSCI, V17, P625; Vafa B, 1998, INT REV NEUROBIOL, V42, P285, DOI 10.1016/S0074-7742(08)60613-3; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	57	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2931	2937		10.1074/jbc.M109334200	http://dx.doi.org/10.1074/jbc.M109334200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711541	Green Submitted, hybrid			2022-12-25	WOS:000173421500073
J	Chen, LW; Wu, YJ; Lee, V; Kiani, C; Adams, ME; Yao, YQ; Yang, BB				Chen, LW; Wu, YJ; Lee, V; Kiani, C; Adams, ME; Yao, YQ; Yang, BB			The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; KNEE-JOINT FLUID; CORE PROTEIN; ARTICULAR-CARTILAGE; LINK PROTEIN; G1 DOMAIN; BIOSYNTHESIS; NANOMELIA; FRAGMENTS; SEQUENCE	Aggrecan is the major proteoglycan in the extracellular matrix of cartilage. A notable exception is nanomelic cartilage, which lacks aggrecan in its matrix. The example of nanomelia and other evidence leads us to believe that the G3 domain plays an important role in aggrecan processing, and it has indeed been confirmed that G3 allows glycosaminoglycan (GAG) chain attachment and product secretion. However, it is not clear how G3, which contains at least a carbohydrate recognition domain (CRD) and a complement binding protein (CBP) motif, plays these two functional roles. The present study was designed to dissect the mechanisms of this phenomenon and specially 1) to determine the effects of various cysteine residues in GAG modification and product secretion as well as 2) to investigate which of the two processing events is the critical step in the product processing. Our studies demonstrated that removal of the two amino-terminal cysteines in the CRD motif and the single cysteine in the amino terminus of CBP inhibited secretion of CRD and CBP. Use of the double mutant CRD construct also allowed us to observe a deviation from the usual strict coupling of GAG modification and product secretion steps. The presence of a small chondroitin sulfate fragment overcame the secretion-inhibitory effects once the small chondroitin sulfate fragment was modified by GAG.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave,Res Bldg, Toronto, ON M4N 3M5, Canada.	Burton.Yang@swchsc.on.ca						BINETTE F, 1994, J BIOL CHEM, V269, P19116; Cao L, 1998, MATRIX BIOL, V17, P379, DOI 10.1016/S0945-053X(98)90090-7; CASTOR CW, 1983, ARTHRITIS RHEUM, V26, P522, DOI 10.1002/art.1780260411; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GOETINCK PF, 1991, CURRENT TOPICS DEV B, P111; HAGGERTY JG, 1994, J CELL PHYSIOL, V158, P39, DOI 10.1002/jcp.1041580106; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; KOLSET SO, 1986, BIOCHEM J, V238, P209, DOI 10.1042/bj2380209; LI H, 1993, J BIOL CHEM, V268, P23504; LOHMANDER LS, 1989, ARTHRITIS RHEUM, V32, P1434, DOI 10.1002/anr.1780321113; LOHMANDER LS, 1993, J RHEUMATOL, V20, P1362; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; Luo W, 2000, J BONE MINER METAB, V18, P51, DOI 10.1007/s007740050011; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SCHWARTZ NB, 1979, J BIOL CHEM, V254, P2271; STIRPE NS, 1987, DEV BIOL, V124, P77, DOI 10.1016/0012-1606(87)90461-1; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; VERTEL BM, 1993, J CELL SCI, V104, P939; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; VILIM V, 1994, BIOCHEM J, V304, P887, DOI 10.1042/bj3040887; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YANG BB, 1997, MATRIX BIOL, V16, P537; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999	34	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2657	2665		10.1074/jbc.M101153200	http://dx.doi.org/10.1074/jbc.M101153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714693	hybrid			2022-12-25	WOS:000173421500038
J	Masuda, Y; Takahashi, M; Fukuda, S; Sumii, M; Kamiya, K				Masuda, Y; Takahashi, M; Fukuda, S; Sumii, M; Kamiya, K			Mechanisms of dCMP transferase reactions catalyzed by mouse Rev1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-SENSITIVE STRAINS; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; YEAST; CHECKPOINT; GENE; MUTAGENESIS; REPAIR; LIGHT	The Rev1 protein, a member of a large family of translesion DNA polymerases, catalyzes a dCMP transfer reaction. Recombinant mouse Rev1 protein was found to insert a dCMP residue opposite guanine, adenine, thymine, cytosine, uracil, and an apurinic/apyrimidinic site and to have weak ability for transfer to a mismatched terminus. The mismatch-extension ability was strongly enhanced by a guanine residue on the template near the mismatched terminus; this was not the case with an apurinic/apyrimidinic site and the other template nucleotides. Kinetic analysis of the dCMP transferase reaction provided evidence for high affinity for dCTP with template G but not the other templates, whereas the template nucleotide did not much affect the V-max value. Furthermore, it could be established that the mouse Rev1 protein inserts dGMP and dTMP residues opposite template guanine at a V-max similar to that for dCMP.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Baynton K, 1999, MOL MICROBIOL, V34, P124, DOI 10.1046/j.1365-2958.1999.01583.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Harfe BD, 2000, MOL CELL, V6, P1491, DOI 10.1016/S1097-2765(00)00145-3; KALINOWSKI DP, 1995, MUTAT RES-FUND MOL M, V331, P149, DOI 10.1016/0027-5107(95)00064-P; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE CW, 1974, J MOL BIOL, V85, P137, DOI 10.1016/0022-2836(74)90134-X; LAWRENCE CW, 1978, J MOL BIOL, V122, P1, DOI 10.1016/0022-2836(78)90104-3; LAWRENCE CW, 1976, GENETICS, V82, P207; LAWRENCE CW, 1970, GENETICS, V64, P836; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	27	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3040	3046		10.1074/jbc.M110149200	http://dx.doi.org/10.1074/jbc.M110149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711549	hybrid			2022-12-25	WOS:000173421500087
J	Bubeck, A; Reusch, U; Wagner, M; Ruppert, T; Muranyi, W; Kloetzel, PM; Koszinowski, UH				Bubeck, A; Reusch, U; Wagner, M; Ruppert, T; Muranyi, W; Kloetzel, PM; Koszinowski, UH			The glycoprotein gp48 of murine cytomegalovirus - Proteasome-dependent cytosolic dislocation and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; HERPESVIRUS GENOME; SECRETORY PATHWAY; HEAVY-CHAINS; ER; GENE; COMPLEX	Degradation of misfolded or unassembled proteins that are co-translationally inserted into the endoplasmic reticulum involves the cytosolic proteasome system. Different principles may exist for the export of proteins into the cytosol for proteasomal degradation. Here we studied the degradation pathway of the viral glycoprotein gp48, a type I transmembrane protein, encoded by the m06 gene of murine cytomegalovirus. In cells stably transfected with the cytomegalovirus m06 gene or infected with the virus itself, two populations of gp48 can be distinguished that have different fates. Complexes of gp48 and the major histocompatibility complex (MHC) class I molecule, are transported to the lysosome for degradation. Unassembled gp48 is degraded by the cytosolic proteasome. Proteasomal inhibitors stabilize the unassembled gp48 in its core-glycosylated and membrane-associated form in the endoplasmic reticulum (ER)-Golgi intermediate compartment. This implicates that both endoplasmic reticulum and ER-Golgi intermediate compartment export gp48 and that degradation is coupled to a functional proteasome. Analysis of gp48 mutants revealed that the cytosolic part of gp48 was not responsible for the proteasome-dependent substrate transport out of the ER-Golgi intermediate compartment. Thus an indirect interaction between the proteasome and its substrate has to be discussed.	Univ Munich, Genzentrum, Max Von Pettenkofer Inst, D-81377 Munich, Germany; Zentrum Expt Med, Charite, Inst Biochem, D-10098 Berlin, Germany	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Koszinowski, UH (corresponding author), Max Von Pettenkofer Inst, Lehrstuhl Virol, Pettenkofer Str 9A, D-80336 Munich, Germany.		Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				Bordallo J, 1999, FEBS LETT, V448, P244, DOI 10.1016/S0014-5793(99)00362-2; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hengel H, 1999, IMMUNOL REV, V168, P167, DOI 10.1111/j.1600-065X.1999.tb01291.x; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kozlowski L, 2001, TUMOR BIOL, V22, P211, DOI 10.1159/000050618; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; OHE Y, 1995, HUM GENE THER, V6, P325, DOI 10.1089/hum.1995.6.3-325; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE J, 1991, J CELL SCI, V100, P415; Sijts AJAM, 2000, J EXP MED, V191, P503, DOI 10.1084/jem.191.3.503; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; TABAS I, 1979, J BIOL CHEM, V254, P1655; Wagner M, 2000, J VIROL, V74, P10729, DOI 10.1128/JVI.74.22.10729-10736.2000; Wagner M, 1999, J VIROL, V73, P7056, DOI 10.1128/JVI.73.8.7056-7060.1999; WAGNER M, 2001, IN PRESS METHOS MOL; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wigley WC, 1999, J CELL BIOL, V145, P481; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	49	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2216	2224		10.1074/jbc.M104178200	http://dx.doi.org/10.1074/jbc.M104178200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707434	hybrid			2022-12-25	WOS:000173421300082
J	Sanyal, S; Kim, JY; Kim, HJ; Takeda, J; Lee, YK; Moore, DD; Choi, HS				Sanyal, S; Kim, JY; Kim, HJ; Takeda, J; Lee, YK; Moore, DD; Choi, HS			Differential regulation of the orphan nuclear receptor small heterodimer partner (SHP) gene promoter by orphan nuclear receptor ERR isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RESPONSE ELEMENTS; RETINOID-X-RECEPTOR; HORMONE-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; EXPRESSION; ACTIVATION; DNA; CONFORMATION; SUPERFAMILY; COACTIVATOR	The orphan nuclear receptor small heterodimer partner (SHP; NROB2) interacts with a wide array of nuclear receptors and represses their transcriptional activity. SHP expression is regulated by several other members of the nuclear receptor superfamily, including the orphan receptors SF-1 and LRH-1, and the bile acid receptor FXR. We have found that the SHP promoter is also activated by the estrogen receptor-related receptor gamma (ERRgamma) but not the related ERRalpha and ERRbeta isoforms. SHP and ERRgamma mRNAs are coexpressed in several tissues, including pancreas, kidney, and heart, confirming the potential relevance of this transactivation. ERRgamma transactivation is dependent on only one of five previously characterized DNA-binding sites for SF-1, and this element differs from previously reported ERR response elements. However, treatment with the histone deacetylase inhibitor trichostatin A significantly increased ERRalpha and ERRbeta activity on this element indicating that the lack of activity of ERRalpha and -beta may depend on their association with co-repressor in vivo. Furthermore, using protease sensitivity assays on DNA bound receptors it was demonstrated that DNA sequence of different response elements may cause allosteric modulation of ERR proteins, which in turn may be responsible for the differential activities of these receptors on different response elements. SHP inhibits ERRgamma transactivation and physically interacts with all three members of ERR subfamily, as demonstrated by both yeast two-hybrid and biochemical assays. As with other SHP targets, this interaction is dependent on the AF-2 coactivator-binding site of ERRgamma and the previously described N-terminal receptor interaction domain of SHP. Several recently described SHP mutations associated with moderate obesity in humans block the inhibition of ERRgamma activity. Overall, these results identify a new autoregulatory loop controlling SHP gene expression and significantly extend the potential functional roles of the three ERRs.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Labs Mol Genet, Gunma 3718512, Japan; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Chonnam National University; Chonnam National University; Gunma University; Baylor College of Medicine	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	hsc@chonnam.chonnam.ac.kr	Sanyal, Sabyasachi/E-8034-2010	Sanyal, Sabyasachi/0000-0002-8603-3828				Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Tremblay GB, 2001, ENDOCRINOLOGY, V142, P4572, DOI 10.1210/en.142.10.4572; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1998, CANCER RES, V58, P5695; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	41	131	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1739	1748		10.1074/jbc.M106140200	http://dx.doi.org/10.1074/jbc.M106140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11705994	hybrid			2022-12-25	WOS:000173421300017
J	Woods, TC; Blystone, CR; Yoo, J; Edelman, ER				Woods, TC; Blystone, CR; Yoo, J; Edelman, ER			Activation of EphB2 and its ligands promotes vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; HUMAN ENDOTHELIAL-CELLS; RAT CAROTID-ARTERY; PLASMINOGEN-ACTIVATOR; TRANSMEMBRANE LIGANDS; HEPARIN FRAGMENTS; NITRIC-OXIDE; GROWTH; FAMILY; ANGIOGENESIS	EphB2 and its ligands regulate interactions between endothelial and mesenchymal cells in developing arteries. In adult arteries, the relationship between smooth muscle cells and overlying intact endothelium is responsible for maintaining the health of the vessel. Heparin inhibits vascular smooth muscle cell growth in culture and intimal hyperplasia following endothelial denudation. Using gene microarrays, we identified the tyrosine kinase receptor EphB2 as being differentially expressed in response to continuous intravenous heparin administration in the rabbit model of arterial injury. EphB2 protein levels increased in cultured bovine vascular smooth muscle cells following serum stimulation and were decreased in a dose-dependent fashion by heparin. Fc chimeras of the binding domain of the EphB2 ligands blocked the formation of the EphB2 ligand-receptor complex and reduced growth of serum-stimulated vascular smooth muscle cells in a dose-dependent fashion. Activation of the ligand by an Fc chimera to EphB2 followed a parabolic dose-response growth curve, indicating growth stimulation until the chimera begins to compete with native receptors. Co-administration of EphB2/Fc chimera with heparin shifted the dose-response curve to the right. These data indicate a possible new route of Heparin's antiproliferative effect and a role of EphB2 and its ligands in vascular smooth muscle cell proliferation.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Emisphere Technol Inc, Tarrytown, NY 10591 USA	Harvard University; Massachusetts Institute of Technology (MIT)	Woods, TC (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, 16-343,400 Main St, Cambridge, MA 02139 USA.			Edelman, Elazer/0000-0002-7832-7156	NHLBI NIH HHS [HL 60407] Funding Source: Medline; NIGMS NIH HHS [GM/HL 49039] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060407] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; AU YPT, 1993, HAEMOSTASIS, V23, P177; AU YPT, 1992, J BIOL CHEM, V267, P3438; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BECK DW, 1986, J NEUROPATH EXP NEUR, V45, P503, DOI 10.1097/00005072-198609000-00002; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; Daum G, 1997, CIRC RES, V81, P17, DOI 10.1161/01.RES.81.1.17; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DESMOULIERE A, 1991, ARTERIOSCLER THROMB, V11, P244, DOI 10.1161/01.ATV.11.2.244; Douglas MS, 1997, IMMUNOLOGY, V92, P512, DOI 10.1046/j.1365-2567.1997.00385.x; DOUGLAS MS, 1997, BIOCH SOC T S, V25, P194; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; Helbling PM, 2000, DEVELOPMENT, V127, P269; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; Lille S, 1997, J SURG RES, V70, P178, DOI 10.1006/jsre.1997.5114; Miller SJ, 1998, THROMB HAEMOSTASIS, V80, P481; Norrby K, 2000, INT J EXP PATHOL, V81, P191, DOI 10.1046/j.1365-2613.2000.00150.x; Oberhoff M, 1998, CARDIOVASC RES, V38, P751, DOI 10.1016/S0008-6363(98)00049-2; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855; Poole TJ, 2001, DEV DYNAM, V220, P1, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2; Rogers C, 1996, ARTERIOSCL THROM VAS, V16, P1312, DOI 10.1161/01.ATV.16.10.1312; Sakano S, 1996, ONCOGENE, V13, P813; Steiner RD, 2000, J INHERIT METAB DIS, V23, P88, DOI 10.1023/A:1005663200288; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Upchurch GR, 1997, CIRCULATION, V95, P2115, DOI 10.1161/01.CIR.95.8.2115; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; YOKOKAWA K, 1993, J CLIN INVEST, V92, P2080, DOI 10.1172/JCI116805; Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163-7258(97)00112-5	41	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1924	1927		10.1074/jbc.M108189200	http://dx.doi.org/10.1074/jbc.M108189200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706028	hybrid			2022-12-25	WOS:000173421300042
J	Zheng, YC; Hirschberg, B; Yuan, J; Wang, AP; Hunt, DC; Ludmerer, SW; Schmatz, DM; Cully, DF				Zheng, YC; Hirschberg, B; Yuan, J; Wang, AP; Hunt, DC; Ludmerer, SW; Schmatz, DM; Cully, DF			Identification of two novel Drosophila melanogaster histamine-gated chloride channel subunits expressed in the eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE MONOPOLAR CELLS; NERVOUS-SYSTEM; NEUROTRANSMITTER CANDIDATE; PHOTORECEPTORS; RECEPTOR; CLONING; GENE; BARNACLES; NEURONS; LOBSTER	Histamine has been shown to play a role in arthropod vision; it is the major neurotransmitter of arthropod photoreceptors. Histamine-gated chloride channels have been identified in insect optic lobes. We report the first isolation of cDNA clones encoding histamine-gated chloride channel subunits from the fruit fly Drosophila melanogaster. The encoded proteins, HisCl1 and HisCl2, share 60% amino acid identity with each other. The closest structural homologue is the human glycine alpha3 receptor, which shares 45 and 43% amino acid identity respectively. Northern hybridization analysis suggested that hisCl1 and hisCl2 mRNAs are predominantly expressed in the insect eye. Oocytes injected with in vitro transcribed RNA, encoding either HisCl1 or HisCl2, produced substantial chloride currents in response to histamine but not in response to GABA, glycine, and glutamate. The histamine sensitivity was similar to that observed in insect laminar neurons. Histamine-activated currents were not blocked by picrotoxinin, fipronil, strychnine, or the H2 antagonist cimetidine. Co-injection of both hisCl1 and hisCl2 RNAs resulted in expression of a histamine-gated chloride channel with increased sensitivity to histamine, demonstrating coassembly of the subunits. The insecticide ivermectin reversibly activated homomeric HisCl1 channels and, more potently, HisCl1 and HisCl2 heteromeric channels.	Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA	Merck & Company	Hirschberg, B (corresponding author), Merck & Co Inc, Merck Res Labs, POB 2000,R80N-C31, Rahway, NJ 07065 USA.							ARENA JP, 1991, MOL PHARMACOL, V40, P368; BATTELLE BA, 1991, J COMP NEUROL, V305, P527, DOI 10.1002/cne.903050402; BAYER TA, 1989, J EXP BIOL, V145, P133; BUCHNER E, 1993, CELL TISSUE RES, V273, P119, DOI 10.1007/BF00304618; BURG MG, 1993, EMBO J, V12, P911, DOI 10.1002/j.1460-2075.1993.tb05732.x; Callaway JC, 1999, MICROSC RES TECHNIQ, V44, P94, DOI 10.1002/(SICI)1097-0029(19990115/01)44:2/3<94::AID-JEMT4>3.0.CO;2-F; CLAIBORNE BJ, 1984, J NEUROSCI, V4, P708; COOMBE PE, 1986, J COMP PHYSIOL A, V159, P655, DOI 10.1007/BF00612038; ELIAS MS, 1983, J NEUROCHEM, V41, P562, DOI 10.1111/j.1471-4159.1983.tb04776.x; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; HARDIE RC, 1987, J COMP PHYSIOL A, V161, P201, DOI 10.1007/BF00615241; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; Hatton GI, 2001, J NEUROSCI, V21, P2974, DOI 10.1523/JNEUROSCI.21-09-02974.2001; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Melzig J, 1998, J NEUROSCI, V18, P7160; Melzig J, 1996, J COMP PHYSIOL A, V179, P763, DOI 10.1007/BF00207355; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; POLLACK I, 1991, CELL TISSUE RES, V266, P391, DOI 10.1007/BF00318195; SARTHY PV, 1991, J NEUROCHEM, V57, P1757, DOI 10.1111/j.1471-4159.1991.tb06378.x; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SKINGSLEY DR, 1995, J COMP PHYSIOL A, V176, P611, DOI 10.1007/BF01021581; Stuart AE, 1999, NEURON, V22, P431, DOI 10.1016/S0896-6273(00)80699-6; Wassle H, 1998, VISION RES, V38, P1411, DOI 10.1016/s0042-6989(97)00300-3; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YANG QZ, 1994, NEUROSCIENCE, V61, P955, DOI 10.1016/0306-4522(94)90415-4; Yuan J, 1999, BIOINFORMATICS, V15, P862, DOI 10.1093/bioinformatics/15.10.862	27	126	134	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2000	2005		10.1074/jbc.M107635200	http://dx.doi.org/10.1074/jbc.M107635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11714703	hybrid			2022-12-25	WOS:000173421300053
J	Rosenfeldt, HM; Hobson, JP; Maceyka, M; Olivera, A; Nava, VE; Milstien, S; Spiegel, S				Rosenfeldt, HM; Hobson, JP; Maceyka, M; Olivera, A; Nava, VE; Milstien, S; Spiegel, S			EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; motility; Src; FAK	PROTEIN-COUPLED RECEPTORS; HUMAN ENDOTHELIAL-CELLS; AIRWAY SMOOTH-MUSCLE; SPHINGOSINE 1-PHOSPHATE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; FAMILY KINASES; DEFICIENT MICE	Sphingosine-1-phosphate (SPP), formed by sphingosine kinase, is the ligand for EDG-1, a GPCR important for cell migration and vascular maturation. Here we show that cytoskeletal rearrangements, lamel-lipodia extensions, and cell motility induced by platelet-derived growth factor (PDGF) are abrogated in EDG-1 null fibroblasts. However, EDG-1 appears to be dispensable for mitogenicity and survival effects, even those induced by its ligand SPP and by PDGF. Furthermore, PDGF induced focal adhesion formation and activation of FAK, Src, and stress-activated protein kinase 2, p38, were dysregulated in the absence of EDG-1. In contrast, tyrosine phosphorylation of the PDGFR and activation of extracellular signal regulated kinase (ERK1/2), important for growth and survival, were unaltered. Our results suggest that EDG-1 functions as an integrator linking the PDGFR to lamel-lipodia extension and cell migration. PDGF, which stimulates sphingosine kinase, leading to increased SPP levels in many cell types, also induces translocation of sphingosine kinase to membrane ruffles. Hence, recruitment of sphingosine kinase to the cell's leading edge and localized formation of SPP may spatially and temporally stimulate EDG-1, resulting in activation and integration of downstream signals important for directional movement toward chemoattractants, such as PDGF. These results may also shed light on the vital role of EDG-1 in vascular maturation.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, W226A Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	spiegel@bc.georgetown.edu	Maceyka, Michael/B-9277-2008		NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Cary LA, 1996, J CELL SCI, V109, P1787; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Edsall LC, 1997, J NEUROSCI, V17, P6952; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	64	135	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2649	2659		10.1096/fj.01-0523com	http://dx.doi.org/10.1096/fj.01-0523com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726541				2022-12-25	WOS:000172964800035
J	Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M				Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M			Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition	ONCOGENE			English	Article						c-Fos; oncogene; protein degradation; proteasome; PEST motif	KAPPA-B-ALPHA; IN-VIVO; TRANSCRIPTION FACTORS; INSTABILITY DETERMINANTS; TRANSFORMING ACTIVITY; MEDIATED PROTEOLYSIS; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PEST SEQUENCES; 26S PROTEASOME	c-Fos proto-oncoprotein is rapidly and transiently expressed in cells undergoing the G(0)-to-S phase transition in response to stimulation for growth by serum. Under these conditions, the rapid decay of the protein occurring after induction is accounted for by efficient recognition and degradation by the proteasome. PEST motifs are sequences rich in Pro, Glu, Asp, Ser and Thr which have been proposed to constitute protein instability determinants. c-Fos contains three such motifs, one of which comprises the C-terminal 20 amino acids and has already been proposed to be the major determinant of c-Fos instability. Using site-directed mutagenesis and an expression system reproducing c-fos gene transient expression in transfected cells, we have analysed the turnover of c-Fos mutants deleted of the various PEST sequences in synchronized mouse embryo fibroblasts. Our data showed no role for the two internal PEST motifs in c-Fos instability. However, deletion of the C-terminal PEST region led to only a twofold stabilization of the protein. Taken together, these data indicate that c-Fos instability during the G0-to-S phase transition is governed by a major non-PEST destabilizer and a C-terminal degradation-accelerating element. Further dissection of c-Fos C-terminal region showed that the degradation-accelerating effect is not contributed by the whole PEST sequence but by a short PTL tripeptide which cannot be considered as a PEST motif and which can act in the absence of any PEST environment. Interestingly, the PTL motif is conserved in other members of the fos multigene family. Nevertheless, its contribution to protein instability is restricted to c-Fos suggesting that the mechanisms whereby the various Fos proteins are broken down are, at least partially, different. MAP kinases-mediated phosphorylation of two serines close to PTL, which are both phosphorylated all over the G(0)-to-S phase transition, have been proposed by others to stabilize c-Fos protein significantly. We, however, showed that the PTL motif does not exert its effect by counteracting a stabilizing effect of these phosphorylations under our experimental conditions.	Inst Genet Mol, CNRS, UMR 5535, IFR 24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR 24, 1919 route de Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Boudjelal M, 2000, CANCER RES, V60, P2247; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Coffino P, 1998, UBIQUITIN BIOL CELL, P411; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Harlow E., 1999, USING ANTIBODIES LAB; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1988, UBIQUITIN BIOL CELL; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAEMMLI EK, 1971, NATURE, V227, P6800; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; PETERS JM, 1998, UBIQUITIN BIOL CELL; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Sambrook J, 1989, MOL CLONING; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHUERMANN M, 1991, ONCOGENE, V6, P567; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803	64	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7563	7572		10.1038/sj.onc.1204880	http://dx.doi.org/10.1038/sj.onc.1204880			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709728				2022-12-25	WOS:000171976900013
J	Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Greene, DA; Stevens, MJ				Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Greene, DA; Stevens, MJ			An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense	FASEB JOURNAL			English	Review						diabetic neuropathy; NAD(+)/NADH ratio; nerve blood flow; nerve conduction; oxidative stress; reversal	PROTEIN-KINASE-C; ENDONEURIAL BLOOD-FLOW; ALPHA-LIPOIC ACID; NICOTINAMIDE-ADENINE DINUCLEOTIDE; DORSAL-ROOT GANGLIA; CONDUCTION-VELOCITY; ENERGY-METABOLISM; SCIATIC-NERVE; SORBITOL DEHYDROGENASE; OXIDATIVE STRESS	Aldose reductase inhibitors (ARIs) prevent peripheral nerve dysfunction and morphological abnormalities in diabetic animal models. However, some experimental intervention studies and clinical trials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate design and, in particular, insufficient correction of the sorbitol pathway activity or 2) the inability to reverse established functional and metabolic deficits of diabetic neuropathy by AR inhibition in general. We evaluated whether diabetes-induced changes in nerve function, metabolism, and antioxidative defense are corrected by the dose of ARI (sorbinil, 65 mg/kg/d in the diet), resulting in complete inhibition of increased sorbitol pathway activity. The groups included control rats and streptozotocin-diabetic rats treated with/without ARI for 2 weeks after 4 weeks of untreated diabetes. ARI treatment corrected diabetes-induced nerve functional changes; that is, decrease in endoneurial nutritive blood flow, motor and sensory nerve conduction velocities, and metabolic abnormalities (i.e., mitochondrial and cytosolic NAD(+)/NADH redox imbalances and energy deficiency). ARI restored nerve concentrations of two major non-enzymatic antioxidants, reduced glutathione (GSH) and ascorbate, and completely arrested diabetes-induced lipid peroxidation. In conclusion, treatment with adequate doses of ARIs (that is, doses that completely inhibit increased sorbitol pathway activity) is an effective approach for reversal of, at least, early diabetic neuropathy.	Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Obrosova, IG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB 2,Room 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu						[Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; Ashizawa N, 1997, JPN J PHARMACOL, V73, P133, DOI 10.1254/jjp.73.133; BertiMattera L, 1996, METABOLISM, V45, P320, DOI 10.1016/S0026-0495(96)90285-1; BRAVENBOER B, 1992, DIABETOLOGIA, V35, P813, DOI 10.1007/BF00399926; BRISMAR T, 1981, ACTA PHYSIOL SCAND, V112, P495, DOI 10.1111/j.1748-1716.1981.tb06851.x; BRISMAR T, 1993, J PHYSIOL-LONDON, V460, P365, DOI 10.1113/jphysiol.1993.sp019476; BRUBACHER G, 1974, CLIN BIOCH PRINCIPLE, V2, P989; CALCUTT NA, 1994, EUR J PHARMACOL, V251, P27, DOI 10.1016/0014-2999(94)90439-1; Calcutt NA, 1998, METABOLISM, V47, P650, DOI 10.1016/S0026-0495(98)90025-7; CAMERON NE, 1992, EXP PHYSIOL, V77, P89, DOI 10.1113/expphysiol.1992.sp003585; Cameron NE, 1996, J DIABETES COMPLICAT, V10, P43, DOI 10.1016/1056-8727(94)00076-X; Cameron NE, 1999, DIABETOLOGIA, V42, P1120, DOI 10.1007/s001250051280; CAMERON NE, 1994, DIABETOLOGIA, V37, P651, DOI 10.1007/s001250050160; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; Cameron NE, 1997, DIABETOLOGIA, V40, P271, DOI 10.1007/s001250050674; CAMERON NE, 1986, DIABETOLOGIA, V29, P168, DOI 10.1007/BF02427088; Cameron NE, 1996, METABOLISM, V45, P1147, DOI 10.1016/S0026-0495(96)90015-3; COTTER M, 1989, Q J EXP PHYSIOL CMS, V74, P65, DOI 10.1113/expphysiol.1989.sp003240; Cotter MA, 1998, J PERIPHER NERV SYST, V3, P217; Dewhurst M, 1997, BRIT J PHARMACOL, V120, P593, DOI 10.1038/sj.bjp.0700946; DIEMEL LT, 1992, NEUROSCI LETT, V137, P253, DOI 10.1016/0304-3940(92)90416-5; Erdelmeier I, 1998, CHEM RES TOXICOL, V11, P1184, DOI 10.1021/tx970180z; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Greene DA, 1999, NEUROLOGY, V53, P580, DOI 10.1212/WNL.53.3.580; GUPTA S, 2001, IN PRESS AM J PHYSL; Heesom AE, 1998, J NEUROL NEUROSUR PS, V64, P213, DOI 10.1136/jnnp.64.2.213; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HO ECM, 2000, J PERIPHER NERV SYST, V5, P169; Hohman T. C., 1997, Diabetologia, V40, pA549; Hotta N, 1996, DIABETES, V45, P361, DOI 10.2337/diabetes.45.3.361; Hotta N, 1996, J PHARMACOL EXP THER, V276, P49; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Ido Y, 1996, DIABETOLOGIA, V39, P943; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Ishii H, 1998, DIABETOLOGIA, V41, P362, DOI 10.1007/s001250050916; Ito M, 1998, EUR J PHARMACOL, V354, P189, DOI 10.1016/S0014-2999(98)00448-8; Ito T, 1997, DIABETES RES CLIN PR, V36, P161, DOI 10.1016/S0168-8227(97)00046-6; Kalichman MW, 1998, BRAIN RES, V810, P130, DOI 10.1016/S0006-8993(98)00898-1; Kalichman MW, 1998, ACTA NEUROPATHOL, V95, P47, DOI 10.1007/s004010050764; KAMIJO M, 1994, DIABETES RES CLIN PR, V25, P117, DOI 10.1016/0168-8227(94)90037-X; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; Kato N, 2000, DIABETES RES CLIN PR, V50, P77, DOI 10.1016/S0168-8227(00)00164-9; KIHARA M, 1994, AM J PHYSIOL, V266, pE980, DOI 10.1152/ajpendo.1994.266.6.E980; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; Kilic F, 1999, EXP EYE RES, V69, P291, DOI 10.1006/exer.1999.0697; KIM J, 1991, DIABETES, V40, P1545, DOI 10.2337/diabetes.40.11.1545; Kishi Y, 1999, DIABETES, V48, P2045, DOI 10.2337/diabetes.48.10.2045; Kurata C, 1997, J NUCL MED, V38, P1677; Kuruvilla R, 1998, J NEUROCHEM, V71, P775; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Love A, 1996, EUR J CLIN INVEST, V26, P698, DOI 10.1111/j.1365-2362.1996.tb02156.x; LOW PA, 1988, EXP NEUROL, V99, P201, DOI 10.1016/0014-4886(88)90139-2; LOW PA, 1985, AM J PHYSIOL, V248, pE457, DOI 10.1152/ajpendo.1985.248.4.E457; LOWITT S, 1995, METABOLISM, V44, P677, DOI 10.1016/0026-0495(95)90128-0; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCMANIS PG, 1986, AM J PHYSIOL, V251, pE92, DOI 10.1152/ajpendo.1986.251.1.E92; Mizisin AP, 1997, DIABETES, V46, P647, DOI 10.2337/diabetes.46.4.647; Mizuno K, 1999, J DIABETES COMPLICAT, V13, P141, DOI 10.1016/S1056-8727(99)00038-0; MIZUNO K, 1992, METABOLISM, V41, P1081, DOI 10.1016/0026-0495(92)90289-M; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; NUKADA H, 1992, J NEUROPATH EXP NEUR, V51, P523, DOI 10.1097/00005072-199209000-00007; Oates, 1999, Expert Opin Investig Drugs, V8, P2095, DOI 10.1517/13543784.8.12.2095; Obrosova I, 1998, DIABETOLOGIA, V41, P1442, DOI 10.1007/s001250051090; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 1999, DIABETOLOGIA, V42, P1187, DOI 10.1007/s001250051290; Obrosova IG, 2000, OXIDAT STRESS DIS, V4, P93; Obrosova IG, 2000, FASEB J, V14, P1548, DOI 10.1096/fj.14.11.1548; Obrosova IG, 2000, DIABETOLOGIA, V43, P1048, DOI 10.1007/s001250051488; Ohi T, 1998, EXP NEUROL, V151, P215, DOI 10.1006/exnr.1998.6821; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; Patel J, 1999, MUSCLE NERVE, V22, P1403, DOI 10.1002/(SICI)1097-4598(199910)22:10<1403::AID-MUS10>3.0.CO;2-Z; Pfeifer MA, 1997, DIABETES, V46, pS82, DOI 10.2337/diab.46.2.S82; Pop-Busui R, 2001, EXP NEUROL, V168, P259, DOI 10.1006/exnr.2000.7591; Raccah D, 1998, J DIABETES COMPLICAT, V12, P154, DOI 10.1016/S1056-8727(97)00093-7; Ryle C, 1997, MUSCLE NERVE, V20, P577, DOI 10.1002/(SICI)1097-4598(199705)20:5<577::AID-MUS6>3.0.CO;2-6; Sagara M, 1996, DIABETOLOGIA, V39, P263; Sasaki H, 1997, ACTA NEUROPATHOL, V93, P118, DOI 10.1007/s004010050592; SCHMIDT RE, 1989, DIABETES, V38, P569, DOI 10.2337/diabetes.38.5.569; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; SREDY J, 1991, P SOC EXP BIOL MED, V197, P135; STEVENS EJ, 1994, J PHYSIOL-LONDON, V475P, pP68; STEVENS MJ, 1993, DIABETOLOGIA, V36, P608, DOI 10.1007/BF00404069; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; TOMLINSON DR, 1984, DIABETES, V33, P470, DOI 10.2337/diabetes.33.5.470; TOMLINSON DR, 1982, NEUROSCI LETT, V31, P189, DOI 10.1016/0304-3940(82)90115-X; Tomlinson DR, 1998, DIABETIC MED, V15, P579, DOI 10.1002/(SICI)1096-9136(199807)15:7<579::AID-DIA633>3.3.CO;2-X; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; van Dam PS, 1999, EUR J PHARMACOL, V376, P217, DOI 10.1016/S0014-2999(99)00376-3; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Vinik Aaron I., 1999, American Journal of Medicine, V107, p17S; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Yagihashi S, 1996, DIABETES, V45, P56, DOI 10.2337/diabetes.45.1.56; YAN SD, 1994, J BIOL CHEM, V269, P9889; YASUDA H, 1989, DIABETES, V38, P832, DOI 10.2337/diabetes.38.7.832; YIM HS, 1995, J BIOL CHEM, V270, P28228; ZATECHKA DS, 2000, EXP EYE RES, V71, pS42; ZHANG WX, 1990, DIABETES, V39, P613, DOI 10.2337/diabetes.39.5.613; ZOLLMAN PJ, 1991, EXP NEUROL, V114, P315, DOI 10.1016/0014-4886(91)90157-8	103	165	175	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					123	+		10.1096/fj.01-0603fje	http://dx.doi.org/10.1096/fj.01-0603fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709499	Green Submitted			2022-12-25	WOS:000172420500032
J	Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F				Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F			The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes	ONCOGENE			English	Article						fibroblast growth factor binding protein; HPV16; E6 oncogene; E7 oncogene; promoter	FIBROBLAST GROWTH-FACTOR; K14-HPV16 TRANSGENIC MICE; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BINDING PROTEIN; TYPE-16 E6; HISTONE DEACETYLASE; TELOMERASE ACTIVITY; E7 ONCOPROTEIN; WILD-TYPE; P53	Fibroblast growth, factor binding protein (FGF-BP) is a secreted protein that binds, FGF-1 and FGF-2 and is involved in mobilization and activation of FGFs from the extracellular matrix. FGF-BP overexpression as, well as ribozyme-mediated reduction of endogenous FGF-BP revealed that FGF-BP can be rate-limiting for tumor growth and angiogenesis. Recent studies showed that FGF-BP expression is up-regulated during early phases of tumorigenesis, indicating that the role of FGF-BP in angiogenesis is a critical early step in the development and progression of tumors.. Human papillomavirus type, 16 (HPV 16) is highly associated with the development of anogenital cancers. Here we demonstrate that the stable expression of the E6 oncogene of HPV 16 leads to an activation of the FGF-BP promoter in primary human foreskin keratinocytes (one of the natural host cells of these viruses). This is associated with, an increase in the steady state levels, of FGF-BP mRNA and FGF-BP protein in cells stably expressing E6. Transient E6 expression revealed that the observed activation of the FGF-BP promoter by the viral oncogene is, an early process which is. independent from immortalization/transformation, events in the cells.	Univ Marburg, Dept Pharmacol, D-35033 Marburg, Germany	Philipps University Marburg	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.	czubayko@mailer.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Arbeit JM, 1996, ONCOGENE, V13, P1847; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Harris VK, 2000, J BIOL CHEM, V275, P39801; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Nair P, 1999, PATHOL RES PRACT, V195, P163, DOI 10.1016/S0344-0338(99)80029-6; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Shino Y, 1997, J VIROL, V71, P4310, DOI 10.1128/JVI.71.6.4310-4318.1997; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	53	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7430	7436		10.1038/sj.onc.1204957	http://dx.doi.org/10.1038/sj.onc.1204957			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704874				2022-12-25	WOS:000171894200017
J	Powell, RM; Parkhurst, KM; Parkhurst, LJ				Powell, RM; Parkhurst, KM; Parkhurst, LJ			Comparison of TATA-binding protein recognition of a variant and consensus DNA promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; EUKARYOTIC TRANSCRIPTION; CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; YEAST; TBP; ELEMENT; OLIGONUCLEOTIDE; KINETICS	Assembly of transcription pre-initiation complexes proceeds from the initial complex formed between "TATA" bearing promoter DNA and the TATA-binding protein (TBP). Our laboratory has been investigating the relationships among TATA sequence, TBR.TATA solution structure, recognition mechanisms, and transcription efficiency. TBR.TATA interactions have been modeled by global analysis of detailed kinetic and thermodynamic data obtained using fluorimetric and fluorometric techniques in conjunction with fluorescence resonance energy transfer. We have reported recently that TBP recognition of two consensus promoters, adenovirus major late (AdMLP: TATAAAAG) and E4 (TATATATA), is well described by a linear two-intermediate mechanism with simultaneous DNA binding and bending. Similar DNA geometries and high transcription efficiencies characterize these TBP.TATA complexes. Here we show that, in contrast to the consensus sequences, TBP recognition of a variant sequence (C7: TATAAACG) is described by a three-step model with two branching pathways. One pathway proceeds. through an intermediate having severely bent DNA, reminiscent of the consensus interactions, with the other branch yielding a unique conformer with shallowly bent DNA. The resulting TBP.C7 complex has a dramatically different solution conformation than for TBR.DNA(CONSENSUS) and is correlated with diminished relative transcription activity. The temperature dependence of the TBP.C7 helical bend is postulated to derive from population shifts between the conformers with slightly and severely bent DNA.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Parkhurst, LJ (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.				NCI NIH HHS [CA76049] Funding Source: Medline; NIGMS NIH HHS [GM59346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHEUNG HC, 1991, TOPICS FLUORESCENCE, P157; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; Cox JM, 1997, P NATL ACAD SCI USA, V94, P13475, DOI 10.1073/pnas.94.25.13475; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; de Souza ON, 1998, BIOPOLYMERS, V46, P403; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; Liu YC, 2001, BIOCHEMISTRY-US, V40, P6257, DOI 10.1021/bi0019794; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Pardo L, 1998, BIOPHYS J, V75, P2411, DOI 10.1016/S0006-3495(98)77685-4; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; PARKHURST LJ, 1994, P SOC PHOTO-OPT INS, V2137, P475, DOI 10.1117/12.182758; Pastor N, 1997, BIOPHYS J, V73, P640, DOI 10.1016/S0006-3495(97)78099-8; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; Powell RM, 2001, J BIOL CHEM, V276, P29782, DOI 10.1074/jbc.M104099200; Qian XL, 2001, J MOL BIOL, V308, P681, DOI 10.1006/jmbi.2001.4617; STARR DB, 1995, J MOL BIOL, V250, P434; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	46	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7776	7784		10.1074/jbc.M110147200	http://dx.doi.org/10.1074/jbc.M110147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11726667	hybrid			2022-12-25	WOS:000174268000021
J	Miserey-Lenkei, S; Parnot, C; Bardin, S; Corvol, P; Clauser, E				Miserey-Lenkei, S; Parnot, C; Bardin, S; Corvol, P; Clauser, E			Constitutive internalization of constitutively active angiotensin II AT(1A) receptor mutants is blocked by inverse agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INDUCED UP-REGULATION; RAT AT(1A); LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; INTRACELLULAR TRAFFICKING; INDUCED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL	As constitutively active mutants (CAMs) mimic an active conformation, they can be used to characterize the process of G protein-coupled receptor activation. Here, we used CAMs to study the link between activation and internalization of the angiotensin II AT(1A) receptor. The cellular localization of fluorescently tagged N111A, I245T, and L305Q mutants was determined by confocal microscopy. In the absence of ligand, CAMs were mostly located in intracellular vesicles, whereas the wild-type AT(1A) was found at the cell surface. After 2 h incubation with inverse agonist, losartan, CAMs were translocated to the plasma membrane. Similar observations were made in H295, a human adrenocortical cell line which expresses physiologically the AT(1) receptor. This phenomenon, which was not dependent on protein synthesis and the pharmacology and kinetics of which were similar to the recycling of the wild-type receptor, was called "externalization". After externalization and losartan removal, the L305Q CAM underwent rapid ligand-independent endocytocis, with the same kinetics and temperature sensitivity as the angiotensin II-induced internalization of the wild-type AT(1A) Moreover, the addition of a second mutation known to block internalization (Delta329 truncation) prevented intracellular localization of the CAM. These data show that AT(1A) CAMs are constitutively and permanently internalized and recycled. This mechanism is different from the down-regulation observed for CAMs of other G protein-coupled receptors and thus defines a new paradigm for the cellular regulation of CAMs.	Inst Cochin, Fac Med Cochin, INSERM EPI 0103, ICGM, F-75014 Paris, France; Coll France, INSERM U36, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Clauser, E (corresponding author), Inst Cochin, Fac Med Cochin, INSERM EPI 0103, ICGM, Port Royal,24 Rue Fg St Jacques, F-75014 Paris, France.	clauser@cochin.inserm.fr		Parnot, Charles/0000-0002-7346-5883				Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHAKI S, 1994, KIDNEY INT, V46, P1492, DOI 10.1038/ki.1994.427; CONCHON S, 1994, BIOCHEM BIOPH RES CO, V199, P1347, DOI 10.1006/bbrc.1994.1379; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; GAZDAR AF, 1990, CANCER RES, V50, P5488; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Lee TW, 1997, BIOCHEM J, V325, P733, DOI 10.1042/bj3250733; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; MacEwan DJ, 1996, FEBS LETT, V399, P108, DOI 10.1016/S0014-5793(96)01300-2; MacEwan DJ, 1996, MOL PHARMACOL, V50, P1479; McCune DF, 2000, MOL PHARMACOL, V57, P659, DOI 10.1124/mol.57.4.659; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Min KS, 1998, J BIOL CHEM, V273, P34911, DOI 10.1074/jbc.273.52.34911; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Miserey-Lenkei S, 2001, MOL ENDOCRINOL, V15, P294, DOI 10.1210/me.15.2.294; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; Segredo V, 1997, J NEUROCHEM, V68, P2395; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Stevens PA, 2000, MOL PHARMACOL, V58, P438, DOI 10.1124/mol.58.2.438; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	55	57	59	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5891	5901		10.1074/jbc.M108398200	http://dx.doi.org/10.1074/jbc.M108398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11729186	hybrid			2022-12-25	WOS:000173989200027
J	Elsner, P; Quistorff, B; Hansen, GH; Grunnet, N				Elsner, P; Quistorff, B; Hansen, GH; Grunnet, N			Partly ordered synthesis and degradation of glycogen in cultured rat myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE GLYCOGEN; PROTEIN PHOSPHATASE-1; TARGETING SUBUNIT; PROGLYCOGEN; METABOLISM; ACTIVATION; SYNTHASE	The following questions concerning glycogen synthesis and degradation were examined in cultured rat myotubes. 1) Is synthesis and degradation of the individual glycogen molecule a strictly ordered process, with the last glucosyl unit incorporated into the molecule being the first to be released (the last-in-first-out principle), or is it a random process? 2) Are all glycogen molecules in skeletal muscle synthesized and degraded in phase (simultaneous order) or out of phase (sequential order)? Basal glycogen stores were minimized by fasting and were subsequently replenished in two intervals, the first (0-0.5 h) with tritium-labeled and the second (0.5-3 h) with carbon-labeled glucose as precursor. Glycogen degradation was initiated by addition of forskolin. The kinetics of glycogen accumulation as well as degradation could be approximated by monoexponential equations with rate constants of 0.81 and 1.39 h(-1), respectively. The degradation of glycogen largely followed the last-in-first-out principle, particularly in the initial period. Analysis of the size of the glycogen molecules and the beta-dextrin limit during glycogen accumulation and degradation showed that both synthesis and degradation of glycogen molecules are largely sequential and the small deviation from this order is most pronounced at the beginning of the accumulation and at the end of the degradation period. This pattern may reflect the number of synthase and phosphorylase molecules and fits well with the role of glycogen in skeletal muscle as a readily available energy store and with the known structure of the glycogen molecule. It is emphasized that the observed nonlinear relation between the change in glycogen concentration and release of label during glycogen degradation may have important practical consequences for interpretation of experimental data.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Elsner, P (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	elsner@imbg.ku.dk						ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Baque S, 1996, J BIOL CHEM, V271, P2594, DOI 10.1074/jbc.271.5.2594; DANIELS MP, 1990, J CELL SCI, V97, P615; DEVLIN TM, 1997, TXB BIOCH, P312; DEVOS P, 1979, EUR J BIOCHEM, V99, P161, DOI 10.1111/j.1432-1033.1979.tb13242.x; DEVOS P, 1980, BIOCHEM BIOPH RES CO, V95, P1031, DOI 10.1016/0006-291X(80)91576-4; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; FUNANAGE VL, 1992, J CELL PHYSIOL, V150, P251, DOI 10.1002/jcp.1041500205; GOLDSMITH E, 1982, J MOL BIOL, V156, P411, DOI 10.1016/0022-2836(82)90336-9; Katz J, 1976, Curr Top Cell Regul, V10, P237; KUHL U, 1982, DEV BIOL, V93, P344, DOI 10.1016/0012-1606(82)90122-1; Lerin C, 2000, J BIOL CHEM, V275, P39991, DOI 10.1074/jbc.M006251200; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1993, FASEB J, V7, P1386, DOI 10.1096/fasebj.7.14.8224611; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERS DJ, 1957, ADV CARBOHYD CHEM, V12, P261; Melendez R, 1997, J MOL EVOL, V45, P446, DOI 10.1007/PL00006249; MENLENDEZHEVIA E, 1993, BIOCHEM J, V295, P477; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Shulman RG, 2001, ANNU REV PHYSIOL, V63, P15, DOI 10.1146/annurev.physiol.63.1.15; Suarez RK, 1997, P NATL ACAD SCI USA, V94, P7065, DOI 10.1073/pnas.94.13.7065; TURO KA, 1982, AM J PHYSIOL, V243, pC278, DOI 10.1152/ajpcell.1982.243.5.C278	24	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4831	4838		10.1074/jbc.M108226200	http://dx.doi.org/10.1074/jbc.M108226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724782	hybrid			2022-12-25	WOS:000173962900038
J	Mach, CM; Hargrove, BW; Kunkel, GR				Mach, CM; Hargrove, BW; Kunkel, GR			The small RNA gene activator protein, SphI postoctamer homology-binding factor/selenocysteine tRNA gene transcription activating factor, stimulates transcription of the human interferon regulatory factor-3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; POLYMERASE-III PROMOTER; MOLECULAR-CLONING; DISTAL REGION; TATA BOX; U6; ELEMENTS; STAF; ENHANCER; COMPLEX	Many small nuclear RNA gene promoters are activated by SphI postoctamer homology (SPH)-binding factor/selenocysteine tRNA gene transcription activating factor (SBF/Staf). Whereas this transcription factor was initially identified by its ability to bind to SPH elements in such promoters, it was more recently shown to have the capacity to activate transcription of a synthetic mRNA gene promoter through a distinct activation domain. Here, we show that the human interferon regulatory factor-3 (IRF-3) gene promoter contains a functional SPH element that is bound by SBF/Staf in vitro and in transfected cells.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Kunkel, GR (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.			Kunkel, Gary/0000-0002-4199-369X				Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; GOOMER RS, 1992, NUCLEIC ACIDS RES, V20, P4903, DOI 10.1093/nar/20.18.4903; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Kunkel GR, 1998, NUCLEIC ACIDS RES, V26, P1536, DOI 10.1093/nar/26.6.1536; Kunkel GR, 1996, GENE EXPRESSION, V6, P59; KUNKEL GR, 1992, J BIOL CHEM, V267, P14250; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; ROEBUCK KA, 1987, MOL CELL BIOL, V7, P4185, DOI 10.1128/MCB.7.12.4185; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schaub M, 1999, J BIOL CHEM, V274, P24241, DOI 10.1074/jbc.274.34.24241; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; YOON JB, 1995, MOL CELL BIOL, V15, P2019; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	38	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4853	4858		10.1074/jbc.M108308200	http://dx.doi.org/10.1074/jbc.M108308200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724783	hybrid			2022-12-25	WOS:000173962900041
J	Ludford-Menting, MJ; Thomas, SJ; Crimeen, B; Harris, LJ; Loveland, BE; Bills, M; Ellis, S; Russell, SM				Ludford-Menting, MJ; Thomas, SJ; Crimeen, B; Harris, LJ; Loveland, BE; Bills, M; Ellis, S; Russell, SM			A functional interaction between CD46 and DLG4 - A role for DLG4 in epithelial polarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; LARGE TUMOR-SUPPRESSOR; MEASLES-VIRUS INFECTION; NITRIC-OXIDE PRODUCTION; DARBY CANINE KIDNEY; PDZ DOMAINS; RECEPTOR ACTIVATION; MOUSE MACROPHAGES; CELLULAR RECEPTOR; HUMAN HOMOLOG	Using a yeast two-hybrid screen, we identified a physical interaction between CD46 and DLG4. CD46 is, a ubiquitous human cell-surface receptor for the complement components C3b and C4b and for measles virus and human herpesvirus 6. DLG4 is a scaffold protein important for neuronal signaling and is homologous to the Drosophila tumor suppressor DLG. We show that an interaction between CD46 and DLG4 is important for polarization in epithelial cells. Specifically we show W biochemical evidence for an interaction between CD46 and DLG4, (ii) that this interaction is specific for the Cyt1 (but not Cyt2) domain of CD46, (iii) that both CD,16 and an alternatively spliced isoform of DLG4 are polarized in normal human epithelial cells, and (iv) that the polarized expression of CD46 in epithelial cells requires the DLG4-binding domain and alters with expression of a truncated form of DLG4. This is the first identification of a direct and cytoplasmic domain-specific interaction between CD46 and an intracellular signaling molecule and provides a molecular mechanism for the polarization of CD46. These data also indicate that, in addition to the known role for DLG4 in neuronal cells, DLG4 may be important for polarization in epithelial cells.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Austin Res Inst, Heidelberg, Vic 3084, Australia	Peter Maccallum Cancer Center; Austin Research Institute	Russell, SM (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.	s.russell@pmci.unimelb.edu.au	Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641; Ellis, Sarah/0000-0002-5772-6051				Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hirano A, 1999, J VIROL, V73, P4776, DOI 10.1128/JVI.73.6.4776-4785.1999; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Imani F, 1999, J IMMUNOL, V162, P1597; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; James P, 1996, GENETICS, V144, P1425; JOHNSTONE RW, 1993, MOL IMMUNOL, V30, P1231, DOI 10.1016/0161-5890(93)90038-D; JONES TA, 1994, O MANUAL; Karp CL, 1999, IMMUNOL REV, V168, P91, DOI 10.1111/j.1600-065X.1999.tb01285.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Katayama Y, 2000, J VIROL, V74, P1252, DOI 10.1128/JVI.74.3.1252-1257.2000; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kurita-Taniguchi M, 2000, J IMMUNOL, V165, P5143, DOI 10.4049/jimmunol.165.9.5143; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; Manchester M, 2000, J VIROL, V74, P3967, DOI 10.1128/JVI.74.9.3967-3974.2000; Marie JC, 2001, IMMUNITY, V14, P69, DOI 10.1016/S1074-7613(01)00090-5; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; SCHEIDERSCHAULI.S, 1999, ARCH VIROL         S, V15, P139; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Stathakis DG, 1999, J NEUROCHEM, V73, P2250, DOI 10.1046/j.1471-4159.1999.0732250.x; Stathakis DG, 1997, GENOMICS, V44, P71, DOI 10.1006/geno.1997.4848; Teuchert M, 1999, J BIOL CHEM, V274, P19979, DOI 10.1074/jbc.274.28.19979; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thorley BR, 1997, EUR J IMMUNOL, V27, P726, DOI 10.1002/eji.1830270322; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Wang GX, 2000, J IMMUNOL, V164, P1839, DOI 10.4049/jimmunol.164.4.1839; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740	55	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4477	4484		10.1074/jbc.M108479200	http://dx.doi.org/10.1074/jbc.M108479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11714708	Green Published, hybrid			2022-12-25	WOS:000173813900090
J	Roje, S; Chan, SY; Kaplan, F; Raymond, RK; Horne, DW; Appling, DR; Hanson, AD				Roje, S; Chan, SY; Kaplan, F; Raymond, RK; Horne, DW; Appling, DR; Hanson, AD			Metabolic engineering in yeast demonstrates that S-adenosylmethionine controls flux through the methylenetetrahydrofolate reductase reaction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLIC-ACID DERIVATIVES; C-13 NMR ANALYSIS; ONE-CARBON POOLS; RED-BLOOD-CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; METHYLTETRAHYDROFOLATE; PURIFICATION; INHIBITION	One-carbon flux into methionine and S-adenosylmethionine (AdoMet) is thought to be controlled at the methylenetetrahydrofolate reductase (MTHFR) step. Mammalian MTHFRs are inhibited by AdoMet in vitro, and it has been proposed that methyl group biogenesis is regulated in vivo by this feedback loop. In this work, we used metabolic engineering in the yeast Saccharomyces cerevisiae to test this hypothesis. Like mammalian MTHFRs, the yeast MTHFR encoded by the MET13 gene is NADPH-dependent and is inhibited by AdoMet in vitro. This contrasts with plantMTHFRs, which areNADH-dependent and AdoMet-insensitive. To manipulate flux through the MTHFR reaction in yeast, the chromosomal copy of MET13 was replaced by an Arabidopsis MTHFR cDNA (AtMTHFR-1) or by a chimeric sequence (Chimera-1) comprising the yeast N-terminal domain and the AtMTHFR-1 C-terminal domain. Chimera-1 used both NADH and NADPH and was insensitive to AdoMet, supporting the view that the C-terminal domain is responsible for AdoMet inhibition. Engineered yeast expressing Chimera-1 accumulated 140-fold more AdoMet and 7-fold more methionine than did the wild-type and grew normally. Yeast expressing AtMTHFR-l accumulated 8-fold more AdoMet. This is the first in vivo evidence that the AdoMet sensitivity and pyridine nucleotide preference of MTHFR control methylneogenesis. C-13 labeling data indicated that glycine cleavage becomes a more prominent source of one-carbon units when Chimera-1 is expressed. Possibly related to this shift in one-carbon fluxes, total folate levels are doubled in yeast cells expressing Chimera-1.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Texas, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Vet Affairs Med Ctr, Nashville, TN 37212 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Austin; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.		Kaplan, Fatma/AAJ-7666-2020	Kaplan, Fatma/0000-0002-9565-0211; Roje, Sanja/0000-0002-6302-5382	NIDDK NIH HHS [DK32189, DK26657] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032189, P30DK026657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Appling DR, 1997, METHOD ENZYMOL, V281, P218; Bagley PJ, 1998, P NATL ACAD SCI USA, V95, P13217, DOI 10.1073/pnas.95.22.13217; CLELAND WW, 1971, ENZYMES, V2, P35; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GREEN JM, 1988, FASEB J, V2, P42, DOI 10.1096/fasebj.2.1.3335280; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; HORNE DW, 1988, CLIN CHEM, V34, P2357; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; KATZEN HM, 1965, J BIOL CHEM, V240, P825; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; MATTHEWS RG, 1980, J BIOL CHEM, V255, P6014; MATTHEWS RG, 1984, J BIOL CHEM, V259, P1647; Matthews RG, 1998, EUR J PEDIATR, V157, pS54, DOI 10.1007/PL00014305; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; Murakami Y, 1996, BIOSCI BIOTECH BIOCH, V60, P1874, DOI 10.1271/bbb.60.1874; Pasternack LB, 1996, ARCH BIOCHEM BIOPHYS, V326, P158, DOI 10.1006/abbi.1996.0060; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Ranocha P, 2001, PLANT J, V25, P575, DOI 10.1046/j.1365-313x.2001.00988.x; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; SAINTGIRONS I, 1983, NUCLEIC ACIDS RES, V11, P6723, DOI 10.1093/nar/11.19.6723; SCHLENK F, 1965, TRANSMETHYLATION MET, P48; Sheppard CA, 1999, J BACTERIOL, V181, P718, DOI 10.1128/JB.181.3.718-725.1999; SUMNER J, 1986, J BIOL CHEM, V261, P7697; VANONI MA, 1984, BIOCHEMISTRY-US, V23, P5272, DOI 10.1021/bi00317a027; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WILSON SD, 1984, ANAL BIOCHEM, V142, P529, DOI 10.1016/0003-2697(84)90502-5; Wise CK, 1997, J CHROMATOGR B, V696, P145, DOI 10.1016/S0378-4347(97)00213-2; WOHLFARTH G, 1991, ARCH MICROBIOL, V155, P378	33	36	42	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4056	4061		10.1074/jbc.M110651200	http://dx.doi.org/10.1074/jbc.M110651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11729203	hybrid			2022-12-25	WOS:000173813900036
J	Worgall, TS; Johnson, RA; Seo, T; Gierens, H; Deckelbaum, RJ				Worgall, TS; Johnson, RA; Seo, T; Gierens, H; Deckelbaum, RJ			Unsaturated fatty acid-mediated decreases in sterol regulatory element-mediated gene transcription are linked to cellular sphingolipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE SPHINGOMYELIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; BINDING PROTEINS; NEUTRAL SPHINGOMYELINASE; CHOLESTEROL POOLS; MOUSE-LIVER; PROTEOLYSIS; APOPTOSIS	A major physiological feedback mechanism of cholesterol in transcription of a number of lipid metabolism-related genes is mediated by sterol regulatory elements (SREs) and their binding proteins (SREBPs). Polyunsaturated free fatty acids alone, as well as synergistically with sterols, decrease SRE-mediated gene expression up to 80% in a dose-dependent manner by decreasing levels of the active transcription factor SREBP. We investigated potential mechanisms for this effect. We hypothesized that free fatty acids reduce SREBP-mediated gene transcription by increasing intracellular cholesterol content through the hydrolysis of cellular sphingomyelin, which has a high affinity for free cholesterol. We also questioned whether the lipid second messenger ceramide, a product of sphingomyelin hydrolysis, can decrease SRE-mediated gene transcription. First we investigated the effect of fatty acids on sphingomyelin hydrolysis. Incubation of [H-3]choline-labeled cells with unsaturated (but not saturated) fatty acids induced hydrolysis of [H-3]choline-labeled sphingomyelin. Also, incubation of cell extracts from fatty acid-treated cells with [H-3]sphingomyelin increased generation of [H-3]ceramide compared with control cells in vitro. We found that addition of ceramide analogs alone and additively with fatty acids decreased SIZE expression and that ceramide analogs reduced levels of the transcriptionally active forms of SREBP-1 and SREBP-2. Increasing intracellular ceramide levels by exogenous sphingomyelinase or inhibition of ceramidase decreased SRE-mediated gene expression. None of the above conditions induced apoptosis. Incubation with U18666A, a compound that inhibits intracellular cholesterol movement, increased SRE-mediated gene transcription. C-2-ceramide abrogated the effect of U18666A on SRE-mediated gene transcription, suggesting cholesterol-independent regulation of SREBP. We provide evidence that sphingomyelin hydrolysis and intermediates of sphingomyelin metabolism (in addition to cholesterol and fatty acids) contribute to regulation of SRE-mediated gene transcription.	Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA; Univ Freiburg, Dept Clin Chem, D-79106 Freiburg, Germany	Columbia University; Columbia University; University of Freiburg	Deckelbaum, RJ (corresponding author), Columbia Univ, Inst Human Nutr, 630 W 168th St PH 1512, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007715] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07343-22, HL40404] Funding Source: Medline; NIDDK NIH HHS [T32DK07715] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARENHOLZ Y, 1982, SPHINGOMYELIN METABO, V4, P29; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown RE, 1998, J CELL SCI, V111, P1; CARMICHAEL J, 1987, CANCER RES, V47, P936; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; GALLAHER WR, 1973, BIOCHEM BIOPH RES CO, V52, P1252, DOI 10.1016/0006-291X(73)90635-9; GALLAHER WR, 1975, ARCH BIOCHEM BIOPHYS, V168, P104, DOI 10.1016/0003-9861(75)90233-7; GUPTA AK, 1991, J LIPID RES, V32, P125; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1994, J BIOL CHEM, V269, P29371; Lange Y, 1999, J LIPID RES, V40, P2264; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Robinson BS, 1997, IMMUNOLOGY, V91, P274, DOI 10.1046/j.1365-2567.1997.d01-2227.x; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; Santana P, 1998, Methods Mol Biol, V105, P217; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Seo T, 2001, BIOCHEMISTRY-US, V40, P4756, DOI 10.1021/bi0022947; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; Sutterlin C, 1997, J CELL SCI, V110, P2703; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; TURNER JD, 1974, LIPIDS, V9, P49, DOI 10.1007/BF02533213; van Echten-Deckert G, 1997, J LIPID RES, V38, P2569; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200	54	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3878	3885		10.1074/jbc.M102393200	http://dx.doi.org/10.1074/jbc.M102393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11707431	hybrid			2022-12-25	WOS:000173813900013
J	Colavitti, R; Pani, G; Bedogni, B; Anzevino, R; Borrello, S; Waltenberger, J; Galeotti, T				Colavitti, R; Pani, G; Bedogni, B; Anzevino, R; Borrello, S; Waltenberger, J; Galeotti, T			Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE PHOSPHORYLATION; GENERATION; INHIBITION; ACTIVATION; HYPOXIA; VEGF; KDR; INACTIVATION; PROTECTION	Recent evidence shows the involvement of reactive oxygen species (ROS) in the mitogenic cascade initiated by the tyrosine kinase receptors of several growth factor peptides. We have asked whether also the vascular endothelial growth factor (VEGF) utilizes ROS as messenger intermediates downstream of the VEGF receptor-2 (VEGFR-2)/KDR receptor given that the proliferation of endothelial cells during neoangiogenesis is physiologically regulated by oxygen and likely by its derivative species. In porcine aortic endothelial cells stably expressing human KDR, receptor activation by VEGF is followed by a rapid increase in the intracellular generation of hydrogen peroxide as revealed by the peroxide-sensitive probe dichlorofluorescein diacetate. Genetic and pharmacological studies suggest that such oxidant burst requires as upstream events the activation of phosphatidylinositol 3-kinase and the small GTPase Rac-1 and is likely initiated by lipoxygenases. Interestingly, ROS generation in response to VEGF is not blocked but rather potentiated by endothelial nitric-oxide synthase inhibitors diphenyleneiodonium and N(G)methyl-L-arginine, ruling out the possibility of nitric oxide being the oxidant species here detected in VEGF-stimulated cells. Inhibition of KDR-dependent generation of ROS attenuates early signaling events including receptor autophosphorylation and binding to a phospholipase C-gamma-glutathione S-transferase fusion protein. Moreover, catalase, the lipoxygenase inhibitor nordihydroguaiaretic acid, the synthetic ROS scavenger EUK-134, and phosphatidylinositol 3-kinase inhibitor wortmannin all reduce ERK phosphorylation in response to VEGF, and antioxidants prevent VEGF-dependent mitogenesis. Finally, cell culture and stimulation in a nearly anoxic environment mimic the effect of ROS scavenger on receptor and ERK phosphorylation, reinforcing the idea that ROS are necessary components of the mitogenic signaling cascade initiated by KDR. These data identify ROS as a new class of intracellular angiogenic mediators and may represent a potential premise for new antioxidant-based antiangiogenic therapies.	Catholic Univ, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Ulm University	Galeotti, T (corresponding author), Catholic Univ, Sch Med, Inst Gen Pathol, Largo F Vito 1, I-00168 Rome, Italy.	Tgaleotti@rm.unicatt.it	Pani, Giovambattista/AAB-1446-2019; Waltenberger, Johannes/I-1813-2013	Pani, Giovambattista/0000-0001-7133-8728; Waltenberger, Johannes/0000-0002-2417-9880				AMELLEM O, 1991, CELL PROLIFERAT, V24, P127, DOI 10.1111/j.1365-2184.1991.tb01144.x; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Cai T, 1999, LAB INVEST, V79, P1151; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee C, 2000, J BIOL CHEM, V275, P38965, DOI 10.1074/jbc.M006341200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Ray PS, 2001, ANTIOXID REDOX SIGN, V3, P89, DOI 10.1089/152308601750100560; Rhee S.G., 2000, SCI STKE; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WANG YX, 1993, BRIT J PHARMACOL, V110, P1232, DOI 10.1111/j.1476-5381.1993.tb13947.x; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199	37	314	322	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3101	3108		10.1074/jbc.M107711200	http://dx.doi.org/10.1074/jbc.M107711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11719508	hybrid			2022-12-25	WOS:000173688000008
J	Kuwabara, I; Kuwabara, Y; Yang, RY; Schuler, M; Green, DR; Zuraw, BL; Hsu, DK; Liu, FT				Kuwabara, I; Kuwabara, Y; Yang, RY; Schuler, M; Green, DR; Zuraw, BL; Hsu, DK; Liu, FT			Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; RADIATION-INDUCED APOPTOSIS; THYMIC EPITHELIAL-CELLS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ENDOGENOUS LECTIN; T-CELLS; RYANODINE RECEPTOR; STRESS-RESPONSE	Galectin-7 is normally expressed in all types of stratified epithelia, but is significantly down-regulated in squamous cell carcinomas. This protein was recently found to be highly inducible by p53 in a colon carcinoma cell line, DLD-1, and designated as PIG1 (for (p) under bar 53-(i) under bar nduced gene (1) under bar). We studied transfectants of HeLa and DLD-1 cells ectopically expressing this protein and found that they were more susceptible to apoptosis than control transfectants. This was observed in apoptosis induced by mechanistically distinct stimuli, suggesting that galectin-7 acts on a common point in the apoptosis signaling pathways. Further analyses of actinomycin D-induced apoptosis demonstrated that galectin-7 expression causes enhanced caspase-3 activity and poly(ADPribose) polymerase cleavage, and the potentiation of apoptosis by galectin-7 was completely abrogated by a caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone. In addition, galectin-7 transfectants displayed accelerated mitochondrial cytochrome c release and up-regulated JNK activity upon apoptosis induction. Several lines of evidence indicate that the effect on apoptosis is not due to the lectin functioning extracellularly through interactions with cell surface glycoconjugates. In fact, this lectin is found to localize in nuclei and cytoplasm of the transfectants and the transformed keratinocyte line HaCaT. Therefore, galectin-7 is a pro-apoptotic protein that functions intracellularly upstream of JNK activation and cytochrome c release. DNA microarray analysis revealed genes that are differentially expressed between galectin-7 and control transfectants. Some of them are potentially contributory to this lectin's proapoptotic function and these include redox-related genes monoamine oxidase B, ryanodine receptor 2, and glutathione S-transferase Mu 3.	La Jolla Inst Allergy & Immunol, Div Allergy, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	La Jolla Institute for Immunology; La Jolla Institute for Immunology; Scripps Research Institute	Kuwabara, I (corresponding author), La Jolla Inst Allergy & Immunol, Div Allergy, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018; Liu, FU-TONG/A-5749-2019; Yang, Riyao/R-7593-2019	Green, Douglas R/0000-0002-7332-1417; Liu, FU-TONG/0000-0002-3354-1001; Yang, Riyao/0000-0002-0278-4385; Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [R01 AI-20958, AI-39620] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039620, R01AI020958] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akahani S, 1997, CANCER RES, V57, P5272; AKIMOTO Y, 1993, EXP CELL RES, V205, P251, DOI 10.1006/excr.1993.1084; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Chomez P, 2001, CANCER RES, V61, P5544; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ellerhorst J, 1999, INT J ONCOL, V14, P225; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; Hadari YR, 2000, J CELL SCI, V113, P2385; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARRISON FL, 1992, J CELL SCI, V101, P635; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Heibein JA, 1999, J IMMUNOL, V163, P4683; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Inohara H, 1996, CANCER RES, V56, P4530; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JENNER P, 1996, NEUROLOGY S3, V47, P161; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pace KE, 1999, J IMMUNOL, V163, P3801; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	80	168	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3487	3497		10.1074/jbc.M109360200	http://dx.doi.org/10.1074/jbc.M109360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11706006	hybrid			2022-12-25	WOS:000173688000058
J	Faubert, A; Samaan, A; Thibodeau, J				Faubert, A; Samaan, A; Thibodeau, J			Functional analysis of tryptophans alpha 62 and beta 120 on HLA-DM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; INVARIANT CHAIN; ANTIGEN PRESENTATION; DR MOLECULES; INTRACELLULAR-TRANSPORT; PEPTIDE BINDING; CONFORMATIONAL-CHANGES; STRUCTURAL FEATURES; CYTOPLASMIC TAIL; TARGETING SIGNAL	In the endocytic pathway of antigen-presenting cells, HLA-DM catalyzes the exchange between class IT-associated invariant chain peptide (CLIP) and antigenic peptides onto major histocompatibility complex class 11 molecules. At low pH of lysosomal compartments, both HLA-DM and HLA-DR undergo conformational changes, and it was recently postulated that two partially exposed tryptophans on HLA-DM might be involved in the interaction between the two molecules. To define contact regions on HLA-DM, we have conducted site-directed mutagenesis on those two hydrophobic residues. The HLA-DM alphaW62A,betaW120A (DMW62A/W120A) double mutant was expressed in HIA-DR+ HeLa cells expressing invariant chain, and the activity of this DM molecule was assessed. Flow cytometry analysis of cell surface DR-CLIP complexes revealed that DMW62A/WI20A removes CLIP as efficiently as its wild-type counterpart. DMW62A/W120A was found in the endocytic pathway by immunofluorescence, and DM-DR complexes were immunoprecipitated from these cells at pH 5. Finally, mutations alphaW62A and betaW120A on HLA-DM did not affect the association with HLA-DO. The complex egresses the endoplasmic reticulum and accumulates in endocytic vesicles. Moreover, DO and DMW62A/W120A were co-immunoprecipitated at pH 7. We conclude that the alpha62 and 13120 tryptophan residues are not required for the activity of DM, nor are they directly implicated in the interaction with DR or DO.	Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada; Hop St Louis, INSERM U462, F-75475 Paris, France	Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Thibodeau, J (corresponding author), Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.							Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Brunet A, 2000, J BIOL CHEM, V275, P37062, DOI 10.1074/jbc.M005112200; Busch R, 1998, J BIOL CHEM, V273, P27557, DOI 10.1074/jbc.273.42.27557; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Copier J, 1996, J IMMUNOL, V157, P1017; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Doebele RC, 2000, IMMUNITY, V13, P517, DOI 10.1016/S1074-7613(00)00051-0; Fremont DH, 1998, IMMUNITY, V9, P385, DOI 10.1016/S1074-7613(00)80621-4; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Guerra CB, 1998, J IMMUNOL, V160, P4289; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jensen PE, 1998, CURR BIOL, V8, pR128, DOI 10.1016/S0960-9822(98)70988-1; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; Kropshofer H, 1998, EMBO J, V17, P2971, DOI 10.1093/emboj/17.11.2971; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; Lavoie PM, 1997, P NATL ACAD SCI USA, V94, P6892, DOI 10.1073/pnas.94.13.6892; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MONJI T, 1994, J IMMUNOL, V153, P4468; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; Perraudeau M, 2000, EUR J IMMUNOL, V30, P2871, DOI 10.1002/1521-4141(200010)30:10<2871::AID-IMMU2871>3.0.CO;2-B; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; Thibodeau J, 1998, MOL IMMUNOL, V35, P885, DOI 10.1016/S0161-5890(98)00061-3; Ullrich HJ, 1997, P NATL ACAD SCI USA, V94, P13163, DOI 10.1073/pnas.94.24.13163; van Ham M, 2000, IMMUNOGENETICS, V51, P765, DOI 10.1007/s002510000208; van Ham M, 2000, J EXP MED, V191, P1127, DOI 10.1084/jem.191.7.1127; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x	46	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2750	2755		10.1074/jbc.M110300200	http://dx.doi.org/10.1074/jbc.M110300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11713260	hybrid			2022-12-25	WOS:000173421500050
J	Jaulin-Bastard, F; Arsanto, JP; Le Bivic, A; Navarro, C; Vely, F; Saito, H; Marchetto, S; Hatzfeld, M; Santoni, MJ; Birnbaum, D; Borg, JP				Jaulin-Bastard, F; Arsanto, JP; Le Bivic, A; Navarro, C; Vely, F; Saito, H; Marchetto, S; Hatzfeld, M; Santoni, MJ; Birnbaum, D; Borg, JP			Interaction between Erbin and a catenin-related protein in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN PROTEIN; CAENORHABDITIS-ELEGANS; ARMADILLO FAMILY; POLARITY; COMPLEX; LOCALIZATION; MEMBRANE; PSD-95; P0071; SCRIBBLE	Integrity of epithelial tissues relies on the proper apical-basolateral polarity of epithelial cells. Members of the LAP (LRR and PDZ) protein family such as LET-413 and Scribble are involved in maintaining epithelial cell polarity in Caenorhabditis elegans and Drosophila melanogaster, respectively. We previously described Erbin as a mammalian LET-413 homologue interacting with ERBB2/HER2, an epidermal growth factor receptor family member. Erbin and ERBB2/HER2 are located in the basolateral membranes of epithelial cells. We show here that Erbin interacts with p0071 (also called plakophilin-4), an armadillo repeat protein linked to the cytoskeleton. Erbin binds to p0071 in vitro and in vivo in a PDZ domain-dependent manner, and both proteins colocalized in desmosomes of epithelial cells. Using a dominant negative approach, we found that integrity of epithelial cell monolayer is impaired when interaction between Erbin and p0071 is disrupted. We propose that Erbin is connected by p0071 to cytoskeletal networks in an interaction crucial for epithelial homeostasis.	INSERM U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Fac Sci Luminy, LGPD, IBDM, F-13288 Marseille, France; Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille 09, France; Univ Halle Wittenberg, Mol Biol Grp, D-06097 Halle Saale, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Martin Luther University Halle Wittenberg	Borg, JP (corresponding author), INSERM U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Jaulin, Fanny/D-7152-2017; Vély, Frédéric/HHM-3894-2022; Borg, Jean-Paul/AAX-8096-2020	Jaulin, Fanny/0000-0002-5110-1800; Borg, Jean-Paul/0000-0001-8418-3382; Santoni, Marie-Josee/0000-0002-2619-7257; Vely, Frederic/0000-0002-1682-0949				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NAT CELL BIOL, V2, pE114, DOI 10.1038/35017119; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hildebrand JD, 1999, CELL, V99, P485, DOI 10.1016/S0092-8674(00)81537-8; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Hung TJ, 1999, DEVELOPMENT, V126, P127; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; McMahon L, 2001, J CELL SCI, V114, P2265; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Rosnet O, 1996, LEUKEMIA, V10, P238; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8	46	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2869	2875		10.1074/jbc.M109652200	http://dx.doi.org/10.1074/jbc.M109652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711544	hybrid			2022-12-25	WOS:000173421500066
J	Park, HS; Kim, MS; Huh, SH; Park, JH; Chung, JK; Kang, SS; Choi, EJ				Park, HS; Kim, MS; Huh, SH; Park, JH; Chung, JK; Kang, SS; Choi, EJ			Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; C-JUN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; CELL-SURVIVAL; ACTIVATION; JNK; PATHWAY; EXPRESSION	The protein serine-threonine kinase Akt mediates cell survival signaling initiated by various growth-promoting factors such as insulin. Here we report that SEK1 is a target of Akt in intact cells. Insulin inhibited the anisomycin-induced stimulation of both endogenous SEK1 and its substrate c-Jun N-terminal kinase (JNK), but not that of the upstream kinase MEKK1, in 293T cells. The inhibitory action of insulin on SEK1 or JNK1 activation was prevented by the phosphatidylinositol 3-kinase inhibitor LY294002. Expression of a constitutively active form of Akt also inhibited both SEK1 and JNK1 activation, but not that of MEKK1, in transfected 293T cells. Co-immunoprecipitation analysis revealed that endogenous Akt physically interacted with endogenous SEK1 in cells and that this interaction was promoted by insulin. In vitro and in vivo P-32 labeling indicated that Akt phosphorylated SEK1 on serine 78. The SEK1 mutant SEK1(S78A) was resistant to Akt-induced inhibition. Finally, activated Akt inhibited SEK1-mediated apoptosis, and this effect of Akt was prevented by overexpression of SEK(S78A). Taken together, these results suggest that Akt suppresses stress-activated signaling by targeting SEK1.	Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea; Chungbuk Natl Univ, Div Sci Educ, Chonju 361763, South Korea	Korea University; Korea Advanced Institute of Science & Technology (KAIST); Chungbuk National University	Choi, EJ (corresponding author), Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea.							Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Levresse V, 2000, J NEUROSCI RES, V62, P799; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; YAN MH, 1994, NATURE, V372, P798	32	118	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2573	2578		10.1074/jbc.M110299200	http://dx.doi.org/10.1074/jbc.M110299200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707464	hybrid			2022-12-25	WOS:000173421500027
J	Srivastava, A; Wang, JF; Majumder, R; Rezaie, AR; Stenflo, J; Esmon, CT; Lentz, BR				Srivastava, A; Wang, JF; Majumder, R; Rezaie, AR; Stenflo, J; Esmon, CT; Lentz, BR			Localization of phosphatidylserine binding sites to structural domains of factor X-a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION-FACTOR-XA; BOVINE FACTOR-X; MEMBRANE-BINDING; CALCIUM-BINDING; CA2+ BINDING; ACTIVE-SITE; FACTOR-VA; PROTHROMBINASE COMPLEX; PHOSPHOLIPID BINDING	Binding of short chain phosphatidylserine (C6PS) enhances the proteolytic activity of factor X-a by 60-fold (Koppaka, V., Wang, J., Banerjee, M., and Lentz, B. R. (1996) Biochemistry 35, 7482-7491). In the present study, we locate three C6PS binding sites to different domains of factor X-a using a combination of activity, circular dichroism, fluorescence, and equilibrium dialysis measurements on proteolytic and biosynthetic fragments of factor X-a. Our results demonstrate that the structural responses of human and bovine factor X. to C6PS binding are somewhat different. Despite this difference, data obtained with fragments from both human and bovine factor X-a are consistent with a common hypothesis for the location of C6PS binding sites to different structural domains. First, the gamma-carboxyglutamic acid (Gla) domain binds C6PS only in the absence of Ca2+ (k(d) similar to 1 mm), although this PS site does not influence the functional response of factor X-a. Second, a Ca2+-dependent binding site is in the epidermal growth factor domains (EGF(NC)) that are linked by Ca2+ and C6PS binding to the Gla domain. This site appears to be the lipid regulatory site of factor X-a. Third, a Ca2+-requiring site seems to be in the EGF(C)-catalytic domain. This site appears not to be a lipid regulatory site but rather to share residues with the substrate recognition site. Finally, the full functional response to C6PS requires linkage of the Gla, EGF(NC), and catalytic domains in the presence of Ca2+, meaning that PS regulation of factor X-a involves linkage between widely separated parts of the protein.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Lund Univ, Malmo Gen Hosp, Dept Clin Chem, S-21401 Malmo, Sweden; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Dept Biochem & Biophys & Pathol, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	University of North Carolina; University of North Carolina Chapel Hill; Lund University; Saint Louis University; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Lentz, BR (corresponding author), Univ N Carolina, Dept Biochem & Biophys, MEJB 7260, Chapel Hill, NC 27599 USA.	uncbrl@med.unc.edu	Majumder, Rinku/J-7512-2019	Lentz, Barry/0000-0001-9685-8690; majumder, Rinku/0000-0002-1727-7220	NHLBI NIH HHS [P01 HL54804, HL62565, HL45916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045916, P01HL054804, R01HL062565] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAHLBACK B, 1980, EUR J BIOCHEM, V104, P549, DOI 10.1111/j.1432-1033.1980.tb04458.x; Ellison EH, 1997, BIOPHYS J, V72, P2605, DOI 10.1016/S0006-3495(97)78904-5; FUJIMURA H, 1995, THROMB HAEMOSTASIS, V74, P1381; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HENRIKSEN RA, 1975, ARCH BIOCHEM BIOPHYS, V170, P149, DOI 10.1016/0003-9861(75)90106-X; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jesty J, 1976, Methods Enzymol, V45, P95; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kamata K, 1998, P NATL ACAD SCI USA, V95, P6630, DOI 10.1073/pnas.95.12.6630; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; LECOMPTE MF, 1980, BIOCHEMISTRY-US, V19, P3439, DOI 10.1021/bi00556a006; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; Mann K G, 1976, Methods Enzymol, V45, P123; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; MORITA T, 1986, J BIOL CHEM, V261, P4015; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NOSSEL HL, 1964, THROMB DIATH HAEMOST, V12, P505; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEARCE KH, 1993, J BIOL CHEM, V268, P22984; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1991, J BIOL CHEM, V266, P2453; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STENFLO J, 1991, BLOOD, V78, P1637; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; VALCARCE C, 1993, METHOD ENZYMOL, V222, P416; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; Vindigni A, 2000, PROTEIN SCI, V9, P619	47	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1855	1863		10.1074/jbc.M105697200	http://dx.doi.org/10.1074/jbc.M105697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11707438	hybrid			2022-12-25	WOS:000173421300032
J	Vostrov, AA; Taheny, MJ; Quitschke, WW				Vostrov, AA; Taheny, MJ; Quitschke, WW			A region to the N-terminal side of the CTCF zinc finger domain is essential for activating transcription from the amyloid precursor protein promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; ALZHEIMERS-DISEASE; FACTOR-BINDING; TRANSGENIC MICE; DOWNS-SYNDROME; MESSENGER-RNA; EXPRESSION; SEQUENCES; APP; DIFFERENTIATION	Transcription from the amyloid precursor protein (APP) promoter is largely dependent on a nuclear factor binding site designated as APBbeta. The protein that binds to this site is the multifunctional transcription factor CTCF, which consists of 727 amino acids and contains a domain of 11 zinc finger motifs that is flanked by 267 amino acids on the N-terminal side and 150 amino acids on the C-terminal side. Depleting HeLa cell nuclear extract of endogenous CTCF specifically reduced transcriptional activity from the APP promoter. However, transcriptional activity was restored by replenishing the depleted extract with recombinant CTCF. Deleting 201 amino acids from the C-terminal end of CTCF had no detrimental effect on transcriptional activation, whereas deleting either 248 or 284 amino acids from the N-terminal end abolished transcriptional activation. Competing endogenous CTCF in vivo was accomplished by cotransfecting COS-1 cells with a plasmid overexpressing CTCF constructs and a reporter plasmid containing the APP promoter. Under these conditions, an N-terminal deletion of CTCF reduced expression from the APP promoter, whereas the C-terminal deletion had no effect. These results demonstrate that CTCF activates transcription from the APP promoter and that the activation domain is located on the N-terminal side of the zinc finger domain.	SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quitschke, WW (corresponding author), SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30994] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; Delgado MD, 1999, FEBS LETT, V444, P5, DOI 10.1016/S0014-5793(99)00013-7; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fox NW, 1997, BIOCHEM BIOPH RES CO, V240, P759, DOI 10.1006/bbrc.1997.7728; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GU J, 1994, BIOTECHNIQUES, V17, P257; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001; KOHNE AC, 1993, J MOL BIOL, V232, P747, DOI 10.1006/jmbi.1993.1428; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MANN DMA, 1990, ACTA NEUROPATHOL, V80, P318, DOI 10.1007/BF00294651; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; Quitschke WW, 2000, NUCLEIC ACIDS RES, V28, P3370, DOI 10.1093/nar/28.17.3370; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; Quitschke WW, 1996, J BIOL CHEM, V271, P22231, DOI 10.1074/jbc.271.36.22231; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RICHARDS SJ, 1991, EMBO J, V10, P297, DOI 10.1002/j.1460-2075.1991.tb07950.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; Yang YX, 1999, J NEUROCHEM, V73, P2286, DOI 10.1046/j.1471-4159.1999.0732286.x	38	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1619	1627		10.1074/jbc.M109748200	http://dx.doi.org/10.1074/jbc.M109748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11706010	hybrid			2022-12-25	WOS:000173166800098
J	Besson, A; Davy, A; Robbins, SM; Yong, VW				Besson, A; Davy, A; Robbins, SM; Yong, VW			Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells	ONCOGENE			English	Article						ERK; MAPK; glioma; integrin; migration; PKC	PROTEIN-KINASE-C; IN-VITRO; PATHWAY UPSTREAM; GROWTH-FACTOR; INTEGRIN; INVASION; MOTILITY; TRANSDUCTION; INHIBITION; DOWNSTREAM	Protein kinase C (PKC) is. a family of serine/threonine kinases. involved in. the transduction of a variety of signals. There is increasing evidence to indicate that specific PKC isoforms are involved in the regulation of distinct cellular processes. In glioma, cells, PKC alpha was found to be a critical regulator of proliferation and cell cycle progression, white PKC epsilon was found to regulate adhesion and migration. Herein, we. report that specific PKC isoforms are able to differentially activate extracellular-signal regulated kinase (ERK)! in distinct cellular locations: while PKC alpha induces the activation of nuclear ERK, PKC epsilon induces, the activation of ERK at focal adhesions. Inhibition of the ERK pathway completely abolished the PKC-induced integrin-mediated adhesion and migration. Thus, we present the first evidence that PKC epsilon is able to, activate ERK at focal adhesions to mediate glioma cell adhesion and motility, providing a molecular mechanism to. explain the different biological functions of PKC alpha and epsilon in glioma cells.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Yong, VW (corresponding author), 3300 Hosp Dr NW,HMRB 191, Calgary, AB T2N 4N1, Canada.		Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943; Yong, V. Wee/0000-0002-2600-3563; Robbins, Stephen/0000-0001-7475-1665				Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; El-Obeid A, 1997, CANCER RES, V57, P5598; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Friedlander DR, 1996, CANCER RES, V56, P1939; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillespie GY, 1999, CANCER RES, V59, P2076; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Rigot V, 1998, J CELL SCI, V111, P3119; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Sieg DJ, 1999, J CELL SCI, V112, P2677; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TYSNES OB, 1993, ANTICANCER RES, V13, P1325; Zhang W, 1997, CANCER LETT, V120, P31, DOI 10.1016/S0304-3835(97)00287-5	26	79	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7398	7407		10.1038/sj.onc.1204899	http://dx.doi.org/10.1038/sj.onc.1204899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704869				2022-12-25	WOS:000171894200012
J	Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J				Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J			Gastrin induces over-expression of genes involved in human U373 glioblastoma cell migration	ONCOGENE			English	Article						glioblastoma; proliferation; migration; gastrin; gene overexpression	CALCIUM-BINDING PROTEINS; GLIOMA-CELLS; EXTRACELLULAR-MATRIX; ASTROCYTIC TUMORS; RHO; MODULATION; KINASE; FIBROBLASTS; INCREASES; INVASION	Astrocytic tumors are the most common and the most malignant primary tumors of the central nervous system. We had previously observed that gastrin could significantly modulate both cell proliferation and migration of astrocytoma cells. We have investigated in the present study which genes could be targeted by gastrin in tumor astrocyte migration. Using a subtractive hybridization PCR technique we have cloned genes differentially overexpressed in human astrocytoma U373 cells treated or not with gastrin. We found about 70 genes overexpressed by gastrin. Among the genes overexpressed by gastrin, we paid particular attention to tenascin-C, S100A6 and MLCK genes because their direct involvement in cell migration features. Their gastrin-induced overexpression was quantitatively determined by competitive RT-PCR technique. We also showed by means of a reporter gene system that S100A6 and tenascin-C respective promoters were upregulated after gastrin treatment. These data show that gastrin-mediated effects in glioblastoma cells occur through activation of a number of genes involved in cell migration and suggest that gastrin could be a target in new therapeutic strategies against malignant gliomas.	Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Univ Montpellier 2, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Free Univ Brussels, Fac Med, Lab Histopathol, B-1050 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Martinez, J (corresponding author), Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, 15 Av C Flahault, F-34060 Montpellier, France.	martinez@colombes.pharma.univ-montpl.fr	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621; Decaestecker, Christine/0000-0002-5495-1931; pannequin, julie/0000-0002-9956-373X; KUCHARCZAK, Jerome/0000-0001-7722-8490				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Camby I, 1996, J NATL CANCER I, V88, P594, DOI 10.1093/jnci/88.9.594; Camby I, 1999, BRAIN PATHOL, V9, P1; CAMBY I, 1994, J NEURO-ONCOL, V20, P67, DOI 10.1007/BF01057963; Camby I, 2001, BRAIN PATHOL, V11, P12; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; De la Fuente M, 1998, NEUROPEPTIDES, V32, P225, DOI 10.1016/S0143-4179(98)90041-5; Decaestecker C, 1998, BRAIN PATHOL, V8, P29; DelaFuente M, 1997, J ENDOCRINOL, V153, P475, DOI 10.1677/joe.0.1530475; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Enam SA, 1998, NEUROSURGERY, V42, P599, DOI 10.1097/00006123-199803000-00030; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Giese A, 1996, J CELL SCI, V109, P2161; Giese A, 1996, NEUROSURGERY, V38, P755, DOI 10.1227/00006123-199604000-00026; GIESE A, 1994, CANCER RES, V54, P3897; Gillespie GY, 1999, CANCER RES, V59, P2076; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; Kleihues P, 2000, PATHOLOGY GENETICS T; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUCZYNSKI A, 1995, INT J ONCOL, V6, P473; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Sasaki H, 1998, CANCER, V82, P1921, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1921::AID-CNCR16>3.0.CO;2-V; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; Taniguchi T, 1996, ONCOGENE, V12, P1357; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treasurywala S, 1998, GLIA, V24, P236, DOI 10.1002/(SICI)1098-1136(199810)24:2<236::AID-GLIA8>3.3.CO;2-1; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Zhang H, 1998, J NEUROSCI, V18, P2370; [No title captured]	44	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7021	7028		10.1038/sj.onc.1204882	http://dx.doi.org/10.1038/sj.onc.1204882			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704826				2022-12-25	WOS:000171739300005
J	Boudreau, RTM; Garduno, R; Lin, TJ				Boudreau, RTM; Garduno, R; Lin, TJ			Protein phosphatase 2A and protein kinase C alpha are physically associated and are involved in Pseudomonas aeruginosa-induced interleukin 6 production by mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; HISTAMINE-RELEASE; CYSTIC-FIBROSIS; RBL-2H3 CELLS; ESCHERICHIA-COLI; PHOSPHOLIPASE-C; CALYCULIN-A; TNF-ALPHA; PHOSPHORYLATION; ACTIVATION	Pulmonary infection with Pseudomonas aeruginosa is characterized by massive airway inflammation, which comprises significant cytokine production. Although mast cells are abundant in the lung and are potent sources of various cytokines, a role of mast cells in P. aeruginosa infection remains undefined, and P. aeruginosa-induced signaling mechanisms in mast cells have not been studied previously. Here we demonstrate that human cord blood-derived mast cells, mouse bone marrow-derived mast cells, and the mouse mast cell line MC/9 produce significant amounts of interleukin 6 (IL-6) in response to P. aeruginosa. This response was accompanied by a stimulation of protein kinase Calpha (PKCalpha) phosphorylation and PKC activity and was significantly blocked by the PKC inhibitors Ro 31-8220 and PKCalpha pseudosubstrate. Interestingly, mast cells treated with P. aeruginosa had reduced protein levels of phosphatase 2A catalytic unit (PP2Ac), which prompted us to determine whether a direct association between PKCalpha and PP2A occurs in mast cells. In mouse bone marrow-derived mast cells and MC/9 cells, as well as in the human mast cell line HMC-1, PP2A coimmunoprecipitated with PKCalpha either using PKCalpha- or PP2Ac-specific antibodies, suggesting that PKCalpha and PP2Ac are physically associated in mast cells. The PP2A inhibitor okadaic acid induced P. aeruginosa-like responses in mast cells including increased PKCalpha phosphorylation, stimulated PKC activity, and augmented IL-6 production, the last being blocked by the PKC inhibitor Ro 31-8220. Finally, okadaic acid potentiated the P. aeruginosa-induced IL-6 production. Collectively, these data provide, to our knowledge, the first evidence of both a direct physical association of PP2A and PKCalpha in mammalian cells and their coinvolvement in regulating mast cell activation in response to P. aeruginosa.	Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Med, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS B3J 3G9, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Lin, TJ (corresponding author), IWK Hlth Ctr, Dept Pediat, 5850 Univ Ave, Halifax, NS B3J 3G9, Canada.	tlin@is.dal.ca						Bassini A, 1999, BLOOD, V93, P1178, DOI 10.1182/blood.V93.4.1178.404k28_1178_1188; BAUMGARTNER RA, 1994, MOL BIOL CELL, V5, P475, DOI 10.1091/mbc.5.4.475; BEDARD M, 1993, AM J RESP CELL MOL, V9, P455, DOI 10.1165/ajrcmb/9.4.455; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BERGMANN U, 1989, INFECT IMMUN, V57, P2187, DOI 10.1128/IAI.57.7.2187-2195.1989; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chang EY, 1997, J IMMUNOL, V159, P2624; Chen CC, 2000, MOL PHARMACOL, V58, P1479, DOI 10.1124/mol.58.6.1479; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Crane JK, 1997, INFECT IMMUN, V65, P3277, DOI 10.1128/IAI.65.8.3277-3285.1997; DORING G, 1988, CHEST, V94, pS109, DOI 10.1378/chest.94.2.109S; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; ESTEVEZ MD, 1994, BIOCHEM PHARMACOL, V47, P591, DOI 10.1016/0006-2952(94)90194-5; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FRIEDL P, 1992, IMMUNOLOGY, V76, P86; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HODSON ME, 1980, THORAX, V35, P801, DOI 10.1136/thx.35.11.801; Holm A, 2001, CELL MICROBIOL, V3, P439, DOI 10.1046/j.1462-5822.2001.00127.x; Jao HC, 2001, SHOCK, V15, P130, DOI 10.1097/00024382-200115020-00009; Kamath S, 1998, MOL MICROBIOL, V30, P933, DOI 10.1046/j.1365-2958.1998.01121.x; Kitani S, 1996, INT ARCH ALLERGY IMM, V110, P339, DOI 10.1159/000237326; Kube D, 2001, AM J PHYSIOL-LUNG C, V280, pL493, DOI 10.1152/ajplung.2001.280.3.L493; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li SH, 1998, J CELL PHYSIOL, V176, P402, DOI 10.1002/(SICI)1097-4652(199808)176:2<402::AID-JCP19>3.0.CO;2-4; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Lin TJ, 1999, J LEUKOCYTE BIOL, V66, P1031, DOI 10.1002/jlb.66.6.1031; Liu Y, 2001, J LEUKOCYTE BIOL, V69, P831; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Mandil R, 2001, CANCER RES, V61, P4612; Newell SW, 1996, CANCER LETT, V98, P241; Nixon LS, 1998, AM J RESP CRIT CARE, V157, P1764, DOI 10.1164/ajrccm.157.6.9704086; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PEACHELL PT, 1993, J IMMUNOL, V151, P3808; Peirce MJ, 1999, AM J PHYSIOL-CELL PH, V277, pC1021, DOI 10.1152/ajpcell.1999.277.6.C1021; Peirce MJ, 1997, BRIT J PHARMACOL, V120, P239, DOI 10.1038/sj.bjp.0700915; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RAZIN E, 1995, IMMUNOL TODAY, V16, P370, DOI 10.1016/0167-5699(95)80003-4; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TAKEI M, 1993, J PHARM PHARMACOL, V45, P750, DOI 10.1111/j.2042-7158.1993.tb07102.x; Tam M, 1999, AM J RESP CELL MOL, V20, P710, DOI 10.1165/ajrcmb.20.4.3223; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; van Heeckeren AM, 2000, AM J RESP CRIT CARE, V161, P271, DOI 10.1164/ajrccm.161.1.9903019; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; WALKER TR, 1992, BRIT J PHARMACOL, V105, P627, DOI 10.1111/j.1476-5381.1992.tb09030.x; Wang HQ, 1999, J CELL SCI, V112, P3497; Wang JM, 2000, J IMMUNOL, V165, P4051, DOI 10.4049/jimmunol.165.7.4051; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zitnik Ralph J., 1993, V61, P229	63	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5322	5329		10.1074/jbc.M108623200	http://dx.doi.org/10.1074/jbc.M108623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11706031	hybrid			2022-12-25	WOS:000173962900099
J	Lee, HJ; Shin, SY; Choi, C; Lee, YH; Lee, SJ				Lee, HJ; Shin, SY; Choi, C; Lee, YH; Lee, SJ			Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMAL PROTEIN AGGREGATION; PARKINSONS-DISEASE; SKELETAL-MUSCLE; LEWY BODIES; COMPLEX-I; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PATHOGENESIS; PROTEASOME; DEMENTIA	Mitochondrial dysfunction has been associated with Parkinson's disease. However, the role of mitochondrial defects in the formation of Lewy bodies, a pathological hallmark of Parkinson's disease has not been addressed directly. In this report, we investigated the effects of inhibitors of the mitochondria) electron-transport chain on the aggregation of alpha-synuclein, a major protein component of Lewy bodies. Treatment with rotenone, an inhibitor of complex I, resulted in an increase of detergent-resistant alpha-synuclein aggregates and a reduction in ATP level. Another inhibitor of the electron-transport chain, oligomycin, also showed temporal correlation between the formation of aggregates and ATP reduction. Microscopic analyses showed a progressive evolution of small aggregates of alpha-synuclein to a large perinuclear inclusion body. The inclusions were co-stained with ubiquitin, 20 S proteasome, gamma-tubulin, and vimentin. The perinuclear inclusion bodies, but not the small cytoplasmic aggregates, were thioflavin S-positive, suggesting the amyloid-like conformation. Interestingly, the aggregates disappeared when the cells were replenished with inhibitor-free medium. Disappearance of aggregates coincided with the recovery of mitochondrial metabolism and was partially inhibited by proteasome inhibitors. These results suggest that the formation of alpha-synuclein inclusions could be initiated by an impaired mitochondrial function and be reversed by restoring normal mitochondrial metabolism.	Parkinsons Inst, Sunnyvale, CA 94098 USA; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705035, South Korea; Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju 501190, South Korea	Yeungnam University; Chonnam National University	Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94098 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Baba M, 1998, AM J PATHOL, V152, P879; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T; BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8; CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PUCHTLER H, 1985, Applied Pathology, V3, P5; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	56	225	240	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5411	5417		10.1074/jbc.M105326200	http://dx.doi.org/10.1074/jbc.M105326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11724769	hybrid			2022-12-25	WOS:000173962900110
J	Saldana, C; Naranjo, D; Coria, R; Pena, A; Vaca, L				Saldana, C; Naranjo, D; Coria, R; Pena, A; Vaca, L			Splitting the two pore domains from TOK1 results in two cationic channels with novel functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; K+ CHANNEL; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; CL CHANNELS; YEAST; EXPRESSION; TANDEM; FAMILY; ISK	Potassium channels are membrane-spanning proteins with several transmembrane segments and a single pore region where ion conduction takes place (Biggin, P. C., Roosild, T., and Choe, S. (2000) Curr. Opiu. Struct. Biol. 4, 456-461; Doyle, D. A., Morais Cabral, J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77). TOK1, a potassium channel identified in the yeast Saccharomyces cerevasiae, was the first described member from a growing new family of potassium channels with two pore domains in tandem (2P) (Ketchum, K. A., Joiner, W. J., Sellers, A. J., Kaczmarek, L. K., and Goldstein, S. A. (1995) Nature 376, 690-695). In an attempt to understand the relative contribution of each one of the 2P from TOK1 to the functional properties of this channel, we split and expressed the pore domains separately or in combination. Expression of the two domains separately rescued a potassium transport-deficient yeast mutant, suggesting that each domain forms functional potassium-permeable channels in yeast. In Xenopus laevis oocytes expression of each pore domain resulted in the appearance of unique inwardly rectifying cationic channels with novel gating and pharmacological properties. Both pore domains were poorly selective to potassium; however, upon co-expression they partially restored TOK1 channel selectivity. The single channel conductance was different in both pore domains with 7 +/- 1 (n = 12) and 15 +/- 2 (n = 12) picosiemens for the first and second domain, respectively. In light of the known structure of the Streptomyces lividans KcsA potassium channel pore (see Doyle et al. above), these results suggest a novel non-four-fold-symmetric architecture for 2P potassium-selective channels.	Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico; Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Mol Genet, Mexico City 04510, DF, Mexico; Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biofis, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Vaca, L (corresponding author), Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biol Celular, Ciudad Univ, Mexico City 04510, DF, Mexico.			Vaca, Luis/0000-0003-2266-4847; Naranjo, David/0000-0003-3482-5126				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Bauer CK, 1996, PFLUG ARCH EUR J PHY, V432, P812, DOI 10.1007/s004240050203; BenEfraim I, 1996, J BIOL CHEM, V271, P8768, DOI 10.1074/jbc.271.15.8768; Bertl A, 1998, J MEMBRANE BIOL, V162, P67, DOI 10.1007/s002329900343; BIGGINS PC, 2000, CURR OPIN STRUC BIOL, V4, P456; Chapman ML, 2001, J PHYSIOL-LONDON, V530, P21, DOI 10.1111/j.1469-7793.2001.0021m.x; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fairman C, 1999, J MEMBRANE BIOL, V168, P149, DOI 10.1007/s002329900505; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Garcia E, 1999, J GEN PHYSIOL, V114, P141, DOI 10.1085/jgp.114.1.141; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, J BIOL CHEM, V271, P4183; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Salvador C, 2001, BBA-BIOMEMBRANES, V1512, P135, DOI 10.1016/S0005-2736(01)00314-5; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; SHA Q, 2001, J PHYSL, V5035, P407; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x	28	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4797	4805		10.1074/jbc.M107957200	http://dx.doi.org/10.1074/jbc.M107957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11714706	hybrid			2022-12-25	WOS:000173962900034
J	Jiang, Y; Blanga, S; Amitsur, M; Meidler, R; Krivosheyev, E; Sundaram, M; Bajji, AC; Davis, DR; Kaufmann, G				Jiang, Y; Blanga, S; Amitsur, M; Meidler, R; Krivosheyev, E; Sundaram, M; Bajji, AC; Davis, DR; Kaufmann, G			Structural features of tRNA(Lys) favored by anticodon nuclease as inferred from reactivities of anticodon stem and loop substrate analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSFER-RNA SEQUENCES; REVERSE-TRANSCRIPTION; PRIMER TRNA(LYS,3); DNA; REGION; COMPILATION; NUCLEOSIDES; EXPRESSION; INITIATION	The bacterial tRNA(Lys)-specific PrrC-anticodon nuclease efficiently cleaved an anticodon stem-loop (ASL) oligoribonucleotide containing the natural modified bases, suggesting this region harbors the specificity determinants. Assays of ASL analogs indicated that the 6-threo-nylcarbamoyl adenosine modification (t(6)A37) enhances the reactivity. The side chain of the modified wobble base 5-methylaminomethyl-2-thiouridine (mnm(5)s(2)U34) has a weaker positive effect depending on the context of other modifications. The s(2)U34 modification apparently has none and the pseudouridine (Psi39) was inhibitory in most modification contexts. GC-rich but not IC-rich stems abolished the activity. Correlating the reported structural effects of the base modifications with their effects on anticodon nuclease activity suggests preference for substrates where the anticodon nucleotides assume a stacked A-RNA conformation and base pairing interactions in the stem are destabilized. Moreover, the proposal that PrrC residue Asp(287) contacts mnm(5)s(2)U34 was reinforced by the observations that the mammalian tRNA(Lys-3) wobble base 5-methoxycarbonyl methyl-2-thiouridine (mcm(5)s(2)U) is inhibitory and that the D287H mutant favors tRNA(Lys-3) over Escherichia coli tRNA(Lys). The detection of this mutation and ability of PrrC to cleave the isolated ASL suggest that anticodon nuclease may be used to cleave tRNA(Lys-3) primer molecules annealed to the genomic RNA template of the human immunodeficiency virus.	Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Tel Aviv University; Utah System of Higher Education; University of Utah	Kaufmann, G (corresponding author), Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.	gabika@tauex.tau.ac.il			NIGMS NIH HHS [GM55508] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; AMITSUR M, 1992, EMBO J, V11, P3129, DOI 10.1002/j.1460-2075.1992.tb05385.x; Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523; Bajji AC, 2000, ORG LETT, V2, P3865, DOI 10.1021/ol006605h; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Durant PC, 1999, J MOL BIOL, V285, P115, DOI 10.1006/jmbi.1998.2297; Elgavish T, 1999, J MOL BIOL, V285, P449, DOI 10.1006/jmbi.1998.2310; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Jiang Y, 2001, J MOL BIOL, V305, P377, DOI 10.1006/jmbi.2000.4282; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; LEVITZ R, 1990, EMBO J, V9, P1383, DOI 10.1002/j.1460-2075.1990.tb08253.x; LINDER P, 1990, NUCLEIC ACIDS RES, V18, P7170, DOI 10.1093/nar/18.23.7170; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; Meidler R, 1999, J MOL BIOL, V287, P499, DOI 10.1006/jmbi.1999.2634; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORAD I, 1993, J BIOL CHEM, V268, P26842; PENNER M, 1995, J MOL BIOL, V249, P857, DOI 10.1006/jmbi.1995.0343; Puglisi EV, 1998, NAT STRUCT BIOL, V5, P1033, DOI 10.1038/4141; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; SHTERMAN N, 1995, NUCLEIC ACIDS RES, V23, P1744, DOI 10.1093/nar/23.10.1744; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Stuart JW, 2000, BIOCHEMISTRY-US, V39, P13396, DOI 10.1021/bi0013039; Sundaram M, 2000, BIOCHEMISTRY-US, V39, P12575, DOI 10.1021/bi0014655; Sundaram M, 2000, J ORG CHEM, V65, P5609, DOI 10.1021/jo000338b; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TYNDALL C, 1994, J MOL BIOL, V237, P266, DOI 10.1006/jmbi.1994.1230; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995	29	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3836	3841		10.1074/jbc.M110072200	http://dx.doi.org/10.1074/jbc.M110072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11723135	hybrid			2022-12-25	WOS:000173813900007
J	Price, PA; Thomas, GR; Pardini, AW; Figueira, WF; Caputo, JM; Williamson, MK				Price, PA; Thomas, GR; Pardini, AW; Figueira, WF; Caputo, JM; Williamson, MK			Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-HS GLYCOPROTEIN; MESSENGER-RNA EXPRESSION; GLA-PROTEIN; BONE-RESORPTION; CELLS; GENE; CALCIFICATION; CARTILAGE; IDENTIFICATION; COUNTERPART	In the present study we report the discovery of a novel protein-mineral complex in the serum of rats treated with doses of the bone-active bisphosphonate etidronate that inhibit normal bone mineralization. The composition of this high molecular mass protein-mineral complex consists of about 18% mineral, 80% fetuin, and 2% matrix Gla protein (MGP) by weight, and the presence of the complex in serum after an injection of 8 mg etidronate/100 g of body weight elevates calcium by 1.8-fold (to 4.3 nm), phosphate by 1.6-fold (to 5.6 mM), and MGP by 25-fold (to 12 mug/ml). The serum mineral complex reaches maximal levels at 6 h after subcutaneous injection of etidronate and is subsequently cleared from serum by 24 h. This highly specific complex of fetuin, MGP, and mineral prevents the growth, aggregation, and precipitation of the mineral component, which indicates that the previously reported calcification inhibitory activities of fetuin and MGP may be related to their ability to form stable complexes with nascent mineral nuclei. Treatment with the vitamin K-antagonist warfarin prevents the increase in serum MGP after etidronate injection, which shows that the increase in serum MGP is due to new synthesis and that the gamma-carboxylation of MGP is necessary for its binding to the serum mineral complex.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Div Biol, 0368, La Jolla, CA 92093 USA.		Thomas, Gethin P/A-3624-2011; Figueira, Will/A-5163-2009	Figueira, Will/0000-0001-9472-8710	NIAMS NIH HHS [AR25921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Antic VN, 1996, CALCIFIED TISSUE INT, V58, P443, DOI 10.1007/s002239900073; Binkert C, 1999, J BIOL CHEM, V274, P28514, DOI 10.1074/jbc.274.40.28514; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; CANCELA ML, 1992, ENDOCRINOLOGY, V130, P102, DOI 10.1210/en.130.1.102; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; FRASER JD, 1988, J BIOL CHEM, V263, P11033; FRASER JD, 1988, J BIOL CHEM, V263, P911; HALE JE, 1991, J BIOL CHEM, V266, P21145; HALE JE, 1988, J BIOL CHEM, V263, P5820; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Kazi JA, 1998, J BIOCHEM-TOKYO, V124, P179, DOI 10.1093/oxfordjournals.jbchem.a022077; KEUTEL J, 1972, Birth Defects Original Article Series, V8, P60; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MCKEE MD, 1993, J BONE MINER RES, V8, P485; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; OHNISHI T, 1993, J BONE MINER RES, V8, P367; Price P, 1981, CHEM BIOL MINERALIZE, V1, P327; Price P. A., 1979, VITAMIN K METABOLISM, P219; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRICE PA, 1994, PROTEIN SCI, V3, P822; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; RANNELS SR, 1993, AM J PHYSIOL, V265, pL270, DOI 10.1152/ajplung.1993.265.3.L270; RICE JS, 1994, J BONE MINER RES, V9, P567; SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219; SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Teebi AS, 1998, AM J MED GENET, V78, P182, DOI 10.1002/(SICI)1096-8628(19980630)78:2<182::AID-AJMG18>3.3.CO;2-K; Terkelsen OBF, 1998, ANAT EMBRYOL, V197, P125, DOI 10.1007/s004290050124; WENDEL M, 1993, MATRIX, V13, P331, DOI 10.1016/S0934-8832(11)80029-6	35	160	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3926	3934		10.1074/jbc.M106366200	http://dx.doi.org/10.1074/jbc.M106366200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724771	hybrid			2022-12-25	WOS:000173813900019
J	Zhang, KZ; Kurachi, S; Kurachi, K				Zhang, KZ; Kurachi, S; Kurachi, K			Genetic mechanisms of age regulation of protein C and blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-IX GENE; GLASGOW MONICA SURVEY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; NUCLEOTIDE-SEQUENCE; ACTIVATION MARKERS; SEX; REGION; ASSOCIATIONS; EPIDEMIOLOGY	Blood coagulation activity in humans increases with age. We previously identified two genetic elements, age-related stability element (ASE; GAGGAAG) and age-related increase element (AIE; unique stretch of dinucleotide repeats), which were responsible for age-related stable and increasing expression patterns, respectively, and together recapitulated normal age regulation of the human factor IX (hFIX) gene. Here we report the age-regulatory mechanisms of human anticoagulant protein C (hPC), which shows an age-stable pattern of circulatory levels. The murine protein C gene showed an age-related stable expression pattern in general agreement with that of the hPC. Through longitudinal analyses of transgenic mice carrying hPC minigenes, the hPC gene was found to have a functional age-related stability element (hPC ASE; CAGGAAG) in the 5'-upstream proximal region but was found to lack any age-related increase element. Three other ASE-like sequences present in the hPC gene, GAGGAAA and (G/C)AGGATG, also bound nuclear proteins but were not active in the age regulation of the hPC gene. Functional hPC ASE and hFIX ASE were apparently generated through convergent evolution, and hFIX ASE can fully substitute for the hPC ASE in conferring age-related stable expression pattern of the hPC gene. In the presence of the hPC ASE, hFIX AIE can convert the age-stable expression pattern of the hPC gene to a hFIX-like age-related increase pattern. These results support the universality of ASE and AIE functions across different genes. Clearance of hPC protein from the circulation was not significantly affected by age. We now have established the basic mechanisms responsible for the age-related increase of blood coagulation activity.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kurachi, K (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.	kkurachi@umich.edu		Zhang, Kezhong/0000-0002-6062-235X	NCRR NIH HHS [M01-RR-00042] Funding Source: Medline; NHLBI NIH HHS [HL38644, HL64522] Funding Source: Medline; NIAMS NIH HHS [5-P60-AR-20557] Funding Source: Medline; NIDDK NIH HHS [5P60 DK20572] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064522, R01HL038644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREW M, 1992, BLOOD, V80, P1998, DOI 10.1182/blood.V80.8.1998.1998; BAUER KA, 1987, J CLIN INVEST, V80, P1527, DOI 10.1172/JCI113238; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CONLON MG, 1994, THROMB HAEMOSTASIS, V72, P551; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DODDS WJ, 1987, ANN NY ACAD SCI, V516, P631, DOI 10.1111/j.1749-6632.1987.tb33078.x; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; Hsu W, 1999, THROMB HAEMOSTASIS, V82, P1782, DOI 10.1055/s-0037-1614923; Jalbert LR, 1998, THROMB HAEMOSTASIS, V79, P310, DOI 10.1055/s-0037-1615006; KONKEL DA, 1978, CELL, V15, P1125, DOI 10.1016/0092-8674(78)90040-5; Kurachi S, 1999, SCIENCE, V285, P739, DOI 10.1126/science.285.5428.739; Kurachi S, 1996, THROMB HAEMOSTASIS, V76, P965; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; Miao CH, 1996, J BIOL CHEM, V271, P9587, DOI 10.1074/jbc.271.16.9587; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SWEENEY JD, 1993, AM J CLIN PATHOL, V99, P687, DOI 10.1093/ajcp/99.6.687; Turkay A, 1999, THROMB HAEMOSTASIS, V81, P727; Vlieg AV, 2000, BLOOD, V95, P3678; Woodward M, 1997, BRIT J HAEMATOL, V97, P785, DOI 10.1046/j.1365-2141.1997.1232935.x; WU SM, 1990, GENE, V86, P275, DOI 10.1016/0378-1119(90)90290-8; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAO SN, 1991, THROMB HAEMOSTASIS, V65, P52; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	28	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4532	4540		10.1074/jbc.M109524200	http://dx.doi.org/10.1074/jbc.M109524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11719515	hybrid			2022-12-25	WOS:000173813900097
J	Hashmi, S; Britton, C; Liu, J; Guiliano, DB; Oksov, Y; Lustigman, S				Hashmi, S; Britton, C; Liu, J; Guiliano, DB; Oksov, Y; Lustigman, S			Cathepsin L is essential for embryogenesis and development of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; YOLK PROTEINS; C-ELEGANS; GENE; EXPRESSION; CLONING; IDENTIFICATION; ORGANIZATION; DEGRADATION; INHIBITION	Cysteine proteases play critical biological roles in both intracellular and extracellular processes. We characterized Ce-cpl-1, a Caenorhabditis elegans cathepsin L-like cysteine protease. RNA interference with Ce-cpl-1 activity resulted in embryonic lethality and a transient delayed growth of larvae to egg producing adults, suggesting an essential role for cpl-1 during embryogenesis, and most likely during post-embryonic development. Cpl-1 gene (Ce-cpl-1:lacZ) is widely expressed in the intestine and hypodermal cells of transgenic worms, while the fusion protein (Ce-CPL-1::GFP) was expressed in the hypodermis, pharynx, and gonad. The CPL-1 native protein accumulates in early to late stage embryos and becomes highly concentrated in gut cells during late embryonic development. CPL-1 is also present near the periphery of the eggshell as well as in the cuticle of larval stages suggesting that it may function not only in embryogenesis but also in further development of the worm. Although the precise role of Ce-CPL-1 during embryogenesis is not yet clear it could be involved in the processing of nutrients responsible for synthesis and/or in the degradation of eggshell. Moreover, an increase in the cpl-1 mRNA is seen in the intermolt period approximately 4 h prior to each molt. During this process Ce-CPL-1 may act as a proteolytic enzyme in the processing/degradation of cuticular or other proteins. Similar localization of a related cathepsin L in the filarial nematode Onchocerca volvulus, eggshell and cuticle, suggests that some of the Ce-CPL-1 function during development may be conserved in other parasitic nematodes.	New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, New York, NY 10021 USA; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	New York Blood Center; University of Glasgow; University of Edinburgh	Lustigman, S (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, 310 E 67th St, New York, NY 10021 USA.	sara_lustigman@nybc.org		Britton, Collette/0000-0002-5165-312X	NIAID NIH HHS [1 R21-AI48057-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048057] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BRENNER S, 1974, GENETICS, V77, P71; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Britton C, 1999, MOL BIOCHEM PARASIT, V103, P171, DOI 10.1016/S0166-6851(99)00121-8; BYERLY L, 1976, DEV BIOL, V51, P23, DOI 10.1016/0012-1606(76)90119-6; CHAUHAN SS, 1991, CANCER RES, V51, P1478; Cho WL, 1999, J BIOL CHEM, V274, P13311, DOI 10.1074/jbc.274.19.13311; COLE SCJ, 1993, FEMS MICROBIOL LETT, V113, P189, DOI 10.1016/0378-1097(93)90267-6; DASTON GP, 1991, TERATOLOGY, V43, P253, DOI 10.1002/tera.1420430309; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; Falcone FH, 2000, EXP PARASITOL, V94, P201, DOI 10.1006/expr.2000.4489; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GRUBB JD, 1991, PLACENTA, V12, P143, DOI 10.1016/0143-4004(91)90018-B; Hashmi S, 2001, TRENDS PARASITOL, V17, P387, DOI 10.1016/S1471-4922(01)01986-9; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KEMPHUES KJ, 1986, DEV BIOL, V113, P449, DOI 10.1016/0012-1606(86)90180-6; Kilpatrick KE, 1997, HYBRIDOMA, V16, P381, DOI 10.1089/hyb.1997.16.381; KIMBLE J, 1983, DEV BIOL, V96, P189, DOI 10.1016/0012-1606(83)90322-6; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Koiwa H, 2000, FEBS LETT, V471, P67, DOI 10.1016/S0014-5793(00)01368-5; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; Lustigman S, 1996, J BIOL CHEM, V271, P30181, DOI 10.1074/jbc.271.47.30181; LUSTIGMAN S, 1991, MOL BIOCHEM PARASIT, V45, P65, DOI 10.1016/0166-6851(91)90028-5; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; McKerrow J. H., 1994, PERSPECT DRUG DISCOV, V2, P437; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRATT D, 1992, MOL BIOCHEM PARASIT, V51, P209, DOI 10.1016/0166-6851(92)90071-Q; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; RICHTER JK, 1992, EXP PARASITOL, V75, P303; RIDDLE D.L., 1997, C ELEGANS, P1; SAMUELS RI, 1995, COMP BIOCHEM PHYS B, V110, P661, DOI 10.1016/0305-0491(94)00205-9; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; SHARROCK WJ, 1983, DEV BIOL, V96, P182, DOI 10.1016/0012-1606(83)90321-4; Shompole S, 2001, J BIOL CHEM, V276, P2928, DOI 10.1074/jbc.M007321200; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Sol-Church K, 1999, ARCH BIOCHEM BIOPHYS, V372, P375, DOI 10.1006/abbi.1999.1520; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; TAKAHASHI SY, 1993, J BIOCHEM, V114, P267, DOI 10.1093/oxfordjournals.jbchem.a124165; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2	47	91	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3477	3486		10.1074/jbc.M106117200	http://dx.doi.org/10.1074/jbc.M106117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11707440	hybrid			2022-12-25	WOS:000173688000057
J	Curtis, KK; Kane, PM				Curtis, KK; Kane, PM			Novel vacuolar H+-ATPase complexes resulting from overproduction of Vma5p and Vma13p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; YEAST V-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASES; ESCHERICHIA-COLI; SHUTTLE VECTORS; SUBUNIT VMA13P; GENE; (H+)-ATPASE; MUTANTS	The vacuolar H+-ATPase (V-ATPase) is a multisubunit complex composed of two sectors: V-1, a peripheral membrane sector responsible for ATP hydrolysis, and V-0, an integral membrane sector that forms a proton pore. Vma5p and Vmal3p are V-1 sector subunits that have been implicated in the structural and functional coupling of the V-ATPase. Cells overexpressing Vma5p and Vmal3p demonstrate a classic Vma(-) growth phenotype. Closer biochemical examination of Vmal3p-overprodueing strains revealed a functionally uncoupled V-ATPase in vacuolar vesicles. The ATP hydrolysis rate was 72% of the wild-type rate; but there was no proton translocation, and two V, subunits (Vma4p and Vma8p) were present at lower levels. Vma5p overproduction moderately affected both V-ATPase activity and proton translocation without affecting enzyme assembly. High level overexpression of Vma5p and Vmal3p was lethal even in wild-type cells. In the absence of an intact V-0 sector, overproduction of Vma5p and Vmal3p had a more detrimental effect on growth than their deletion. Overproduced Vma5p associated with cytosolic V, complexes; this association may cause the lethality.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@mail.upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sherman F., 1982, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; Zhou ZM, 1999, J BIOL CHEM, V274, P15913, DOI 10.1074/jbc.274.22.15913; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	47	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2716	2724		10.1074/jbc.M107777200	http://dx.doi.org/10.1074/jbc.M107777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11717306	hybrid			2022-12-25	WOS:000173421500046
J	Ponimaskin, EG; Heine, M; Joubert, L; Sebben, M; Bickmeyer, U; Richter, DW; Dumuis, A				Ponimaskin, EG; Heine, M; Joubert, L; Sebben, M; Bickmeyer, U; Richter, DW; Dumuis, A			The 5-hydroxytryptamine(4a) receptor is palmitoylated at two different sites, and acylation is critically involved in regulation of receptor constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; 5-HT4 RECEPTORS; POSTTRANSLATIONAL MODIFICATION; THROMBIN RECEPTOR; CYTOPLASMIC TAIL; FATTY ACYLATION; BINDING-SITES; SEROTONIN; RHODOPSIN	We have reported recently that the mouse 5-hydroxytryptamine(4a) (5-HT4(a)) receptor undergoes dynamic palmitoylation (Ponimaskin, E. G., Schmidt, M. F., Heine, M., Bickmeyer, U., and Richter, D. W. (2001) Biochem. J. 353, 627-663). In the present study, conserved cysteine residues 328/329 in the carboxyl terminus of the 5-HT4(a) receptor were identified as potential acylation sites. In contrast to other palmitoylated G-protein-coupled receptors, the additional cysteine residue 386 positioned close to the COOH-terminal end of the receptor was also found to be palmitoylated. Using pulse and pulse-chase labeling techniques, we demonstrated that palmitoylation of individual cysteines is a reversible process and that agonist stimulation of the 5-HT4(a) receptor independently increases the rate of palmitate turnover for both acylation sites. Analysis of acylation-deficient mutants revealed that non-palmitoylated 5-HT4(a) receptors were indistinguishable from the wild type in their ability to interact with G(s), to stimulate the adenylyl cyclase activity and to activate cyclic nucleotide-sensitive cation channels after agonist stimulation. The most distinctive finding of the present study was the ability of palmitoylation to modulate the agonist-independent constitutive 5-HT4(a) receptor activity. We demonstrated that mutation of the proximal palmitoylation site (Cys(328) --> Ser/Cys(329) --> Ser) significantly increases the capacity of receptors to convert from the inactive (R) to the active (R*) form in the absence of agonist. In contrast, the rate of isomerization from R to R* for the Cys(386) --> Ser as well as for the triple, nonpalmitoylated mutant (Cys(328) --> Ser/CyS329 --> Ser/Cys(386) -->Ser) was similar to that obtained for the wild type.	Univ Gottingen, Inst Physiol, Abt Neuro & Sinnesphysiol, D-37073 Gottingen, Germany; CNRS, UPR 9023, F-34094 Montpellier 5, France	University of Gottingen; Centre National de la Recherche Scientifique (CNRS)	Richter, DW (corresponding author), Univ Gottingen, Inst Physiol, Abt Neuro & Sinnesphysiol, Humbpldtallee 23, D-37073 Gottingen, Germany.			Ponimaskin, evgeni/0000-0002-4570-5130; Bickmeyer, Ulf/0000-0002-5351-2902				Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Ansanay H, 1996, EUR J PHARMACOL, V298, P165, DOI 10.1016/0014-2999(95)00786-5; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bender E, 2000, J NEUROCHEM, V74, P478, DOI 10.1046/j.1471-4159.2000.740478.x; BOCKAERT J, 1997, HDB EXPT PHARM SEROT, P439; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONHOMME N, 1995, BRAIN RES, V675, P215, DOI 10.1016/0006-8993(95)00067-Z; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Claeysen S, 1999, MOL PHARMACOL, V55, P910; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EGLEN RM, 1995, TRENDS PHARMACOL SCI, V16, P391, DOI 10.1016/S0165-6147(00)89081-1; FANGI L, 1992, BRIT J PHARMACOL, V105, P973; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HEINE M, 2001, PFLUEGERS ARCH EUR J; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hoyer D, 1997, NEUROPHARMACOLOGY, V36, P419, DOI 10.1016/S0028-3908(97)00036-1; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Krieger J, 1999, INSECT BIOCHEM MOLEC, V29, P255, DOI 10.1016/S0965-1748(98)00134-9; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; MarchettiGauthier E, 1997, NEUROPHARMACOLOGY, V36, P697, DOI 10.1016/S0028-3908(97)00058-0; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 2001, J NEUROCHEM, V76, P269, DOI 10.1046/j.1471-4159.2001.00005.x; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OMARY MB, 1981, J BIOL CHEM, V256, P4715; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; Ponimaskin E, 1998, VIROLOGY, V249, P325, DOI 10.1006/viro.1998.9303; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P227; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; Wong EHF, 1996, BEHAV BRAIN RES, V73, P249; Workman AJ, 1998, CARDIOVASC RES, V40, P436; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	61	57	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2534	2546		10.1074/jbc.M106529200	http://dx.doi.org/10.1074/jbc.M106529200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11706023	hybrid, Green Published			2022-12-25	WOS:000173421500023
J	Seykora, JT; Mei, L; Dotto, GP; Stein, PL				Seykora, JT; Mei, L; Dotto, GP; Stein, PL			Srcasm: a novel Src activating and signaling molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; LONG-TERM POTENTIATION; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; REVERSE 2-HYBRID; BINDING DOMAIN; SH3 DOMAINS; VHS DOMAIN	The Src family tyrosine kinase, Fyn, can facilitate regulation of cell proliferation and differentiation. Mice with mutations in the fyn gene have defects in the brain, immune system, and epidermal differentiation. To identify molecules that may interact with Fyn in the epidermis, we performed a yeast two-hybrid interaction screen of a murine keratinocyte library. A novel adaptor-like molecule was isolated and termed Srcasm for Src activating and signaling molecule. Murine Srcasm is a 52.7-kDa protein that contains a VHS membrane association domain and a number of tyrosine motifs suggesting that it may be a substrate for Src family kinases and serve as an adaptor protein. Northern blot analysis of murine tissues demonstrates that Srcasm expression is highest in brain and kidney. In situ hybridization analysis reveals that srcasm mRNA is expressed in regions of the epidermis and hair follicle where keratinocyte differentiation occurs. In the brain, srcasm mRNA distribution correlates with that of fyn, with both being highly expressed in the hippocampal and cerebellar Purkinje neurons. Fyn can phosphorylate Srcasm, and association of these molecules relies on cooperative binding between the SH2 and SH3 domains of Fyn and corresponding canonical binding sites in Srcasm. Srcasm is capable of interacting with Grb2 and the regulatory subunit of phosphoinositide 3-kinase, p85, in a phosphorylation-dependent manner. The evidence suggests that Srcasm may help promote Src family kinase signaling in cells.	Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	University of Pennsylvania; Harvard University; Massachusetts General Hospital; Harvard University	Stein, PL (corresponding author), Rm 217,Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	steinp@mail.med.upenn.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR047597, T32AR007465] Funding Source: NIH RePORTER; NIAMS NIH HHS [K08 AR047597, ARO7465] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1995, J EXP MED, V182, P811, DOI 10.1084/jem.182.3.811; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DALY RJ, 1994, ONCOGENE, V9, P2723; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DEL PL, 1997, SCIENCE, V278, P687; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Gadue P, 1999, J EXP MED, V190, P1189, DOI 10.1084/jem.190.8.1189; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KEETON M, 1993, AM J PATHOL, V142, P59; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCGUIRE J, 1977, ANAL BIOCHEM, V83, P75, DOI 10.1016/0003-2697(77)90512-7; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SAINSBURY JRC, 1987, LANCET, V1, P1398; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; van der Heyden MA, 1997, BBA-MOL CELL RES, V1359, P211, DOI 10.1016/S0167-4889(97)00105-5; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	40	51	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2812	2822		10.1074/jbc.M106813200	http://dx.doi.org/10.1074/jbc.M106813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711534	hybrid			2022-12-25	WOS:000173421500059
J	Arpagaus, S; Rawyler, A; Braendle, R				Arpagaus, S; Rawyler, A; Braendle, R			Occurrence and characteristics of the mitochondrial permeability transition in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; CYCLOSPORINE-A; MEMBRANE TRANSITION; INORGANIC-PHOSPHATE; CALCIUM-TRANSPORT; INNER MEMBRANE; POTATO CELLS; PORE; OXYGEN	dThe behavior of purified potato mitochondria toward the main effectors of the animal mitochondrial permeability transition has been studied by light scattering, fluorescence, SDS-polyacrylamide gel electrophoresis, and immunoblotting techniques. The addition of Ca2+ induces a phosphate-dependent swelling that is fully inhibited by cyclosporin A if dithioerythritol is present. Mg2+ cannot be substituted for Ca2+ but competes with it. Disruption of the outer membrane and release of several proteins, including cytochrome c, occur upon completion of swelling. Ca2+-induced swelling is delayed and its rate is decreased when pH is shifted from 7.4 to 6.6. It is accelerated by diamide, phenylarsine oxide, and linolenic acid. In the absence of Ca2+, however, linolenic acid (less than or equal to20 mum) rapidly dissipates the succinate-driven membrane potential while having no effect on mitochondrial volume. Anoxic conditions favor in vitro swelling and the concomitant release of cytochrome c and of other proteins in a pH-dependent way. These data indicate that the classical mitochondrial permeability transition occurs also in plants. This may have important implications for our understanding of cell stress and death processes.	Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland	University of Bern	Arpagaus, S (corresponding author), Univ Bern, Inst Plant Sci, Altenbergrain 23, CH-3013 Bern, Switzerland.	silvio.arpagaus@ips.unibe.ch						AKERMAN KEO, 1983, BIOCHEM BIOPH RES CO, V114, P1176, DOI 10.1016/0006-291X(83)90686-1; ANDERSSON BS, 1987, AM J PHYSIOL, V252, pC349, DOI 10.1152/ajpcell.1987.252.4.C349; Arpagaus S, 2000, J EXP BOT, V51, P1475, DOI 10.1093/jexbot/51.349.1475; Balk J, 1999, FEBS LETT, V463, P151, DOI 10.1016/S0014-5793(99)01611-7; Balk J, 2001, PLANT CELL, V13, P1803, DOI 10.1105/tpc.13.8.1803; Beers EP, 1997, CELL DEATH DIFFER, V4, P649, DOI 10.1038/sj.cdd.4400297; BERGMAN A, 1980, PLANT PHYSIOL, V66, P442, DOI 10.1104/pp.66.3.442; BERNARDI P, 1996, BIOCHIM BIOPHYS ACTA, V275, P5; BREIMAN A, 1992, J BIOL CHEM, V267, P21293; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CARNIERI EGS, 1987, BRAZ J MED BIOL RES, V20, P635; Casolo V, 2000, FEBS LETT, V474, P53, DOI 10.1016/S0014-5793(00)01576-3; Crawford RMM, 1996, J EXP BOT, V47, P145, DOI 10.1093/jxb/47.2.145; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAY DA, 1984, PHYSIOL VEG, V22, P241; DIETER P, 1980, PLANTA, V150, P1, DOI 10.1007/BF00385606; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; Douce R., 1985, MITOCHONDRIA HIGHER, P45; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Fortes F, 2001, J BIOENERG BIOMEMBR, V33, P43, DOI 10.1023/A:1005672623709; FUJII Y, 1994, HEPATOLOGY, V20, P177; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Griffiths EJ, 2000, CELL CALCIUM, V27, P87, DOI 10.1054/ceca.1999.0094; HACKENBROCK CR, 1969, J CELL BIOL, V42, P221, DOI 10.1083/jcb.42.1.221; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; Jones A, 2000, TRENDS PLANT SCI, V5, P225, DOI 10.1016/S1360-1385(00)01605-8; Jones AM, 2001, PLANT PHYSIOL, V125, P94, DOI 10.1104/pp.125.1.94; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krasnikov BF, 1997, FEBS LETT, V419, P137, DOI 10.1016/S0014-5793(97)01450-6; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam E, 2000, PLANT MOL BIOL, V44, P417, DOI 10.1023/A:1026509012695; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, CARDIOVASC RES, V44, P470, DOI 10.1016/S0008-6363(99)00368-5; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTINS IS, 1985, BIOCHEM BIOPH RES CO, V129, P943, DOI 10.1016/0006-291X(85)91982-5; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Moore A L, 1993, Methods Mol Biol, V19, P133; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nomura Y, 1996, ADV EXP MED BIOL, V388, P225; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Pavelic D, 2000, PLANT PHYSIOL, V124, P1285, DOI 10.1104/pp.124.3.1285; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRUSSA E, 1992, FEBS LETT, V307, P267, DOI 10.1016/0014-5793(92)80692-A; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Rawyler A, 1999, PLANT PHYSIOL, V120, P293, DOI 10.1104/pp.120.1.293; Rawyler AJ, 2001, PLANT PHYSIOL, V127, P240, DOI 10.1104/pp.127.1.240; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SILVA MAP, 1992, PLANT PHYSIOL, V98, P452, DOI 10.1104/pp.98.2.452; Sokolove PM, 1996, J BIOENERG BIOMEMBR, V28, P199, DOI 10.1007/BF02110651; Stein JC, 1999, PLANT PHYSIOL, V121, P71, DOI 10.1104/pp.121.1.71; Stitt M, 1998, BOT ACTA, V111, P167, DOI 10.1111/j.1438-8677.1998.tb00692.x; Subbaiah CC, 2000, J EXP BOT, V51, P721, DOI 10.1093/jexbot/51.345.721; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P52, DOI 10.1006/abbi.2000.2195; Sun YL, 1999, FEBS LETT, V462, P317, DOI 10.1016/S0014-5793(99)01539-2; Teixeira BMAR, 1999, BIOSCIENCE REP, V19, P525, DOI 10.1023/A:1020210827389; VIANELLO A, 1994, FEBS LETT, V349, P407, DOI 10.1016/0014-5793(94)00712-8; VIANELLO A, 1995, FEBS LETT, V371, P258, DOI 10.1016/0014-5793(95)00897-I; Vianello A, 1999, PHYSIOL PLANTARUM, V105, P763, DOI 10.1034/j.1399-3054.1999.105422.x; Wojtczak L, 1999, J BIOENERG BIOMEMBR, V31, P447, DOI 10.1023/A:1005444322823; Xia JH, 1996, PLANT PHYSIOL, V111, P227, DOI 10.1104/pp.111.1.227; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	77	110	125	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1780	1787		10.1074/jbc.M109416200	http://dx.doi.org/10.1074/jbc.M109416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704674	hybrid			2022-12-25	WOS:000173421300022
J	Coulpier, M; Anders, J; Ibanez, CF				Coulpier, M; Anders, J; Ibanez, CF			Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase - Importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TRANSFORMING ACTIVITY; SIGNALING PATHWAY; INSULIN-RECEPTOR; DOCKING SITE; FAMILY; PROTOONCOGENE; ASSOCIATION; EXPRESSION; MUTATION	The catalytic and signaling activities of RET, a tyrosine kinase receptor for glial cell line-derived neurotrophic factor (GDNF), are controlled by the autophosphorylation of several tyrosine residues in the RET cytoplasmic domain. To analyze the phosphorylation state of individual tyrosines, we generated antibodies recognizing specific phosphotyrosine sites involved in the catalytic (Tyr(905)) and downstream signaling (Tyr(1015), Tyr(1062), and Tyr(1096)) activities of this receptor. Stimulation with GDNF induced coordinated phosphorylation of the 4 tyrosine residues in neuronal cell lines and in primary cultures of sympathetic neurons isolated from rat superior cervical ganglia. Neurturin and artemin, two other members of the GDNF ligand family, also induced synchronized phosphorylation of RET tyrosines with kinetics comparable to those observed with GDNF. Tyrosine phosphorylation was maximal 15 min after ligand stimulation, decaying thereafter with similar kinetics in all 4 residues. Co-stimulation with a soluble form of the GFRalpha1 co-receptor potentiated ligand-dependent phosphorylation of different intracellular tyrosines to a similar extent and increased the survival of superior cervical ganglion neurons compared with treatment with GDNF alone. In vivo, high levels of phosphorylated Tyr(905), Tyr(1015), and Tyr(1062) were detected in embryonic mouse dorsal root ganglia, with a sharp decline at early postnatal stages. Protein transduction of anti-Tyr(P)(1062) antibodies into cultured cells reduced activation of MAPKs ERK1 and ERK2 and the AKT kinase in response to GDNF and diminished GDNF-dependent neuronal differentiation and survival of embryonic sensory neurons from the nodose ganglion. These results demonstrate synchronized utilization of individual RET tyrosine residues in neurons in vivo and reveal an important role for RET Tyr(1062) in mediating neuronal survival by GDNF.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Retzius Vag 8,A2 2, S-17177 Stockholm, Sweden.			Coulpier, Muriel/0000-0001-5400-8727				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Akerud P, 1999, J NEUROCHEM, V73, P70, DOI 10.1046/j.1471-4159.1999.0730070.x; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Baudet C, 2000, DEVELOPMENT, V127, P4335; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; DICKENS M, 1991, BIOCHEM BIOPH RES CO, V174, P772, DOI 10.1016/0006-291X(91)91484-T; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Iwashita T, 1996, ONCOGENE, V12, P481; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Sariola H, 1999, INT J DEV BIOL, V43, P413; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Worley DS, 2000, DEVELOPMENT, V127, P4383; Yu T, 1998, J NEUROSCI, V18, P4684	42	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1991	1999		10.1074/jbc.M107992200	http://dx.doi.org/10.1074/jbc.M107992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11713247	Green Published, hybrid			2022-12-25	WOS:000173421300052
J	Fukui, N; McAlinden, A; Zhu, Y; Crouch, E; Broekelmann, TJ; Mecham, RP; Sandell, LJ				Fukui, N; McAlinden, A; Zhu, Y; Crouch, E; Broekelmann, TJ; Mecham, RP; Sandell, LJ			Processing of type II procollagen amino propeptide by matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-D; CROSS-LINKING SITES; TERMINAL PROPEPTIDE; OSTEOARTHRITIC CARTILAGE; N-PROTEINASE; COLLAGEN; EXPRESSION; CLEAVAGE; CHORDIN; CELLS	in many embryonic tissues, type IIA procollagen is synthesized and deposited into the extracellular matrix containing the NH2-propeptide, the cysteine-rich domain of which binds to bone morphogenic proteins. To investigate whether matrix metalloproteinases (MMPs) synthesized during development and disease can cleave the NH2 terminus of type 11 procollagens, we tested eight types of enzymes. Recombinant trimeric type IIA collagen NH2-propeptide encoded by exons 1-8 fused to the lectin domain of rat surfactant protein D was used as a substrate. The latter allowed trimerization of the propeptide domain and permitted isolation by saccharide affinity chromatography. Although NEAPs 1, 2, and 8 did not show cleavage, MMPs 3, 7, 9, 13, and 14 cleaved the recombinant protein both at the telopeptide region and at the procollagen N-proteinase cleavage site. MMPs 7 and 13 demonstrated other cleavage sites in the type 11 collagen-specific region of the N-propeptide; MMP-7 had another cleavage site close to the COOH terminus of the cysteine-rich domain. To prove that an I MP can cleave the native type IIA procollagen in situ, we demonstrated that MMP-7 removes the NH2-propeptide from collagen fibrils in the extracellular matrix of fetal cartilage and identified the cleavage products. Because the N-proteinase and telopeptidase cleavage sites are present in both type IIA and type IIB procollagens and the telopeptide cleavage site is retained in the mature collagen fibril, this processing could be important to type IIB procollagen and to mature collagen fibrils as well.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, St Louis, MO 63110 USA.			McAlinden, Audrey/0000-0001-8433-4224				Aigner T, 1999, ARTHRITIS RHEUM, V42, P1443, DOI 10.1002/1529-0131(199907)42:7<1443::AID-ANR18>3.0.CO;2-A; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BISHOP PN, 1994, BIOCHEM BIOPH RES CO, V203, P289, DOI 10.1006/bbrc.1994.2180; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; BROCKS DG, 1993, MATRIX, V13, P381, DOI 10.1016/S0934-8832(11)80043-0; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; Edwards JCW, 1996, J ANAT, V188, P355; FISHER LW, 1987, J BIOL CHEM, V262, P13457; FLEISCHMAJER R, 1985, ANN NY ACAD SCI, V460, P246, DOI 10.1111/j.1749-6632.1985.tb51172.x; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; Kinoh H, 1996, J CELL SCI, V109, P953; Larrain J, 2000, DEVELOPMENT, V127, P821; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Melkko J, 1996, CLIN CHEM, V42, P947; NAH HD, 1991, J BIOL CHEM, V266, P23446; Nah HD, 2001, DEV DYNAM, V220, P307, DOI 10.1002/dvdy.1109; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; Ohta S, 1998, LAB INVEST, V78, P79; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Reardon A, 2000, MATRIX BIOL, V19, P169, DOI 10.1016/S0945-053X(00)00058-5; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Rousseau JC, 2000, ARTHRITIS RHEUM, V43, pS351; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; Tuckermann JP, 2000, J BONE MINER RES, V15, P1257, DOI 10.1359/jbmr.2000.15.7.1257; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1991, T ORTHOP RES SOC, V16, P27; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069; Zhu Y, 2001, DEV DYNAM, V220, P350, DOI 10.1002/dvdy.1115	41	36	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2193	2201		10.1074/jbc.M105485200	http://dx.doi.org/10.1074/jbc.M105485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11705992	hybrid			2022-12-25	WOS:000173421300079
J	Matata, BM; Galinanes, M				Matata, BM; Galinanes, M			Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; TYROSINE PHOSPHORYLATION; BLOOD; DEGRADATION; DAMAGE; CELLS; LUNG	The mechanism of release of proinflammatory cytokines by peripheral blood monocytes is unknown. Peroxynitrite (ONOO-) formed by the reaction of nitric oxide (NO) and superoxide is released predominantly by inflammatory cells at the site of injury in several inflammatory pathologies. Here we show that human monocytes treated with ONOO- at micromolar concentrations induce a dose-dependent release of proinflammatory cytokines. These effects were not antagonized by up to 100 muM epigallocatechin gallate, an inhibitor of protein nitration. However, the proteasome inhibitor Z-Ile-Glu(OtBu)-Ala-Leu-CHO and 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (111) chloride, a cell-permeable scavenger of ONOO-, almost completely inhibited the release of cytokines and the nuclear translocation of the nuclear factor (NF)-kappaB transcription factor. SDS-PAGE electrophoresis separation with Western blotting of cell extracts also indicated that phosphorylation and nitration of tyrosine residues in IkappaB-alpha molecules correlated with NF-kappaB translocation and cytokine release. In addition, the DNA binding activity of the NF-kappaB from the nuclear extracts also correlated with its nuclear translocation. These findings indicate ONOO- plays an essential role in the mechanism of proinflammatory cytokine release by monocytes and that Rel/NF-kappaB activation is the obligatory pathway.	Univ Leicester, Dept Integrat Human Cardiovasc Physiol, Glenfield Hosp, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Galinanes, M (corresponding author), Univ Leicester, Dept Integrat Human Cardiovasc Physiol, Glenfield Hosp, Groby Rd, Leicester LE3 9QP, Leics, England.		Galiñanes, Manuel/H-8195-2012	/0000-0003-2896-8059				Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Filep JG, 1998, J IMMUNOL, V161, P5656; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Khan J, 1998, BIOCHEM J, V330, P795, DOI 10.1042/bj3300795; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Lefer DJ, 1997, J CLIN INVEST, V99, P684, DOI 10.1172/JCI119212; Ma XL, 2000, J PHARMACOL EXP THER, V292, P912; MIERZWA S, 1987, BIOCHEM J, V246, P37, DOI 10.1042/bj2460037; MUSZYNSKA G, 1976, BIOCHEMISTRY-US, V15, P46, DOI 10.1021/bi00646a008; Nossuli TO, 1997, CIRCULATION, V96, P2317; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; Zouki C, 2001, FASEB J, V15, P25	22	182	193	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2330	2335		10.1074/jbc.M106393200	http://dx.doi.org/10.1074/jbc.M106393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706022	hybrid			2022-12-25	WOS:000173421300093
J	Paine-Saunders, S; Viviano, BL; Economides, AN; Saunders, S				Paine-Saunders, S; Viviano, BL; Economides, AN; Saunders, S			Heparan sulfate proteoglycans retain Noggin at the cell surface - A potential mechanism for shaping bone morphogenetic protein gradients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEMANN ORGANIZER; XENOPUS EMBRYOS; FIBROBLAST GROWTH; BINDING PROTEIN; BMP-4; BIOSYNTHESIS; FOLLISTATIN; DROSOPHILA; CHORDIN; DIFFERENTIATION	Bone morphogenetic proteins (BMPs) are expressed broadly and regulate a diverse array of developmental events in vivo. Essential to many of these functions is the establishment of activity gradients of BMP, which provide positional information that influences cell fates. Secreted polypeptides, such as Noggin, bind BMPs and inhibit their function by preventing interaction with receptors on the cell surface. These BNIP antagonists are assumed to be diffusible and therefore potentially important in the establishment of BNIP activity gradients in vivo. Nothing is known, however, about the potential interactions between Noggin and components of the cell surface or extracellular matrix that might limit its diffusion. We have found that Noggin binds strongly to heparin in vitro, and to heparan sulfate proteoglycans on the surface of cultured cells. Noggin is detected only on the surface of cells that express heparan sulfate, can be specifically displaced from cells by heparin, and can be directly cross-linked to a cell surface proteoglycan in culture. Heparan sulfate-bound Noggin remains functional and can bind BMP4 at the plasma membrane. A Noggin mutant with a deletion in a putative heparin binding domain has reduced binding to heparin and does not bind to the cell surface but has preserved BMP binding and antagonist functions. Our results imply that interactions between Noggin and heparan sulfate proteoglycans in vivo regulate diffusion and therefore the formation of gradients of BMP activity.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Washington Univ, Sch Med, Dept Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Regeneron; Washington University (WUSTL)	Saunders, S (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.			Economides, Aris/0000-0002-6508-8942	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056063] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56063] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497; Bachiller D, 2000, NATURE, V403, P658, DOI 10.1038/35001072; Baeg GH, 2001, DEVELOPMENT, V128, P87; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blitz IL, 2000, DEV BIOL, V223, P120, DOI 10.1006/dbio.2000.9740; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Dale L, 1999, SEMIN CELL DEV BIOL, V10, P319, DOI 10.1006/scdb.1999.0308; Dosch R, 1997, DEVELOPMENT, V124, P2325; ECONOMIDES AN, 2000, Patent No. 6075007; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; Friedl A, 1997, AM J PATHOL, V150, P1443; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sugino Hiromu, 1997, Journal of Medical Investigation, V44, P1; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	41	175	186	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2089	2096		10.1074/jbc.M109151200	http://dx.doi.org/10.1074/jbc.M109151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11706034	hybrid			2022-12-25	WOS:000173421300065
J	Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R				Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R			CRBP suppresses breast cancer cell survival and anchorage-independent growth	ONCOGENE			English	Article						FABP; soft agar; anoikis; retinol; retinoic acid	RETINOL-BINDING PROTEIN; EPITHELIAL-CELLS; CARCINOMA CELLS; LIPID BODIES; ACID; APOPTOSIS; GENE; EXPRESSION; INHIBITION; TISSUE	We showed earlier that cellular retinol-binding protein (CRBP) expression is downregulated in a subset of human breast cancers. We have now investigated the outcome of ectopic CRBP expression in MTSV1-7 cells, a SV40 T antigen-transformed human breast epithelial cell line devoid of endogenous CRBP expression. We found that: (i) CRBP did not inhibit adherent cell growth but suppressed foci formation in post-confluent cultures and colony formation in soft agar; (ii) this effect was due to CRBP inhibition of cell survival, as demonstrated by viability and TUNEL assays of cells in soft-agar or plated on polyHEMA-coated dishes; (iii) CRBP inhibited protein kinase B/Akt activation in cells in suspension but not in adherent cells and the CRBP suppression of anchorage-independent growth was mimicked by cell treatment with the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002; (iv) CRBP enhanced retinyl ester formation and storage but did not regulate retinoic acid synthesis or retinoic acid receptor activity. Ectopic CRBP-mediated inhibition of anchorage-independent cell survival and colony formation in the absence of significantly altered responses to either retinol or retinoic acid was also documented in T47D human breast cancer cells. In conclusion, the data suggest two novel and linked CRBP functions in mammary epithelial cells: inhibition of the PI3K/Akt survival pathway and suppression of anchorage-independent growth.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo 142, Japan	Icahn School of Medicine at Mount Sinai; Vanderbilt University; Showa University	Kuppumbatti, YS (corresponding author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA54273] Funding Source: Medline; NICHD NIH HHS [5T32HD07043] Funding Source: Medline; NIDDK NIH HHS [R01DK32642] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007043] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054273, R29CA054273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chang TH, 2000, CANCER RES, V60, P1129; DAWSON MI, 1995, CANCER RES, V55, P4446; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HUYNH HT, 1995, CANCER RES, V55, P2225; Jing YK, 1997, CANCER RES, V57, P1668; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Li GY, 1999, CANCER RES, V59, P6267; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; PAPPAS RS, 1993, BIOL REPROD, V48, P235, DOI 10.1095/biolreprod48.2.235; Ruff SJ, 2000, FEBS LETT, V487, P282, DOI 10.1016/S0014-5793(00)02366-8; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sapi E, 1999, CANCER RES, V59, P5578; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shi YE, 1997, CANCER RES, V57, P3084; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575; Yamamoto M, 1998, EUR J BIOCHEM, V257, P344, DOI 10.1046/j.1432-1327.1998.2570344.x; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085	31	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7413	7419		10.1038/sj.onc.1204749	http://dx.doi.org/10.1038/sj.onc.1204749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704871				2022-12-25	WOS:000171894200014
J	Kim, KC; Kim, TS; Kang, KH; Choi, KH				Kim, KC; Kim, TS; Kang, KH; Choi, KH			Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73 beta function through protein-protein interactions	ONCOGENE			English	Article						p73; amphiphysin IIb-1; SH3 domain; NLS; yeast two-hybrid; splicing variants	KINASE C-ABL; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; ADENOVIRUS TYPE-5; INDUCE APOPTOSIS; MAMMALIAN-CELLS; 3-HYBRID SYSTEM; E4ORF6 PROTEINS; BREAST-CANCER	p73 is a nuclear protein that is similar in structure and function to p53. Notably, the C-terminal region of p73 has a regulatory function, through interactions with a positive or negative regulator. In this study, we use the yeast two-hybrid technique to identify a novel p73 beta binding protein, designated amphiphysin IIb-1. Amphiphysin IIb-1 is one of the splicing variants of amphiphysin II, and has a shorter protein product than amphiphysin IIb, which has been previously reported. We confirmed that amphiphysin IIb-1 binds full-length p73 beta, both in vitro and in vivo. This association is mediated via the SH3 domain of amphiphysin IIb-1 and C-terminal amino acids 321-376 of p73 beta. Double immunofluorescence patterns revealed that p73 beta is relocalized to the cytoplasm in the presence of amphiphysin IIb-1. Overexpression of amphiphysin IIb-1 was found to significantly inhibit the transcriptional activity of p73 beta in a dose-dependent manner. In addition, the cell death function of p73 beta was inhibited by amphiphysin IIb-1. These findings offer a new insight into the regulation mechanism of p73 beta, and suggest that amphiphysin IIb-1 modulates p73 beta function by direct binding.	Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Seoul 156756, South Korea	Chung Ang University	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Heuksuk Dong, Seoul 156756, South Korea.							Agami R, 1999, NATURE, V399, P809; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Gong JG, 1999, NATURE, V399, P806; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kleihues P, 1997, AM J PATHOL, V150, P1; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; MARTIN MC, 1998, MOL CELL BIOL, V18, P6316; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Ozaki T, 1999, CANCER RES, V59, P5902; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	44	12	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6689	6699		10.1038/sj.onc.1204839	http://dx.doi.org/10.1038/sj.onc.1204839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709703				2022-12-25	WOS:000171551600005
J	Akakura, R; Winans, SC				Akakura, R; Winans, SC			Constitutive mutations of the OccR regulatory protein affect DNA bending in response to metabolites released from plant tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LAC-PROMOTER; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATOR; AGROBACTERIUM-TUMEFACIENS; SALMONELLA-TYPHIMURIUM; RNA-POLYMERASE; PSEUDOMONAS-AERUGINOSA; REGIONS IMPORTANT; BINDING-SITES; LYSR FAMILY	OccR is a LysR-type transcriptional regulator of Agrobacterium tumefaciens that positively regulates the octopine catabolism operon of the Ti plasmid and is also an autorepressor. Positive control of the occ genes oc. curs in response to octopine, a nutrient released from crown gall tumors. OccR binds to a site upstream of the occQ promoter in the presence and absence of octopine. Octopine causes prebound OccR to undergo a conformational change at the DNA binding site that causes changes in footprint length and DNA bending. To determine the roles of these conformational changes in transcriptional activation, we isolated 22 OccR mutants that were able to activate the occQ promoter in the absence of octopine. Thirteen of these mutants contained single amino acid substitutions, and nine contained two base pair changes resulting in two amino acid substitutions, which in most cases acted synergistically. These mutations spanned the entire length of the protein. Most of these mutant proteins in the absence of octopine displayed DNA binding and bending properties characteristic of transcriptionally active OccR-octopine complexes.	Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Cornell University	Winans, SC (corresponding author), Cornell Univ, Dept Microbiol, 360A Wing Hall, Ithaca, NY 14853 USA.	scw2@cornell.edu						BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; CANGELOSI GA, 1991, METHODS ENZYMOL; Cebolla A, 1997, J BIOL CHEM, V272, P3986, DOI 10.1074/jbc.272.7.3986; CHEN CY, 1991, J BACTERIOL, V173, P1139, DOI 10.1128/jb.173.3.1139-1144.1991; Cho KY, 1996, J BACTERIOL, V178, P1872, DOI 10.1128/jb.178.7.1872-1880.1996; CHO KY, 1993, J BACTERIOL, V175, P7715, DOI 10.1128/JB.175.23.7715-7719.1993; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Chugani SA, 1997, J BACTERIOL, V179, P2221, DOI 10.1128/jb.179.7.2221-2227.1997; COLYER TE, 1994, MOL MICROBIOL, V13, P797, DOI 10.1111/j.1365-2958.1994.tb00472.x; Colyer TE, 1996, MOL MICROBIOL, V21, P247, DOI 10.1046/j.1365-2958.1996.6301347.x; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; GAO J, 1991, EMBO J, V10, P4137, DOI 10.1002/j.1460-2075.1991.tb04991.x; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P279; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HRYNIEWICZ MM, 1995, J BACTERIOL, V177, P2343, DOI 10.1128/jb.177.9.2343-2353.1995; Jorgensen C, 1999, J BACTERIOL, V181, P4397; Jourdan AD, 1998, J BACTERIOL, V180, P4865, DOI 10.1128/JB.180.18.4865-4871.1998; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; Liu ST, 1998, ANAL BIOCHEM, V255, P158, DOI 10.1006/abio.1997.2457; Lochowska A, 2001, J BIOL CHEM, V276, P2098, DOI 10.1074/jbc.M007192200; LORENZ E, 1995, J BACTERIOL, V177, P4113, DOI 10.1128/jb.177.14.4113-4120.1995; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MILLER JH, 1992, SHORT COURSE BACTERI, P143; PARSEK MR, 1992, J BACTERIOL, V174, P7798, DOI 10.1128/JB.174.23.7798-7806.1992; PARSEK MR, 1995, MOL MICROBIOL, V15, P819, DOI 10.1111/j.1365-2958.1995.tb02352.x; Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; Pineiro S, 1997, J BACTERIOL, V179, P5407, DOI 10.1128/jb.179.17.5407-5413.1997; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SHELL M, 1989, J BACTERIOL, V171, P837; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAO K, 1995, J BACTERIOL, V177, P6740, DOI 10.1128/jb.177.23.6740-6744.1995; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; Tyrrell R, 1997, STRUCTURE, V5, P1017, DOI 10.1016/S0969-2126(97)00254-2; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; WANG L, 1995, J MOL BIOL, V253, P691, DOI 10.1006/jmbi.1995.0583; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	47	36	37	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5866	5874		10.1074/jbc.M110555200	http://dx.doi.org/10.1074/jbc.M110555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11717314	hybrid			2022-12-25	WOS:000173989200024
J	Papouli, E; Defais, M; Larminat, F				Papouli, E; Defais, M; Larminat, F			Overexpression of metallothionein-II sensitizes rodent cells to apoptosis induced by DNA cross-linking agent through inhibition of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; FANCONI-ANEMIA CELLS; MITOMYCIN-C; ANTICANCER DRUGS; MOUSE METALLOTHIONEIN; ALKYLATING-AGENTS; ZINC; GENE; CISPLATIN; REPAIR	DNA cross-linking agents such as mitomycin C (MM4) and cisplatin are used as chemotherapeutic agents in cancer treatment. However, the molecular mechanism underlying their antitumor activity is not entirely clear. Critical steps in cytotoxicity toward cross-linking agents can involve DNA repair efficiency, inhibition of replication, cell-cycle checkpoints, regulation, and induction of apoptosis. The complexity of the mechanisms of the mammalian cell defense against cross-linking agents is reflected by the existence of many complementation groups identified in rodent cells that are specifically sensitive to MMC. We recently showed that increased induction of apoptosis contributes to the MMC sensitivity of the group represented by the V-H4 hamster mutant cell line. In this study, through the analyses of a substractive library, we discovered that sensitive V-H4 cells display a 40-fold increase of steady-state expression of metallothionein II (MT-II) mRNA compared with resistant parental V79 cells. Down-regulation of MT-II by antisense oligonucleotides partially restores MMC resistance in V-H4 cells, indicating that MT-II overexpression is directly involved in MMC hypersensitivity of these cells. MTs have been reported to regulate the activation of NF-kappaB, one of the key proteins that modulates the apoptotic response. Here we found that NF-kappaB activation by MMC is impaired in V-H4 cells and is partially restored following down-regulation of MT-II by antisense oligonucleotides. All these data suggest that the overexpression of MT-II in V-H4 cells impairs NF-kappaB activation by MMC, resulting in decreased cell survival and enhanced induction of apoptosis.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Larminat, F (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.	flol@ipbs.fr						Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Chaung WR, 1997, NUCLEIC ACIDS RES, V25, P992, DOI 10.1093/nar/25.5.992; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; He T, 2000, CELL MOL BIOL, V46, P383; Ho LH, 2000, BIOCHEM BIOPH RES CO, V268, P148, DOI 10.1006/bbrc.2000.2090; Iversen Patrick L., 1992, Biological Signals, V1, P293; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jankowski-Hennig MA, 2000, BIOCHEM BIOPH RES CO, V271, P250, DOI 10.1006/bbrc.2000.2608; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; JONES NJ, 1994, MUTAGENESIS, V9, P477, DOI 10.1093/mutage/9.5.477; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Kohn KW, 1996, CANCER RES, V56, P5533; KOROPATNICK J, 1993, MOL PHARMACOL, V44, P44; LARMINAT F, 1994, NUCLEIC ACIDS RES, V22, P3005, DOI 10.1093/nar/22.15.3005; Larminat F, 1998, FEBS LETT, V437, P97, DOI 10.1016/S0014-5793(98)01209-5; Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; MESTRE B, 1995, BIOCONJUGATE CHEM, V6, P466, DOI 10.1021/bc00034a017; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Oteiza PI, 2000, FREE RADICAL BIO MED, V28, P1091, DOI 10.1016/S0891-5849(00)00200-8; Oteiza PI, 2001, J NUTR, V131, P21, DOI 10.1093/jn/131.1.21; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Papouli E, 2000, BIOCHEM PHARMACOL, V59, P1101, DOI 10.1016/S0006-2952(00)00234-3; PLOOY ACM, 1985, CANCER RES, V45, P4178; ROBSON T, 1992, MUTAT RES, V274, P177, DOI 10.1016/0921-8777(92)90064-A; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Samson SLA, 1998, PROG NUCLEIC ACID RE, V59, P257, DOI 10.1016/S0079-6603(08)61034-X; SARTORELLI AC, 1994, ONCOL RES, V6, P501; Schwartz SA, 1999, SURG ONCOL, V8, P143, DOI 10.1016/S0960-7404(00)00012-8; Tang CM, 1999, MOL CELL BIOL, V19, P680; TELLEMAN P, 1995, CANCER RES, V55, P3412; Tomasz M, 1997, PHARMACOL THERAPEUT, V76, P73, DOI 10.1016/S0163-7258(97)00088-0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZDZIENICKA MZ, 1987, MUTAT RES, V178, P235, DOI 10.1016/0027-5107(87)90274-0; ZDZIENICKA MZ, 1990, SOMAT CELL MOLEC GEN, V16, P575, DOI 10.1007/BF01233098	52	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4764	4769		10.1074/jbc.M108447200	http://dx.doi.org/10.1074/jbc.M108447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11713249	hybrid			2022-12-25	WOS:000173962900029
J	Bowman, BJ; Bowman, EJ				Bowman, BJ; Bowman, EJ			Mutations in subunit c of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; MEMBRANE H+-ATPASE; NEUROSPORA-CRASSA; ADENOSINE-TRIPHOSPHATASES; SELECTIVE INHIBITORS; PROTEOLIPID SUBUNIT; PROTON PUMPS; GENE; MITOCHONDRIAL; SYNTHASE	Bafilomycin A1, a potent inhibitor of vacuolar H+- ATPases (V-ATPase), inhibited growth of Neurospora crassa in medium adjusted to alkaline pH. Ninety-eight mutant strains were selected for growth on medium (pH 7.2) containing 0.3 or 1.0 muM bafilomycin. Three criteria suggested that 11 mutant strains were altered in the V-ATPase: 1) these strains accumulated high amounts of arginine when grown at pH 5.8 in the presence of bafilomycin, 2) the mutation mapped to the locus of vma-3, which encodes the proteolipid subunit c of the V-ATPase, and 3) V-ATPase activity in purified vacuolar membranes was resistant to bafilomycin. Sequencing of the genomic DNA encoding vma-3 identified the following mutations: T32I (two strains), F136L (two strains), Y143H (two strains), and Y143N (five strains). Characterization of V-ATPase activity in the four kinds of mutant strains showed that the enzyme was resistant to bafilomycin in vitro, with half-maximal inhibition obtained at 80-400 nm compared with 6.3 nm for the wildtype enzyme. Surprisingly, the mutant enzymes showed only weak resistance to concanamycin. Interestingly, the positions of two mutations corresponded to positions of oligomycin-resistant mutations in the c subunit of F1F0-ATP synthases (F-ATPases), suggesting that bafilomycin and oligomycin utilize a similar binding site and mechanism of inhibition in the related F- and V-ATPases.	Univ Calif Santa Cruz, Dept MCD Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Bowman, BJ (corresponding author), Univ Calif Santa Cruz, Dept MCD Biol, Santa Cruz, CA 95064 USA.	bowman@biology.ucsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028703, R25GM058903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28703, GM-58903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1997, BIOMEMBRANE, P861; BOWMAN J, 1996, MYCOTA, V3, P57; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Davis RH, 2000, NEUROSPORA CONTRIBUT, P283; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Drose S, 2001, BIOCHEMISTRY-US, V40, P2816, DOI 10.1021/bi001759q; EVANS DA, 1993, TETRAHEDRON LETT, V34, P6871, DOI 10.1016/S0040-4039(00)91817-3; Farina C, 2001, FARMACO, V56, P113, DOI 10.1016/S0014-827X(01)01013-8; Farina C, 1999, DRUG DISCOV TODAY, V4, P163, DOI 10.1016/S1359-6446(99)01321-5; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gagliardi S, 1998, J MED CHEM, V41, P1568, DOI 10.1021/jm9800144; Gagliardi S, 1998, J MED CHEM, V41, P1883, DOI 10.1021/jm9707838; GALANIS M, 1989, FEBS LETT, V249, P333, DOI 10.1016/0014-5793(89)80653-2; Grabe M, 2000, BIOPHYS J, V78, P2798, DOI 10.1016/S0006-3495(00)76823-8; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; Kelling DJ, 1997, ANN NY ACAD SCI, V834, P600, DOI 10.1111/j.1749-6632.1997.tb52329.x; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SISTA H, 1994, MOL GEN GENET, V243, P82, DOI 10.1007/BF00283879; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Toshima K, 2001, J ORG CHEM, V66, P1708, DOI 10.1021/jo001377q; Toshima K, 1997, J ORG CHEM, V62, P3271, DOI 10.1021/jo970314d; Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877; ZHANG WW, 1994, CANCER GENE THER, V1, P5	39	115	117	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3965	3972		10.1074/jbc.M109756200	http://dx.doi.org/10.1074/jbc.M109756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11724795	hybrid			2022-12-25	WOS:000173813900024
J	Huy, NT; Kamei, K; Yamamoto, T; Kondo, Y; Kanaori, K; Takano, R; Tajima, K; Hara, S				Huy, NT; Kamei, K; Yamamoto, T; Kondo, Y; Kanaori, K; Takano, R; Tajima, K; Hara, S			Clotrimazole binds to heme and enhances heme-dependent hemolysis - Proposed antimalarial mechanism of clotrimazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; RESISTANT PLASMODIUM-BERGHEI; FERRIPROTOPORPHYRIN-IX; IN-VITRO; PHOSPHOLIPID MONOLAYERS; FALCIPARUM; CHLOROQUINE; GLUTATHIONE; MEMBRANE; INHIBITION	Two recent studies have demonstrated that clotrimazole, a potent antifungal agent, inhibits the growth of chloroquine-resistant strains of the malaria parasite, Plasmodium falciparum, in vitro. We explored the mechanism of antimalarial activity of clotrimazole in relation to hemoglobin catabolism in the malaria parasite. Because free heme produced from hemoglobin catabolism is highly toxic to the malaria parasite, the parasite protects itself by polymerizing heme into insoluble nontoxic hemozoin or by decomposing heme coupled to reduced glutathione. We have shown that clotrimazole has a high binding affinity for heme in aqueous 40% dimethyl sulfoxide solution (association equilibrium constant: K-a = 6.54 x 10(8) M-2). Even in water, clotrimazole formed a stable and soluble complex with heme and suppressed its aggregation. The results of optical absorption spectroscopy and electron spin resonance spectroscopy revealed that the heme-clotrimazole complex assumes a ferric low spin state (S = (1)/(2)), having two nitrogenous ligands derived from the imidazole moieties of two clotrimazole molecules. Furthermore, we found that the formation of heme-clotrimazole complexes protects heme from degradation by reduced glutathione, and the complex damages the cell membrane more than free heme. The results described herein indicate that the antimalarial activity of clotrimazole might be due to a disturbance of hemoglobin catabolism in the malaria parasite.	Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan	Kyoto Institute of Technology	Kamei, K (corresponding author), Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	kame@ipe.kit.ac.jp	Huy, Nguyen Tien/B-2573-2010	Huy, Nguyen Tien/0000-0002-9543-9440				Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; ATAMNA H, 1995, J BIOL CHEM, V270, P24876, DOI 10.1074/jbc.270.42.24876; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; BRAULT D, 1974, BIOCHEM BIOPH RES CO, V57, P654, DOI 10.1016/0006-291X(74)90596-8; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; CAMPBELL VM, 1981, THESIS U WITWATERSTR; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; COLLIER GS, 1979, BIOCHEM J, V179, P281, DOI 10.1042/bj1790281; DUTTA P, 1983, J PHARMACOL EXP THER, V225, P729; Egan TJ, 1997, J INORG BIOCHEM, V68, P137, DOI 10.1016/S0162-0134(97)00086-X; FITCH CD, 1974, ANTIMICROB AGENTS CH, V6, P757, DOI 10.1128/AAC.6.6.757; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GALLAGHER WA, 1968, BIOCHEM J, V108, P131, DOI 10.1042/bj1080131; GINSBURG H, 1983, BIOCHIM BIOPHYS ACTA, V732, P316, DOI 10.1016/0005-2736(83)90219-5; GINSBURG H, 1984, CHEM PHYS LIPIDS, V35, P331, DOI 10.1016/0009-3084(84)90076-8; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; INSELBURG J, 1985, AM J TROP MED HYG, V34, P417, DOI 10.4269/ajtmh.1985.34.417; KADISH KM, 2000, PORPHYRIN HDB, V9, P221; KAMINSKY LS, 1972, ARCH BIOCHEM BIOPHYS, V150, P355, DOI 10.1016/0003-9861(72)90049-5; KATAGIRI M, 1987, BIOCHEM BIOPH RES CO, V149, P1070, DOI 10.1016/0006-291X(87)90517-1; Luersen K, 2000, BIOCHEM J, V346, P545, DOI 10.1042/0264-6021:3460545; MOMENTEAU M, 1973, BIOCHIM BIOPHYS ACTA, V304, P814, DOI 10.1016/0304-4165(73)90228-6; PASTERNACK RF, 1978, J AM CHEM SOC, V100, P2613, DOI 10.1021/ja00477a005; Platel DFN, 1999, MOL BIOCHEM PARASIT, V98, P215, DOI 10.1016/S0166-6851(98)00170-4; ROSE MY, 1985, J BIOL CHEM, V260, P6632; Sahini VE, 1996, BIOPHYS CHEM, V58, P245, DOI 10.1016/0301-4622(95)00110-7; Saliba KJ, 1998, T ROY SOC TROP MED H, V92, P666, DOI 10.1016/S0035-9203(98)90805-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAKLAI N, 1985, BIOCHIM BIOPHYS ACTA, V821, P355, DOI 10.1016/0005-2736(85)90106-3; SHVIRO Y, 1987, BIOCHEM PHARMACOL, V36, P3801, DOI 10.1016/0006-2952(87)90441-2; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; TAJIMA K, 1989, INORG CHIM ACTA, V163, P115, DOI 10.1016/S0020-1693(00)87150-9; Tiffert T, 2000, P NATL ACAD SCI USA, V97, P331, DOI 10.1073/pnas.97.1.331; Tiffert T, 2000, J PHYSIOL-LONDON, V525, P125, DOI 10.1111/j.1469-7793.2000.00125.x; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; VANHOLDE KE, 1971, PHYSICAL BIOCH, P62; WOOD PA, 1993, AM J TROP MED HYG, V48, P465, DOI 10.4269/ajtmh.1993.48.465	44	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4152	4158		10.1074/jbc.M107285200	http://dx.doi.org/10.1074/jbc.M107285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11707446	hybrid			2022-12-25	WOS:000173813900050
J	Stanciu, M; DeFranco, DB				Stanciu, M; DeFranco, DB			Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CORTICAL-NEURONS; NERVE GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTORS; LONG-TERM; GLUCOCORTICOID RECEPTOR; GLUTAMATE TOXICITY; TRANSLOCATION; STRESS; ERK	In the HT22 mouse hippocampal cell line and primary immature embryonic rat cortical neurons, glutamate-induced oxidative toxicity is associated with a delayed but chronic activation of extracellular signal-regulated kinase-1/2 (ERK-1/2). ERK-1/2 is also activated in HT22 cells that undergo caspase-dependent cell death upon inhibition of proteasome-dependent protein degradation brought about by MG132 treatment. As in glutamate-treated HT22 cells and primary neurons, inhibition of MEK-1, an upstream activator of ERK-1/2 protects against MG132-induced toxicity. Furthermore, activated ERK-1/2 is retained within the nucleus in glutamate- and MG132-treated HT22 cells. Although previous studies suggested that ERK-1/2 activation was downstream of many cell death-inducing signals in HT22 cells, we show here that cycloheximide, the Z-vad caspase inhibitor, and a nonlethal heat shock protect against glutamate- and MG132-induced toxicity without diminishing ERK-1/2 activation. In these cases, ERK-1/2, although chronically activated, is not retained within the nucleus but accumulates within the cytoplasm. Thus, persistent nuclear retention of activated ERK-1/2 may be a critical factor in eliciting proapoptotic effects in neuronal cells subjected to oxidative stress or proteasome inhibition.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E1354 BSTWR, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038319] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38319] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe K, 2000, NEUROSCI LETT, V292, P1, DOI 10.1016/S0304-3940(00)01415-4; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Berman DE, 1998, J NEUROSCI, V18, P10037; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Blum S, 1999, J NEUROSCI, V19, P3535; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrigno P, 1999, ONCOGENE, V18, P6129, DOI 10.1038/sj.onc.1203132; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Garrido YCS, 1998, BRAIN RES BULL, V47, P223, DOI 10.1016/S0361-9230(98)00075-6; Giuliano M, 1999, CANCER RES, V59, P5586; GOTOH Y, 1995, MOL REPROD DEV, V42, P486, DOI 10.1002/mrd.1080420417; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Krejsa CM, 1998, ENVIRON HEALTH PERSP, V106, P1179, DOI 10.2307/3433983; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Maher P, 1996, J NEUROSCI, V16, P6394; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattison CP, 2000, GENE DEV, V14, P1229; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Reiser V, 1999, GENE EXPRESSION, V7, P247; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Schafe GE, 1999, LEARN MEMORY, V6, P97; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Sgambato V, 1998, J NEUROSCI, V18, P8814; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Singer CA, 1999, J NEUROSCI, V19, P2455; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tirosh O, 2000, NEUROSCIENCE, V97, P531, DOI 10.1016/S0306-4522(00)00028-2; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wang Z, 1998, DEVELOPMENT, V125, P4841; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao NQ, 1999, J NEUROCHEM, V72, P95, DOI 10.1046/j.1471-4159.1999.0720095.x; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199	71	126	129	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4010	4017		10.1074/jbc.M104479200	http://dx.doi.org/10.1074/jbc.M104479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11726647	hybrid			2022-12-25	WOS:000173813900030
J	Lin, HJ; Luo, CW; Chen, YH				Lin, HJ; Luo, CW; Chen, YH			Localization of the transglutaminase cross-linking site in SVSIII, a novel glycoprotein secreted from mouse seminal vesicle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDOMINANT PROTEINS; SEMENOGELIN-II; SPERM MOTILITY; FACTOR-XIIIA; HUMAN SEMEN; AUTOANTIGEN; INHIBITOR; CLONING	The nucleotide sequence of MpSv-1, a novel androgen-regulated gene exclusively expressed in mouse seminal vesicle, was analyzed to establish a 5'-flanking region of 2123 bp, three exons of 95, 765, and 330 bp, and two introns of 222 and 811 bp. The transcription unit is organized with the first exon encoding a signal peptide, and the second a secreted protein, whereas the third encompasses a T-non-translated nucleotide that shares common features of rapid evolving substrates of transglutaminase gene family. The protein sequence deduced from this gene contains 265 amino acid residues in which the central part, residues 116-145, is a region composed of five short tandem repeats, consisting of four amino acid residues, QXK(S/T), where X is an aliphatic amino acid residue. Among the mouse seminal vesicle secretory proteins that could be resolved by SDS-PAGE into seven major components, SVS I-VII, the antiserum against residues 77-109 of the MpSv-1-translated protein only reacted with SVS III. Matrix-assisted laser desorption/ionization-time of flight mass spectral analysis from a trypsin digest of SVS III supported this protein as derived from MpSv-1. SVS III was immunolocalized to the epithelium of both the primary and secondary folds of the seminal vesicle and the copulatory plug. All of mouse SVS I-IH were proven to be substrates of transglutaminase and could be cross-linked readily after the enzyme reaction. The transglutaminase cross-linking site of SVS III was identified to be the tandem repeats of QXK(S/T) in the central part of this protein molecule.	Natl Taiwan Univ, Inst Biochem Sci, Coll Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan	National Taiwan University; Academia Sinica - Taiwan	Chen, YH (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Coll Sci, POB 23-106, Taipei 106, Taiwan.	bc304@gate.sinica.edu.tw		Lin, Han-Jia/0000-0002-4929-6573				Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; CHEN YH, 1987, MOL ENDOCRINOL, V1, P707, DOI 10.1210/mend-1-10-707; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Esposito C, 1996, J BIOL CHEM, V271, P27416, DOI 10.1074/jbc.271.44.27416; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gong BW, 2000, BIOTECHNIQUES, V28, P846, DOI 10.2144/00285bm04; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; Hagstrom JE, 1996, J BIOL CHEM, V271, P21114, DOI 10.1074/jbc.271.35.21114; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; Huang YH, 2000, BIOL REPROD, V63, P1562, DOI 10.1095/biolreprod63.5.1562; IZAWA M, 1990, ENDOCRINOL JAPON, V37, P233; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI ML, 1991, ARCH BIOCHEM BIOPHYS, V290, P265, DOI 10.1016/0003-9861(91)90540-Y; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Lundwall A, 1997, EUR J BIOCHEM, V249, P39, DOI 10.1111/j.1432-1033.1997.t01-2-00039.x; Lundwall A, 1996, EUR J BIOCHEM, V235, P424, DOI 10.1111/j.1432-1033.1996.00424.x; LUNDWALL A, 1995, FEBS LETT, V374, P53, DOI 10.1016/0014-5793(95)01076-Q; Luo CW, 2001, J BIOL CHEM, V276, P6913, DOI 10.1074/jbc.M006954200; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; PEITZ B, 1986, BIOL REPROD, V35, P608, DOI 10.1095/biolreprod35.3.608; Peter A, 1998, EUR J BIOCHEM, V252, P216, DOI 10.1046/j.1432-1327.1998.2520216.x; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRODE J, 1979, J BIOL CHEM, V254, P653; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; VELASCO PT, 1988, BIOCHEM BIOPH RES CO, V152, P505, DOI 10.1016/S0006-291X(88)80066-4; WILLIAMSASHMAN HG, 1984, MOL CELL BIOCHEM, V58, P51, DOI 10.1007/BF00240604; YU LC, 1993, BIOCHEM J, V296, P571, DOI 10.1042/bj2960571	35	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3632	3639		10.1074/jbc.M107578200	http://dx.doi.org/10.1074/jbc.M107578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11723121	Green Published, hybrid			2022-12-25	WOS:000173688000076
J	Hawkes, NA; Otero, G; Winkler, GS; Marshall, N; Dahmus, ME; Krappmann, D; Scheidereit, C; Thomas, CL; Schiavo, G; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Hawkes, NA; Otero, G; Winkler, GS; Marshall, N; Dahmus, ME; Krappmann, D; Scheidereit, C; Thomas, CL; Schiavo, G; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			Purification and characterization of the human Elongator complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TERMINAL DOMAIN PHOSPHATASE; HISTONE ACETYLTRANSFERASE; TRANSCRIPTION; SENSITIVITY; HOLOENZYME; PROTEIN; INITIATION; COMPONENT; SUBUNIT	Human Elongator complex was purified to virtual homogeneity from HeLa cell extracts. The purified factor can exist in two forms: a six-subunit complex, holo-Elongator, which has histone acetyltransferase activity directed against histone H3 and H4, and a three-subunit core form, which does not have histone acetyltransferase activity despite containing the catalytic Elp3 subunit. Elongator is a component of early elongation complexes formed in HeLa nuclear extracts and can interact directly with RNA polymerase 11 in solution. Several human homologues of the yeast Elongator subunits were identified as subunits of the human Elongator complex, including StIP1 ( STAT-interacting protein 1) and IKAP (IKK complex-associated protein). Mutations in IKAP can result in the severe human disorder familial dysautonomia, raising the possibility that this disease might be due to compromised Elongator function and therefore could be a transcription disorder.	Imperial Canc Res Fund, Clare Hall Labs, Mechanisms Gene Transcript Lab, S Mimms EN6 3LD, Herts, England; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Imperial Canc Res Fund, Mol Neuropathobiol Lab, London WC2A 3PX, England; Mem Sloan Kettering Canc Ctr, Mol Biol Programme, New York, NY 10021 USA	University of California System; University of California Davis; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Cancer Research UK; Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Mechanisms Gene Transcript Lab, Blanche Lane, S Mimms EN6 3LD, Herts, England.		Krappmann, Daniel/ABF-4038-2021; Krappmann, Daniel/AAT-4354-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Winkler, Sebastiaan/0000-0002-0476-162X; Schiavo, Giampietro/0000-0002-4319-8745; Svejstrup, Jesper/0000-0003-4964-6147; Tempst, Paul/0000-0002-6680-3987	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM-33300] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson SL, 2001, AM J HUM GENET, V68, P753, DOI 10.1086/318808; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Collum RG, 2000, P NATL ACAD SCI USA, V97, P10120, DOI 10.1073/pnas.170192197; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; Harlow E., 1988, ANTIBODIES LAB MANUA; KANG ME, 1993, J BIOL CHEM, V268, P25033; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Slaugenhaupt SA, 2001, AM J HUM GENET, V68, P598, DOI 10.1086/318810; Takeoka S, 2001, J HUM GENET, V46, P57, DOI 10.1007/s100380170109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	26	202	223	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3047	3052		10.1074/jbc.M110445200	http://dx.doi.org/10.1074/jbc.M110445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11714725				2022-12-25	WOS:000173421500088
J	Rodgers, ND; Wang, ZR; Kiledjian, M				Rodgers, ND; Wang, ZR; Kiledjian, M			Characterization and purification of a mammalian endoribonuclease specific for the alpha-globin mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; POLY(C) BINDING-PROTEIN; 3'-UNTRANSLATED REGION; ENDONUCLEOLYTIC CLEAVAGE; DECAPPING ENZYME; POLIOVIRUS RNA; IN-VITRO; COMPLEX; TURNOVER	The alpha-globin mRNA has previously been shown to be the target of an erythroid-enriched endoribonuclease (ErEN) activity which cleaves the mRNA within the 3'-untranslated region. We have currently undertaken a biochemical approach to purify this enzyme and have begun characterization of the enzyme to determine requirements for substrate recognition as well as optimal cleavage conditions. Through mutational analysis and truncations we show that a 26-nucleotide region of the alpha-globin W-untranslated region is an autonomous element that is both necessary and sufficient for cleavage by ErEN. Mutations throughout this region abolish cleavage activity by ErEN suggesting that the entire sequence is important for recognition and cleavage. ErEN is most active under biological salt concentrations and temperature and activity of the enzyme does not require cations. The size for ErEN was estimated by denaturing gel filtration analysis and is similar to40 kDa. Interestingly, the exquisite specificity of ErEN cleavage became compromised with increased purity of the enzyme suggesting the involvement of other proteins in specificity of ErEN cleavage. Nondenaturing gel filtration of MEL extract demonstrated that ErEN is a component of an similar to160 kDa complex implying that additional proteins may regulate ErEN activity and provide increased cleavage specificity.	Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kiledjian, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA.				NIDDK NIH HHS [DK51611] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051611] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BINDER R, 1990, PROG CLIN BIOL RES, V322, P227; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Brouwer R, 2001, J BIOL CHEM, V276, P6177, DOI 10.1074/jbc.M007603200; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Chernokalskaya E, 1998, RNA, V4, P1537, DOI 10.1017/S1355838298980451; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; Cunningham KS, 2001, NUCLEIC ACIDS RES, V29, P1156, DOI 10.1093/nar/29.5.1156; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gamarnik AV, 1997, RNA, V3, P882; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Heise T, 2001, J VIROL, V75, P6874, DOI 10.1128/JVI.75.15.6874-6883.2001; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; NUSS DL, 1975, CELL, V6, P21, DOI 10.1016/0092-8674(75)90069-0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Parsley TB, 1997, RNA, V3, P1124; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Russell JE, 1997, PROG NUCLEIC ACID RE, V57, P249, DOI 10.1016/S0079-6603(08)60283-4; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Trifillis P, 1999, RNA, V5, P1071, DOI 10.1017/S1355838299981803; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Yu J, 2001, MOL CELL BIOL, V21, P5879, DOI 10.1128/MCB.21.17.5879-5888.2001	54	17	18	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2597	2604		10.1074/jbc.M108330200	http://dx.doi.org/10.1074/jbc.M108330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11711537	hybrid			2022-12-25	WOS:000173421500030
J	Thuringer, D; Maulon, L; Frelin, C				Thuringer, D; Maulon, L; Frelin, C			Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; VEGF; PATHWAY; SIGNAL; TRANSLOCATION; CALCIUM; BETA	Bradykinin (BK) and vascular endothelial growth factor (VEGF)-165 stimulate vasodilatation, microvascular permeability, and angiogenesis via the activation of the B2-type and KDR/Flk-1 receptors. To delineate the signal transduction pathways distal to the receptor activation in microvascular permeability, we compared their effects on two downstream targets, i.e. endothelial nitric-oxide (NO) synthase (eNOS) and F-actin, in primary cultures of cardiac capillary endothelial cells. The two mediators induced a similar cytoskeletal reorganization and both the translocation and activation of eNOS, leading to NO release within the first minutes of cell exposure. At the same time, BK produced the tyrosine phosphorylation and internalization of KDR/Flk-1 as did VEGF itself. This transactivation was blocked by the selective inhibitor of VEGF receptor tyrosine kinase activity but not by inhibitors of epidermal growth factor receptor or protein kinase C activity. The selective inhibitor of VEGF receptor tyrosine kinase activity totally prevented the effects of VEGF but only partially inhibited NO release induced by BK without affecting the concomitant cytoskeletal reorganization. Thus, BK transactivated KDR/Flk-1 through an intrinsic kinase activity of KDR/Flk-1, resulting in a further eNOS activation in endothelial cells. This represents a novel mechanism whereby a G protein-coupled receptor activates a receptor tyrosine kinase to generate biological response.	CNRS, Unite Mixte Rech 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Thuringer, D (corresponding author), CNRS, Unite Mixte Rech 6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	thuringer@ipmc.cnrs.fr	Thuringer, Dominique/AAA-7448-2020					Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Alexander JS, 2000, CIRC RES, V87, P268, DOI 10.1161/01.RES.87.4.268; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; Busse R, 1996, DIABETES, V45, pS8, DOI 10.2337/diab.45.1.S8; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 2001, CIRC RES, V88, P129; GLIKI G, 1930, BIOCHEM J, V353, P503; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Huang QB, 1997, AM J PHYSIOL-HEART C, V273, pH2442, DOI 10.1152/ajpheart.1997.273.5.H2442; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thuringer D, 2000, CARDIOVASC RES, V47, P726, DOI 10.1016/S0008-6363(00)00141-3; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; Wang W, 1996, AM J PHYSIOL-CELL PH, V271, pC1973, DOI 10.1152/ajpcell.1996.271.6.C1973; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	45	101	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2028	2032		10.1074/jbc.M109493200	http://dx.doi.org/10.1074/jbc.M109493200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11711543	hybrid			2022-12-25	WOS:000173421300057
J	Zdraveski, ZZ; Mello, JA; Farinelli, CK; Essigmann, JM; Marinus, MG				Zdraveski, ZZ; Mello, JA; Farinelli, CK; Essigmann, JM; Marinus, MG			MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN MUTS; MISMATCH-REPAIR; ESCHERICHIA-COLI; CELLULAR-RESPONSES; IN-VITRO; ADDUCTS; RECOMBINATION; RESISTANCE; REPLICATION; SPECIFICITY	Loss of mismatch repair leads to tumor resistance by desensitizing cells to specific DNA-damaging agents, including the anticancer drug cisplatin. Cisplatin analogs with a diamminocyclohexane (DACH) carrier ligand, such as oxaliplatin and Pt(DACH)Cl-2, do not elicit resistance in mismatch repair-deficient cells and therefore present promising therapeutic agents. This study compared the interactions of the purified Escherichia coli mismatch repair protein MutS with DNA modified to contain cisplatin and DACH adducts. MutS recognized the cisplatin-modified DNA with 2-fold higher affinity in comparison to the DACH-modified DNA. ADP stimulated the binding of MutS to cisplatin-modified DNA, whereas it had no effect on the MutS interaction with DNA modified by DACH or EN adducts. In parallel cytotoxicity experiments, methylation-deficient E. coli dam mutants were 2-fold more sensitive to cisplatin than DACH compounds. A panel of recombination-deficient mutants showed striking sensitivity to both compounds, indicating that both types of adducts are strong replication blocks. The differential affinity of MutS for DNA modified with the different platinum analogs could provide the molecular basis for the distinctive cellular responses to cisplatin and oxaliplatin.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester	Essigmann, JM (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	jessig@mit.edu; martin.marinus@umassmed.edu			NCI NIH HHS [R01 CA086061, CA86061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chaney SG, 1999, J INORG BIOCHEM, V77, P71, DOI 10.1016/S0162-0134(99)00149-X; CHU G, 1994, J BIOL CHEM, V269, P787; Culy CR, 2000, DRUGS, V60, P895, DOI 10.2165/00003495-200060040-00005; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1997, CANCER RES, V57, P1841; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; GIBBONS GR, 1991, CARCINOGENESIS, V12, P2253, DOI 10.1093/carcin/12.12.2253; Gong JG, 1999, NATURE, V399, P806; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSON GL, 1966, INORG SYNTH, V8, P242; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; KECK MV, 1992, J AM CHEM SOC, V114, P3386, DOI 10.1021/ja00035a033; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nehme A, 1997, CANCER RES, V57, P3253; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Reitmair AH, 1997, CANCER RES, V57, P3765; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Saris CP, 1996, CARCINOGENESIS, V17, P2763, DOI 10.1093/carcin/17.12.2763; Scheeff ED, 1999, MOL PHARMACOL, V56, P633, DOI 10.1124/mol.56.3.633; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; TSENG YC, 1994, MUTAT RES, V315, P1; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; Vaisman A, 1998, CANCER RES, V58, P3579; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; WATT GW, 1968, INORG CHEM, V7, P335, DOI 10.1021/ic50060a034; Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; Wu TH, 1999, J BIOL CHEM, V274, P5948, DOI 10.1074/jbc.274.9.5948; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8; [No title captured]	51	89	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1255	1260		10.1074/jbc.M105382200	http://dx.doi.org/10.1074/jbc.M105382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11705991	hybrid			2022-12-25	WOS:000173166800051
J	Light, PE; Kanji, HD; Fox, JEM; French, RJ				Light, PE; Kanji, HD; Fox, JEM; French, RJ			Distinct myoprotective roles of cardiac sarcolemmal and mitochondrial K-ATP channels during metabolic inhibition and recovery	FASEB JOURNAL			English	Article						ischemic preconditioning; protein kinase C; adenosine	SENSITIVE POTASSIUM CHANNELS; PROTEIN-KINASE-C; ADENOSINE; MECHANISMS; PROTECTION; RECEPTOR; STRESS; CARDIOPROTECTION; EFFECTORS; TRIGGERS	The protective roles of sarcolemmal (sarc) and mitochondrial (mito) K-ATP channels are unclear despite their apparent importance to ischemic preconditioning. We examined these roles by monitoring intracellular calcium ([Ca](int)), using fura-2 and fluo-3, in enzymatically isolated rat right ventricular myocytes. Myocyte mortality, estimated using a trypan blue assay, changed approximately in parallel with changes in [Ca](int). Chemically induced hypoxia (CIH), induced by application of cyanide and 2-deoxy-glucose, caused a steady rise in [Ca](int). Calcium increased more rapidly on 'reoxygenation' by return to control solutions. The protein kinase C (PKC) activator PMA abolished both phases of calcium increase. The mitoK(ATP) channel-selective blocker 5-hydroxydecanoate partially prevented the PMA-induced protection during CIH, but not during reoxygenation. In contrast, HMR 1098, a sarcK(ATP) channel-selective blocker, abolished protection only during the reoxygenation. Adenosine (A(1)) receptor activation prevented or reduced increases in [Ca](int) and improved cell viability via a PKC and mito/sarcK(ATP) channel-dependent mechanism. PKC-dependent protection against cytoplasmic calcium increases was also observed in a human cell line (tsA201) transiently expressing sarcK(ATP) channels. Protection was abolished only during the reoxygenation phase by the amino acid substitution (T180A) in the pore-forming Kir6.2 subunit, a mutation previously shown to prevent PKC-dependent modulation. Our data suggest that sarc and mitoK(ATP) channel populations play distinct protective roles, triggered by PKC and/or adenosine, during chemically induced hypoxia/reoxygenation.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada	University of Alberta; University of Calgary	Light, PE (corresponding author), Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada.	peter.light@ualberta.ca						Blondeau N, 2000, NEUROSCIENCE, V100, P465, DOI 10.1016/S0306-4522(00)00304-3; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; COATES J, 1994, GEN PHARMACOL, V25, P387, DOI 10.1016/0306-3623(94)90185-6; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Diaz RJ, 1999, CIRC RES, V84, P763; Downey JM, 1997, ADV EXP MED BIOL, V430, P39; Gross GJ, 2000, CIRC RES, V87, P431; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; LAWSON CS, 1993, CARDIOVASC RES, V27, P542, DOI 10.1093/cvr/27.4.542; Light P, 1998, J MEMBRANE BIOL, V162, P217; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; Light PE, 1996, CIRC RES, V79, P399, DOI 10.1161/01.RES.79.3.399; Light PE, 1999, CAN J CARDIOL, V15, P1123; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; Liu YG, 1999, ANN NY ACAD SCI, V874, P27, DOI 10.1111/j.1749-6632.1999.tb09222.x; LOHSE MJ, 1988, N-S ARCH PHARMACOL, V337, P687; Miura T, 1999, CLIN EXP PHARMACOL P, V26, P92, DOI 10.1046/j.1440-1681.1999.03003.x; Nakano A, 2000, PHARMACOL THERAPEUT, V86, P263, DOI 10.1016/S0163-7258(00)00058-9; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; Pain T, 2000, CIRC RES, V87, P460; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Piper HM, 1999, ANN THORAC SURG, V68, P1913, DOI 10.1016/S0003-4975(99)01025-5; Sanada S, 2001, AM J PHYSIOL-HEART C, V280, pH256, DOI 10.1152/ajpheart.2001.280.1.H256; Sato T, 2000, CIRCULATION, V102, P800, DOI 10.1161/01.CIR.102.7.800; Schwarz ER, 1997, CURR OPIN CARDIOL, V12, P475, DOI 10.1097/00001573-199712050-00007; Toyoda Y, 2000, CIRCULATION, V102, P326; Toyoda Y, 2000, AM J PHYSIOL-HEART C, V279, pH2694, DOI 10.1152/ajpheart.2000.279.6.H2694; Wirth KJ, 2000, N-S ARCH PHARMACOL, V361, P155, DOI 10.1007/s002109900166; Wu S, 1999, CIRC RES, V84, P1388; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0	38	85	88	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2586	2594		10.1096/fj.01-0188com	http://dx.doi.org/10.1096/fj.01-0188com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726534				2022-12-25	WOS:000172964800028
J	White, DE; Cardiff, RD; Dedhar, S; Muller, WJ				White, DE; Cardiff, RD; Dedhar, S; Muller, WJ			Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice	ONCOGENE			English	Article						integrin linked kinase; ILK; transgenic mice; mammary epithelium; breast cancer; tumorigenesis	AP-1 TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; CELL-ADHESION; BETA-CATENIN; PHENOTYPE; OVEREXPRESSION; INHIBITION; ACTIVATION; B/AKT	The integrin linked kinase (ILK) is a cytoplasmic effector of integrin receptors, involved in the regulation of integrin binding properties as well as the activation of cell survival and proliferative pathways, including those involving MAP kinase, PKB/Akt and GSK-3 beta. Overexpression of ILK in cultured intestinal and mammary epithelial cells has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth, invasiveness, suppression of anoikis and tumorigenicity in nude mice. In order to determine if ILK overexpression can result in the formation of mammary tumors in vivo, we generated transgenic mice expressing ILK in the mammary epithelium, under the transcriptional control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). By the age of 6 months, female MMTV/ILK mice developed a hyperplastic mammary phenotype, which was accompanied by the constitutive phosphorylation of PKB/Akt, GSK-3 beta and MAP kinase. Focal mammary tumors subsequently appeared in 34% of the animals at an average age of 18 months. Given the focal nature and long latency of the tumors, however, additional genetic events are likely required for tumor induction in the MMTV/ILK mice. These results provide the first direct demonstration of a potential oncogenic role for ILK, which is upregulated in human tumors and tumor cell lines.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; University of California System; University of California Davis; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; McMaster University	Muller, WJ (corresponding author), McMaster Univ, MOBIX, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	mullerw@mcmaster.ca		Dedhar, Shoukat/0000-0003-4355-1657				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Somasiri A, 2001, J CELL SCI, V114, P1125; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Streuli CH, 1998, J MAMMARY GLAND BIOL, V3, P151, DOI 10.1023/A:1018742822565; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	37	106	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7064	7072		10.1038/sj.onc.1204910	http://dx.doi.org/10.1038/sj.onc.1204910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704830				2022-12-25	WOS:000171739300009
